Ïîèñê ïî áàçå äîêóìåíòîâ:

 

ÌÈÍÈÑÒÅÐÑÒÂÎ ÇÄÐÀÂÎÎÕÐÀÍÅÍÈß ÐÎÑÑÈÉÑÊÎÉ ÔÅÄÅÐÀÖÈÈ

 

ÃÎÑÓÄÀÐÑÒÂÅÍÍÛÉ ÐÅÅÑÒÐ ËÅÊÀÐÑÒÂÅÍÍÛÕ ÑÐÅÄÑÒÂ

 

ÎÔÈÖÈÀËÜÍÎÅ ÈÇÄÀÍÈÅ

(äàííûå ïî ñîñòîÿíèþ íà 1 íîÿáðÿ 1998 ã.)

 

×àñòü I,  ãëàâà 1, ðàçäåëû 1, 2

 

×àñòü I,  ãëàâà 1, ðàçäåëû 3-6, ãëàâû 2, 3, 4

 

×àñòü II, ãëàâà 1, ðàçäåëû 1, 2 (íà÷àëî îò À äî Ä)

 

×àñòü II, ãëàâà 1, ðàçäåë  2 (ïðîäîëæåíèå îò Å äî Ï)

 

×àñòü II, ãëàâà 1, ðàçäåë  2 (îêîí÷àíèå îò Ð äî ß)

 

×àñòü II, ãëàâà 1, ðàçäåëû 3-5, ãëàâû 2-5

 

Ïðèëîæåíèå 1.

 

ÏÅÐÅ×ÅÍÜ

ÏÐÅÏÀÐÀÒÎÂ, ÍÎÌÅÐÀ ÐÅÃÈÑÒÐÀÖÈÈ ÊÎÒÎÐÛÕ

ÀÍÍÓËÈÐÎÂÀÍÛ Â 1997-1998 Ã.

 

┌──────────────────────────────┬───────────────────────────────────┬──────────────────────────────┬────────────────────┐

     Òîðãîâîå íàçâàíèå                 Ôîðìà âûïóñêà                    Ôèðìà (Ñòðàíà)               Íîìåð         

├──────────────────────────────┼───────────────────────────────────┼──────────────────────────────┼────────────────────┤

│8 Çëàêîâ è ìåä                                                   │Mylupa Sa (ÔÐÃ/Èñïàíèÿ)       │004111             

│HB-Âàêñ II                    │ñóñïåíçèÿ                          │Merck Sharp & Dohme (ÑØÀ)     │14/94-00032840     

                                                                                                                  

│L-Àðãèíèí                     │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00980              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Àñïàðàãèíîâàÿ êèñëîòà       │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00961              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Âàëèí                       │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00978              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Ãèñòèäèí                    │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00981              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Ãëóòàìèí                    │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00964              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                   

│L-Ãëóòàìèíîâàÿ êèñëîòà        │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00963              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Ëèçèíà àöåòàò               │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00983              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Ñåðèí                       │àìèíîêèñëîòà äëÿ ïàðåíòåðàëüíîãî   │Kyowa Hakko Kogyo Co Ltd      │00974              

                              │ïèòàíèÿ                            │(ßïîíèÿ)                                         

                                                                                                                  

│L-Òèðîêñèí                    │òàáëåòêè 100 ìêã                   │Henning Berlin Gmbh (Ãåðìàíèÿ)│02001              

│À-10                                                             │Durr (ÔÐÃ)                    │004336             

                                                                                                                  

│Àáðèêîñîâî-ãðóøåâîå ïþðå ñ                                       │Fructal/Sloveniales (Ñëîâåíèÿ)│004366             

│ìåäîì                                                                                                             

                                                                                                                  

│Àâåëèçèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Arzneimittelwerk Dresden Gmbh │00685              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÔÐÃ)                                             

                              │250000 ÌÅ                                                                           

                                                                                                                  

│Àâåëèçèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Arzneimittelwerk Dresden Gmbh │002850             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÔÐÃ)                                            

                              │100000, 250000 ÅÄ                                                                   

                                                                                                                  

│Àâèöåë                        │ïîðîøîê                            │Fms Corporation (ÑØÀ)         │00919              

│Àâîêñèí                       │òàáëåòêè 100 ìã                    │Krka (Ñëîâåíèÿ)               │002482             

│Àããðèñòèí ïëþñ Àäðåíàëèí, ÀÄÔ │ðåàêòèâû (íàáîð)                   │Reanal (Âåíãðèÿ)              │2826               

│Àãèîëàêñ                      │ãðàíóëû                            │Madaus Cerapharm Sa (Èñïàíèÿ) │002389             

│Àäàïòèê                       │ìàòåðèàë ïëîìáèðîâî÷íûé            │Johnson & Johnson (ÑØÀ)       │00605              

                                                                                                                  

│Àäâåðçóòåí                    │òàáëåòêè 1 ìã, 5 ìã                │Arzneimittelwerk Dresden Feb  │01342              

                                                                 │(ÃÄÐ)                                            

                                                                                                                  

│Àääàìåëü Í                    │êîíöåíòðàò ìèêðîýëåìåíòîâ äëÿ      │Kabi Pharmacia (Øâåöèÿ)       │002765             

                              │äîáàâëåíèÿ â ïàðåíòåðàëüíîå                                                         

                              │ïèòàíèå (ôëàêîíû) 10 ìë                                                             

                                                                                                                   

│Àäèóðåêðèíà ðàñòâîð 20 ÅÄ/ìë  │ðàñòâîð íàçàëüíûé                  │Ðîññèÿ                        │87/295/7           

                              │(òþáèê-êàïåëüíèöû) 20 ÅÄ/ìë - 1.5                                                   

                              │ìë; ðàñòâîð íàçàëüíûé (ôëàêîíû) 20 │                                                 

                              │ÅÄ/ìë - 5 ìë                                                                        

                                                                                                                  

│Àäèóðåòèí ÑÄ                  │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 4    │Spofa (×åõîñëîâàêèÿ)          │2764               

                              │ìêã - 1 ìë                                                                          

                                                                                                                  

│Àäðèáëàñòèí                   │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Farmitalia Carlo Erba (Èòàëèÿ)│002307             

                              │èíúåêöèîííîãî ðàñòâîðà                                                              

                              │áûñòðîðàñòâîðèìûé (ôëàêîíû) 10, 50 │                                                 

                              │ìã                                                                                  

                                                                                                                  

│Àçàêòàì                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bristol-Myers Squibb (ÑØÀ)    │002361             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1, 2 ã                                                                         

                                                                                                                   

│Àçîíà                         │êàïñóëû 25, 50, 100 ìã             │Farmos Group (Ôèíëÿíäèÿ)      │01093              

│Àçó                           │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2888               

│Àçóëèí                        │ïàñòà çóáíàÿ                       │Merima (ÑÔÐÞ)                 │01622              

│Àéðîë                         │êðåì 0.05%; ëîñüîí 0.05%           │Hoffmann La Roche (Øâåéöàðèÿ) │00456              

│Àêâàäåíò                      │ïàñòà çóáíàÿ                       │Dolphin Sales Pvt Ltd (Èíäèÿ) │02000              

│Àêâàôðåø                      │ïàñòà çóáíàÿ                       │Beecham (Âåëèêîáðèòàíèÿ)      │01631              

│Àêâàôðåø                      │ïàñòà çóáíàÿ                       │Beecham Group (Åãèïåò)        │01808              

                                                                                                                  

│Àêèíåòîí                      │òàáëåòêè 2 ìã; ðàñòâîð äëÿ         │Knoll Ag (ÔÐÃ)                │01232              

                              │èíúåêöèé (àìïóëû) 5 ìã - 1 ìë                                                       

                                                                                                                  

│Àêñèä                         │êàïñóëû 150, 300 ìã; ðàñòâîð äëÿ   │Eli Lilly & Elanco (ÑØÀ)      │002726             

                              │âíóòðèâåííîãî ââåäåíèÿ (àìïóëû) 25 │                                                 

                              │ìã/ìë - 4 ìë                                                                        

                                                                                                                  

│ÀÊÒ                           │ðàñòâîð äëÿ ïîëîñêàíèÿ ðòà         │Johnson & Johnson (ÑØÀ)       │04021              

│Àêòåëëèê                      │êîíöåíòðàò ýìóëüñèîííûé 50%        │ICI (Âåëèêîáðèòàíèÿ)          │00744              

                                                                                                                  

│Àêòèâ                         │ïàñòà çóáíàÿ                       │Miss Chery Cosmetic Pvt Ltd   │04001               

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Àêòèâåðà-30 Òà                                                  │Is Martens (Íîðâåãèÿ)         │01774              

                                                                                                                  

│Àêòèëèçå                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Boehringer Ingelheim Gmbh     │01859              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÔÐÃ)                                            

                              │50 ìã                                                                               

                                                                                                                  

│Àêòèôåððèí                    │ñèðîï (ôëàêîíû) 3.42 ã - 100 ìë;   │Ludwig Merckle Gmbh (Àâñòðèÿ) │002859             

                              │êàïëè (ôëàêîíû) 1.416 ã - 30 ìë;                                                    

                              │êàïñóëû 300 ìã - 113.85 ìã                                                          

                                                                                                                  

│Àêòîâåãèí                     │ðàñòâîð äëÿ èíôóçèé ñ ãëþêîçîé     │Hafslund Nycomed (Àâñòðèÿ)    │002193             

                              │(ôëàêîíû) 10% - 250 ìë; ðàñòâîð                                                     

                              │äëÿ èíôóçèé èçîòîíè÷åñêèé                                                           

                              │(ôëàêîíû) 20% - 250 ìë; ðàñòâîð                                                     

                              │äëÿ èíôóçèé ñ íàòðèÿ õëîðèäîì                                                        

                              │(ôëàêîíû) 10% - 250 ìë                                                              

                                                                                                                   

│Àêòîâåãèí                     │äðàæå ôîðòå 200 ìã; ðàñòâîð äëÿ    │Krka (ÑÔÐÞ)                   │002254             

                              │èíúåêöèé (àìïóëû)80 ìã/2 ìë, 200                                                    

                              │ìã/5 ìë, 400 ìã/10 ìë; ðàñòâîð äëÿ │                                                 

                              │èíôóçèé ñ ãëþêîçîé (ôëàêîíû) 10%;                                                   

                              │ðàñòâîð äëÿ èíôóçèé ñ íàòðèÿ                                                        

                              │õëîðèäîì (ôëàêîíû) 10%, 20%                                                         

                                                                                                                  

│Àêòîâåãèí                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2,   │Unique Pharmaceutical         │01543              

                              │5, 10 ìë                           │Laboratories (Èíäèÿ)                             

                                                                                                                  

│Àêòîâåãèí                     │ìàçü 5%; æåëå 20%                  │Unique Pharmaceutical         │02022              

                                                                 │Laboratories (Èíäèÿ)                             

                                                                                                                  

│Àêòðàôàí HM ïåíôèë 100        │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû    │Novo Nordisk (Äàíèÿ)          │002241             

                              │äëÿ øïðèöðó÷êè) 100 ÌÅ/ìë - 1.5 ìë │                                                 

                                                                                                                  

│ÀëÀÒ                                                             │Labsystems (Ôèíëÿíäèÿ)        │01337               

│Àëáóôàí                       │ïîëîñêè                            │Lachema (×ÑÔÐ)                │2635               

│Àëäèçåì                       │òàáëåòêè 60 ìã                     │Alkaloid (ÑÔÐÞ)               │01999              

│Àëäèçåì                       │òàáëåòêè 90 ìã                     │Alkaloid (ÑÔÐÞ)               │002446             

                                                                                                                  

│Àëåêñàí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 100  │Mack (ÔÐÃ)                    │01487              

                              │ìã - 5 ìë                                                                           

                                                                                                                  

│Àëåêñàí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 40   │Mack (ÔÐÃ)                    │00239              

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Àëåêñàí                       │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 500 │Mack (ÔÐÃ)                    │003114             

                              │ìã/10 ìë, 1000 ìã/20 ìë; ðàñòâîð                                                    

                              │äëÿ èíúåêöèé (àìïóëû) 500 ìã/10                                                    

                              │ìë, 1000 ìã/20 ìë                                                                   

                                                                                                                  

│Àëåðãîôòàë                    │ðàñòâîð îôòàëüìîëîãè÷åñêèé         │Laboratorious Cusi (Èñïàíèÿ)  │003234             

                              │(ôëàêîíû) 10 ìë                                                                     

                                                                                                                  

│Àëèìåíòóì                                                        │Abbott Laboratories (ÑØÀ)     │01640               

│Àëêà-Çåëüòöåð                 │òàáëåòêè ðàñòâîðèìûå               │Bayer Ag (ÔÐÃ)                │00603              

                                                                                                                  

│Àëëîâîðàí                     │òàáëåòêè ñ êèøå÷íîðàñòâîðèìîé      │Tad Pharmazeutisches Werk     │003376             

                              │îáîëî÷êîé 25, 50 ìã; òàáëåòêè      │Gmbh (Ãåðìàíèÿ)                                  

                              │ðåòàðä 100 ìã; ðàñòâîð äëÿ                                                          

                              │èíúåêöèé (àìïóëû) 75 ìã - 3 ìë;                                                     

                              │ñâå÷è 50, 100 ìã                                                                    

                                                                                                                  

│Àëëîçèì                       │òàáëåòêè 100 ìã                    │Sawai Pharmaceutical Co Ltd   │003013             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Àëëîôåðèí                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Hoffmann La Roche (Øâåéöàðèÿ) │00159              

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Àëñèäðåêñ-à                  │òàáëåòêè                           │Menon Pharma (Èíäèÿ)          │002661             

│Àëñîé                         │ñìåñü ñóõàÿ                        │Nestle (Øâåéöàðèÿ)            │004260             

                                                                                                                   

│Àëñóêðàë                      │òàáëåòêè 500, 1000 ìã              │Orion Pharmaceutica           │01844              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Àëóïåíò                       │òàáëåòêè 20 ìã; ðàñòâîð äëÿ        │Zdravle (Þãîñëàâèÿ)           │00117              

                              │èíúåêöèé (àìïóëû) 0.5 ìã/1 ìë;                                                      

                              │àýðîçîëü                                                                            

                                                                                                                  

│Àëüáóòåðîë (Ñàëüáóòàìîë)      │òàáëåòêè 2 ìã, 4 ìã                │Mir Pharmaceutical Inc/Lemmon │007679             

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Àëüäàêòîí                     │òàáëåòêè 25, 100 ìã                │Searle Pharmaceutical         │002438             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Àëüäåôóì                      │ýëåêòðîôóìèãàòîð                   │Ðîññèÿ                        │0004-7             

│Àëüìèðîí                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Nutricia (Ãîëëàíäèÿ)          │01650              

│Àëüôà-ôåòî (Àëüôà-ôåòîïðîòåèí)│                                   │Abbott Laboratories (ÑØÀ)     │01131              

                                                                                                                  

│Àëüôàöåò                      │êàïñóëû 250, 500 ìã; ñèðîï 125     │Galenika (ÑÔÐÞ)               │002184             

                              │ìã|5 ìë, 250 ìã|5 ìë                                                                 

                                                                                                                  

│Àëþãàñòðèí                    │âçâåñü (ôëàêîíû) 340 ìã|5 ìë - 250 │Polfa (Ïîëüøà)                │2857               

                              │ìë                                                                                  

                                                                                                                  

│Àìàçîë                        │òàáëåòêè                           │Ðîññèÿ                        │70/151/26          

                                                                                                                  

│Àìáèçîì                       │ëèîôèëèç.ïîðîøîê äëÿ èíôóçèé       │Nexstar Pharmaceuticals Inc   │009523             

                              │(ôëàêîíû) 50 ìã                    │(Áåëüãèÿ)                                        

                                                                                                                  

│Àìáðîáåíå                     │òàáëåòêè 30 ìã; ðàñòâîð äëÿ        │Ludwig Merckle Gmbh (Àâñòðèÿ) │002513             

                              │èíúåêöèé (àìïóëû) 15 ìã - 2 ìë;                                                     

                              │êàïñóëû ðåòàðä 75 ìã; ñèðîï 15                                                      

                              │ìã|5 ìë; ðàñòâîð 7.5 ìã/ìë                                                          

                                                                                                                  

│Àìáðîñàí                      │òàáëåòêè 30 ìã                     │Pro.Med.Cs (×åõèÿ)            │003140             

                                                                                                                  

│Àìçîëèí                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │M.J.Pharmaceuticals Ltd       │002951             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Èíäèÿ)                                          

                              │0.25, 0.5, 1 ã                                                                       

                                                                                                                  

│Àìèäîïèðèí (Ïèðàìèäîí)        │ñóáñòàíöèÿ                         │Ðîññèÿ                        │64/228/7           

                                                                                                                  

│Àìèêàöèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Galenika (Þãîñëàâèÿ)          │00851              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                     

                                                                                                                  

│Àìèëîðèäà                     │òàáëåòêè 5 ìã/50 ìã                │Biocraft Laboratories Inc     │002355             

│ãèäðîõëîðèä+ãèäðîõëîðîòèàçèä                                     │(ÑØÀ)                                            

                                                                                                                  

│Àìèíîìàë                      │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Malesci Menarini (Èòàëèÿ)     │002907             

                              │(àìïóëû) 240 ìã - 10 ìë                                                             

                                                                                                                  

│Àìèíîñòåðèë II                │ðàñòâîð äëÿ èíôóçèé                │Farmos Group (Ôèíëÿíäèÿ)      │01110              

│Àìèíîñòåðèë III               │ðàñòâîð äëÿ èíôóçèé                │Farmos Group (Ôèíëÿíäèÿ)      │01111              

│Àìèíîñòåðèë Ãåïà              │ðàñòâîð äëÿ èíôóçèé 5%             │Fresenius (ÔÐÃ)               │01283              

│Àìèíîñòåðèë Ãåïà              │ðàñòâîð äëÿ èíôóçèé 8%             │Fresenius (ÔÐÃ)               │01284              

│Àìèíîñòåðèë ÊÅ                │ðàñòâîð äëÿ èíôóçèé                │Fresenius (ÔÐÃ)               │01286              

│Àìèíîñòåðèë ÊÅ 10%            │ðàñòâîð äëÿ èíôóçèé                │Fresenius (ÔÐÃ)               │01287              

                                                                                                                   

│Àìèíîñòåðèë ÊÅ 800            │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 500  │Hemofarm D.D. (Þãîñëàâèÿ)     │005381             

                              │ìë                                                                                  

                                                                                                                  

│Àìèíîñòåðèë ÊÅ Íåôðî          │ðàñòâîð äëÿ èíôóçèé                │Fresenius (ÔÐÃ)               │01285              

                                                                                                                  

│Àìèíîñòåðèë Ë 600             │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 500  │Hemofarm D.D. (Þãîñëàâèÿ)     │005262             

                              │ìë                                                                                  

                                                                                                                  

│Àìèíîôèëëèí                   │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Far-Ca (Èòàëèÿ)               │002635             

                              │(àìïóëû) 240 ìã - 10 ìë                                                             

                                                                                                                  

│Àìèíîôèëëèí                   │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2.4% │Polfa (Ïîëüøà)                │2895               

                              │- 10 ìë                                                                             

                                                                                                                  

│Àìèîäàðîí-Ðèâîôàðì            │òàáëåòêè 200 ìã                    │Rivopharm Sa (Øâåéöàðèÿ)      │005132             

                                                                                                                  

│Àìèòðèä ìèòå                  │òàáëåòêè                           │Houhtamyaki Leiras Oy         │002076              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Àìíèîöåí äëÿ èíúåêöèé         │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû) 5 │Ðîññèÿ                        │87/295/4           

                              │ìë                                                                                  

                                                                                                                  

│Àìîêñèêëàâ                    │òàáëåòêè 500 ìã/125 ìã; ñóñïåíçèÿ  │Lek (ÑÔÐÞ)                    │002235             

                              │ôîðòå 100 ìë; êàïëè 20 ìë                                                           

                                                                                                                  

│Àìîêñèöèëëèí                  │êàïñóëû 250, 500 ìã                │Mir Pharmaceutical            │007701             

                                                                 │Inc/Biocraft Laboratories Inc │                   

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Àìîêñèöèëëèí                  │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Mir Pharmaceutical            │007890             

                              │ñóñïåíçèè äëÿ âíóòðåííåãî          │Inc/Biocraft Laboratories Inc │                   

                              │ïðèìåíåíèÿ (ôëàêîíû) 125 ìã|5 ìë - │(ÑØÀ)                                            

                              │80, 100, 150 ìë; ïîðîøîê äëÿ                                                        

                              │ïðèãîòîâëåíèÿ ñóñïåíçèè äëÿ                                                         

                              │âíóòðåííåãî ïðèìåíåíèÿ (ôëàêîíû)                                                    

                              │250 ìã|5 ìë - 80, 100, 150 ìë                                                        

                                                                                                                  

│Àìïèçèä                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Ludwig Merckle Gmbh (Àâñòðèÿ) │003323             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1, 2 ã /â êîìïëåêòå ñ                                                          

                              │ðàñòâîðèòåëåì/; ïîðîøîê äëÿ                                                         

                              │ïðèãîòîâëåíèÿ èíôóçèîííîãî                                                          

                              │ðàñòâîðà (ôëàêîíû) 5 ã /â                                                           

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                          

                                                                                                                  

│Àìïèöèëëèí                    │êàïñóëû 250, 500 ìã                │Mir Pharmaceutical            │007887             

                                                                 │Inc/Biocraft Laboratories Inc │                   

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Àìñèäèë                       │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Godecke/Parke-Davis (ÔÐÃ)     │002252             

                              │âíóòðèâåííîãî ðàñòâîðà (àìïóëû)                                                     

                              │1.7 ìë /â êîìïëåêòå ñ                                                               

                              │ðàñòâîðèòåëåì/                                                                       

                                                                                                                  

│Àíàëîã ÕР                    │ñìåñü ñóõàÿ                        │Valio (Ôèíëÿíäèÿ)             │004105              

│Àíàëüãèí                      │òàáëåòêè 500 ìã                    │Aganall Traders Ltd (Èíäèÿ)   │002160             

│Àíàëüãèí                      │òàáëåòêè 500 ìã                    │Alkaloid (ÑÔÐÞ)               │002152             

│Àíàëüãèí                      │òàáëåòêè 500 ìã                    │Berlin-Chemie Ag (ÔÐÃ)        │003227             

                                                                                                                  

│Àíàëüãèí                      │òàáëåòêè 500 ìã; ðàñòâîð äëÿ       │Dee-Pharma Ltd (Èíäèÿ)        │003405             

                              │èíúåêöèé (àìïóëû) 2 ìë, 5 ìë                                                        

                                                                                                                  

│Àíàëüãèí                      │òàáëåòêè 500 ìã                    │J.R.Sharma Overseas Private   │002161             

                                                                 │Ltd (Èíäèÿ)                                      

                                                                                                                  

│Àíàëüãèí                      │òàáëåòêè 500 ìã                    │R.C.A. Electrochem Private    │002256             

                                                                 │Ltd, Gafar Laboratories Ltd                      

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Àíàíàñû àðò.275                                                  │Hipp (Àâñòðèÿ)                │004032             

│Àíàïèðèí                      │òàáëåòêè                           │Pharmachim (Áîëãàðèÿ)         │2138               

│Àíàôðàíèë                     │äðàæå 25 ìã                        │Ciba-Geigy (Èíäîíåçèÿ)        │003191              

                                                                                                                  

│Àíàôðàíèë                     │òàáëåòêè â îáîëî÷êå èç ñàõàðà 25   │Ciba-Geigy (Èñïàíèÿ)          │002268             

                             │ìã; ðàñòâîð äëÿ èíúåêöèé (àìïóëû)                                                   

                              │25 ìã - 2 ìë                                                                        

                                                                                                                  

│Àíàöèä                        │ñóñïåíçèÿ (ôëàêîíû) 240 ìë;        │Galena Opava (×ÑÔÐ)           │2646               

                              │ñóñïåíçèÿ (ïàêåòèêè) 5, 10 ìë                                                       

                                                                                                                  

│Àíäðîêóð                      │òàáëåòêè 50 ìã                     │Salutas Fahlberg-List (ÔÐÃ)   │002785             

│Àíåòà                         │ïàñòà çóáíàÿ                       │Pharmachim (ÍÐÁ)              │2940               

│Àíêîôåí                       │òàáëåòêè                           │Ðîññèÿ                        │70/151/61          

│Àíîìåòðèí 25%                 │êîíöåíòðàò ýìóëüñèè                │Ðîññèÿ                        │0004-9             

│Àíñåéä                        │òàáëåòêè 50, 100 ìã                │Upjohn (ÑØÀ)                  │003120             

                                                                                                                  

│Àíòàãîçàí                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû)      │Behringwerke Ag (ÔÐÃ)         │002495             

                              │20000 ÊÈÅ/ìë                                                                        

                                                                                                                  

│Àíòåëåïñèí@                   │òàáëåòêè 0.25 ìã                   │Arzneimittelwerk Dresden Gmbh │00762              

                                                                 │(ÔÐÃ)                                             

                                                                                                                  

│Àíòåëåïñèí@                   │òàáëåòêè 1 ìã                      │Arzneimittelwerk Dresden Gmbh │00676              

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Àíòåîâèí                      │òàáëåòêè                           │Gedeon Richter (Âåíãðèÿ)      │2901               

│Àíòèêîì                       │ïîðîøîê                            │Ðîññèÿ                        │0004-8             

│Àíòèñåêò                      │ïîðîøîê                            │Ðîññèÿ                        │0009-2             

│Àíòèòðîìáèí-III (ÀÒ-III)                                         │Belgian Chemical (Áåëüãèÿ)    │00952              

│ÀÎÕ-1 (àêòèâíûå îêèñëû õëîðà) │æèäêîñòü                           │Ðîññèÿ                        │0004-4             

                                                                                                                  

│Àïàóðèí@                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Krka (Ñëîâåíèÿ)               │002451             

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Àïåëüñèíîâûé ñîê 02100                                           │Gerber (ÑØÀ)                  │004168             

│ÀÏÈ 20 À                                                         │Api System (Ôðàíöèÿ)          │01363              

│ÀÏÈ 20 Å                                                         │Api System (Ôðàíöèÿ)          │01362              

│ÀÏÈ 20 ÍÅ                                                        │Api System (Ôðàíöèÿ)          │01365               

│ÀÏÈ 20 Ñòðåï                                                     │Api System (Ôðàíöèÿ)          │01366              

│ÀÏÈ Ñòàô                                                         │Api System (Ôðàíöèÿ)          │01367              

│Àïî-Àìèòðèïòèëèí              │òàáëåòêè 75 ìã                     │Apotex Inc (Êàíàäà)           │002916             

│Àïî-Ãèäðî                     │òàáëåòêè 25, 50, 100 ìã            │Apotex Inc (Êàíàäà)           │003230             

│Àïî-Èáóïðîôåí                 │òàáëåòêè 200, 300, 500 ìã          │Apotex Inc (Êàíàäà)           │002755             

│Àïî-Êàïòî                     │òàáëåòêè 12.5, 25, 50, 100 ìã      │Apotex Inc (Êàíàäà)           │002713             

│Àïî-Íàïðîêñåí                 │òàáëåòêè 125, 250, 375, 500 ìã     │Apotex Inc (Êàíàäà)           │002756             

│Àïîíòè ïêó-äèýò 40            │ïîðîøîê                            │Aponty Gmbh (ÔÐÃ)             │01038              

│Àïî-Òèìîë                     │òàáëåòêè 5, 10, 20 ìã              │Apotex Inc (Êàíàäà)           │002936             

│Àïî-Òèìîï                     │êàïëè ãëàçíûå 0.25%, 0.5%          │Apotex Inc (Êàíàäà)           │003149             

│Àïî-Ôóðîñåìèä                 │òàáëåòêè 20, 40 ìã                 │Apotex Inc (Êàíàäà)           │002937             

                                                                                                                  

│Àïðîë                         │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Bilim Ilac Sanayi (Òóðöèÿ)    │002914             

                              │îáîëî÷êîé 275 ìã                                                                    

                                                                                                                  

│Àïðîòèìáèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Biochemie Gmbh (Àâñòðèÿ)      │002460             

                              │ìë - 100000, 500000 ÊÈÅ                                                             

                                                                                                                  

│Àïòàìèë                       │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Interpromex Gmbh (ÔÐÃ)        │01385               

│ÀÏÒ                                                             │Reanal (Âåíãðèÿ)              │2825               

│Àðäåêñ Ä                                                         │Archer Daniels Midland (ÑØÀ)  │01065              

│Àðäåêñ Äà                                                      │Archer Daniels Midland (ÑØÀ)  │01064              

│Àðäåêñ Ì                                                         │Archer Daniels Midland (ÑØÀ)  │01040              

│Àðäåêñ ÑÏ6                                                       │Archer Daniels Midland (ÑØÀ)  │01041              

│Àðäåêñ Ô                                                         │Archer Daniels Midland (ÑØÀ)  │01063              

                                                                                                                  

│Àðäóàí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Themis Chemicals Ltd (Èíäèÿ)  │002971             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû) 4                                                   

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Àðèôîí                        │äðàæå 2.5 ìã                       │Laboratoires Servier (Ôðàíöèÿ)│01323              

│Àðèôîí                        │äðàæå 2.5 ìã                       │Zorka (Þãîñëàâèÿ)             │01351              

│Àðêîí ÂÔ                                                         │Adm (ÑØÀ)                     │01656              

│Àðêîí Ò                                                          │Adm (ÑØÀ)                     │01657              

│Àðêîí Ô                                                          │Adm (ÑØÀ)                     │01655              

│Àðêîí-à                                                         │Adm (ÑØÀ)                     │004056             

│Àððèâî                        │êîíöåíòðàò ýìóëüñèîííûé 25%        │Fms Corporation (ÑØÀ)         │004202             

│Àðòàìèí                       │êàïñóëû 150, 250 ìã                │Biochemie Gmbh (Àâñòðèÿ)      │01783               

                                                                                                                  

│Àðòåïàðîí                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 50   │Luitpold-Werk (ÔÐÃ)           │00772              

                              │ìã - 1 ìë                                                                           

                                                                                                                  

│Àðóáåíäîë                     │àýðîçîëü äîçèðîâàííûé              │Ankerpharm Gmbh, Ankerwerk    │003034             

                                                                 │Rudolstadt (ÔÐÃ)                                 

                                                                                                                  

│Àðóòèìîë                      │êàïëè ãëàçíûå (ôëàêîíû) 0.25%, 0.5%│Ankerwerk Rudolstadt (ÃÄÐ)    │01595              

│ÀñÀÒ                                                             │Labsystems (Ôèíëÿíäèÿ)        │01336              

                                                                                                                  

│Àñêîðáèíîâàÿ êèñëîòà          │òàáëåòêè 500 ìã                    │Cox Pharmaceuticals           │003200             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Àñêîðáèíîâàÿ êèñëîòà (âèòàìèí │òàáëåòêè 250, 500, 1000 ìã         │Dabur India Ltd (Èíäèÿ)       │002629             

│Ñ)                                                                                                                

                                                                                                                  

│Àñïèðèí                       │òàáëåòêè 325 ìã                    │A&z Pharmaceutical (ÑØÀ)      │002528              

                                                                                                                  

│Àñïèðèí                       │òàáëåòêè 75, 300 ìã                │Cox Pharmaceuticals           │003201             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Àñïèðèí                       │òàáëåòêè 324 ìã                    │L.T.York Company (ÑØÀ)        │002650             

                                                                                                                  

│Àñïèðèí                       │òàáëåòêè 300 ìã                    │M&a Pharmachem Ltd            │002552             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Àñïèðèí                       │òàáëåòêè 325 ìã                    │Pde Labs Inc (ÑØÀ)            │002571             

│Àñïèðèí ÓÏÑÀ ñ âèòàìèíîì C    │òàáëåòêè øèïó÷èå                   │Laboratoires Upsa (Ôðàíöèÿ)   │002478             

                                                                                                                  

│Àñòàëèí                       │àýðîçîëü äîçèðîâàííûé 100          │Cipla Ltd (Èíäèÿ)             │002614             

                              │ìêã/äîçà; êàïñóëû äëÿ èíãàëÿöèé                                                     

                              │200 ìêã                                                                             

                                                                                                                  

│Àñòèìèí ôîðòå                 │êàïñóëû                            │Tablets (India) Ltd (Èíäèÿ)   │002613             

                                                                                                                  

│Àñòèìèí-3                     │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 200  │Tablets (India) Ltd (Èíäèÿ)   │002612              

                              │ìë                                                                                  

                                                                                                                  

│Àñòìîïåíò                     │òàáëåòêè 20 ìã; ðàñòâîð äëÿ        │Polfa (Ïîëüøà)                │2499               

                              │èíúåêöèé (àìïóëû) 0.5 ìã - 1 ìë                                                     

                                                                                                                  

│ÀÒÁ ÀÍÀ                                                          │Api System (Ôðàíöèÿ)          │01364              

                                                                                                                  

│ÀÒÃ-Ôðåçåíèóñ                 │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Fresenius (ÔÐÃ)               │002686             

│(Àíòè÷åëîâå÷åñêèé-            │èíôóçèîííîãî ðàñòâîðà (ôëàêîíû) 20 │                                                 

│Ò-ëèìôîöèòî-ãëîáóëèí êðîëèêà) │ìã/ìë - 5 ìë                                                                        

                                                                                                                  

│Àòåíîáåíå                     │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ludwig Merckle Gmbh (Àâñòðèÿ) │002980             

                              │îáîëî÷êîé 50, 100 ìã                                                                

                                                                                                                  

│Àòåíîâà                       │òàáëåòêè 50, 100 ìã                │Lupin Laboratories Ltd (Èíäèÿ)│002619             

│Àòåíîëîë                      │òàáëåòêè 50, 100 ìã                │Schiapparelli Searle (ÑØÀ)    │002582             

│Àòðîâåíò                      │àýðîçîëü                           │Boehringer Ingelheim (ÔÐÃ)    │00943              

                                                                                                                  

│Àóãìåíòèí                     │òàáëåòêè 375 ìã; ïîðîøîê äëÿ       │Beecham Pharmaceuticals       │01927               

                              │ïðèãîòîâëåíèÿ èíúåêöèîííîãî        │(Âåëèêîáðèòàíèÿ)                                 

                              │ðàñòâîðà 0.6, 1.2 ã; ïîðîøîê äëÿ                                                    

                              │ïðèãîòîâëåíèÿ ñèðîïà 156 ìã|5 ìë                                                    

                                                                                                                  

│Àóãìåíòèí                     │òàáëåòêè 375, 625 ìã; ïîðîøîê äëÿ  │Fako Ilaclary As (Òóðöèÿ)     │002157             

                              │ïðèãîòîâëåíèÿ èíúåêöèîííîãî                                                         

                              │ðàñòâîðà 0.6, 1.2 ã;                                                                

                              │ñèðîï-ñóñïåíçèÿ 156.25 ìã|5 ìë,                                                     

                              │312.5 ìã|5 ìë                                                                       

                                                                                                                  

│Àóãìåíòèí                     │òàáëåòêè 375 ìã                    │German Remedies Ltd (Èíäèÿ)   │002706             

                                                                                                                  

│Àóãìåíòèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │German Remedies Ltd (Èíäèÿ)   │002880             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │1.2 ã                                                                               

                                                                                                                  

│Àóãìåíòèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ ñèðîïà   │Smithkline Beecham            │002689              

                              │312.5 ìã|5 ìë                      │Pharmaceuticals                                  

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Àóðîðèêñ                      │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Hoffmann La Roche (Øâåéöàðèÿ) │002718             

                              │îáîëî÷êîé 100, 150 ìã                                                               

                                                                                                                  

│Àóñàá                                                            │Abbott Laboratories (Ãåðìàíèÿ)│00707              

│Àóñçèìå                                                          │Abbott Laboratories (Ãåðìàíèÿ)│00711              

│Àóñðèà 11-125                                                    │Abbott Laboratories (Ãåðìàíèÿ)│00708              

│Àóñöåëü                                                          │Abbott Laboratories (Ãåðìàíèÿ)│00706              

                                                                                                                  

│ÀÕÄ 2000                      │ðàñòâîð                            │Lysoform Desifection          │003178             

                                                                 │(Øâåéöàðèÿ)                                      

                                                                                                                  

│Àöåñàë                        │òàáëåòêè 500 ìã                    │Oranienburger Pharmawerk Gmbh │002633             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Àöåòàìèíîôåí                  │òàáëåòêè 500 ìã                    │Private Formulation Inc (ÑØÀ) │003251             

│Àöåòàìèíîôåí                  │òàáëåòêè 325, 500 ìã               │Watson Laboratories Inc (ÑØÀ) │002626              

│Àöåòèëèí                      │òàáëåòêè 500 ìã                    │Bristol-Myers Squibb (ÑØÀ)    │002049             

│Àöåòèëñàëèöèëáåíå             │òàáëåòêè 100, 300, 500 ìã          │Ludwig Merckle Gmbh (Àâñòðèÿ) │002988             

│Àöåòèëñàëèöèëáåíå+Ñ           │òàáëåòêè øèïó÷èå 600 ìã/200 ìã     │Ludwig Merckle Gmbh (Àâñòðèÿ) │003324             

                                                                                                                  

│Àöåòèëöèñòåèí                 │òàáëåòêè 100 ìã; ðàñòâîð äëÿ       │Berlin-Chemie Ag (ÔÐÃ)        │003067             

                              │èíãàëÿöèé (àìïóëû) 400 ìã - 2 ìë                                                    

                                                                                                                 

│Àýðîäåçèí 2000                │æèäêîñòü                           │Lysoform Dr.Hans Rosemann     │003867             

                                                                 │Gmbh (Ãåðìàíèÿ)                                  

                                                                                                                  

│Áàêëîôåí                      │òàáëåòêè 10, 25 ìã                 │Polfa, Starogardzkie          │2665               

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Áàêòåêîä                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 400    │Biogalenique (Ôðàíöèÿ)        │003208             

                              │ìã/80 ìã, 800 ìã/160 ìã; ñóñïåíçèÿ │                                                 

                              │îðàëüíàÿ 200 ìã/40 ìã|5 ìë                                                          

                                                                                                                   

│Áàêòðèì                       │òàáëåòêè ôîðòå                     │Hoffmann La Roche (Øâåéöàðèÿ) │01908              

                                                                                                                   

│Áàêòðîáàí                     │ìàçü                               │Beecham Pharmaceuticals       │01963              

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Áàíàìèíò                      │ïàñòà çóáíàÿ                       │Pollena-Uroda (Ïîëüøà)        │2981               

│Áàíàí ñ àíàíàñîì 02642                                           │Gerber (ÑØÀ)                  │004177             

│Áàíàíîâûé éîãóðò                                                 │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004308             

                                                                                                                  

│Áàíàíû è ïåðñèêè ñ ÿáëîêàìè                                      │Hipp (Àâñòðèÿ)                │004030             

│àðò.269                                                                                                           

                                                                                                                  

│Áàðàêè                        │áðèêåòû ïàðàôèíîâûå                │Roussel Uclaf (Ôðàíöèÿ)       │0003-8             

                                                                                                                  

│Áàðáàñîë                      │êðåì äëÿ áðèòüÿ ñ àëîý; êðåì äëÿ   │Pfizer International Inc (ÑØÀ)│004329             

                              │áðèòüÿ îðèãèíàëüíûé; êðåì äëÿ                                                       

                              │áðèòüÿ ñ ìåíòîëîì; êðåì äëÿ áðèòüÿ │                                                 

                              │ñ ëàíîëèíîì                                                                         

                                                                                                                   

│Áàðêëèä@                      │òàáëåòêè äåëèìûå 0.15 ìã           │Laboratoires Biogalenique     │002405             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Áàðüåð-Ý.1 (â äâóõ            │ïðèìàíêà çåðíîâàÿ                  │Ðîññèÿ                        │0004-36            

│ìîäèôèêàöèÿõ: Áàðüåð-Ý.1ê è                                                                                       

│Áàðüåð-Ý.1ó)                                                                                                      

                                                                                                                  

│Áàðüåð-Ý.2 2 0                │ïðèìàíêà çåðíîâàÿ                  │Ðîññèÿ                        │0008-8             

                                                                                                                  

│Áàðüåð-Ý.3 (â äâóõ            │ïðèìàíêà çåðíîâàÿ                  │Ðîññèÿ                        │0008-9             

│ìîäèôèêàöèÿõ: Áàðüåð-Ý.3ê è                                                                                       

│Áàðüåð-Ý.3ó)                                                                                                      

                                                                                                                  

│Áàòðàôåí                      │êðåì; ïóäðà; ðàñòâîð               │Hoechst Ag (ÔÐÃ)              │01349              

                                                                                                                  

│Áàòðàôåí                      │ëàê äëÿ íîãòåé 8%                  │Kassela Ridel Pharma          │005618             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Áàóáàñ                        │êàðàíäàøè                          │Ðîññèÿ                        │0004-10             

│Áåáà 1                        │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Nestle (Øâåéöàðèÿ)            │01661              

│Áåáà 2                        │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Nestle (Øâåéöàðèÿ)            │01662              

│Áåáåëàê 1                     │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Lijemf (Íèäåðëàíäû)           │01745              

│Áåáåëàê 2                     │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Lijemf (Íèäåðëàíäû)           │01747              

│Áåáåëàê Z-15                  │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Lijemf (Íèäåðëàíäû)           │01875              

│Áåáåëàê êðèì âàíèëà           │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Lijemf (Íèäåðëàíäû)           │01938              

│Áåáåëàê-ÔË                    │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Lijemf (Íèäåðëàíäû)           │01748              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01588              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01582              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01586              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01584              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01583              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01580              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01587              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01589              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01585              

│Áåáèìèêñ                                                         │Pliva (ÑÔÐÞ)                  │01581              

│Áåáèìèë 1                                                        │Pliva (ÑÔÐÞ)                  │01697              

│Áåáèìèë 2                                                        │Pliva (ÑÔÐÞ)                  │01698               

│Áåáèïàïà-áàíàí                                                   │Pliva (ÑÔÐÞ)                  │01743              

│Áåáèïàïà-êàðàìåëü                                                │Pliva (ÑÔÐÞ)                  │01590              

│Áåáèïàïà-ëåñíîé îðåõ                                             │Pliva (ÑÔÐÞ)                  │01593              

│Áåáèïàïà-ëåñíûå ÿãîäû                                            │Pliva (ÑÔÐÞ)                  │01744              

│Áåáèïàïà-ìåä                                                     │Pliva (ÑÔÐÞ)                  │01591              

│Áåáèïàïà-øîêîëàä                                                 │Pliva (ÑÔÐÞ)                  │01592              

                                                                                                                  

│Áåçàëèï                       │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Boehringer Mannheim Gmbh      │002220             

                              │îáîëî÷êîé 200 ìã                   │(Àâñòðèÿ)                                        

                                                                                                                  

│Áåêëàçîí                      │àýðîçîëü 50, 100, 250 ìêã/äîçà     │Norton Healthcare Ltd         │003574             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Áåêëàçîí ëåãêîå äûõàíèå       │àýðîçîëü (èíãàëÿòîð ñ              │Norton Healthcare             │009747             

                              │îïòèìèçàòîðîì) 50, 100, 250        │(Âåëèêîáðèòàíèÿ)                                 

                              │ìêã/äîçà - 200 äîç; àýðîçîëü                                                        

                              │(áàëëîí÷èêè) 50, 100, 250 ìêã/äîçà │                                                  

                              │- 200 äîç                                                                           

                                                                                                                  

│Áåêëàò                        │àýðîçîëü                           │Cipla Ltd (Èíäèÿ)             │002396             

                                                                                                                  

│Áåêëîìåò                      │àýðîçîëü äëÿ èíãàëÿöèé 250 ìêã|äîçà│Orion Pharmaceutica           │002244             

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Áåêëîìåò                      │àýðîçîëü äëÿ èíãàëÿöèé 50 ìêã/äîçà │Orion Pharmaceutica           │00792              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Áåêîòèä                       │àýðîçîëü äëÿ èíãàëÿöèé             │Glaxo (Âåëèêîáðèòàíèÿ)        │00591              

│Áåëàìèí                       │ïîðîøîê                            │Ðîññèÿ                        │0001-1             

                                                                                                                  

│Áåëêîâî-âèòàìèííî-ìèíåðàëüíûé │                                   │Protein Technologies          │004117             

│îáîãàòèòåëü (ÁÂÌ)                                                │International (ÑØÀ)                              

                                                                                                                  

│Áåëêîâî-âèòàìèííî-ìèíåðàëüíûé │                                   │Riliges Corporation Zikoukay  │004100             

│îáîãàòèòåëü Ìîìîòàðî Å-25                                        │(ßïîíèÿ)                                         

                                                                                                                   

│Áåëëîèä                       │äðàæå                              │Gedeon Richter (Âåíãðèÿ)      │2019               

│Áåëóñòèí                      │êàïñóëû 40 ìã                      │Roger Bellon (Ôðàíöèÿ)        │002458             

│Áåíàëüãèí                     │òàáëåòêè                           │Pharmachim (ÍÐÁ)              │2560               

│Áåí-Ãåé                       │êðåì; ãåëü; ìàçü                   │Pfizer Overseas Inc (ÑØÀ)     │002861             

│Áåíåìèöèí                     │êàïñóëû 150 ìã                     │Polfa (Ïîëüøà)                │2317               

│Áåíçîöèä (Áåíçèë áåíçîàò)     │ðàñòâîð ýìóëüñèîííûé 12.5%, 25%    │Trima (Èçðàèëü)               │002632             

                                                                                                                  

│Áåíèêîë                       │ñèðîï (ôëàêîíû) 100 ìë             │Roche Mustahzarlari Sanayi As │002625             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Áåïàíòåí                      │ìàçü 5%; êðåì 5%; êðåì ïëþñ 5%;    │Hoffmann La Roche (Øâåéöàðèÿ) │002811             

                              │ëîñüîí 2.5%; àýðîçîëü íàçàëüíûé 5% │                                                 

                                                                                                                  

│Áåïðèêîð                      │òàáëåòêè 100, 200, 300 ìã          │Organon (Íèäåðëàíäû)          │002546             

                                                                                                                  

│Áåðèïëàñò ÕÑ                  │âåùåñòâî ñóõîå äëÿ ïðèãîòîâëåíèÿ   │Behringwerke Ag (ÔÐÃ)         │002681             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                     

                              │0.5, 1, 3 ìë /â êîìïëåêòå ñ                                                         

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Áåðëèäîðì 10@                 │òàáëåòêè 10 ìã                     │Berlin-Chemie Ag (ÔÐÃ)        │003225             

│Áåðëîôåí                      │ïîðîøîê                            │Berlin-Chemie Feb (ÃÄÐ)       │00152              

                                                                                                                  

│Áåðëîöèä                      │ñóñïåíçèÿ îðàëüíàÿ (ôëàêîíû) 200   │Berlin-Chemie Ag (ÔÐÃ)        │002727             

                              │ìã/40 ìã|5 ìë - 100 ìë; ãðàíóëÿò                                                    

                              │äëÿ ïðèãîòîâëåíèÿ îðàëüíîé                                                          

                              │ñóñïåíçèè (ôëàêîíû) 200 ìã/40 ìã|5 │                                                 

                              │ìë - 100 ìë                                                                         

                                                                                                                  

│Áåðîêêà                       │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Hoffmann La Roche (Øâåéöàðèÿ) │002715             

                              │îáîëî÷êîé                                                                           

                                                                                                                  

│Áåðîêêà Ñà+Ìg                 │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Hoffmann La Roche (Øâåéöàðèÿ) │002716             

                              │îáîëî÷êîé; òàáëåòêè ðàñòâîðèìûå                                                     

                                                                                                                  

│Áåðîòåê                       │àýðîçîëü äëÿ èíãàëÿöèé äîçèðîâàííûé│Polfa (Ïîëüøà)                │2703                

                                                                                                                  

│Áåòàäèí                       │ðàñòâîð 10%; ìàçü; ñâå÷è           │Egis (Âåíãðèÿ)                │002336             

                              │âàãèíàëüíûå                                                                         

                                                                                                                  

│Áåòà-Êàðîòèí 1%                                                  │Hoffmann La Roche (Øâåéöàðèÿ) │004043             

                                                                                                                  

│Áåòà-Êàðîòèí 10% ðàñòâîðèìûé                                     │Hoffmann La Roche (Øâåéöàðèÿ) │004045             

│ñóõîé                                                                                                             

                                                                                                                  

│Áåòà-Êàðîòèí 30%              │ñóñïåíçèÿ                          │Hoffmann La Roche (Øâåéöàðèÿ) │004044             

│Áåòà-Êàðîòèí 5%               │ýìóëüñèÿ                           │Hoffmann La Roche (Øâåéöàðèÿ) │004042             

│Áåòàêàðä                      │òàáëåòêè 50, 100 ìã                │Torrent Exports Ltd (Èíäèÿ)   │002116             

│Áåòàêýï ÒР                   │êàïñóëû 40, 80, 120 ìã             │Natco Pharma Ltd (Èíäèÿ)      │003089             

                                                                                                                  

│Áåòàìàê Ò100                  │òàáëåòêè ïîêðûòûå îáîëî÷êîé 100 ìã │Sawai Pharmaceutical Co Ltd   │002954             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                   

│Áåòàìàê Ò200                  │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200 ìã │Sawai Pharmaceutical Co Ltd   │002954             

                                                                 │(ßïîíèÿ)                                          

                                                                                                                  

│Áåòàìàê Ò50                   │òàáëåòêè ïîêðûòûå îáîëî÷êîé 50 ìã  │Sawai Pharmaceutical Co Ltd   │002954             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Áåòàìåòàçîí âàëåðèàò          │êðåì 0.1%                          │M.J.Pharmaceuticals Ltd       │003138             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Áåòà-Ìèêîòåð                  │êðåì 1%                            │Laboratorious Cusi (Èñïàíèÿ)  │003160             

                                                                                                                  

│Áåòàíàç                       │òàáëåòêè 5 ìã                      │Cadila Laboratories Ltd       │002097             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Áåòàðåí                       │òàáëåòêè 25, 50 ìã; òàáëåòêè       │Dexon Ltd (Èçðàèëü)           │003265             

                              │ðåòàðä 100 ìã                                                                       

                                                                                                                  

│Áåòàñåðê                      │òàáëåòêè 8 ìã                      │Duphar B.V. (Ãîëëàíäèÿ)       │01006              

│Áåòîïòèê                      │êàïëè ãëàçíûå                      │Alcon (ÑØÀ)                   │002189              

│Áå-òîòàë                      │ñèðîï (ôëàêîíû) 100 ìë             │Farmitalia Carlo Erba (Èòàëèÿ)│003438             

│Áèëè-ëàáñòèêñ                 │ïîëîñêè                            │Aims-Labstix (Âåëèêîáðèòàíèÿ) │00576              

│Áèëè-ëàáñòèêñ                 │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2559               

│Áèëèôàí                       │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2774               

                                                                                                                  

│Áèìàðàë                       │êàïëè äëÿ äåòåé (ôëàêîíû) 20 ìë;   │Alkaloid (Ìàêåäîíèÿ)          │003016             

                              │ñâå÷è äëÿ äåòåé 10 ìã                                                               

                                                                                                                  

│Áèíàêà                        │ïàñòà çóáíàÿ                       │Reckitt&colman (Èíäèÿ)        │01533              

│Áèîâèòàëü                     │äðàæå                              │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│003562             

│Áèîâèòàëü âèòàìèí Å           │êàïñóëû                            │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│003394             

│Áèîâèòàëü âèòàìèí Ñ 500       │òàáëåòêè æåâàòåëüíûå               │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│003393             

                                                                                                                 

│Áèîâèòàëü ãåëü äëÿ äåòåé      │ãåëü îðàëüíûé (òóáû)               │Rhone-Poulenc Rorer           │005175             

                                                                 │(Øâåéöàðèÿ)                                      

                                                                                                                  

│Áèîâèòàëü æèäêèé              │ðàñòâîð îðàëüíûé (ôëàêîíû)         │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│005117             

                                                                                                                  

│Áèîãóëèí Ëåíòå Ó40            │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Biobras S/a (Áðàçèëèÿ)        │002969              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Áèîãóëèí Ðåãóëÿð Ó40          │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Biobras S/a (Áðàçèëèÿ)        │002970             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Áèî-Ëà-Òåñò ÀëÀÒ-ÓÔ ìèêðî                                        │Lachema (×åõîñëîâàêèÿ)        │2898               

│Áèî-Ëà-Òåñò àëüáèë                                               │Lachema (×åõîñëîâàêèÿ)        │2676               

│Áèî-Ëà-Òåñò àëüáóìèí                                             │Lachema (×åõîñëîâàêèÿ)        │2842               

│Áèî-Ëà-Òåñò àëüáóìèí ìèêðî                                       │Lachema (×ÑÑÐ)                │2934               

│Áèî-Ëà-Òåñò àëüôà-àìèëàçà                                        │Lachema (×åõîñëîâàêèÿ)        │2768               

                                                                                                                  

│Áèî-Ëà-Òåñò àìèíîòðàíñôåðàçû                                     │Lachema (×åõîñëîâàêèÿ)        │2555               

│(ÀëÀÒ)                                                                                                            

                                                                                                                  

│Áèî-Ëà-Òåñò àìèíîòðàíñôåðàçû                                     │Lachema (×åõîñëîâàêèÿ)        │2556               

│(ÀñÀÒ è ÀëÀÒ)                                                                                                     

                                                                                                                   

│Áèî-Ëà-Òåñò àìèíîòðàíñôåðàçû                                     │Lachema (×åõîñëîâàêèÿ)        │2557               

│(ÀñÀÒ)                                                                                                             

                                                                                                                  

│Áèî-Ëà-Òåñò ÀñÀÒ-ÓÔ ìèêðî                                        │Lachema (×åõîñëîâàêèÿ)        │2899               

│Áèî-Ëà-Òåñò áåòà-ëèïîïðîòåèíû │                                   │Lachema (×åõîñëîâàêèÿ)        │2840               

│Áèî-Ëà-Òåñò áèëèðóáèí                                            │Lachema (×åõîñëîâàêèÿ)        │2554               

│Áèî-Ëà-Òåñò áèëèðóáèí ýòàëîí  │íàáîð ðåàêòèâîâ                    │Lachema (×ÑÑÐ)                │2474               

                                                                                                                  

│Áèî-Ëà-Òåñò                   │íàáîð ðåàêòèâîâ                    │Lachema (×ÑÑÐ)                │2478               

│ãàììà-ãëóòàìèëòðàíñôåðàçà                                                                                         

                                                                                                                  

│Áèî-Ëà-Òåñò ãëþêîçà                                              │Lachema (×åõîñëîâàêèÿ)        │2630               

│Áèî-Ëà-Òåñò ãëþêîçà Á                                            │Lachema (×åõîñëîâàêèÿ)        │2841               

│Áèî-Ëà-Òåñò æåëåçî                                               │Lachema (×åõîñëîâàêèÿ)        │2482               

│Áèî-Ëà-Òåñò æåëåçî ÏÑÒ                                           │Lachema (×åõîñëîâàêèÿ)        │2844               

│Áèî-Ëà-Òåñò êàëüöèé                                              │Lachema (×åõîñëîâàêèÿ)        │2471               

│Áèî-Ëà-Òåñò êàëüöèé ÊÕ                                           │Lachema (×ÑÑÐ)                │2933               

│Áèî-Ëà-Òåñò êèñëàÿ ôîñôàòàçà                                     │Lachema (×åõîñëîâàêèÿ)        │2678               

│Áèî-Ëà-Òåñò êîìïëåêñîíàò êàëèÿ│                                   │Lachema (×åõîñëîâàêèÿ)        │2679                

                                                                                                                  

│Áèî-Ëà-Òåñò êîíòðîëüíàÿ                                          │Lachema (×ÑÑÐ)                │2641               

│ñûâîðîòêà êðîâè Ðó                                                                                                

                                                                                                                  

│Áèî-Ëà-Òåñò êðåàòèíèí                                            │Lachema (×ÑÑÐ)                │2484               

                                                                                                                  

│Áèî-Ëà-Òåñò êðåàòèíèí Êèí                                        │Lachema (×åõîñëîâàêèÿ)        │2855               

│ñòàòèìòåñò                                                                                                        

                                                                                                                  

│Áèî-Ëà-Òåñò êðåàòèíèí ýòàëîí                                     │Lachema (×ÑÑÐ)                │2483               

│Áèî-Ëà-Òåñò êðåàòèíêèíàçà                                        │Lachema (×åõîñëîâàêèÿ)        │2769               

│Áèî-Ëà-Òåñò ìàãíèé ìèêðî                                         │Lachema (×ÑÑÐ)                │2936               

│Áèî-Ëà-Òåñò ìåäü                                                 │Lachema (×ÑÔÐ)                │2643               

                                                                                                                  

│Áèî-Ëà-Òåñò ìî÷åâàÿ êèñëîòà                                      │Lachema (×åõîñëîâàêèÿ)        │2900               

│ôåðìåíòàòèâíî                                                                                                     

                                                                                                                  

│Áèî-Ëà-Òåñò ìî÷åâèíà 150 è 450│                                   │Lachema (×åõîñëîâàêèÿ)        │2476               

│Áèî-Ëà-Òåñò ìî÷åâèíà Ô                                           │Lachema (×åõîñëîâàêèÿ)        │2772                

                                                                                                                  

│Áèî-Ëà-Òåñò ìî÷åâèíà                                             │Lachema (×ÑÑÐ)                │2937               

│ôåðìåíòàòèâíî ìèêðî                                                                                               

                                                                                                                  

│Áèî-Ëà-Òåñò îáùàÿ ñâÿçûâàþùàÿ │                                   │Lachema (×ÑÔÐ)                │2480               

│ñïîñîáíîñòü                                                                                                       

                                                                                                                 

│Áèî-Ëà-Òåñò îáùèå ëèïèäû                                         │Lachema (×ÑÔÐ)                │2639               

│Áèî-Ëà-Òåñò îáùèé áåëîê                                          │Lachema (×ÑÔÐ)                │2642               

│Áèî-Ëà-Òåñò îáùèé áåëîê ìèêðî │                                   │Lachema (×ÑÑÐ)                │2935               

│Áèî-Ëà-Òåñò îêñîõðîì ãëþêîçà                                     │Lachema (×åõîñëîâàêèÿ)        │2839               

│Áèî-Ëà-Òåñò ñåäèìåíò ìî÷è                                        │Lachema (×ÑÔÐ)                │2640               

│Áèî-Ëà-Òåñò ñîëþíîðì ãëþêîçà                                     │Lachema (×åõîñëîâàêèÿ)        │2835               

                                                                                                                  

│Áèî-Ëà-Òåñò ñîëþíîðì                                             │Lachema (×åõîñëîâàêèÿ)        │2836               

│ãëþêîçà-ìî÷åâèíà                                                                                                  

                                                                                                                   

│Áèî-Ëà-Òåñò ñîëþíîðì                                             │Lachema (×åõîñëîâàêèÿ)        │2833               

│êàëüöèé-ìàãíèé                                                                                                     

                                                                                                                  

│Áèî-Ëà-Òåñò ñîëþíîðì ìî÷åâèíà │                                   │Lachema (×åõîñëîâàêèÿ)        │2837               

                                                                                                                  

│Áèî-Ëà-Òåñò ñîëþíîðì                                             │Lachema (×åõîñëîâàêèÿ)        │2832               

│íàòðèé-êàëèé                                                                                                      

                                                                                                                  

│Áèî-Ëà-Òåñò ñîëþíîðì                                             │Lachema (×åõîñëîâàêèÿ)        │2834               

│îñìîëÿðíîñòü                                                                                                      

                                                                                                                  

│Áèî-Ëà-Òåñò ñîëþíîðì ôîñôîð                                      │Lachema (×åõîñëîâàêèÿ)        │2831               

│Áèî-Ëà-Òåñò ñîëþíîðì õëîðèäû                                     │Lachema (×åõîñëîâàêèÿ)        │2838               

                                                                                                                  

│Áèî-Ëà-Òåñò òèìîëîâàÿ ïðîáà                                      │Lachema (×ÑÔÐ)                │2475               

│150, 300, 3000                                                                                                    

                                                                                                                  

│Áèî-Ëà-Òåñò òðèãëèöåðèäû                                         │Lachema (×åõîñëîâàêèÿ)        │2677               

│Áèî-Ëà-Òåñò óðàñîë                                               │Lachema (×åõîñëîâàêèÿ)        │2843                

│Áèî-Ëà-Òåñò Ôîñôîð            │íàáîð ðåàêòèâîâ                    │Lachema (×ÑÔÐ)                │2481               

                                                                                                                  

│Áèî-Ëà-Òåñò õëîðèäû                                              │Lachema (×ÑÔÐ)                │2477               

│òèòðîìåòðè÷åñêè                                                                                                   

                                                                                                                  

│Áèî-Ëà-Òåñò õëîðèäû                                              │Lachema (×ÑÔÐ)                │2479               

│ôîòîìåòðè÷åñêè                                                                                                    

                                                                                                                  

│Áèî-Ëà-Òåñò õîëåñòåðèí                                           │Lachema (×åõîñëîâàêèÿ)        │2793               

│Áèî-Ëà-Òåñò õîëèíýñòåðàçà                                        │Lachema (×åõîñëîâàêèÿ)        │2846               

                                                                                                                  

│Áèî-Ëà-Òåñò öèíêñóëüôàòíàÿ                                       │Lachema (×åõîñëîâàêèÿ)        │2553               

│ïðîáà                                                                                                             

                                                                                                                  

│Áèî-Ëà-Òåñò ùåëî÷íàÿ                                             │Lachema (×ÑÑÐ)                │2938               

│ôîñôàòàçà ìèêðî                                                                                                   

                                                                                                                  

│Áèî-Ëà-Òåñò Ýíòåðî-òåñò I     │ïëàñòèíû                           │Lachema (×åõîñëîâàêèÿ)        │2847               

│Áèî-Ëà-Òåñò Ýíòåðî-òåñò II    │ïëàñòèíû                           │Lachema (×åõîñëîâàêèÿ)        │2848                

│Áèîëîò-1                      │ïîðîøîê                            │Ðîññèÿ                        │0009-1             

│Áèñàêîäèë                     │äðàæå                              │Polfa (Ïîëüøà)                │2396               

│Áèñàêîäèë                     │ñâå÷è                              │Polfa (Ïîëüøà)                │2420               

                                                                                                                  

│Áèñåïòîë                      │òàáëåòêè 120, 480 ìã               │Polfa, Przedsiebiorstwo       │007302             

                                                                 │Farmaceutyczne W Rzeszowie Sa │                   

                                                                 │(Ïîëüøà)                                         

                                                                                                                  

│Áèñåïòîë 480                  │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5 ìë │Polfa (Ïîëüøà)                │2878               

│Áëåä-à-ìåä                    │ïàñòà çóáíàÿ                       │Blendax (ÔÐÃ)                 │01554              

│Áëåíäàêñ óíèâåðñàë            │ïàñòà çóáíàÿ                       │Procter & Gamble (Èíäèÿ)      │01766              

│Áëåíäàêñ óíèâåðñàë 2          │ïàñòà çóáíàÿ                       │Procter & Gamble (ÔÐÃ)        │004206             

                                                                                                                  

│Áëåíäàêñ óíèâåðñàë ñ          │ïàñòà çóáíàÿ                       │Easten Industrial Investment  │01497              

│ðåìîäåíòîì                                                       │Co (Åãèïåò)                                      

                                                                                                                  

│Áëåíäàêñ óíèâåðñàë ñ          │ïàñòà çóáíàÿ                       │Procter & Gamble (Èíäèÿ)      │01974              

│ðåìîäåíòîì                                                                                                        

                                                                                                                   

│Áëåíäàêñ-áëåíäè               │ïàñòà çóáíàÿ                       │Procter & Gamble (ÔÐÃ)        │004340             

│Áëåíäàêñ-þíèîð                │ïàñòà çóáíàÿ                       │Procter & Gamble (ÔÐÃ)        │004339             

│Áëåíä-à-ìåä ìåíò              │ïàñòà çóáíàÿ                       │Procter & Gamble (Èíäèÿ)      │01729              

│Áëåíä-À-Ôèëë                  │ìàòåðèàë ïëîìáèðîâî÷íûé            │Blendax (ÔÐÃ)                 │01761              

                                                                                                                  

│Áëåñèí                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 25 ìã  │Sawai Pharmaceutical Co Ltd   │002956             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Áëåñê                         │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2854               

│Áëåôàìèä                      │êàïëè ãëàçíûå                      │Pharm-Allergan Gmbh (Ãåðìàíèÿ)│002392             

│ÁËÏ                           │ïîðîøîê                            │Ðîññèÿ                        │0001-Á 2           

│Áëþ ñêàé òðàíñïàðåíò áè-ôëþîð │ïàñòà çóáíàÿ                       │Teijin Ltd (ÊÍÐ)              │01635              

│Áîíà-ñîÿ                      │ñìåñü ñóõàÿ                        │Kumos (Ôèíëÿíäèÿ)             │004361             

                                                                                                                  

│Áîíöåôèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Alkaloid (Þãîñëàâèÿ)          │01147              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã, 2 ã                                                                               

                                                                                                                  

│Áðèåòàë                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Eli Lilly & Elanco (ÑØÀ)      │003127             

                             │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │500 ìã                                                                              

                                                                                                                  

│Áðèêàíèë                      │òàáëåòêè 2.5 ìã                    │Eczacibasi (Òóðöèÿ)           │002573             

│Áðèëëåäåíò                    │ïàñòà çóáíàÿ                       │Tako (Ñàð)                    │01634              

│Áðîìãåêñèí                    │òàáëåòêè 8 ìã; äðàæå 12 ìã         │Fahlberg-List Gmbh (ÔÐÃ)      │002423             

│Áðîìãåêñèí                    │òàáëåòêè 8 ìã                      │Nycomed Dak As (Äàíèÿ)        │003041             

│Áðîìãåêñèí                    │òàáëåòêè 16 ìã                     │Salutas Fahlberg-List (ÔÐÃ)   │002701             

│Áðîìãåêñèí 8                  │êàïëè 20 ìë                        │Meuselbach Pharma Gmbh (ÔÐÃ)  │002250             

│Áðîìãåêñèí 8 Áåðëèí-Õåìè      │äðàæå 8 ìã                         │Berlin-Chemie Ag (ÔÐÃ)        │002728             

│Áðîìýðãîí                     │òàáëåòêè 2.5, 10 ìã                │Lek (Ñëîâåíèÿ)                │002366             

│Áðîíèòåí                      │òàáëåòêè 1 ìã                      │Menon Pharma (Èíäèÿ)          │002662             

│Áðîíõèêóì                     │÷àé ðàñòèòåëüíûé                   │Nattermann Gmbh (ÔÐÃ)         │002351             

                                                                                                                  

│Áðîíõîêîä                     │ñèðîï äëÿ âçðîñëûõ (ôëàêîíû) 5     │Biogalenique (Ôðàíöèÿ)        │003402             

                              │ã|100 ìë - 125, 300 ìë; ñèðîï äëÿ                                                   

                              │äåòåé (ôëàêîíû) 2 ã|100 ìë - 125                                                     

                              │ìë; ðàñòâîð äëÿ âçðîñëûõ áåç                                                        

                              │ñàõàðà (ôëàêîíû) 5 ã|100 ìë - 125, │                                                 

                              │300 ìë; ðàñòâîð äëÿ äåòåé áåç                                                       

                              │ñàõàðà (ôëàêîíû) 2 ã|100 ìë - 125                                                   

                              │ìë                                                                                  

                                                                                                                  

│Áðîíõîëèòèí                   │ñèðîï                              │Bulgarska Rosa (Áîëãàðèÿ)     │002359             

│Áóðíèë                        │ðàñòâîð íàçàëüíûé 0.05%, 0.1%      │Kurtsan Ilaclary As (Òóðöèÿ)  │002894             

│Áýáè ëèî ãîâÿäèíà                                                │Lioprodotti (Èòàëèÿ)          │004227             

│Áýáè ëèî êóðèöà                                                  │Lioprodotti (Èòàëèÿ)          │004229             

│Áýáè ëèî êóðèöà+òåëÿòèíà                                         │Lioprodotti (Èòàëèÿ)          │004230             

│Áýáè ëèî òåëÿòèíà                                                │Lioprodotti (Èòàëèÿ)          │004228             

│Â-10                                                             │Durr (ÔÐÃ)                    │004337             

│Â-40                                                             │Durr (ÔÐÃ)                    │004338             

│Âàäåìåêóì ôëåð ýò ïëàíòñ      │ïàñòà çóáíàÿ                       │Sober Handelce (Øâåöèÿ)       │01701              

│Âàäåìåêóì-2                   │ïàñòà çóáíàÿ                       │Sober Handelce (Øâåöèÿ)       │01702              

│Âàçöèí                        │ïàñòà                              │Ðîññèÿ                        │0004-37            

                                                                                                                  

│Âàéãîñåïò (ìîäèôèêàöèè)                                          │Dr.Waygert Chemishe Fabric    │004343             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Âàéò äåíò ôëóîð               │ïàñòà çóáíàÿ                       │Eka/Sinikos (Ôèíëÿíäèÿ)       │01346              

                                                                                                                  

│Âàêñèãðèïï                    │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 10, │Pasteur Merieux Serums Et     │00471              

                              │25, 50 äîç; ðàñòâîð äëÿ èíúåêöèé   │Vaccins (Ôðàíöèÿ)                                

                              │(øïðèöû) 1 äîçà                                                                     

                                                                                                                  

│Âàêöèíà àíòèðàáè÷åñêàÿ        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Institute Merieux (Ôðàíöèÿ)   │00470              

                              │èíúåêöèîííîãî ðàñòâîðà                                                              

                                                                                                                  

│Âàêöèíà ìåíèíãîêîêêîâàÿ À     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pasteur Merieux Serums Et     │00468              

                              │èíúåêöèîííîãî ðàñòâîðà             │Vaccins (Ôðàíöèÿ)                                

                                                                                                                  

│Âàêöèíà ìåíèíãîêîêêîâàÿ À+Ñ   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Institute Merieux (Ôðàíöèÿ)   │00469              

                              │èíúåêöèîííîãî ðàñòâîðà                                                              

                                                                                                                   

│Âàëèòåí                       │ëîñüîí                             │Lavifarm (Ãðåöèÿ)             │0009-7             

│Âàìèí 14                      │ðàñòâîð äëÿ èíôóçèé                │Kabi Pharmacia (Øâåöèÿ)       │002262             

│Âàìèí 14 áåç ýëåêòðîëèòîâ     │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Kabi Pharmacia (Øâåöèÿ)       │002263             

│Âàìèí 18 áåç ýëåêòðîëèòîâ     │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Kabi Pharmacia (Øâåöèÿ)       │002288             

│Âàìèí 9 áåç ýëåêòðîëèòîâ      │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Kabi Pharmacia (Øâåöèÿ)       │002261             

│Âàìèí Í                       │ðàñòâîð äëÿ èíôóçèé                │Kabi Pharmacia (Øâåöèÿ)       │00680              

│Âàìèíîëàêò                    │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Kabi Pharmacia (Øâåöèÿ)       │002270             

                                                                                                                  

│Âàíêîöèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Eli Lilly & Elanco (ÑØÀ)      │002060             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Âåäæåáóðãåð                   │ñìåñü ñóõàÿ                        │Adm (ÑØÀ)                     │01930              

                                                                                                                  

│Âåëáå                         │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Eli Lilly & Elanco (ÑØÀ)      │002763             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │10 ìã                                                                                

                                                                                                                  

│Âåíòåð                        │ãðàíóëû                            │Krka (ÑÔÐÞ)                   │002214              

                                                                                                                  

│Âåíòîäèñê                     │ïîðîøîê (êàïñóëû - â êîìïëåêòå ñ   │Glaxo (Âåëèêîáðèòàíèÿ)        │002876             

                              │äèñêõàëåðîì) 200, 400 ìêã                                                           

                                                                                                                  

│Âåíòîëèí                      │òàáëåòêè 2 ìã; àýðîçîëü (èíãàëÿòîð │Glaxo (Âåëèêîáðèòàíèÿ)        │00238              

                              │äîçèðîâàííûé) 100 ìêã/äîçà - 200                                                    

                              │äîç                                                                                 

                                                                                                                  

│Âåíòðèñîë                     │ðàñòâîð                            │Polfa (Ïîëüøà)                │002741             

                                                                                                                  

│Âåïàìèë                       │äðàæå ðåòàðä 120 ìã; ðàñòâîð äëÿ   │Sbrolek (ÑÔÐÞ)                │002308             

                              │èíúåêöèé (àìïóëû) 5 ìã - 2 ìë                                                       

                                                                                                                  

│Âåïåçèä                       │êàïñóëû 50, 100 ìã; ðàñòâîð äëÿ    │Bristol-Myers Squibb          │003312             

                              │èíúåêöèé (àìïóëû) 100 ìã - 5 ìë    │(Èíäîíåçèÿ)                                      

                                                                                                                  

│Âåïåçèä                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 20   │Bristol-Myers Squibb (ÑØÀ)    │01865               

                              │ìã/ìë - 5 ìë                                                                        

                                                                                                                  

│Âåïèêîìáèí                    │òàáëåòêè 300000, 500000, 1000000   │Nycomed Dak As (Äàíèÿ)        │003363             

                              │ÌÅ; êàïëè 500000 ÌÅ/ìë; ñóñïåíçèÿ                                                   

                              │îðàëüíàÿ (ôëàêîíû) 30000 ÌÅ/ìë                                                      

                                                                                                                  

│Âåðàìèë                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 40, 80 │Themis Chemicals Ltd (Èíäèÿ)  │002130             

                              │ìã                                                                                  

                                                                                                                  

│Âåðàïàìèëà ãèäðîõëîðèä        │òàáëåòêè 80, 120 ìã                │Searle (ÑØÀ)                  │003426             

                                                                                                                  

│Âåðòèçèí                      │òàáëåòêè 25 ìã; òàáëåòêè ôîðòå 75  │Torrent Exports Ltd (Èíäèÿ)   │002230             

                              │ìã                                                                                 

                                                                                                                  

│Âåñåííèå îâîùè ñ öûïëåíêîì                                       │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004301             

│Âåòîèí                        │òàáëåòêè 200 ìã                    │Labohain-Wolf (Áåëüãèÿ)       │002647             

│Âåò÷èíà ñ îâîùàìè                                                │Nestle (Ãåðìàíèÿ)             │004224             

│Âåò÷èíà ñ îâîùàìè 00426                                          │Gerber (ÑØÀ)                  │004184             

│Âè-2                          │êàïñóëû                            │Pharco Pharmaceutical (Àðå)   │003188              

                                                                                                                  

│Âèáðàìèöèí                    │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Polfa (ÏÍÐ)                   │2543               

                              │(ôëàêîíû) 100 ìã                                                                    

                                                                                                                  

│Âèâîíåêñ                      │ïîðîøîê                            │Norwich Eaton (ÑØÀ)           │00996              

│Âèäàéëèí-Ì                    │ñèðîï                              │Galenika (ÑÔÐÞ)               │002179             

                                                                                                                  

│Âèçèí                         │ðàñòâîð îôòàëüìîëîãè÷åñêèé         │Pfizer Corporation (Áåëüãèÿ)  │002864             

                              │(ôëàêîíû) 0.05% - 15 ìë                                                             

                                                                                                                  

│Âèêñàí                        │ïàñòà çóáíàÿ                       │Continental Chemical Ltd      │004204             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Âèíêðèñòèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1    │Pierre Fabre Medicament       │002417             

                              │ìã/ìë - 1, 2, 5 ìë                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Âèíêðèñòèíà ñóëüôàò           │ðàñòâîð äëÿ èíúåêöèé (øïðèöû) 1    │David Bull Laboratories       │002709             

                              │ìã/1 ìë, 2 ìã/2 ìë                 │(Àâñòðàëèÿ)                                      

                                                                                                                   

│Âèíêðèñòèíà ñóëüôàò           │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Rhone-Poulenc Rorer (Ôðàíöèÿ) │003090             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ìã                                                                                  

                                                                                                                  

│Âèíïîöåòèí                    │òàáëåòêè 5 ìã                      │Covex Sa (Èñïàíèÿ)            │002685             

│Âèîñåïò                       │ìàçü                               │Polfa (Ïîëüøà)                │2588               

│Âèïðàòîêñ                     │ìàçü                               │Serumwerk Bernburg (ÃÄÐ)      │00483              

│Âèïñîãàë                      │ìàçü                               │Galenika (ÑÔÐÞ)               │01884              

                                                                                                                  

│Âèðàçîë                       │ëèîôèëèç.ïîðîøîê äëÿ àýðîçîëüíîãî  │ICN Galenika (ÑÔÐÞ)           │002388             

                              │ïðèìåíåíèÿ (ôëàêîíû) 6 ã                                                            

                                                                                                                  

│Âèðåãèò-Ê                     │êàïñóëû                            │Egis (Âåíãðèÿ)                │2417               

                                                                                                                  

│Âèðêîí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Naturan (Ïîëüøà)              │004205             

                              │äåçèíôèöèðóþùåãî ðàñòâîðà                                                           

                                                                                                                   

│Âèðêîí                        │ïîðîøîê                            │Naturan (Ïîëüøà)              │0001-À2            

│Âèðòîêñ                       │êàðàíäàøè                          │Ðîññèÿ                        │0004-12            

│Âèñìåòðèí                     │êîíöåíòðàò ýìóëüñèè                │Ðîññèÿ                        │0004-11            

│Âèñîé/íóðñîé                  │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Wyeth (ÑØÀ)                   │01649              

                                                                                                                  

│Âèñòàãàí ëèêâèôèëì            │ðàñòâîð îôòàëüìîëîãè÷åñêèé         │Pharm-Allergan Gmbh (ÔÐÃ)     │002543             

                              │(ôëàêîíû) 0.5% - 5 ìë                                                               

                                                                                                                  

│Âèñòîñàí                      │êàïëè ãëàçíûå                      │Pharm-Allergan Gmbh (ÔÐÃ)     │002393             

│Âèòà Èîäóðîë òðèôîñôàäåíèí    │êàïëè ãëàçíûå                      │Laboratoires H.Faure (Ôðàíöèÿ)│01107              

│Âèòàêèäñ                      │òàáëåòêè æåâàòåëüíûå äëÿ äåòåé     │Alpha Omega (ÑØÀ)             │002512             

                                                                                                                  

│Âèòàëèïèä Í âçðîñëûé è äåòñêèé│ýìóëüñèÿ äëÿ äîáàâëåíèÿ â          │Kabi Pharmacia (Øâåöèÿ)       │002271             

                              │èíôóçèîííûå ðàñòâîðû (àìïóëû) 10 ìë│                                                 

                                                                                                                  

│Âèòàìèí À è Ä                 │êàïñóëû ìÿãêèå                     │Union Pharma Co (ÑØÀ)         │003305             

│Âèòàìèí Â-1                   │êàïñóëû ìÿãêèå 100, 400 ìã         │Union Pharma Co (ÑØÀ)         │003306             

│Âèòàìèí Å                     │êàïñóëû 400, 800 ÌÅ                │Union Pharma Co (ÑØÀ)         │003308             

│Âèòàìèí Ñ                     │òàáëåòêè 500 ìã                    │Union Pharma Co (ÑØÀ)         │003307              

│Âèòàìèí Ñ                     │òàáëåòêè ðàñòâîðèìûå 1 ã           │Weimer Pharma Gmbh (ÔÐÃ)      │003206             

                                                                                                                  

│Âèòàìèííî-ìèíåðàëüíûé ïðåìèêñ │ïîðîøîê /ïèùåâàÿ äîáàâêà/          │Hoffmann La Roche (Øâåéöàðèÿ) │004151             

│10797                                                                                                             

                                                                                                                  

│Âèòàìèííî-ìèíåðàëüíûé ïðåìèêñ │ïîðîøîê /ïèùåâàÿ äîáàâêà/          │Hoffmann La Roche (Øâåéöàðèÿ) │004150             

│986                                                                                                              

                                                                                                                  

│Âèòàìèííûé ïðåìèêñ 730/4      │ïîðîøîê /ïèùåâàÿ äîáàâêà/          │Hoffmann La Roche (Øâåéöàðèÿ) │01740              

                                                                                                                  

│Âèòàôàêîë                     │êàïëè ãëàçíûå (ôëàêîíû) 10 ìë      │Ciba Vision Ophthalmics       │008206             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Âèòàôàêîë                     │êàïëè ãëàçíûå                      │Laboratoires H.Faure (Ôðàíöèÿ)│00350              

│Âèøíåâûé                      │êðåì-ìàñêà ïèòàòåëüíûé             │Helia-D (Âåíãðèÿ)             │2971               

│Âêóñíîå ôðóêòîâîå ïþðå                                           │Nestle (Ãåðìàíèÿ)             │004215             

                                                                                                                   

│Âîëüïàí                       │ñèðîï (ôëàêîíû) 120 ìã|5 ìë - 150  │Bilim Ilac Sanayi (Òóðöèÿ)    │002403             

                              │ìë                                                                                   

                                                                                                                  

│Âîëüòàðåí ÑР                 │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ciba-Geigy (Øâåéöàðèÿ)        │003020             

                              │îáîëî÷êîé 75 ìã                                                                     

                                                                                                                  

│Âñåïîãîäíûå ðîäåíòèöèäíûå     │áðèêåòû ïàðàôèíèðîâàííûå           │Casing Corp (ÑØÀ)             │0003-9             

│ïðèìàíî÷íûå áëîêè èòîíà                                                                                           

                                                                                                                  

│Âóìîí                         │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 50   │Bristol-Myers Squibb (ÑØÀ)    │003361             

                              │ìã - 5 ìë                                                                           

                                                                                                                  

│Ãàëàçîëèí                     │êàïëè íàçàëüíûå 0.1%               │Polfa (Ïîëüøà)                │2175               

│Ãàëàçîëèí                     │êàïëè íàçàëüíûå äëÿ äåòåé 0.05%    │Polfa (Ïîëüøà)                │2531               

│Ãàëèäîð                       │òàáëåòêè 100 ìã                    │Egit (Âåíãðèÿ)                │2810               

│Ãàëèäîð                       │òàáëåòêè 100 ìã                    │Egit (Âåíãðèÿ)                │2048               

                                                                                                                  

│Ãàëîïåð                       │òàáëåòêè 1, 2, 5 ìã                │Ct-Arzneimittel Chemishe      │003083             

                                                                 │Tempelchof Gmbh (Ãåðìàíèÿ)                        

                                                                                                                  

│Ãàëîïåðèäîë                   │ðàñòâîð 0.2% - 10 ìë               │Gedeon Richter (Âåíãðèÿ)      │2053               

                                                                                                                  

│Ãàëîïåðèäîë                   │òàáëåòêè 1.5, 5, 10, 20 ìã         │Norton Healthcare Ltd         │003240             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ãàñòðàëþãåëü                  │òàáëåòêè                           │Laboratoires Biogalenique     │002602             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ãàñòðèë                       │òàáëåòêè 25, 50 ìã; ðàñòâîð äëÿ    │Torrent Exports Ltd (Èíäèÿ)   │002231             

                              │èíúåêöèé (àìïóëû) 5 ìã|1 ìë                                                         

                                                                                                                  

│Ãàñòðîçåì                     │òàáëåòêè 25 ìã                     │Alkaloid (ÑÔÐÞ)               │002469             

                                                                                                                  

│Ãàñòðîöåïèí                   │òàáëåòêè 50 ìã                     │Boehringer Ingelheim Gmbh     │003427             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ãàñòðîöåïèí                   │òàáëåòêè 25 ìã                     │Boehringer Ingelheim          │01002              

                                                                 │International Gmbh (Ãåðìàíèÿ) │                    

                                                                                                                  

│Ãàñòðîöåïèí                   │òàáëåòêè 25 ìã; ïîðîøîê äëÿ        │Zdravle (Þãîñëàâèÿ)           │01085              

                              │ïðèãîòîâëåíèÿ èíúåêöèîííîãî                                                         

                              │ðàñòâîðà (ôëàêîíû) 10 ìã /â                                                         

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                          

                                                                                                                  

│Ãåêñàáðèêñ 320                │ðàñòâîð äëÿ èíúåêöèé (àìïóëû);     │Byk Gulden Gmbh (ÔÐÃ)         │002414             

                              │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû)                                                      

                                                                                                                  

│Ãåêñàëèç                      │òàáëåòêè ñóáëèíãâàëüíûå            │Laboratoires Doms (Ôðàíöèÿ)   │01780              

                                                                                                                  

│Ãåêñàïíåâìèí                  │ñâå÷è äëÿ âçðîñëûõ; ñâå÷è äëÿ      │Laboratoires Doms (Ôðàíöèÿ)   │002501             

                              │äåòåé; ñâå÷è äëÿ íîâîðîæäåííûõ                                                      

                                                                                                                  

│Ãåêñàñòàò                     │êàïñóëû 100 ìã                     │Leiras (Ôèíëÿíäèÿ)            │01317              

│Ãåêñàôàí                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2798               

│Ãåêñîäåíò ôîðòå               │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2803                

│Ãåêñîëü                       │ïîðîøîê                            │Ðîññèÿ                        │0001-À4            

│Ãåëèîñ ñóïåð                  │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2802                

                                                                                                                  

│Ãåëüôîñ                       │ãåëü îðàëüíûé (ïàêåòèêè) 20 ã      │Boryung Pharmaceutical Co Ltd │002729             

                                                                 │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                  

│Ãåìà-êîìáèñòèêñ                                                  │Aims Company (Âåëèêîáðèòàíèÿ) │00577              

│Ãåìàñòèêñ                                                        │Aims Company (Âåëèêîáðèòàíèÿ) │00583              

│Ãåìàòîãåí äåòñêèé             │ïëèòêè                             │Ðîññèÿ                        │70/367/13          

                                                                                                                  

│Ãåìèòîí@                      │òàáëåòêè 0.075, 0.3 ìã             │Arzneimittelwerk Dresden Gmbh │003530             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ãåìîêêóëüò                                                       │Roehm Pharma (ÔÐÃ)            │00856              

                                                                                                                  

│Ãåìîôàêòîð ÍÒ                 │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Grifols Sa (Èñïàíèÿ)          │002819             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │500 ÅÄ                                                                              

                                                                                                                   

│Ãåìîôàí                       │ïîëîñêè                            │Lachema (×ÑÔÐ)                │2634               

│Ãåíåðàòîð òåõíåöèÿ 99ìÒñ                                         │Oris (Ôðàíöèÿ)                │01245              

                                                                                                                 

│Ãåíîòðîïèí                    │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Kabi Pharmacia (Øâåöèÿ)       │002690             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû                                                      

                              │äâóõñåêöèîííûå) 16 ÌÅ /â êîìïëåêòå │                                                 

                              │ñ ðàñòâîðèòåëåì/                                                                    

                                                                                                                  

│Ãåíòàìèí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 80   │Agio Pharmaceuticals Ltd      │009427             

                              │ìã - 2 ìë                          │(Èíäèÿ)                                          

                                                                                                                  

│Ãåíòàìèñèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 40   │Deva Holding As (Òóðöèÿ)      │002432             

                              │ìã/1 ìë, 20 ìã/2 ìë, 80 ìã/2 ìë                                                     

                                                                                                                  

│Ãåíòàìèöèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 20   │Bosnalijek (ÑÔÐÞ)             │002380             

                              │ìã/2 ìë, 40 ìã/2 ìë, 80 ìã/2 ìë,                                                    

                              │120 ìã/2 ìë, 160 ìã/2 ìë                                                            

                                                                                                                  

│Ãåíòàìèöèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 40   │Lek (ÑÔÐÞ)                    │002167              

                              │ìã/2 ìë, 80 ìã/2 ìë, 120 ìã/2 ìë;                                                   

                              │ìàçü 0.1%                                                                           

                                                                                                                  

│Ãåíòàìèöèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 40   │Podravka-Belupo (ÑÔÐÞ)        │002234             

                              │ìã/2 ìë, 80 ìã/2 ìë, 120 ìã/2 ìë                                                    

                                                                                                                  

│Ãåíòàìèöèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 80   │Shin Poong Ltd (Êîðåÿ Þæíàÿ)  │002734             

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Ãåíòàìèöèíà ñóëüôàò           │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 160  │Panpharma (Ôðàíöèÿ)           │003023             

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Ãåíóãåëü Êàððàãåíàí ÑÍÐ-2                                        │Copenhagen Pectin (Äàíèÿ)     │004333             

│Ãåïàëèâ                       │òàáëåòêè                           │Torrent Exports Ltd (Èíäèÿ)   │002218             

                                                                                                                  

│Ãåïàðèáåíå êàëüöèé            │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5000 │Ludwig Merckle Gmbh (Àâñòðèÿ) │003325             

                              │ÅÄ/0.2 ìë, 20000 ÅÄ/0.8 ìë;                                                          

                              │ðàñòâîð äëÿ èíúåêöèé                                                                

                              │(øïðèö-àìïóëû) 5000 ÅÄ/0.2 ìë                                                       

                                                                                                                  

│Ãåïàðèáåíå íàòðèé             │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5000 │Ludwig Merckle Gmbh (Àâñòðèÿ) │003326             

                              │ÅÄ - 0.2 ìë; ðàñòâîð äëÿ èíúåêöèé                                                   

                              │(øïðèö-àìïóëû) 5000 ÅÄ - 0.2 ìë;                                                    

                              │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû)                                                      

                              │25000 ÅÄ - 5 ìë                                                                     

                                                                                                                  

│Ãåïàðèí ÁÑ                    │ðàñòâîð äëÿ èíúåêöèé 25000 ÌÅ - 5  │Biochemie Gmbh (Àâñòðèÿ)      │01829              

                              │ìë                                                                                  

                                                                                                                  

│Ãåïàðèí è Ìèíè-ãåïàðèí                                           │Belgian Chemical (Áåëüãèÿ)    │00951              

│Ãåïàðîèä                      │ìàçü                               │Spofa (×åõîñëîâàêèÿ)          │2518               

│Ãåïòàôàí                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2794               

│Ãåðèàòðèê-Ôàðìàòîí            │êàïñóëû                            │Pharmaton (Øâåéöàðèÿ)         │00939              

│Ãåðìåòèê äåëüòîí              │ôèññóðíûé ñèëàíò                   │Johnson & Johnson (ÑØÀ)       │01946              

                                                                                                                  

│Ãåñòàãíîñò                                                       │Institute Of Serum And        │2400                

                                                                 │Vaccines (×ÑÑÐ)                                  

                                                                                                                  

│Ãèáèñêðàá                     │ðàñòâîð 4%                         │ICI (Âåëèêîáðèòàíèÿ)          │002692             

│Ãèãàñåïò ÔÔ                   │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0005-1             

                                                                                                                  

│Ãèäðåà                        │êàïñóëû 500 ìã                     │Bristol-Myers Squibb          │007416             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ãèäðåà                        │êàïñóëû 500 ìã                     │Bristol-Myers Squibb (ÑØÀ)    │01841              

│Ãèäðîêàð                      │ðàñòâîð                            │Pharm-Allergan Gmbh (ÔÐÃ)     │01819              

│Ãèäðîêàð ôèççè                │òàáëåòêè                           │Pharm-Allergan Gmbh (ÔÐÃ)     │01820              

│Ãèäðîêñèóðåà                  │êàïñóëû 500 ìã                     │Polfa (Ïîëüøà)                │2462               

│Ãèäðîõëîðòèàçèä               │òàáëåòêè 50 ìã                     │Confab (Êàíàäà)               │003078             

│Ãèëåìàë                       │òàáëåòêè 5 ìã                      │Chinoin (Âåíãðèÿ)             │2569               

                                                                                                                  

│Ãèëóðèòìàë                    │äðàæå 50 ìã; ðàñòâîð äëÿ           │Giulini Pharma Gmbh (ÔÐÃ)     │00637              

                              │âíóòðèâåííîãî ââåäåíèÿ (àìïóëû) 50 │                                                  

                              │ìã - 10 ìë; ðàñòâîð äëÿ                                                             

                              │ïðèãîòîâëåíèÿ èíôóçèîííîãî                                                           

                              │ðàñòâîðà êîíöåíòðèðîâàííûé                                                          

                              │(àìïóëû) 50 ìã - 2 ìë                                                               

                                                                                                                  

│Ãèëóñòåíîí                    │êàïñóëû ðåòàðä 6.5 ìã              │Giulini Pharma Gmbh (ÔÐÃ)     │002170             

│Ãèëóñòåíîí ôîðòå              │êàïñóëû ðåòàðä 9 ìã                │Giulini Pharma Gmbh (ÔÐÃ)     │002171             

                                                                                                                  

│Ãèíî-Äàêòàðèí                 │ñâå÷è âàãèíàëüíûå 100 ìã           │Janssen Pharmaceutica         │002638             

                                                                 │(Áåëüãèÿ)                                        

                                                                                                                  

│Ãèñìàíàë                      │òàáëåòêè 10 ìã                     │Eczacibasi (Òóðöèÿ)           │002289             

│Ãèñìàíàë                      │òàáëåòêè 10 ìã                     │Lupin Laboratories Ltd (Èíäèÿ)│002243             

│Ãèñìàíàë                      │òàáëåòêè 10 ìã                     │Slovakofarma Sa (×ÑÔÐ)        │002505             

│Ãëàóâåíò                      │äðàæå 10, 40 ìã                    │Pharmachim (Áîëãàðèÿ)         │2143               

│Ãëèâåíîë                      │êàïñóëû 400 ìã                     │Ciba-Geigy (Øâåéöàðèÿ)        │00029              

│Ãëèíèë                        │òàáëåòêè 5 ìã                      │Usha Intercontinental (Èíäèÿ) │002472             

│Ãëóêîôàí                      │ïîëîñêè                            │Lachema (×ÑÑÐ)                │2633               

                                                                                                                   

│Ãëóòðèë                       │òàáëåòêè 25 ìã                     │Roche Mustahzarlari Sanayi As │002207             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Ãëþðåíîðì                     │òàáëåòêè 30 ìã                     │Boehringer Ingelheim          │007301             

                                                                 │International Gmbh (Ãåðìàíèÿ) │                   

                                                                                                                  

│Ãëþðåíîðì                     │òàáëåòêè 30 ìã                     │Eczacibasi (Òóðöèÿ)           │01536              

                                                                                                                  

│Ãîâÿäèíà â òîìàòå ñ ðèñîì                                        │Hipp (Àâñòðèÿ)                │004029             

│àðò.254                                                                                                           

                                                                                                                  

│Ãîâÿäèíà â òîìàòå ñ ÿéöàìè                                       │Hipp (Àâñòðèÿ)                │004034             

│àðò.332                                                                                                          

                                                                                                                  

│Ãîâÿäèíà ñ ëàïøîé 00409                                          │Gerber (ÑØÀ)                  │004189             

                                                                                                                  

│Ãîâÿäèíà ñ ìàêàðîíàìè è                                          │Gerber (ÑØÀ)                  │004190             

│òîìàòîì 02606                                                                                                     

                                                                                                                   

│Ãîâÿäèíà ñ îâîùàìè 00404                                         │Gerber (ÑØÀ)                  │004185             

│Ãîâÿäèíà ñ îâîùàìè 02604                                         │Gerber (ÑØÀ)                  │004187             

                                                                                                                  

│Ãîâÿäèíà ñ îâîùàìè è                                             │Nestle (Ãåðìàíèÿ)             │004221             

│êàðòîôåëåì                                                                                                        

                                                                                                                  

│Ãîâÿäèíà ñ ðèñîì è îâîùàìè                                       │Hipp (Àâñòðèÿ)                │004036             

│àðò.377                                                                                                           

                                                                                                                  

│Ãîäðåäæ                       │ïàñòà çóáíàÿ                       │Godrege Soups Ltd (Èíäèÿ)     │04018              

│Ãîêèëàò                       │äóñò 5%                            │Sumitomo Chemical (ßïîíèÿ)    │0004-13            

│Ãîêèëàò                       │äóñò 10%                           │Sumitomo Chemical (ßïîíèÿ)    │0004-14            

                                                                                                                  

│Ãîíàâèñëàéä                                                      │Moshida Pharmaceutical        │00743              

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ãîíîçàéì                                                         │Abbott Laboratories (ÑØÀ)     │01133              

│Ãðàâèìóí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû)      │Sachsisches Serumwerk (ÃÄÐ)   │00746              

│Ãðàìóðèí                      │òàáëåòêè 250 ìã                    │Chinoin (Âåíãðèÿ)             │2545                

│Ãðèëåí                        │æèäêîñòü                           │Ðîññèÿ                        │0001-À3            

│Ãðóøåâîå ïþðå ñ øîêîëàäîì                                        │Fructal/Sloveniales (Ñëîâåíèÿ)│004373             

│Ãðóøåâûé éîãóðò                                                  │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004306             

                                                                                                                  

│Ãðóøè ñîðòà âèëüÿì êðèñò                                         │Hipp (Àâñòðèÿ)                │004033             

│àðò.279                                                                                                           

                                                                                                                  

│Ãóä ìîðíèíã                   │ïàñòà çóáíàÿ                       │Fenix Overseas Ltd (Èíäèÿ)    │004082             

│Äàáóð                         │ïàñòà çóáíàÿ                       │Dabur India Ltd (Èíäèÿ)       │01773              

                                                                                                                  

│Äàêàðáàçèí                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Dome Laboratories             │00767              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Âåëèêîáðèòàíèÿ)                                 

                              │100, 200 ìã                                                                         

                                                                                                                  

│Äàêàðáàçèí                    │ëèîôèëèç.ïîðîøîê (ôëàêîíû) 100,    │Lachema (×ÑÔÐ)                │3006               

                              │200 ìã                                                                              

                                                                                                                   

│Äàêòàðèí                      │êðåì 20 ìã/ã                       │Janssen Pharmaceutica         │002641             

                                                                 │(Áåëüãèÿ)                                        

                                                                                                                  

│Äàëàöèí Ö                     │êàïñóëû 150 ìã                     │Eczacibasi (Òóðöèÿ)           │01882              

                                                                                                                  

│Äàëàöèí Ö                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 300  │Unichem Laboratories Ltd      │002131             

                              │ìã - 2 ìë; êàïñóëû 150 ìã          │(Èíäèÿ)                                          

                                                                                                                  

│Äàíîãåí                       │êàïñóëû 200 ìã                     │Cipla Ltd (Èíäèÿ)             │002173             

│Äàíïðî-S                                                         │Orhus Oliefabrik (Äàíèÿ)      │004038             

│Äàíïðî-Í                                                         │Orhus Oliefabrik (Äàíèÿ)      │004039             

│Äàíïðîòåêñ Â-50                                                  │Orhus Oliefabrik (Äàíèÿ)      │004134             

│Äàíïðîòåêñ-Í-40                                                  │Orhus Oliefabrik (Äàíèÿ)      │004040             

│Äàíïðîôèáðû-90                                                   │Orhus Oliefabrik (Äàíèÿ)      │004037             

                                                                                                                  

│Äàíòðîëåí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Roehm Pharma (ÔÐÃ)            │002369             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │20 ìã /â êîìïëåêòå ñ ðàñòâîðèòåëåì/│                                                 

                                                                                                                   

│Äàîíèë                        │òàáëåòêè 5 ìã                      │Hoechst Ltd (Èíäèÿ)           │003870             

│Äàðòåëèí                      │òàáëåòêè 400 ìã                    │Lek D.D. (Ñëîâåíèÿ)           │003418             

                                                                                                                  

│Äàóíîçîì                      │ðàñòâîð êîíöåíòðèðîâàííûé äëÿ      │Nexstar Pharmaceuticals Inc   │009612             

                              │èíôóçèé (ôëàêîíû) 50 ìã|25 ìë - 50 │(Áåëüãèÿ)                                        

                              │ìë                                                                                  

                                                                                                                 

│Äàôàëãàí                      │êàïñóëû 500 ìã                     │Laboratoires Upsa (Ôðàíöèÿ)   │002805             

                                                                                                                  

│Äâóîñíîâíàÿ ñîëü 20           │ïîðîøîê                            │Ðîññèÿ                        │0001-À5            

│ãèïîõëîðèòà 20 êàëüöèÿ (ÄÑÃÊ) │                                                                                    

                                                                                                                  

│Äåáèäåíò ñ ðåìîäåíòîì         │ïàñòà çóáíàÿ                       │Easten Industrial Investment  │04015              

                                                                 │Co (Åãèïåò)                                      

                                                                                                                  

│Äåæèçàí                       │ïðèñûïêà                           │Leipziger Arzneimittelwerk    │01423              

                                                                 │Gmbh (ÃÄÐ)                                        

                                                                                                                  

│Äåçàìèíîîêñèòîöèíà òàáëåòêè   │òàáëåòêè äëÿ ðàññàñûâàíèÿ 50 ÅÄ    │Ðîññèÿ                        │81/761/9            

│50 ÅÄ                                                                                                             

                                                                                                                  

│Äåçàìèò                       │æèäêîñòü                           │Ðîññèÿ                        │0001-3             

│Äåçàìèò                       │æèäêîñòü                           │Ðîññèÿ                        │0001-À7            

│Äåçîêñîí-1                    │æèäêîñòü                           │Ðîññèÿ                        │0001-À6            

│Äåçîêñîí-4                    │æèäêîñòü                           │Ðîññèÿ                        │0004-2             

│Äåçóðèê                       │òàáëåòêè 100 ìã                    │Labaz (Áåëüãèÿ)               │00846              

                                                                                                                  

│Äåêàïåïòèë-äåïî               │ìèêðîêàïñóëû äëÿ ïðèãîòîâëåíèÿ     │Ferring Arzneimittel Gmbh     │002714             

                              │âíóòðèìûøå÷íîãî ðàñòâîðà (øïðèö    │(ÔÐÃ)                                            

                              │îäíîðàçîâûé) 172 ìã /â êîìïëåêòå ñ │                                                 

                              │ñóñïåíçèðóþùèì âåùåñòâîì 2 ìë/                                                      

                                                                                                                  

│Äåêëîáàí                      │ìàçü                               │Laboratorious Cusi (Èñïàíèÿ)  │003161             

                                                                                                                  

│Äåêñàìåòàçîí                  │òàáëåòêè 0.5 ìã                    │Orion Pharmaceutica           │00671              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Äåêñàìåòàçîí                  │êàïëè ãëàçíûå (ôëàêîíû) 0.1%       │Weimer Pharma Gmbh (ÔÐÃ)      │002844             

│Äåêñîëàê ðèñîâàÿ êàøà                                            │Wockhardt Ltd (Èíäèÿ)         │004272             

│Äåêñòðîçà                     │ðàñòâîð äëÿ èíôóçèé 5%, 10%        │Gujarat Inject Ltd (Èíäèÿ)    │002843             

                                                                                                                  

│Äåêñòðîçà                     │ðàñòâîð äëÿ èíôóçèé 5%, 10%, 20%;  │Promed Exports Pvt Ltd (Èíäèÿ)│002064             

                              │ðàñòâîð äëÿ èíôóçèé (àìïóëû) 5% /ñ │                                                 

                              │íàòðèÿ õëîðèäîì 0.9%/                                                               

                                                                                                                  

│Äåêñòðîñòèêñ                  │ïîëîñêè                            │Aims Company (Âåëèêîáðèòàíèÿ) │00293              

│Äåëàãèë                       │òàáëåòêè 250 ìã                    │Alkaloida (Âåíãðèÿ)           │2031               

│Äåìîñ                         │æèäêîñòü                           │Ðîññèÿ                        │0021-2             

│Äåíòàë ôëîññ                  │íèòè çóáíûå                        │Jordan (Íîðâåãèÿ)             │00773              

│Äåíòàëüíûå ôëîññû             │íèòè çóáíûå ýëàñòè÷íûå             │Johnson & Johnson (ÑØÀ)       │01947              

│Äåíòàñ                        │ïàñòà çóáíàÿ                       │Bosnalijek (ÑÔÐÞ)             │01741              

│Äåíòîñåïò Ë                   │ïàñòà çóáíàÿ                       │Pollena-Lechia (Ïîëüøà)       │2988               

│Äåïàêèí                       │òàáëåòêè 300 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │01962              

                                                                                                                  

│Äåïàêèí-õðîíî                 │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Sanofi/labaz (Ôðàíöèÿ)        │002808              

                              │ïðîëîíãèðîâàííîãî äåéñòâèÿ 500 ìã                                                   

                                                                                                                  

│Äåïàìèä                       │òàáëåòêè 300 ìã                    │Labaz (Ôðàíöèÿ)               │01320              

                                                                                                                  

│Äåïî-Ìåäðîë                   │ñóñïåíçèÿ äëÿ èíúåêöèé âîäíàÿ      │Eczacibasi (Òóðöèÿ)           │002731             

                              │(ôëàêîíû) 40 ìã/ìë - 1 ìë                                                           

                                                                                                                  

│Äåïî-Ïðîâåðà                  │ñóñïåíçèÿ äëÿ èíúåêöèé âîäíàÿ      │Eczacibasi (Òóðöèÿ)           │002142             

                              │(ôëàêîíû) 500, 1000 ìã                                                              

                                                                                                                  

│Äåïîñòàò                      │ðàñòâîð äëÿ èíúåêöèé ìàñëÿíûé      │Salutas Fahlberg-List (ÔÐÃ)   │002786             

                              │(àìïóëû) 200 ìã - 2 ìë                                                              

                                                                                                                  

│Äåðåâåíñêàÿ òóøåíàÿ òåëÿòèíà                                     │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004303             

│ñ êàðòîôåëåì                                                                                                      

                                                                                                                  

│Äåðåâåíñêèå îâîùè ñ ðèñîì                                        │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004291             

│Äåðåâåíñêèå îâîùè ñ ÷å÷åâèöåé │                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004289             

│Äåðìîâåéò                     │êðåì; ìàçü                         │Glaxo (Âåëèêîáðèòàíèÿ)        │01972               

│Äåñåðò èç ëåòíèõ ôðóêòîâ                                         │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004293             

│Äåñåðò èç ïåðñèêîâ                                               │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004294             

│Äåñåðò èç ñìåñè ôðóêòîâ                                          │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004298             

                                                                                                                  

│Äåñåðò èç òðîïè÷åñêèõ ôðóêòîâ │                                   │Gerber (ÑØÀ)                  │004174             

│02443                                                                                                             

                                                                                                                  

│Äåñåðò èç òðîïè÷åñêèõ ôðóêòîâ │                                   │Gerber (ÑØÀ)                  │004173             

│02445                                                                                                             

                                                                                                                  

│Äåñåðò èç ÿáëîê è àïåëüñèíîâ                                     │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004296             

│Äåñåðò èç ÿáëîê è áàíàíîâ                                        │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004297             

│Äåñèòèí                       │êðåì äëÿ äåòåé                     │Pfizer International Inc (ÑØÀ)│004332             

│Äåñêîðä                       │ïîðîøîê ñìà÷èâàþùèéñÿ              │Ðîññèÿ                        │0009-3             

                                                                                                                  

│Äåòèöåí                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Rhone-Poulenc Rorer (Ôðàíöèÿ) │003177             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                     

                              │100, 200 ìã                                                                         

                                                                                                                  

│Äåòñêèå ïîëèâèòàìèíû ñ        │òàáëåòêè â âèäå ôèãóðîê æèâîòíûõ   │Michealson&johns (ÑØÀ)        │002997             

│áåòà-êàðîòèíîì                                                                                                    

                                                                                                                  

│Äåòñêîå ïèòàíèå íà çëàêîâîé                                      │H.J.Heinz (ÑØÀ)               │01737              

│îñíîâå                                                                                                            

                                                                                                                  

│Äåòñêîå ïèòàíèå íà çëàêîâîé                                      │H.J.Heinz (ÑØÀ)               │01736              

│îñíîâå ñ ôðóêòàìè èëè îâîùåé                                                                                      

                                                                                                                  

│Äåòñêîå ïèòàíèå íà ìÿñíîé                                        │H.J.Heinz (ÑØÀ)               │01733              

│îñíîâå                                                                                                            

                                                                                                                  

│Äåòñêîå ïèòàíèå íà îâîùíîé                                       │H.J.Heinz (ÑØÀ)               │01731              

│îñíîâå                                                                                                            

                                                                                                                  

│Äåòñêîå ïèòàíèå íà îâîùíîé                                       │H.J.Heinz (ÑØÀ)               │01732              

│îñíîâå ñ ìÿñîì                                                                                                     

                                                                                                                  

│Äåòñêîå ïèòàíèå íà îñíîâå                                        │H.J.Heinz (ÑØÀ)               │01735              

│éîãóðòà è ôðóêòîâ                                                                                                 

                                                                                                                  

│Äåòñêîå ïèòàíèå íà ôðóêòîâîé                                     │H.J.Heinz (ÑØÀ)               │01734              

│îñíîâå                                                                                                            

                                                                                                                  

│Äåôèöèòíûå ïëàçìû ôàêòîðîâ                                       │Belgian Chemical (Áåëüãèÿ)    │00954              

│II, V, VIII, IX, X, XI, XII                                                                                       

                                                                                                                  

│Äæàñïðèí                      │òàáëåòêè 300, 500 ìã               │J.R.Sharma Overseas Ltd       │003223             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Äæàñïðèí Ñ                    │òàáëåòêè ðàñòâîðèìûå 350 ìã        │J.R.Sharma Overseas Ltd       │003228             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Äæåé êåé ôëþîðèä              │ïàñòà çóáíàÿ                       │Highten International (Èíäèÿ) │01699               

│Äæîíñîí                       │ïðèñûïêà äëÿ äåòåé                 │Johnson & Johnson (ÑØÀ)       │01987              

│Äæîíñîí                       │ìàñëî äëÿ äåòåé                    │Johnson & Johnson (ÑØÀ)       │01988              

│Äæîíñîí                       │ìûëî æèäêîå äëÿ äåòåé              │Johnson & Johnson (ÑØÀ)       │01983              

│Äæîíñîí                       │êðåì æèäêèé äëÿ äåòåé              │Johnson & Johnson (ÑØÀ)       │01986              

│Äæîíñîí                       │øàìïóíü                            │Johnson & Johnson (ÑØÀ)       │01989              

│Äæîíñîí                       │øàìïóíü äëÿ äåòåé                  │Johnson & Johnson (ÑØÀ)       │01985              

│Äèàáåíèë                      │êàïëè ãëàçíûå                      │Ankerpharm Gmbh (ÔÐÃ)         │002926             

                                                                                                                  

│Äèàçåïàáåíå@                  │òàáëåòêè 2, 5, 10 ìã; ðàñòâîð äëÿ  │Ludwig Merckle Gmbh (Àâñòðèÿ) │003328             

                              │èíúåêöèé (àìïóëû) 10 ìã - 2 ìë;                                                     

                              │ñâå÷è 5 ìã, 10 ìã                                                                   

                                                                                                                  

│Äèàçåïàì@                     │òàáëåòêè 5 ìã                      │Confab (Êàíàäà)               │003076             

│Äèàçåïàì@                     │òàáëåòêè 5 ìã                      │Rivopharm Sa (Íèäåðëàíäû)     │003085             

│Äèàçåïàì@                     │òàáëåòêè 5 ìã                      │Usha Intercontinental (Èíäèÿ) │003441             

                                                                                                                  

│Äèàêàðá                       │òàáëåòêè 250 ìã                    │Polfa, Starogardzkie          │2179               

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                   

│Äèàíå-35                      │äðàæå                              │Birlesik Alman Ilaclary As    │002061             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Äèàíå-35                      │äðàæå                              │Salutas Fahlberg-List (ÔÐÃ)   │002787             

│Äèàñòèêñ                                                         │Aims Company (Âåëèêîáðèòàíèÿ) │00587              

│Äèàôàí                        │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2795               

│Äèãåñòàë                      │äðàæå                              │Galenika (Þãîñëàâèÿ)          │00995              

                                                                                                                  

│Äèãèòàëèñ-àíòèäîò ÁÌ          │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Boehringer Mannheim Gmbh      │002802             

                              │èíôóçèîííîãî ðàñòâîðà (ôëàêîíû)    │(Àâñòðèÿ)                                        

                              │192 ìã - 80 ìã/75 ìã                                                                

                                                                                                                  

│Äèãîêñèí                      │òàáëåòêè 0.25 ìã                   │Sandoz Urunleri Ilac (Òóðöèÿ) │002187             

│Äèåòòà-ñîÿ                                                       │Medyfood (Øâåöèÿ)             │004196             

                                                                                                                  

│Äèåòòà-ñîÿ                                                       │Orion Pharmaceutica           │01813              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Äèêëàê                        │ôèëìòàáëåòêè 25, 50 ìã; òàáëåòêè   │Hexal Pharma Gmbh (Ãåðìàíèÿ)  │005091              

                              │ðåòàðä 100 ìã                                                                       

                                                                                                                  

│Äèêëîáåíå                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2    │Ludwig Merckle Gmbh (Àâñòðèÿ) │003687             

                              │ìë; ãåëü (òóáû) 1% - 40, 100 ã                                                      

                                                                                                                  

│Äèêëîáåíå                     │ñâå÷è 25, 50, 100 ìã               │Ludwig Merckle Gmbh (Àâñòðèÿ) │003029             

                                                                                                                  

│Äèêëîáåíå                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 25, 50 │Ludwig Merckle Gmbh (Àâñòðèÿ) │005020             

                              │ìã; êàïñóëû 100 ìã                                                                  

                                                                                                                  

│Äèêëîêñàöèëëèí                │êàïñóëû 250, 500 ìã                │Mir Pharmaceutical            │007675             

                                                                 │Inc/Biocraft Laboratories Inc │                   

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Äèêëîíàò Ï                    │òàáëåòêè ðåòàðä 100 ìã; ñâå÷è 50   │Pliva (Õîðâàòèÿ)              │002750             

                              │ìã; ðàñòâîð äëÿ èíúåêöèé (àìïóëû)                                                   

                              │75 ìã - 3 ìë                                                                         

                                                                                                                  

│Äèêîðä                        │æèäêîñòü                           │Ðîññèÿ                        │0008-2             

                                                                                                                  

│Äèëàíàöèí                     │òàáëåòêè 0.25 ìã                   │Arzneimittelwerk Dresden Feb  │01768              

                                                                 │(ÃÄÐ)                                            

                                                                                                                  

│Äèëòèàçåìà ãèäðîõëîðèä        │òàáëåòêè 60 ìã                     │Confab (Êàíàäà)               │003077             

                                                                                                                  

│Äèëòèàçåìà ãèäðîõëîðèä        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 30,    │Mir Pharmaceutical Inc/Copley │007677             

                              │60, 90, 120 ìã                     │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Äèëòèàçåì-Ðàòèîôàðì 60        │òàáëåòêè 60 ìã                     │Merckle Gmbh (ÔÐÃ)            │002908             

                                                                                                                 

│Äèëòèçåì                      │òàáëåòêè 60 ìã                     │Mustafa Nevzat Ilac Sanayi As │002443             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Äèíèò                         │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 200  │Leiras (Ôèíëÿíäèÿ)            │002373             

                              │ìã/ìë                                                                               

                                                                                                                   

│Äèïðîñàëèê                    │ìàçü; ëîñüîí                       │Schering-Plough (ÑØÀ)         │002427             

                                                                                                                  

│Äèïðîñïàí                     │ñóñïåíçèÿ äëÿ èíúåêöèé âîäíàÿ      │Eczacibasi (Òóðöèÿ)           │002732             

                              │(àìïóëû) 2 ìã|5 ìã - 1 ìë                                                           

                                                                                                                  

│Äèïðîñïàí                     │ñóñïåíçèÿ äëÿ èíúåêöèé âîäíàÿ      │Schering-Plough (ÑØÀ)         │002509             

                              │(àìïóëû) 1 ìë                                                                       

                                                                                                                  

│Äèñåïòîí                      │òàáëåòêè 480 ìã                    │Creat Laboratoires (Ôðàíöèÿ)  │009052             

                                                                                                                  

│Äèñïðèí                       │òàáëåòêè 500 ìã                    │Reckitt&colman Of India Ltd   │002636             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Äèòàìèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1 ìã │Lek (Þãîñëàâèÿ)               │01189              

                              │- 1 ìë; ðàñòâîð îðàëüíûé (ôëàêîíû) │                                                 

                              │2 ìã/ìë - 30 ìë; òàáëåòêè ðåòàðä                                                    

                              │2.5 ìã                                                                               

                                                                                                                  

│Äèòåê                         │àýðîçîëü äîçèðîâàííûé              │Boehringer Ingelheim Gmbh     │002092              

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Äèòåê                         │àýðîçîëü äîçèðîâàííûé              │Zdravle (Þãîñëàâèÿ)           │002794             

                                                                                                                  

│Äèòðàñòèê                     │êàðàíäàøè 1.5%, 3%                 │Orion Pharmaceutica           │01467              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Äèôàíòîèí                     │òàáëåòêè 100 ìã; ðàñòâîð äëÿ       │Labohain-Wolf (Áåëüãèÿ)       │002648             

                              │èíúåêöèé (àìïóëû) 250 ìã - 5 ìë                                                     

                                                                                                                  

│Äèôëþêàí                      │êàïñóëû 50, 100, 150, 200 ìã;      │Pfizer (Áåëüãèÿ)              │002210             

                              │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │                                                 

                              │2 ìã/ìë                                                                             

                                                                                                                  

│Äèôëþêàí                      │êàïñóëû 50, 100, 150, 200 ìã;      │Pfizer (Èòàëèÿ)               │003299             

                              │ðàñòâîð äëÿ âíóòðèâåííîãî                                                           

                              │êàïåëüíîãî ââåäåíèÿ 2 ìã/ìë                                                          

                                                                                                                  

│Äèõëîðàíòèí                   │ïîðîøîê                            │Ðîññèÿ                        │0001-À8            

│Äèõëîôîñ-Äåî                  │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0024-19            

│Äèõëîôîñ-Ï                    │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0025-11            

                                                                                                                  

│Äîáóæåêò                      │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Houhtamyaki Leiras Oy         │01572              

                              │èíôóçèîííîãî ðàñòâîðà 50 ìã/ìë     │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Äîáóòðåêñ                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 250  │Eli Lilly & Elanco (ÑØÀ)      │01445              

                              │ìã - 20 ìë                                                                          

                                                                                                                  

│Äîêñèëåê                      │êàïñóëû 500 ìã                     │Lek (ÑÔÐÞ)                    │01893              

│Äîêñèöèêëèí                   │êàïñóëû 100 ìã                     │Polfa (Ïîëüøà)                │002168             

                                                                                                                  

│Äîêñîðóáèöèí                  │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Tobin Chemical &              │002362             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │Pharmacological Co (ÊÍÐ)                         

                              │10, 20, 50 ìã                                                                       

                                                                                                                  

│Äîêñîðóáèöèí-Ýáåâå            │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Ebewe Arzneimittel Gmbh       │007126              

                              │ìã - 5 ìë; ðàñòâîð äëÿ èíúåêöèé    │(Àâñòðèÿ)                                        

                              │(ôëàêîíû) 50 ìã - 25 ìë                                                             

                                                                                                                  

│Äîêòîð Õîðíñò                 │ïîðîøîê äëÿ ôèêñàöèè çóáíûõ        │Fittident (Àâñòðèÿ)           │004258             

                              │ïðîòåçîâ                                                                            

                                                                                                                  

│Äîìïåðîí                      │òàáëåòêè 10 ìã                     │Cadila Laboratories Ltd       │003400             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Äîíîðìèë                      │òàáëåòêè 15 ìã; òàáëåòêè øèïó÷èå   │Laboratoires Upsa (Ôðàíöèÿ)   │003432             

                              │15 ìã                                                                               

                                                                                                                  

│Äîôàìèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 50   │Arzneimittelwerk Dresden Gmbh │002140             

                              │ìã - 5 ìë                          │(ÔÐÃ)                                            

                                                                                                                  

│Äîôàìèí                       │ðàñòâîð äëÿ èíôóçèé (àìïóëû) 50 ìã │Bosnalijek (Þãîñëàâèÿ)        │00753              

                              │- 10 ìë                                                                              

                                                                                                                  

│Äîôàìèí Äæóëèíè 200           │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Giulini Pharma Gmbh (Ãåðìàíèÿ)│002087              

                              │èíôóçèîííîãî ðàñòâîðà (àìïóëû) 200 │                                                 

                              │ìã - 10 ìë                                                                          

                                                                                                                  

│ÄÏ-4                          │ïîðîøîê                            │Ðîññèÿ                        │0001-À9            

                                                                                                                  

│Äðîêñèë                       │êàïñóëû 500 ìã; ïîðîøîê äëÿ        │United Pharmaceutical         │002945             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè   │Manufacturing Co Ltd                             

                              │250 ìã|5 ìë                        │(Èîðäàíèÿ)                                       

                                                                                                                  

│Äóëüêîëàêñ                    │äðàæå 5 ìã                         │Boehringer Ingelheim          │003464             

                                                                 │International Gmbh (Ãåðìàíèÿ) │                   

                                                                                                                  

│Äóðàêàð                       │ðàñòâîð                            │Pharm-Allergan Gmbh (ÔÐÃ)     │01823              

│Äóðàêëåàí                     │ðàñòâîð                            │Pharm-Allergan Gmbh (ÔÐÃ)     │01824              

│Äþôàñòîí                      │òàáëåòêè 10 ìã                     │Duphar B.V. (Íèäåðëàíäû)      │002302             

│Åëüöåìåä                      │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh (ÔÐÃ)    │004063             

│Åôåðìèíò                      │ïàñòà çóáíàÿ                       │Denrifreeses P.O. Mala (Èíäèÿ)│04002               

│Æåíñêèå ãèãèåíè÷åñêèå òàìïîíû │òàìïîíû æåíñêèå ãèãèåíè÷åñêèå      │Johnson & Johnson (ÑØÀ)       │00747              

                                                                                                                  

│Æåíüøåíü ñ âèòàìèíàìè è       │êàïñóëû                            │Lyka Labs Ltd (Èíäèÿ)         │002276             

│ìèíåðàëüíûìè âåùåñòâàìè                                                                                           

                                                                                                                  

│Æèâîòíûé àíòèãëîáóëèí,        │ðàñòâîð äëÿ èíúåêöèé (àìïóëû)      │Sevak (×ÑÔÐ)                  │2549               

│ìå÷åííûé                                                                                                          

│ôëóîðåñöåèí-èçîòèîöèàíàòîì                                                                                        

                                                                                                                  

│Çàâòðàê èç ôðóêòîâ è çëàêîâ                                      │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004287             

│Çàäèòåí                       │òàáëåòêè 1 ìã                      │Krka (ÑÔÐÞ)                   │002113             

│Çàíòàê                        │òàáëåòêè 150 ìã                    │Glaxo (Âåëèêîáðèòàíèÿ)        │01214              

                                                                                                                  

│Çàíòàê                        │ðàñòâîð äëÿ èíúåêöèé 25 ìã/ìë;     │Glaxo (Âåëèêîáðèòàíèÿ)        │01955              

                              │òàáëåòêè 300 ìã                                                                     

                                                                                                                  

│Çàïåêàíêà èç îâîùåé ñ                                            │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004292             

│ìàêàðîíàìè                                                                                                        

                                                                                                                   

│Çàïåêàíêà ñ ðûáîé è ïîìèäîðàìè│                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004305             

                                                                                                                  

│Çàïå÷åííûå áîáû è ïîìèäîðû ñ                                     │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004290             

│ÿéöàìè                                                                                                            

                                                                                                                  

│Çàïîëÿðíûé                    │êàðàíäàøè                          │Ðîññèÿ                        │0004-15            

│Çàùèòíèê äîìà                 │áàëëîíû àýðîçîëüíûå                │Don Hwa Farm (Êîðåÿ Þæíàÿ)    │0025-12            

│Çåôèð                         │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2709               

│Çèêñîðèí                      │êàïëè ýìóëüñèîííûå                 │Gedeon Richter (Âåíãðèÿ)      │002333             

│Çèêñîðèí                      │êàïñóëû                            │Gedeon Richter (Âåíãðèÿ)      │2696               

│Çèííàò                        │òàáëåòêè 125, 250, 500 ìã          │Glaxo (Âåëèêîáðèòàíèÿ)        │002873             

│Çèòàçîíèóì                    │òàáëåòêè 10 ìã                     │Egis (Âåíãðèÿ)                │2766               

│Çëàêè è ïå÷åíüå                                                  │Mylupa Sa (ÔÐÃ/Èñïàíèÿ)       │004110             

                                                                                                                  

│Çîàöèä                        │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 500  │Tata Pharma (Èíäèÿ)           │002909             

                              │ìã - 100 ìë                                                                         

                                                                                                                   

│Çîâèðàêñ                      │òàáëåòêè 200 ìã; ïîðîøîê äëÿ       │Wellcome Foundation Ltd       │01356              

                              │ïðèãîòîâëåíèÿ èíôóçèîííîãî         │(Âåëèêîáðèòàíèÿ)                                  

                              │ðàñòâîðà (ôëàêîíû) 250 ìã; êðåì                                                     

                              │äëÿ íàðóæíîãî ïðèìåíåíèÿ 5%;  ìàçü │                                                 

                              │ãëàçíàÿ 3%                                                                          

                                                                                                                  

│Çîðàí                         │òàáëåòêè 150 ìã                    │Dr.Reddy's Laboratories Ltd   │002401             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Çîôðàí                        │òàáëåòêè 4, 8 ìã; ðàñòâîð äëÿ      │Glaxo (Âåëèêîáðèòàíèÿ)        │003015             

                              │èíúåêöèé (àìïóëû) 2 ìã/ìë - 2, 4 ìë│                                                 

                                                                                                                  

│Èáåðåò ôèëìòàá                │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003345             

│Èáåðåò-500 ëèêâèä             │æèäêîñòü                           │Abbott Laboratories (ÑØÀ)     │003349             

│Èáåðåò-500 ôèëìòàá            │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003346             

│Èáåðåò-ëèêâèä                 │æèäêîñòü                           │Abbott Laboratories (ÑØÀ)     │003348             

│Èáåðåò-ôîëèê-500 ôèëìòàá      │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003347             

                                                                                                                  

│Èáóïðîô                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200,   │Ct-Arzneimittel Chemishe      │003444              

                              │400, 600 ìã                        │Tempelchof Gmbh (Ãåðìàíèÿ)                       

                                                                                                                  

│Èáóïðîôåí                     │ñóñïåíçèÿ äëÿ ïðèåìà âíóòðü        │Polfa (ÏÍÐ)                   │2930               

                                                                                                                  

│Èáóòàä                        │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Tad Pharmazeutisches Werk     │003375             

                              │îáîëî÷êîé 200, 400, 600 ìã         │Gmbh (Ãåðìàíèÿ)                                  

                                                                                                                  

│Èâèìèöèí                      │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû)     │Fdc Private Ltd (Èíäèÿ)       │003407             

                              │100, 250, 500 ìã - 2 ìë                                                             

                                                                                                                  

│Èäàðóáèöèí (Çàâåäîñ)          │ëèîôèëèçàò äëÿ ïðèãîòîâëåíèÿ       │Farmitalia Carlo Erba (Èòàëèÿ)│002559             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 5 │                                                 

                              │ìã                                                                                  

                                                                                                                  

│Èçî Ìàê ðåòàðä                │êàïñóëû 20, 40 ìã                  │Mack (ÔÐÃ)                    │01429              

                                                                                                                  

│Èçîäèíèò                      │òàáëåòêè 10 ìã; òàáëåòêè äëÿ       │Pharmachim (Áîëãàðèÿ)         │2799               

                              │ðàññàñûâàíèÿ; òàáëåòêè ðåòàðä 20 ìã│                                                 

                                                                                                                   

│Èçîêàë                        │ïîðîøîê                            │Mead Johnson Nutritionalist   │002379             

                                                                 │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Èçîêàðä 20                    │êàïñóëû 20 ìã                      │Dar Al Dava (Èîðäàíèÿ)        │002964             

│Èçîêàðä 40                    │êàïñóëû 40 ìã                      │Dar Al Dava (Èîðäàíèÿ)        │002964             

                                                                                                                  

│Èçîêåò                        │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 0.1% │Schwarz Pharma Ag (Ãåðìàíèÿ)  │002544             

                              │- 50, 100 ìë                                                                        

                                                                                                                  

│Èçîêåò                        │òàáëåòêè ðåòàðä 60 ìã; àýðîçîëü    │Schwarz Pharma Ag (ÔÐÃ)       │01692              

                                                                                                                  

│Èçîìîíàò                      │òàáëåòêè 40 ìã                     │Boehringer Mannheim Gmbh      │002094             

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                  

│Èçîïòèí                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 40, 80 │Birlesik Alman Ilaclary As    │002298             

                              │ìã                                 │(Òóðöèÿ)                                          

                                                                                                                  

│Èçîïòèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5 ìã │Birlesik Alman Ilaclary As    │002919             

                              │- 2 ìë                             │(Òóðöèÿ)                                         

                                                                                                                  

│Èçîïòèí                       │òàáëåòêè â îáîëî÷êå èç ñàõàðà 40,  │Knoll Ag (ÔÐÃ)                │002518             

                              │80 ìã; ðàñòâîð äëÿ èíúåêöèé                                                         

                              │(àìïóëû) 5 ìã - 2 ìë                                                                

                                                                                                                  

│Èçîïòèí                       │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Knoll Ag (ÔÐÃ)                │002634             

                              │îáîëî÷êîé 40, 80 ìã                                                                 

                                                                                                                  

│Èçîïòèí ÑР                   │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Birlesik Alman Ilaclary As    │003190             

                              │îáîëî÷êîé çàìåäëåííîãî             │(Òóðöèÿ)                                         

                              │âûñâîáîæäåíèÿ 240 ìã                                                                

                                                                                                                  

│Èçîïòèí ÑР                   │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Knoll Ag (ÔÐÃ)                │002519             

                              │îáîëî÷êîé 120 ìã                                                                    

                                                                                                                  

│Èçîïòèí ÑР                   │òàáëåòêè ðåòàðä 240 ìã             │Knoll Ag (ÔÐÃ)                │002048              

                                                                                                                  

│Èçîôàí Èíñóëèí ÃÌ             │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Galenika (ÑÔÐÞ)               │002182             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èêòîòåñò                                                         │Aims Company (Âåëèêîáðèòàíèÿ) │00589              

│Èêòîôàí                       │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2773               

                                                                                                                  

│Èìîäèóì                       │êàïñóëû 2 ìã                       │Janssen Pharmaceutica         │002349             

                                                                 │(Áåëüãèÿ)                                        

                                                                                                                  

│Èìïðàìèí                      │òàáëåòêè 25 ìã                     │Sun Pharmaceutical Industries │003157             

                                                                 │Ltd (Èíäèÿ)                                      

                                                                                                                  

│Èìïðåññ                       │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Krueger Gmbh (ÔÐÃ)            │01685              

│Èìïðåññ                       │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Krueger Gmbh (ÔÐÃ)            │01700              

│Èìïðåññ                       │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Krueger Gmbh (ÔÐÃ)            │01724              

│Èìïðåññ ìèëüõ                 │êàøà ìîëî÷íî-áàíàíîâàÿ             │Krueger Gmbh (ÔÐÃ)            │01707              

│Èìïðåññ ìèëüõ                 │êàøà ìîëî÷íî-øîêîëàäíàÿ            │Krueger Gmbh (ÔÐÃ)            │01706              

│Èíàïðîë                       │òàáëåòêè 250, 500 ìã               │Bilim Ilac Sanayi (Òóðöèÿ)    │002404              

                                                                                                                  

│Èíãàêîðò                      │àýðîçîëü (áàëëîíû) 6 ìë            │Boehringer Ingelheim          │003436             

                                                                 │International Gmbh (Ãåðìàíèÿ) │                   

                                                                                                                  

│Èíäåéêà ñ îâîùàìè 02607                                          │Gerber (ÑØÀ)                  │004188             

│Èíäåðàë                       │òàáëåòêè 40 ìã                     │Galenika (Þãîñëàâèÿ)          │00267              

│Èíäèëîé                       │àìàëüãàìà                          │Shofu Inc (ßïîíèÿ)            │00537              

│Èíäîâàçèí                     │ãåëü                               │Pharmachim (ÍÐÁ)              │2962               

│Èíäîìåòàöèí                   │êàïñóëû 25 ìã                      │Chinoin (ÂÍÐ)                 │2928               

│Èíäóêòîðû àãðåãàöèè           │ðåàêòèâû (íàáîð)                   │Belgian Chemical (Áåëüãèÿ)    │00955              

│Èíäóêòîðû àäãåçèè                                                │Belgian Chemical (Áåëüãèÿ)    │00956              

│Èíåé                          │êàðàíäàøè                          │Ðîññèÿ                        │0008-3             

                                                                                                                  

│Èíìóíîôåðîí                   │êàïñóëû 500 ìã; ïîðîøîê îðàëüíûé   │Laboratorious Andromaco Sa    │003170             

                              │(ñàøå) 500 ìã                      │(Èñïàíèÿ)                                        

                                                                                                                  

│Èíñåêòåí-Êèëëåð               │æèäêîñòü                           │Perycut (Àíãëèÿ)              │0007-3              

│Èíñåêòîãåëü-Ï                 │ãåëü                               │Ðîññèÿ                        │0001-5             

│Èíñåêòîãåëü-Ö                 │ãåëü                               │Ðîññèÿ                        │0004-16            

                                                                                                                  

│Èíñòåíîí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2    │Alkaloid (ÑÔÐÞ)               │00393              

                              │ìë; äðàæå                                                                           

                                                                                                                  

│Èíñòåíîí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2    │Hafslund Nycomed Pharma Ag    │002556             

                              │ìë; òàáëåòêè ïîêðûòûå îáîëî÷êîé    │(Àâñòðèÿ)                                        

                                                                                                                  

│Èíñòèëëàãåëü                  │ãåëü (øïðèö îäíîðàçîâûé) 6, 11 ìë  │Farco-Pharma Gmbh (ÔÐÃ)       │02012              

                                                                                                                  

│Èíñóëèí Àêòðàïèä              │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Novo Industry (Äàíèÿ)         │01264              

                              │ÅÄ/ìë - 10 ìë                                                                      

                                                                                                                  

│Èíñóëèí Àêòðàïèä              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Torrent Exports Ltd (Èíäèÿ)   │01915              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóëèí Àêòðàïèä HM           │ðàñòâîð äëÿ èíúåêöèé 40 ÅÄ/ìë      │Novo Industry (Äàíèÿ)         │01406              

│Èíñóëèí Àêòðàïèä HM           │ðàñòâîð äëÿ èíúåêöèé 40 ÅÄ/ìë      │Torrent Exports Ltd (Èíäèÿ)   │01918               

                                                                                                                  

│Èíñóëèí Àêòðàïèä HM ïåíôèë    │ðàñòâîð äëÿ èíúåêöèé (ïåíôèëë) 100 │Novo Industry (Äàíèÿ)         │01408              

                              │ÅÄ/ìë - 1.5 ìë                                                                      

                                                                                                                  

│Èíñóëèí Àêòðàïèä ÌÊ           │ðàñòâîð äëÿ èíúåêöèé 40 ÅÄ/ìë      │Novo Industry (Äàíèÿ)         │01401              

                                                                                                                  

│Èíñóëèí Àêòðàïèä ÌÊ           │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Torrent Exports Ltd (Èíäèÿ)   │002245             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíñóëèí Ëåíòå                 │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Novo Industry (Äàíèÿ)         │01261              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóëèí Ëåíòå                 │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Torrent Exports Ltd (Èíäèÿ)   │01912              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóëèí Ëåíòå GP              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Galenika (ÑÔÐÞ)               │002181             

                              │40 ÅÄ/ìë - 10 ìë                                                                     

                                                                                                                  

│Èíñóëèí Ëåíòå MC              │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Novo Industry (Äàíèÿ)         │01403               

                                                                                                                  

│Èíñóëèí Ëåíòå ÑÏÏ             │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Galenika (ÑÔÐÞ)               │002441             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóëèí Ìîíîòàðä HM           │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Novo Industry (Äàíèÿ)         │01407              

│Èíñóëèí Ìîíîòàðä HM           │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Torrent Exports Ltd (Èíäèÿ)   │01919              

│Èíñóëèí Ìîíîòàðä MC           │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Novo Industry (Äàíèÿ)         │01402              

│Èíñóëèí Ìîíîòàðä MC           │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Torrent Exports Ltd (Èíäèÿ)   │003040             

                                                                                                                  

│Èíñóëèí Ïðîòàôàí HM ïåíôèëë   │ñóñïåíçèÿ äëÿ èíúåêöèé (ïåíôèëë)   │Novo Nordisk (Äàíèÿ)          │002138             

                              │100 ÅÄ/ìë - 1.5 ìë                                                                  

                                                                                                                  

│Èíñóëèí Ñåìèëåíòå MC          │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Torrent Exports Ltd (Èíäèÿ)   │002246             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíñóëèí Óëüòðàëåíòå MC        │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Torrent Exports Ltd (Èíäèÿ)   │003039             

                              │40 ÅÄ/ìë - 10 ìë                                                                     

                                                                                                                  

│Èíñóëèí Óëüòðàòàðä HM         │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Novo Industry (Äàíèÿ)         │01462              

│Èíñóëèí Óëüòðàòàðä HM         │ñóñïåíçèÿ äëÿ èíúåêöèé 40 ÅÄ/ìë    │Torrent Exports Ltd (Èíäèÿ)   │01920              

                                                                                                                  

│Èíñóëðàï                      │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Pliva (Þãîñëàâèÿ)             │01384              

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíñóìàí Áàçàë                 │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Hoechst Ag (ÔÐÃ)              │002342             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóìàí Êîìá 15/85            │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Hoechst Ag (ÔÐÃ)              │002344             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóìàí Êîìá 25/75            │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Hoechst Ag (ÔÐÃ)              │002343             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóìàí Êîìá 25/75 äëÿ        │ñóñïåíçèÿ äëÿ èíúåêöèé (àìïóëû äëÿ │Hoechst Ag (ÔÐÃ)              │002348             

│îïòèïåíà                      │øïðèöðó÷êè) 100 ÅÄ/ìë                                                               

                                                                                                                   

│Èíñóìàí Êîìá 50/50            │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Hoechst Ag (ÔÐÃ)              │002345             

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Èíñóìàí Ðàïèä                 │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Hoechst Ag (ÔÐÃ)              │002346             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíñóìàí Ðàïèä äëÿ îïòèïåíà    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû äëÿ   │Hoechst Ag (ÔÐÃ)              │002347             

                              │øïðèöðó÷êè) 100 ÅÄ/ìë                                                               

                                                                                                                  

│Èíòà-Âèð                      │òàáëåòêè                           │Ðîññèÿ                        │0008-4             

│Èíòà-Ö                        │òàáëåòêè                           │Ðîññèÿ                        │0008-5             

                                                                                                                  

│Èíòàë                         │ïîðîøîê äëÿ èíãàëÿöèé â êàïñóëàõ   │Lek (Þãîñëàâèÿ)               │00327              

                              │20 ìã                                                                               

                                                                                                                  

│Èíòåòðèêñ                     │êàïñóëû                            │Farmakos (ÑÔÐÞ)               │002146             

│Èíòðàôóçèí                    │ðàñòâîð äëÿ èíôóçèé 10%            │Pfrimmer-Kabi Gmbh (ÔÐÃ)      │002264             

                                                                                                                  

│Èíòðîí À                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Schering-Plough (ÑØÀ)         │002313              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │3000000, 5000000, 10000000,                                                         

                              │30000000 ÌÅ                                                                         

                                                                                                                  

│Èíóòðàë Èíñóëèí ÃÌ            │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Galenika (ÑÔÐÞ)               │002183             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíóòðàë ÑÏÏ                   │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Galenika (ÑÔÐÞ)               │002442             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Èíôàìèë                                                          │Bristol-Myers (ÑØÀ)           │01644              

│Èíôàìèë ñ æåëåçîì                                                │Bristol-Myers (ÑØÀ)           │01645              

│Èíõèáåéñ                      │ôèëìòàáëåòêè 0.5, 1, 2.5, 5 ìã     │Hoffmann La Roche (Øâåéöàðèÿ) │002719             

                                                                                                                  

│Èïåíòàë                       │äðàæå ñ êèøå÷íîðàñòâîðèìîé         │Ipca Laboratories Ltd (Èíäèÿ) │002660             

                              │îáîëî÷êîé                                                                           

                                                                                                                   

│Èïåðòðîôàí                    │òàáëåòêè ïîêðûòûå îáîëî÷êîé 50000  │Spa (Èòàëèÿ)                  │002315             

                              │ÅÄ                                                                                  

                                                                                                                  

│Èðîâèò                        │êàïñóëû                            │Mesco Laboratories Ltd (Èíäèÿ)│002960             

│Èðóêñîë                       │ìàçü                               │Knoll Ag (ÔÐÃ)                │002792             

│Èðóêñîë                       │ìàçü                               │Pliva (Þãîñëàâèÿ)             │00506              

                                                                                                                  

│Èñèïåí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Krka (Ñëîâåíèÿ)               │002312             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã, 2 ã                                                                              

                                                                                                                  

│Èñïàðÿþùàÿñÿ æèäêîñòü íà      │æèäêîñòü                           │Sumitomo Chemical (ßïîíèÿ)    │0008-6             

│îñíîâå ýòîêà                                                                                                      

                                                                                                                  

│Éîãóðò ñ òðîïè÷åñêèìè ôðóêòàìè│                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004311             

                                                                                                                  

│Éîãóðò ñ ÿáëîêàìè è                                              │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004310             

│ìàíäàðèíàìè                                                                                                       

                                                                                                                   

│Éîãóðò ñ ÿáëîêàìè, àáðèêîñàìè │                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004307             

│è ïåðñèêàìè                                                                                                       

                                                                                                                  

│Êàáèêèíàçà                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Kabi Pharmacia (Øâåöèÿ)       │002708             

                              │èíôóçèîííîãî ðàñòâîðà (ôëàêîíû)                                                     

                              │1500000 ÌÅ                                                                          

                                                                                                                  

│Êàâåðäæåêò                    │ïîðîøîê ñòåðèëüíûé (ôëàêîíû) 10,   │N.V.Upjohn Sa (Áåëüãèÿ)       │007095             

                              │20 ìêã /â êîìïëåêòå ñ                                                               

                              │ðàñòâîðèòåëåì - øïðèö îäíîðàçîâûé/ │                                                 

                                                                                                                  

│Êàâèíòîí                      │òàáëåòêè 5 ìã; ðàñòâîð äëÿ         │Gedeon Richter (Âåíãðèÿ)      │2602               

                              │èíúåêöèé (àìïóëû) 10 ìã - 2 ìë                                                      

                                                                                                                  

│Êàëäîïà                       │òàáëåòêè 250, 500 ìã               │Cadila Laboratories Ltd       │002463             

                                                                 │(Èíäèÿ)                                          

                                                                                                                   

│Êàëèé-íîðìèí                  │òàáëåòêè                           │Alkaloida (Âåíãðèÿ)           │2954               

                                                                                                                   

│Êàëèìèí ôîðòå                 │äðàæå 60 ìã                        │Arzneimittelwerk Dresden Feb  │00190              

                                                                 │(ÃÄÐ)                                            

                                                                                                                  

│Êàëèÿ õëîðèä                  │òàáëåòêè ïðîëîíãèðîâàííîãî         │Mir Pharmaceutical Inc/Copley │007889             

                              │äåéñòâèÿ 600 ìã                    │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Êàëìåçå@                      │òàáëåòêè 1 ìã, 2 ìã                │Themis Chemicals Ltd (Èíäèÿ)  │002206             

│Êàëüöåâèòà                    │òàáëåòêè ðàñòâîðèìûå               │Hoffmann La Roche (Øâåéöàðèÿ) │002717             

                                                                                                                  

│Êàëüöèãàðä                    │êàïñóëû 5, 10 ìã; òàáëåòêè ðåòàðä  │Torrent Exports Ltd (Èíäèÿ)   │01975              

                              │20 ìã                                                                               

                                                                                                                  

│Êàëüöèíîâà                    │òàáëåòêè                           │Krka (Ñëîâåíèÿ)               │002738             

                                                                                                                  

│Êàìåçîë                       │òàáëåòêè 200 ìã                    │Cadila Laboratories Ltd       │003395             

                                                                 │(Èíäèÿ)                                          

                                                                                                                   

│Êàìïîâèò ôîðò                 │êàïñóëû æåëàòèíîâûå                │Union Pharma Co (ÑØÀ)         │003309             

│Êàíåñòåí                      │òàáëåòêè âàãèíàëüíûå; ðàñòâîð; ìàçü│Egis (ÂÍÐ)                    │2568               

                                                                                                                 

│Êàíåñòåí                      │òàáëåòêè âàãèíàëüíûå; ðàñòâîð 1%;  │Polfa (Ïîëüøà)                │2583               

                              │êðåì 1%                                                                             

                                                                                                                  

│ÊÀÏÄ 2                        │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01529              

│ÊÀÏÄ 2Ê                       │ðàñòâîð                            │Fresenius (ÔÐÃ)               │01310              

│ÊÀÏÄ 2Ê                       │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01528              

│ÊÀÏÄ 3                        │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01527              

│ÊÀÏÄ 3Ê                       │ðàñòâîð                            │Fresenius (ÔÐÃ)               │01310              

│ÊÀÏÄ 3Ê                       │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01526              

│ÊÀÏÄ 4                        │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01525              

│ÊÀÏÄ 4Ê                       │ðàñòâîð                            │Inex Hemofarm (Þãîñëàâèÿ)     │01524              

│Êàïîçèä                       │òàáëåòêè 25, 50 ìã                 │Bristol-Myers Squibb (ÑØÀ)    │003362             

│Êàïîòåí                       │òàáëåòêè 12.5 ìã                   │Bristol-Myers Squibb (ÑØÀ)    │002459             

│Êàïîòåí                       │òàáëåòêè 25, 50 ìã                 │Fako Ilaclary As (Òóðöèÿ)     │002158             

│Êàïîòåí                       │òàáëåòêè 25, 50 ìã                 │Squibb (Âåëèêîáðèòàíèÿ)       │01124              

│Êàïîòåí                       │òàáëåòêè 25, 50 ìã                 │Zorka (Þãîñëàâèÿ)             │01371               

│Êàïîòåí                       │òàáëåòêè 25, 50 ìã                 │Zorka Pharma (ÑÐ Þãîñëàâèÿ)   │008474             

                                                                                                                  

│Êàïðèë                        │òàáëåòêè 12.5, 25, 50 ìã           │Boryung Pharmaceutical Co Ltd │002779             

                                                                 │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                  

│Êàïðèë                        │òàáëåòêè 25, 50 ìã                 │Mustafa Nevzat Ilac Sanayi As │002444             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Êàïðèí Ô                      │ïîðîøîê                            │Ðîññèÿ                        │0008-7             

                                                                                                                  

│Êàïñèïëàñò                    │ïëàñòûðü - 15 ìì/10 ìì, 10 ìì/8 ìì │Viskoplast (ÏÍÐ)              │2961               

                              │/íà òêàíåâîé îñíîâå/                                                                

                                                                                                                  

│Êàðáàìàçåïèí                  │òàáëåòêè 200 ìã                    │Mir Pharmaceutical Inc/Lemmon │007702             

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Êàðáàòîë                      │òàáëåòêè 200 ìã                    │Dar Al Dava (Èîðäàíèÿ)        │002586             

                                                                                                                  

│Êàðáî ìåäèöèíàëèñ             │òàáëåòêè; êàïñóëû                  │Paul Hauser Chepharin         │002790             

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                  

│Êàðáîôîñ                      │êîíöåíòðàò ýìóëüñèè                │Ðîññèÿ                        │0001-Á 3           

│Êàðäèêýï                      │êàïñóëû 20, 40 ìã                  │Natco Pharma Ltd (Èíäèÿ)      │003074             

                                                                                                                  

│Êàðäèë                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 120 ìã │Orion Pharmaceutica           │01812              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Êàðäèë (Äèëçåì)               │òàáëåòêè 60 ìã                     │Orion Pharmaceutica           │01508              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Êàðäóðà                       │òàáëåòêè 2 ìã, 4 ìã                │Pliva Sa (Õîðâàòèÿ)           │006076             

│Êàðñèë                        │äðàæå                              │Bulgarska Rosa (Áîëãàðèÿ)     │002360             

│Êàñòåëëà                      │ïàñòà çóáíàÿ                       │Castella (Åãèïåò)             │01410              

│Êàòàìèí-ÀÁ                    │æèäêîñòü                           │Ðîññèÿ                        │0001-À10           

│Êàòàìèí-ÀÁ                    │æèäêîñòü                           │Ðîññèÿ                        │0004-3             

│Êàòîïèë                       │òàáëåòêè 25, 50 ìã                 │Galenika (Þãîñëàâèÿ)          │01498               

│Êàôåðãîò                      │òàáëåòêè                           │Sandoz Urunleri Ilac (Òóðöèÿ) │002188             

│Êàôôåòèí                      │òàáëåòêè                           │Alkaloid (Ìàêåäîíèÿ)          │002603             

                                                                                                                  

│Êàøà ìîëî÷íàÿ ïøåíè÷íàÿ ñ                                        │Gerber (ÑØÀ)                  │004160             

│ìåäîì 03115                                                                                                       

                                                                                                                  

│Êàøà ìîëî÷íàÿ ïøåíè÷íàÿ ñ                                        │Gerber (ÑØÀ)                  │004157             

│ÿáëîêîì 03124                                                                                                     

                                                                                                                  

│Êàøà ìîëî÷íàÿ ðèñîâàÿ 03121                                      │Gerber (ÑØÀ)                  │004156             

                                                                                                                  

│Êàøà ìîëî÷íàÿ ðèñîâàÿ ñ                                          │Gerber (ÑØÀ)                  │004159             

│áàíàíàìè 03110                                                                                                    

                                                                                                                  

│Êâåñòðàí                      │ïîðîøîê                            │Bristol-Myers Company Ltd     │00241              

                                                                 │(Àíãëèÿ)                                         

                                                                                                                   

│Êâèíàêñ                       │êàïëè ãëàçíûå                      │Alcon Pharmaceutical Ltd (ÑØÀ)│002515             

│Êåíàêîðò                      │òàáëåòêè                           │Squibb (Âåëèêîáðèòàíèÿ)       │00353               

│Êåíàëîã                       │ñóñïåíçèÿ äëÿ èíúåêöèé 10, 40 ìã/ìë│Squibb (Âåëèêîáðèòàíèÿ)       │00353              

                                                                                                                  

│Êåòàìèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 250  │Panpharma (Ôðàíöèÿ)           │002675             

                              │ìã - 5 ìë                                                                           

                                                                                                                  

│Êåòàìèíà ãèäðîõëîðèä          │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 50  │J.R.Sharma Overseas Ltd       │003454             

                              │ìã/ìë - 10 ìë                      │(Èíäèÿ)                                          

                                                                                                                  

│Êåòî-äèàñòèêñ                                                    │Aims Company (Âåëèêîáðèòàíèÿ) │00586              

                                                                                                                  

│Êåòîïðîôåí                    │òàáëåòêè ïîêðûòûå îáîëî÷êîé 50,    │Ct-Arzneimittel Chemishe      │003437             

                              │100 ìã; ñâå÷è 100 ìã               │Tempelchof Gmbh (Ãåðìàíèÿ)                       

                                                                                                                  

│Êåòîðîë                       │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Dr.Reddy's Laboratories Ltd   │002684             

                              │èíúåêöèé (àìïóëû) 30 ìã - 1 ìë     │(Èíäèÿ)                                          

                                                                                                                  

│Êåòîñòèêñ                                                        │Aims Company (Âåëèêîáðèòàíèÿ) │00582               

│Êåòîôàí                       │ïîëîñêè                            │Lachema (×ÑÔÐ)                │2636               

                                                                                                                  

│Êåòîöåô                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pliva (Þãîñëàâèÿ)             │00760              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 750, 1500 ìã                                                                   

                                                                                                                  

│Êåôåêñèí                      │òàáëåòêè 250, 500 ìã; ãðàíóëû äëÿ  │Eczacibasi (Òóðöèÿ)           │002238             

                              │ïðèãîòîâëåíèÿ ìèêñòóðû 50 ìã/ìë                                                     

                                                                                                                  

│Êåôîòåêñ                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Gepack International (Èíäèÿ)  │002710             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ìã                                                                   

                                                                                                                 

│Êèáåðíèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Behringwerke Ag (ÔÐÃ)         │002496             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │500, 1000 ÅÄ /â êîìïëåêòå ñ                                                         

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Êèíåòàë-400                   │òàáëåòêè 400 ìã                    │Cipla Ltd (Èíäèÿ)             │002530              

│Êèññ-ñìàéë                    │ïàñòà çóáíàÿ                       │Borbek (ÔÐÃ)                  │004046             

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0002-1             

│êàðàíäàøè                                                                                                         

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0003-1             

│êàðàíäàøè (ìàðê-êà óï-êè 046) │                                                                                    

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0003-3             

│êàðàíäàøè (ìàðê-êà óï-êè                                                                                          

│87-014)                                                                                                           

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0003-2             

│êàðàíäàøè (ìàðê-êà óï-êè                                                                                          

│88-006)                                                                                                           

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0009-4             

│êàðàíäàøè (ìàðê-êà óï-êè:                                                                                         

│-04-003)                                                                                                           

                                                                                                                  

│Êèòàéñêèå èíñåêòèöèäíûå       │êàðàíäàøè                          │Ðîññèÿ                        │0009-5             

│êàðàíäàøè(ìàðê-êà óï-êè                                                                                           

│91-04-0010)                                                                                                       

                                                                                                                  

│Êèòàéñêèå êàðàíäàøè -         │êàðàíäàøè                          │Ðîññèÿ                        │0002-2             

│Áèîëîãè÷åñêèé Óíèêàëüíûé                                                                                          

│90-002"                                                                                                           

                                                                                                                  

│Êèòàéñêèå êàðàíäàøè Âàíõóàëî  │êàðàíäàøè                          │Ðîññèÿ                        │0002-3             

│90-04-006, 91-04-0012"                                                                                            

                                                                                                                  

│Êèòàéñêèé èíñåêòèöèäíûé       │êàðàíäàøè                          │Ðîññèÿ                        │0007-4             

│êàðàíäàø Miraculous                                                                                               

                                                                                                                  

│Êèòàéñêèé èíñåêòèöèäíûé       │êàðàíäàøè                          │Ðîññèÿ                        │0006-3             

│êàðàíäàø (ìàðê-êà óï-êè                                                                                            

│90-04-007)                                                                                                        

                                                                                                                  

│Êëàìèñåò                                                         │Orion Diagnostic (Ôèíëÿíäèÿ)  │01318              

│Êëàðèòèí                      │òàáëåòêè 10 ìã                     │Schering-Plough (ÑØÀ)         │002829             

                                                                                                                  

│Êëàôîðàí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Hoechst Pharmaceutical        │003433             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │(Èíäîíåçèÿ)                                      

                              │ã                                                                                   

                                                                                                                  

│Êëàôîðàí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Roussel Pharma (Èòàëèÿ)       │002424             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                   

                                                                                                                  

│Êëåìàñòèí ôóìàðàò             │òàáëåòêè 1.34 ìã, 2.68 ìã          │Mir Pharmaceutical Inc/Lemmon │007680             

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Êëèèí-Ò                       │ïàñòà çóáíàÿ                       │Itochu&co Ltd (ßïîíèÿ)        │01708              

                                                                                                                  

│Êëèìèöèí                      │êàïñóëû 150 ìã; ðàñòâîð äëÿ        │Lek (Ñëîâåíèÿ)                │002327              

                              │èíúåêöèé (àìïóëû) 300 ìã - 2 ìë                                                     

                                                                                                                  

│Êëèíäàöèí                     │êàïñóëû 150 ìã                     │United Pharmaceutical         │002946             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Êëèíèçîòåñò áèëèðóáèí                                           │Isinta (Âåíãðèÿ)              │2964               

│Êëèíèçîòåñò ãëþêîçà                                              │Isinta (Âåíãðèÿ)              │2967               

│Êëèíèçîòåñò êàëüöèé                                              │Isinta (Âåíãðèÿ)              │2966               

│Êëèíèçîòåñò êðåàòèíèí                                            │Isinta (Âåíãðèÿ)              │2965               

│Êëèíèçîòåñò íàòðèé-êàëèé                                         │Isinta (Âåíãðèÿ)              │2969               

│Êëèíèçîòåñò ôîñôîð                                               │Isinta (Âåíãðèÿ)              │2968               

│Êëèíèçîòåñò õîëèíýñòåðàçà                                        │Isinta (Âåíãðèÿ)              │2963               

│Êëèíèòåñò                                                        │Aims Company (Âåëèêîáðèòàíèÿ) │00585              

                                                                                                                  

│Êëèíîêñèí                     │êàïñóëû 150 ìã; ðàñòâîð äëÿ        │Deva Holding As (Òóðöèÿ)      │002433             

                              │èíúåêöèé (àìïóëû) 300 ìã - 2 ìë                                                      

                                                                                                                  

│Êëèíîðèë                      │òàáëåòêè 200 ìã                    │Merck Sharp & Dohme (ÑØÀ)     │003152              

│Êëèîñòîì                      │ìàçü                               │Gedeon Richter (Âåíãðèÿ)      │002229             

│Êëèôò                         │òàáëåòêè 0.25 ìã                   │Knoll Ag (ÔÐÃ)                │01296              

                                                                                                                  

│Êëîäåðì                       │êðåì 0.05%; ìàçü 0.05%             │United Pharmaceutical         │002947             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Êëîêñàöèëëèí                  │êàïñóëû 250, 500 ìã                │Mir Pharmaceutical            │007676             

                                                                 │Inc/Biocraft Laboratories Inc │                   

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Êëîñòèëáåãèò                  │òàáëåòêè 50 ìã                     │Egis (Âåíãðèÿ)                │2517               

                                                                                                                  

│Êëîòðèìàçîë                   │àýðîçîëü (ôëàêîíû) 10 ìã/ìë - 40 ìë│Ct-Arzneimittel Chemishe      │003084             

                                                                 │Tempelchof Gmbh (Ãåðìàíèÿ)                       

                                                                                                                  

│Êëîôåçîí                      │ñâå÷è 400 ìã                       │Polfa (Ïîëüøà)                │002742              

│Êëóáíè÷íûé éîãóðò                                                │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004309             

│Êëóáíè÷íûé êèñåëü                                                │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004295             

│Êîáà                          │ïîðîøîê                            │Ðîññèÿ                        │0004-17            

│Êîâèò                         │êàïñóëû                            │Eipico (Åãèïåò)               │002830             

│Êîçèëàò                       │ïîðîøîê                            │Egis (Âåíãðèÿ)                │2893               

                                                                                                                  

│Êîêàðáîêñèëàçà                │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Polfa (Ïîëüøà)                │2184               

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû) 50 │                                                 

                              │ìã /â êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                    

                                                                                                                  

│Êî-êîäàìîë                    │òàáëåòêè 8 ìã/500 ìã               │Cox Pharmaceuticals           │003202             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Êîëà-êàî                      │ïîðîøîê                            │Nutrexpa (Èñïàíèÿ)            │00740              

│Êîëáèîöèí                     │êàïëè ãëàçíûå; ìàçü ãëàçíàÿ        │S.I.F.I. Spa (Èòàëèÿ)         │01921              

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Bather (Òóðöèÿ)       │01658              

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Palmolive (Èíäèÿ)     │01504              

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Palmolive (Èòàëèÿ)    │04019              

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Palmolive (Ôðàíöèÿ)   │04020               

                                                                                                                  

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Palmolive Company     │004251             

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Êîëãåéò                       │ïàñòà çóáíàÿ                       │Colgate Palmolive Company     │004069             

                                                                 │(ÔÐÃ/ÑØÀ)                                        

                                                                                                                  

│Êîëãåéò äóàë ôëþîðèä          │ïàñòà çóáíàÿ                       │Colgate Palmolive Company     │004068             

                                                                 │(Åãèïåò)                                         

                                                                                                                  

│Êîëãåéò òàðòàð                │ïàñòà çóáíàÿ                       │Colgate Palmolive (Èíäèÿ)     │01973              

│Êîëãåéò Ôëóîðèãàðä            │ðàñòâîð äëÿ ïîëîñêàíèÿ ðòà         │Colgate Palmolive (ÑØÀ)       │004362             

                                                                                                                  

│Êîëäðåêñ - ïîðîøîê ëèìîííûé   │ïîðîøîê                            │Sterling Health               │003033             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Êîëäðåêñ - ïîðîøîê            │ïîðîøîê                            │Sterling Health               │003032             

│÷åðíîñìîðîäèííûé                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                   

│Êîëèíîñ                       │ïàñòà çóáíàÿ                       │Joffri Manners Co Ltd (Èíäèÿ) │01578              

│Êîëèíîñ-ñóïåð áåëûé           │ïàñòà çóáíàÿ                       │Nevena (ÑÔÐÞ)                 │01785              

                                                                                                                  

│Êîëèðêóçè Áåòàìèäà            │êàïëè ãëàçíûå è óøíûå (ôëàêîíû) 5  │Laboratorious Cusi (Èñïàíèÿ)  │003237             

                              │ìë                                                                                  

                                                                                                                  

│Êîëôàðèò                      │òàáëåòêè 500 ìã                    │Bayer Ag (ÔÐÃ)                │01475              

│Êîìáèñòåðèë FGX 24            │ðàñòâîð äëÿ èíôóçèé                │Fresenius (ÔÐÃ)               │01289              

│Êîìáèñòåðèë FGX 40            │ðàñòâîð äëÿ èíôóçèé                │Fresenius (ÔÐÃ)               │01290              

│Êîìïîò èç ÿáëîê è áàíàíîâ                                        │Nestle (Ãåðìàíèÿ)             │004216             

│Êîíâóëåêñ                     │òàáëåòêè 300 ìã                    │Gerot Pharmazeutika (Àâñòðèÿ) │00842              

│Êîíñàéç                       │ìàòåðèàë ïëîìáèðîâî÷íûé            │Zm (Øâåéöàðèÿ)                │00545              

│Êîíñóë                        │ïàñòà çóáíàÿ                       │Pollena-Lechia (ÏÍÐ)          │2948               

│Êîíòåêñ-10                                                       │Soy Meinz (ÔÐÃ)               │004147             

│Êîíòåêñ-120                                                      │Soy Meinz (ÔÐÃ)               │004145             

│Êîíòðîëüíàÿ ïëàçìà êîàãóëÿöèè │                                   │Belgian Chemical (Áåëüãèÿ)    │00957              

│Êîðàá                                                            │Abbott (ÔÐÃ)                  │00709               

│Êîðàëë                        │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2866               

                                                                                                                  

│Êîðãàðä                       │òàáëåòêè 40, 80 ìã                 │Bristol-Myers Squibb          │003313             

                                                                 │(Èíäîíåçèÿ)                                      

                                                                                                                  

│Êîðãàðä                       │òàáëåòêè 40, 80 ìã                 │Bristol-Myers Squibb Egypt    │002219             

                                                                 │(Åãèïåò)                                         

                                                                                                                  

│Êîðãàðä                       │òàáëåòêè 40, 80 ìã                 │Fako Ilaclary As (Òóðöèÿ)     │002159             

                                                                                                                  

│Êîðäàðîí                      │òàáëåòêè 200 ìã                    │Dogu Ilac Fabricasi As        │002848             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Êîðäàðîí                      │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Krka (ÑÔÐÞ)                   │00829              

                              │(àìïóëû) 150 ìã - 3 ìë                                                              

                                                                                                                  

│Êîðäàðîí                      │òàáëåòêè 200 ìã                    │Sanofi/labaz (Ôðàíöèÿ)        │00491              

│Êîðäàôåí                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10 ìã  │Polfa (ÏÍÐ)                   │2920               

                                                                                                                   

│Êîðåáåðîí                     │äðàæå 20 ìã                        │Arzneimittelwerk Dresden Feb  │01229              

                                                                 │(ÃÄÐ)                                            

                                                                                                                  

│Êîðåãà òýáñ - äåíòà êëèíñåð   │òàáëåòêè äëÿ ïðèãîòîâëåíèÿ ðàñòâîðà│Block Drug Company Inc (ÔÐÃ)  │004060             

│òýáëåòñ                                                                                                           

                                                                                                                  

│Êî-ðåíèòåê                    │òàáëåòêè 10 ìã/25 ìã               │Merck Sharp & Dohme (ÑØÀ)     │003079             

│Êîðíîëàê                      │êàøà ìîëî÷íàÿ                      │Codrico (Íèäåðëàíäû)          │004345             

                                                                                                                  

│Êîðòèêîòðîïèí äëÿ èíúåêöèé    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Ðîññèÿ                        │70/729/35          

                              │èíúåêöèîííîãî ðàñòâîðà                                                              

                                                                                                                  

│Êîñìîïëàñò                    │ëåéêîïëàñòûðü                      │Kurtsan Hartmann Medical      │002643             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Êîòèíóñ                       │ýëèêñèð çóáíîé                     │Pelpusta (Âåíãðèÿ)            │2830               

                                                                                                                   

│Êî-òðèìîêñàçîë-Ðèâîôàðì       │òàáëåòêè 120, 480, 960 ìã;         │Rivopharm Sa (Øâåéöàðèÿ)      │003891             

                              │ñóñïåíçèÿ îðàëüíàÿ (ôëàêîíû) 240                                                    

                              │ìã|5 ìë                                                                             

                                                                                                                  

│Êîòðèìîêñàçîë                 │òàáëåòêè 400 ìã/80 ìã; ñóñïåíçèÿ   │Promed Exports Pvt Ltd (Èíäèÿ)│003046             

                              │îðàëüíàÿ 200 ìã/40 ìã|5 ìë                                                          

                                                                                                                  

│Êîòðèì-Ðàòèîôàðì              │òàáëåòêè 480 ìã; òàáëåòêè ôîðòå    │Ratiopharm Gmbh & Co          │003414             

                              │960 ìã; ñîê äëÿ âçðîñëûõ (ôëàêîíû) │(Ãåðìàíèÿ)                                       

                              │100 ìë                                                                              

                                                                                                                  

│Ê-îòðèí Ôëîó                  │æèäêîñòü                           │Roussel Uclaf (Ôðàíöèÿ)       │0001-à 1           

│Êðåì-21                       │êðåì äíåâíîé                       │Henkel Kgaa (ÔÐÃ)             │004201             

│Êðåîí                         │êàïñóëû 300 ìã                     │Kali-Chemie Pharma Gmbh (ÔÐÃ) │002057             

│Êðåñò                         │ïàñòà çóáíàÿ                       │Procter & Gamble (ÑØÀ)        │01441              

                                                                                                                  

│Êðåñò                         │ïàñòà çóáíàÿ                       │Procter & Gamble India Ltd    │01500              

                                                                 │(Èíäèÿ)                                          

                                                                                                                   

│Êðåñò ìÿòíûé                  │ïàñòà çóáíàÿ                       │Procter & Gamble (ÑØÀ)        │01982              

│Êðåñò-òàðòàð                  │ïàñòà çóáíàÿ                       │Procter & Gamble (Èíäèÿ)      │01730              

                                                                                                                  

│Êðèîñòàò ÑÄ-2                 │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Grifols Sa (Èñïàíèÿ)          │002820             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ÅÄ                                                                   

                                                                                                                  

│Êðèïòî-Ãåì ÑÑ                                                   │Serumwerk Drezden (ÃÄÐ)       │01306              

                                                                                                                  

│Êðîìîëèí                      │ïîðîøîê äëÿ èíãàëÿöèé â êàïñóëàõ   │Orion Pharmaceutica           │002073             

                              │20 ìã                              │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Êñåíèä                        │òàáëåòêè 25, 50 ìã; òàáëåòêè       │Biogalenique (Ôðàíöèÿ)        │003209             

                              │ðåòàðä 100 ìã; ñâå÷è 25, 100 ìã;                                                    

                              │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 75                                                    

                              │ìã - 3 ìë                                                                           

                                                                                                                   

│Êñèëåñòåçèí                   │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 20   │Espe (Ãåðìàíèÿ)               │003378             

                              │ìã - 1.8 ìë                                                                          

                                                                                                                  

│Êñèìåëèí                      │ñïðåé äëÿ íîñà (ôëàêîíû ñòåêëÿííûå │Nycomed Dak As (Äàíèÿ)        │003255             

                              │ñ ïðèñïîñîáëåíèåì äëÿ                                                               

                              │âïðûñêèâàíèÿ) 0.5, 1 ìã/ìë - 15                                                     

                              │ìë; êàïëè äëÿ íîñà (ôëàêîíû                                                         

                              │ïëàñòèêîâûå) 0.5, 1 ìã/ìë - 10 ìë; │                                                 

                              │êàïëè äëÿ íîñà (àìïóëû                                                              

                              │ïëàñòèêîâûå) 0.5, 1 ìã/ìë - 0.3 ìë │                                                 

                                                                                                                  

│Êóçèêðîì                      │ðàñòâîð îôòàëüìîëîãè÷åñêèé         │Laboratorious Cusi (Èñïàíèÿ)  │003235             

                              │(ôëàêîíû) 4% - 10 ìë                                                                

                                                                                                                  

│Êóçèìîëîë                     │êàïëè ãëàçíûå 0.25%, 0.5%          │Laboratorious Cusi (Èñïàíèÿ)  │003162             

                                                                                                                  

│Êóêñàíîðì                     │òàáëåòêè 50, 100 ìã                │Tad Pharmazeutisches Werk     │003374             

                                                                 │Gmbh (Ãåðìàíèÿ)                                  

                                                                                                                   

│Êóëüïàí-Ñ                     │òàáëåòêè                           │Daewoong Pharmaceutical Co    │002536             

                                                                 │Ltd (Êîðåÿ Þæíàÿ)                                

                                                                                                                  

│Êóðèöà ñ ìîðêîâüþ                                                │Nestle (Ãåðìàíèÿ)             │004223             

                                                                                                                  

│Êóðèöà ñ îâîùàìè è ëàïøîé                                        │Hipp (Àâñòðèÿ)                │004035             

│àðò.368                                                                                                           

                                                                                                                  

│ÊÔÊ                                                              │Labsystems (Ôèíëÿíäèÿ)        │01338              

│Êýàôðèè                       │ïðîêëàäêè æåíñêèå ãèãèåíè÷åñêèå    │Johnson & Johnson (ÑØÀ)       │01949              

│ÊÝ×                           │ëîâóøêà êëåéêàÿ                    │Babolna (Âåíãðèÿ)             │0004-18            

│Ëàáñòèêñ                      │ïîëîñêè                            │Aims Company (Âåëèêîáðèòàíèÿ) │00292              

│Ëàáñòèêñ                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2558               

                                                                                                                  

│Ëàäèîìèë                      │òàáëåòêè 25, 50 ìã; ðàñòâîð äëÿ    │Pliva (Õîðâàòèÿ)              │002548             

                              │èíúåêöèé (àìïóëû) 25 ìã - 2 ìë                                                      

                                                                                                                  

│Ëàçèêñ                        │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìë │Hoechst (Èíäèÿ)               │01197              

│Ëàçèêñ                        │òàáëåòêè 40 ìã                     │Hoechst Ltd (Èíäèÿ)           │003730              

                                                                                                                  

│Ëàçèêñ                        │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 20   │Servo-Michal (Þãîñëàâèÿ)      │00200              

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Ëàçóðü                        │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2708               

│Ëàêè ìèíò                     │ïàñòà çóáíàÿ                       │Lucky Gold Star (Êîðåÿ Þæíàÿ) │01721              

│Ëàêðèñèôè                     │êàïëè ãëàçíûå                      │S.I.F.I. Spa (Èòàëèÿ)         │01922              

│Ëàêñàêîäèë                    │òàáëåòêè 5 ìã                      │Torrent Exports Ltd (Èíäèÿ)   │002247             

│Ëàêòàò íàòðèÿ (Àðëàê Ñ)                                          │Adm (ÑØÀ)                     │004363             

│Ëàìàäèí                       │òàáëåòêè 10 ìã                     │Alkaloid (ÑÔÐÞ)               │002075             

                                                                                                                  

│Ëàíèòîï                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 0.2  │Boehringer Mannheim Gmbh      │002164             

                              │ìã - 2 ìë                          │(Àâñòðèÿ)                                        

                                                                                                                  

│Ëàðèïðîíò                     │òàáëåòêè                           │Mack (Ãåðìàíèÿ)               │00641              

                                                                                                                  

│Ëàñòåò                        │êàïñóëû 100 ìã; ðàñòâîð äëÿ        │Nippon Kayaku Co Ltd (ßïîíèÿ) │002045             

                              │èíúåêöèé 100 ìã                                                                     

                                                                                                                   

│Ëàòèêîðò                      │êðåì; ìàçü                         │Polfa (Ïîëüøà)                │2881               

│ËÄà                                                             │Labsystems (Ôèíëÿíäèÿ)        │01339              

│ËÄÃ-òåñò                                                         │Reanal (Âåíãðèÿ)              │2939               

│Ëåâîäîïà+Êàðáèäîïà            │òàáëåòêè                           │Dabur India Ltd (Èíäèÿ)       │002059             

                                                                                                                  

│Ëåéêîìàêñ                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Schering-Plough/sandoz Pharma │002487             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÑØÀ/øâåéöàðèÿ)                                  

                              │50, 150, 400, 700, 1500 ìêã                                                         

                                                                                                                  

│Ëåéíàçà                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Kyowa Hakko Kogyo Co Ltd      │003094             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ßïîíèÿ)                                         

                              │5000, 10000 ÌÅ                                                                      

                                                                                                                  

│Ëåêðîëèí                      │êàïëè ãëàçíûå (ôëàêîíû) 20 ìã/ìë - │Leiras (Ôèíëÿíäèÿ)            │005610             

                              │10 ìë; êàïëè ãëàçíûå                                                                

                              │(òþáèê-êàïåëüíèöû) 20 ìã/ìë - 0.25 │                                                 

                              │ìë                                                                                   

                                                                                                                  

│Ëåêñèëèóì@                    │òàáëåòêè 1.5, 3, 6 ìã              │Alkaloid (Þãîñëàâèÿ)          │01149              

│Ëåêñîòàí@                     │òàáëåòêè 1.5, 3, 6 ìã              │Hoffmann La Roche (Øâåéöàðèÿ) │00633              

                                                                                                                  

│Ëåíäàöèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Lek (Ñëîâåíèÿ)                │002448             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 1000 ìã                                                                        

                                                                                                                  

│Ëåíòå Èëåòèí II               │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │02034              

                              │40, 100 ÅÄ/ìë - 10 ìë                                                               

                                                                                                                  

│Ëåïîíåêñ                      │òàáëåòêè 25, 100 ìã; ðàñòâîð äëÿ   │Bosnalijek (Þãîñëàâèÿ)        │01369              

                              │èíúåêöèé (àìïóëû) 50 ìã - 2 ìë                                                      

                                                                                                                  

│Ëåïðîòåê                      │äðàæå 35 ìã                        │Zdravle (ÑÔÐÞ)                │002143             

│Ëèáåêñèí                      │òàáëåòêè                           │Chinoin (Âåíãðèÿ)             │2671               

│Ëèáðàêñ                       │äðàæå                              │Hoffmann La Roche (Øâåéöàðèÿ) │00462              

│Ëè-áóòîë                      │òàáëåòêè 200, 400, 800 ìã          │Lyka Labs Ltd (Èíäèÿ)         │002292             

                                                                                                                   

│Ëèâ-52                        │òàáëåòêè; êàïëè; ñèðîï             │Himalaya Drug Company Ltd     │00631              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ëèâîìèí                       │òàáëåòêè                           │Charak Pharmaceutical (Èíäèÿ) │01168              

                                                                                                                  

│Ëèäàïðèì                      │òàáëåòêè äëÿ äåòåé 120 ìã;         │Hafslund Nycomed (Àâñòðèÿ)    │002192             

                              │òàáëåòêè 480 ìã; òàáëåòêè ôîðòå                                                     

                              │960 ìã; ðàñòâîð äëÿ âíóòðèâåííîãî                                                   

                              │ââåäåíèÿ (ôëàêîíû) 250 ìë;                                                          

                              │ñóñïåíçèÿ äëÿ äåòåé 240 ìã|5 ìë                                                     

                                                                                                                  

│Ëèäî                          │ïàñòà çóáíàÿ                       │Itochu&co Ltd (ßïîíèÿ)        │01709              

│Ëèäîêàèí                      │àýðîçîëü 10%                       │Egis (Âåíãðèÿ)                │2519               

                                                                                                                  

│Ëèäîêàèí                      │ðàñòâîð äëÿ âíóòðèìûøå÷íûõ         │Egis (Âåíãðèÿ)                │2622               

                              │èíúåêöèé (àìïóëû) 10% - 2 ìë                                                        

                                                                                                                   

│Ëèäîêàèí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2% - │Egit (Âåíãðèÿ)                │2391               

                              │2, 10 ìë                                                                             

                                                                                                                  

│Ëèäîêàèíà ãèäðîõëîðèä         │ãåëü (òóáû) 2% - 30 ã              │Mir Pharmaceutical Inc/Copley │007703             

                                                                 │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Ëèçåòîë ÀÔ                    │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0005-2             

│Ëèçî-Á                        │òàáëåòêè ñóáëèíãâàëüíûå            │Bosnalijek (Þãîñëàâèÿ)        │00933              

                                                                                                                  

│Ëèçîëèí                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Lyka Labs Ltd (Èíäèÿ)         │002257             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ìã                                                                   

                                                                                                                  

│Ëèêàöèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû)500   │Lisapharma (Èòàëèÿ)           │01711              

                              │ìã/2 ìë, 1000 ìã/4 ìë                                                               

                                                                                                                  

│Ëèíêîìèöèíà ãèäðîõëîðèä       │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 600 │Shin Poong Ltd (Êîðåÿ Þæíàÿ)  │002780             

                              │ìã - 2 ìë                                                                           

                                                                                                                   

│Ëèíêîöèí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 300  │Eczacibasi (Òóðöèÿ)           │002572             

                              │ìã/ìë - 2 ìë                                                                        

                                                                                                                  

│Ëèíîñèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 600  │Deva Holding As (Òóðöèÿ)      │002434             

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Ëèïàíòèë                      │êàïñóëû 100 ìã                     │Lecleark & Co (Øâåéöàðèÿ)     │002196             

                                                                                                                  

│Ëèïèîäîë Óëüòðà-Ôëþèä         │ðàñòâîð äëÿ èíúåêöèé ìàñëÿíûé      │Byk Gulden Gmbh (Ãåðìàíèÿ)    │00803              

                              │(àìïóëû) 5, 10 ìë                                                                   

                                                                                                                  

│Ëèïèòîð                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10,    │Godecke Ag/Pfizer             │009678             

                              │20, 40 ìã                          │International Inc (Ãåðìàíèÿ)                     

                                                                                                                  

│Ëèïîìàë                       │òàáëåòêè 250 ìã                    │Alkaloid (Ìàêåäîíèÿ)          │002655             

                                                                                                                  

│Ëèïîñòàáèë                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 500  │Bosnalijek (Þãîñëàâèÿ)        │01516              

                              │ìã - 10 ìë; êàïñóëû ôîðòå 350 ìã                                                    

                                                                                                                   

│Ëèïîôèêñ                      │êëåé                               │Ðîññèÿ                        │0001-7             

│Ëîäåðèêñ                      │òàáëåòêè 1 ìã                      │Egis (Âåíãðèÿ)                │002201             

│Ëîìàãåðïàí                    │êðåì                               │Eudac Ag (Øâåéöàðèÿ)          │002273             

│Ëîìóçîë                       │àýðîçîëü íàçàëüíûé äîçèðîâàííûé    │Fisons (Âåëèêîáðèòàíèÿ)       │002222             

                                                                                                                  

│Ëîíãàöåô                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Galenika (Þãîñëàâèÿ)          │01355              

                              │âíóòðèâåííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 1000 ìã; ïîðîøîê äëÿ                                                           

                              │ïðèãîòîâëåíèÿ âíóòðèìûøå÷íîãî                                                       

                              │ðàñòâîðà (ôëàêîíû) 250, 1000 ìã                                                     

                                                                                                                  

│Ëîíöèä                        │ëîñüîí                             │Ðîññèÿ                        │0001-16            

                                                                                                                  

│Ëîïðåñîð                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé ðåòàðä │Ciba-Geigy (Øâåéöàðèÿ)        │002236             

                              │200 ìã                                                                              

                                                                                                                  

│Ëîðèíäåí                      │ýìóëüñèÿ                           │Polfa (Ïîëüøà)                │2460                

│Ëîðèíäåí Ñ                    │ìàçü                               │Polfa (Ïîëüøà)                │2308               

                                                                                                                   

│Ëîòåíñèí                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10, 20 │Ciba-Geigy (Øâåéöàðèÿ)        │003019             

                              │ìã                                                                                  

                                                                                                                  

│Ëîòèíîñ                       │ïàñòà çóáíàÿ                       │M.Camal Loutphy (Ñèðèÿ)       │01210              

│Ëîôåíàëàê                     │ïîðîøîê                            │Bristol-Myers Squibb (ÑØÀ)    │00242              

│ËÑ-65 Í                       │ðàñòâîð                            │Pharm-Allergan Gmbh (ÔÐÃ)     │01822              

                                                                                                                  

│Ëóâàòðåí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5    │Cilag-Chemie (Øâåéöàðèÿ)      │00701              

                              │ìã/1 ìë                                                                             

                                                                                                                  

│Ëóíîïëàíò                     │ïàñòà çóáíàÿ                       │Luns (ÔÐÃ)                    │01765              

│Ëþäèîìèë                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 25 ìã  │Ciba-Geigy (Èíäîíåçèÿ)        │003192             

                                                                                                                  

│Ëþäèîìèë                      │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ciba-Geigy (Èñïàíèÿ)          │002269             

                              │îáîëî÷êîé 25 ìã                                                                     

                                                                                                                  

│Ëþäèîìèë                      │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ciba-Geigy Ilac (Òóðöèÿ)      │002069              

                              │îáîëî÷êîé 25, 75 ìã; ðàñòâîð äëÿ                                                    

                              │èíúåêöèé (àìïóëû) 25 ìã - 2 ìë                                                      

                                                                                                                 

│Ëþêñ-À-Ôèëë                   │ìàòåðèàë ïëîìáèðîâî÷íûé            │Blendax (ÔÐÃ)                 │004054             

                                                                                                                  

│Ëþòðåëåô                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Ferring Arzneimittel Gmbh     │002601             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÔÐÃ)                                            

                              │0.8, 3.2 ìã                                                                         

                                                                                                                  

│Ì.Äæ.Ìàãèê áàëüçàì            │ìàçü                               │M.J.Pharmaceuticals Ltd       │003372             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ìààëîêñ                       │òàáëåòêè 400 ìã/400 ìã             │Berlin-Chemie Ag (ÔÐÃ)        │002900             

                                                                                                                  

│Ìààëîêñ-70                    │ñóñïåíçèÿ (ïàêåòû) 10 ìë;          │Rhone-Poulenc Rorer (Ôðàíöèÿ) │002609             

                              │ñóñïåíçèÿ (ôëàêîíû) 250 ìë                                                          

                                                                                                                  

│Ìàáðîí@                       │êàïñóëû 50 ìã; ðàñòâîð äëÿ         │Medochemie Ltd (Êèïð)         │002574             

                              │èíúåêöèé (àìïóëû) 100 ìã - 2 ìë                                                      

                                                                                                                  

│Ìàãíåñîë                      │òàáëåòêè øèïó÷èå 150 ìã            │Krka (Ñëîâåíèÿ)               │002483             

│Ìàäîïàð                       │êàïñóëû 125, 250 ìã                │Hoffmann La Roche (Øâåéöàðèÿ) │00457              

                                                                                                                  

│Ìàæåïòèë                      │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Torrent Exports Ltd (Èíäèÿ)   │002081             

                              │îáîëî÷êîé 10 ìã; ðàñòâîð äëÿ                                                        

                              │èíúåêöèé (àìïóëû) 1% - 1 ìë                                                         

                                                                                                                  

│Ìàé áîé                       │ñìåñü ìîëî÷íàÿ ðèñîâàÿ ñ áàíàíàìè  │Coberco Omefa (Íèäåðëàíäû)    │004211             

│Ìàé áîé ýëäîïëþñ                                                 │Coberco Omefa (Íèäåðëàíäû)    │004212             

│Ìàé áîé ýëäîðèí                                                  │Coberco Omefa (Íèäåðëàíäû)    │004210             

│Ìàêëèíç                       │ïàñòà çóáíàÿ                       │Nmm Ltd (Èíäèÿ)               │01696              

│Ìàêëèíç ìèëäìèíò              │ïàñòà çóáíàÿ                       │Attar Cauli Vros (Ñèðèÿ)      │01291              

│Ìàêëèíç ìèëäìèíò              │ïàñòà çóáíàÿ                       │Beecham Group (Âåëèêîáðèòàíèÿ)│01343              

│Ìàêëèíç ôðåøìèíò              │ïàñòà çóáíàÿ                       │Attar Cauli Vros (Ñèðèÿ)      │01292              

│Ìàêëèíç ôðåøìèíò              │ïàñòà çóáíàÿ                       │Beecham Group (Âåëèêîáðèòàíèÿ)│01344              

                                                                                                                   

│Ìàêìèðîð                      │äðàæå 200 ìã; ñâå÷è 250 ìã         │Poli Industria Chimica Spa    │002224             

                                                                 │(Èòàëèÿ)                                         

                                                                                                                  

│Ìàê-î-äåíò                    │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2805               

                                                                                                                  

│Ìàêðîïåí                      │òàáëåòêè 400 ìã; ïîðîøîê äëÿ       │Krka (Ñëîâåíèÿ)               │002563             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè                                                    

                              │175 ìã|5 ìë                                                                         

                                                                                                                  

│Ìàêñàì                        │ïàñòà çóáíàÿ                       │Shanhai Branch (ÊÍÐ)          │01633              

│Ìàêñàìàèä ÕР                 │ñìåñü ñóõàÿ                        │Valio (Ôèíëÿíäèÿ)             │004106             

│Ìàêñàìóì ÕР                  │ñìåñü ñóõàÿ                        │Valio (Ôèíëÿíäèÿ)             │004107             

                                                                                                                  

│Ìàêñèãàí                      │òàáëåòêè 0.6 ã                     │Unichem Laboratories Ltd      │002134             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ìàêñèãëîáèí                   │êîíöåíòðàò                         │Veverska Bytishka             │2824               

                                                                 │(×åõîñëîâàêèÿ)                                   

                                                                                                                   

│Ìàêñèòèíñ ðåãóëÿð, ñóïåð      │ïðîêëàäêè æåíñêèå ãèãèåíè÷åñêèå    │Tambrands (ÑØÀ)               │01872              

│Ìàëåíüêèé ïèðîã ñ îâîùàìè                                        │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004300             

│Ìàííèòîë                      │ðàñòâîð äëÿ èíôóçèé 20%            │Eczacibasi (Òóðöèÿ)           │01883              

                                                                                                                  

│Ìàííûå õëîïüÿ áýáè                                               │Kolynska/Sloveniales          │004369             

                                                                 │(Ñëîâåíèÿ)                                       

                                                                                                                  

│Ìàííûå õëîïüÿ ñî âêóñîì                                          │Kolynska/Sloveniales          │004371             

│àïåëüñèíà áýáè                                                   │(Ñëîâåíèÿ)                                       

                                                                                                                  

│Ìàííûå õëîïüÿ ñî âêóñîì ÿáëîê │                                   │Kolynska/Sloveniales          │004370             

│áýáè                                                             │(Ñëîâåíèÿ)                                       

                                                                                                                  

│Ìàðàòîíèê                     │ãðàíóëÿò                           │Krka (ÑÔÐÞ)                   │002111             

│Ìàðâåëîí                      │òàáëåòêè 0.15 ìã/0.03 ìã           │Organon (Èíäîíåçèÿ)           │003186             

│Ìàðâåëîí                      │òàáëåòêè                           │Organon (Íèäåðëàíäû)          │002058             

                                                                                                                   

│Ìàðèíáèô-R                                                       │Niigata Engenering Co Ltd     │01048              

                                                                 │(ßïîíèÿ)                                          

                                                                                                                  

│Ìàðèíáèô-W                                                       │Niigata Engenering Co Ltd     │01047              

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ìàðèíèë îðèãèíàë              │òàáëåòêè 500 ìã                    │Sivid (Øâåöèÿ)                │002630             

│Ìàðèíèë ñïîðò                 │òàáëåòêè 650 ìã                    │Sivid (Øâåöèÿ)                │002190             

│Ìàòåðíà                       │òàáëåòêè                           │Lederle (ÑØÀ)                 │002473             

│Ìàòîèí                        │òàáëåòêè 200 ìã                    │Labohain-Wolf (Áåëüãèÿ)       │002649             

│Ìàøåíüêà                      │êàðàíäàøè èíñåêòèöèäíûå            │Ðîññèÿ                        │0009-6             

│ÌÄÑ                           │ïîðîøîê                            │Ðîññèÿ                        │0001-À11           

│Ìåáåíäàçîë                    │òàáëåòêè 100 ìã                    │Confab (Êàíàäà)               │003075             

                                                                                                                  

│Ìåáåíäàçîë                    │òàáëåòêè æåâàòåëüíûå 100 ìã        │Mir Pharmaceutical Inc/Copley │007888             

                                                                 │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Ìåâàêîð                       │òàáëåòêè 10, 40 ìã                 │Merck Sharp & Dohme (ÑØÀ)     │002800             

│Ìåãåéñ                        │òàáëåòêè 40 ìã                     │Bristol-Myers Squibb (ÑØÀ)    │002350              

│Ìåäîêëàöèä                    │òàáëåòêè 80 ìã                     │Medochemie Ltd (Êèïð)         │003205             

│Ìåäðîë                        │òàáëåòêè 4 ìã, 16 ìã               │Upjohn (Áåëüãèÿ)              │002318             

│Ìåéäæè ÔÌ-Ò                                                      │Magy Milk Products (ßïîíèÿ)   │01742              

                                                                                                                  

│Ìåêñàëåí                      │òàáëåòêè 500 ìã; ñèðîï (ôëàêîíû)   │Ludwig Merckle Gmbh (Àâñòðèÿ) │002494             

                              │200 ìã|5 ìë; ñâå÷è 125, 250, 500,                                                   

                              │1000 ìã                                                                             

                                                                                                                  

│Ìåëàòîêñ                      │êàðàíäàøè                          │Ðîññèÿ                        │0004-19            

                                                                                                                  

│Ìåëèïðàìèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 25   │Egis (Âåíãðèÿ)                │2820               

                              │ìã - 2 ìë                                                                           

                                                                                                                 

│Ìåëèïðàìèí                    │äðàæå 25 ìã                        │Egis (Âåíãðèÿ)                │2670               

│Ìåëèïðàìèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìë │Egit (Âåíãðèÿ)                │2067               

                                                                                                                  

│Ìåëëåðèë                      │òàáëåòêè â îáîëî÷êå èç ñàõàðà 10,  │Sandoz Urunleri Ilac (Òóðöèÿ) │002310             

                              │25, 100 ìã                                                                          

                                                                                                                   

│Ìåëëèí-1                                                         │Mellin (Èòàëèÿ)               │004136             

                                                                                                                  

│Ìåíåôëîêñ                     │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Mustafa Nevzat Ilac Sanayi As │003151             

                              │îáîëî÷êîé 200 ìã                   │(Òóðöèÿ)                                         

                                                                                                                  

│Ìåíçèì                        │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Menon Pharma (Èíäèÿ)          │002663             

                              │îáîëî÷êîé; òàáëåòêè â îáîëî÷êå èç                                                   

                              │ñàõàðà                                                                              

                                                                                                                  

│Ìåïèâàñòåçèí                  │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 30   │Espe (Ãåðìàíèÿ)               │003379             

                              │ìã - 1.8 ìë                                                                         

                                                                                                                  

│Ìåïîðå                        │ïîâÿçêà ïëàñòûðíîãî òèïà           │Melnluke Ab (Øâåöèÿ)          │004273             

│Ìåðëèò@                       │òàáëåòêè 1, 2.5 ìã                 │Ebewe (Àâñòðèÿ)               │002658             

                                                                                                                  

│Ìåòàäîêñèë                    │òàáëåòêè 500 ìã; ðàñòâîð äëÿ       │Laboratoiri Baldacci Spa      │002053             

                              │èíúåêöèé (àìïóëû) 300 ìã - 5 ìë    │(Èòàëèÿ)                                          

                                                                                                                  

│Ìåòàêåëüôèí                   │òàáëåòêè 525 ìã                    │Farmitalia Carlo Erba (Èòàëèÿ)│003461              

                                                                                                                  

│Ìåòåðãèí                      │òàáëåòêè â îáîëî÷êå èç ñàõàðà      │Sandoz Urunleri Ilac (Òóðöèÿ) │002208             

                              │0.125 ìã                                                                            

                                                                                                                  

│Ìåòèçîë                       │òàáëåòêè 5 ìã                      │Polfa (Ïîëüøà)                │3010               

│Ìåòèíäîë                      │ìàçü                               │Polfa (Ïîëüøà)                │2792               

│Ìåòèíäîë                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 25 ìã  │Polfa (Ïîëüøà)                │2868               

                                                                                                                  

│Ìåòèíäîë                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 3% - │Polfa (Ïîëüøà)                │2867               

                              │2 ìë                                                                                

                                                                                                                  

│Ìåòèíäîë                      │òàáëåòêè ðåòàðä 75 ìã              │Polfa (Ïîëüøà)                │2902               

│Ìåòèîâèò                      │êàïñóëû æåëàòèíîâûå                │Union Pharma Co (ÑØÀ)         │003310             

                                                                                                                  

│Ìåòîêëîïðàìèä                 │òàáëåòêè 10 ìã                     │Biocraft Laboratories Inc     │002356             

                                                                 │(ÑØÀ)                                            

                                                                                                                   

│Ìåòîêëîïðàìèä                 │òàáëåòêè 5, 10 ìã; ðàñòâîð         │Mir Pharmaceutical            │007698             

                              │îðàëüíûé (ôëàêîíû) 5 ìã|5 ìë - 473 │Inc/Biocraft Laboratories Inc │                   

                              │ìë                                 │(ÑØÀ)                                            

                                                                                                                  

│Ìåòîëîë                       │òàáëåòêè 50, 100 ìã                │Ludwig Merckle Gmbh (Àâñòðèÿ) │003330             

                                                                                                                  

│Ìåòîïðåññ                     │òàáëåòêè                           │M.J.Pharmaceuticals Ltd       │003373             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ìåòîòðåêñàò                   │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 50  │David Bull Laboratories       │003139             

                              │ìã/2 ìë, 0.5 ã/20 ìë, 1 ã/10 ìë, 5 │(Àâñòðàëèÿ)                                      

                              │ã/50 ìë                                                                             

                                                                                                                  

│Ìåòïàìèä                      │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Sifar Ilaclary Sanayi As      │002499             

                              │èíúåêöèé (àìïóëû) 10 ìã - 2 ìë     │(Òóðöèÿ)                                         

                                                                                                                  

│Ìåòðîäèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Ares-Serono Group (Øâåéöàðèÿ) │002095             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû) 75 │                                                 

                              │ÌÅ /â êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                     

                                                                                                                  

│Ìåòðîíèäàçîë                  │òàáëåòêè 200, 250, 400 ìã          │Grossons Pharmaceutical       │003453             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ìåòðîíèäàçîë                  │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Polfa (Ïîëüøà)                │2885               

                              │(àìïóëû) 0.5% - 20 ìë                                                               

                                                                                                                 

│Ìåòðîíèäàçîë                  │ðàñòâîð äëÿ èíôóçèé èçîòîíè÷åñêèé  │Polfa (Ïîëüøà)                │003164             

                              │(åìêîñòè ïîëèýòèëåíîâûå) 0.5% -                                                     

                              │100 ìë                                                                              

                                                                                                                  

│Ìåòðîíèäàçîë                  │òàáëåòêè 200 ìã                    │Rima Pharmaceutical Ltd       │002962             

                                                                 │(Èðëàíäèÿ)                                       

                                                                                                                  

│Ìåòðîíèäàçîë                  │òàáëåòêè 250 ìã                    │Rivopharm Sa (Íèäåðëàíäû)     │003087             

│Ìåòðîíèäàçîë                  │òàáëåòêè 250 ìã                    │Watson Laboratories Inc (ÑØÀ) │002476             

│Ìåòôîðìèí                     │òàáëåòêè 500 ìã                    │Polfa (Ïîëüøà)                │2886               

│Ìåôèêñ                        │ïëàñòûðü ðóëîííûé                  │Melnluke Ab (Øâåöèÿ)          │004274             

│Ìèàíñàí                       │òàáëåòêè 10, 30 ìã                 │Zorka (Þãîñëàâèÿ)             │01244               

│Ìèäîêàëì                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 50 ìã  │Themis Chemicals Ltd (Èíäèÿ)  │002972             

                                                                                                                  

│Ìèêîíàçîëà íèòðàò             │êðåì âàãèíàëüíûé (òóáû) 2% - 45 ã  │Mir Pharmaceutical Inc/Copley │007704             

                                                                 │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Ìèêîñïîð                      │êðåì 1%; ðàñòâîð 1%                │Bayer Ag (ÔÐÃ)                │01463              

                                                                                                                  

│Ìèêðî òðàê Õëàìèäèà òðàõîìàòèñ│                                   │Siva International            │01607              

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ìèêðîãèíîí                    │äðàæå                              │Schering Ag (ÔÐÃ)             │003062             

│Ìèêðîïàê Êîëîí                │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ ñóñïåíçèè│Aspro-Nicholas Gmbh (Àâñòðèÿ) │002381             

│Ìèêðîñòèêñ-3                                                     │Aims Company (Âåëèêîáðèòàíèÿ) │00581              

│Ìèêðîñòèêñ-Êàíäèäà                                               │Aims Company (Âåëèêîáðèòàíèÿ) │00588              

│Ìèêðîöèä                      │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0005-3             

│Ìèêðîöèä                      │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0024-06            

│Ìèëàçàí                                                          │Mittelelbe (ÔÐÃ)              │004078              

│Ìèëüäèáå                                                         │Egis (Âåíãðèÿ)                │2972               

│Ìèíäåíò                       │ïàñòà çóáíàÿ                       │Cashlyan Takkedin (Ñàð)       │01720              

│Ìèíåðâèò                      │äðàæå                              │Krka (ÑÔÐÞ)                   │002216             

│Ìèíèôàæ (Ïîíäåðàë)            │êàïñóëû ðåòàðä 60 ìã               │Laboratoires Servier (Ôðàíöèÿ)│01184              

                                                                                                                  

│Ìèîâèí                        │ìàçü 2%                            │Cadila Laboratories Ltd       │002156             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ìèîãàðä                       │êàïñóëû 10 ìã                      │United Pharmaceutical         │003043             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Ìèîëàñòàí@                    │òàáëåòêè 50 ìã                     │Laboratoires Clin-Midy        │01279              

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ìèðåíèë                       │äðàæå 1 ìã                         │Polfa (Ïîëüøà)                │2171               

│Ìèðòèëåíå ôîðòå               │êàïñóëû                            │S.I.F.I. Spa (Èòàëèÿ)         │01923              

                                                                                                                  

│Ìèòîêñàíòðîí                  │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 20  │Polfa, Jelfa Sa (Ïîëüøà)      │005581              

                              │ìã - 10 ìë                                                                          

                                                                                                                  

│Ìèòîìèöèí-Ñ                   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Kyowa Hakko Kogyo Co Ltd      │00598              

                              │èíúåêöèîííîãî ðàñòâîðà             │(ßïîíèÿ)                                         

                                                                                                                  

│ÌÌÐ II                        │ëèîôèëèçàò                         │Merck Sharp & Dohme (ÑØÀ)     │13/94-00032840     

                                                                                                                  

│Ìîá                           │ñòóëü÷èê äëÿ ñáîðà ìî÷è è          │Autotechna (Þãîñëàâèÿ)        │01417              

                              │ìî÷åñáîðíèê äëÿ äåòåé                                                               

                                                                                                                  

│Ìîâîí                         │êàïñóëû 10, 20 ìã                  │Ipca Laboratories Ltd (Èíäèÿ) │005995             

│Ìîãàäîí@                      │òàáëåòêè                           │Galenika (Þãîñëàâèÿ)          │00412              

                                                                                                                  

│Ìîäåêåéò                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 25   │Squibb & Sons (Âåëèêîáðèòàíèÿ)│00178              

                              │ìã/ìë - 0.5, 1 ìë                                                                   

                                                                                                                  

│Ìîëèêîð                       │òàáëåòêè 2 ìã                      │Sbrolek (ÑÔÐÞ)                │002309             

                                                                                                                  

│Ìîëî÷íàÿ ñìåñü ð 7 à                                             │Snow Brand Milk Products Co   │01642               

                                                                 │Ltd (ßïîíèÿ)                                     

                                                                                                                  

│Ìîíèçèä                       │òàáëåòêè 20, 40 ìã                 │Pharmachim (ÍÐÁ)              │3007               

                                                                                                                  

│Ìîíîêëàò-Ï                    │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Armour Pharmaceuticals        │002898             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │Company (ÑØÀ)                                    

                              │1000 ÌÅ /â êîìïëåêòå ñ                                                              

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Ìîíîñàí                       │òàáëåòêè 20 ìã                     │Pro.Med.Cs (×åõèÿ)            │003141             

│Ìîíîñàí                       │òàáëåòêè 40 ìã                     │Pro.Med.Cs (×åõèÿ)            │006770             

                                                                                                                  

│Ìîðèàìèí ôîðòå                │êàïñóëû                            │Morishita Pharmaceutical Co,  │002617             

                                                                 │Ltd (ßïîíèÿ)                                     

                                                                                                                  

│Ìîðèàìèí-Ñ-2                  │ðàñòâîð äëÿ èíôóçèé (êîíòåéíåðû    │Roussel Morishita Co, Ltd     │003193             

                              │ïëàñòèêîâûå) 200, 500 ìë           │(ßïîíèÿ)                                          

                                                                                                                  

│Ìîðèí                         │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0024-18            

                                                                                                                 

│Ìîðèíàãà ÁÔ                                                      │Morinaga Milk Industry        │004203             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ìîðêîâíî-ÿáëî÷íîå ïþðå 115                                       │Fructal/Sloveniales (Ñëîâåíèÿ)│004365             

                                                                                                                  

│Ìîòèëèóì                      │òàáëåòêè ëàêèðîâàííûå 10 ìã        │Janssen Pharmaceutica         │002640             

                                                                 │(Áåëüãèÿ)                                        

                                                                                                                  

│Ìîòðèí                        │òàáëåòêè 200, 400 ìã               │Upjohn (Âåëèêîáðèòàíèÿ)       │002611             

│Ìóêà îâñÿíàÿ 03101                                               │Gerber (ÑØÀ)                  │004161             

│Ìóêà ðèñîâàÿ 03100                                               │Gerber (ÑØÀ)                  │004162             

│Ìóêîìèñò                      │ðàñòâîð 20%                        │Bristol-Myers Company (Àíãëèÿ)│00243              

│Ìóêîôëþèä                     │àýðîçîëü íàçàëüíûé                 │Ucb Sa (Áåëüãèÿ)              │00928              

│Ìóëüòèáèîíòà                  │ðàñòâîð äëÿ èíôóçèé (àìïóëû) 10 ìë │Merck (ÔÐÃ)                   │003254             

│Ìóëüòèâèòàìèí-Ì               │òàáëåòêè øèïó÷èå                   │Pharmavit (Âåíãðèÿ)           │002529             

│Ìóëüòèâèòàìèí-ìóëüòèìèíåðàë   │òàáëåòêè                           │Dabur India Ltd (Èíäèÿ)       │002320              

│Ìóëüòè-Ñåëåíà                 │òàáëåòêè                           │Leiras (Ôèíëÿíäèÿ)            │002374             

│Ìóëüòèñòèêñ                                                      │Aims Company (Âåëèêîáðèòàíèÿ) │00579              

                                                                                                                  

│Ìóòàìèöèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bristol-Myers Squibb (ÑØÀ)    │002774             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │5, 20, 40 ìã                                                                        

                                                                                                                  

│Ìÿòíàÿ                        │ïàñòà çóáíàÿ                       │Pollena-Uroda (ÏÍÐ)           │2955               

                                                                                                                  

│Íàáîð äëÿ îïðåäåëåíèÿ         │íàáîð                              │Sevak (×ÑÔÐ)                  │2552               

│ïëàçìàòè÷åñêèõ áåëêîâ ÈÄÏ                                                                                         

│Ñåâàê                                                                                                             

                                                                                                                  

│Íàçåíñïðàé Å-ðàòèîôàðì        │ôëàêîíû ñ äîçèðóþùèì êëàïàíîì 10 ìë│Ratiopharm Gmbh & Co          │003412             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Íàçåíñïðàé Ê-Ðàòèîôàðì        │àýðîçîëü íàçàëüíûé                 │Ratiopharm Gmbh & Co (ÔÐÃ)    │003117             

                                                                                                                  

│Íàêëîôåí                      │òàáëåòêè 50 ìã; òàáëåòêè ðåòàðä    │Krka (Ñëîâåíèÿ)               │002595             

                              │100 ìã; ñâå÷è 50 ìã; ðàñòâîð äëÿ                                                    

                              │èíúåêöèé (àìïóëû) 2.5% - 3 ìë                                                       

                                                                                                                  

│Íàêîì                         │òàáëåòêè                           │Lek (Þãîñëàâèÿ)               │00514              

                                                                                                                  

│Íàêñåí                        │òàáëåòêè 250 ìã                    │Chung Kun Dah Corporation     │002477             

                                                                 │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                  

│Íàêñîë                        │àýðîçîëü                           │Human (Âåíãðèÿ)               │2859               

│Íàëèêñàí                      │òàáëåòêè 250 ìã                    │Lyka Labs Ltd (Èíäèÿ)         │002258             

                                                                                                                  

│Íàëîðôèí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5 ìã │Chinoin (Âåíãðèÿ)             │2672               

                              │- 1 ìë                                                                              

                                                                                                                  

│Íàí                                                              │Nestle (Øâåéöàðèÿ)            │01663              

                                                                                                                  

│Íàïðîêñåí                     │òàáëåòêè 250, 375, 500 ìã          │Mir Pharmaceutical Inc/Copley │007671              

                                                                 │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Íàïðîêñåí                     │òàáëåòêè 250, 500 ìã               │Norton Healthcare Ltd         │003247             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Íàïðîñèí                      │ñóñïåíçèÿ äëÿ ïðèåìà âíóòðü        │Krka (Ñëîâåíèÿ)               │008009             

                              │(ôëàêîíû) 125 ìã|5 ìë - 100 ìë                                                      

                                                                                                                  

│Íàïðîñèí                      │òàáëåòêè 250 ìã                    │Krka (ÑÔÐÞ)                   │00498              

│Íàïðîñèí                      │ñâå÷è                              │Krka (Þãîñëàâèÿ)              │01213              

                                                                                                                  

│Íàòî                          │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Natco Pharma Ltd (Èíäèÿ)      │003198             

                              │èíúåêöèé (àìïóëû) 30 ìã - 1 ìë                                                      

                                                                                                                  

│Íàòðèóì ôëóîðàòóì             │òàáëåòêè äëÿ ðàññàñûâàíèÿ 1 ìã     │Polfa (ÏÍÐ)                   │2943               

│Íàòóëàí                       │êàïñóëû 50 ìã                      │Hoffmann La Roche (Øâåéöàðèÿ) │00208              

                                                                                                                   

│Íåáöèí                        │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Eli Lilly (Øâåéöàðèÿ)         │00628              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                      

                                                                                                                  

│Íåâîôàì                       │òàáëåòêè 20, 40 ìã                 │Mustafa Nevzat Ilac Sanayi As │003377             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Íåéðîáåíå                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1 ìã │Ludwig Merckle Gmbh (Àâñòðèÿ) │003331             

                              │- 1 ìë                                                                              

                                                                                                                  

│Íåéðîòðàò S ôîðòå             │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Knoll Ag (Ãåðìàíèÿ)           │007756             

                                                                                                                  

│Íåéòðàëüíûé àíîëèò (óñòàíîâêà │æèäêîñòü                           │Ðîññèÿ                        │0004-56            

│Ñòýë è Ñòýë-ÌÒ-1)                                                                                                 

                                                                                                                  

│Íåéòðàëüíûé àíîëèò (óñòàíîâêà │æèäêîñòü                           │Ðîññèÿ                        │0001-À14           

│ÝÕÀ-30)                                                                                                           

                                                                                                                  

│Íåëîâà                        │òàáëåòêè                           │Watson Laboratories Inc       │002297             

                                                                 │(Áåëüãèÿ)                                         

                                                                                                                  

│Íåëîðåí                       │êàïñóëû 500 ìã; ðàñòâîð äëÿ        │Lek (Ñëîâåíèÿ)                │002328             

                              │èíúåêöèé (àìïóëû) 300 ìã/1 ìë, 600 │                                                 

                              │ìã/2 ìë                                                                             

                                                                                                                  

│Íåìåñòðàí                     │êàïñóëû 2.5 ìã                     │Roussel Uclaf (Ôðàíöèÿ)       │002428             

│Íåìîöèä                       │òàáëåòêè; ñóñïåíçèÿ îðàëüíàÿ       │Ipca Laboratories Ltd (Èíäèÿ) │01490              

│Íåíàòàë                                                          │Nutricia (Ãîëëàíäèÿ)          │01722              

│Íåíàòàë                                                          │Nutricia (Íèäåðëàíäû)         │004142             

│Íåî-Ãèëóðèòìàë                │òàáëåòêè 20 ìã                     │Giulini Pharma Gmbh (ÔÐÃ)     │00862              

                                                                                                                  

│Íåîäèøåð (ìîäèôèêàöèè)                                           │Dr.Waygert Chemishe Fabric    │004342             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Íåîèíòåñòîïàí                 │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.63 ã │Sandoz (India) Ltd (Èíäèÿ)    │003472             

                                                                                                                  

│Íåîìîñêàí (ìîäèôèêàöèè)                                          │Dr.Waygert Chemishe Fabric    │004344             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                   

│Íåîïîìîðèí                    │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2710               

                                                                                                                  

│Íåîñåïòàë (ìîäèôèêàöèè)                                          │Dr.Waygert Chemishe Fabric    │004341             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Íåîñòîïàí                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 915 ìã │Sandoz Pharma (Øâåéöàðèÿ)     │002931             

                                                                                                                  

│Íåîòîí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Torrent Exports Ltd (Èíäèÿ)   │002080             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1 ã /â êîìïëåêòå ñ                                                             

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Íåðî áýáè                     │êàøà ìîëî÷íàÿ èç ïøåíè÷íîé ìóêè    │Hero Baby (Èñïàíèÿ)           │004266             

│Íåðî áýáè                                                        │Hero Baby (Èñïàíèÿ)           │004267             

│Íåðî áýáè                                                        │Hero Baby (Èñïàíèÿ)           │004268             

│Íåñôîñ-2                      │óïàêîâêà áåñïðîïåëëåíòíàÿ          │Ðîññèÿ                        │0019-19            

                                                                                                                   

│Íåòðîìèöèí                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 200  │Schering Corporation (ÑØÀ)    │01260              

                              │ìã - 2 ìë                                                                            

                                                                                                                  

│Íåóëåïòèë                     │êàïñóëû 10 ìã; ðàñòâîð îðàëüíûé 4% │Rhone-Poulenc (India) Ltd     │002149             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Íåóëåïòèë                     │êàïñóëû 10 ìã; êàïëè 4%            │Torrent Exports Ltd (Èíäèÿ)   │002082             

                                                                                                                  

│Íåôðàìèí                      │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 5.4% │Eczacibasi (Òóðöèÿ)           │02006              

                              │- 500 ìë                                                                            

                                                                                                                  

│Íåôðîôàí                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2797               

                                                                                                                  

│Íèäàçîë                       │òàáëåòêè 500 ìã                    │Dr.Ibrahim Atem Ulagay Sanayi │003021             

                                                                 │As (Òóðöèÿ)                                      

                                                                                                                  

│Íèêîøïàí                      │òàáëåòêè                           │Chinoin (Âåíãðèÿ)             │2074               

│Íèëüñ-2 2 0                   │ïðèìàíêà çåðíîâàÿ                  │Ðîññèÿ                        │0001-2             

│Íèëüñ-3                       │ïðèìàíêà çåðíîâàÿ                  │Ðîññèÿ                        │0001-3              

│Íèìîëü                        │òàáëåòêè                           │Ðîññèÿ                        │0004-21            

│Íèòèëîí                       │ëîñüîí                             │Ðîññèÿ                        │0004-35            

                                                                                                                  

│Íèòðàäèñê                     │òðàíñäåðìàëüíàÿ òåðàïåâòè÷åñêàÿ    │Searle (ÑØÀ)                  │003059             

                              │ñèñòåìà (ïëàñòûðü) 5 ìã|24 ÷, 10                                                    

                              │ìã|24 ÷                                                                             

                                                                                                                  

│Íèòðèôàí                      │ïîëîñêè                            │Lachema (×ÑÔÐ)                │2631               

                                                                                                                  

│Íèòðî                         │ìàçü 2%                            │Orion Pharmaceutica           │01084              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Íèòðî                         │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Orion Pharmaceutica           │01769              

                              │èíôóçèîííîãî ðàñòâîðà (àìïóëû) 5   │(Ôèíëÿíäèÿ)                                      

                              │ìã/ìë - 2 ìë                                                                        

                                                                                                                  

│Íèòðî Ìàê                     │êàïñóëû ðåòàðä 5 ìã                │Farmakos (ÑÔÐÞ)               │002526             

│Íèòðî Ìàê                     │êàïñóëû ðåòàðä 2.5 ìã              │Mack (Ãåðìàíèÿ)               │00551              

                                                                                                                   

│Íèòðîíã                       │òàáëåòêè 2.6 ìã                    │Orion Corporation, Farmos     │00838              

                                                                 │Group (Ôèíëÿíäèÿ)                                

                                                                                                                  

│Íèòòèôîð                      │ðàñòâîð 60 ìë                      │Biogal (Âåíãðèÿ)              │2791               

│Íèôàäèë                       │òàáëåòêè 10 ìã                     │Alkaloid (Ìàêåäîíèÿ)          │003165             

                                                                                                                  

│Íèôåãåêñàë                    │êàïñóëû 10 ìã; òàáëåòêè ðåòàðä 20  │Hexal Pharma Gmbh (ÔÐÃ)       │003184             

                              │ìã                                                                                  

                                                                                                                  

│Íèôåäèïèí                     │êàïñóëû 5, 10 ìã                   │Norton Healthcare Ltd         │003245             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Íèôåäèïèí                     │äðàæå 10 ìã                        │Pharmachim (ÍÐÁ)              │2992               

│Íèôåêàðä                      │êàïñóëû 10 ìã                      │Dar Al Dava (Èîðäàíèÿ)        │002965             

│Íèôåëàò                       │êàïñóëû 10 ìã                      │Biogalenique (Ôðàíöèÿ)        │003210             

│Íèôåëàò                       │òàáëåòêè ðåòàðä 20 ìã              │Biogalenique (Ôðàíöèÿ)        │003401             

│Íèôåñàí                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10 ìã  │Pro.Med.Cs (×åõèÿ)            │003142             

                                                                                                                  

│Íèôèêàðä                      │êàïñóëû 10 ìã                      │Ranbaxy Laboratories Ltd      │002562              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Íèôëóðèë                      │êàïñóëû 250 ìã                     │Laboratoires Upsa (Ôðàíöèÿ)   │002740             

│Í-ëàáñòèêñ                                                       │Aims Company (Âåëèêîáðèòàíèÿ) │00578              

│Í-ìóëüòèñòèêñ                                                    │Aims Company (Âåëèêîáðèòàíèÿ) │00580              

                                                                                                                  

│Íîâàíòðîí                     │ðàñòâîð äëÿ ïðèãîòîâëåíèÿ          │Lederle (ÑØÀ)                 │002275             

                              │èíôóçèîííîãî ðàñòâîðà                                                               

                              │êîíöåíòðèðîâàííûé (ôëàêîíû) 2                                                       

                              │ìã/ìë - 5, 10, 12.5, 15 ìë                                                          

                                                                                                                  

│Íîâèãàí                       │òàáëåòêè 400 ìã                    │Dr.Reddy's Laboratories Ltd   │002550             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Íîâî-Äæåñèê                   │òàáëåòêè 325, 500 ìã               │Novopharm Ltd (Êàíàäà)        │003319             

                                                                                                                  

│Íîâî-Ëåêñèí                   │êàïñóëû 250, 500 ìã; ñóñïåíçèÿ     │Novopharm Ltd (Êàíàäà)        │003390              

                              │îðàëüíàÿ (ôëàêîíû) 125 ìã|5 ìë,                                                     

                              │250 ìã|5 ìë                                                                         

                                                                                                                  

│Íîâî-Íèäàçîë                  │òàáëåòêè 250 ìã                    │Novopharm Ltd (Êàíàäà)        │003293             

│Íîâî-Íèôåäèí                  │êàïñóëû 10 ìã                      │Novopharm Ltd (Êàíàäà)        │003388             

│Íîâî-Ïàññèò                   │ñèðîï (ôëàêîíû) 100 ìë             │Spofa (×ÑÔÐ)                  │002772             

│Íîâî-Ïðàíîë                   │òàáëåòêè 10, 20, 40, 80, 120 ìã    │Novopharm Ltd (Êàíàäà)        │003389             

│Íîâîöåô                       │òàáëåòêè 125, 250, 500 ìã          │Pliva (Õîðâàòèÿ)              │002838             

│Íîâî-Öèìåòèí                  │òàáëåòêè 200, 300, 400, 600 ìã     │Novopharm Ltd (Êàíàäà)        │003320             

│Íîëâàäåêñ                     │òàáëåòêè 10 ìã                     │ICI (Âåëèêîáðèòàíèÿ)          │00774              

│Íîëâàäåêñ-ôîðòå               │òàáëåòêè 20, 40 ìã                 │ICI (Âåëèêîáðèòàíèÿ)          │002693             

│Íîìèãðýéí                     │êàïñóëû 5 ìã                       │Torrent Exports Ltd (Èíäèÿ)   │002293             

                                                                                                                  

│Íîîòðîïèë                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1 ã  │Polfa (Ïîëüøà)                │2599               

                              │- 5 ìë; êàïñóëû 400 ìã                                                              

                                                                                                                  

│Íîðâàñê                       │òàáëåòêè 5, 10 ìã                  │Pfizer Corporation (Áåëüãèÿ)  │002865             

│Íîðåòèí 1/35Å                 │òàáëåòêè                           │Schiapparelli Searle (ÑØÀ)    │002439             

│Íîðèíèë                       │òàáëåòêè                           │Syntex Laboratories Inc (ÑØÀ) │002390              

│Íîðìàçå                       │ñèðîï (ôëàêîíû) 100, 200, 400 ìë   │Inalco Spa (Èòàëèÿ)           │007307             

│Íîðìàçå                       │ñèðîï                              │Molteni (Èòàëèÿ)              │002323             

                                                                                                                  

│Íîðìîëèï                      │êàïñóëû 300 ìã                     │Sun Pharmaceutical Industries │003051             

                                                                 │Ltd (Èíäèÿ)                                      

                                                                                                                  

│Íîðôèí@                       │òàáëåòêè ñóáëèíãâàëüíûå 0.2 ìã     │Unichem Laboratories Ltd      │002132             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Íîðôëîêñ                      │òàáëåòêè 400 ìã                    │Cipla Ltd (Èíäèÿ)             │002415             

│Íîðýòèñòåðîí                  │äðàæå 0.5, 5 ìã                    │Jenapharm Gmbh (ÔÐÃ)          │00716              

│Íîôåëàí                       │ïîðîøîê                            │Polfa (Ïîëüøà)                │2863               

│Íî-øïà                        │òàáëåòêè                           │Chinoin (Âåíãðèÿ)             │2673               

                                                                                                                  

│Íî-øïà                        │òàáëåòêè 40 ìã; ðàñòâîð äëÿ        │Torrent Exports Ltd (Èíäèÿ)   │002673             

                              │èíúåêöèé (àìïóëû) 40 ìã - 2 ìë                                                      

                                                                                                                   

│ÍÏÕ Èëåòèí II                 │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │02033              

                              │40, 100 ÅÄ/ìë - 10 ìë                                                                

                                                                                                                  

│Íóòðàìèãåí                                                       │Mead Johnson Nutritionalist   │004318             

                                                                 │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Íóòðèëîí                                                         │Nutricia (Ãîëëàíäèÿ)          │01651              

│Íóòðèëîí                                                         │Nutricia (Íèäåðëàíäû)         │004143             

│Íóòðèñàí                      │êàïñóëû                            │Sandoz (India) Ltd (Èíäèÿ)    │002203             

│Íóòðè-ñîÿ                                                        │Nutricia (Íèäåðëàíäû)         │01746              

│Íóòðèöèà ìèëê ñèðèàë                                             │Nutricia (Íèäåðëàíäû)         │004154             

│Íÿì-íÿì îâåðñåëë                                                 │Oversell (Ôðàíöèÿ)            │004070             

│Îâåñòèí                       │òàáëåòêè                           │Organon (Íèäåðëàíäû)          │00374              

│Îâîùè ñ òåëÿòèíîé è ìàêàðîíàìè│                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004304             

│Îâîùíîå àññîðòè                                                  │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004288             

│Îâñÿíàÿ êàøà ñî ñëèâêàìè                                         │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004285             

│Îäåñòîí                       │òàáëåòêè 200 ìã                    │Polfa (Ïîëüøà)                │2861               

                                                                                                                   

│Îäíîçîíàëüíàÿ ïðåöèïèòèðóþùàÿ │ëèîôèëèç.ïîðîøîê                   │Sevak (×ÑÔÐ)                  │2551               

│ñûâîðîòêà äëÿ                                                                                                     

│èììóíîýëåêòðîôîðåçà                                                                                               

                                                                                                                  

│Îêñàçîëü                      │óïàêîâêà àýðîçîëüíàÿ               │Ðîññèÿ                        │0001-8             

│Îêñèãåíîë ôòîð                │ïàñòà çóáíàÿ                       │Oxyhenol Oy (Ôèíëÿíäèÿ)       │01396              

│Îêñèãåíîë ýêñòðà ôòîð         │ïàñòà çóáíàÿ                       │Oxyhenol Oy (Ôèíëÿíäèÿ)       │01397              

│Îêñèñåïò ñèñòåì                                                  │Pharm-Allergan Gmbh (ÔÐÃ)     │01818              

│Îêñîðàëåí óëüòðà              │êàïñóëû 10 ìã                      │ICN Galenika (Þãîñëàâèÿ)      │003334             

│Îêòåíèäåðì                    │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0007-2             

│Îêòåíèìàí                     │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0007-1             

│Îêòèëèÿ                       │êàïëè ãëàçíûå                      │S.I.F.I. Spa (Èòàëèÿ)         │01924              

                                                                                                                  

│Îêóïðåñ-Å                     │ðàñòâîð-êàïëè ãëàçíûå (ôëàêîíû)    │Cadila Laboratories Ltd       │01541              

                              │0.25%, 0.5% - 5 ìë                 │(Èíäèÿ)                                          

                                                                                                                  

│Îëâàðèò êîä 107                                                  │Nutricia (Íèäåðëàíäû)         │004321             

│Îëâàðèò êîä 117                                                  │Nutricia (Íèäåðëàíäû)         │004322             

│Îëâàðèò êîä 119                                                  │Nutricia (Íèäåðëàíäû)         │004323              

│Îëâàðèò êîä 200                                                  │Nutricia (Íèäåðëàíäû)         │004325             

│Îëâàðèò êîä 215                                                  │Nutricia (Íèäåðëàíäû)         │004326             

│Îëâàðèò êîä 400                                                  │Nutricia (Íèäåðëàíäû)         │004327             

│Îëâàðèò êîä 425                                                  │Nutricia (Íèäåðëàíäû)         │004324             

│Îëâàðèò êîä 454                                                  │Nutricia (Íèäåðëàíäû)         │004328             

                                                                                                                  

│Îëåàíäàöåòèë                  │ãðàíóëû äëÿ ïðèãîòîâëåíèÿ îðàëüíîé │Pharmachim (ÍÐÁ)              │2325               

                              │ñóñïåíçèè (ôëàêîíû) 1500000 ÌÅ -                                                    

                              │30 ã                                                                                

                                                                                                                  

│Îëèâèí                        │òàáëåòêè 10, 20 ìã                 │Lek (Ñëîâåíèÿ)                │002397             

│Îëèãîâèò                      │äðàæå                              │Galenika (ÑÔÐÞ)               │002180             

│Îëèêàðä                       │êàïñóëû ðåòàðä 40, 60 ìã           │Giulini Pharma Gmbh (ÔÐÃ)     │01997              

│Îëü-àìèí                      │äðàæå                              │Therabel (Áåëüãèÿ)            │002211             

                                                                                                                  

│Îìåç                          │êàïñóëû 20 ìã                      │Dr.Reddy's Laboratories Ltd   │002551             

                                                                 │(Èíäèÿ)                                           

                                                                                                                  

│Îìíèäåíò                      │ïàñòà çóáíàÿ                       │Omnia Nuova (Èòàëèÿ)          │01704              

                                                                                                                  

│Îìíèïàê                       │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû      │Nycomed (Íîðâåãèÿ)            │003018             

                              │ïîëèïðîïèëåíîâûå) 300 ìã éîäà/ìë - │                                                 

                              │50 ìë; ðàñòâîð äëÿ èíúåêöèé                                                         

                              │(ôëàêîíû ïîëèïðîïèëåíîâûå) 350 ìã                                                   

                              │éîäà/ìë - 50 ìë                                                                     

                                                                                                                  

│Îìíèïëàñò                     │ëåéêîïëàñòûðü                      │Kurtsan Hartmann Medical      │002644             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Îìíîäåíò                      │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2712               

│Îíåàëüôà                      │òàáëåòêè 0.25, 0.5, 1 ìêã          │Teijin Limited (ßïîíèÿ)       │009367             

                                                                                                                  

│Îíêîêðèñòèí                   │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Tamilnadu Dadha               │003048             

                              │1 ìã/ìë                            │Pharmaceuticals Ltd (Èíäèÿ)                      

                                                                                                                  

│Îíêîïëàòèí                    │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 0.5 │Tamilnadu Dadha               │003336              

                              │ìã/ìë - 20, 100 ìë                 │Pharmaceuticals Ltd (Èíäèÿ)                      

                                                                                                                  

│Îïàêîðäýí                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200 ìã │Polfa, Starogardzkie          │006870             

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Îïèíî ãåëü                    │æåëå                               │Krka (ÑÔÐÞ)                   │00756              

│Îïèíî ðåòàðä                  │äðàæå                              │Krka (ÑÔÐÞ)                   │00757              

│Îïîôîñ 2                      │òàáëåòêè                           │Ðîññèÿ                        │0004-34            

│Îïðàäîë                       │òàáëåòêè 500 ìã                    │Tata Pharma (Èíäèÿ)           │002126             

│Îïòèëåòñ-500 ôèëìòàá          │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003350             

│Îïòèëåòñ-Ì-500 ôèëìòàá        │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003351             

                                                                                                                  

│Îðàáåò                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 500,   │Bristol-Myers Squibb (Äàíèÿ)  │007819             

                              │850 ìã                                                                              

                                                                                                                  

│Îðàäåëüò                      │ïîðîøîê                            │Ðîññèÿ                        │0004-22            

                                                                                                                   

│Îðàöåô                        │êàïñóëû 250, 500 ìã; ïîðîøîê äëÿ   │Krka (Ñëîâåíèÿ)               │002940             

                              │ïðèãîòîâëåíèÿ ñóñïåíçèè 250 ìã|5 ìë│                                                  

                                                                                                                  

│Îðèòàêñèì                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Cadila Laboratories Ltd       │002996             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Èíäèÿ)                                          

                              │250, 500, 1000 ìã                                                                   

                                                                                                                  

│Îðìèäîë                       │òàáëåòêè 100 ìã                    │Podravka-Belupo (ÑÔÐÞ)        │01937              

                                                                                                                  

│Îðíèöåòèë                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Alkaloid (ÑÔÐÞ)               │00454              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │2, 5 ã                                                                              

                                                                                                                  

│Îñïåí                         │êàïëè                              │Biochemie Gmbh (Àâñòðèÿ)      │01409              

│Îñïåí                         │ñèðîï 750                          │Biochemie Gmbh (Àâñòðèÿ)      │01409              

│Îñòåîõèí                      │òàáëåòêè 200 ìã                    │Chinoin (Âåíãðèÿ)             │002093             

│Îñòåð ìèëê                                                       │Farley (Âåëèêîáðèòàíèÿ)       │01553              

│Îñòåð ïðèì                                                       │Farley (Âåëèêîáðèòàíèÿ)       │01551              

│Îñòåð ñîé                                                        │Farley (Âåëèêîáðèòàíèÿ)       │01552               

│Îòèíóì                        │êàïëè óøíûå                        │Polfa (Ïîëüøà)                │2906               

│Îóè                           │ïàñòà çóáíàÿ                       │Cato Aromatic (Àðå)           │01460              

                                                                                                                  

│Îôòàëüìîòðèì                  │ðàñòâîð îôòàëüìîëîãè÷åñêèé         │Laboratorious Cusi (Èñïàíèÿ)  │003236             

                              │(ôëàêîíû) 5 ìë                                                                      

                                                                                                                  

│Îôòàí Äåêñàìåòàçîí            │êàïëè ãëàçíûå 1 ìã/ìë              │Leiras (Ôèíëÿíäèÿ)            │006577             

│Îôòàí Èäó                     │êàïëè ãëàçíûå 0.1%                 │Leiras (Ôèíëÿíäèÿ)            │00898              

│Îôòàí Êàòàõðîì                │êàïëè ãëàçíûå                      │Star (Ôèíëÿíäèÿ)              │00639              

│Îôòàí Ïèëîêàðïèí              │êàïëè ãëàçíûå 1%, 2%               │Star (Ôèíëÿíäèÿ)              │00793              

                                                                                                                  

│Îôòàí Òèìîëîë                 │êàïëè ãëàçíûå (ôëàêîíû) 0.25%,     │Leiras Oy (Ôèíëÿíäèÿ)         │008060             

                              │0.5% - 5 ìë                                                                        

                                                                                                                  

│Îôòåíñèí                      │êàïëè ãëàçíûå 0.25%, 0.5%          │Polfa (Ïîëüøà)                │002527             

                                                                                                                  

│Ïàâóëîí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 4 ìã │Organon (Íèäåðëàíäû)          │00334              

                              │- 2 ìë                                                                              

                                                                                                                   

│Ïàêâèí                        │êðåì äëÿ ñóõîé êîæè                │Pfizer International Inc (ÑØÀ)│004330             

│Ïàêâèí                        │êðåì                               │Pfizer International Inc (ÑØÀ)│004331             

                                                                                                                  

│Ïàêñåëàäèí                    │êàïñóëû 40 ìã                      │Beaufour-Ipsen International  │003025             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ïàëèí                         │òàáëåòêè ëàêèðîâàííûå 400 ìã;      │Lek (Þãîñëàâèÿ)               │01531              

                              │ñâå÷è âàãèíàëüíûå 200 ìã                                                            

                                                                                                                  

│Ïàëèòðåêñ                     │êàïñóëû 250 ìã; ñóñïåíçèÿ îðàëüíàÿ │Galenika (Þãîñëàâèÿ)          │00766              

                              │250 ìã|5 ìë                                                                         

                                                                                                                  

│Ïàëêîäåíò                     │ïàñòà çóáíàÿ                       │Palco Hemihandelse Gmbh (ÔÐÃ) │04017              

                                                                                                                  

│Ïàíàäåèí                      │òàáëåòêè 500 ìã/8 ìã               │Sterling Health               │002817             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                   

│Ïàíàäîë                       │ñâå÷è 125, 250 ìã                  │Sterling Health Productos     │007615             

                                                                 │Pharmaceuti-cos Ltd, a                            

                                                                 │division of Smithkline                           

                                                                 │Beecham Consumer Healthcare                      

                                                                 │(Ïîðòóãàëèÿ/Âåëèêîáðèòàíèÿ)                      

                                                                                                                  

│Ïàíãðîë 400                   │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Berlin-Chemie Ag (ÔÐÃ)        │003068             

                              │îáîëî÷êîé                                                                           

                                                                                                                  

│Ïàíêðåàòèí                    │òàáëåòêè                           │Houhtamyaki Leiras Oy         │00653              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ïàíêóðìåí                     │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Berlin-Chemie Feb (ÃÄÐ)       │01501              

                              │îáîëî÷êîé                                                                           

                                                                                                                  

│Ïàíòåíîë                      │òàáëåòêè 100 ìã; ðàñòâîð äëÿ       │Jenapharm (Ãåðìàíèÿ)          │00794              

                              │èíúåêöèé (àìïóëû) 500 ìã - 2 ìë                                                     

                                                                                                                  

│Ïàíòðèïèí                                                        │Ðîññèÿ                        │69/942/4           

│Ïàïàâèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìë │Torrent Exports Ltd (Èíäèÿ)   │002762             

│Ïàðàäåíòîç Ïàñòà              │ïàñòà                              │Laboratoires Spad (Ôðàíöèÿ)   │00297              

│Ïàðàìîë                       │òàáëåòêè 500 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │002670             

                                                                                                                  

│Ïàðàïëàòèí                    │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 50, │Bristol-Myers Squibb (ÑØÀ)    │002363             

                              │150, 450 ìã                                                                         

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã                    │Aganall Traders Ltd (Èíäèÿ)   │002063             

│Ïàðàöåòàìîë                   │ñâå÷è 250 ìã                       │Berlin-Chemie Ag (ÔÐÃ)        │002286             

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã                    │Cox Pharmaceuticals           │003203             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ïàðàöåòàìîë                   │ñèðîï                              │Dabur India Ltd (Èíäèÿ)       │002137             

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã                    │J.R.Sharma Overseas Ltd       │002062             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã; òàáëåòêè          │Lyka Labs Ltd (Èíäèÿ)         │002260              

                              │ðàñòâîðèìûå 120 ìã                                                                  

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã; ðàñòâîð îðàëüíûé  │Pierre Fabre Medicament       │003466             

                              │äëÿ äåòåé (ôëàêîíû) 3%             │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ïàðàöåòàìîë                   │òàáëåòêè 500 ìã                    │Weimer Pharma Gmbh (ÔÐÃ)      │003072             

│Ïàðàöåòàìîë 200               │ìèêñòóðà 200 ìã|5 ìë               │Berlin-Chemie Ag (ÔÐÃ)        │003296             

│Ïàðàöåòàìîë-Ðàòèîôàðì         │ñâå÷è äëÿ äåòåé 125 ìã             │Merckle Gmbh (ÔÐÃ)            │002939             

                                                                                                                  

│Ïàðæèí                        │ðàñòâîð îðàëüíûé (àìïóëû) 5 ìã -   │Laboratoires Sarget (Ôðàíöèÿ) │002191             

                              │10 ìë                                                                               

                                                                                                                  

│Ïàðêîïàí 2@                   │òàáëåòêè 2 ìã                      │Hexal Pharma Gmbh (Ãåðìàíèÿ)  │007229             

│Ïàðêîïàí 5@                   │òàáëåòêè 5 ìã                      │Hexal Pharma Gmbh (Ãåðìàíèÿ)  │007230             

│Ïàðîæåíñèë Áè-àêòèâ           │ïàñòà çóáíàÿ                       │Laboratoires Gupile (Ôðàíöèÿ) │005449             

                                                                                                                  

│Ïàðòóñèñòåí èíòðàïàðòàëüíûé   │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Boehringer Ingelheim          │003446             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │International Gmbh (Ãåðìàíèÿ) │                   

                              │25 ìêã/ìë                                                                            

                                                                                                                  

│Ïåå Õîî                       │òàáëåòêè; ñóñïåíçèÿ                │Orion Pharmaceutica           │01209              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ïåå-Õîî                       │òàáëåòêè; ñóñïåíçèÿ îðàëüíàÿ       │Eczacibasi (Òóðöèÿ)           │002147             

│Ïåëåíòàí                      │òàáëåòêè 300 ìã                    │Spofa (×åõîñëîâàêèÿ)          │2259               

│Ïåíàòåí                       │êðåì ïðîòèâ îïðåëîñòåé äëÿ äåòåé   │Johnson & Johnson (ÑØÀ)       │01984              

│Ïåíãëîá                       │òàáëåòêè 400, 800 ìã               │Astra (Øâåöèÿ)                │002440             

                                                                                                                  

│Ïåí-îñ                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Eczacibasi (Òóðöèÿ)           │003382             

                              │1000000 ÅÄ                                                                          

                                                                                                                  

│Ïåíñåëèí                      │òàáëåòêè 25 ìã                     │Sawai Pharmaceutical Co Ltd   │003154             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ïåíòàêàðä-10                  │òàáëåòêè 10 ìã                     │Cedona Pharmaceutical         │003036             

                                                                 │(Íèäåðëàíäû)                                      

                                                                                                                  

│Ïåíòàêàðä-20                  │òàáëåòêè 20 ìã                     │Cedona Pharmaceutical         │003036             

                                                                 │(Íèäåðëàíäû)                                     

                                                                                                                  

│Ïåíòàêàðä-40                  │òàáëåòêè 40 ìã                     │Cedona Pharmaceutical         │003036             

                                                                 │(Íèäåðëàíäû)                                     

                                                                                                                  

│Ïåíòàêàðèíàò                  │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│003392             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │300 ìã; ïîðîøîê äëÿ ïðèãîòîâëåíèÿ                                                   

                              │èíãàëÿöèîííîãî ðàñòâîðà (ôëàêîíû)                                                   

                              │300 ìã                                                                              

                                                                                                                  

│Ïåíòàëãèí                     │òàáëåòêè                           │Ðîññèÿ                        │71/528/31          

│Ïåíòàôàí                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2796               

                                                                                                                  

│Ïåíòèëèí                      │òàáëåòêè 400 ìã; ðàñòâîð äëÿ       │Krka (Ñëîâåíèÿ)               │002596             

                              │èíúåêöèé (àìïóëû) 100 ìã - 5 ìë                                                     

                                                                                                                   

│Ïåíòîãåêñàë                   │òàáëåòêè ðåòàðä 600 ìã             │Hexal Pharma Gmbh (Ãåðìàíèÿ)  │005142             

│Ïåíòîêñèôèëëèí-Ðàòèîôàðì      │òàáëåòêè ðåòàðä 400 ìã             │Ratiopharm Gmbh & Co (ÔÐÃ)    │003216             

                                                                                                                  

│Ïåíòðåêñèë                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Galenika (Þãîñëàâèÿ)          │00269              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500 ìã; êàïëè äëÿ äåòåé                                                        

                              │(ôëàêîíû) 100 ìã/ìë - 20 ìë                                                         

                                                                                                                  

│Ïåíòðåêñèë                    │ñóñïåíçèÿ äëÿ äåòåé                │Galenika (Þãîñëàâèÿ)          │00613              

│Ïåïèòà                        │ïàñòà çóáíàÿ                       │Nordtend (Øâåöèÿ)             │01779              

                                                                                                                  

│Ïåïëîöèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Nippon Kayaku Co Ltd (ßïîíèÿ) │02046              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │10 ìã                                                                               

                                                                                                                  

│Ïåïñ ôòîðíûé                  │ïàñòà çóáíàÿ                       │Fisons Ltd (Áàíãëàäåø)        │01530              

│Ïåïñîäåíò                     │ïàñòà çóáíàÿ                       │Unilever Export (Íèäåðëàíäû)  │01345              

│Ïåðãîòàéì                     │òàáëåòêè 50 ìã                     │Ares-Serono Group (Øâåéöàðèÿ) │002096             

                                                                                                                   

│Ïåðäèïèí                      │òàáëåòêè 20 ìã                     │Yamanouchi Pharmaceutical Co  │002656             

                                                                 │Ltd (ßïîíèÿ)                                     

                                                                                                                  

│Ïåðèäîíòîí                    │ïàñòà                              │Septodent (Ôðàíöèÿ)           │00532              

                                                                                                                  

│Ïåðèíîðì                      │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Ipca Laboratories Ltd (Èíäèÿ) │01815              

                              │èíúåêöèé (àìïóëû) 2 ìë; æèäêîñòü                                                    

                              │(ôëàêîíû) 100 ìë                                                                    

                                                                                                                  

│Ïåðèòîë                       │òàáëåòêè 4 ìã                      │Egis (Âåíãðèÿ)                │2390               

│Ïåðèòîë                       │ñèðîï                              │Egis (ÂÍÐ)                    │2572               

│Ïåðëîäîíò                     │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh (ÔÐÃ)    │004064             

│Ïåðìåò                        │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0004-23            

                                                                                                                  

│Ïåðîêñîãèäðàò ôòîðèäà êàëèÿ   │ïîðîøîê                            │Ðîññèÿ                        │0008-1             

│(ÏÔÊ-1)                                                                                                           

                                                                                                                   

│Ïåððè-Ë                       │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0004-25            

                                                                                                                  

│Ïåðñàíòèí                     │äðàæå 25, 75 ìã                    │Boehringer Ingelheim          │00167              

                                                                 │International Gmbh (Ãåðìàíèÿ) │                   

                                                                                                                  

│Ïåðñèêè àðò.271                                                  │Hipp (Àâñòðèÿ)                │004031             

│Ïåðñèêîâîå ïþðå 01401                                            │Gerber (ÑØÀ)                  │004123             

                                                                                                                  

│Ïåðñèêîâîå ïþðå ñ ñàõàðîì                                        │Gerber (ÑØÀ)                  │004124             

│01401                                                                                                             

                                                                                                                  

│Ïåðñèêîâûé äåñåðò 02643                                          │Gerber (ÑØÀ)                  │004121             

                                                                                                                  

│Ïåðòè                         │òàáëåòêè 400 ìã                    │Dr.Reddy's Laboratories Ltd   │002688             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïåðôîëîí                      │ëîñüîí                             │Ðîññèÿ                        │0006-1             

│Ïåðôîðì                       │ïîðîøîê                            │Schulke & Mayr (Ãåðìàíèÿ)     │0005-4             

                                                                                                                   

│Ïåòèëèë                       │äðàæå 25 ìã; ðàñòâîð äëÿ èíúåêöèé  │Arzneimittelwerk Dresden Gmbh │002975             

                              │(àìïóëû) 25 ìã - 2 ìë              │(ÔÐÃ)                                            

                                                                                                                  

│Ïåôëàöèí                      │òàáëåòêè 400 ìã; ðàñòâîð äëÿ       │Eczacibasi (Òóðöèÿ)           │002239             

                              │èíúåêöèé (àìïóëû) 400 ìã - 5 ìë                                                     

                                                                                                                  

│Ïèãðèí                        │øíóð ïèðîòåõíè÷åñêèé               │Ðîññèÿ                        │0004-26            

│Ïèêîëàê                                                          │Krka (Ñëîâåíèÿ)               │004347             

                                                                                                                  

│Ïèëòòè                                                           │Houhtamyaki/yalostaya         │004234             

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ïèëòòè-êîìïëåêò 1                                                │Houhtamyaki/yalostaya         │01652              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ïèëòòè-êîìïëåêò 2                                                │Houhtamyaki/yalostaya         │01653              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Ïèëòòè-êîìïëåêò 3                                                │Houhtamyaki/yalostaya         │01654              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ïèíàìèí ôîðòå                                                    │Global (Ãåðìàíèÿ)             │004200             

                                                                                                                  

│Ïèíã-Ïîíã-Ïýíòñ               │ïîäãóçíèêè                         │Nissyo Ivai Corporation       │01684              

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ïèîí-1                        │òàáëåòêè ïèðîòåõíè÷åñêèå           │Ðîññèÿ                        │0001-Á 7           

│Ïèïè                          │ïàñòà çóáíàÿ                       │Pharmachim (ÍÐÁ)              │2941               

                                                                                                                  

│Ïèïîðòèë                      │òàáëåòêè 10 ìã                     │Rhone-Poulenc (India) Ltd     │002150             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïèïîðòèë                      │êàïëè 4%                           │Rhone-Poulenc Pharma Sa       │002384             

                                                                 │(Èñïàíèÿ)                                        

                                                                                                                  

│Ïèïîðòèë                      │òàáëåòêè 10 ìã                     │Torrent Exports Ltd (Èíäèÿ)   │002083              

                                                                                                                  

│Ïèïîðòèë Ë4                   │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2.5% │Rhone-Poulenc Pharma Sa       │002385             

                              │- 1 ìë, 4 ìë                       │(Èñïàíèÿ)                                        

                                                                                                                  

│Ïèðàáóòîë                     │äðàæå; ðàñòâîð äëÿ èíúåêöèé        │Spofa (×åõîñëîâàêèÿ)          │2260               

                              │(àìïóëû) 5 ìë                                                                       

                                                                                                                  

│Ïèðàçèíàìèä                   │òàáëåòêè                           │Armour (Èíäèÿ)                │02040              

                                                                                                                  

│Ïèðàçèíàìèä                   │òàáëåòêè 250, 500 ìã               │Cheil Foods&chemicals Inc     │002842             

                                                                 │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                  

│Ïèðàçèíàìèä                   │òàáëåòêè 250, 500 ìã               │Yuhan Corporation (Êîðåÿ      │003219             

                                                                 │Þæíàÿ)                                           

                                                                                                                  

│Ïèðàìåèí                      │òàáëåòêè                           │Ðîññèÿ                        │73/461/62          

│Ïèðàíàë                       │òàáëåòêè                           │Pharmachim (Áîëãàðèÿ)         │2141               

│Ïèðàíàë                       │òàáëåòêè                           │Pharmachim (ÍÐÁ)              │2565               

│Ïèðàíòåë                      │òàáëåòêè 250 ìã                    │Polfa (Ïîëüøà)                │2686                

                                                                                                                  

│Ïèðàöåòàì                     │êàïñóëû 400 ìã                     │Polfa, Starogardzkie          │006709             

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Ïèðàöåòàì                     │êàïñóëû 400 ìã                     │Polpharma Pharmaceutical      │008483             

                                                                 │Works Sa (Ïîëüøà)                                

                                                                                                                  

│Ïèðåíöåïèí                    │òàáëåòêè 50 ìã                     │Ct-Arzneimittel Chemishe      │003212             

                                                                 │Tempelchof Gmbh (ÔÐÃ)                            

                                                                                                                  

│Ïèðèêàì                       │êàïñóëû 10, 20 ìã                  │Cadila Laboratories Ltd       │002998             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïèðêîôåí                      │òàáëåòêè                           │Ðîññèÿ                        │71/609/3           

│Ïèðîã ðûáàêà                                                     │H.J.Heinz (ÑØÀ)               │004109             

                                                                                                                  

│Ïèðîêàì                       │òàáëåòêè 10, 20 ìã; ñâå÷è 20 ìã;   │Ludwig Merckle Gmbh (Àâñòðèÿ) │002983              

                              │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1, 2 │                                                 

                              │ìë                                                                                  

                                                                                                                  

│Ïèðîêñ                        │êàïñóëû 10, 20 ìã                  │Cipla Ltd (Èíäèÿ)             │002068             

│Ïèðîêñèêàì                    │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10 ìã  │Polfa (Ïîëüøà)                │2874               

│Ïèðîêñèêàì                    │êàïñóëû 10, 20 ìã                  │Schiapparelli Searle (ÑØÀ)    │002627             

│Ïèùåâîé àëëåðãåí Â1 - òåëÿòèíà│                                   │Pharmachim (Áîëãàðèÿ)         │2725               

│Ïèùåâîé àëëåðãåí Â12 - ïåðñèêè│                                   │Pharmachim (Áîëãàðèÿ)         │2727               

│Ïèùåâîé àëëåðãåí Â13 - ñëèâû                                     │Pharmachim (Áîëãàðèÿ)         │2728               

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â14 -                                           │Pharmachim (Áîëãàðèÿ)         │2729               

│àáðèêîñû                                                                                                          

                                                                                                                 

│Ïèùåâîé àëëåðãåí Â15 - ãðóøè                                     │Pharmachim (Áîëãàðèÿ)         │2730               

│Ïèùåâîé àëëåðãåí Â16 - áàíàíû │                                   │Pharmachim (Áîëãàðèÿ)         │2731               

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â17 -                                           │Pharmachim (Áîëãàðèÿ)         │2732               

│êëóáíèêà                                                                                                          

                                                                                                                   

│Ïèùåâîé àëëåðãåí Â18 - ìàëèíà │                                   │Pharmachim (Áîëãàðèÿ)         │2733               

│Ïèùåâîé àëëåðãåí Â19 - ÷åðåøíè│                                   │Pharmachim (Áîëãàðèÿ)         │2734               

│Ïèùåâîé àëëåðãåí Â20 - äûíè                                      │Pharmachim (Áîëãàðèÿ)         │2735               

│Ïèùåâîé àëëåðãåí Â21 - àðáóçû │                                   │Pharmachim (Áîëãàðèÿ)         │2736               

│Ïèùåâîé àëëåðãåí Â22 - øïèíàò │                                   │Pharmachim (Áîëãàðèÿ)         │2737               

│Ïèùåâîé àëëåðãåí Â23 - êàïóñòà│                                   │Pharmachim (Áîëãàðèÿ)         │2738               

│Ïèùåâîé àëëåðãåí Â28 - òûêâà                                     │Pharmachim (Áîëãàðèÿ)         │2739               

│Ïèùåâîé àëëåðãåí Â32 - îðåõè                                     │Pharmachim (Áîëãàðèÿ)         │2740               

│Ïèùåâîé àëëåðãåí Â33 - ìèíäàëü│                                   │Pharmachim (Áîëãàðèÿ)         │2741               

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â34 - ëåñíûå │                                   │Pharmachim (Áîëãàðèÿ)         │2742               

│îðåõè                                                                                                             

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â36 - êîôå                                      │Pharmachim (Áîëãàðèÿ)         │2743               

│Ïèùåâîé àëëåðãåí Â37 - áîáû                                      │Pharmachim (Áîëãàðèÿ)         │2744               

│Ïèùåâîé àëëåðãåí Â38 - ãîðîõ                                     │Pharmachim (Áîëãàðèÿ)         │2745               

                                                                                                                   

│Ïèùåâîé àëëåðãåí Â39 -                                           │Pharmachim (Áîëãàðèÿ)         │2746               

│÷å÷åâèöà                                                                                                           

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â45 - ðûáà                                      │Pharmachim (Áîëãàðèÿ)         │2747               

│ñêóìáðèÿ                                                                                                          

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â46 - ëóê                                       │Pharmachim (Áîëãàðèÿ)         │2748               

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â48 - îâå÷üÿ │                                   │Pharmachim (Áîëãàðèÿ)         │2749               

│áðûíçà                                                                                                            

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â49 -                                           │Pharmachim (Áîëãàðèÿ)         │2750               

│êîðîâüÿ áðûíçà                                                                                                    

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â5 - îâå÷üå                                     │Pharmachim (Áîëãàðèÿ)         │2726               

│ìîëîêî                                                                                                            

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â56 -                                           │Pharmachim (Áîëãàðèÿ)         │2751               

│êîï÷åíàÿ êîëáàñà                                                                                                   

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â57 -                                           │Pharmachim (Áîëãàðèÿ)         │2752               

│ï÷åëèíûé ìåä                                                                                                      

                                                                                                                  

│Ïèùåâîé àëëåðãåí Â66 - àðàõèñ │                                   │Pharmachim (Áîëãàðèÿ)         │2753               

│Ïèùåâîé àëëåðãåí Â68 - ñîÿ                                       │Pharmachim (Áîëãàðèÿ)         │2754               

                                                                                                                  

│Ïëàêâåíèë                     │òàáëåòêè 200 ìã                    │Sterling-Winthrop             │01268              

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ïëàòèäèàì                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Lachema (×ÑÔÐ)                │002186             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │50 ìã                                                                               

                                                                                                                  

│Ïëàòèíîë                      │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 10, │Bristol-Myers Squibb (ÑØÀ)    │002364             

                              │25, 50 ìã                                                                           

                                                                                                                  

│Ïëàöåíòû êîíñåðâèðîâàííîé     │ðàñòâîð (àìïóëû) 1 ìë              │Ðîññèÿ                        │72/334/10          

│ýêñòðàêò â àìïóëàõ ïî 1 ìë                                                                                         

                                                                                                                  

│Ïëåíäèë                       │òàáëåòêè äëèòåëüíîãî âûñâîáîæäåíèÿ │Astra (Øâåöèÿ)                │002752             

                              │5, 10 ìã                                                                            

                                                                                                                  

│Ïëåíèë                        │òàáëåòêè øèïó÷èå ðàñòâîðèìûå,      │Laboratoires Upsa (Ôðàíöèÿ)   │002806             

                              │òàáëåòêè æåâàòåëüíûå                                                                

                                                                                                                 

│Ïëèâàçèì                                                         │Pliva Sa (ÑÔÐÞ)               │01495              

│Ïëèâàëãèí                     │òàáëåòêè                           │Pliva (Õîðâàòèÿ)              │002456             

│Ïëèâàñåïò                     │ðàñòâîð ïåíîîáðàçóþùèé 4.5 ã|100 ìë│Pliva Sa (Õîðâàòèÿ)           │003839             

                                                                                                                  

│Ïì                                                               │Snow Brand Milk Products Co   │04016              

                                                                 │Ltd (ßïîíèÿ)                                     

                                                                                                                  

│Ïîëè-âè-ñîë ñ âèòàìèíàìè      │òàáëåòêè                           │Mead Johnson Nutritionalist   │002376             

                                                                 │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                             

                                                                                                                  

│Ïîëè-âè-ñîë ñ âèòàìèíàìè è    │òàáëåòêè                           │Mead Johnson Nutritionalist   │002377              

│ìèíåðàëüíûìè âåùåñòâàìè                                          │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Ïîëè-âè-ôëîð ñ âèòàìèíàìè,    │òàáëåòêè                           │Mead Johnson Nutritionalist   │002378             

│ìèíåðàëüíûìè âåùåñòâàìè è                                        │Company Bristol-Myers Squibb                     

│ôòîðîì                                                           │(ÑØÀ)                                            

                                                                                                                  

│Ïîëîïîð                       │ïëàñòûðü - 5 ì/25 ìì, 5 ì/50 ìì    │Viskoplast (ÏÍÐ)              │2960               

                              │/íà íåòêàíåâîé îñíîâå êàòóøå÷íûé/                                                   

                                                                                                                  

│Ïîëüêîðòîëîí                  │ìàçü 0.1%; êðåì 0.1%               │Polfa (Ïîëüøà)                │2887               

│Ïîëüêîðòîëîí ÒÑ               │àýðîçîëü                           │Polfa (Ïîëüøà)                │2362               

                                                                                                                  

│Ïîëüïðåññèí                   │òàáëåòêè 1, 2, 5 ìã                │Polfa, Starogardzkie          │006202             

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Ïîìîðèí                       │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2714                

│Ïîìîðèí                       │æåâàòåëüíàÿ ðåçèíêà                │Pharmachim (ÍÐÁ)              │2566               

│Ïîðîøîê äëÿ àáðèêîñîâîé êàøè                                     │Meira Oy (Ôèíëÿíäèÿ)          │01545              

│Ïîðîøîê äëÿ ÿáëî÷íîé êàøè                                        │Meira Oy (Ôèíëÿíäèÿ)          │01544              

│Ïîðîøîê êàðòîôåëüíîãî ïþðå                                       │Meira Oy (Ôèíëÿíäèÿ)          │01546              

                                                                                                                  

│Ïîðîøîê                                                          │Meira Oy (Ôèíëÿíäèÿ)          │01547              

│êàðòîôåëüíî-ìîðêîâíîãî ïþðå                                                                                       

                                                                                                                  

│Ïîðòàãåí                                                         │Mead Johnson Nutritionalist   │004320             

                                                                 │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Ïðàéç                         │ïàñòà çóáíàÿ                       │Balsara Hygien Products Ltd   │01493              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïðàêòîí                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Laboratoires Biogalenique     │002406             

                              │äåëèìûå 50 ìã                      │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ïðåàïòàìèë                                                       │Interpromex Gmbh (ÔÐÃ)        │01386               

                                                                                                                  

│Ïðåãåñòèìèë                                                      │Mead Johnson Nutritionalist   │004319             

                                                                 │Company Bristol-Myers Squibb                     

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Ïðåãíèë                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Organon Ilaclary (Òóðöèÿ)     │003044             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                     

                              │500, 1500, 5000 ÌÅ /â êîìïëåêòå ñ                                                   

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Ïðåäíèãåêñàë                  │ñóñïåíçèÿ äëÿ èíúåêöèé (àìïóëû)    │Hexal Pharma Gmbh (ÔÐÃ)       │003185             

                              │25, 50 ìã - 1 ìë                                                                    

                                                                                                                  

│Ïðåäíèçîëîí                   │ìàçü 0.5%                          │Gedeon Richter (Âåíãðèÿ)      │2668               

                                                                                                                  

│Ïðåäíèçîëîí                   │òàáëåòêè 5 ìã; ðàñòâîð äëÿ         │M.J.Pharmaceuticals Ltd       │006207             

                              │èíúåêöèé (àìïóëû) 30 ìã - 1 ìë     │(Èíäèÿ)                                           

                                                                                                                  

│Ïðåäíîë                       │òàáëåòêè 4, 16 ìã                  │Mustafa Nevzat Ilac Sanayi As │002564              

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Ïðåäíîë-Ë                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Mustafa Nevzat Ilac Sanayi As │002253             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)    │(Òóðöèÿ)                                         

                              │20, 40, 250 ìã                                                                      

                                                                                                                  

│Ïðå-íàí                                                          │Nestle (Øâåéöàðèÿ)            │004259             

│Ïðåíàöèä                      │êàïëè ãëàçíûå; ìàçü ãëàçíàÿ        │S.I.F.I. Spa (Èòàëèÿ)         │01925              

                                                                                                                  

│Ïðå-ïàð                       │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Duphar B.V. (Íèäåðëàíäû)      │00677              

                              │èíúåêöèé (àìïóëû) 10 ìã/ìë                                                          

                                                                                                                  

│Ïðåïèëòòè                                                        │Yalostaya (Ôèíëÿíäèÿ)         │01548              

                                                                                                                  

│Ïðåñîìåí                      │äðàæå 0.6 ìã; äðàæå êîìïîçèòóì 0.6 │Kali-Chemie Pharma Gmbh (ÔÐÃ) │002144             

                              │ìã                                                                                  

                                                                                                                   

│Ïðåñîìåí                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 1.25 ìã│Kali-Chemie Pharma Gmbh (ÔÐÃ) │002086             

│Ïðåòóòòåëè                                                       │Valio (Ôèíëÿíäèÿ)             │004067             

                                                                                                                 

│Ïðåöèïèòèðóþùàÿ ñûâîðîòêà äëÿ │ïîðîøîê                            │Sevak (×ÑÔÐ)                  │2550               

│èììóíîýëåêòðîôîðåçà                                                                                               

                                                                                                                  

│Ïðèìà                         │ïîäãóçíèêè                         │Eczacibasi (Òóðöèÿ)           │01705              

│Ïðî Ôàì 646                                                      │Adm (ÑØÀ)                     │004334             

│Ïðî Ôàì 974                                                      │Adm (ÑØÀ)                     │004335             

│Ïðîáîí                        │äðàæå 300 ìã                       │Chinoin (Âåíãðèÿ)             │2386               

│Ïðîâåðà                       │òàáëåòêè 100 ìã                    │Eczacibasi (Òóðöèÿ)           │002993             

│Ïðîâåðà                       │òàáëåòêè 100 ìã                    │Upjohn (Áåëüãèÿ)              │00869              

│Ïðîâåðà                       │òàáëåòêè 250, 500 ìã               │Upjohn (ÑØÀ/âåëèêîáðèòàíèÿ)   │002500             

│Ïðîçàê                        │êàïñóëû 20 ìã                      │Eli Lilly & Elanco (ÑØÀ)      │002233             

│Ïðîêñàöèí                     │òàáëåòêè 250, 500 ìã               │Fako Ilaclary As (Òóðöèÿ)     │002606             

                                                                                                                  

│Ïðîëåéêèí                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Eurocetus Italy Spa (Èòàëèÿ)  │002409             

                              │èíôóçèîííîãî ðàñòâîðà 18000000                                                      

                              │ÌÅ/ìë = 1 ìã/ìë                                                                      

                                                                                                                  

│Ïðîëèïàçà                     │êàïñóëû                            │Cilag International Ag        │003214             

                                                                 │(Øâåéöàðèÿ)                                      

                                                                                                                  

│Ïðîìèí HV                                                        │Central Soy (ÑØÀ)             │004208             

                                                                                                                  

│Ïðîìèñ                        │ïàñòà çóáíàÿ                       │Balsara Hygien Products Ltd   │01494              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïðîìèò                        │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 150  │Kabi Pharmacia (Øâåöèÿ)       │003232             

                              │ìã/ìë - 20 ìë                                                                       

                                                                                                                  

│Ïðîìîâèë                                                         │Central Soy (ÑØÀ)             │004207             

│Ïðîìîñîé                                                         │Central Soy (ÑØÀ)             │004209             

                                                                                                                  

│Ïðîíàêñåí                     │òàáëåòêè 250, 500 ìã               │Orion Pharmaceutica           │003102             

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Ïðîïðàíîáåíå                  │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ludwig Merckle Gmbh (Àâñòðèÿ) │003332             

                              │îáîëî÷êîé 10, 40, 80 ìã                                                             

                                                                                                                  

│Ïðîñêàð                       │òàáëåòêè 5 ìã                      │Merck Sharp & Dohme           │003106             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ïðîñîáè                                                          │Bristol-Myers (ÑØÀ)           │01643              

│Ïðîñîÿë                                                          │Fdc Private Ltd (Èíäèÿ)       │01432              

                                                                                                                  

│Ïðîñòèí ÂР                   │ðàñòâîð äëÿ èíôóçèé (àìïóëû) 0.5   │Upjohn (Áåëüãèÿ)              │002431             

                              │ìã - 1 ìë                                                                           

                                                                                                                  

│Ïðîñòèí ÂР                   │ðàñòâîð äëÿ èíúåêöèé äëÿ äåòåé     │Upjohn (Áåëüãèÿ)              │003222             

                              │(àìïóëû) 0.5 ìã/ìë - 0.2, 0.5 ìë                                                    

                                                                                                                  

│Ïðîñòèí Å2                    │òàáëåòêè 0.5 ìã                    │Upjohn (Áåëüãèÿ)              │00860              

                                                                                                                  

│Ïðîñòèí Å2                    │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Upjohn (Áåëüãèÿ)              │003221              

                              │(àìïóëû) 1 ìã/ìë - 0.75 ìë;                                                         

                              │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10                                                    

                              │ìã/ìë - 0.5 ìë; ðàñòâîð äëÿ                                                         

                              │ýêñòðààìíèîòè÷åñêîãî ââåäåíèÿ                                                       

                              │(àìïóëû) 10 ìã/ìë - 0.5 ìë /â                                                       

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì -                                                         

                              │ôëàêîíû 50 ìë/                                                                      

                                                                                                                  

│Ïðîòàíàë ÅÂÐÔ 250             │àëãèíàò                            │Protan (Íîðâåãèÿ)             │01119              

│Ïðîòàíàë ËÔ 250 À             │àëãèíàò                            │Protan (Íîðâåãèÿ)             │01118              

                                                                                                                  

│Ïðîòàôàí HM                   │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Novo Nordisk (Äàíèÿ)          │003064             

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Ïðîôàçè                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Ares-Serono Group (Øâåéöàðèÿ) │01864              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                     

                              │500, 1000, 1500, 2000, 5000 ÌÅ /â                                                    

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                          

                                                                                                                   

│Ïðîôèëàð                      │òàáëåòêè 1 ìã                      │United Pharmaceutical         │002948             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Ïðóäåíò                       │ïàñòà çóáíàÿ                       │U.K.Paintce (India) Ltd       │01382              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ïñîðàêñ                       │êðåì; êðåì ôîðòå                   │Kurtsan Ilaclary As (Òóðöèÿ)  │002895             

                                                                                                                  

│ÏÒ 2000                                                          │Protein Technologies          │004097             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│ÏÒ 2600                                                          │Protein Technologies          │004098             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ïòèöà ñ ìîðêîâüþ è ðèñîì                                         │Nestle (Ãåðìàíèÿ)             │004222             

│Ïóëåâà áåç ãëþòåíà                                               │Uniasa (Èñïàíèÿ)              │004264              

│Ïóëåâà èç 7 çëàêîâ                                               │Uniasa (Èñïàíèÿ)              │004262             

│Ïóëåâà ñ ìåäîì                                                   │Uniasa (Èñïàíèÿ)              │004263             

│Ïóëåâà ñ ôðóêòàìè                                                │Uniasa (Èñïàíèÿ)              │004265             

│Ïóëåâà ñîÿ                                                       │Uniasa (Èñïàíèÿ)              │004261             

                                                                                                                  

│Ïóëüìèêîðò                    │ñóñïåíçèÿ 50 ìêã/äîçà (áàëëîíû     │Astra (Øâåöèÿ)                │002743             

                              │àýðîçîëüíûå) 1 ìã/ìë - 200 äîç;                                                     

                              │ñóñïåíçèÿ 200 ìêã/äîçà (áàëëîíû                                                     

                              │àýðîçîëüíûå) 4 ìã/ìë - 100 äîç                                                      

                                                                                                                  

│Ïóðèíîë                       │òàáëåòêè 100, 300 ìã               │Ludwig Merckle Gmbh (Àâñòðèÿ) │002985             

│Ïóðñåííèä                     │òàáëåòêè â îáîëî÷êå èç ñàõàðà 12 ìã│Sandoz (Òóðöèÿ)               │002099             

                                                                                                                 

│Ïóòöè                         │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh          │004135             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ïøåíè÷íàÿ ìóêà ñ ìîëîêîì                                         │Cato Aromatic (Àðå)           │004269             

                                                                                                                  

│ÏÝÃ-L-àñïàðàãèíàçà (Îíêàñïàð) │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû)     │Enson (ÑØÀ)                   │002628              

                              │3750 ÌÅ - 5 ìë                                                                      

                                                                                                                  

│Ïþðå àáðèêîñîâîå ñ òàïèîêîì                                      │Gerber (ÑØÀ)                  │004126             

│00438                                                                                                             

                                                                                                                  

│Ïþðå áàíàíîâîå ñ òàïèîêîì                                        │Gerber (ÑØÀ)                  │004125             

│01401                                                                                                             

                                                                                                                  

│Ïþðå èç çåëåíîãî ãîðîøêà 00412│                                   │Gerber (ÑØÀ)                  │004180             

                                                                                                                  

│Ïþðå èç èíäåéêè ñ îâîùàìè                                        │Gerber (ÑØÀ)                  │004130             

│02607                                                                                                             

                                                                                                                  

│Ïþðå èç ìîðêîâè 00411                                            │Gerber (ÑØÀ)                  │004179             

│Ïþðå èç ìîðêîâè 02611                                            │Gerber (ÑØÀ)                  │004178             

│Ïþðå èç îâîùåé                                                   │Nestle (Ãåðìàíèÿ)             │004219             

                                                                                                                   

│Ïþðå èç ïåðñèêîâ è þæíîãî                                        │Nestle (Ãåðìàíèÿ)             │004217             

│ôðóêòà ìàðàêóÿ                                                                                                     

                                                                                                                  

│Ïþðå èç ïåðñèêîâ ñ ðèñîì 117                                     │Fructal/Sloveniales (Ñëîâåíèÿ)│004367             

                                                                                                                  

│Ïþðå èç ðàííåé ìîðêîâè è                                         │Nestle (Ãåðìàíèÿ)             │004220             

│êàðòîôåëÿ                                                                                                         

                                                                                                                  

│Ïþðå èç ñâåêëû 00413                                             │Gerber (ÑØÀ)                  │004181             

│Ïþðå èç ñâèíèíû (îêîðîê) 01215│                                   │Gerber (ÑØÀ)                  │004129             

│Ïþðå èç ñìåøàííûõ îâîùåé 00414│                                   │Gerber (ÑØÀ)                  │004182             

│Ïþðå èç ñìåøàííûõ îâîùåé 02614│                                   │Gerber (ÑØÀ)                  │004183             

│Ïþðå èç òåëÿòèíû 01223                                           │Gerber (ÑØÀ)                  │004128             

                                                                                                                  

│Ïþðå èç òîíêîèçìåëü÷åííîé                                        │Nestle (Ãåðìàíèÿ)             │004218             

│ìîðêîâè                                                                                                           

                                                                                                                  

│Ïþðå êóðèíîå ñ îâîùàìè 00402                                     │Gerber (ÑØÀ)                  │004131             

│Ïþðå ÿáëî÷íî-àáðèêîñîâîå 00433│                                   │Gerber (ÑØÀ)                  │004119              

│Ïþðå ÿáëî÷íîå 01401                                              │Gerber (ÑØÀ)                  │004118             

│Ðàâåðîí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1 ìë │Robapharm Ag (Øâåéöàðèÿ)      │00328              

│Ðàä-î-ìåä                     │ïàñòà çóáíàÿ                       │Pharmachim (ÍÐÁ)              │2942               

│Ðàçíûå îâîùè àðò.203                                             │Hipp (Àâñòðèÿ)                │004027             

│Ðàé-ñîÿ ìèëê                                                     │Codrico (Íèäåðëàíäû)          │004346             

│Ðàìèïðèë                      │êàïñóëû 2.5, 5, 10 ìã              │Hoechst Ag (ÔÐÃ)              │002177             

│Ðàíèáåðë                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 150 ìã │Berlin-Chemie Ag (Ãåðìàíèÿ)   │005563             

│Ðàíèñàí                       │òàáëåòêè 150 ìã                    │Pro.Med.Cs (×ÑÔÐ)             │002682             

│Ðàíèòèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìë │Torrent Exports Ltd (Èíäèÿ)   │01976              

                                                                                                                  

│Ðàíèòèí                       │òàáëåòêè 150, 300 ìã               │Torrent Laboratories Ltd      │01873              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ðàïèä 20 Å                                                       │Api System (Ôðàíöèÿ)          │01368              

│Ðàïèäàë                       │òàáëåòêè 60 ìã                     │Ifidesa-Aristegui (Èñïàíèÿ)   │003037             

                                                                                                                  

│Ðàñòîöèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Pliva (Õîðâàòèÿ)              │002618             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │10 ìã                                                                                

                                                                                                                  

│Ðåàáàí                        │òàáëåòêè 750 ìã                    │Pfizer Overseas Inc (ÑØÀ)     │002862             

                                                                                                                  

│Ðåàêòèâû äëÿ îêðàøèâàíèÿ ïî                                      │Medimpex (Âåíãðèÿ)            │2882               

│Ðîìàíîâñêè-Ãèåìçà                                                                                                 

                                                                                                                  

│Ðåàêòèâû äëÿ îïðåäåëåíèÿ                                        │Medimpex (Âåíãðèÿ)            │2884               

│ãàììà-ÃÒ, ÃÎÒ è ÃÏà                                                                                              

                                                                                                                  

│Ðåàêòèâû äëÿ îïðåäåëåíèÿ                                         │Medimpex (Âåíãðèÿ)            │2883               

│òðàíñàìèíà ÃÎÒ, ÃÏÒ è ÃÎÒ/ÃÏÒ │                                                                                    

                                                                                                                  

│Ðåàíàë                                                           │Reanal (Âåíãðèÿ)              │2761               

│Ðåàíàë                                                           │Reanal (Âåíãðèÿ)              │2783               

                                                                                                                  

│Ðåãèäðîí                      │ïîðîøîê äîçèðîâàííûé               │Orion Pharmaceutica           │01300              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Ðåãèòèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Ciba-Geigy (Øâåéöàðèÿ)        │002070              

                              │ìã/1 ìë, 50 ìã/5 ìë                                                                 

                                                                                                                  

│Ðåãóëàð Èëåòèí II             │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40, │Eli Lilly & Elanco (ÑØÀ)      │02035              

                              │100 ÅÄ/ìë - 10 ìë                                                                   

                                                                                                                  

│Ðåãóëüòîí                     │òàáëåòêè                           │Knoll Ag (ÔÐÃ)                │01719              

                                                                                                                  

│Ðåä-âàéò Ô                    │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh          │004226             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ðåçåðïèí                      │òàáëåòêè 0.1, 0.25 ìã              │Polfa (Ïîëüøà)                │2193               

                                                                                                                  

│Ðåçèáåëàêòà                   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Laboratories Atral Sa         │002991             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │(Ïîðòóãàëèÿ)                                     

                              │ã /â êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                     

                                                                                                                  

│ÐåêÂÈ×                                                           │Medicuba (Êóáà)               │3008                

                                                                                                                  

│Ðåêîðìîí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Boehringer Mannheim Gmbh      │002221             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)    │(Àâñòðèÿ)                                        

                              │1000, 2000, 5000 ÌÅ                                                                 

                                                                                                                  

│Ðåëàäîðì                      │òàáëåòêè                           │Polfa (Ïîëüøà)                │2625               

                                                                                                                  

│Ðåëàíèóì@                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Polfa (Ïîëüøà)                │2587               

                              │ìã - 2 ìë                                                                           

                                                                                                                  

│Ðåìàãåëü                      │ñóñïåíçèÿ îðàëüíàÿ                 │Rehise Inc (ÑØÀ)              │003370             

│Ðåìàãåëü À                    │ñóñïåíçèÿ îðàëüíàÿ                 │Rehise Inc (ÑØÀ)              │003371             

│Ðåìîêñèêàì                    │êàïñóëû 10, 20 ìã                  │Alkaloid (Ìàêåäîíèÿ)          │002604             

│Ðåîìàêðîäåêñ                  │ðàñòâîð äëÿ èíôóçèé                │Eczacibasi (Òóðöèÿ)           │01809              

                                                                                                                  

│Ðåòàôèë                       │òàáëåòêè ïðîëîíãèðîâàííîãî         │Orion Pharmaceutica           │01448              

                              │äåéñòâèÿ 200, 300 ìã               │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ðåòèí À                       │ëîñüîí 0.05%                       │Cilag-Chemie (Øâåéöàðèÿ)      │00499               

                                                                                                                  

│Ðåòðîâèð                      │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Wellcome Foundation Ltd       │01413              

                              │(ôëàêîíû) 200 ìã - 10 ìë; êàïñóëû  │(Âåëèêîáðèòàíèÿ)                                 

                              │100, 250 ìã                                                                         

                                                                                                                  

│ÐÈÀ                                                              │Farmos Diagnostic (Ôèíëÿíäèÿ) │01456              

│ÐÈÀ-íàáîð: FSH                                                   │Farmos Diagnostic (Ôèíëÿíäèÿ) │01455              

│ÐÈÀ-íàáîð: LH                                                    │Farmos Diagnostic (Ôèíëÿíäèÿ) │01454              

│ÐÈÀ-íàáîð: SHBG                                                  │Farmos Diagnostic (Ôèíëÿíäèÿ) │01452              

│ÐÈÀ-íàáîð: TSH                                                   │Farmos Diagnostic (Ôèíëÿíäèÿ) │01453              

│Ðèàïàí À                      │ïîðîøîê                            │Ðîññèÿ                        │0004-27            

│Ðèáîð                         │ïîðîøîê                            │Ðîññèÿ                        │0001-9             

                                                                                                                  

│Ðèáîôëàâèí ÔÑÄ                │ñóáñòàíöèÿ                         │Basf Health & Nutrition A/s   │009536             

                                                                 │(Äàíèÿ)                                          

                                                                                                                  

│Ðèâîòðèë@                     │òàáëåòêè 0.5, 2 ìã; ðàñòâîð äëÿ    │Hoffmann La Roche (Øâåéöàðèÿ) │00889              

                              │èíúåêöèé (àìïóëû) 1 ìã - 2 ìë                                                       

                                                                                                                   

│Ðèä                           │øàìïóíü                            │Pfizer Overseas Inc (ÑØÀ)     │002863             

                                                                                                                  

│Ðèäàçèí                       │òàáëåòêè 10, 25, 50, 100 ìã        │Al-Hikma Pharmaceuticals      │002599             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Ðèëà Ñ                        │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2713               

│Ðèðè                                                             │Ryry Baby Food Co (Àðå)       │004113             

│Ðèðè áàíàíà                                                      │Ryry Baby Food Co (Àðå)       │004146             

│Ðèñ ñ ìîëîêîì                                                    │Cato Aromatic (Àðå)           │004270             

                                                                                                                  

│Ðèñ ñ òîìàòíûì ñîóñîì è                                          │Gerber (ÑØÀ)                  │004133             

│ãîâÿäèíîé 01621                                                                                                   

                                                                                                                  

│Ðèñîâàÿ êàøà ñ ÿáëîêîì è                                         │Gerber (ÑØÀ)                  │004127             

│áàíàíîì 00467                                                                                                     

                                                                                                                  

│Ðèñîâûå õëîïüÿ áýáè                                              │Kolynska/Sloveniales          │004368              

                                                                 │(Ñëîâåíèÿ)                                       

                                                                                                                  

│Ðèñîâûé ïóäèíã                                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004286             

│Ðèòìîäàí                      │êàïñóëû                            │Laboratoires Roussel (Ôðàíöèÿ)│00539              

│Ðèòìîíîðì                     │ðàñòâîð äëÿ èíúåêöèé 70 ìã - 20 ìë │Knoll Ag (ÔÐÃ)                │002784             

│Ðèôàìîð                       │êàïñóëû 150, 300 ìã                │Galenika (Þãîñëàâèÿ)          │00268              

│Ðèôàìïèí                      │êàïñóëû 150, 300 ìã                │Ipca Laboratories Ltd (Èíäèÿ) │006950             

                                                                                                                  

│Ðèôàìïèí                      │êàïñóëû 150, 300 ìã; òàáëåòêè 450, │Yuhan Corporation (Êîðåÿ      │003233             

                              │600 ìã                             │Þæíàÿ)                                           

                                                                                                                  

│Ðèôàìïèöèí                    │êàïñóëû 450 ìã                     │Mesco Laboratories Ltd (Èíäèÿ)│002961             

                                                                                                                  

│Ðèôîãàë                       │ðàñòâîð äëÿ âíóòðèìûøå÷íûõ         │Galenika (Þãîñëàâèÿ)          │00118              

                              │èíúåêöèé è ìåñòíîãî ïðèìåíåíèÿ                                                      

                              │(àìïóëû) 125 ìã/1.5 ìë, 250 ìã/3                                                    

                              │ìë; ðàñòâîð äëÿ âíóòðèâåííîãî                                                       

                              │ââåäåíèÿ (àìïóëû) 500 ìã - 10 ìë                                                    

                                                                                                                   

│Ðèôîäåêñ                      │êàïñóëû 150, 300 ìã; òàáëåòêè 300, │Chung Kun Dah Corporation     │002624             

                              │450, 600 ìã                        │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                  

│Ðîàêêóòàí                     │êàïñóëû 10, 20 ìã                  │Hoffmann La Roche (Øâåéöàðèÿ) │02003              

│Ðîáåáè À                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Egis (Âåíãðèÿ)                │004115             

│Ðîáåáè Á                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Egis (Âåíãðèÿ)                │004116             

│Ðîáîëàêò                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Egis (Âåíãðèÿ)                │004114             

│Ðîâèôàðèí 955                 │ñìåñü                              │Hoffmann La Roche (Øâåéöàðèÿ) │004073             

│Ðîâèôàðèí 965                 │ñìåñü                              │Hoffmann La Roche (Øâåéöàðèÿ) │004072             

│Ðîâèôàðèí 966                 │ñìåñü                              │Hoffmann La Roche (Øâåéöàðèÿ) │004071             

│Ðîãèïíîë@                     │òàáëåòêè 1 ìã                      │Hoffmann La Roche (Øâåéöàðèÿ) │00752              

│Ðîãèïíîë@                     │òàáëåòêè 1 ìã; ðàñòâîð äëÿ èíúåêöèé│Spofa (×åõîñëîâàêèÿ)          │2892               

│Ðîêàëüòðîë                    │êàïñóëû 0.25, 0.5 ìêã              │Hoffmann La Roche (Øâåéöàðèÿ) │002321             

│Ðîíàë                         │òàáëåòêè 500 ìã                    │Rhone-Poulenc Rorer (Ãåðìàíèÿ)│003391             

                                                                                                                  

│Ðîò-âàéñ                      │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh          │004065             

                                                                 │(Ãåðìàíèÿ)                                        

                                                                                                                  

│Ðîôåðîí À                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Hoffmann La Roche (Øâåéöàðèÿ) │002812             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │3000000, 9000000, 18000000 ÌÅ /â                                                    

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                          

                                                                                                                  

│Ðóâàêñ                        │ëèîôèëèç.æèâàÿ âàêöèíà (ôëàêîíû -  │Pasteur Merieux Serums Et     │002455             

                              │â êîìïëåêòå ñ ðàñòâîðèòåëåì) 1     │Vaccins (Ôðàíöèÿ)                                

                              │äîçà, 10 äîç                                                                        

                                                                                                                  

│Ðóäîòåëü@                     │òàáëåòêè                           │Oranienburger Pharmawerk Gmbh │00410              

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Ðûáà â ñûðíîì ñîóñå                                              │H.J.Heinz (ÑØÀ)               │004108             

│Ñàãðîëèíä Ï                   │êðåì-ëîñüîí                        │Schulke & Mayr (Ãåðìàíèÿ)     │0025-23            

                                                                                                                  

│Ñàëàìîë                       │àýðîçîëü                           │Norton Healthcare Ltd         │003246             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                   

│Ñàëàìîë ëåãêîå äûõàíèå        │àýðîçîëü (áàëëîí÷èêè) 100 ìêã/äîçà │Norton Healthcare             │009438             

                              │- 200 äîç; àýðîçîëü (áàëëîí÷èêè)   │(Âåëèêîáðèòàíèÿ)                                 

                              │100 ìêã/äîçà - 200 äîç /â                                                           

                              │êîìïëåêòå ñ èíãàëÿòîðîì                                                             

                              │îïòèìèçàòîðîì äîçû/                                                                 

                                                                                                                  

│Ñàëîôàëüê                     │òàáëåòêè 250 ìã; ñâå÷è 250 ìã;     │Zdravle (Þãîñëàâèÿ)           │002798             

                              │ñóñïåíçèÿ ðåêòàëüíàÿ 4 ã/60 ã                                                       

                                                                                                                  

│Ñàëüáóâåíò                    │òàáëåòêè 2 ìã, 4 ìã; àýðîçîëü äëÿ  │Leiras (Ôèíëÿíäèÿ)            │00596              

                              │èíãàëÿöèé 0.1 ìã/äîçà; ìèêñòóðà                                                     

                              │0.4 ìã/ìë                                                                           

                                                                                                                  

│Ñàëüáóòàìîë                   │òàáëåòêè 2 ìã, 4 ìã                │Polfa (Ïîëüøà)                │2974               

│Ñàíà                          │ëîñüîí                             │Ðîññèÿ                        │0006-2             

                                                                                                                  

│Ñàíäèììóí                     │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Sandoz (Øâåéöàðèÿ)            │01187              

                              │èíôóçèîííîãî ðàñòâîðà (àìïóëû) 50                                                   

                              │ìã/1 ìë, 250 ìã/5 ìë; ðàñòâîð                                                        

                              │îðàëüíûé (ôëàêîíû) 100 ìã/ìë                                                        

                                                                                                                  

│Ñàíäèììóí                     │êàïñóëû æåëàòèíîâûå ìÿãêèå 25, 50, │Sandoz Pharma (Øâåéöàðèÿ)     │002398             

                              │100 ìã                                                                              

                                                                                                                  

│Ñàíåêòà                                                          │Holland Sweetner Company      │01901              

                                                                 │(Íèäåðëàíäû)                                     

                                                                                                                  

│Ñàíèíî                        │ïàñòà çóáíàÿ                       │Aviap As (Òóðöèÿ)             │004083             

│Ñàíîñàí                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Lek D.D. (Ñëîâåíèÿ)           │006425             

│Ñàíïà                         │òàáëåòêè 20 ìã                     │Bilim Ilac Sanayi (Òóðöèÿ)    │002128             

│Ñàíïëàñòûðü                   │ðîëèêè                             │Pharmachim (Áîëãàðèÿ)         │2624               

│Ñàíò-Å-Ãàë                    │äðàæå                              │Galenika (ÑÔÐÞ)               │002185             

│Ñàðèäîí                       │òàáëåòêè                           │Hoffmann La Roche (Øâåéöàðèÿ) │002720             

                                                                                                                  

│ÑÅÀ - Êàðöèíî-ýìáðèîíàëüíûé                                      │Abbott Laboratories (ÑØÀ)     │01132              

│àíòèãåí                                                                                                            

                                                                                                                  

│Ñåâàòåñò Ýëèñà                                                   │Sevak (×åõîñëîâàêèÿ)          │2765               

│Ñåâàòåñò-ðåïðî                │ôëàêîíû                            │Imuna (×åõîñëîâàêèÿ)          │2629               

│Ñåâåðàë ôëóîð                 │ïàñòà çóáíàÿ                       │Chemotrade (Øâåéöàðèÿ)        │01703              

                                                                                                                  

│Ñåäàêîðîí                     │òàáëåòêè 200 ìã; ðàñòâîð äëÿ       │Ebewe Arzneimittel Gmbh       │002387             

                              │èíúåêöèé (àìïóëû) 150 ìã - 3 ìë    │(Àâñòðèÿ)                                        

                                                                                                                  

│Ñåäàëüãèí                     │òàáëåòêè                           │Pharmachim (Áîëãàðèÿ)         │2132               

                                                                                                                  

│Ñåäîêàðä-ðåòàðä               │òàáëåòêè 20, 40 ìã                 │Cedona Pharmaceutical         │002674             

                                                                 │(Íèäåðëàíäû)                                     

                                                                                                                 

│Ñåêìàìà ñ áàíàíîì                                                │Sek (Òóðöèÿ)                  │004137             

│Ñåêìàìà ñ âàíèëèíîì                                              │Sek (Òóðöèÿ)                  │004139             

│Ñåêìàìà ñ çåìëÿíèêîé                                             │Sek (Òóðöèÿ)                  │004138             

│Ñåêìàìà ñ ïåðñèêîì                                               │Sek (Òóðöèÿ)                  │004140             

│Ñåêìàìà ñ ÿáëîêîì                                                │Sek (Òóðöèÿ)                  │004141             

│Ñåêòðàë                       │òàáëåòêè 200 ìã                    │Polfa (Ïîëüøà)                │2998                

                                                                                                                  

│Ñåêòðàë                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 0.5% │Specia (Ôðàíöèÿ)              │01088              

                              │- 5 ìë                                                                              

                                                                                                                  

│Ñåêóðîïåí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bayer Ag (ÔÐÃ)                │01399              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5 ã, 2 ã                                                                          

                                                                                                                  

│Ñåëåãèëèí Êíîëëü              │òàáëåòêè 5 ìã                      │Knoll Ag (Ãåðìàíèÿ)           │007757             

│Ñåëåíîìåòèîíèí 75Ñå           │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01255              

│Ñåìèëêî-1                                                        │Nestle (Ãåðìàíèÿ)             │004225             

│Ñåíçèò                        │äðàæå 50 ìã                        │Chinoin (Âåíãðèÿ)             │2656               

│Ñåíñîäàéí-ìèíò                │ïàñòà çóáíàÿ                       │Block Drug Company Inc (ÔÐÃ)  │004062             

│Ñåíñîäàéí-ôëþîðèä             │ïàñòà çóáíàÿ                       │Block Drug Company Inc (ÔÐÃ)  │004061             

                                                                                                                  

│Ñåïåêñèí                      │òàáëåòêè 125 ìã; êàïñóëû 250, 500  │Lyka Labs Ltd (Èíäèÿ)         │002259             

                              │ìã                                                                                   

                                                                                                                  

│Ñåïòîëåòå                     │äðàæå                              │Krka (Ñëîâåíèÿ)               │002484              

│Ñåïòî-ïàê                     │ïàñòà                              │Septodent (Ôðàíöèÿ)           │00534              

                                                                                                                  

│Ñåïòðèí                       │ðàñòâîð äëÿ âíóòðèìûøå÷íûõ         │Wellcome Foundation Ltd       │00755              

                              │èíúåêöèé (àìïóëû) 3 ìë             │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ñåðåëàê                                                          │Nestle (Øâåéöàðèÿ)            │04025              

│Ñåðåëàê                                                          │Nestle (Øâåéöàðèÿ)            │04024              

│Ñåðåëàê                                                          │Nestle (Øâåéöàðèÿ)            │04022              

│Ñåðåëàê                                                          │Nestle (Øâåéöàðèÿ)            │04023              

│Ñåðåíà                        │ñàëôåòêè æåíñêèå ãèãèåíè÷åñêèå     │Johnson & Johnson (ÑØÀ)       │01950              

│Ñåðåíà Äåî                    │ñàëôåòêè æåíñêèå ãèãèåíè÷åñêèå     │Johnson & Johnson (ÑØÀ)       │01951              

│Ñåðîòðîë Í, Ï, 25 Í           │ñûâîðîòêè (íàáîð)                  │Human (Âåíãðèÿ)               │2827               

                                                                                                                  

│Ñåô                           │òàáëåòêè 250, 500 ìã; ñóñïåíçèÿ    │Mustafa Nevzat Ilac Sanayi As │003196             

                              │îðàëüíàÿ (ôëàêîíû) 250 ìã|5 ìë     │(Òóðöèÿ)                                         

                                                                                                                  

│Ñåôàãåí                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bilim Ilac Sanayi (Òóðöèÿ)    │002303              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Ñåôàçîë                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Mustafa Nevzat Ilac Sanayi As │002517             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Òóðöèÿ)                                         

                              │250, 500, 1000 ìã                                                                   

                                                                                                                  

│Ñèáèêîðò                      │êðåì                               │Orion Pharmaceutica           │01449              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ñèáðèë-äåî                    │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2807               

│Ñèêîðòåí ïëþñ                 │êðåì 0.05%                         │Ciba-Geigy (Øâåéöàðèÿ)        │002165             

│Ñèëêà Ô                       │ïàñòà çóáíàÿ                       │Florena (ÃÄÐ)                 │01353              

│Ñèëêîò                        │ðàñòâîð                            │Septodent (Ôðàíöèÿ)           │00533              

│Ñèëóáèí ðåòàðä                │äðàæå 100 ìã                       │Grunenthal Gmbh (ÔÐÃ)         │00183              

│Ñèìèëàê 60/40                                                    │Abbott Laboratories (ÑØÀ)     │01641              

│Ñèìèëàê ñïåòèàë êýà 24                                           │Abbott Laboratories (ÑØÀ)     │01728              

│Ñèìèëàê ñïåøèàë êýà 20                                           │Abbott Laboratories (ÑØÀ)     │01727              

│Ñèìïëåññ                                                         │Nutrasweet (ÑØÀ)              │01647               

                                                                                                                  

│Ñèíàêòåí äåïî                 │ñóñïåíçèÿ äëÿ èíúåêöèé (àìïóëû) 1  │Ciba-Geigy (Øâåéöàðèÿ)        │00067              

                              │ìã/1 ìë, 2 ìã/2 ìë                                                                  

                                                                                                                  

│Ñèíàëàð                       │ãåëü                               │Galenika (Þãîñëàâèÿ)          │00271              

│Ñèíàëàð                       │ìàçü                               │Galenika (Þãîñëàâèÿ)          │00262              

│Ñèíåêâàí                      │êàïñóëû 10 ìã, 25 ìã               │Alkaloid (ÑÔÐÞ)               │00453              

│Ñèíåêâàí                      │êàïñóëû 10 ìã, 25 ìã               │Polfa (Ïîëüøà)                │2684               

│Ñèíêóìàð                      │òàáëåòêè 2 ìã                      │Alkaloida (Âåíãðèÿ)           │2100               

│Ñèíôàñèê                      │òàáëåòêè çåëåíûå è ãîëóáûå         │Syntex Laboratories Inc (ÑØÀ) │002391             

│Ñèðåíà                        │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2801               

│Ñèñêîð                        │òàáëåòêè ëàêèðîâàííûå 10 ìã        │Bayer Ag (ÔÐÃ)                │002194             

│Ñèòè                          │øàøêè ïèðîòåõíè÷åñêèå              │Ðîññèÿ                        │0004-28            

                                                                                                                  

│Ñèôàêñ                        │øàìïóíü                            │Sifar Ilaclary Sanayi As      │004250             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                   

│Ñèôåíîë                       │òàáëåòêè æåâàòåëüíûå 80 ìã         │Sifar Ilaclary Sanayi As      │002560             

                                                                 │(Òóðöèÿ)                                          

                                                                                                                  

│Ñëèâêè ñ îâîùàìè àðò.208                                         │Hipp (Àâñòðèÿ)                │004028             

│Ñìà âàéò êàï                                                     │Wyeth (ÑØÀ)                   │01929              

│Ñìà ãîëä êàï                                                     │Wyeth (ÑØÀ)                   │01648              

│Ñîåâàÿ ìóêà ADM                                                  │Adm (ÑØÀ)                     │004283             

│Ñîê èç ñìåøàííûõ ôðóêòîâ 02108│                                   │Gerber (ÑØÀ)                  │004167             

│Ñîê èç ñìåøàííûõ ôðóêòîâ 02138│                                   │Gerber (ÑØÀ)                  │004169             

                                                                                                                  

│Ñîê èç ÿáëîêà è ãðåéïôðóòà                                       │Gerber (ÑØÀ)                  │004170             

│02140                                                                                                             

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004354             

│áàíàíîâî-ìîðêîâíî- ÿáëî÷íûé                                                                                       

│áîáî-ôðóò                                                                                                         

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004357             

│áàíàíîâî-òûêâåííî- ÿáëî÷íûé                                                                                        

│áîáî-ôðóò                                                                                                         

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004355             

│áàíàíîâî-ÿáëî÷íûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004352             

│ìàëèíîâî-ÿáëî÷íî- êëóáíè÷íûé                                                                                      

│áîáî-ôðóò                                                                                                         

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004348             

│ìàëèíîâî-ÿáëî÷íî-                                                                                                 

│÷åðíîñìîðîäèíîâûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004353             

│ìîðêîâíî-ëèìîííûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004351             

│ìîðêîâíî-ÿáëî÷íî- àáðèêîñîâûé │                                                                                    

│áîáî-ôðóò                                                                                                          

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004350             

│ìîðêîâíî-ÿáëî÷íûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004356             

│ÿáëî÷íî-áàíàíîâî-                                                                                                 

│÷åðíîñìîðîäèíîâûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ñ ìÿêîòüþ                                                    │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004349             

│ÿáëî÷íî-òûêâåííûé áîáî-ôðóò                                                                                       

                                                                                                                  

│Ñîê ÿáëî÷íî-âèøíåâûé 02135                                       │Gerber (ÑØÀ)                  │004171             

                                                                                                                  

│Ñîê-íåêòàð êëóáíè÷íûé                                            │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004359             

│áîáî-ôðóò                                                                                                         

                                                                                                                  

│Ñîê-íåêòàð ÿáëî÷íûé áîáî-ôðóò │                                   │Alima-Gerber Sa (Ïîëüøà/ÑØÀ)  │004358             

│Ñîëâèí                        │òàáëåòêè 8 ìã; ýëèêñèð             │Ipca Laboratories Ltd (Èíäèÿ) │01857              

│Ñîëêîâàãèí                    │ðàñòâîð äëÿ ìåñòíîãî ïðèìåíåíèÿ    │Solco (Øâåéöàðèÿ)             │002195              

│Ñîëêîäåðì                     │ðàñòâîð äëÿ íàðóæíîãî ïðèìåíåíèÿ   │Solco Basel Ag (Øâåéöàðèÿ)    │002127             

│Ñîëêîí                                                           │Soy Meinz (ÔÐÃ)               │004148             

                                                                                                                  

│Ñîëêîñåðèë                    │ìàçü 5%; æåëå 10%; ðàñòâîð äëÿ     │Alkaloid (ÑÔÐÞ)               │00295              

                              │èíúåêöèé (àìïóëû) 2 ìë                                                              

                                                                                                                  

│Ñîëêîñåðèë                    │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Solco Basel Ag (Øâåéöàðèÿ)    │00866              

                                                                                                                  

│Ñîëêîñåðèë äåíòàë àäãåçèâíàÿ  │ïàñòà                              │Solco Basel Ag (Øâåéöàðèÿ)    │002227             

│ïàñòà                                                                                                             

                                                                                                                  

│ÑîëêîÒðèõîâàê                 │ëèîôèëèçàò äëÿ ïðèãîòîâëåíèÿ       │Solco Basel Ag (Øâåéöàðèÿ)    │002565             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû,                                                    

                              │ñîäåðæàùèå 7 ìëðä ëàêòîáàöèëë)                                                      

                                                                                                                  

│Ñîëëè                         │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2853               

                                                                                                                   

│Ñîëïàäåèí                     │òàáëåòêè                           │Smithkline Beecham Consumer   │009409             

                                                                 │Healthcare (Âåëèêîáðèòàíèÿ)                      

                                                                                                                 

│Ñîëóâèò Í                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Kabi Pharmacia (Øâåöèÿ)       │002411             

                              │èíôóçèîííîãî ðàñòâîðà                                                               

                                                                                                                  

│Ñîëó-Ìåäðîë                   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Upjohn (Áåëüãèÿ)              │002319             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250 ìã - 4 ìë                                                                       

                                                                                                                  

│Ñîëó-Ìåäðîë                   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Upjohn (Áåëüãèÿ)              │00861              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû                                                     

                              │äâóõåìêîñòíûå) 40, 125 ìã; ïîðîøîê │                                                 

                              │äëÿ ïðèãîòîâëåíèÿ èíúåêöèîííîãî                                                     

                              │ðàñòâîðà (ôëàêîíû) 500, 1000 ìã /â │                                                 

                              │êîìïëåêòå ñ ðàñòâîðèòåëåì/                                                          

                                                                                                                  

│Ñîìàòîòðîïèí ÷åëîâåêà äëÿ     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Ðîññèÿ                        │76/647/6           

│èíúåêöèé                      │èíúåêöèîííîãî ðàñòâîðà                                                               

                                                                                                                  

│Ñîíàïàêñ                      │äðàæå 10, 25, 100 ìã               │Polfa (Ïîëüøà)                │2195               

│Ñîïðî ÒÂ-325                                                     │Soyprotein (Þãîñëàâèÿ)        │004252             

│Ñîïðîòåêñ                                                       │Soyprotein (Þãîñëàâèÿ)        │004253             

│Ñîïðîòåêñ Í                                                      │Soyprotein (Þãîñëàâèÿ)        │004254             

                                                                                                                  

│Ñîòàëîë ÀÂÄ 160               │òàáëåòêè 160 ìã                    │Arzneimittelwerk Dresden Gmbh │007597             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ñîòàëîë ÀÂÄ 80                │òàáëåòêè 80 ìã                     │Arzneimittelwerk Dresden Gmbh │007596             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ñîôðàäåêñ                     │êàïëè ãëàçíûå; êàïëè óøíûå         │Roussel (India)               │01019              

                                                                 │Pharmaceutical Ltd (Èíäèÿ)                       

                                                                                                                  

│Ñîôò äåíò                     │ïàñòà çóáíàÿ                       │Eka/Sinikos (Ôèíëÿíäèÿ)       │01347              

│Ñîÿë                                                             │Fdc Private Ltd (Èíäèÿ)       │01431               

│Ñïàãåòòè ïî-áîëîíñêè                                             │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004299             

                                                                                                                  

│Ñïàãåòòè ñ òîìàòíûì ñîóñîì è                                     │Gerber (ÑØÀ)                  │004132             

│ãîâÿäèíîé 01620                                                                                                   

                                                                                                                  

│Ñïàäýòèë                      │àýðîçîëü                           │Laboratoires Spad (Ôðàíöèÿ)   │00298              

│Ñïàçâèí                       │òàáëåòêè                           │Wave International (Èíäèÿ)    │003261             

│Ñïàçìîâåðàëãèí                │òàáëåòêè                           │Slovakofarma Sa (×ÑÔÐ)        │002567             

│Ñïàñîäåíò                     │ïàñòà çóáíàÿ                       │Space Enterprises (Èíäèÿ)     │01723              

│Ñïèðàòåñò                     │òðóáêè èíäèêàòîðíûå                │Reanal (Âåíãðèÿ)              │2823               

                                                                                                                  

│Ñïèðîíîëàêòîí                 │òàáëåòêè 25, 100 ìã                │Norton Healthcare Ltd         │003244             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Ñïèðîíîëàêòîí-Ðàòèîôàðì       │òàáëåòêè 100 ìã                    │Ratiopharm Gmbh & Co          │003413             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ñïîíãîñòàí                    │ãóáêà ãåìîñòàòè÷åñêàÿ              │Ferrosan (Äàíèÿ)              │00592              

│Ñïîôà-òåñò àëüôà-àìèëàçà      │òàáëåòêè                           │Spofa (×åõîñëîâàêèÿ)          │2775                

                                                                                                                  

│Ñïðåîð                        │ñóñïåíçèÿ äëÿ îðàëüíûõ èíãàëÿöèé   │Laboratoires Biogalenique     │002435             

                              │äîçèðîâàííàÿ (áàëëîíû àýðîçîëüíûå) │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ñòàçåïèí                      │òàáëåòêè 200 ìã                    │Polfa (Ïîëüøà)                │2395               

│Ñòåéôðè                       │ïàêåòû æåíñêèå ãèãèåíè÷åñêèå       │Johnson & Johnson (ÑØÀ)       │004053             

                                                                                                                  

│Ñòèëàìèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Serono (ÔÐÃ)                  │01258              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                     

                              │250 ìêã, 3 ìã                                                                       

                                                                                                                  

│Ñòðîôàíòèí-à                 │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 0.25 │Jenapharm Gmbh (ÔÐÃ)          │002272             

                              │ìã - 1 ìë                                                                           

                                                                                                                  

│Ñòóãåðîí                      │òàáëåòêè 25 ìã; êàïñóëû ôîðòå 75   │Janssen Pharmaceutica         │002084             

                              │ìã; ñóñïåíçèÿ 75 ìã/ìë             │(Áåëüãèÿ)                                        

                                                                                                                   

│Ñóêðàëîçà                                                        │Tate&laile (Âåëèêîáðèòàíèÿ)   │004375             

                                                                                                                   

│Ñóêðàëüôàò                    │òàáëåòêè 1 ã                       │Unichem Laboratories Ltd      │002133             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ñóëüôàìåòîêñàçîë/Òðèìåòîïðèì  │òàáëåòêè 800 ìã/160 ìã, 400 ìã/80  │Mir Pharmaceutical            │007700             

                              │ìã; ñóñïåíçèÿ (ôëàêîíû) 200 ìã/40  │Inc/Biocraft Laboratories Inc │                   

                              │ìã|5 ìë - 100, 150, 200, 473 ìë    │(ÑØÀ)                                            

                                                                                                                  

│Ñóëüôàòðèì-ÑÑ                 │òàáëåòêè 400 ìã/80 ìã              │Watson Laboratories Inc (ÑØÀ) │002581             

│Ñóëüôîõëîðàíòèí 2             │ïîðîøîê                            │Ðîññèÿ                        │0001-À12           

│Ñóëüôîõëîðàíòèí-Ì             │ïîðîøîê                            │Ðîññèÿ                        │0001-À12           

│Ñóìåòðîëèì                    │òàáëåòêè                           │Egis (Âåíãðèÿ)                │2392               

│Ñóìåòðîëèì                    │ñèðîï                              │Egis (ÂÍÐ)                    │2567               

│Ñóíåòò                                                           │Hoechst Ag (ÔÐÃ)              │004282             

                                                                                                                  

│Ñóïåð Êîðåãà - Êîðåãà         │êðåì äëÿ ôèêñàöèè çóáíûõ ïðîòåçîâ  │Block Drug Company Inc (ÔÐÃ)  │004058             

│ôèêñàòèâ êðèì                                                                                                     

                                                                                                                   

│Ñóïåð Êîðåãà - Êîðåãà         │ïîðîøîê äëÿ ôèêñàöèè çóáíûõ        │Block Drug Company Inc (ÔÐÃ)  │004059             

│ôèêñàòèâ ïàóäåð               │ïðîòåçîâ                                                                            

                                                                                                                  

│Ñóïïîçèòîðèè ñ ãëèöåðèíîì     │ñâå÷è 1, 2, 3 ã                    │Paul Hauser Chepharin         │003189             

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                  

│Ñóïðàäèí Ðîø                  │òàáëåòêè ðàñòâîðèìûå               │Hoffmann La Roche (Øâåéöàðèÿ) │006500             

                                                                                                                  

│Ñóïðî 1751                                                       │Protein Technologies          │004096             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ñóïðî 500 Å                                                      │Protein Technologies          │004080             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ñóïðî 500 Ô                                                      │Protein Technologies          │004093             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ñóïðî 590                                                        │Protein Technologies          │004094             

                                                                 │International (ÑØÀ)                               

                                                                                                                  

│Ñóïðî 710                                                        │Protein Technologies          │004095             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ñóïðî 760                                                        │Protein Technologies          │004081             

                                                                 │International (ÑØÀ)                              

                                                                                                                  

│Ñóðáåêñ 750 c öèíêîì          │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003344             

│Ñóðáåêñ 750 ñ æåëåçîì         │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003343             

│Ñóðáåêñ ñ Ñ ôèëìòàá           │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003341             

│Ñóðáåêñ ôèëìòàá               │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003340             

│Ñóðáåêñ-Ò ôèëìòàá             │òàáëåòêè                           │Abbott Laboratories (ÑØÀ)     │003342             

│Ñóðãàì                        │òàáëåòêè 300 ìã                    │Hosbon (Èñïàíèÿ)              │002429             

│Ñóðãàì                        │òàáëåòêè 300 ìã; ñâå÷è 300 ìã      │Roussel (Èíäèÿ)               │002893             

                                                                                                                  

│Ñóôðåêñàë                     │òàáëåòêè ëàêèðîâàííûå 20, 40 ìã    │Janssen Pharmaceutica         │002639             

                                                                 │(Áåëüãèÿ)                                         

                                                                                                                  

│Ñûð ñ ìàêàðîíàìè                                                 │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004313              

│Ñûð ñ ìàêàðîíàìè è ïîìèäîðàìè │                                   │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004315             

│Ñûð ñ ìîðêîâüþ 02621                                             │Gerber (ÑØÀ)                  │004193             

│Ñûð ñ îâîùàìè                                                    │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004312             

│Ñûð ñ öâåòíîé êàïóñòîé                                           │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004314             

                                                                                                                  

│Òàâåãèë                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìã │Egis (Âåíãðèÿ)                │2626               

                              │- 2 ìë                                                                              

                                                                                                                  

│Òàìîêñèôåí                    │òàáëåòêè 10, 20, 30, 40 ìã         │Ebewe (Àâñòðèÿ)               │003700             

│Òàìïîíû ãèãèåíè÷åñêèå         │òàìïîíû æåíñêèå ãèãèåíè÷åñêèå      │Tambrands (ÑØÀ)               │01419              

│Òàíäêðàì                      │ïàñòà çóáíàÿ                       │Dentozal (Øâåöèÿ)             │01479              

│Òàðèâèä                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200 ìã │Hoechst (India) Ltd (Èíäèÿ)   │005323             

│Òàðèâèä                       │ðàñòâîð äëÿ èíôóçèé 200 ìã - 100 ìë│Hoechst Ag (ÔÐÃ)              │01996              

│Òàðèâèä                       │òàáëåòêè 200 ìã                    │Hoechst Ag (ÔÐÃ)              │01374              

                                                                                                                  

│Òàñèìàéä                      │òàáëåòêè 40 ìã; ðàñòâîð äëÿ        │Tamilnadu Dadha               │003384             

                              │èíúåêöèé (àìïóëû) 20 ìã - 2 ìë     │Pharmaceuticals Ltd (Èíäèÿ)                       

                                                                                                                  

│Òàòà äåêñèí 10                │ðàñòâîð äëÿ èíôóçèé ñ íàòðèÿ       │Tata Pharma (Èíäèÿ)           │003126             

                              │õëîðèäîì (ôëàêîíû) 10% - 500 ìë                                                     

                                                                                                                  

│Òàòà äåêñèí 5                 │ðàñòâîð äëÿ èíôóçèé ñ íàòðèÿ       │Tata Pharma (Èíäèÿ)           │003126             

                              │õëîðèäîì (ôëàêîíû) 5% - 500 ìë                                                      

                                                                                                                  

│Òàòà äåêñò 10                 │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Tata Pharma (Èíäèÿ)           │003125             

                              │(ôëàêîíû) 10% - 500 ìë                                                              

                                                                                                                  

│Òàòà äåêñò 5                  │ðàñòâîð äëÿ èíôóçèé âîäíûé         │Tata Pharma (Èíäèÿ)           │003125             

                              │(ôëàêîíû) 5% - 500 ìë                                                               

                                                                                                                  

│Òàòà ñàëèí                    │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 0.9% │Tata Pharma (Èíäèÿ)           │003124             

                              │- 500 ìë                                                                            

                                                                                                                  

│Òàóðåäîí                      │ðàñòâîð äëÿ âíóòðèìûøå÷íûõ         │Byk Gulden Gmbh (ÔÐÃ)         │01381              

                              │èíúåêöèé (àìïóëû) 0.5 ìë - 10, 20, │                                                 

                              │50 ìã                                                                                

                                                                                                                  

│Òàô ëàéí                      │ïàñòà çóáíàÿ                       │Himani Ltd (Èíäèÿ)            │04026              

│Òåãðåòîë                      │òàáëåòêè 200 ìã                    │Pliva (Þãîñëàâèÿ)             │2454               

│Òåëäàí                        │òàáëåòêè 60, 120 ìã                │Marion Merrel Dow (Èòàëèÿ)    │002516             

│Òåëåáðèêñ 300                 │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Byk Gulden Gmbh (ÔÐÃ)         │00801              

│Òåëåáðèêñ 380                 │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Byk Gulden Gmbh (ÔÐÃ)         │00800              

│Òåíîëîë                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 100 ìã │Ipca Laboratories Ltd (Èíäèÿ) │01816              

│Òåíîðåòèê                     │òàáëåòêè 100 ìã/25 ìã              │ICI (Âåëèêîáðèòàíèÿ)          │002694             

│Òåíîðèê                       │òàáëåòêè                           │Ipca Laboratories Ltd (Èíäèÿ) │01817              

│Òåíîðìèí                      │òàáëåòêè                           │ICI (Âåëèêîáðèòàíèÿ)          │00882              

│Òåíîðìèí                      │òàáëåòêè 100 ìã                    │Lachema (×åõèÿ)               │003470             

│Òåîòàðä                       │êàïñóëû ðåòàðä 200, 350, 500 ìã    │Krka (ÑÔÐÞ)                   │002106             

│Òåðàâèò Ì                     │êàïñóëû æåëàòèíîâûå                │Union Pharma Co (ÑØÀ)         │003311             

│Òåðàëåí                       │òàáëåòêè 5 ìã                      │Berlin-Chemie Ag (ÔÐÃ)        │002901             

│Òåððàëèí (ÒÐÍ 5225)           │æèäêîñòü                           │Schulke & Mayr (Ãåðìàíèÿ)     │0005-5             

│Òåðôåä                        │òàáëåòêè 60 ìã                     │Cipla Ltd (Èíäèÿ)             │003411             

                                                                                                                   

│Òåðôåíà ôîðòå                 │òàáëåòêè 120 ìã                    │Sifar Ilaclary Sanayi As      │002700             

                                                                 │(Òóðöèÿ)                                          

                                                                                                                  

│Òåðôåíà-Ñèôàð                 │ñóñïåíçèÿ (ôëàêîíû) 30 ìã|5 ìë -   │Sifar Ilaclary Sanayi As      │002172             

                              │120 ìë                             │(Òóðöèÿ)                                         

                                                                                                                  

│Òåòðàôàí                      │ïîëîñêè                            │Lachema (×åõîñëîâàêèÿ)        │2638               

                                                                                                                  

│Òåòðàöèêëèí                   │ãðàíóëû äëÿ ïðèãîòîâëåíèÿ îðàëüíîé │Pharmachim (ÍÐÁ)              │2373               

                              │ñóñïåíçèè 30 ã - 1500000, 3000000                                                   

                              │ÌÅ                                                                                  

                                                                                                                  

│Òåòðàöèêëèí                   │ìàçü 3%                            │Pharmachim (ÍÐÁ)              │2609               

│Òèàìàçîë                      │òàáëåòêè 5 ìã                      │Henning Berlin Gmbh (ÔÐÃ)     │002452             

│Òèäîêîë                       │òàáëåòêè 400 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │003113             

│Òèçàìèä                       │òàáëåòêè 500 ìã                    │Eczacibasi (Òóðöèÿ)           │002290             

                                                                                                                  

│Òèçàìèä                       │òàáëåòêè 500 ìã                    │Orion Pharmaceutica           │01194              

                                                                 │(Ôèíëÿíäèÿ)                                       

                                                                                                                  

│Òèêëèä                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 250 ìã │Dogu Ilac Fabricasi As        │002209             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Òèêëèä                        │òàáëåòêè 250 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │01868              

                                                                                                                  

│Òèëêîòèë                      │òàáëåòêè 20 ìã                     │Roche Mustahzarlari Sanayi As │002322             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Òèíèäàçîë                     │òàáëåòêè 500 ìã                    │Polfa, Starogardzkie          │2674               

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Òèíñåò                        │òàáëåòêè 30 ìã                     │Gedeon Richter (Âåíãðèÿ)      │002334             

                                                                                                                  

│Òèîèíîçèå                     │ðàñòâîð äëÿ èíúåêöèé âîäíûé        │Roussel Morishita Co, Ltd     │003194             

                              │(ôëàêîíû) 100 ìã - 10 ìë           │(ßïîíèÿ)                                         

                                                                                                                  

│Òèîðèë                        │òàáëåòêè 25, 100 ìã                │Torrent Exports Ltd (Èíäèÿ)   │01977              

│Òèñàñåí                       │äðàæå                              │Alkaloida (ÂÍÐ)               │2570                

│Òèñàöèä                       │òàáëåòêè 500 ìã                    │Alkaloida (Âåíãðèÿ)           │2984               

│Òîêàé-àñó                     │êðåì-ìàñêà ïèòàòåëüíûé             │Helia-D (Âåíãðèÿ)             │2970               

│Òîëèíàçå                      │òàáëåòêè 250 ìã                    │Upjohn (Âåëèêîáðèòàíèÿ)       │002547             

                                                                                                                  

│Òîïàëêàí                      │òàáëåòêè æåâàòåëüíûå; ïîðîøîê äëÿ  │Pierre Fabre Medicament       │002922             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè   │(Ôðàíöèÿ)                                        

                                                                                                                  

│Òîðàäîë                       │òàáëåòêè 10 ìã; ðàñòâîð äëÿ        │Syntex Pharma Ag (Øâåéöàðèÿ)  │005147             

                              │èíúåêöèé (àìïóëû) 30 ìã - 1 ìë                                                      

                                                                                                                  

│Òîðàëãèí                      │òàáëåòêè 500 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │002669             

                                                                                                                  

│Òîðãåçèê@                     │òàáëåòêè ñóáëèíãâàëüíûå 0.2 ìã;    │Torrent Exports Ltd (Èíäèÿ)   │002118             

                              │ðàñòâîð äëÿ èíúåêöèé ñ ãëþêîçîé                                                     

                              │(àìïóëû) 0.3 ìã - 1 ìë                                                              

                                                                                                                  

│Òîòàöåô                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bristol-Myers Squibb (ÑØÀ)    │002775             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ìã                                                                    

                                                                                                                  

│Òðàìàë@                       │êàïñóëû 50 ìã; ðàñòâîð äëÿ         │Polfa, Starogardzkie          │005953             

                              │èíúåêöèé (àìïóëû) 50 ìã/1 ìë, 100  │Pharmaceutical Works (Ïîëüøà) │                   

                              │ìã/2 ìë; êàïëè îðàëüíûå (ôëàêîíû)                                                   

                              │100 ìã/ìë                                                                           

                                                                                                                  

│Òðàìàë@                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 50   │Zorka (Þãîñëàâèÿ)             │01507              

                              │ìã/1 ìë, 100 ìã/2 ìë; êàïñóëû 50                                                    

                              │ìã; ñâå÷è 100 ìã                                                                    

                                                                                                                  

│Òðàíêñåí@                     │êàïñóëû 5 ìã, 10 ìã                │Laboratoires Clin-Midy        │00423              

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Òðàöåôóçèí                    │êîíöåíòðàò äëÿ äîáàâëåíèÿ â        │Houhtamyaki Leiras Oy         │002124             

                              │èíôóçèîííûå ðàñòâîðû               │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Òðåáîí Ôëîó                   │êîíöåíòðàò ýìóëüñèè                │Iskra (ßïîíèÿ)                │0001-Ã2             

                                                                                                                  

│Òðåíòàë                       │äðàæå; ðàñòâîð äëÿ èíúåêöèé        │Hoechst (Èíäèÿ)               │02043              

                             │(àìïóëû) 100 ìã - 5 ìë                                                              

                                                                                                                  

│Òðåíòàë                       │äðàæå 100 ìã                       │Hoechst Iberica (Èñïàíèÿ)     │002532             

                                                                                                                  

│Òðåíòàë                       │äðàæå 100 ìã; ðàñòâîð äëÿ èíúåêöèé │Turk Hoechst As (Òóðöèÿ)      │003281             

                              │(àìïóëû) 100 ìã - 5 ìë                                                              

                                                                                                                  

│Òðåíòàë                       │äðàæå 400 ìã                       │Turk Hoechst As (Òóðöèÿ)      │003360             

│Òðåíòàë 400                   │ôèëìòàáëåòêè 400 ìã                │Hoechst (India) Ltd (Èíäèÿ)   │003742             

                                                                                                                  

│Òðåíòàë-400                   │äðàæå çàìåäëåííîãî âûñâîáîæäåíèÿ   │Hoechst Ag (ÔÐÃ)              │002178             

                              │400 ìã                                                                              

                                                                                                                  

│Òðèàíîë                       │êàïñóëû 25 ìã                      │Lek (Þãîñëàâèÿ)               │01379              

                                                                                                                  

│Òðèáåêñîë                     │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Deva Holding As (Òóðöèÿ)      │003104             

                              │îáîëî÷êîé                                                                            

                                                                                                                  

│Òðèáèìîë                      │òàáëåòêè 120 ìã                    │Torrent Exports Ltd (Èíäèÿ)   │002079             

                                                                                                                  

│Òðèäàë                        │òàáëåòêè 100 ìã; ðàñòâîð äëÿ       │Alkaloid (ÑÔÐÞ)               │002324             

                              │èíúåêöèé (àìïóëû) 100 ìã - 2 ìë                                                     

                                                                                                                  

│Òðèäåðì                       │êðåì                               │Schering-Plough (ÑØÀ)         │003204             

                                                                                                                  

│Òðèêàíèêñ                     │ðàñòâîð äëÿ èíôóçèé (ôëàêîíû) 5    │Orion Pharmaceutica           │01205              

                              │ìã/ìë - 100 ìë                     │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Òðèêâèëàð                     │äðàæå                              │Birlesik Alman Ilaclary As    │002353             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Òðèêâèëàð                     │äðàæå                              │Salutas Fahlberg-List (ÔÐÃ)   │002788             

│Òðèêâèëàð                     │äðàæå                              │Schering Ag (Ãåðìàíèÿ)        │01068              

│Òðèëàí                        │ïîðîøîê; ãðàíóëû                   │Ðîññèÿ                        │0004-4             

                                                                                                                  

│Òðèìîïàí                      │òàáëåòêè 100 ìã; ìèêñòóðà 10 ìã/ìë │Orion Corporation, Farmos     │00867              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Òðèíîâóì                      │òàáëåòêè                           │Cilag Ag (Øâåéöàðèÿ)          │002104             

│Òðèíîðäèîë                    │äðàæå                              │Wyeth Pharma Gmbh (ÔÐÃ)       │003128             

│Òðè-ðåãîë                     │òàáëåòêè òðåõ âèäîâ                │Gedeon Richter (Âåíãðèÿ)      │002331             

│Òðèòìåíò Ñïàä                 │ïàñòà                              │Laboratoires Spad (Ôðàíöèÿ)   │00299              

                                                                                                                  

│Òðèòîôåí                      │òàáëåòêè 1 ìã; ñèðîï (ôëàêîíû) 1   │Fdc Private Ltd (Èíäèÿ)       │002923             

                              │ìã|5 ìë - 60 ìë                                                                     

                                                                                                                  

│Òðèòòèêî                      │òàáëåòêè êîíòðîëèðóåìîãî           │Angelini Acraf Spa (Èòàëèÿ)   │002050             

                              │âûñâîáîæäåíèÿ 75, 150 ìã                                                            

                                                                                                                  

│Òðèõîïîë                      │òàáëåòêè 250 ìã                    │Polfa, Starogardzkie          │2197               

                                                                 │Pharmaceutical Works (Ïîëüøà) │                   

                                                                                                                  

│Òðîìáîâàð                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 3% - │Laboratoires Promedica        │002205              

                              │2 ìë                               │(Ôðàíöèÿ)                                        

                                                                                                                  

│Òðîìåòàìîë êîìïîçèòóì         │ðàñòâîð äëÿ èíôóçèé                │Berlin-Chemie Feb (ÃÄÐ)       │00520              

                                                                                                                  

│Òðîïàðèí êîìïîçèòóì           │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 0.5  │Biochemie Gmbh (Àâñòðèÿ)      │002462             

                              │ìë                                                                                  

                                                                                                                  

│Òðîôîäåðìèí                   │êðåì                               │Farmitalia Carlo Erba (Èòàëèÿ)│01680              

│Òðýêñ                         │ïîðîøîê                            │Ðîññèÿ                        │0004-31            

                                                                                                                  

│ÒÑÊ-1 (Íàáîð ê Ãåíåðàòîðó     │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01247              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-10 (Íàáîð ê Ãåíåðàòîðó    │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01249              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-12 (Íàáîð ê Ãåíåðàòîðó    │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01250              

│99ìÒñ)                                                                                                            

                                                                                                                   

│ÒÑÊ-15 (Íàáîð ê Ãåíåðàòîðó    │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01251              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-15-Ñ (Íàáîð ê Ãåíåðàòîðó  │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01252              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-17 (Íàáîð ê Ãåíåðàòîðó    │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01253              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-18 (Íàáîð ê Ãåíåðàòîðó    │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01254              

│99ìÒñ)                                                                                                            

                                                                                                                  

│ÒÑÊ-8 (Íàáîð ê Ãåíåðàòîðó     │ðàñòâîð äëÿ èíúåêöèé               │Oris (Ôðàíöèÿ)                │01248              

│99ìÒñ)                                                                                                            

                                                                                                                  

│Òóñóïðåêñ                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 10, 20 │Polfa (Ïîëüøà)                │2597               

                              │ìã                                                                                   

                                                                                                                  

│Òóòòåëè                       │êàøà ìîëî÷íî-ÿáëî÷íàÿ              │Valio (Ôèíëÿíäèÿ)             │04012              

│Òóòòåëè                       │êàøà ìîëî÷íî-îâñÿíàÿ               │Valio (Ôèíëÿíäèÿ)             │04007              

│Òóòòåëè                       │êàøà ìîëî÷íî-ìó÷íàÿ                │Valio (Ôèíëÿíäèÿ)             │04010              

│Òóòòåëè                                                          │Valio (Ôèíëÿíäèÿ)             │04005              

│Òóòòåëè                       │êàøà ÿáëî÷íî-áðóñíè÷íàÿ            │Valio (Ôèíëÿíäèÿ)             │04014              

│Òóòòåëè                       │êàøà ìó÷íàÿ                        │Valio (Ôèíëÿíäèÿ)             │04011              

│Òóòòåëè                       │êàøà êàðòîôåëüíî-ìîðêîâíàÿ ìîëî÷íàÿ│Valio (Ôèíëÿíäèÿ)             │04009              

│Òóòòåëè                                                          │Valio (Ôèíëÿíäèÿ)             │04004              

│Òóòòåëè                                                          │Valio (Ôèíëÿíäèÿ)             │004194             

│Òóòòåëè                       │êàøà àáðèêîñîâî-ðèñîâàÿ            │Valio (Ôèíëÿíäèÿ)             │04013              

│Òóòòåëè                       │êàøà ìîëî÷íî-ìó÷íàÿ                │Valio (Ôèíëÿíäèÿ)             │04008              

│Òóòòåëè                                                          │Valio (Ôèíëÿíäèÿ)             │04006              

│Òóòòåëè-ñîÿ                                                      │Valio (Ôèíëÿíäèÿ)             │004284             

│Óàéò ñàíñòàð-Ô                │ïàñòà çóáíàÿ                       │Mitsubishi Corp (ßïîíèÿ)      │01754              

│Óàéò ýíä óàéò ëàéîí           │ïàñòà çóáíàÿ                       │Lion Corporation (ßïîíèÿ)     │01931              

│Óáãôàí                        │ïîëîñêè                            │Lachema (×ÑÔÐ)                │2632               

                                                                                                                  

│Óáðåòèä                       │òàáëåòêè 5 ìã; ðàñòâîð äëÿ         │Hafslund Nycomed Pharma Ag    │002558              

                              │èíúåêöèé 0.5, 1 ìã - 2 ìë          │(Àâñòðèÿ)                                        

                                                                                                                  

│Óëêîäèí                       │òàáëåòêè 150 ìã                    │Alkaloid (Ìàêåäîíèÿ)          │002605             

│Óëüòðàáðàéò                   │ïàñòà çóáíàÿ                       │Omnia Nuova (Èòàëèÿ)          │01428              

│Óëüòðàçèì                     │òàáëåòêè                           │Pharm-Allergan Gmbh (ÔÐÃ)     │01821              

│Óëüòðàêàèí Ä-Ñ                │ðàñòâîð äëÿ èíúåêöèé               │Hoechst Ag (ÔÐÃ)              │01993              

│Óëüòðàêàèí Ä-Ñ ôîðòå          │ðàñòâîð äëÿ èíúåêöèé               │Hoechst Ag (ÔÐÃ)              │01993              

│Óëüòðàïðîêò                   │ìàçü; ñâå÷è                        │Meuselbach Pharma Gmbh (ÔÐÃ)  │002789             

│Óëüòðàïðîêò                   │ñâå÷è; ìàçü                        │Schering Ag (ÔÐÃ)             │002725             

                                                                                                                  

│Óìàí Êðàé                     │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Pharma-Biajini Spa (Èòàëèÿ)   │002383             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ÅÄ /â êîìïëåêòå ñ                                                    

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Óìàí-àëüáóìèí 20%             │ðàñòâîð (ôëàêîíû) 20% - 10, 20, 50 │Pharma-Biajini Spa (Èòàëèÿ)   │02038              

                              │ìë                                                                                   

                                                                                                                  

│Óìàí-àëüáóìèí 25%             │ðàñòâîð (ôëàêîíû) 25% - 10, 20, 50 │Pharma-Biajini Spa (Èòàëèÿ)   │02038               

                              │ìë                                                                                  

                                                                                                                  

│Óìàí-àëüáóìèí 5%              │ðàñòâîð (ôëàêîíû) 5% - 10, 20, 50  │Pharma-Biajini Spa (Èòàëèÿ)   │02038              

                              │ìë                                                                                  

                                                                                                                  

│Óìàí-Êîìïëåêñ                 │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Farma Biagini Spa (Èòàëèÿ)    │002489             

                              │èíúåêöèîííîãî ðàñòâîðà                                                              

                              │(àìïóëû)200, 500 ÌÅ /â êîìïëåêòå ñ │                                                 

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Óíàçèí                        │òàáëåòêè 375 ìã; ïîðîøîê äëÿ       │Krka (Ñëîâåíèÿ)               │002485             

                              │ïðèãîòîâëåíèÿ ñóñïåíçèè 250 ìã|5 ìë│                                                 

                                                                                                                  

│Óíàçèí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Krka (ÑÔÐÞ)                   │002115             

                              │èíúåêöèîííîãî ðàñòâîðà 0.75, 1.5,                                                   

                              │3 ã                                                                                 

                                                                                                                   

│Óíàçèí                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé 375    │Pfizer (Áåëüãèÿ)              │002368             

                              │ìã; ïîðîøîê äëÿ ïðèãîòîâëåíèÿ                                                       

                              │îðàëüíîé ñóñïåíçèè (ôëàêîíû) 250                                                    

                              │ìã|5 ìë                                                                             

                                                                                                                  

│Óíàçèí                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pfizer Sa (Èñïàíèÿ)           │002294             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.75, 1.5, 3 ã                                                                      

                                                                                                                  

│Óíèïðåñ                       │òàáëåòêè 10, 20 ìã                 │Krka (Ñëîâåíèÿ)               │002737             

                                                                                                                  

│Óîëø-àñàëãèí                  │òàáëåòêè 325 ìã                    │Bob Walsh Enterprises, Vitec  │003286             

                                                                 │Corporation (ÑØÀ)                                

                                                                                                                  

│Ó-ïàí@                        │òàáëåòêè 1 ìã                      │Sawai Pharmaceutical Co Ltd   │003155             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│ÓÏÑÀ-Ñ                        │òàáëåòêè øèïó÷èå                   │Laboratoires Upsa (Ôðàíöèÿ)   │002481             

│Óðçîôàëüê                     │êàïñóëû 250 ìã                     │Falk (ÔÐÃ)                    │002051              

│Óðçîôàëüê                     │êàïñóëû 250 ìã                     │Zdravle (Þãîñëàâèÿ)           │002799             

                                                                                                                  

│Óðèêñ                         │òàáëåòêè 40 ìã; ðàñòâîð äëÿ        │Torrent Exports Ltd (Èíäèÿ)   │003403             

                              │èíúåêöèé (àìïóëû) 10 ìã/ìë - 2 ìë                                                   

                                                                                                                  

│Óðèêóëüò                      │ãåëü                               │Orion Diagnostic (Ôèíëÿíäèÿ)  │01237              

│Óðèñòèêñ                                                        │Aims Company (Âåëèêîáðèòàíèÿ) │00584              

                                                                                                                  

│Óðîãðàôèí                     │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Birlesik Alman Ilaclary As    │002248             

                              │(àìïóëû) 20 ìë - 60%, 76%          │(Òóðöèÿ)                                         

                                                                                                                  

│Óðîìèòåêñàí                   │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 200  │Asta Pharma Ag (ÔÐÃ)          │002491             

                              │ìã/2 ìë, 400 ìã/4 ìë                                                                

                                                                                                                  

│Óðñî 100                      │òàáëåòêè 100 ìã                    │Tokyo Tanabe Co Ltd (ßïîíèÿ)  │01470              

│Óøà                           │ïàñòà çóáíàÿ                       │Usha Intercontinental (Èíäèÿ) │01549              

│Ôà                            │ïàñòà çóáíàÿ                       │Henkel Kgaa (ÔÐÃ)             │01579              

                                                                                                                  

│Ôàêòîð IX Ï                   │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Behringwerke Ag (Ãåðìàíèÿ)    │003386              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │300, 600, 1200 ÅÄ /â êîìïëåêòå ñ                                                    

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Ôàëèáàðèò                     │ïîðîøîê îðàëüíûé                   │Salutas Fahlberg-List Pharma  │003179             

                                                                 │Gmbh (ÔÐÃ)                                       

                                                                                                                  

│Ôàëèáàðèò ÕÄÅ                 │ïîðîøîê îðàëüíûé                   │Salutas Fahlberg-List Pharma  │003180             

                                                                 │Gmbh (ÔÐÃ)                                       

                                                                                                                  

│Ôàëèìèíò                      │äðàæå                              │Salutas Fahlberg-List Pharma  │00439              

                                                                 │Gmbh (ÔÐÃ)                                       

                                                                                                                  

│Ôàìîãàðä                      │òàáëåòêè 20, 40 ìã                 │M.J.Pharmaceuticals Ltd       │003136             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ôàìîñàí                       │òàáëåòêè 20, 40 ìã                 │Alkaloid (ÑÔÐÞ)               │002504              

                                                                                                                  

│Ôàíñèäàð                      │òàáëåòêè; ðàñòâîð äëÿ èíúåêöèé     │Hoffmann La Roche (Øâåéöàðèÿ) │01112              

                              │(àìïóëû) 2.5 ìë                                                                     

                                                                                                                  

│Ôàðåêñ                                                           │Farley (Âåëèêîáðèòàíèÿ)       │01623              

│Ôàðåñòîí                      │òàáëåòêè 20, 60 ìã                 │Farmos Group (Ôèíëÿíäèÿ)      │01712              

│Ôàðëàê                        │êàøà ìîëî÷íàÿ                      │Farley (Âåëèêîáðèòàíèÿ)       │01624              

│Ôàðëàêò                                                          │Farley (Âåëèêîáðèòàíèÿ)       │01980              

                                                                                                                  

│Ôàðìàôèëëèí                   │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │System Control (Èòàëèÿ)       │002471             

                              │(àìïóëû) 240 ìã - 10 ìë                                                             

                                                                                                                  

│Ôàðìîäåíò                     │ïàñòà çóáíàÿ ãåëüíàÿ               │Pharmachim (Áîëãàðèÿ)         │2808               

                                                                                                                  

│Ôàðìîðóáèöèí                  │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Farmitalia Carlo Erba         │003095             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Èíäîíåçèÿ)                                      

                              │10 ìã                                                                               

                                                                                                                  

│Ôàðìîðóáèöèí                  │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Farmitalia Carlo Erba (Èòàëèÿ)│002306              

                              │èíúåêöèîííîãî ðàñòâîðà 10, 50 ìã                                                    

                                                                                                                  

│Ôàóñòàí@                      │òàáëåòêè 5 ìã                      │Arzneimittelwerk Dresden Gmbh │006002             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ôåâàðèí                       │òàáëåòêè 50 ìã                     │Duphar B.V. (Íèäåðëàíäû)      │002748             

                                                                                                                  

│Ôåëîðàí                       │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Pharmachim (Áîëãàðèÿ)         │2851               

                              │îáîëî÷êîé 25 ìã                                                                     

                                                                                                                  

│Ôåëîðàí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 75   │Pharmachim (ÍÐÁ)              │2923               

                              │ìã - 3 ìë                                                                           

                                                                                                                  

│Ôåëîðàí ðåòàðä                │òàáëåòêè ïîêðûòûå îáîëî÷êîé 100 ìã │Pharmachim (Áîëãàðèÿ)         │003876             

│Ôåìèíà                        │âêëàäêè âàãèíàëüíûå (íàáîð)        │Autotechna (Þãîñëàâèÿ)        │01416              

│Ôåíàêñ                        │ïîðîøîê                            │Ðîññèÿ                        │0001-Á8            

│Ôåíàêñ-2                      │ïîðîøîê                            │Ðîññèÿ                        │0004-32            

│Ôåíàêñèí                      │ïîðîøîê                            │Ðîññèÿ                        │0010-17            

│Ôåíèë-ôðè                                                        │Bristol-Myers Squibb (ÑØÀ)    │004155              

│Ôåíîçîëü Ë                    │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0001-10            

│Ôåíîçîëü Ï                    │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0001-11            

│Ôåððîïëåêñ                    │äðàæå                              │Biogal (Âåíãðèÿ)              │2389               

│Ôåñòàë                        │äðàæå                              │Hoechst (Èíäèÿ)               │01196              

│Ôåòèìèí                       │êðåì 1%                            │Krka (Ñëîâåíèÿ)               │002542             

│Ôèáðèíîãåí                                                       │Belgian Chemical (Áåëüãèÿ)    │00953              

│Ôèíàëãîí                      │ìàçü                               │Boehringer Ingelheim (ÔÐÃ)    │002821             

                                                                                                                  

│Ôèíëåïñèí                     │òàáëåòêè 200 ìã                    │Arzneimittelwerk Dresden Feb  │00519              

                                                                 │(ÃÄÐ)                                            

                                                                                                                  

│Ôèííäåíò                      │ïàñòà çóáíàÿ                       │Oxyhenol Oy (Ôèíëÿíäèÿ)       │01777              

                                                                                                                  

│Ôèíîïòèí                      │òàáëåòêè 120 ìã; òàáëåòêè          │Orion Pharmaceutica           │02005              

                              │ïðîëîíãèðîâàííîãî äåéñòâèÿ 200 ìã  │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ôèíîïòèí                      │òàáëåòêè 40, 80 ìã; ðàñòâîð äëÿ    │Orion Pharmaceutica           │00672               

                              │èíúåêöèé (àìïóëû) 2.5 ìã/ìë - 2 ìë │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ôèòåêñ                        │ðàñòâîð äëÿ íàðóæíîãî ïðèìåíåíèÿ   │Ucb Sa (Áåëüãèÿ)              │00541              

                              │(ôëàêîíû) 20, 60 ìë                                                                 

                                                                                                                  

│Ôèòîìåíàäèîí                  │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 10   │Weimer Pharma Gmbh (Ãåðìàíèÿ) │003073             

                              │ìã/ìë                                                                               

                                                                                                                  

│Ôèòîïîìîðèí                   │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2755               

│Ôèòòèäåíò                     │òàáëåòêè                           │Fittident (Àâñòðèÿ)           │004256             

                                                                                                                  

│Ôèòòèäåíò                     │ïðîêëàäêè äëÿ ôèêñàöèè çóáíûõ      │Fittident (Àâñòðèÿ)           │004255             

                              │ïðîòåçîâ                                                                            

                                                                                                                  

│Ôèòòèäåíò                     │êëåé äëÿ ôèêñàöèè çóáíûõ ïðîòåçîâ  │Fittident (Àâñòðèÿ)           │004257             

                                                                                                                  

│Ôëåãàìèí                      │òàáëåòêè 8 ìã; ðàñòâîð äëÿ         │Polfa (ÏÍÐ)                   │2950               

                              │èíúåêöèé (àìïóëû) 4 ìã - 2 ìë                                                       

                                                                                                                   

│Ôëåãàìèí                      │ñèðîï                              │Polfa (Ïîëüøà)                │2975               

                                                                                                                  

│Ôëèêñîíàçå                    │ñïðåé íàçàëüíûé äîçèðîâàííûé       │Glaxo (Âåëèêîáðèòàíèÿ)        │005358             

                              │âîäíûé 50 ìêã/äîçà                                                                  

                                                                                                                  

│Ôëîðèíåô                      │òàáëåòêè 0.1 ìã                    │Bristol-Myers Squibb (ÑØÀ)    │01945              

                                                                                                                  

│Ôëîðìèäàë@                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 15   │Galenika (ÑÔÐÞ)               │02037              

                              │ìã - 3 ìë                                                                           

                                                                                                                  

│Ôëîñòåðîí                     │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1 ìë │Krka (Ñëîâåíèÿ)               │01201              

│Ôëóêîðò                       │ëîñüîí 0.01%; ãåëü 0.025%          │Lyka Labs Ltd (Èíäèÿ)         │002090             

│Ôëóêîðò-Í                     │ìàçü                               │Lyka Labs Ltd (Èíäèÿ)         │02019              

│Ôëóêîðò-Ö                     │ìàçü                               │Lyka Labs Ltd (Èíäèÿ)         │02020              

│Ôëóîäåíò                      │ïàñòà çóáíàÿ ãåëüíàÿ               │Pharmachim (Áîëãàðèÿ)         │2715               

                                                                                                                  

│Ôëóîðîóðàöèë                  │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 250  │Bosnalijek (ÑÔÐÞ)             │002467             

                              │ìã - 5 ìë                                                                           

                                                                                                                  

│Ôëóîð-òàéì                    │ïàñòà çóáíàÿ                       │Dental Cosmetic Gmbh (ÔÐÃ)    │004066             

                                                                                                                  

│Ôëóôåíàçèíà ãèäðîõëîðèä       │ðàñòâîð îðàëüíûé (êîíöåíòðàò)      │Mir Pharmaceutical Inc/Copley │007699             

                              │(ôëàêîíû) 5 ìã/ìë - 120 ìë         │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│Ôëóöèíàð                      │ãåëü                               │Polfa (ÏÍÐ)                   │2947               

│Ôëóöèíàð Í                    │ìàçü                               │Polfa (Ïîëüøà)                │2461               

│Ôëóöèíîì                      │òàáëåòêè 250 ìã                    │Fulford (India) Ltd (Èíäèÿ)   │002085             

│Ôëóöèíîì                      │òàáëåòêè 250 ìã                    │Schering Corporation (ÑØÀ)    │01569              

│Ôëóöèíîì                      │òàáëåòêè 250 ìã                    │Schering-Plough (Èíäîíåçèÿ)   │003280             

│Ôëóöèíîì                      │òàáëåòêè 250 ìã                    │Schering-Plough (Èñïàíèÿ)     │002266             

│Ôëþîãàì                       │æåâàòåëüíàÿ ðåçèíêà                │Laboratoires Juilie (Ôðàíöèÿ) │00494              

│Ôëþîêàðèëü áè ôëþîðå          │ïàñòà çóáíàÿ                       │Laboratoires Gupile (Ôðàíöèÿ) │00496              

│Ôëþîêàðèëü áè ôëþîðå          │ãåëü                               │Laboratoires Gupile (Ôðàíöèÿ) │00497              

│Ôëþîð äåíò õëîðîôèëë          │ïàñòà çóáíàÿ                       │Eka/Sinikos (Ôèíëÿíäèÿ)       │01348              

│Ôëþîðîäåíò                    │ïàñòà çóáíàÿ                       │Pollena-Lechia (Ïîëüøà)       │2987               

                                                                                                                   

│Ôëþîðî-óðàöèë                 │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 250  │Hoffmann La Roche (Øâåéöàðèÿ) │00175              

                              │ìã - 5 ìë                                                                           

                                                                                                                  

│Ôîëëèêóëèíà ðàñòâîð äëÿ       │ðàñòâîð äëÿ èíúåêöèé â ìàñëå       │Ðîññèÿ                        │74/331/53          

│èíúåêöèé â ìàñëå              │0.05%, 0.1%                                                                         

                                                                                                                  

│Ôîðàïèí                       │ìàçü; ëèíèìåíò                     │Mack (ÔÐÃ)                    │00765              

                                                                                                                  

│Ôîðãåíàê                      │òàáëåòêè 50 ìã; ðàñòâîð äëÿ        │Laboratorio Giorgio Zoja      │003447             

                              │èíúåêöèé (àìïóëû) 75 ìã - 3 ìë     │Chimico-Farmaceutica (Èòàëèÿ) │                   

                                                                                                                  

│Ôîðòðàë@                      │òàáëåòêè 50 ìã; ðàñòâîð äëÿ        │Krka (Þãîñëàâèÿ)              │00333              

                              │èíúåêöèé (àìïóëû) 30 ìã - 1 ìë                                                      

                                                                                                                  

│Ôîðòóì                        │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Glaxo (Âåëèêîáðèòàíèÿ)        │01568              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000, 2000 ìã                                                              

                                                                                                                  

│Ôîðõàí Ñ                      │ïàñòà çóáíàÿ                       │M.J.Exports Private Ltd       │01393               

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ôîòèë                         │êàïëè ãëàçíûå (ôëàêîíû) 20 ìã/6.84 │Leiras (Ôèíëÿíäèÿ)            │006971             

                              │ìã|1 ìë                                                                             

                                                                                                                  

│Ôîòèë ôîðòå                   │êàïëè ãëàçíûå (ôëàêîíû) 40 ìã/6.84 │Leiras (Ôèíëÿíäèÿ)            │006972             

                              │ìã|1 ìë                                                                             

                                                                                                                  

│Ôðàãìèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû)      │Kabi Pharmacia (Øâåöèÿ)       │002430             

                              │10000 ÌÅ/1 ìë; ðàñòâîð äëÿ                                                          

                              │èíúåêöèé (øïðèö îäíîðàçîâûé) 2500                                                   

                              │ÌÅ/0.2 ìë, 5000 ÌÅ/0.2 ìë                                                           

                                                                                                                  

│Ôðåñ                          │ïàñòà çóáíàÿ                       │Vam International (Èíäèÿ)     │004085             

│Ôðåø Í ÀÏ                     │ïàñòà çóáíàÿ                       │Hindustan Liver Ltd (Èíäèÿ)   │01491              

│Ôðèçèóì@                      │òàáëåòêè 10, 20 ìã                 │Hoechst (Èíäèÿ)               │002341             

│Ôðèçèóì@                      │òàáëåòêè 10, 20 ìã                 │Hoechst Ag (Ãåðìàíèÿ)         │002339              

│Ôðèçèóì@                      │òàáëåòêè 10 ìã                     │Hoechst Iberica (Èñïàíèÿ)     │002533             

│Ôðèçîëàê Í                                                       │Frizland (Íèäåðëàíäû)         │004087             

│Ôðèçîìèë                                                         │Frizland (Íèäåðëàíäû)         │004086             

                                                                                                                  

│Ôðóêòîâîå ïþðå èç ÿáëîê è                                        │Nestle (Ãåðìàíèÿ)             │004213             

│áàíàíîâ ñ îâñÿíîé ìóêîé èç                                                                                        

│çåðíà                                                                                                             

                                                                                                                  

│Ôðóêòîâîå ïþðå èç ÿáëîê è                                        │Nestle (Ãåðìàíèÿ)             │004214             

│ìîðêîâè ñ îâñÿíîé ìóêîé èç                                                                                        

│öåëüíîãî çåðíà                                                                                                    

                                                                                                                  

│Ôðóêòîâûé äåñåðò 00440                                           │Gerber (ÑØÀ)                  │004122             

│Ôðóêòû                        │ñìåñü ìîëî÷íàÿ ôðóêòîâî-çëàêîâàÿ   │Mylupa Sa (ÔÐÃ/Èñïàíèÿ)       │004112             

│Ôðóòè                         │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2711               

                                                                                                                  

│ÔÑÌÅ-Áóëèí                    │æèäêîñòü                           │Immuno Akziengazelchaft       │4/93-00032840      

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                   

│ÔÑÌÅ-Èììóí Èíæåêò             │ñóñïåíçèÿ                          │Immuno Akziengazelchaft       │3/93-00032840      

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                  

│Ôòîðíàÿ                       │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2806               

                                                                                                                  

│Ôóëïåí À                      │òàáëåòêè 4 ìã                      │Sawai Pharmaceutical Co Ltd   │002955             

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Ôóìèòîêñ                      │ïëàñòèíû                           │Ðîññèÿ                        │0001-12            

                                                                                                                  

│Ôóíãèçèä-Ðàòèîôàðì            │àýðîçîëü (ôëàêîíû) 40 ìë           │Ratiopharm Gmbh & Co          │003457             

                                                                 │(Ãåðìàíèÿ)                                       

                                                                                                                  

│Ôóíãèçîí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Bristol-Myers Squibb (ÑØÀ)    │002652             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │50 ìã                                                                               

                                                                                                                   

│Ôóðåçèñ êîìïîçèòóì            │òàáëåòêè                           │Farmos Group (Ôèíëÿíäèÿ)      │01109              

                                                                                                                   

│Ôóðîçåìèêñ                    │òàáëåòêè äåëèìûå 40 ìã             │Laboratoires Biogalenique     │002407             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Ôóðîí                         │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 20   │Ludwig Merckle Gmbh (Àâñòðèÿ) │002986             

                              │ìã - 2 ìë; êîíöåíòðàò äëÿ                                                           

                              │ïðèãîòîâëåíèÿ èíôóçèîííîãî                                                          

                              │ðàñòâîðà (àìïóëû) 250 ìã - 25 ìë;                                                   

                              │òàáëåòêè 40 ìã                                                                      

                                                                                                                  

│Ôóðîñåìèä                     │òàáëåòêè 40 ìã                     │Alkaloid (Ìàêåäîíèÿ)          │003439             

│Ôóðîñåìèä                     │òàáëåòêè 40 ìã                     │Farmos Group (Ôèíëÿíäèÿ)      │00658              

                                                                                                                  

│Ôóðîñåìèä                     │òàáëåòêè 40 ìã; ðàñòâîð äëÿ        │Polfa (Ïîëüøà)                │2198               

                              │èíúåêöèé (àìïóëû) 1% - 2 ìë                                                         

                                                                                                                  

│Ôóðîñåìèä                     │òàáëåòêè 20, 40, 80 ìã             │Watson Laboratories Inc (ÑØÀ) │002299             

                                                                                                                   

│ÕF 2-ôòîð                     │ïàñòà çóáíàÿ                       │Karl Lark Production          │01295              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│ÕF ôòîð                       │ïàñòà çóáíàÿ                       │Karl Lark Production          │01294              

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Õàéíö                                                            │Plazmon (Èòàëèÿ)              │004199             

│Õàéíö                                                            │Plazmon (Èòàëèÿ)              │004153             

│Õàéíö                                                            │Plazmon (Èòàëèÿ)              │004198             

│Õàôàá                                                            │Abbott Laboratories (Ãåðìàíèÿ)│00710              

                                                                                                                  

│Õåìàòý Ï                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Behringwerke Ag (Ãåðìàíèÿ)    │003387             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ÌÅ /â êîìïëåêòå ñ                                                    

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Õåðáèí                        │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2804               

                                                                                                                  

│Õèêîíöèë                      │êàïñóëû 250, 500 ìã; êàïëè äëÿ     │Krka (ÑÔÐÞ)                   │00745               

                              │äåòåé 100 ìã/ìë; ñóñïåíçèÿ 125                                                      

                              │ìã|5 ìë                                                                             

                                                                                                                  

│Õèëàê ôîðòå                   │êàïëè                              │Ludwig Merckle Gmbh (Àâñòðèÿ) │002860             

                                                                                                                  

│Õèíèäèí äüþðóëñ               │òàáëåòêè ñ ïëåíî÷íûì ïîêðûòèåì 200 │Astra (Øâåöèÿ)                │002129             

                              │ìã                                                                                  

                                                                                                                  

│Õèíèäèíà ñóëüôàò              │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Mir Pharmaceutical Inc/Copley │007669             

                              │ïðîëîíãèðîâàííîãî äåéñòâèÿ 300 ìã  │Pharmaceutical Inc (ÑØÀ)                         

                                                                                                                  

│ÕË-1                          │íàïèòîê                            │Collett-Marwell Hauge         │00651              

                                                                 │(Íîðâåãèÿ)                                       

                                                                                                                  

│Õëîðàñåïò                     │ïîðîøîê                            │Ðîññèÿ                        │0001-À13           

│Õëîðãåêñèäèí äèãëþêîíàò       │ðàñòâîð 20%                        │Fermion (Ôèíëÿíäèÿ)           │00638              

                                                                                                                   

│Õëîðèíà                       │ïîðîøîê                            │Lysoform Dr.Hans Rosemann     │003863             

                                                                 │Gmbh (Ãåðìàíèÿ)                                   

                                                                                                                  

│Õëîðïðîïàìèä                  │òàáëåòêè 250 ìã                    │Polfa (Ïîëüøà)                │2598               

│Õëîðïðîòèêñåí 15 Ëå÷èâà@      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 15 ìã  │Lechiva Praha Sa (×åõèÿ)      │007212             

                                                                                                                  

│Õîëîêñàí                      │âåùåñòâî ñóõîå äëÿ ïðèãîòîâëåíèÿ   │Asta Pharma Ag (Ãåðìàíèÿ)     │002422             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.2, 0.5, 1, 2 ã                                                                    

                                                                                                                  

│Õîìîðàï 100 ïåíôèë            │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû äëÿ  │Pliva (ÑÔÐÞ)                  │002199             

                              │øïðèöðó÷êè) 1.5 ìë                                                                  

                                                                                                                  

│Õîìîôàí 100 ïåíôèë            │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû äëÿ  │Pliva (ÑÔÐÞ)                  │002200             

                              │øïðèöðó÷êè) 100 ÅÄ/ìë - 1.5 ìë                                                      

                                                                                                                  

│Õîðìîïëåêñ                    │äðàæå 1.25 ìã                      │Galenika (ÑÔÐÞ)               │01886              

                                                                                                                  

│Õóìàíà                                                           │Byk Gulden Pharmaceutical     │00438               

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàíà 0                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Byk Gulden Pharmaceutical     │004091             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàíà 1                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Byk Gulden Pharmaceutical     │004090             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàíà 2                      │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Byk Gulden Pharmaceutical     │004092             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàíà ëå÷åáíàÿ ñ ÑÖÒ         │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Byk Gulden Pharmaceutical     │004088             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàíà ÑË                     │ñìåñü ìîëî÷íàÿ ñóõàÿ               │Byk Gulden Pharmaceutical     │004089             

                                                                 │(ÔÐÃ)                                            

                                                                                                                  

│Õóìàòðîï                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Eli Lilly & Elanco (ÑØÀ)      │01971              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû) 4                                                    

                              │ÌÅ                                                                                  

                                                                                                                  

│Õóìåãîí                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Organon (Íèäåðëàíäû)          │01896              

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû)                                                     

                              │75, 150 ÌÅ                                                                          

                                                                                                                  

│Õóìóëèí M1 10/90              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │002281             

                              │40 ÅÄ/ìë - 10 ìë; ñóñïåíçèÿ äëÿ                                                     

                              │èíúåêöèé (ïàòðîí÷èêè äëÿ                                                            

                              │èíúåêòîðà) 100 ÅÄ/ìë - 1.5 ìë                                                       

                                                                                                                  

│Õóìóëèí M2 20/80              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │002282             

                              │40 ÅÄ/ìë - 10 ìë; ñóñïåíçèÿ äëÿ                                                     

                              │èíúåêöèé (ïàòðîí÷èêè äëÿ                                                            

                              │èíúåêòîðà) 100 ÅÄ/ìë - 1.5 ìë                                                       

                                                                                                                  

│Õóìóëèí M3 30/70              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │002283             

                              │40 ÅÄ/ìë - 10 ìë; ñóñïåíçèÿ äëÿ                                                     

                              │èíúåêöèé (ïàòðîí÷èêè äëÿ                                                             

                              │èíúåêòîðà) 100 ÅÄ/ìë - 1.5 ìë                                                       

                                                                                                                  

│Õóìóëèí M4 40/60              │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly & Elanco (ÑØÀ)      │002284             

                              │40 ÅÄ/ìë - 10 ìë; ñóñïåíçèÿ äëÿ                                                     

                              │èíúåêöèé (ïàòðîí÷èêè äëÿ                                                            

                              │èíúåêòîðà) 100 ÅÄ/ìë - 1.5 ìë                                                       

                                                                                                                  

│Õóìóëèí Ëåíòå                 │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly (ÑØÀ)               │01940              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Õóìóëèí ÍÏÕ                   │ñóñïåíçèÿ äëÿ èíúåêöèé (ïàòðîí÷èêè │Eli Lilly & Elanco (ÑØÀ)      │002450             

                              │äëÿ èíúåêòîðà) 100 ÌÅ/ìë - 1.5 ìë                                                   

                                                                                                                  

│Õóìóëèí ÍÏÕ                   │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly (ÑØÀ)               │01801              

                              │40 ÅÄ/ìë - 10 ìë                                                                    

                                                                                                                  

│Õóìóëèí Ðåãóëÿð               │ðàñòâîð äëÿ èíúåêöèé (ïàòðîí÷èêè   │Eli Lilly & Elanco (ÑØÀ)      │002449              

                              │äëÿ èíúåêòîðà) 100 ÌÅ/ìë - 1.5 ìë                                                   

                                                                                                                  

│Õóìóëèí Ðåãóëÿð               │ðàñòâîð äëÿ èíúåêöèé (ôëàêîíû) 40  │Eli Lilly (ÑØÀ)               │01800              

                              │ÅÄ/ìë - 10 ìë                                                                       

                                                                                                                  

│Õóìóëèí Óëüòðàëåíòå           │ñóñïåíçèÿ äëÿ èíúåêöèé (ôëàêîíû)   │Eli Lilly (ÑØÀ)               │01941              

                              │40 ÌÅ/ìë - 10 ìë                                                                    

                                                                                                                  

│Öåçîëèí                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Lupin Laboratories Ltd (Èíäèÿ)│002929             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250 ìã                                                                              

                                                                                                                  

│Öåêëîð                        │êàïñóëû 250, 500 ìã; ïîðîøîê äëÿ   │Eli Lilly & Elanco (ÑØÀ)      │002100             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè                                                    

                              │125 ìã|5 ìë, 250 ìã|5 ìë                                                            

                                                                                                                  

│Öåêëîð                        │êàïñóëû 250, 500 ìã; ãðàíóëÿò äëÿ  │Eli Lilly-Gohar Private Ltd   │002833             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè   │(Ïàêèñòàí)                                       

                              │125 ìã|5 ìë, 250 ìã|5 ìë                                                             

                                                                                                                  

│Öåêëîð                        │êàïñóëû 250, 500 ìã; ãðàíóëÿò äëÿ  │Obrb (Ïîëüøà)                 │002839             

                              │ïðèãîòîâëåíèÿ îðàëüíîé ñóñïåíçèè                                                    

                              │125 ìã|5 ìë, 250 ìã|5 ìë                                                            

                                                                                                                  

│Öåëåñòîäåðì                  │êðåì 0.1%; ìàçü 0.1%               │Essex-Chemie (Øâåéöàðèÿ)      │00162              

│Öåëåñòîäåðì                  │êðåì; ìàçü                         │Schering-Plough (Èíäèÿ)       │002967             

│Öåëåñòîäåðì                  │êðåì; ìàçü                         │Schering-Plough (Êîðåÿ Þæíàÿ) │002697             

│Öåëåñòîäåðì  ñ ãàðàìèöèíîì   │êðåì; ìàçü                         │Schering-Plough (Èíäèÿ)       │002968             

│Öåëåñòîäåðì  ñ ãàðàìèöèíîì   │êðåì; ìàçü                         │Schering-Plough (Êîðåÿ Þæíàÿ) │002698             

│Öåëåñòîäåðì-                 │êðåì                               │Eczacibasi (Òóðöèÿ)           │01957              

│Öåëåñòîí                      │òàáëåòêè 0.5 ìã                    │Eczacibasi (Òóðöèÿ)           │002240             

│Öåëåñòîí                      │òàáëåòêè 0.5 ìã                    │Schering-Plough (ÑØÀ)         │002464             

                                                                                                                  

│Öåëåñòîí                      │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 4 ìã │Schering-Plough (ÑØÀ)         │003285             

                              │- 1 ìë                                                                              

                                                                                                                   

│Öåìèä                         │òàáëåòêè 10, 20, 30, 40 ìã         │Wyeth Pharma Gmbh (ÔÐÃ)       │003129             

│Öåìèäèí                       │òàáëåòêè 200, 400 ìã               │Dexon Ltd (Èçðàèëü)           │003266             

│Öåíòðóì                       │òàáëåòêè                           │Lederle (ÑØÀ)                 │002474             

                                                                                                                  

│Öåíòðóì äåòñêèé               │òàáëåòêè ñ æåëåçîì; òàáëåòêè ñ     │Lederle (ÑØÀ)                 │002475             

                              │âèòàìèíîì C; òàáëåòêè ñ êàëüöèåì                                                    

                                                                                                                  

│Öåðâèïðîñò                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Organon International         │002749             

                              │èíòðàöåðâèêàëüíîãî ãåëÿ (øïðèö     │(Íèäåðëàíäû)                                     

                              │äâóõêàìåðíûé) 0.5 ìã /â êîìïëåêòå                                                   

                              │ñ ðàñòâîðèòåëåì/                                                                    

                                                                                                                  

│Öåðåáîë                       │òàáëåòêè 100 ìã; ñóñïåíçèÿ         │Themis Chemicals Ltd (Èíäèÿ)  │003406             

                              │îðàëüíàÿ 100 ìã|5 ìë                                                                

                                                                                                                  

│Öåðíèëòîí                     │òàáëåòêè 400 ìã                    │Krka (Ñëîâåíèÿ)               │002498             

│Öåñîë                         │òàáëåòêè 150 ìã                    │Merck (India) Ltd (Èíäèÿ)     │002871             

                                                                                                                  

│Öåôàáåíå                      │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Ludwig Merckle Gmbh (Àâñòðèÿ) │002987              

                              │îáîëî÷êîé 500, 1000 ìã; ïîðîøîê                                                     

                              │äëÿ ïðèãîòîâëåíèÿ ñèðîïà 250 ìã|5                                                   

                              │ìë                                                                                  

                                                                                                                  

│Öåôàäæåò                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Armour Chemicals Ltd (Èíäèÿ)  │002502             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500, 1000 ìã                                                                   

                                                                                                                  

│Öåôàçîëèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Mir Pharmaceutical Inc/Lemmon │007670             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(ÑØÀ)                                            

                              │0.25, 0.5, 1 ã - 10 ìë; ðàñòâîð                                                     

                              │äëÿ ïðèãîòîâëåíèÿ èíôóçèîííîãî                                                      

                              │ðàñòâîðà (ôëàêîíû) 0.5, 1 ã - 100                                                   

                              │ìë                                                                                  

                                                                                                                  

│Öåôàçîëèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pharmachim (ÍÐÁ)              │3013               

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                  

                              │ã, 2 ã                                                                              

                                                                                                                   

│Öåôàçîëèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pharmachim (ÍÐÁ)              │3005               

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │250, 500 ìã                                                                         

                                                                                                                  

│Öåôàçîëèí íàòðèåâûé           │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Panpharma (Ôðàíöèÿ)           │003022             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                   

                                                                                                                  

│Öåôàëåêñ                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé 500,   │Ct-Arzneimittel Chemishe      │002892             

                              │1000 ìã                            │Tempelchof Gmbh (ÔÐÃ)                            

                                                                                                                  

│Öåôàëåêñèí                    │êàïñóëû 250, 500 ìã; ïîðîøîê äëÿ   │Mir Pharmaceutical            │007891             

                              │ïðèãîòîâëåíèÿ ñóñïåíçèè äëÿ        │Inc/Biocraft Laboratories Inc │                   

                              │âíóòðåííåãî ïðèìåíåíèÿ (ôëàêîíû)   │(ÑØÀ)                                            

                              │125 ìã|5 ìë - 80, 100, 150 ìë;                                                      

                              │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ                                                           

                              │ñóñïåíçèè äëÿ âíóòðåííåãî                                                            

                              │ïðèìåíåíèÿ (ôëàêîíû) 250 ìã|5 ìë - │                                                 

                              │80, 100, 150 ìë                                                                     

                                                                                                                  

│Öåôàìåçèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Dong-A Pharmaceuticals Co Ltd │002145             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Êîðåÿ Þæíàÿ)                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Öåôàìåçèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Eczacibasi (Òóðöèÿ)           │01473              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Öåôàìåçèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Fujisawa Pharmaceutical Co    │002352             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │Ltd (Òàéâàíü)                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Öåôàìåçèí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Krka (Þãîñëàâèÿ)              │00418              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                   

                                                                                                                   

│Öåôàïèçîí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Shin Poong Ltd (Êîðåÿ Þæíàÿ)  │002735             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                   

                                                                                                                  

│Öåôåêîí                       │ñâå÷è                              │Ðîññèÿ                        │76/788/7           

                                                                                                                  

│Öåôìåòàçîí                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Sankyo Co Ltd (ßïîíèÿ)        │002869             

                              │âíóòðèâåííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5 ã, 1 ã, 2 ã; ïîðîøîê äëÿ                                                        

                              │ïðèãîòîâëåíèÿ âíóòðèìûøå÷íîãî                                                       

                              │ðàñòâîðà (ôëàêîíû) 0.5 ã                                                            

                                                                                                                  

│Öåôîáèä                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Biogal (Âåíãðèÿ)              │002523             

                              │èíúåêöèîííîãî ðàñòâîðà (àìïóëû) 1                                                   

                              │ã, 2 ã                                                                              

                                                                                                                  

│Öåôîáèä                       │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Pfizer (Èíäîíåçèÿ)            │003213             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                    

                                                                                                                  

│Öåôîáèä                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pfizer (ÑØÀ)                  │01483              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1, 2 ã                                                                         

                                                                                                                  

│Öåôîáèä                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Pfizer Sa (Èñïàíèÿ)           │002295             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5 ã, 1 ã, 2 ã                                                                     

                                                                                                                  

│Öåôîòàêñèì                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Han Mi Pharmaceutical Co Ltd  │002488             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │(Êîðåÿ Þæíàÿ)                                    

                              │ã                                                                                   

                                                                                                                  

│Öåôîòàêñèì                    │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Lek (Ñëîâåíèÿ)                │002326             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã, 2 ã                                                                              

                                                                                                                   

│Öåôîòåòàí                     │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Biochemie Gmbh (Àâñòðèÿ)      │002354             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │                                                 

                              │ã                                                                                   

                                                                                                                  

│Öåôðàäèí                      │êàïñóëû 250, 500 ìã                │Mir Pharmaceutical            │007668             

                                                                 │Inc/Biocraft Laboratories Inc │                   

                                                                 │(ÑØÀ)                                            

                                                                                                                  

│Öåôñïàí                       │êàïñóëû 100 ìã; ìèêðîãðàíóëû 5%    │Fujisawa Pharmaceutical Co    │02009              

                                                                 │Ltd (ßïîíèÿ)                                     

                                                                                                                  

│Öåôô                          │êàïñóëû 250 ìã                     │Lupin Laboratories Ltd (Èíäèÿ)│002621             

                                                                                                                  

│Öèêëîïëàòèí                   │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Lachema (×ÑÔÐ)                │3011               

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │50, 200 ìã                                                                          

                                                                                                                  

│Öèìåâåí                       │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Syntex (Øâåéöàðèÿ)            │002285             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                     

                              │500 ìã - 10 ìë                                                                      

                                                                                                                  

│Öèìåãåêñàëü                   │òàáëåòêè ïîêðûòûå ïëåíî÷íîé        │Hexal Pharma Gmbh (ÔÐÃ)       │002773             

                              │îáîëî÷êîé 200, 400, 800 ìã                                                          

                                                                                                                  

│Öèìåäèí                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200,   │Dar Al Dava (Èîðäàíèÿ)        │003147             

                              │400 ìã                                                                              

                                                                                                                  

│Öèìåòèäèí                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 200,   │Mir Pharmaceutical            │007886             

                              │400, 800 ìã                        │Inc/Pharbita B.V.                                

                                                                 │(íèäåðëàíäû) (ÑØÀ)                               

                                                                                                                  

│Öèìåòèäèí                     │òàáëåòêè 200, 400, 800 ìã          │Norton Healthcare Ltd         │003248             

                                                                 │(Âåëèêîáðèòàíèÿ)                                 

                                                                                                                  

│Öèíåäèë                       │òàáëåòêè 75 ìã                     │Alkaloid (Ìàêåäîíèÿ)          │003419             

│Öèíê-êîðòèêîòðîïèíà ñóñïåíçèÿ │ñóñïåíçèÿ äëÿ èíúåêöèé             │Ðîññèÿ                        │77/441/6           

│Öèííàðèçèí                    │òàáëåòêè 25 ìã                     │Wave International (Èíäèÿ)    │002990             

                                                                                                                   

│Öèíîôô                        │ïîðîøîê ñìà÷èâàþùèéñÿ 40%;         │Fms Corporation (ÑØÀ)         │004197             

                              │êîíöåíòðàò ýìóëüñèîííûé 24.8%                                                       

                                                                                                                  

│Öèïðèíîë                      │òàáëåòêè 250, 500 ìã; ðàñòâîð äëÿ  │Krka (ÑÔÐÞ)                   │002287             

                              │âíóòðèâåííîãî ââåäåíèÿ (àìïóëû)                                                     

                              │100 ìã - 10 ìë                                                                      

                                                                                                                  

│Öèïðîëåò                      │òàáëåòêè 250, 500 ìã; ðàñòâîð äëÿ  │Dr.Reddy's Laboratories Ltd   │002470             

                              │èíôóçèé (ôëàêîíû) 200 ìã - 100 ìë  │(Èíäèÿ)                                          

                                                                                                                  

│Öèïðîíàò                      │òàáëåòêè 250, 500 ìã; ðàñòâîð äëÿ  │Natco Pharma Ltd (Èíäèÿ)      │003239             

                              │èíôóçèé (ôëàêîíû) 200 ìã - 100 ìë                                                   

                                                                                                                  

│Öèñïëàòèí                     │êîíöåíòðàò äëÿ ïðèãîòîâëåíèÿ       │Ebewe (Àâñòðèÿ)               │002659             

                              │èíôóçèîííîãî ðàñòâîðà (ôëàêîíû) 10 │                                                 

                              │ìã/20 ìë, 25 ìã/50 ìë, 50 ìã/100 ìë│                                                 

                                                                                                                   

│Öèñòèöèä                      │òàáëåòêè 500 ìã                    │Merck (India) Ltd (Èíäèÿ)     │002872             

│Öèòîïëàñòûðü                  │ëåíòà                              │Pharmachim (Áîëãàðèÿ)         │2623               

                                                                                                                  

│Öèòîñòàçàí                    │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Jenapharm Gmbh (ÔÐÃ)          │002410             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │25 ìã                                                                               

                                                                                                                  

│Öèòðàò áåòàèíà Áîôóð          │ãðàíóëû                            │Beaufour-Ipsen International  │003024             

                                                                 │(Ôðàíöèÿ)                                        

                                                                                                                  

│Öèôðàí                        │òàáëåòêè 250, 500 ìã; ïîðîøîê äëÿ  │Ranbaxy Laboratories Ltd      │02008              

                              │ïðèãîòîâëåíèÿ èíôóçèîííîãî         │(Èíäèÿ)                                          

                              │ðàñòâîðà 100 ìã/50 ìë, 200 ìã/100                                                   

                              │ìë                                                                                  

                                                                                                                  

│Öûïëåíîê ñ ëàïøîé 00408                                          │Gerber (ÑØÀ)                  │004191             

│Öûïëåíîê ñ îâîùàìè è ðèñîì                                       │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004302             

│×èðñ                          │ïàñòà çóáíàÿ                       │Parfico (Åãèïåò)              │01563              

                                                                                                                   

│×îéñ                          │ïàñòà çóáíàÿ                       │U.K.Paintce (India) Ltd       │01418              

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│×óïà ×óïñ                     │êàðàìåëü                           │Chupa Chups (Èñïàíèÿ)         │004271             

                                                                                                                  

│Øîâà Ìèòåêñ 200                                                  │Nissyo Ivai Corporation       │01725              

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Øîâà Ôðåø Ôëîð Ñ-55                                              │Nissyo Ivai Corporation       │01726              

                                                                 │(ßïîíèÿ)                                         

                                                                                                                  

│Øîêîëàäíûé äåñåðò                                                │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004317             

│Ýáðàíòèë                      │êàïñóëû ðåòàðä 60, 90 ìã           │Byk Gulden Gmbh (ÔÐÃ)         │002225             

                                                                                                                  

│Ýáðàíòèë                      │êàïñóëû ðåòàðä 30 ìã; ðàñòâîð äëÿ  │Byk Gulden Gmbh (ÔÐÃ)         │002151             

                              │èíúåêöèé (àìïóëû) 25 ìã/5 ìë, 50                                                    

                              │ìã/10 ìë                                                                             

                                                                                                                  

│Ýáðèìèöèí                     │ãåëü                               │Chinoin (Âåíãðèÿ)             │002524              

│Ýâèòîë                        │äðàæå                              │Krka (Ñëîâåíèÿ)               │002486             

│Ýâêàáàë                       │ýìóëüñèÿ (ôëàêîíû) 100 ìë          │Esparma (ÔÐÃ)                 │003014             

│Ýâêàëèïòè                     │ïàñòà çóáíàÿ                       │Pollena-Uroda (Ïîëüøà)        │2982               

                                                                                                                  

│Ýãèôåðîí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Egis (Âåíãðèÿ)                │002251             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │1000000, 3000000 ÌÅ /â êîìïëåêòå ñ │                                                 

                              │ðàñòâîðèòåëåì/                                                                      

                                                                                                                  

│Ýçåìòàí                       │ëîñüîí                             │Schulke & Mayr (Ãåðìàíèÿ)     │0025-24            

│Ýêçà-òåñò                     │ôëàêîíû                            │Imuna (×åõîñëîâàêèÿ)          │2627               

                                                                                                                  

│Ýêèáàð                        │òàáëåòêè ïîêðûòûå îáîëî÷êîé        │Biogalenique (Ôðàíöèÿ)        │003211             

                              │íåäåëèìûå 250, 500 ìã                                                               

                                                                                                                  

│Ýêñòðàäåíò                    │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2800               

│Ýêñòðàäåíò Ô                  │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2816                

│Ýêñòðàäåíò ÔÌ                 │ïàñòà çóáíàÿ                       │Pharmachim (Áîëãàðèÿ)         │2852               

│Ýêñòðàìèò ñ ëàâàíäîé          │ïëàñòèíû                           │Ðîññèÿ                        │0032-16            

│Ýêñôîñ                        │áàëëîíû àýðîçîëüíûå                │Ðîññèÿ                        │0001-14            

│Ýêòîôåð                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 2 ìë │Eczacibasi (Òóðöèÿ)           │01539              

│Ýëäåïðèë                      │òàáëåòêè 5 ìã                      │Farmos Group (Ôèíëÿíäèÿ)      │002265             

                                                                                                                  

│Ýëåâèò                        │ñèðîï                              │Roche Mustahzarlari Sanayi As │002304             

                                                                 │(Òóðöèÿ)                                         

                                                                                                                  

│Ýëåêòðîôóìèãèðóþùåå ñðåäñòâî  │ïëàñòèíû                           │Sumitomo Chemical (ßïîíèÿ)    │0001-15            

│Ýëìåêñ                        │ïàñòà çóáíàÿ; ãåëü; ðàñòâîð        │Gaba International (Øâåéöàðèÿ)│01562              

│Ýëüìåòàöèí                    │ðàñòâîð 1%                         │Luitpold-Werk (ÔÐÃ)           │002056             

                                                                                                                  

│Ýíàì                          │òàáëåòêè 2.5, 5, 10, 20 ìã         │Dr.Reddy's Laboratories Ltd   │002402             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ýíàïðèí                       │òàáëåòêè 10 ìã                     │Chung Kun Dah Corporation     │002736             

                                                                 │(Êîðåÿ Þæíàÿ)                                    

                                                                                                                   

│Ýíåëáèí                       │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 40   │Lechiva Joint-Stock Company   │010134             

                              │ìã - 5 ìë                          │(×åøñêàÿ Ðåñïóáëèêà)                             

                                                                                                                  

│Ýíåðáîë                       │äðàæå                              │Polfa (Ïîëüøà)                │2522               

│Ýíåðãîíàïèòîê ïëþñ                                               │Pharmavit (Âåíãðèÿ)           │3004               

                                                                                                                  

│Ýíçàïðîñò-Ô                   │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 1    │Chinoin (Âåíãðèÿ)             │2546               

                              │ìã/1 ìë, 5 ìã/5 ìë                                                                  

                                                                                                                  

│Ýíçèñòàë                      │äðàæå                              │Torrent Exports Ltd (Èíäèÿ)   │002135             

│Ýíñóëàê Ì                                                        │Cofranlate (Ôðàíöèÿ)          │004084             

│Ýíòåðîïîëàð Ò.Ý.Í.            │ñìåñü ñóõàÿ                        │Farmos Group (Ôèíëÿíäèÿ)      │01304              

│Ýíòåðîïîëàð òåõî              │ñìåñü ñóõàÿ                        │Farmos Group (Ôèíëÿíäèÿ)      │01305              

│Ýíôàëàê ïîñëåäóþùàÿ ôîðìóëà                                      │Mead Johnson (Âåëèêîáðèòàíèÿ) │01739              

                                                                                                                  

│Ýíöåôàáîë                     │ñóñïåíçèÿ îðàëüíàÿ (ôëàêîíû) 100   │Merck (India) Ltd (Èíäèÿ)     │00790              

                              │ìã|5 ìë - 200 ìë; òàáëåòêè                                                           

                              │ïîêðûòûå îáîëî÷êîé 100 ìã                                                           

                                                                                                                  

│Ýíöèïàëüìåä                   │äðàæå                              │Trima (Èçðàèëü)               │002597             

│Ýïàñåë                        │êàïñóëû                            │Biorex (Âåíãðèÿ)              │002651             

                                                                                                                  

│Ýïîöåëèí                      │ëèîôèëèç.ïîðîøîê äëÿ ïðèãîòîâëåíèÿ │Al-Hikma Pharmaceuticals      │002591             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │(Èîðäàíèÿ)                                       

                              │0.5, 2 ã                                                                            

                                                                                                                  

│Ýïîöåëèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Al-Hikma Pharmaceuticals      │002277             

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû) 1 │(Èîðäàíèÿ)                                       

                              │ã                                                                                   

                                                                                                                  

│Ýïîöåëèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Eczacibasi (Òóðöèÿ)           │01474              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)                                                    

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Ýïîöåëèí                      │ïîðîøîê äëÿ ïðèãîòîâëåíèÿ          │Fujisawa Pharmaceutical Co    │01228              

                              │èíúåêöèîííîãî ðàñòâîðà (ôëàêîíû)   │Ltd (ßïîíèÿ)                                      

                              │0.5, 1 ã                                                                            

                                                                                                                  

│Ýðàöèí                        │òàáëåòêè 200, 400 ìã               │Orion Pharmaceutica           │002228             

                                                                 │(Ôèíëÿíäèÿ)                                      

                                                                                                                  

│Ýðèäåðì                       │ðàñòâîð 2%                         │Abbott Laboratories (ÑØÀ)     │003339             

│Ýðèê                          │êàïñóëû 250 ìã                     │Biogal (Âåíãðèÿ)              │002141             

│Ýðèòðîìèöèí                   │òàáëåòêè 200 ìã                    │Polfa (Ïîëüøà)                │2873               

                                                                                                                  

│Ýðèòðîìèöèí ëàêòîáèîíàò       │ðàñòâîð äëÿ âíóòðèâåííîãî ââåäåíèÿ │Abbott Laboratories (ÑØÀ)     │003339             

                              │(ôëàêîíû) 0.3, 1 ã                                                                  

                                                                                                                  

│Ýðèòðîìèöèí Ïñè Äèñïåðòàá     │òàáëåòêè ïîêðûòûå îáîëî÷êîé 333 ìã │Abbott Laboratories (ÑØÀ)     │003339             

│Ýðèòðîìèöèí ñòåàðåéò          │òàáëåòêè 250, 500 ìã               │Abbott Laboratories (ÑØÀ)     │003339             

                                                                                                                  

│Ýðèòðîïåä                     │ãðàíóëû äëÿ ïðèãîòîâëåíèÿ îðàëüíîé │Abbott Laboratories (ÑØÀ)     │003339             

                              │ñóñïåíçèè 250 ìã|5 ìë                                                                

                                                                                                                  

│Ýñêóçàí                       │äðàæå                              │Jenapharm Gmbh (ÔÐÃ)          │002408              

│Ýñïåðàëü                      │òàáëåòêè äëÿ èìïëàíòàöèé           │Laboratoires Solyak (Ôðàíöèÿ) │00845              

│Ýññåë ôîðòå                   │êàïñóëû                            │Nabros Pharma Pvt Ltd (Èíäèÿ) │007065             

                                                                                                                  

│Ýññåíöèàëå                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5    │Berlin-Chemie Ag (ÔÐÃ)        │002902             

                              │ìë; êàïñóëû ôîðòå                                                                   

                                                                                                                  

│Ýññåíöèàëå                    │ðàñòâîð äëÿ èíúåêöèé (àìïóëû) 5,   │Bosnalijek (ÑÔÐÞ)             │00531              

                              │10 ìë                                                                               

                                                                                                                  

│Ýññåíöèàëå                    │êàïñóëû ôîðòå                      │Torrent Exports Ltd (Èíäèÿ)   │002232             

│Ýñòèìàëà òàáëåòêè@            │òàáëåòêè 100, 200 ìã               │Ðîññèÿ                        │82/848/6           

                                                                                                                  

│Ýñòðàäåðì ÒÒÑ 100             │òðàíñäåðìàëüíàÿ òåðàïåâòè÷åñêàÿ    │Ciba-Geigy (Øâåéöàðèÿ)        │002166             

                              │ñèñòåìà (ïëàñòûðü) 8 ìã|20 êâ. ñì                                                   

                                                                                                                  

│Ýñòðàäåðì ÒÒÑ 25              │òðàíñäåðìàëüíàÿ òåðàïåâòè÷åñêàÿ    │Ciba-Geigy (Øâåéöàðèÿ)        │002166             

                              │ñèñòåìà (ïëàñòûðü) 2 ìã|5 êâ. ñì                                                     

                                                                                                                  

│Ýñòðàäåðì ÒÒÑ 50              │òðàíñäåðìàëüíàÿ òåðàïåâòè÷åñêàÿ    │Ciba-Geigy (Øâåéöàðèÿ)        │002166             

                              │ñèñòåìà (ïëàñòûðü) 4 ìã|10 êâ. ñì                                                   

                                                                                                                  

│Ýñòðàöèò                      │àìïóëû 150, 300 ìã                 │Leo (Øâåöèÿ)                  │00600              

│Ýñòóëèê                       │òàáëåòêè 1 ìã                      │Egis (Âåíãðèÿ)                │002522             

│Ýòèäîêñèí                     │êàïñóëû 100 ìã                     │Ethypharm (Ôðàíöèÿ)           │002783             

│Ýòèôèëëèí                     │êàïñóëû 100, 200, 300 ìã           │Ethypharm (Ôðàíöèÿ)           │003163             

│Ýòîê-10                       │ïëàñòèíû                           │Sumitomo Chemical (ßïîíèÿ)    │0004-33            

│Ýóáåòàë àíòèáèîòèê            │êàïëè ãëàçíûå; ìàçü ãëàçíàÿ        │S.I.F.I. Spa (Èòàëèÿ)         │01926              

                                                                                                                  

│Ýóãëþêîí                      │òàáëåòêè 5 ìã                      │Boehringer Mannheim Gmbh      │002139             

                                                                 │(Àâñòðèÿ)                                        

                                                                                                                  

│Ýóãëþêîí                      │òàáëåòêè 5 ìã                      │Boehringer Mannheim Ltd       │002413             

                                                                 │(Èíäèÿ)                                          

                                                                                                                  

│Ýóôèëëèí                      │òàáëåòêè ïîêðûòûå îáîëî÷êîé ðåòàðä │Byk Gulden Gmbh (ÔÐÃ)         │002810             

                              │ìèòå Í 125 ìã; òàáëåòêè ïîêðûòûå                                                     

                              │îáîëî÷êîé ðåòàðä Í 250 ìã; ðàñòâîð │                                                 

                              │äëÿ âíóòðèâåííîãî ââåäåíèÿ                                                          

                              │(àìïóëû) 240 ìã - 10 ìë                                                             

                                                                                                                  

│Ýóôèëîíã                      │êàïñóëû 375 ìã; êàïñóëû ìèíîð 250  │Byk Gulden Gmbh (ÔÐÃ)         │002314             

                              │ìã                                                                                  

                                                                                                                  

│Ýôåðîêñ                       │òàáëåòêè ïîêðûòûå îáîëî÷êîé 25,    │Wyeth Group (ÔÐÃ)             │002849             

                              │50, 100, 150 ìêã                                                                    

                                                                                                                  

│Ýôôåðàëãàí                    │ðàñòâîð ïåäèàòðè÷åñêèé äëÿ ïðèåìà  │Laboratoires Upsa (Ôðàíöèÿ)   │002479             

                              │âíóòðü 3 ã|100 ìë                                                                   

                                                                                                                  

│Ýôôåðàëãàí ñ âèòàìèíîì C      │òàáëåòêè øèïó÷èå                   │Laboratoires Upsa (Ôðàíöèÿ)   │002480             

│Þâåìîí (ðåö Ïø-005 è Ïø-2ì)   │ãðàíóëû                            │Ðîññèÿ                        │0001-13            

                                                                                                                  

│Þíèäîêñ                       │êàïñóëû 100 ìã                     │United Pharmaceutical         │002949             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                        

                                                                                                                  

│Þíèêàì                        │êàïñóëû 20 ìã                      │United Pharmaceutical         │002950             

                                                                 │Manufacturing Co Ltd                             

                                                                 │(Èîðäàíèÿ)                                       

                                                                                                                  

│Þíèêàï Ì                      │òàáëåòêè                           │Upjohn (ÑØÀ)                  │002153             

│Þíèêàï Ò                      │òàáëåòêè                           │Upjohn (ÑØÀ)                  │002154             

│Þíèêàï Þ                      │òàáëåòêè æåâàòåëüíûå äëÿ äåòåé     │Upjohn (ÑØÀ)                  │002155             

│ßáëîêè 02631                                                     │Gerber (ÑØÀ)                  │004172             

│ßáëîêè ñ åæåâèêîé 02647                                          │Gerber (ÑØÀ)                  │004175             

│ßáëîêî ñ àáðèêîñîì 00433                                         │Gerber (ÑØÀ)                  │004176             

│ßáëî÷íî-áàíàíîâûé äåñåðò 00449│                                   │Gerber (ÑØÀ)                  │004120             

│ßáëî÷íî-áàíàíîâûé ñîê 02109                                      │Gerber (ÑØÀ)                  │004165             

│ßáëî÷íîå ïþðå 116                                                │Fructal/Sloveniales (Ñëîâåíèÿ)│004364             

                                                                                                                  

│ßáëî÷íîå ïþðå ñ àïåëüñèíîâûì                                     │Fructal (Ñëîâåíèÿ)            │004374             

│ñîêîì                                                                                                              

                                                                                                                  

│ßáëî÷íûé ñîê 02101                                               │Gerber (ÑØÀ)                  │004163             

│ßáëî÷íûé ñîê 02131                                               │Gerber (ÑØÀ)                  │004164             

│ßè÷íûé äåñåðò                                                    │Cow&gate (Íèäåðëàíäû/Èðëàíäèÿ)│004316             

│ßñìèíà                        │ïàñòà çóáíàÿ                       │Yasmina (Åãèïåò)              │01814              

└──────────────────────────────┴───────────────────────────────────┴──────────────────────────────┴────────────────────┘

 

 

 

 

 

                          Ïðèëîæåíèå 2.

 

                             ÏÅÐÅ×ÅÍÜ

                ÌÅÆÄÓÍÀÐÎÄÍÛÕ ÍÀÇÂÀÍÈÉ ÏÐÅÏÀÐÀÒÎÂ,

             ÈÌÅÞÙÈÕ ÁÎËÅÅ ÎÄÍÎÃÎ ÒÎÐÃÎÂÎÃÎ ÍÀÇÂÀÍÈß

 

┌─────────────────────────────────────────────┬─────────────────────────────────────────────┐

       Ìåæä. íàçâàíèå/ôàðì. ãðóïïà                              Ñèíîíèìû                 

├─────────────────────────────────────────────┼─────────────────────────────────────────────┤

│Àäåíîçèíà ôîñôàò - ìåòàáîëè÷åñêîå ñðåäñòâî   │Àäåíîêîð, Ôîñôàäåí, Ôîñôàäåíà ðàñòâîð äëÿ   

                                             │èíúåêöèé 2%, Ôîñôàäåíà òàáëåòêè             

                                                                                         

│Àäèïèîäîí - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî     │Áèëèãíîñò 50%, Õîëàìáðèí (Áèëèãíîñò)        

                                                                                         

│Àçàêëîðçèí& - êîðîíàðîäèëàòèðóþùåå ñðåäñòâî  │Íîíàõëàçèí, Íîíàõëàçèíà ðàñòâîð 1.5%,       

                                             │Íîíàõëàçèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.03 │

                                             │ã                                           

                                                                                          

│Àçàìåòîíèÿ áðîìèä - ãàíãëèîáëîêàòîð          │Ïåíòàìèí, Ïåíòàìèíà ðàñòâîð äëÿ èíúåêöèé 5% 

│Àçàòèîïðèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Àçàòèîïðèíà òàáëåòêè 0.05 ã, Èìóðàí         

                                                                                          

│Àçèòðîìèöèí - àíòèáèîòèê, ìàêðîëèä           │Àçèâîê, Àçèòðîìèöèí, Àçèòðîöèí 0.25 ã â     

                                             │êàïñóëàõ, Çèìàêñ, Ñóìàìåä                   

                                                                                         

│Àçëîöèëëèí - àíòèáèîòèê, ïåíèöèëëèí          │Àçëîöèëëèíà íàòðèåâàÿ ñîëü, Ñåêóðîïåí       

                                                                                         

│Àéìàëèí - àíòèàðèòìè÷åñêîå ñðåäñòâî          │Àéìàëèíà ðàñòâîð äëÿ èíúåêöèé 2.5%, Àéìàëèíà │

                                             │òàáëåòêè 0.05 ã, Ãèëóðèòìàë 10              

                                                                                          

│Àêòèâèðîâàííûé óãîëü - ýíòåðîñîðáèðóþùåå     │Àêòèâèðîâàííûé óãîëü Ìåêñ, Àêòèâèðîâàííûé   

│ñðåäñòâî                                     │óãîëü ÑÊÍ, Êàðáàêòèí, Êàðáîëîíã,            

                                             │Ìèêðîñîðá-Ï, Ìèêðîñîðá-Ï àêòèâèðîâàííîãî    

                                             │óãëÿ ïàñòà, Óãëÿ àêòèâèðîâàííîãî ÊÌ òàáëåòêè │

                                             │0.25 ã, Óãëÿ àêòèâèðîâàííîãî òàáëåòêè, Óãîëü │

                                             │àêòèâèðîâàííûé, Óãîëü àêòèâèðîâàííûé ÔÀÑ-Ý, 

                                             │Óëüòðà-àäñîðá, Ýíòåðîñîðáåíò ÃÑ-01-Ý,       

                                             │Ýíòåðîñîðáåíò ÑÓÌÑ-1                         

                                                                                         

│Àëáåíäàçîë - ïðîòèâîãåëüìèíòíîå ñðåäñòâî     │Àëüáåíäàçîë, Àëüáåíäàçîëà òàáëåòêè 0.2 ã    

                                                                                          

│Àëãåëäðàò - àíòàöèäíîå ñðåäñòâî              │Àëþìèíèÿ ãèäðîîêèñü, Àëþìèíèÿ               

                                             │ãèäðîîêèñü-Ðèâîôàðì, Ðîêæåëü                

                                                                                         

│Àëãåëäðàò+Ìàãíèÿ ãèäðîêñèä& - àíòàöèäíîå     │Àëìàãåëü, Àëìàôèë, Àëìîë, Àëüìàã,           

│ñðåäñòâî                                     │Àëüïðîãåëü, Àëþìàã, Àëþìàã-Òåâà, Àíàöèä,    

                                             │Áàðòåë äðàãç Àëàìàã, Áàðòåë äðàãç Ïðîëàíòà, 

                                             │Êîàëãåëü 60, Ëàêòàìèë, Ìààëîêñ, Íàìàãåë     

                                             │÷åððè, Íàø âûáîð - æèäêèé àíòàöèä, Ïðîòàá,  

                                             │Ðåìàãåëü, Ðèâîëîêñ, ×åððè íàìàãåë           

                                                                                         

│Àëãåëäðàò+Ìàãíèÿ ãèäðîêñèä+Áåíçîêàèí& -      │Àëìàãåëü À, Ðåìàãåëü À                      

│àíòàöèäíîå ñðåäñòâî                                                                      

                                                                                         

│Àëãåëäðàò+Ìàãíèÿ ãèäðîêñèä+Äèìåòèêîí ñ       │Àëìàêîí, Àëþãåëü ôîðòå, Æèäêèé àíòàöèä Éîðê 

│äâóîêèñüþ êðåìíèÿ& - àíòàöèäíîå ñðåäñòâî     │ñ ñèìåòèêîíîì, Ìààëîêñ ïëþñ, Ìààëîêñ ïëþñ   

                                             │ïîâûøåííîé àêòèâíîñòè, Íàñèãåë ÷åððè,       

                                             │ïìñ-Àëþìèíèÿ                                

                                                                                         

│Àëëàïèíèí& - àíòèàðèòìè÷åñêîå ñðåäñòâî       │Àëëàïèíèí, Àëëàïèíèíà ðàñòâîð äëÿ èíúåêöèé  

                                             │0.5%, Àëëàïèíèíà òàáëåòêè 0.025 ã           

                                                                                         

│Àëëåòðèí - èíñåêòèöèäíîå ñðåäñòâî            │Ðàïòîð-ñïèðàëü (çåëåíàÿ), Ðàïòîð-ñïèðàëü    

                                             │(îðàíæåâàÿ), Ðåéä ýëåêòðîôóìèãàòîð ñ        

                                             │æèäêîñòüþ, Ýêñïåëü-ôóìèãàòîð-îñâîáîäèòåëü   

                                                                                         

│Àëëîïóðèíîë - êñàíòèíîêñèäàçû èíãèáèòîð      │Àëëî, Àëëîïèí, Àëëîïóðèíîë, Àëëîïóðèíîë     

                                             │Íèêîìåä, Àëëîïóðèíîë-Òåâà, Àëëîïóðèíîëà      

                                             │òàáëåòêè 0.1 ã, Àëëóïîë, Àëîïðîí,           

                                             │Àïî-Àëëîïóðèíîë, Çèëîðèê, Ìèëóðèò, Ïóðèíîë, 

                                             │Ðåìèä, Ñàíôèïóðîë                           

                                                                                         

│Àëìàñèëàò - àíòàöèäíîå ñðåäñòâî              │Ìåãàëàê àëìàñèëàò, Ñèìàãåëü                 

                                                                                         

│Àëïèçàðèí& - ïðîòèâîâèðóñíîå ñðåäñòâî        │Àëïèçàðèí, Àëïèçàðèíà òàáëåòêè 0.1 ã,       

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Àëïèçàðèíîâàÿ ìàçü                          

                                                                                         

│Àëïðàçîëàì - àíêñèîëèòè÷åñêîå ñðåäñòâî       │Àëçîëàì, Àëïðàçîëàì, Àëïðàçîëàìà òàáëåòêè,  

                                             │Àëïðîêñ, Çîëäàê, Êàññàäàí, Êñàíàêñ ðåòàðä,  

                                             │Êñàíàêñ, Ëàìîç, Íåóðîë, Õåëåêñ              

                                                                                         

│Àëïðîñòàäèë - âàçîäèëàòèðóþùåå ñðåäñòâî      │Âàçàïðîñòàí, Êàâåðäæåêò, Ïðîñòèí ÂÐ, Ýäåêñ  

                                                                                         

│Àëüáóìèí& - ïëàçìîçàìåùàþùåå ñðåäñòâî        │Àëüáóìèí, Àëüáóìèí ïëàöåíòàðíûé, Àëüáóìèí   

                                             │÷åëîâå÷åñêèé, Àëüáóìèí ÷åëîâå÷åñêèé 20%     

                                             │Èììóíî, Àëüáóìèí ÷åëîâå÷åñêèé Äåññàó,       

                                             │Àëüáóìèíà ïëàöåíòàðíîãî ðàñòâîð, Àëüáóìèíà  

                                             │ðàñòâîð, Çåíàëüá-20, Ïëàçáóìèí-20,          

                                             │Ïëàçáóìèí-5, Ïîñòàá - àëüáóìèí ñóõîé, Ïîñòàá │

                                             │- ðàñòâîð àëüáóìèíà, Óìàí àëüáóìèí          

                                                                                         

│Àëüôàêàëüöèäîë - ðåãóëÿòîð îáìåíà êàëüöèÿ è  │Àëüôà Ä3-Òåâà, Âàí-Àëüôà                    

│ôîñôîðà                                                                                  

                                                                                         

│Àëüôàìåòðèí& - èíñåêòèöèäíîå ñðåäñòâî        │Êàì, Íèêà-3                                 

│Àëþìèíèÿ ôîñôàò - àíòàöèäíîå ñðåäñòâî        │Àëüôîãåëü, Ãàñòåðèí, Ôîñôàëþãåëü            

                                                                                         

│Àìàíòàäèí - äîôàìèí-ñòèìóëÿòîð               │Ãëóäàíòàí, Ãëóäàíòàíà òàáëåòêè 0.2 ã,       

                                             │Ìèäàíòàíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.1 ã, │

                                             │ÏÊ-Ìåðö                                     

                                                                                          

│Àìáåíîíèé õëîðèä - àíòèõîëèíýñòåðàçíîå       │Îêñàçèë, Îêñàçèëà òàáëåòêè                  

│ñðåäñòâî                                                                                 

                                                                                         

│Àìáðîêñîë - ìóêîëèòè÷åñêîå ñðåäñòâî          │Àìáðîáåíå, Àìáðîãåêñàë, Àìáðîêñîë, Àìáðîëàí, │

                                             │Àìáðîñàí, Äåôëåãìèí, Äèãíîáðîêñîë, Êàïëè    

                                             │Áðîíõîâåðí, Ëàçîëâàí, Ìåäîâåíò, Ìóêîñîëüâàí 

                                                                                         

│Àìèêàöèí - àíòèáèîòèê, àìèíîãëèêîçèä         │Àìèêàöèíà ñóëüôàò, Àìèêèí, Àìèêîçèò, Àìèöèí, │

                                             │Èâèìèöèí, Ëèêàöèí, Ìèêàöèí, Ñåëåìèöèí,      

                                             │Ôàðöèêëèí, Õåìàöèí                          

                                                                                         

│Àìèíèòðîçîë - ïðîòèâîïðîòîçîéíîå ñðåäñòâî    │Íèòàçîë, Íèòàçîëà àýðîçîëü, Íèòàçîëà        

                                             │ïåññàðèè, Íèòàçîëà ñóñïåíçèÿ 2.5%, Íèòàçîëà 

                                             │òàáëåòêè 0.1 ã, Ñóïïîçèòîðèè âàãèíàëüíûå ñ  

                                             │íèòàçîëîì 0.12 ã (íà ëàçóïîëå G)            

                                                                                          

│Àìèíîãëóòåòèìèä - ñòåðîèäîâ ñèíòåçà èíãèáèòîð│Ìàìîìèò, Îðèìåòåí                           

                                                                                         

│Àìèíîêàïðîíîâàÿ êèñëîòà - ãåìîñòàòè÷åñêîå    │Àìèíîêàïðîíîâîé êèñëîòû ãðàíóëû äëÿ äåòåé,  

│ñðåäñòâî                                     │Àìèíîêàïðîíîâîé êèñëîòû ðàñòâîð äëÿ èíúåêöèé │

                                             │5%                                          

                                                                                         

│Àìèíîìåòèëáåíçîéíàÿ êèñëîòà -                │Àìáåí, Àìáåíà ðàñòâîð äëÿ èíúåêöèé 1%,      

│ãåìîñòàòè÷åñêîå ñðåäñòâî                     │Ãåìîñòàòè÷åñêàÿ ãóáêà ñ àìáåíîì, Ãóìáèêñ,   

                                             │Ïàìáà                                       

                                                                                         

│Àìèíîñàëèöèëîâàÿ êèñëîòà -                   │Íàòðèÿ ïàðà-àìèíîñàëèöèëàò, Íàòðèÿ          

│ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî                │ïàðà-àìèíîñàëèöèëàòà ãðàíóëû, Íàòðèÿ        

                                             │ïàðà-àìèíîñàëèöèëàòà ðàñòâîð 3%, Íàòðèÿ     

                                             │ïàðà-àìèíîñàëèöèëàòà òàáëåòêè (ðàñòâîðèìûå â │

                                             │êèøå÷íèêå, Íàòðèÿ ïàðà-àìèíîñàëèöèëàòà      

                                             │òàáëåòêè 0.5 ã, Íàòðèÿ ïàðà-àìèíîñàëèöèëàòà 

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.5 ã           

                                                                                         

│Àìèíîôèëëèí - áðîíõîäèëàòèðóþùåå ñðåäñòâî    │Ýóôèëëèí, Ýóôèëëèí-Äàðíèöà, Ýóôèëëèíà       

                                             │ðàñòâîð äëÿ èíúåêöèé 2.4%, Ýóôèëëèíà ðàñòâîð │

                                             │äëÿ èíúåêöèé 24%, Ýóôèëëèíà òàáëåòêè 0.15 ã, │

                                             │Ýóôèëëèíà òàáëåòêè 150 ìã                   

                                                                                         

│Àìèîäàðîí - àíòèàðèòìè÷åñêîå ñðåäñòâî        │Àëüäàðîí, Àìèîäàðîí, Êîðäàðîí, Îïàêîðäýí,   

                                             │Ñåäàêîðîí                                   

                                                                                         

│Àìèðèäèí& - àíòèõîëèíýñòåðàçíîå ñðåäñòâî     │Àìèðèäèí, Àìèðèäèíà ðàñòâîð äëÿ èíúåêöèé,   

                                             │Àìèðèäèíà òàáëåòêè 0.02 ã                   

                                                                                         

│Àìèòðèïòèëèí - àíòèäåïðåññàíò                │Àìèçîë, Àìèíåóðèí, Àìèðîë, Àìèòîí,           

                                             │Àìèòðèïòèëèí, Àìèòðèïòèëèí Íèêîìåä,         

                                             │Àìèòðèïòèëèíà ãèäðîõëîðèä, Àïî-Àìèòðèïòèëèí, │

                                             │Äàìèëåíà ìàëåèíàò, Äàìèëåíà ìàëåèíàò â      

                                             │êàïñóëàõ 0.05 ã, Íîâî-Òðèïòèí, Òðèïòèçîë,   

                                             │Ýëèâåë                                      

                                                                                         

│Àìèòðèïòèëèí+Õëîðäèàçåïîêñèä& -              │Àìèêñèä, Àìèêñèä-5, Àìèêñèä-Í               

│àíòèäåïðåññàíò                                                                           

                                                                                         

│Àìëîäèïèí - ÁÌÊÊ                             │Àìëîâàñ, Íîðâàñê, Ñòàìëî                    

                                                                                          

│Àììèàê& - àíàëåïòè÷åñêîå ñðåäñòâî            │Àììèàê âîäíûé êîíöåíòðèðîâàííûé, Àììèàêà    

                                             │ðàñòâîð, Àììèàêà ðàñòâîð 10%, Àììèàêà       

                                             │ðàñòâîð 10% â àìïóëàõ, Àììèàêà ðàñòâîð 10% â │

                                             │àìïóëàõ ñ îïëåòêîé                          

                                                                                         

│Àììèôóðèí& - ôîòîñåíñèáèëèçèðóþùåå ñðåäñòâî  │Àììèôóðèí, Àììèôóðèíà ðàñòâîð 0.3%,         

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Àììèôóðèíà ðàñòâîð 2%, Àììèôóðèíà òàáëåòêè  

                                             │0.02 ã                                       

                                                                                         

│Àìîáàðáèòàë - ñíîòâîðíîå ñðåäñòâî            │Ýñòèìàë, Ýñòèìàëà òàáëåòêè                  

                                                                                          

│Àìîêñèöèëëèí - àíòèáèîòèê, ïåíèöèëëèí        │Àìèí, Àìîêñèêàð, Àìîêñèëëàò, Àìîêñèëëàò-250, │

                                             │Àìîêñèöèëëèí, Àìîêñèöèëëèí 1000 Ñòàäà       

                                             │ìåæäóíàðîäíûé, Àìîêñèöèëëèí 250 Ñòàäà       

                                             │ìåæäóíàðîäíûé, Àìîêñèöèëëèí â êàïñóëàõ 0.25 

                                             │ã, Àìîêñèöèëëèí-Ðàòèîôàðì,                  

                                             │Àìîêñèöèëëèí-Ðàòèîôàðì 250 ÒÑ,              

                                             │Àìîêñèöèëëèí-Òåâà, Àìîêñèöèëëèíà íàòðèåâàÿ  

                                             │ñîëü ñòåðèëüíàÿ, Àìîêñèöèëëèíà ïîðîøîê äëÿ  

                                             │ñóñïåíçèè 5 ã, Àìîêñèöèëëèíà òàáëåòêè,      

                                             │Àìîêñèöèëëèíà òðèãèäðàò, Àìîêñèöèëëèíà      

                                             │òðèãèäðàò - êîìïàêò, Àìîêñèöèëëèíà òðèãèäðàò │

                                             │- ïîðîøîê, Àìîêñîí, Àìîòèä, Àïî-Àìîêñè,     

                                             │Àòîêñèëèí, Ãîíîôîðì, Ãðþíàìîêñ, Äàíåìîêñ,   

                                             │Êóêñàöèëëèí, Îñïàìîêñ, Ðàíîêñèë, Òàéñèë,    

                                             │Óïñàìîêñ, Ôëåìîêñèí Ñîëþòàá, Õèêîíöèë, Ý-ìîêñ│

                                                                                         

│Àìîêñèöèëëèí+Êëàâóëàíîâàÿ êèñëîòà& -         │Àìîêëàâèí, Àìîêñèêëàâ, Àóãìåíòèí, Êëàâîöèí, 

│àíòèáèîòèê, ïåíèöèëëèí+áåòà-ëàêòàìàç         │Êëàâóíàò, Ìîêñèêëàâ                         

│èíãèáèòîð                                                                                 

                                                                                         

│Àìïèöèëëèí - àíòèáèîòèê, ïåíèöèëëèí          │Àìïèçèä, Àìïèê, Àìïèðåêñ, Àìïèöèëëèí,       

                                             │Àìïèöèëëèí â êàïñóëàõ 0.25 ã, Àìïèöèëëèí    

                                             │Èííîòåê, Àìïèöèëëèí-Òåâà, Àìïèöèëëèíà       

                                             │íàòðèåâàÿ ñîëü, Àìïèöèëëèíà íàòðèåâàÿ ñîëü  

                                             │(ñòåðèëüíàÿ), Àìïèöèëëèíà íàòðèåâàÿ ñîëü    

                                             │êðèñòàëëè÷åñêàÿ, Àìïèöèëëèíà íàòðèåâàÿ ñîëü 

                                             │êðèñòàëëè÷åñêàÿ ñòåðèëüíàÿ, Àìïèöèëëèíà      

                                             │íàòðèåâàÿ ñîëü ñòåðèëüíàÿ, Àìïèöèëëèíà      

                                             │ïîðîøîê äëÿ ñóñïåíçèé 5 ã, Àìïèöèëëèíà      

                                             │òðèãèäðàò, Àìïèöèëëèíà òðèãèäðàò â êàïñóëàõ 

                                             │0.25 ã, Àìïèöèëëèíà òðèãèäðàòà òàáëåòêè 0.25 │

                                             │ã, Àìïëèòàë, Àïî-Àìïè, Äåêàïåí, Çåòñèë,     

                                             │Êàìïèöèëèí, Ìåñöèëëèí, Ïåíîäèë, Ïåíòàðöèí,  

                                             │Ïåíòðåêñèë, Ðîñöèëëèí, Ñòàíäàöèëëèí,        

                                             │Óïñàìïè, Õåëüì-Àìïèöèëëèí, Õýëüì-Àìïèöèëëèí, │

                                             │Ýïèêîöèëëèí                                 

                                                                                         

│Àìïèöèëëèí+Îêñàöèëëèí& - àíòèáèîòèê          │Àìïèîêñ â êàïñóëàõ 0.25 ã, Àìïèîêñ-íàòðèé,  

│êîìáèíèðîâàííûé                              │ÊÌÏ-Àìïèöèëëèíà-Îêñàöèëëèíà íàòðèåâàÿ ñîëü  

                                                                                         

│Àìôåïðàìîí - àíîðåêñèãåííîå ñðåäñòâî         │Ôåïðàíîí, Ôåïðàíîíà äðàæå 0.025 ã           

│Àìôåòàìèí - ïñèõîñòèìóëèðóþùåå ñðåäñòâî      │Ôåíàìèí, Ôåíàìèíà òàáëåòêè 0.01 ã           

                                                                                         

│Àìôîòåðèöèí  - ïðîòèâîãðèáêîâîå ñðåäñòâî    │Àìáèçîì, Àìôîòåðèöèí Â, Àìôîòåðèöèí  äëÿ   

                                             │âíóòðèâåííîãî ââåäåíèÿ, Àìôîòåðèöèíà  ìàçü 

                                             │30000 ÅÄ/ã, Àìôîöèë, Ôóíãèçîí, Ôóíãèëèí     

                                                                                         

│Àíàáàçèí& - ñðåäñòâî îáëåã÷åíèÿ îòêàçà îò    │Àíàáàçèíà ãèäðîõëîðèä, Àíàáàçèíà            

│êóðåíèÿ                                      │ãèäðîõëîðèäà òàáëåòêè 0.003 ã, Ãàìèáàçèí,   

                                             │Ïëåíêè ñ àíàáàçèíà ãèäðîõëîðèäîì            

                                                                                         

│Àíìàðèí& - àíòèñåïòè÷åñêîå ñðåäñòâî          │Àíìàðèí, Àíìàðèíà ãåëü 1%, Àíìàðèíà ëèíèìåíò │

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │1%, Àíìàðèíà ðàñòâîð 0.25%                  

                                                                                         

│Àïèëàê& - áèîñòèìóëèðóþùåå ñðåäñòâî          │Àïèëàê, Àïèëàê - ãëàçíûå ëåêàðñòâåííûå      

                                             │ïëåíêè, Àïèëàê ëèîôèëèçèðîâàííûé, Àïèëàê    

                                             │ìàçü 3%, Àïèëàêà ïîðîøîê, Àïèëàêà òàáëåòêè  

                                             │0.01 ã, Ñâå÷è ñ àïèëàêîì                    

                                                                                         

│Àïîìîðôèí - ðâîòíîå ñðåäñòâî                 │Àïîìîðôèíà ãèäðîõëîðèä, Àïîìîðôèíà          

                                             │ãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé 1%        

                                                                                         

│Àïðîòèíèí - ïðîòåîëèçà èíãèáèòîð             │Ãîðäîêñ, Èíãèïðîë, Èíãèïðîë äëÿ èíúåêöèé,   

                                             │Èíãèòðèë, Êîíòðèêàë, Òðàñèëîë, Òðàñêîëàí    

                                                                                         

│Àïðîôåí& - ñïàçìîëèòè÷åñêîå ñðåäñòâî         │Àïðîôåí, Àïðîôåíà ðàñòâîð äëÿ èíúåêöèé 1%,  

                                             │Àïðîôåíà òàáëåòêè 0.025 ã                   

                                                                                          

│Àðãèíèí - ãåïàòîïðîòåêòîðíîå ñðåäñòâî        │L-Àðãèíèí, L-Àðãèíèíà ãèäðîõëîðèä,          

                                             │L-Àðãèíèíà ìîíîãèäðîõëîðèä                  

                                                                                         

│Àðìèí& - àíòèõîëèíýñòåðàçíîå ñðåäñòâî        │Àðìèí, Àðìèíà ðàñòâîð 0.005%, Àðìèíà ðàñòâîð │

                                             │0.01%                                       

                                                                                         

│Àðòèêàèí+Ýïèíåôðèí& - ìåñòíîàíåñòåçèðóþùåå   │Àëüôàêàèí Í, Àëüôàêàèí ÑÏ, Ñåïòîíåñò ñ      

│ñðåäñòâî                                     │àäðåíàëèíîì 1:100000, Ñåïòîíåñò ñ            

                                             │àäðåíàëèíîì 1:200000, Óëüòðàêàèí Ä-Ñ,       

                                             │Óëüòðàêàèí Ä-Ñ ôîðòå                        

                                                                                          

│Àñêîðáèíîâàÿ êèñëîòà - âèòàìèí               │Àääèòèâà âèòàìèí Ñ øèïó÷èå òàáëåòêè ñ       

                                             │ëèìîííûì âêóñîì, Àñêîðáèíîâàÿ êèñëîòà,      

                                             │Àñêîðáèíîâàÿ êèñëîòà (âèòàìèí Ñ),           

                                             │Àñêîðáèíîâàÿ êèñëîòà äëÿ èíúåêöèé 0.05 ã,   

                                             │Àñêîðáèíîâîé êèñëîòû 0.1 ã è ãëþêîçû 0.8 ã  

                                             │òàáëåòêè, Àñêîðáèíîâîé êèñëîòû 0.1 ã ñ      

                                             │ãëþêîçîé òàáëåòêè, Àñêîðáèíîâîé êèñëîòû     

                                             │äðàæå 0.05 ã, Àñêîðáèíîâîé êèñëîòû ðàñòâîð  

                                             │äëÿ èíúåêöèé 10%, Àñêîðáèíîâîé êèñëîòû      

                                             │ðàñòâîð äëÿ èíúåêöèé 5%, Àñêîðáèíîâîé       

                                             │êèñëîòû ðàñòâîð äëÿ èíúåêöèé 5% (âèòàìèí Ñ), │

                                             │Àñêîðáèíîâîé êèñëîòû òàáëåòêè, Àñêîðáèíîâîé 

                                             │êèñëîòû òàáëåòêè 0.025 ã, Àñêîðáèíîâîé      

                                             │êèñëîòû òàáëåòêè 0.05 ã, Áàðòåë äðàãç       

                                             │Âèòàìèí Ñ, Áàðòåë äðàãç Âèòàìèí Ñ           

                                             │æåâàòåëüíûé ñ àïåëüñèíîâûì âêóñîì, Áèîâèòàëü │

                                             │âèòàìèí Ñ 500, Âèò Ñ, Âèòàìèí Ñ, Âèòàìèí Ñ  

                                             │àïåëüñèíîâûé 500 ìã, Âèòàìèí Ñ Íèêîìåä,     

                                             │Âèòàìèí Ñ ïëþñ, Âèòàìèí Ñ1000, Âèòðóì ïëþñ  

                                             │âèòàìèí Ñ, Æåâàòåëüíûå òàáëåòêè ñ âèòàìèíîì 

                                             │C, Ë (+)Àñêîðáèíîâàÿ êèñëîòà, Ìóëüòè-òàáñ ñ 

                                             │âèòàìèíîì Ñ, Òàêñîôèò âèòàìèí Ñ, Óïñàâèò    

                                             │âèòàìèí-Ñ, Öåëàñêîí ýôôåðâåñöåíñ, Öåòåáå    

                                                                                         

│Àñêîðáèíîâàÿ êèñëîòà+Æåëåçà ñóëüôàò& -       │Ñîðáèôåð äóðóëåñ, Ôåððîãðàä Ñ (Ôåððîãðàä    

│ãåìîïîýçà ñòèìóëÿòîð, ïðåïàðàò æåëåçà        │500), Ôåððîïëåêñ                            

                                                                                          

│Àñïàðàãèíàçà - ïðîòèâîîïóõîëåâîå ñðåäñòâî    │L-àñïàðàãèíàçà, L-àñïàðàãèíàçà äëÿ èíúåêöèé 

│Àñïàðòàì - çàìåíèòåëü ñàõàðà                 │Íóòðàñâèò, Øóãàôðè                          

                                                                                          

│Àñòåìèçîë - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Àñìîâàë 10, Àñòåëîíã, Àñòåìèçîë,            

│áëîêàòîð                                     │Àñòåìèçîë-ICN, Àñòåìèñàí, Ãèñìàíàë,         

                                             │Ãèñòàçîë, Ãèñòàëîíã, Ìèáèðîí, Ñòåëåðò, Ñòåìèç│

                                                                                         

│Àòåíîëîë - áåòà1-àäðåíîáëîêàòîð ñåëåêòèâíûé  │Àçåêòîë, Àïî-Àòåíîë, Àòåí, Àòåíèë,          

                                             │Àòåíîáåíå, Àòåíîâà, Àòåíîë, Àòåíîëàí,       

                                             │Àòåíîëîë, Àòåíîëîë-Ðàòèîôàðì 100,           

                                             │Àòåíîëîë-Ðàòèîôàðì 25, Àòåíîëîë-Ðàòèîôàðì   

                                             │50, Àòåíîëîë-Òåâà, Àòåíîñàí, Àòêàðäèë,      

                                             │Áåòàäóð, Áåòàêàðä-100, Áåòàêàðä-50,         

                                             │Áëîêîòåíîë, Âàçêîòåí, Âåëîðèí 100,          

                                             │Ãåí-Àòåíîëîë, Êàòåíîë, Êóêñàíîðì, Îðìèäîë,  

                                             │Ïðèíîðì, Ñèíàðîì, Òåíîáëîê, Òåíîëîë,        

                                             │Òåíîðìèí, Óíèëîê, Ôàëèòîíçèí, Õàéïîòåí,     

                                             │Õèïðåñ-100, Õèïðåñ-50                       

                                                                                          

│Àòåíîëîë+Õëîðòàëèäîí& - ãèïîòåíçèâíîå        │Àòåãåêñàë êîìïîçèòóì, Àòåíîëîë êîìï.,       

│êîìáèíèðîâàííîå ñðåäñòâî                     │Òåíîðåòèê, Òåíîðèê                          

                                                                                          

│Àòðîïèí - ì-õîëèíîáëîêàòîð                   │Àòðîìåä, Àòðîïèíà ñóëüôàò, Àòðîïèíà ñóëüôàòà │

                                             │ðàñòâîð 0.1%, Àòðîïèíà ñóëüôàòà ðàñòâîð 0.1% │

                                             │â øïðèö-òþáèêàõ, Àòðîïèíà ñóëüôàòà ðàñòâîð  

                                             │1%, Àòðîïèíà ñóëüôàòà ðàñòâîð äëÿ èíúåêöèé  

                                             │0.05%, Àòðîïèíà ñóëüôàòà ðàñòâîð äëÿ        

                                             │èíúåêöèé 0.1%, Àòðîïèíà ñóëüôàòà ðàñòâîð äëÿ │

                                             │èíúåêöèé 1% (äëÿ âåòåðèíàðíîãî,  Àòðîïèíà   

                                             │ñóëüôàòà òàáëåòêè 0.0005 ã, Àòðîïèíîâàÿ ìàçü │

                                             │1%, Ïëåíêè ãëàçíûå ñ àòðîïèíà ñóëüôàòîì     

                                                                                         

│Àòòàïóëãèò - ïðîòèâîäèàðåéíîå ñðåäñòâî       │Êàîïåêòàò, Êàîïåêòàò Àòòàïóëüãèò, Êàïåêò,   

                                             │Íåîèíòåñòîïàí                               

                                                                                         

│Àóðîòèîïðîë - ïðîòèâîâîñïàëèòåëüíîå          │Êðèçàíîë, Êðèçàíîë 5% â àìïóëàõ             

│ñðåäñòâî, ïðåïàðàò çîëîòà                                                                

                                                                                         

│Àöåáóòîëîëà ãèäðîõëîðèä -                    │Àöåáóòîëîë, Àöåêîð, Ñåêòðàë, Ñåêòðàëü       

│áåòà1-àäðåíîáëîêàòîð ñåëåêòèâíûé ñ ÑÌÀ                                                   

                                                                                          

│Àöåêëèäèí - ì-õîëèíîìèìåòèê                  │Àöåêëèäèí, Àöåêëèäèíà ðàñòâîð äëÿ èíúåêöèé  

                                             │0.2%                                        

                                                                                         

│Àöåêñàìîâàÿ êèñëîòà - ðåãåíåðàöèè ñòèìóëÿòîð │Àöåìèí, Àöåìèíà ìàçü, Àöåìèíà ðàñòâîð       

│Àöåòàçîëàìèä - äèóðåòè÷åñêîå ñðåäñòâî        │Äèàêàðá, Äèàêàðáà òàáëåòêè 0.25 ã           

                                                                                         

│Àöåòàðñîë - ïðîòèâîïðîòîçîéíîå ñðåäñòâî      │Îñàðáîí, Îñàðáîí ñóïïîçèòîðèè âàãèíàëüíûå   

                                             │(íà ëàçóïîëå G), Îñàðñîë, Îñàðöèä, Îñàðöèä  

                                             │ñóïïîçèòîðèè âàãèíàëüíûå (íà ëàçóïîëå G)    

                                                                                         

│Àöåòèëñàëèöèëàò ëèçèíà - ÍÏÂÑ                │Àñïèçîë, Àöåëèçèí, Àöåëèçèí 0.2 ã (äëÿ      

                                             │ïèòüÿ), Àöåëèçèí äëÿ èíúåêöèé 1 ã, Àöåëèçèí 

                                             │äëÿ èíúåêöèé 2 ã, Àöåëèçèí äëÿ ïèòüÿ 0.6 ã, 

                                             │Èíúåñïðèí, Ëàñïàë, Ñâå÷è ñ àöåëèçèíîì       

                                                                                         

│Àöåòèëñàëèöèëîâàÿ êèñëîòà - ÍÏÂÑ             │Àíîïèðèí, Àïî-Àñà, Àñïèâàòðèí, Àñïèëàéò,    

                                             │Àñïèðèí, Àñïèðèí Éîðê, Àñïèðèí Êâîëèòè,     

                                             │Àñïèðèí 325 ìã, Àñïèðèí äëÿ äåòåé, Àñïèðèí  

                                             │êàðäèî, Àñïèðèí ÓÏÑÀ, Àñïèðèí-Äèðåêò,       

                                             │Àñïèðèí-Ìèëòîì, Àñïèòðèí, Àñïèòðèí òàáëåòêè 

                                             │0.5 ã, ÀÑÑ-Ðàòèîôàðì, Àöåíòåðèí,            

                                             │Àöåòèëñàëèöèëáåíå, Àöåòèëñàëèöèëîâàÿ        

                                             │êèñëîòà, Àöåòèëñàëèöèëîâàÿ êèñëîòà          

                                             │(Àñïèðèí), Àöåòèëñàëèöèëîâîé êèñëîòû        

                                             │òàáëåòêè, Àöåòèëñàëèöèëîâîé êèñëîòû òàáëåòêè │

                                             │0.25 ã, Àöåòèëñàëèöèëîâîé êèñëîòû òàáëåòêè  

                                             │0.5 ã, Àöåòèëñàëèöèëîâîé êèñëîòû òàáëåòêè   

                                             │äëÿ äåòåé 0.1 ã, Àöèëïèðèí, Áàðòåë äðàãç    

                                             │À.Ñ.Ê., Áóôôåðàí, Áóôôåðèí, Äæàñïðèí,       

                                             │Êèñëîòà àöåòèëñàëèöèëîâàÿ-Äàðíèöà, Êîëôàðèò, │

                                             │Ìèêðèñòèí, Íàø âûáîð - àíàëüãåòèê ïîêðûòûé  

                                             │îáîëî÷êîé, Íàø âûáîð - äåòñêèé àíàëüãåòèê,  

                                             │Íîâàíäîë, Íîâàñàí, Íîâàñåí SpC, Íüþ-àñïåð,  

                                             │ÍÞ-ñèëç 75 êàðäèî-àñïèðèí, Ïëèäîë 100,      

                                             │Ïëèäîë 300, Ðîíàë, Ñàëîðèí, Ñïðèò-Ëàéì,     

                                             │Òðîìáî ÀÑÑ, Óîëø-àñàëãèí, Ýé÷-Ýë-Ïýéí,      

                                             │Ýëêàïèí                                     

                                                                                          

│Àöåòèëñàëèöèëîâàÿ êèñëîòà+Àñêîðáèíîâàÿ       │Àñïèðèí ïëþñ Ñ, Àñïèðèí ÓÏÑÀ ñ âèòàìèíîì C, 

│êèñëîòà& - àíàëüãåòè÷åñêîå íåíàðêîòè÷åñêîå   │Àñïèðèí+Ñ, Àñïèðèí-Ñ, Àñïðî Âèòàìèí Ñ, Àñïðî │

│ñðåäñòâî                                     │ñ Âèòàìèíîì C, ÀÑÑ+Ö-Ðàòèîôàðì,             

                                             │Àöåòèëñàëèöèëáåíå+Ñ, Äæàñïðèí Ñ, Ïëèäîë Ñ,  

                                             │Ôîðòàëãèí Ö                                 

                                                                                         

│Àöåòèëñàëèöèëîâàÿ êèñëîòà+Àñêîðáèíîâàÿ       │Ðèíã Í, Ôèíðåêñèí Ñ-300, Ôèíðåêñèí Ñ-300 Íåî │

│êèñëîòà+Êîôåèí& - àíàëüãåòè÷åñêîå                                                        

│íåíàðêîòè÷åñêîå ñðåäñòâî                                                                 

                                                                                         

│Àöåòèëñàëèöèëîâàÿ êèñëîòà+Êîôåèí& -          │Àñêàôô, Àöåòèëñàëèöèëîâîé êèñëîòû 0.25 ã è  

│àíàëüãåòè÷åñêîå íåíàðêîòè÷åñêîå ñðåäñòâî     │êîôåèíà 0.05 ã òàáëåòêè, Íàø âûáîð -        

                                             │ýêñòðàñèëüíûé àíàëüãåòèê                    

                                                                                         

│Àöåòèëñàëèöèëîâàÿ                            │Àëãîìèí, Àëãîí, Àñêîôåí ïëþñ, Àñêîôåí-Ï,    

│êèñëîòà+Êîôåèí+Ïàðàöåòàìîë& -                │Àöèôåèí, Èðàëãåçèê, Íåóðàíèäàë, Îëäîí,      

│àíàëüãåòè÷åñêîå íåíàðêîòè÷åñêîå ñðåäñòâî     │Òîìàïèðèí, Öèòðàìîí Ï, Öèòðàïàð â êàïñóëàõ, 

                                             │Ýêñåäðèí                                    

                                                                                          

│Àöåòèëñàëèöèëîâàÿ êèñëîòà+Ëèìîííàÿ êèñëîòà&  │Àëüêà-ïðèì, Àñïèðèí, Èíñïðèí, Íàø âûáîð -   

│- ÍÏÂÑ                                       │øèïó÷èå òàáëåòêè îò áîëåé                   

                                                                                          

│Àöåòèëöèñòåèí - ìóêîëèòè÷åñêîå ñðåäñòâî      │Àöåòèëöèñòåèíà ðàñòâîð äëÿ èíãàëÿöèé 20%,   

                                             │Àöåòèëöèñòåèíà ðàñòâîð äëÿ èíúåêöèé 10%,    

                                             │Àöåòèëöèñòåèíà ðàñòâîð äëÿ èíúåêöèé 5%, ÀÖÖ, │

                                             │ÀÖÖ 100, ÀÖÖ 200, ÀÖÖ èíúåêò., ÀÖÖ-100,     

                                             │ÀÖÖ-200, ÀÖÖ-ëîíã, Ìóêî Ñàíèãåí, Ìóêîáåíå,  

                                             │Ìóêîìèñò, Ôëóèìóöèë, Ôëþèìóöèë, Ýêçîìþê     

                                                                                         

│Àöèêëîâèð - ïðîòèâîâèðóñíîå ñðåäñòâî         │Àöèê-îôòàëü, Àöèêëîâèð, Àöèêëîâèð Ãåêñàë,   

                                             │Àöèêëîâèð-Àêðè ìàçü, Àöèêëîâèð-Àêðè òàáëåòêè │

                                             │0.2 ã, Àöèêëîâèð-ÁÌÑ, Àöèêëîâèðà ìàçü 5%,   

                                             │Àöèêëîâèðà òàáëåòêè 0.2 ã, Âèâîðàêñ,        

                                             │Âèðîëåêñ, Ãåðïåðàêñ, Ãåðïåñèí, Çîâèðàêñ,    

                                             │Ëèçàâèð, Ëîâèð, Ìåäîâèð, Ñóïðàâèðàí,        

                                             │Öåâèðèí, Öèêëîâàêñ, Öèêëîâèð, Öèòèâèð       

                                                                                         

│Áàìèïèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ áëîêàòîð│Áàìèïèí-Ðàòèîôàðì, Ñîâåíòîë                 

│Áàðáèòàë - ñíîòâîðíîå ñðåäñòâî               │Áàðáèòàë (Âåðîíàë), Áàðáèòàë-íàòðèé (Ìåäèíàë)│

                                                                                         

│Áàðèÿ ñóëüôàò - ýíòåðîñîðáèðóþùåå ñðåäñòâî   │Àäñîáàð, Áàðèÿ ñóëüôàò, Áàðèÿ ñóëüôàò äëÿ   

                                             │ðåíòãåíîñêîïèè, Ìèêðîïàê ÑÒ, Ñóëüôîáàð,     

                                             │Ôàëèáàðèò, Ôàëèáàðèò ÕÄÅ                    

                                                                                         

│Áàöèòðàöèí+Íåîìèöèí& - àíòèáèîòèê            │Áàíåîöèí, Áèâàöèí                           

│êîìáèíèðîâàííûé                                                                          

                                                                                         

│Áàöèòðàöèí+Íåîìèöèí+Ïîëèìèêñèí& - àíòèáèîòèê │Áàêòåðîë, Áàðòåë äðàãç Òðîéíàÿ              

│êîìáèíèðîâàííûé                              │àíòèáèîòèêîâàÿ ìàçü, Òðèàñåïò                

                                                                                         

│Áåçàôèáðàò - ãèïîëèïèäåìè÷åñêîå ñðåäñòâî     │Áåçàëèï, Áåçàìèäèí, Õîëåñòåíîðì             

│Áåêëàìèä - ïðîòèâîñóäîðîæíîå ñðåäñòâî        │Õëîðàêîí, Õëîðàêîíà òàáëåòêè 250 ìã         

                                                                                         

│Áåêëîìåòàçîí - ãëþêîêîðòèêîñòåðîèä äëÿ       │Àëüäåöèí, Àðóìåò, Áåêëîäæåò 250, Áåêëîêîðò, 

│ìåñòíîãî ïðèìåíåíèÿ                          │Áåêëîìåò-èçèõåéëåð, Áåêëîôîðòå, Áåêîäèñê,   

                                             │Áåêîíàçà, Áåêîíàçå, Áåêîòèä, Áðîíõîòóðáèíàë, │

                                             │Ãíàäèîí, Ïëèáåêîò, Ðèíîñîë                  

                                                                                         

│Áåíàêòèçèí - àíêñèîëèòè÷åñêîå ñðåäñòâî       │Àìèçèë, Àìèçèëà òàáëåòêè                    

                                                                                          

│Áåíäàçîë - âàçîäèëàòèðóþùåå ñðåäñòâî         │Ãëèîôåí, Äèáàçîë, Äèáàçîëà ðàñòâîð äëÿ      

                                             │èíúåêöèé, Äèáàçîëà ðàñòâîð äëÿ èíúåêöèé     

                                             │0.5%, Äèáàçîëà ðàñòâîð äëÿ èíúåêöèé 1%,     

                                             │Äèáàçîëà òàáëåòêè, Äèáàçîëà òàáëåòêè 0.02 ã 

                                                                                         

│Áåíçàëêîíèÿ õëîðèä - êîíòðàöåïòèâíîå ìåñòíîå │Ñåïòóñòèí, Ôàðìàòåêñ                        

│ñðåäñòâî                                                                                 

                                                                                          

│Áåíçàòèí áåíçèëïåíèöèëëèí - àíòèáèîòèê,      │Áèöèëëèí-1, Áèöèëëèí-3, Áèöèëëèí-5,         

│ïåíèöèëëèí                                   │Ðåòàðïåí, Ýêñòåíöèëëèí                      

                                                                                          

│Áåíçèäàìèí - ÍÏÂÑ                            │Òàíòóì, Òàíòóì âåðäå, Òàíòóì ðîçà           

                                                                                         

│Áåíçèëáåíçîàò - ñðåäñòâî óíè÷òîæåíèÿ         │Áåíçèëáåíçîàò ìåäèöèíñêèé, Áåíçèëáåíçîàòà   

│ýêòîïàðàçèòîâ                                │ãåëü, Áåíçèëáåíçîàòà ìàçü, Áåíçèëáåíçîàòà   

                                             │ìåäèöèíñêîãî ìàçü, Áåíçèëáåíçîàòà ýìóëüñèÿ  

                                             │20%                                         

                                                                                         

│Áåíçèëïåíèöèëëèí - àíòèáèîòèê, ïåíèöèëëèí    │Áåíçèëïåíèöèëëèíà êàëèåâàÿ ñîëü              

                                             │êðèñòàëëè÷åñêàÿ, Áåíçèëïåíèöèëëèíà íàòðèåâàÿ │

                                             │ñîëü, Áåíçèëïåíèöèëëèíà íàòðèåâàÿ ñîëü      

                                             │êðèñòàëëè÷åñêàÿ, Ïåíèöèëëèí G íàòðèåâàÿ     

                                             │ñîëü, Ïåíèöèëëèí G íàòðèåâàÿ ñîëü           

                                             │ñòåðèëüíàÿ, Ïåíèöèëëèí-Òåâà                 

                                                                                         

│Áåíçîáàðáèòàë - ïðîòèâîñóäîðîæíîå ñðåäñòâî   │Áåíçîíàë, Áåíçîíàëà òàáëåòêè 0.05 ã,        

                                             │Áåíçîíàëà òàáëåòêè ïî 0.1 ã                 

                                                                                         

│Áåíçîèëà ïåðîêñèä - àíòèñåïòè÷åñêîå ñðåäñòâî │Äåñêâàì, Ïðîäåðì, Ýêëàðàí 10, Ýêëàðàí 5     

                                                                                          

│Áåíçîêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî    │Àíåñòåçèí, Àíåñòåçèíà òàáëåòêè 0.3 ã,       

                                             │Àíåñòåçèíîâàÿ ìàçü 5%, Áàðòåë äðàãç         

                                             │Îáåçáîëèâàþùèé ãåëü äëÿ ãóá è ñëèçèñòîé ðòà 

                                                                                         

│Áåíçîêëèäèí - àíêñèîëèòè÷åñêîå ñðåäñòâî      │Îêñèëèäèí, Îêñèëèäèíà ðàñòâîð äëÿ èíúåêöèé, 

                                             │Îêñèëèäèíà òàáëåòêè                         

                                                                                         

│Áåðîêñàí& - ôîòîñåíñèáèëèçèðóþùåå ñðåäñòâî   │Áåðîêñàí, Áåðîêñàíà ðàñòâîð, Áåðîêñàíà       

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │òàáëåòêè 0.02 ã                             

                                                                                         

│Áåòàèí - ïèùåâàðèòåëüíîå ôåðìåíòíîå ñðåäñòâî │Àöèäèí, Áåòàèí öèòðàò ÓÏÑÀ øèïó÷èé          

                                                                                         

│Áåòàêàðîòåí - âèòàìèí                        │Áåòà-Êàðîòèí, Áåòà-Êàðîòèíà êàïñóëû 0.01 ã, 

                                             │ÁåòàÂèò 10%, ÁåòàÂèò 20%, Êàðîëèí,          

                                             │Êàðîòèíèë, Êàðîòîëèí, Öèêëîêàð, Öèêëîêàð    

                                             │òàáëåòêè                                    

                                                                                         

│Áåòàêñîëîë - áåòà1-àäðåíîáëîêàòîð ñåëåêòèâíûé│Áåòîïòèê, Áåòîïòèê Ñ, Ëîêðåí                

                                                                                          

│Áåòàìåòàçîí - ãëþêîêîðòèêîñòåðîèä äëÿ        │Áåëîäåðì, Áåòàêîðòàë, Áåòàì-Îôòàëü,         

│ìåñòíîãî ïðèìåíåíèÿ                          │Áåòíîâåéò, Âàëîäåðì, Äèïðîëåí, Äèïðîñïàí,   

                                             │Êóòåðèä, Ïåðñèâàò, Ôëîñòåðîí, Öåëåñòîäåðì Â, │

                                             │Öåëåñòîí                                    

                                                                                         

│Áåòàìåòàçîí+Ñàëèöèëîâàÿ êèñëîòà& -           │Áåëîñàëèê, Áåòàäåðìèê, Äèïðîñàëèê           

│ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî äëÿ ìåñòíîãî                                              

│ïðèìåíåíèÿ                                                                               

                                                                                         

│Áåôåíèÿ ãèäðîêñèíàôòîàò - ïðîòèâîãåëüìèíòíîå │Íàôòàìîí, Íàôòàìîíà Ê òàáëåòêè ïîêðûòûå     

│ñðåäñòâî                                     │îáîëî÷êîé, Íàôòàìîíà òàáëåòêè (ðàñòâîðèìûå â │

                                             │êèøå÷íèêå)                                  

                                                                                         

│Áåôîë& - àíòèäåïðåññàíò                      │Áåôîë, Áåôîëà ðàñòâîð äëÿ èíúåêöèé 0.25%,   

                                             │Áåôîëà òàáëåòêè 0.01 ã                      

                                                                                         

│Áèêëîòèìîë - ïðîòèâîìèêðîáíîå ñðåäñòâî       │Ãåêñàäðåïñ, Ãåêñàñïðåé                      

                                                                                         

│Áèîàëëåòðèí - èíñåêòèöèäíîå ñðåäñòâî         │Áàéãîí Äèôôóçîð Ëèêâèä Ãåíèóñ, Áàéãîí       

                                             │Ýëåêòðîèíñåêòåíôðàé                         

                                                                                         

│Áèïåðèäåí - í-õîëèíîáëîêàòîð öåíòðàëüíûé     │Àêèíåòîí, Àêèíåòîí ÑР                      

                                                                                         

│Áèñàêîäèë - ñëàáèòåëüíîå ñðåäñòâî            │Àïî-Áèñàêîäèë, Áèñàäèë, Áèñàêîäèë,          

                                             │Áèñàêîäèëà òàáëåòêè (ðàñòâîðèìûå â          

                                             │êèøå÷íèêå) 0.005 ã, Äóëüêîëàêñ, Ëàêñàêîäèë, 

                                             │Ëàêñàòèí, Ëàêñáåíå, Ïèðèëàêñ, Ñòàäàëàêñ     

                                             │ìåæäóíàðîäíûé                               

                                                                                         

│Áèôîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî        │Áèôîíàçîëà êðåì 1%, Áèôîíàçîëà ïðèñûïêà 1%, 

                                             │Áèôîíàçîëà ðàñòâîð 1%, Ìèêîñïîð, Ìèêîñïîð   

                                             │ãåëü, Ìèêîñïîð êðåì â íàáîðå äëÿ ëå÷åíèÿ    

                                             │íîãòåé, Ìèêîñïîð ïóäðà                      

                                                                                         

│Áëåîìèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Áëåîìèöåòèíà ãèäðîõëîðèä, Áëåîìèöåòèíà      

                                             │ãèäðîõëîðèä äëÿ èíúåêöèé 0.005 ã, Áëåîöèí   

                                                                                         

│Áîíàôòîí& - ïðîòèâîâèðóñíîå ñðåäñòâî         │Áîíàôòîí, Áîíàôòîíà ìàçü, Áîíàôòîíà ìàçü     

                                             │ãëàçíàÿ 0.05%, Áîíàôòîíà òàáëåòêè           

                                             │(ðàñòâîðèìûå â êèøå÷íèêå), Áîíàôòîíà        

                                             │òàáëåòêè (ðàñòâîðèìûå â êèøå÷íèêå) äëÿ äåòåé │

                                                                                         

│Áðåòèëèÿ òîñèëàò - àíòèàðèòìè÷åñêîå ñðåäñòâî │Áðåòèëàò, Îðíèä, Îðíèäà ðàñòâîð 5% â àìïóëàõ │

│Áðîìàäèîëîí - ðîäåíòèöèäíîå ñðåäñòâî         │Ãëîáîëü ðîäåíòèöèä, Ëàíèðàò-êîíöåíòðàò      

                                                                                         

│Áðîìàçåïàì - àíêñèîëèòè÷åñêîå ñðåäñòâî       │Áðîìàçåï, Áðîìàçåïàì Ëàííàõåð, Áðîìèäåì,    

                                             │Êàëìåïàì, Ëåêñèëèóì, Ëåêñîòàí, Íîðìîê       

                                                                                         

│Áðîìãåêñèí - ìóêîëèòè÷åñêîå ñðåäñòâî         │Áèçîëâîí, Áðîìãåêñèí, Áðîìãåêñèí 10         

                                             │Áåðëèí-Õåìè, Áðîìãåêñèí 4 Áåðëèí-Õåìè,      

                                             │Áðîìãåêñèí 4 ìã äëÿ äåòåé, Áðîìãåêñèí 8     

                                             │Áåðëèí-Õåìè, Áðîìãåêñèí 8 ìã, Áðîìãåêñèí    

                                             │Íèêîìåä, Áðîìãåêñèí Ðèâî, Áðîìãåêñèí        

                                             │ýëèêñèð, Áðîìãåêñèí-Ðàòèîôàðì, Áðîìãåêñèíà  

                                             │ãèäðîõëîðèä, Áðîìãåêñèíà ñèðîï, Áðîìãåêñèíà 

                                             │òàáëåòêè 0.008 ã, Áðîìãåêñèíà òàáëåòêè äëÿ  

                                             │äåòåé 0.004 ã, Áðîíõîñàí, Äèàìåëèòóñ,       

                                             │Ñîëâèí, Ôëåãàìèí, Ôëåêîêñèí                 

                                                                                         

│Áðîìèçîâàë - ñåäàòèâíîå ñðåäñòâî             │Áðîìèçîâàë (Áðîìóðàë), Áðîìèçîâàëà òàáëåòêè 

                                             │0.3 ã                                       

                                                                                         

│Áðîìîêðèïòèí - äîôàìèí-ñòèìóëÿòîð            │2-Áðîì-àëüôà-ýðãîêðèïòèíà ìåçèëàò, Àáåðãèí, 

                                             │Àáåðãèíà òàáëåòêè 0.004 ã, Àïî-Áðîìîêðèïòèí, │

                                             │Áðîìîêðèïòèí, Áðîìîêðèïòèí Ïîëè, Áðîìýðãîí, 

                                             │Ëàêòîäåëü, Ïàðëîäåë, Ïàðëîäåëà òàáëåòêè     

                                             │0.0025 ã, Ñåðîêðèïòèí                       

                                                                                          

│Áóäåñîíèä - ãëþêîêîðòèêîñòåðîèä äëÿ ìåñòíîãî │Àïóëåèí, Áóäåñîíèä, Áóäåñîíèä ìèòå,         

│ïðèìåíåíèÿ                                   │Áóäåñîíèä ôîðòå, Áóäåñîíèäà ïîðîøîê äëÿ     

                                             │èíãàëÿöèé, Ãîðàêîðò, Ïóëüìèêîðò òóðáóõàëåð  

                                                                                         

│Áóìåêàèí& - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî    │Ïèðîìåêàèí, Ïèðîìåêàèíà ðàñòâîð, Ïèðîìåêàèíà │

                                             │ðàñòâîð äëÿ èíúåêöèé 1% ñ ãëþêîçîé,         

                                             │Ïèðîìåêàèíîâàÿ ìàçü 5%                      

                                                                                         

│Áóìåòàíèä - äèóðåòè÷åñêîå ñðåäñòâî           │Áóôåíîêñ, Áóôåíîêñà ðàñòâîð äëÿ èíúåêöèé    

                                             │0.025%, Áóôåíîêñà òàáëåòêè 0.001 ã, Þðèíåêñ 

                                                                                          

│Áóïèâàêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî   │Àíåêàèí, Ìàðêàèí                            

                                                                                         

│Áóïðåíîðôèí - àíàëüãåòè÷åñêîå íàðêîòè÷åñêîå  │Áóïðåìåí, Áóïðåíîðôèíà ãèäðîõëîðèä,         

│ñðåäñòâî                                     │Áóïðåíîðôèíà ãèäðîõëîðèäà ðàñòâîð äëÿ       

                                             │èíúåêöèé 0.03%, Áóïðåñèê, Íîïàí, Ñàíãåçèê   

                                                                                         

│Áóñåðåëèí - ïðîòèâîãîíàäîòðîïíîå ñðåäñòâî    │Áóñåðåëèíà àöåòàò, Áóñåðåëèíà àöåòàòà       

                                             │ðàñòâîð 0.2%, Ñóïðåôàêò                      

                                                                                         

│Áóñóëüôàí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Ìèåëîñàí, Ìèåëîñàíà òàáëåòêè 0.002 ã, Ìèëåðàí│

│Áóòàìèðàò - ïðîòèâîêàøëåâîå ñðåäñòâî         │Èíòóññèí, Ñèíåêîä                            

                                                                                         

│Áóòèëãèäðîêñèòîëóîë - ïðîòèâîîïóõîëåâîå      │Äèáóíîë, Äèáóíîëà ëèíèìåíò 10%, Äèáóíîëà    

│ñðåäñòâî                                     │ëèíèìåíò 5%                                 

                                                                                         

│Áóòèðîêñàí& - àëüôà-àäðåíîáëîêàòîð           │Áóòèðîêñàí, Áóòèðîêñàíà ðàñòâîð äëÿ èíúåêöèé │

                                             │1%, Áóòèðîêñàíà òàáëåòêè 0.01 ã             

                                                                                         

│Áóòîðôàíîë - îïèîèäíûõ ðåöåïòîðîâ            │Áåôîðàë, Áóòîðôàíîëà òàðòðàòà ðàñòâîð äëÿ   

│àãîíèñò-àíòàãîíèñò                           │èíúåêöèé 0.2%, Ìîðàäîë, Ñòàäîë, Ñòàäîë ÍÑ   

                                                                                         

│Áóôîðìèí - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ      │Àäåáèò, Ãëèáóòèä, Ãëèáóòèäà òàáëåòêè 0.05 ã, │

│ïåðîðàëüíîãî ïðèåìà                          │Ñèëóáèí ðåòàðä                              

                                                                                         

│Âàëüïðîåâàÿ êèñëîòà - ïðîòèâîñóäîðîæíîå      │Àïèëåïñèí, Àöåäèïðîë, Àöåäèïðîëà ñèðîï 5%,  

│ñðåäñòâî                                     │Àöåäèïðîëà òàáëåòêè 0.3 ã, Äåïàêèí, Äåïàêèí 

                                             │300 ýíòåðèê, Äåïàêèí õðîíî, Äåïàêèí õðîíî   

                                             │500, Äèïðîìàë, Êîíâóëåêñ, Êîíâóëüñîôèí,     

                                             │Îðôèðèë, Ýâåðèäåí, Ýíêîðàò                  

                                                                                          

│Âàíêîìèöèí - àíòèáèîòèê                      │Âàíêîëåä, Âàíêîìèöèí, Âàíêîìèöèí Êâàëèìåä,  

                                             │Âàíêîöèí, Âàíìèêñàí, Ýäèöèí                 

                                                                                         

│Âàïîðòðèí - èíñåêòèöèäíîå ñðåäñòâî           │Àíòèìîëü-Ñóïåð, Ãëîáîëü-àíòèìîëü, Ïëàñòèíû  

                                             │íà îñíîâå âàïîðòðèíà, Ðàïòîð-àíòèìîëü,      

                                             │Ýêñòðàìèò                                   

                                                                                         

│Âàðôàðèí - ðîäåíòèöèäíîå ñðåäñòâî            │Ãåëüêóì, Ëàñêà (â äâóõ ìîäèôèêàöèÿõ Ëàñêà-1 

                                             │è Ëàñêà-2), Ðîäåíò, Ðîäåíò-ÌË               

                                                                                         

│Âåðàïàìèë - ÁÌÊÊ                             │Àöóïàìèë, Âåðàêàðä, Âåðàïàáåíå, Âåðàïàìèë,  

                                             │Âåðàïàìèë (Ìèâàë), Âåðàïàìèë-Ðàòèîôàðì,     

                                             │Âåðàïàìèëà ãèäðîõëîðèä, Âåðàïàìèëà          

                                             │ãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé 0.25%,    

                                             │Âåðàïàìèëà ãèäðîõëîðèäà òàáëåòêè ïîêðûòûå   

                                             │îáîëî÷êîé, Äàíèñòîë, Èçîïòèí, Èçîïòèí SR    

                                             │240, Èçîïòèí ÑÐ, Êàâåðèë, Ëåêîïòèí,         

                                             │Ôàëèêàðä, Ôàëèêàðä ëîíã, Ôèíîïòèí, Ôëàìîí   

                                                                                          

│Âèíáëàñòèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Âåëáå, Âèíáëàñòèí, Âèíáëàñòèí-Òåâà,         

                                             │Âèíáëàñòèíà ñóëüôàò, Ðîçåâèí, Ðîçåâèí       

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé 0.005 ã,     

                                             │Öèòîáëàñòèí âîäíûé                          

                                                                                         

│Âèíêàìèí - âàçîäèëàòèðóþùåå ñðåäñòâî         │Âèíêàíîð, Âèíêàíîðà òàáëåòêè ïîêðûòûå       

                                             │îáîëî÷êîé, Îêñèáðàë, Îêñèáðàë ÑР           

                                                                                         

│Âèíêðèñòèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Âèíêðèñòèí ëèêâèä-Ðèõòåð, Âèíêðèñòèí-Òåâà,  

                                             │Âèíêðèñòèíà ñóëüôàò, Îíêîâèí, Öèòîêðèñòèí,  

                                             │Öèòîìèä                                      

                                                                                         

│Âèíïîöåòèí - âàçîäèëàòèðóþùåå ñðåäñòâî       │Âèíïîöåòèí-Ðèâîôàðì, Âèíïîöåòèíà òàáëåòêè   

                                             │0.005 ã, Êàâèíòîí                           

                                                                                         

│Âèñìóòà ñóáãàëàò - àíòèñåïòè÷åñêîå ñðåäñòâî  │Äåðìàòîë, Äåðìàòîëîâàÿ ìàçü                 

                                                                                         

│Âèñìóòà ñóáñàëèöèëàò - àíòèñåïòè÷åñêîå       │Áàðòåë äðàãç Áèçìàò, Äåñìîë, Íàø âûáîð -    

│êèøå÷íîå ñðåäñòâî                            │Ðîçîâûé âèñìóò                               

                                                                                         

│Âèñìóòà òðèêàëèÿ äèöèòðàò - ïðîòèâîÿçâåííîå  │Áèñíîë, Âåíòðèñîë, Äå-Íîë, Äå-Íîë ãðàíóëÿò, 

│ñðåäñòâî, ïðåïàðàò âèñìóòà                   │Ïèëîöèä, Òðèáèìîë, Òðèìî                    

                                                                                         

│Âèòàìèí Å - âèòàìèí                          │DL-àëüôà-Òîêîôåðîë, àëüôà-Òîêîôåðîëà àöåòàòà │

                                             │ðàñòâîð â ìàñëå (âèòàìèí Å), Áàðòåë äðàãç   

                                             │Âèòàìèí Å, Áèîâèòàëü âèòàìèí Å, Âèòàìèí Å,  

                                             │Âèòàìèí Å Ñëîâàêîôàðìà, Âèòàìèí Å-àöåòàò,   

                                             │Âèòðóì âèòàìèí Å, Äîïïåëüãåðö Âèòàìèí Å     

                                             │ôîðòå, Ðàñòâîð àëüôà-Òîêîôåðîëà àöåòàòà â   

                                             │ìàñëå 50% â êàïñóëàõ, Ñàíò-Å-Ãàë, Òîêîôåð,  

                                             │Òîêîôåðîëà àöåòàò, Ôîðâèòàëå, Ýâèîí, Ýâèòîë 

                                                                                         

│Âîäîðîäà ïåðåêèñü& - àíòèñåïòè÷åñêîå ñðåäñòâî│ÀÑ ìÿãêèé, Âîäîðîäà ïåðåêèñü Æèôðåð,        

                                             │Ïåðåêèñè âîäîðîäà ðàñòâîð, Ïåðåêèñè âîäîðîäà │

                                             │ðàñòâîð êîíöåíòðèðîâàííûé (Ïåðãèäðîëü),     

                                             │Ïåðåêèñè âîäîðîäà ðàñòâîð ñïèðòîâîé 1.5%,   

                                             │Ïåðîêñèìåä                                  

                                                                                          

│Ãàëàçîí - àíòèñåïòè÷åñêîå ñðåäñòâî           │Ïàíòîöèä, Ïàíòîöèäà òàáëåòêè 0.0082 ã       

│Ãàëàêòîçà - êîíòðàñòíîå ñðåäñòâî äëÿ ÓÇÈ     │Ëåâîâèñò, Ýõîâèñò-200                       

                                                                                          

│Ãàëàíòàìèí - àíòèõîëèíýñòåðàçíîå ñðåäñòâî    │Ãàëàíòàìèíà ãèäðîáðîìèä, Ãàëàíòàìèíà        

                                             │ãèäðîáðîìèäà ðàñòâîð äëÿ èíúåêöèé, Íèâàëèí  

                                                                                         

│Ãàëëîïàìèë - ÁÌÊÊ                            │Ïðîêîðóì, Ïðîêîðóì ðåòàðä                   

                                                                                         

│Ãàëîïåðèäîë - àíòèïñèõîòè÷åñêîå              │Àïî-Ãàëîïåðèäîë, Ãàëîïåð, Ãàëîïåðèäîë,      

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │Ãàëîïåðèäîë äåêàíîàò, Ãàëîïåðèäîë-Ðàòèîôàðì, │

                                             │Ñåíîðì, Òðàíêîäîë-5                          

                                                                                         

│Ãàëîòàí - íàðêîçíîå èíãàëÿöèîííîå ñðåäñòâî   │Íàðêîòàí, Ôëþîòàí, Ôòîðîòàí                 

                                                                                          

│Ãàììà-àìèíîìàñëÿíàÿ êèñëîòà - íîîòðîïíîå     │Àìèíàëîí, Àìèíàëîíà òàáëåòêè ïîêðûòûå       

│ñðåäñòâî                                     │îáîëî÷êîé 0.25 ã, Ãàììàëîí                  

                                                                                         

│Ãàíãëåôåí& - ãàíãëèîáëîêàòîð                 │Ãàíãëåðîí, Ãàíãëåðîí â êàïñóëàõ 0.04 ã,     

                                             │Ãàíãëåðîíà ðàñòâîð äëÿ èíúåêöèé 1.5%        

                                                                                         

│Ãâàéôåíåçèí - îòõàðêèâàþùåå ñðåäñòâî         │Âèê ñèðîï ýêñïåêòîðàíò ôîðìóëà 44 ïëþñ äëÿ  

                                             │âçðîñëûõ, Êîëäðåêñ áðîíõî, Òóññèí           

                                                                                         

│Ãåêñàìåòîíèÿ áåíçîñóëüôîíàò - ãàíãëèîáëîêàòîð│Áåíçîãåêñîíèé, Áåíçîãåêñîíèÿ ðàñòâîð äëÿ    

                                             │èíúåêöèé 2.5%, Áåíçîãåêñîíèÿ òàáëåòêè       

                                                                                         

│Ãåêñîïðåíàëèí - áåòà2-àäðåíîñòèìóëÿòîð       │Ãèíèïðàë, Èïðàäîë                           

│ñåëåêòèâíûé                                                                              

                                                                                         

│Ãåêñýñòðîë - ýñòðîãåí                        │Ñèíýñòðîë, Ñèíýñòðîëà ðàñòâîð 2% â îëèâêîâîì │

                                             │ìàñëå â àìïóëàõ, Ñèíýñòðîëà ðàñòâîð â ìàñëå 

                                             │0.1% â àìïóëàõ, Ñèíýñòðîëà ðàñòâîð â ìàñëå  

                                             │äëÿ èíúåêöèé 2%, Ñèíýñòðîëà òàáëåòêè 0.001 ã │

                                                                                         

│Ãåëèîìèöèí& - àíòèáèîòèê                     │Ãåëèîìèöèí, Ãåëèîìèöèíîâàÿ ìàçü 4%          

                                                                                         

│Ãåìèöåëëþëàçà+Æåë÷è êîìïîíåíòû+Ïàíêðåàòèí& - │Äèãåñòàë, Äèãåñòàë ôîðòå, Èïåíòàë, Ïàíêðàë, 

│ïèùåâàðèòåëüíîå ôåðìåíòíîå ñðåäñòâî          │Ïàíîëåç, Ïàíñòàë, Òàãåñòàë, Ôåñòàë, Ôîðòå   

                                             │Åíçèì, Ýíçèñòàë                             

                                                                                         

│Ãåìôèáðîçèë - ãèïîëèïèäåìè÷åñêîå ñðåäñòâî    │Ãåìôèáðîçèëà òàáëåòêè 0.3 ã, Èïîëèïèä,      

                                             │Ðåãóëèï                                     

                                                                                         

│Ãåíòàìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä       │Àìãåíò, Ãàðàìèöèí, Ãåíòàìèñèí, Ãåíòàìèöèí,  

                                             │Ãåíòàìèöèí Ëåðêåí, Ãåíòàìèöèí-Ê,            

                                             │Ãåíòàìèöèí-Ðàòèîôàðì, Ãåíòàìèöèí-Òåâà,      

                                             │Ãåíòàìèöèíà ñóëüôàò, Ãåíòàìèöèíà ñóëüôàò    

                                             │0.08 ã, Ãåíòàìèöèíà ñóëüôàòà ðàñòâîð 0.3%,  

                                             │Ãåíòàìèöèíà ñóëüôàòà ðàñòâîð äëÿ èíúåêöèé    

                                             │4%, Ãåíòàìèöèíîâàÿ ìàçü 0.1%, Ãåíòàöèêîë,   

                                             │Ãåíòèíà, Ãåíöèí                             

                                                                                          

│Ãåíòàìèöèí+Áåòàìåòàçîí& -                    │Áåëîãåíò, Áåòàãåíòàì, Âàëîäåðì-Ã, Ãàðàçîí,  

│ãëþêîêîðòèêîñòåðîèä+ïðîòèâîìèêðîáíîå ñðåäñòâî│Äèïðîãåíò, Êóòåðèä Ã, Öåëåñòîäåðì  ñ       

                                             │ãàðàìèöèíîì                                 

                                                                                         

│Ãåïàðèí êàëüöèé - àíòèêîàãóëÿíò ïðÿìîé       │Ãåïàðèáåíå êàëüöèé, Êàëüöèïàðèí             

                                                                                         

│Ãåïàðèí íàòðèé - àíòèêîàãóëÿíò ïðÿìîé        │Ãåïàðèáåíå íàòðèé, Ãåïàðèí, Ãåïàðèí Áèîõåìè, │

                                             │Ãåïàðèí Ëå÷èâà, Ãåïàðèí-íàòðèé Áðàóí 25000  

                                             │ÌÅ/5 ìë, Ãåïàðèíà íàòðèåâàÿ ñîëü, Ãåïàðèíà  

                                             │ðàñòâîð äëÿ èíúåêöèé, Ãåïàðèíà ðàñòâîð äëÿ  

                                             │èíúåêöèé 5000 ÅÄ/ìë, Ëèîòîí 1000, Íàòðèåâûé 

                                             │ãåïàðèí, Òðîìáîôîá, Òðîïàðèí                

                                                                                         

│Ãåïàðèíîèä& - àíòèêîàãóëÿíò ïðÿìîé äëÿ       │Ãåïàðîèä Ëå÷èâà, Ãèðóäîèä                   

│ìåñòíîãî ïðèìåíåíèÿ                                                                      

                                                                                         

│Ãèàëóðîíèäàçà& - ôåðìåíòíîå ñðåäñòâî         │Àêòèíîãèàë, Ðîíèäàçà                        

                                                                                         

│Ãèäðàçèíà ñóëüôàò& - ïðîòèâîîïóõîëåâîå       │Ñåãèäðèí (Ãèäðàçèíà ñóëüôàò), Ñåãèäðèíà     

│ñðåäñòâî                                     │òàáëåòêè ïîêðûòûå îáîëî÷êîé (ðàñòâîðèìûå â  

                                             │êèøå÷íèêå)                                  

                                                                                         

│Ãèäðàëàçèí - âàçîäèëàòèðóþùåå ñðåäñòâî       │Àïðåññèí, Àïðåññèíà äðàæå, Àïðåññèíà        

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé                 

                                                                                         

│Ãèäðîêîðòèçîí - ãëþêîêîðòèêîñòåðîèä          │Àêîðòèí, Áàðòåë äðàãç Ãèäðîêîðòèçîíîâàÿ 1%  

                                             │ìàçü, Ãèäðîêîðò, Ãèäðîêîðòèçîí,              

                                             │Ãèäðîêîðòèçîí Ëåðêåí, Ãèäðîêîðòèçîí Íèêîìåä, │

                                             │Ãèäðîêîðòèçîí Òåâà, Ãèäðîêîðòèçîí-Ïîñ N1%,  

                                             │Ãèäðîêîðòèçîí-Ïîñ N2.5%, Ãèäðîêîðòèçîíà     

                                             │àöåòàò, Ãèäðîêîðòèçîíà àöåòàòà ñóñïåíçèÿ äëÿ │

                                             │èíúåêöèé 2.5%, Ãèäðîêîðòèçîíà ãåìèñóêöèíàò, 

                                             │Ãèäðîêîðòèçîíà ãåìèñóêöèíàò                 

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé,             

                                             │Ãèäðîêîðòèçîíà íàòðèÿ ñóêöèíàò,             

                                             │Ãèäðîêîðòèçîíîâàÿ ìàçü 1%, Êîðòåéä, Êîðòåô, 

                                             │Ëàòèêîðò, Ëîêîèä, Ëîêîèä êðåëî, Ñîëó Êîðòåô, │

                                             │Ñîïîëüêîðò Í, Õàéòîí                         

                                                                                         

│Ãèäðîêîðòèçîí+Îêñèòåòðàöèêëèí& -             │Ãåîêîðòîí, Ãèîêñèçîí, Îêñèçîí, Îêñèêîðò     

│ãëþêîêîðòèêîñòåðîèä+ïðîòèâîìèêðîáíîå ñðåäñòâî│                                             

                                                                                         

│Ãèäðîêñèäèîí íàòðèÿ ñóêöèíàò - íàðêîçíîå     │Ïðåäèîí äëÿ èíúåêöèé 0.5 ã, Ïðåäèîí-êèñëîòà 

│íåèíãàëÿöèîííîå ñðåäñòâî                                                                 

                                                                                         

│Ãèäðîêñèçèí - àíêñèîëèòè÷åñêîå ñðåäñòâî      │Àòàðàêñ, Ãèäðîêñèçèí                        

│Ãèäðîêñèêàðáàìèä - ïðîòèâîîïóõîëåâîå ñðåäñòâî│Ãèäðåà, Ãèäðîêñèóðåà                        

                                                                                         

│Ãèäðîêñèìåòèëíèêîòèíàìèä - æåë÷åãîííîå       │Íèêîäèí, Íèêîäèíà òàáëåòêè 0.5 ã            

│ñðåäñòâî                                                                                 

                                                                                         

│Ãèäðîêñèïðîãåñòåðîí - ïðîãåñòàãåí            │Îêñèïðîãåñòåðîíà êàïðîíàò, Îêñèïðîãåñòåðîíà 

                                             │êàïðîíàòà ðàñòâîð â ìàñëå 12.5% â àìïóëàõ,  

                                             │Îêñèïðîãåñòåðîíà êàïðîíàòà ðàñòâîð äëÿ      

                                             │èíúåêöèé â ìàñëå, Îêñèïðîãåñòåðîíà êàïðîíàòà │

                                             │ðàñòâîð äëÿ èíúåêöèé â ìàñëå 25%            

                                                                                          

│Ãèäðîêñîêîáàëàìèí - âèòàìèí                  │Îêñèêîáàëàìèí, Îêñèêîáàëàìèíà ðàñòâîð äëÿ   

                                             │èíúåêöèé                                    

                                                                                          

│Ãèäðîòàëöèò - àíòàöèäíîå ñðåäñòâî            │Òàëüöèä, Òèñàöèä                            

                                                                                         

│Ãèäðîõëîðîòèàçèä - äèóðåòè÷åñêîå ñðåäñòâî    │Àïî-Ãèäðî, Ãèäðîõëîðòèàçèä, Ãèïîòèàçèä,     

                                             │Äèçàëóíèë, Äèõëîòèàçèä, Äèõëîòèàçèäà        

                                             │òàáëåòêè, Äèõëîòèàçèäà òàáëåòêè 0.025 ã     

                                                                                         

│Ãèäðîõëîðîòèàçèä+Àìèëîðèä& - äèóðåòè÷åñêîå   │Àìèëîçèä, Àìèëîðåòèê, Äèóðñàí, Äèóðñàí ìèòå, │

│êîìáèíèðîâàííîå ñðåäñòâî                     │Ìîäóðåòèê, Ýêîäóðåêñ                         

                                                                                         

│Ãèäðîõëîðîòèàçèä+Òðèàìòåðåí& - äèóðåòè÷åñêîå │Àïî-Òðèàçèä, Äèàçèä, Òðèàì-êî, Òðèàìïóð     

│êîìáèíèðîâàííîå ñðåäñòâî                     │êîìïîçèòóì, Òðèàìòåçèä                      

                                                                                         

│Ãèäðîõëîðîòèàçèä+Ýíàëàïðèë& - ãèïîòåíçèâíîå  │Êî-ðåíèòåê, Ýíàï-H, Ýíàï-HL                 

│êîìáèíèðîâàííîå ñðåäñòâî                                                                 

                                                                                         

│Ãèíêãî Áèëîáà& - àíãèîïðîòåêòîðíîå ñðåäñòâî  │Áèëîáèë, Ãèíêèî, Ãèíêîáà, Ãèíêîãèíê,         

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Ìåìîïëàíò, Ðåâàéòë Ãèíêî, Òàíàêàí           

                                                                                         

│Ãèîñöèàìèí - ì-õîëèíîáëîêàòîð                │Ãèîñöèàìèíà êàìôîðàò, Ãèîñöèàìèíà ñóëüôàò,  

                                             │Ãèîñöèàìèíà ñóëüôàòà òàáëåòêè 0.0001 ã      

                                                                                         

│Ãèîñöèíà áóòèëáðîìèä - ì-õîëèíîáëîêàòîð      │Áóñêîïàí, Ãèîñöèí-Í-áóòèëáðîìèä, Ñïàíèë     

                                                                                         

│Ãèïðîìåëëîçà - îôòàëüìîëîãè÷åñêîå ñðåäñòâî   │Äàêðîëþêñ, Ëàêðèñèí, Ëàêðèñèôè, Óâëàæíÿþùèå 

                                             │êàïëè                                       

                                                                                         

│Ãèñòàìèí - äèàãíîñòèêóì                      │Ãèñòàìèíà ãèäðîõëîðèä, Ãèñòàìèíà            

                                             │äèãèäðîõëîðèäà ðàñòâîð 0.1% â àìïóëàõ       

                                                                                         

│Ãèñòèäèí - ñðåäñòâî ïàðåíòåðàëüíîãî ïèòàíèÿ, │L-Ãèñòåãèí, L-Ãèñòèäèíà ãèäðîõëîðèä ãèäðàò, 

│àìèíîêèñëîòà                                 │L-Ãèñòèäèíà ìîíîãèäðîõëîðèä ìîíîãèäðàò,     

                                             │Ãèñòèäèíà ãèäðîõëîðèä, Ãèñòèäèíà            

                                             │ãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé 4%        

                                                                                         

│Ãëàóöèí - ïðîòèâîêàøëåâîå ñðåäñòâî           │Ãëàóâåíò, Ãëàóöèíà ãèäðîõëîðèä, Ãëàóöèíà    

                                             │ãèäðîõëîðèäà òàáëåòêè ïîêðûòûå îáîëî÷êîé    

                                             │0.05 ã                                      

                                                                                          

│Ãëèáåíêëàìèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ  │Àíòèáåò, Àïî-Ãëèáóðèä, Áåòàíàç, Ãåí-Ãëèá,   

│ïåðîðàëüíîãî ïðèåìà                          │Ãèëåìàë, Ãëàìèä, Ãëèáàìèä, Ãëèáåíêëàìèä,    

                                             │Ãëèáåíêëàìèä ÀÂÄ 5, Ãëèáåíêëàìèä Íèêîìåä,   

                                             │Ãëèáåíêëàìèä-Òåâà, Ãëèáåíêëàìèäà òàáëåòêè   

                                             │0.005 ã, Ãëèìèäñòàäà 1.75 ìåæäóíàðîäíûé,    

                                             │Ãëèìèäñòàäà 3.5 ìåæäóíàðîäíûé, Ãëèòèçîë,    

                                             │Ãëþêîáåíå, Ãëþêîìèä, Äàîíèë, Äèàá-êîíòðîëü, 

                                             │Äèàáåòà, Ìàíèíèë, Ìàíèíèë 5, Ýóãëþêîí        

                                                                                         

│Ãëèêëàçèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ     │Ãëèîðàë, Äèàáåñò, Äèàáåòîí, Äèàáðåçèä,      

│ïåðîðàëüíîãî ïðèåìà                          │Ìåäîêëàöèä, Ïðåäèàí                         

                                                                                         

│Ãëèïèçèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ      │Àíòèäèàá, Ãëèáåíåç, Ãëèáåíåç-ðåòàðä,        

│ïåðîðàëüíîãî ïðèåìà                          │Ãëþêîòðîë ÕË, Ìèíèäèàá                      

                                                                                         

│Ãëèöåðîë - ñëàáèòåëüíîå ñðåäñòâî             │Ãëèöåðèí, Ëàêñîëèí, Ñâå÷è ñ ãëèöåðèíîì,     

                                             │Ñóïïîçèòîðèè ñ ãëèöåðèíîì                   

                                                                                         

│Ãëóòàìèíîâàÿ êèñëîòà - íîîòðîïíîå ñðåäñòâî   │L-Ãëóòàìèíîâàÿ êèñëîòà, Ãëþòàìèíîâàÿ        

                                             │êèñëîòà, Ãëþòàìèíîâîé êèñëîòû ãðàíóëû äëÿ   

                                             │äåòåé, Ãëþòàìèíîâîé êèñëîòû òàáëåòêè        

                                             │(ðàñòâîðèìûå â êèøå÷íèêå), Ãëþòàìèíîâîé     

                                             │êèñëîòû òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.25 ã, 

                                             │Êàëüöèÿ ãëþòàìèíàò                          

                                                                                         

│Ãëóòàðàë - äåçèíôèöèðóþùåå è ñòåðèëèçóþùåå   │Ãëóòàðàë-Í, Ñòåðàíèîñ 20% êîíöåíòðèðîâàííûé, │

│ñðåäñòâî                                     │Ýðèãèä ôîðòå                                 

                                                                                         

│Ãëþêàãîí - èíñóëèíà àíòàãîíèñò               │ÃëþêàÃåí 1 ìã ÃèïîÊèò, Ãëþêàãîí             

                                                                                          

│Ãîìàòðîïèí ãèäðîáðîìèä - ì-õîëèíîáëîêàòîð    │Ãîìàòðîïèíà ãèäðîáðîìèä, Ãîìàòðîïèíà        

                                             │ãèäðîáðîìèäà ðàñòâîð 0.25% ñ ìåòèëöåëëþëîçîé │

                                                                                         

│Ãîïàíòåíîâàÿ êèñëîòà - íîîòðîïíîå ñðåäñòâî   │Ïàíòîãàì, Ïàíòîãàìà òàáëåòêè                

                                                                                         

│Ãðàìèöèäèí - àíòèáèîòèê                      │Ãðàìèöèäèí Ñ, Ãðàìèöèäèíà Ñ òàáëåòêè        

                                             │çàùå÷íûå 1.5 ìã (1500 ÅÄ), Ãðàìèöèäèíîâàÿ   

                                             │ïàñòà                                        

                                                                                         

│Ãðèçåîôóëüâèí - ïðîòèâîãðèáêîâîå ñðåäñòâî    │Ãðèçåîôóëüâèí-ôîðòå, Ãðèçåîôóëüâèíà ëèíèìåíò │

                                             │2.5%, Ãðèçåîôóëüâèíà ñóñïåíçèÿ,             

                                             │Ãðèçåîôóëüâèíà òàáëåòêè ïî 0.125 ã, Ôóëüöèí 

                                                                                         

│Ãóàíåòèäèí - ñèìïàòîëèòè÷åñêîå ñðåäñòâî      │Îêòàäèí, Îêòàäèíà òàáëåòêè 0.025 ã          

│Äàêàðáàçèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Äàêàðáàçèí Ëàõåìà, Äåòèöåí                  

│Äàêòèíîìèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî    │Äàêòèíîìèöèíà ðàñòâîð äëÿ èíúåêöèé, Êîñìåãåí │

│Äàíàçîë - ïðîòèâîãîíàäîòðîïíîå ñðåäñòâî      │Äàíîâàë, Äàíîãåí, Äàíîäèîë, Äàíîë           

│Äàïñîí - ïðîòèâîëåïðîçíîå ñðåäñòâî           │Äèàôåíèëñóëüôîí, Äèàôåíèëñóëüôîíà òàáëåòêè  

│Äàóíîðóáèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî    │Äàóíîçîì, Ðóáîìèöèíà ãèäðîõëîðèä, Öåðóáèäèí 

                                                                                         

│Äåçîêñèêîðòîí - ìèíåðàëîêîðòèêîñòåðîèä       │Äåçîêñèêîðòèêîñòåðîí òðèìåòèëàöåòàò,        

                                             │Äåçîêñèêîðòèêîñòåðîíà àöåòàò,               

                                             │Äåçîêñèêîðòèêîñòåðîíà àöåòàòà ðàñòâîð äëÿ   

                                             │èíúåêöèé â ìàñëå 0., Äåçîêñèêîðòèêîñòåðîíà  

                                             │àöåòàòà òàáëåòêè 0.05 ã,                    

                                             │Äåçîêñèêîðòèêîñòåðîíà òðèìåòèëàöåòàòà       

                                             │ñóñïåíçèÿ äëÿ èíúåêöèé                       

                                                                                         

│Äåçîêñèïåãàíèíà ãèäðîõëîðèä& -               │Äåçîêñèïåãàíèíà ãèäðîõëîðèä, Äåçîêñèïåãàíèíà │

│àíòèõîëèíýñòåðàçíîå ñðåäñòâî                 │ãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé 1%,       

                                             │Äåçîêñèïåãàíèíà ãèäðîõëîðèäà òàáëåòêè       

                                                                                         

│Äåçîêñèðèáîíóêëåèíîâàÿ êèñëîòà& -            │Äåðèíàòà ðàñòâîð 0.25%, Äåðèíàòà ðàñòâîð    

│ðåãåíåðàöèè ñòèìóëÿòîð                       │0.6% â ðàñòâîðå íàòðèÿ õëîðèäà 0.1%         

                                                                                         

│Äåêàìåòîêñèí& - àíòèñåïòè÷åñêîå ñðåäñòâî     │Äåêàìåòîêñèí, Äåêàìåòîêñèíà ðàñòâîð 0.02%   

                                             │(ãëàçíûå êàïëè), Äåêàìåòîêñèíà ðàñòâîð      

                                             │ñïèðòîâîé 0.05%, Äåêàìåòîêñèíà òàáëåòêè 0.1 ã│

                                                                                         

│Äåêâàëèíèÿ õëîðèä - ïðîòèâîãðèáêîâîå ñðåäñòâî│Äåêàìèí, Äåêàìèíà êàðàìåëü 0.00015 ã,       

                                             │Äåêàìèíîâàÿ ìàçü                            

                                                                                         

│Äåêñàìåòàçîí - ãëþêîêîðòèêîñòåðîèä           │Äàêñèí, Äåêàäðîí, Äåêäàí, Äåêñà-Àëëâîðàí,   

                                             │Äåêñàáåíå, Äåêñàâåí, Äåêñàçîí, Äåêñàêîðò,   

                                             │Äåêñàìåä, Äåêñàìåòàçîí, Äåêñàìåòàçîí        

                                             │Õàôñëóíä Íèêîìåä, Äåêñàìåòàçîí ôîñôàò,      

                                             │Äåêñàìåòàçîíà íàòðèÿ ôîñôàò, Äåêñàìåòàçîíà  

                                             │òàáëåòêè 0.0005 ã, Äåêñàïîñ, Äåêñàôàð,      

                                             │Äåêñîíà, Äåòàçîí, Ìàêñèäåêñ, Îôòàí          

                                             │Äåêñàìåòàçîí, Ñîíäåêñ, Ñóïåðòåíäèí 2000 Í,  

                                             │Ôîðòåêîðòèí, Ôîðòåêîðòèí ìîíî               

                                                                                         

│Äåêñïàíòåíîë - ðåãåíåðàöèè ñòèìóëÿòîð        │Áåïàíòåí, Êîðíåðåãåëü, Ïàíòåíîë, Ïàíòåíîë   

                                             │100 ìã Éåíàôàðì, Ïàíòåíîë 500 ìã Éåíàôàðì,  

                                             │Ïàíòåíîëîâàÿ ìàçü                           

                                                                                         

│Äåêñòðàí                                     │ìîë. ìàññà îêîëî 35000 - ïëàçìîçàìåùàþùåå   

                                             │ñðåäñòâî                                    

                                                                                         

│Äåêñòðàí                                     │ìîë. ìàññà îêîëî 60000 - ïëàçìîçàìåùàþùåå   

                                             │ñðåäñòâî                                    

                                                                                         

│Äåêñòðàí                                     │ìîë. ìàññà îêîëî 70000 - ïëàçìîçàìåùàþùåå   

                                             │ñðåäñòâî                                    

                                                                                         

│Äåêñòðîçà - ñðåäñòâî óãëåâîäíîãî ïèòàíèÿ     │Ãëþêîçà, Ãëþêîçà 10%, Ãëþêîçà 5%, Ãëþêîçà   

                                             │àíãèäðèäíàÿ, Ãëþêîçà äëÿ âíóòðèâåííîãî      

                                             │âëèâàíèÿ 50 ã/ë, Ãëþêîçû ðàñòâîð äëÿ        

                                             │èíôóçèé, Ãëþêîçû ðàñòâîð äëÿ èíúåêöèé,      

                                             │Ãëþêîçû ðàñòâîð äëÿ èíúåêöèé 10%, Ãëþêîçû   

                                             │ðàñòâîð äëÿ èíúåêöèé 40%, Ãëþêîçû ðàñòâîð   

                                             │äëÿ èíúåêöèé 5%, Ãëþêîçû ðàñòâîð äëÿ        

                                             │èíúåêöèé 5% (âî ôëàêîíàõ), Ãëþêîçû ðàñòâîð  

                                             │äëÿ èíúåêöèé âî ôëàêîíàõ, Ãëþêîçû òàáëåòêè, 

                                             │Ãëþêîñòåðèë 10%, Ãëþêîñòåðèë 20%, Äåêñàêâà, 

                                             │Äåêñîðèä, Äåêñòðîçà, Äåêñòðîçà 10%,          

                                             │Äåêñòðîçà 20%, Äåêñòðîçà 5%, Äåêñòðîçà 5% ñ 

                                             │0.9% íàòðèÿ õëîðèäà, Ëèáîòò, Ëèêàäåêñ ÏÔ,   

                                             │Ðàñòâîð Ãëþêîçû, Ðàñòâîð Ãëþêîçû 10%,       

                                             │Ðàñòâîð ãëþêîçû 5% äëÿ èíúåêöèé             

                                                                                         

│Äåëüòàìåòðèí& - èíñåêòèöèäíîå ñðåäñòâî       │Äåëüòàöèä, Ê-îòðèí 2.5% Ôëîó, Îðàäåëüò,     

                                             │Óíèöèä                                      

                                                                                         

│Äåìåêîëöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Êîëõàìèí, Êîëõàìèíà òàáëåòêè 0.002 ã        

│Äåñìîïðåññèí - àíòèäèóðåòè÷åñêîå ñðåäñòâî    │Àäèóðåòèí ÑÄ, Àäèóðåòèí-ÑÄ                  

                                                                                          

│Äèàçåïàì - àíêñèîëèòè÷åñêîå ñðåäñòâî         │Àïàóðèí, Àïî-Äèàçåïàì, Âàëèóì Ðîø,          

                                             │Äèàçåïàáåíå, Äèàçåïàì Äåñèòèí ðåêòàëüíûé    

                                             │òþáèê 10 ìã, Äèàçåïàì Äåñèòèí ðåêòàëüíûé    

                                             │òþáèê 5 ìã, Äèàçåïàì Íèêîìåä,               

                                             │Äèàçåïàì-Ðàòèîôàðì, Äèàçåïàì-Òåâà, Äèàçåïàì, │

                                             │Äèàçåïåêñ, Äèàïàì, Äèçåï-5, Äèêàì, Êàëìïîóç, │

                                             │Íîâî-Äèïàì, Ðåëàíèóì, Ñåäóêñåí, Ñèáàçîí,    

                                             │Ñèáàçîíà ðàñòâîð äëÿ èíúåêöèé 0.5%, Ñèáàçîíà │

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé äëÿ äåòåé,      

                                             │Ñèáàçîíà òàáëåòêè, Ôàóñòàí 5, Ôàóñòàí       

                                                                                          

│Äèáðîñïèäèÿ õëîðèä - ïðîòèâîîïóõîëåâîå       │Ñïèðîáðîìèí, Ñïèðîáðîìèí ëèîôèëèçèðîâàííûé  

│ñðåäñòâî                                     │äëÿ èíúåêöèé 0.1 ã                          

                                                                                         

│Äèãèäðîêâåðöåòèí& - âèòàìèí                  │Äèãèäðîêâåðöåòèí, Äèêâåðòèí, Äèêâåðòèíà     

                                             │òàáëåòêè 0.02 ã                             

                                                                                         

│Äèãèäðîòàõèñòåðîë - ðåãóëÿòîð îáìåíà êàëüöèÿ │À.Ò.10, Äèãèäðîòàõèñòåðîë,                  

│è ôîñôîðà                                    │Äèãèäðîòàõèñòåðîëà ðàñòâîð â ìàñëå 0.1%,    

                                             │Òàõèñòèí                                    

                                                                                         

│Äèãèäðîýðãîòàìèí - àëüôà-àäðåíîáëîêàòîð      │ÄÃ-Ýðãîòàìèí, Äèòàìèí                       

                                                                                         

│Äèãèäðîýðãîòîêñèí& - àëüôà-àäðåíîáëîêàòîð    │ÄÃ-Ýðãîòîêñèí, Ðåäåðãèí, Ðåäåðãèíà òàáëåòêè 

                                             │0.0015 ã                                    

                                                                                         

│Äèãèòîêñèí - êàðäèîòîíè÷åñêîå ñðåäñòâî,      │Äèãèòîêñèíà ñâå÷è 0.00015 ã, Äèãèòîêñèíà    

│ñåðäå÷íûé ãëèêîçèä                           │òàáëåòêè 0.0001 ã                           

                                                                                         

│Äèãîêñèí - êàðäèîòîíè÷åñêîå ñðåäñòâî,        │Äèãîêñèí Íèêîìåä, Äèãîêñèí-Òåâà, Äèãîêñèíà  

│ñåðäå÷íûé ãëèêîçèä                           │ðàñòâîð äëÿ èíúåêöèé 0.025%, Äèãîêñèíà      

                                             │òàáëåòêè 0.00025 ã, Äèãîêñèíà òàáëåòêè äëÿ  

                                             │äåòåé 0.0001 ã, Äèëàêîð, Äèëàíàöèí, Ëàíèêîð, │

                                             │Ëàíîêñèí                                    

                                                                                         

│Äèçîïèðàìèä - àíòèàðèòìè÷åñêîå ñðåäñòâî      │Ðèòìèëåí, Ðèòìîäàí                          

                                                                                         

│Äèèçîïðîïèëàìèí - âàçîäèëàòèðóþùåå ñðåäñòâî  │Äèïðîìîíèé, Äèïðîìîíèé äëÿ èíúåêöèé 0.05 ã,  

                                             │Äèïðîìîíèÿ òàáëåòêè 0.02 ã                  

                                                                                         

│Äèêàðáèí& - àíòèïñèõîòè÷åñêîå                │Êàðáèäèí, Êàðáèäèíà ðàñòâîð äëÿ èíúåêöèé    

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │1.25%, Êàðáèäèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé │

                                             │0.025 ã                                     

                                                                                         

│Äèêëîôåíàê - ÍÏÂÑ                            │Àëëîâîðàí, Àëìèðàë, Àïî-Äèêëî, Àðòðåêñ,     

                                             │Áåòàðåí, Áèîðàí, Áèîðàí ðàïèä, Âåðàë,       

                                             │Âåðíàê, Âîëüòàðåí, Âîëüòàðåí ðàïèä,         

                                             │Âîëüòàðåí Ýìóëüãåëü, Âîòðåêñ, Äèãíîôåíàê    

                                             │100, Äèãíîôåíàê 50, Äèêëî, Äèêëî-Ô,         

                                             │Äèêëîáåíå, Äèêëîáåðë 100, Äèêëîáåðë 25,     

                                             │Äèêëîáåðë 50, Äèêëîáåðë 75, Äèêëîáåðë       

                                             │ðåòàðä, Äèêëîâèò, Äèêëîãåí, Äèêëîæåñèê,     

                                             │Äèêëîìàêñ, Äèêëîìåëàí, Äèêëîíàê, Äèêëîíàò Ï, │

                                             │Äèêëîíàò Ï ðåòàðä 100, Äèêëîðàí, Äèêëîðèóì, 

                                             │Äèêëîôåí, Äèêëîôåí êðåìîãåëü, Äèêëîôåíàê,   

                                             │Äèêëîôåíàê (Áèêëîïàí), Äèêëîôåíàê íàòðèÿ,   

                                             │Äèêëîôåíàê ðåòàðä, Äèêëîôåíàê-Àêðè ìàçü,    

                                             │Äèêëîôåíàê-íàòðèé, Äèêëîôåíàê-Ðàòèîôàðì,    

                                             │Äèêëîôåíàê-Ðèâî, Äèêëîôåíàê-Ðèâîôàðì,       

                                             │Äèêëîôåíàê-Òåâà, Äèôåí, Äèôèçàë, Äèôèçàë-ÑÐ, │

                                             │Êëîôåíàê, Êñåíèä, Íàêëîô, Íàêëîôåí, Íàêëîôåí │

                                             │Äóî, Íàòðèÿ äèêëîôåíàê 25 ìã, Íåîäîë-50,    

                                             │Íîâî-Äèôåíàê, Îëôåí, Îðòîôåí, Îðòîôåíà ìàçü 

                                             │2%, Îðòîôåíà ðàñòâîð äëÿ èíúåêöèé 2.5%,     

                                             │Îðòîôåíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.025  

                                             │ã, Îðòîôåíà òàáëåòêè ïîêðûòûå îáîëî÷êîé äëÿ 

                                             │äåòåé 0.015 ã, Ïàíàìîð ÀÒ-50, Ðåâìàâåê,     

                                             │Ðåâîäèíà 100, Ðåâîäèíà 25, Ðåâîäèíà 50,      

                                             │Ðåâîäèíà 75 ÑÔ, Ðåâîäèíà ðåòàðä, Ðåìåòàí,   

                                             │Ðóìàôåí ÑÐ, Ñàíôèíàê, Ñêèï, Óëüòðàôåí,      

                                             │Óìåðàí, Ôåëîðàí, Ôåëîðàí 25, Ôåëîðàí ðåòàðä, │

                                             │Ôîðãåíàê, Ýêîôåíàê, Ýòèôåíàê                

                                                                                         

│Äèëòèàçåì - ÁÌÊÊ                             │Àëäèçåì, Àëòèàçåì ÐÐ, Àíãèçåì, Àïî-Äèëòèàç, 

                                             │Áëîêàëüöèí 60, Áëîêàëüöèí 90 ðåòàðä,        

                                             │Ãåðáåññåð, Äèàçåì, Äèàêîðäèí, Äèëàêîð XR,   

                                             │Äèëåé Òèàçèì ÑÐ, Äèëæèíà, Äèëçåì, Äèëêàðäèÿ, │

                                             │Äèëêàðäèÿ-ðåòàðä, Äèëòèàçåì, Äèëòèàçåì      

                                             │Ëàííàõåð, Äèëòèàçåì Ãåêñàë ðåòàðä, Äèëòèàçåì │

                                             │Íèêîìåä, Äèëòèàçåì-Ðàòèîôàðì,               

                                             │Äèëòèàçåì-Òåâà, Äèëòèàçåìà ãèäðîõëîðèä,     

                                             │Äèëòèçåì ÑÐ, Äèëüðåí, Äèëüöåì, Çèëüäåí,     

                                             │Êàðäèë, Êîðòèàçåì, Ýòèçåì                   

                                                                                         

│Äèìåáîí& - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ        │Äèìåáîí, Äèìåáîíà òàáëåòêè 0.01 ã, Äèìåáîíà 

│áëîêàòîð                                     │òàáëåòêè äëÿ äåòåé 0.0025 ã                 

                                                                                         

│Äèìåäðîõèí& - í-õîëèíîáëîêàòîð               │Äèìåäðîõèí, Äèìåäðîõèíà ðàñòâîð äëÿ èíúåêöèé │

                                             │1%, Äèìåäðîõèíà òàáëåòêè 0.02 ã             

                                                                                          

│Äèìåêîëèíèÿ èîäèä& - ãàíãëèîáëîêàòîð         │Äèìåêîëèí, Äèìåêîëèíà òàáëåòêè ïîêðûòûå     

                                             │îáîëî÷êîé                                   

                                                                                         

│Äèìåíîêñàäîë& - ïðîòèâîêàøëåâîå ñðåäñòâî     │Ýñòîöèí, Ýñòîöèíà òàáëåòêè                  

│Äèìåòèêîí - âåòðîãîííîå ñðåäñòâî             │Ïîëèñèëàí ãåëü, Öåîëàò                      

                                                                                         

│Äèìåòèêîí â êîìáèíàöèè ñ äâóîêèñüþ êðåìíèÿ&  │Ãàñêîí Äðîï, Äèñôëàòèë, Ñàá ñèìïëåêñ,       

│- âåòðîãîííîå ñðåäñòâî                       │Ñèìèêîë, Ýñïóìèçàí                           

                                                                                         

│Äèìåòèëôòàëàò - ðåïåëëåíòíîå ñðåäñòâî        │Áåëçàìèä, Êàìàðàíò, Êåäð, Ôòàëàð            

                                                                                          

│Äèìåòèíäåí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ      │Ôåíèñòèë, Ôåíèñòèë 24                       

│áëîêàòîð                                                                                 

                                                                                         

│Äèìåòïðàìèä& - ïðîòèâîðâîòíîå ñðåäñòâî,      │Äèìåòïðàìèä, Äèìåòïðàìèäà ðàñòâîð äëÿ       

│äîôàìèí áëîêàòîð öåíòðàëüíûé                 │èíúåêöèé 2%, Äèìåòïðàìèäà òàáëåòêè 0.02 ã   

                                                                                         

│Äèìåôîñôîí& - àíòèàöèäåìè÷åñêîå ñðåäñòâî     │Äèìåôîñôîí, Äèìåôîñôîí äëÿ èíúåêöèé 1 ã,    

                                             │Äèìåôîñôîíà ðàñòâîð 15%                      

                                                                                         

│Äèíîïðîñò - ðîäîâîé äåÿòåëüíîñòè ñòèìóëÿòîð  │Ïðîñòèí F2-àëüôà, Ýíçàïðîñò Ô               

                                                                                         

│Äèíîïðîñòîí - ðîäîâîé äåÿòåëüíîñòè ñòèìóëÿòîð│Ïðåïèäèë ãåëü, Ïðîñòåíîí, Ïðîñòåíîí-ãåëü,   

                                             │Ïðîñòåíîíà ðàñòâîð äëÿ èíôóçèé ñïèðòîâîé    

                                             │êîíöåíòðèðîâàííûé, Ïðîñòèí Å2               

                                                                                         

│Äèîêñèäèí& - ïðîòèâîìèêðîáíîå ñðåäñòâî,      │Äèîêñèäèí, Äèîêñèäèíà ìàçü 5%, Äèîêñèäèíà    

│õèíîêñàëèí                                   │ðàñòâîð äëÿ èíúåêöèé 0.5%, Äèîêñèäèíà       

                                             │ðàñòâîð äëÿ èíúåêöèé 1%                     

                                                                                          

│Äèïèâåôðèí - ïðîòèâîãëàóêîìíîå ñðåäñòâî      │Ä-ýïèôðèí, Îôòàí äèïèâåôðèí                 

                                                                                         

│Äèïèðèäàìîë - âàçîäèëàòèðóþùåå ñðåäñòâî      │Àïî-Äèïèðèäàìîë, Äèïèðèäàìîë, Êóðàíòèë,     

                                             │Êóðàíòèë N25 (Äèïèðèäàìîë), Êóðàíòèë N75    

                                             │(Äèïèðèäàìîë), Ïàðñåäèë, Ïåðñàíòèí, Òðîìáîíèë│

                                                                                         

│Äèïðîôèëëèí - áðîíõîäèëàòèðóþùåå ñðåäñòâî    │Äèïðîôèëëèíà ðàñòâîð 10% â àìïóëàõ,         

                                             │Äèïðîôèëëèíà òàáëåòêè 0.2 ã, Ñóïïîçèòîðèè ñ 

                                             │äèïðîôèëëèíîì 0.5 ã                         

                                                                                         

│Äèñóëüôèðàì - ñðåäñòâî ëå÷åíèÿ àëêîãîëèçìà   │Ëèäåâèí, Ðàäîòåðà òàáëåòêè 0.1 ã, Òåòóðàì   

                                             │(Àíòàáóñ), Òåòóðàìà òàáëåòêè, Ýñïåðàëü      

                                                                                         

│Äèôåíàöèí& - ðîäåíòèöèäíîå ñðåäñòâî          │Äèôà, Çåðàöèä, Ðàòèíäàí, Ðàòèíäàí-0.5,      

                                             │Ðàòèíäàí-1, Ðàòèíäàí-2                      

                                                                                         

│Äèôåíãèäðàìèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ   │Àëëåðãèí, Äèìåäðîë, Äèìåäðîë 1% äëÿ         

│áëîêàòîð                                     │èíúåêöèé, Äèìåäðîëà ðàñòâîð äëÿ èíúåêöèé 1%, │

                                             │Äèìåäðîëà ðàñòâîð äëÿ èíúåêöèé 1% â         

                                             │øïðèö-òþáèêàõ, Äèìåäðîëà òàáëåòêè, Äèìåäðîëà │

                                             │òàáëåòêè 0.05 ã, Äèìåäðîëà òàáëåòêè 0.1 ã,  

                                             │Äèìåäðîëà òàáëåòêè äëÿ äåòåé 0.02 ã, Ïàëî÷êè │

                                             │ñ äèìåäðîëîì, Ñâå÷è ñ äèìåäðîëîì äëÿ äåòåé  

                                                                                         

│Äèôåíèëòðîïèí& - ïðîòèâîïàðêèíñîíè÷åñêîå     │Òðîïàöèí, Òðîïàöèíà òàáëåòêè                

│ñðåäñòâî                                                                                 

                                                                                          

│Äèýòàçèí - í-õîëèíîáëîêàòîð öåíòðàëüíûé      │Äèíåçèí, Äèíåçèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé│

                                                                                         

│Äèýòèëêàðáàìàçèí - ïðîòèâîãåëüìèíòíîå        │Äèòðàçèí, Äèòðàçèíà ôîñôàò, Äèòðàçèíà       

│ñðåäñòâî                                     │öèòðàòà òàáëåòêè                            

                                                                                         

│Äèýòèëñòèëüáýñòðîë - ýñòðîãåí                │Äèìýñòðîë, Äèìýñòðîëà ðàñòâîð â ìàñëå â     

                                             │àìïóëàõ 0.6%, Äèýòèëñòèëüáýñòðîë,           

                                             │Äèýòèëñòèëüáýñòðîëà òàáëåòêè 0.025 ã        

                                                                                         

│Äèýòèëòîëóàìèä - ðåïåëëåíòíîå ñðåäñòâî       │Àíòèêîìàð, Àðíåò, Àðîäýò, Àóòàí,            

                                             │Àóòàí-àýðîçîëü, Àóòàí-êàðàíäàø,             

                                             │Àóòàí-ëîñüîí, Áàðòåë Äðàãç Èíñåêò Ðåïåëëåíò, │

                                             │Áåíãàë, Áèáàí, Âàïå Ïèê Ñòîï Àíòèáàéò,      

                                             │Ãàë-ðýò, Äàéíàê-Ôóìèòîêñ, Äåôèçîëü,         

                                             │Äåôèçîëü-2, Äèïòåðîë ðåïåëëåíò, Äèïòåðîë    

                                             │ðåïåëëåíò ñïðåé, Äèïòåðîë ðåïåëëåíò ñòèê,   

                                             │Äèïòåðîë Ñåíñèòèâ-êàðàíäàø, Äèò-Ïëþñ è Àôòà 

                                             │Áàéò, ÄÝÒÀ ýìóëüñèÿ, ÄÝÒÀ-Í, ÄÝÒÀ-ðåïåëëåíò, │

                                             │Äýòàôòàë, Äýòàôòàë ýìóëüñèÿ, Äýôè, Çóêó,     

                                             │Êîìàðýêñ, Êîìàðýêñ-Èíòåíñèâ, Êðà-Ðåï, Îôô!, 

                                             │Îôô! Ñóïåð ñïðåé, Ðàïòîð-ðåïåëëåíò,         

                                             │Ðàïòîð-ñîôò ïðîòåêò, Ðåôòàìèä ïëþñ, Òàåæíûé, │

                                             │Òàåæíûé-Ë, Óëüòðàòîí, Ôóìèòîêñ-Äàéíàê,      

                                             │Ýêñïåëü                                     

                                                                                         

│Äîáóòàìèí - áåòà-àäðåíîñòèìóëÿòîð            │Äîáóòàìèí Ãåêñàë, Äîáóòàìèí Ãèóëèíè,        

                                             │Äîáóòàìèí Íèêîìåä, Äîáóòðåêñ                

                                                                                         

│Äîêñàçîçèí - àëüôà-àäðåíîáëîêàòîð            │Êàðäóðà, Òîíîêàðäèí                         

                                                                                          

│Äîêñèöèêëèí - àíòèáèîòèê, òåòðàöèêëèí        │Àïî-Äîêñè, Áàññàäî, Âèáðàìèöèí, Äîâèöèí,    

                                             │Äîêñàë, Äîêñèáåíå, Äîêñèáåíå Ì, Äîêñèäàð    

                                             │100, Äîêñèëàí, Äîêñèöèêëèí, Äîêñèöèêëèí 100 

                                             │Ñòàäà ìåæäóíàðîäíûé òàá, Äîêñèöèêëèí 200    

                                             │Ñòàäà ìåæäóíàðîäíûé òàá, Äîêñèöèêëèí        

                                             │Íèêîìåä, Äîêñèöèêëèí-Ðèâî, Äîêñèöèêëèíà     

                                             │ãèäðîõëîðèä, Äîêñèöèêëèíà ãèäðîõëîðèä 0.1 ã, │

                                             │Äîêñèöèêëèíà ãèäðîõëîðèä 0.1 ã â êàïñóëàõ,  

                                             │Äîêñèöèêëèíà ãèäðîõëîðèä â êàïñóëàõ,        

                                             │Äîêñèöèêëèíà ãèäðîõëîðèäà òàáëåòêè ïîêðûòûå 

                                             │îáîëî÷êîé 0.1 ã, Äîêñèöèêëèíà ãèêëàò,       

                                             │Äîêñèöèêëèíà õèêëàò, Äîêñò, Ìåäîìèöèí,      

                                             │Ìîíîêëèí, Íîâî-Äîêñèëèí, Òåòðàäîêñ,         

                                             │Ýòèäîêñèí, Þíèäîêñ ñîëþòàá                  

                                                                                         

│Äîêñîðóáèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî    │Àäðèàìèöèí, Àäðèáëàñòèí áûñòðîðàñòâîðèìûé,  

                                             │Àêñèäîêñî, Áëàñòîöèí, Äîêñîëåì,             

                                             │Äîêñîðóáèöèí, Äîêñîðóáèöèí-Òåâà,            

                                             │Äîêñîðóáèöèí-Ýáåâå, Äîêñîðóáèöèíà            

                                             │ãèäðîõëîðèä, Äîêñîðóáèöèíà ãèäðîõëîðèä äëÿ  

                                             │èíúåêöèé 0.01 ã, Ðàñòîöèí                   

                                                                                          

│Äîìïåðèäîí - ïðîòèâîðâîòíîå ñðåäñòâî,        │Äîìïåðîí, Ìîòèëèóì                          

│äîôàìèí áëîêàòîð öåíòðàëüíûé                                                             

                                                                                         

│Äîïàìèí - êàðäèîòîíè÷åñêîå ñðåäñòâî,         │Äîïàìèí ÀÂÄ, Äîïàìèí Äæóëèíè 50, Äîïàìèíà   

│äîôàìèí-ñòèìóëÿòîð                           │ãèäðîõëîðèä, Äîïìèí, Äîôàìèí, Äîôàìèíà      

                                             │ðàñòâîð äëÿ èíúåêöèé                        

                                                                                         

│Äðîñòàíîëîí - àíòèàíäðîãåí                   │Ìåäðîòåñòðîíà-ïðîïèîíàòà ðàñòâîð â ìàñëå 5% 

                                             │â àìïóëàõ, Ìåòèëäèãèäðîòåñòîñòåðîíà ïðîïèîíàò│

                                                                                         

│Äðîòàâåðèí - ñïàçìîëèòè÷åñêîå ñðåäñòâî       │Äðîâåðèíà ðàñòâîð äëÿ èíúåêöèé 2%,          

                                             │Äðîòàâåðèíà ãèäðîõëîðèä, Äðîòàâåðèíà        

                                             │ãèäðîõëîðèä òàáëåòêè 0.04 ã, Íî-øïà         

                                                                                         

│Æåëåçà ãëþêîíàò - ãåìîïîýçà ñòèìóëÿòîð,      │Àïî-Ôåððîãëþêîíàò, Æåëåçà ãëþêîíàò 300,     

│ïðåïàðàò æåëåçà                              │Ôåððëåöèò, Ôåððîíàë                         

                                                                                         

│Æåëåçà ëàêòàò& - ãåìîïîýçà ñòèìóëÿòîð,       │Æåëåçà çàêèñíîãî ëàêòàò, Æåëåçà ëàêòàò      

│ïðåïàðàò æåëåçà                                                                           

                                                                                         

│Æåëåçà ïîëèèçîìàëüòîçàò& - ãåìîïîýçà         │Ìàëüòîôåð, Ôåððóì Ëåê                       

│ñòèìóëÿòîð, ïðåïàðàò æåëåçà                                                              

                                                                                         

│Æåëåçà ñóëüôàò - ãåìîïîýçà ñòèìóëÿòîð,       │Ãåìîôåð ïðîëîíãàòóì, Æåëåçà çàêèñíîãî       

│ïðåïàðàò æåëåçà                              │ñóëüôàò, ïìñ-Æåëåçà ñóëüôàò, Ôåððî-ãðàäóìåò, │

                                             │Ôåððîãðàäóìåò (Ôåððîãðàä)                   

                                                                                          

│Æåëåçà ôóìàðàò - ãåìîïîýçà ñòèìóëÿòîð,       │Æåëåçà ôóìàðàò 200, Ôåððîíàò, Õåôåðîë       

│ïðåïàðàò æåëåçà                                                                          

                                                                                          

│Æåíü-øåíü& - àäàïòîãåííîå ñðåäñòâî           │Áèîæåíüøåíü, Ãèíñàíà, Ãèíñàíà òîíèê, Ãèíñàíà │

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │òîíèê áåç àëêîãîëÿ, Æåíü-øåíü,              

                                             │Æåíüøåíü-ìàòî÷íîå ìîëî÷êî, Æåíüøåíÿ áèîìàññà │

                                             │ñóõàÿ, Æåíüøåíÿ íàñòîéêà, Íàñòîéêà æåíüøåíÿ, │

                                             │Ïàíàêñåë                                    

                                                                                         

│Çèäîâóäèí - ïðîòèâîâèðóñíîå ñðåäñòâî         │Àçèäîòèìèäèí (Òèìàçèä), Àçèäîòèìèäèí        

                                             │(Òèìàçèä) â êàïñóëàõ 0.1 ã, Ðåòðîâèð,       

                                             │Ðåòðîâèð ÀÇèÒè                              

                                                                                         

│Çîëïèäåìà òàðòðàò - ñíîòâîðíîå ñðåäñòâî      │Èâàäàë, Ñàíâàë                              

                                                                                         

│Çóêëîïåíòèêñîë - àíòèïñèõîòè÷åñêîå           │Êëîïèêñîë, Êëîïèêñîë äåïî, Êëîïèêñîë-àêóôàç 

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                                                              

                                                                                         

│Èáóïðîôåí - ÍÏÂÑ                             │Àäâèë, Àïî-Èáóïðîôåí ÔÑ, Áàðòåë äðàãç        

                                             │Èáóïðîôåí, Áîíèôåí, Áðåí, Áðóôåí, Áóðàíà,   

                                             │Äåòñêèé Ìîòðèí, Äèï Ðèëèô, Äîëãèò êðåì,     

                                             │Èáóïðîí, Èáóïðîô, Èáóïðîôåí, Èáóïðîôåí      

                                             │Ëàííàõåð, Èáóïðîôåí Íèêîìåä, Èáóïðîôåí-Òåâà, │

                                             │Èáóïðîôåíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.2  

                                             │ã, Èáóñàí, Èáóòàä, Èáóòîï ãåëü, Èïðåí,      

                                             │Ìàðêîôåí, ÌÈà 200, Ìîòðèí, Íóðîôåí, Íóðîôåí 

                                             │äëÿ äåòåé, Ïðîôåí, Ïðîôåí 200, Ðåóìàôåí,    

                                             │Ñîëïàôëåêñ                                  

                                                                                         

│Èäàðóáèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Çàâåäîñ, Èäàðóáèöèí                          

│Èçîêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî       │Ãèíî-òðàâîãåí îâóëóì, Òðàâîãåí              

                                                                                         

│Èçîíèàçèä - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî    │Èçîçèä 200, Èçîíèàçèä, Èçîíèàçèä (Òóáàçèä), 

                                             │Èçîíèàçèäà ðàñòâîð äëÿ èíúåêöèé 10%,        

                                             │Èçîíèàçèäà òàáëåòêè, Íèäðàçèä               

                                                                                         

│Èçîíèàçèä+Ðèôàìïèöèí& - ïðîòèâîòóáåðêóëåçíîå │Èçî-Ýðåìôàò 150, Ðèôèíàã, Òèáèíåêñ          

│ñðåäñòâî                                                                                 

                                                                                         

│Èçîíèàçèä+Ðèôàìïèöèí+Ïèðàçèíàìèä& -          │Ðèôàòåð, Òðèêîêñ                            

│ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî                                                             

                                                                                         

│Èçîïðåíàëèí - áåòà-àäðåíîñòèìóëÿòîð          │Èçàäðèí, Èçàäðèíà òàáëåòêè 0.005 ã          

                                                                                         

│Èçîñîðáèä äèíèòðàò - âàçîäèëàòèðóþùåå        │Àýðîñîíèò, Äèíèòðîñîðáèëîíã, Äèòðàò, Èçî    

│ñðåäñòâî                                     │Ìàê, Èçî Ìàê ðåòàðä, Èçîäèíèò, Èçîêåò,      

                                             │Èçîëîíã, Èçîñîðá ðåòàðä, Èçîñîðáèä äèíèòðàò 

                                             │ðåòàðä, ÈÑÄÍ, Êàðäèêåò, Êàðäèêñ, Êàðäèîãàðä 

                                             │ÑÐ, Êàðäîíèò, Íèñîïåðêóòåí, Íèòðîñîðáèä,    

                                             │Íèòðîñîðáèäà òàáëåòêè, Íèòðîñîðáèäà         

                                             │òàáëåòî÷íàÿ ìàññà, Ñîðáèäèí, ÒÄ-ñïðåé Èçî   

                                             │Ìàê, Ýòèäèíèç                               

                                                                                         

│Èçîñîðáèä ìîíîíèòðàò - âàçîäèëàòèðóþùåå      │Èç 5 ìîíî-Ðàòèîôàðì, Èçîìîíàò, Èçîìîíèò     

│ñðåäñòâî                                     │Ãåêñàë, Èçîìîíèò Ãåêñàë ðåòàðä, Êàðäèêñ     

                                             │ìîíî, Êîíïèí, Ìîíèçèä, Ìîíèçîë, Ìîíî Ìàê,   

                                             │Ìîíî ìàê 50 Ä, Ìîíî Ìàê äåïî, Ìîíîëîíã,     

                                             │Ìîíîíèò, Ìîíîíèòðàò ÎÔ, Ìîíîñàí, Ìîíî÷èíêâå, │

                                             │Ìîíî÷èíêâå ðåòàðä, Îëèêàðä 40 ðåòàðä,       

                                             │Îëèêàðä 60 ðåòàðä, Ïëîäèí, Ñîðáèìîí, Ýôîêñ, 

                                             │Ýôîêñ ëîíã                                  

                                                                                         

│Èçîòðåòèíîèí - ðåãåíåðàöèè ñòèìóëÿòîð        │13-öèñ-Ðåòèíîåâàÿ êèñëîòà, Äåðìîðåòèí,      

                                             │Ðåòèíîåâàÿ ìàçü, Ðîàêêóòàí                  

                                                                                         

│Èìèïðàìèí - àíòèäåïðåññàíò                   │Àïî-Èìèïðàìèí, Èìèçèí, Èìèçèíà ðàñòâîð äëÿ  

                                             │èíúåêöèé 1.25%, Èìèçèíà òàáëåòêè ïîêðûòûå   

                                             │îáîëî÷êîé 0.025 ã, Èìïðàìèí, Ìåëèïðàìèí,     

                                             │Ïðèëîéãàí 10, Ïðèëîéãàí 25                  

                                                                                         

│Èìèôîñ& - ïðîòèâîîïóõîëåâîå ñðåäñòâî         │Èìèôîñ, Èìèôîñ äëÿ èíúåêöèé 0.05 ã, Èìèôîñ  

                                             │äëÿ èíúåêöèé 50 ìã                          

                                                                                         

│Èììóíîãëîáóëèí àíòèëèìôîöèòàðíûé& - ÌÈÁÏ -   │Àíòèëèìôîëèí Êç, Àíòèëèìôîëèí Êð,           

│èììóíîìîäóëèðóþùåå ñðåäñòâî                  │ÀÒÃ-Ôðåçåíèóñ                               

                                             │(Àíòè÷åëîâå÷åñêèé-Ò-ëèìôîöèòî-ãëîáóëèí      

                                             │êðîëèêà), Àòãàì, Èììóíîãëîáóëèí             

                                             │àíòèëèìôîöèòàðíûé (ÀËÃ)                     

                                                                                          

│Èììóíîãëîáóëèí ÷åëîâå÷åñêèé íîðìàëüíûé (â/â  │Áèàâåí Â.È., Âåíîãëîáóëèí, Èììóíîãëîáóëèí,  

│ââåäåíèå)& - ÌÈÁÏ - èììóíîñòèìóëèðóþùåå      │Èììóíîãëîáóëèí íîðìàëüíûé ÷åëîâåêà äëÿ      

│ñðåäñòâî                                     │âíóòðèâåííîãî ââåäåíèÿ, Èììóíîãëîáóëèí      

                                             │÷åëîâåêà íîðìàëüíûé, Èíòðàãëîáèí, Îêòàãàì,  

                                             │Ïåíòàãëîáèí, Ñàíäîãëîáóëèí, ÔÑÌÅ-Áóëèí,     

                                             │Öèòîòåêò, Ýíäîáóëèí                         

                                                                                         

│Èíäàïàìèä - äèóðåòè÷åñêîå ñðåäñòâî           │Àðèôîí, Èíäàï, Èíäàïàìèä, Èíäàïñàí, Ëîðâàñ, 

                                             │Ïàìèä                                       

                                                                                         

│Èíäèãî êàðìèí - äèàãíîñòèêóì                 │Èíäèãîêàðìèí, Èíäèãîêàðìèíà ðàñòâîð 0.4% â  

                                             │àìïóëàõ                                     

                                                                                         

│Èíäîìåòàöèí - ÍÏÂÑ                           │Àïî-Èíäîìåòàöèí, Èíäîáåíå, Èíäîâèñ Å.Ñ.,    

                                             │Èíäîìåò-Ðàòèîôàðì, Èíäîìåòàöèí, Èíäîìåòàöèí 

                                             │(Ìîâèìåä), Èíäîìåòàöèí ðåòàðä,              

                                             │Èíäîìåòàöèí-ÀÊÐÈ êàïñóëû 0.025 ã,           

                                             │Èíäîìåòàöèí-Àêðè ìàçü 10%, Èíäîìèí, Èíäîïàí, │

                                             │Èíäîòàðä, Èíäîôàðì, Èíäîöèä, Ìåòèíäîë,       

                                             │Íîâî-Ìåòàöèí SpC, Òðèäîöèí, Ýëüìåòàöèí      

                                                                                         

│Èíîçèí - ìåòàáîëè÷åñêîå ñðåäñòâî             │Èíîçèå-Ô, Èíîçèí, Ðèáîêñèí, Ðèáîêñèí â      

                                             │êàïñóëàõ 0.2 ã, Ðèáîêñèíà ðàñòâîð äëÿ       

                                             │èíúåêöèé 2%, Ðèáîêñèíà òàáëåòêè ïîêðûòûå    

                                             │îáîëî÷êîé 0.2 ã                             

                                                                                         

│Èíîçèí Ïðàíîáåêñ - èììóíîñòèìóëèðóþùåå       │Ãðîïðèíîñèí, Èçîïðèíîçèí                    

│ñðåäñòâî                                                                                 

                                                                                         

│Èíñóëèí-ÁÄ& - èíñóëèí êîðîòêîãî äåéñòâèÿ     │Àêòðàïèä ÌÑ, Àêòðàïèä ÌÑ 40 ÅÄ/ìë, Àêòðàïèä 

                                             │ÍÌ, Àêòðàïèä ÍÌ ïåíôèëë, Áåðëèíñóëèí Í      

                                             │Íîðìàëü U-40, Áåðëèíñóëèí Í Íîðìàëü ïåí,    

                                             │Áèîãóëèí Ðåãóëÿð Ó-100, Áèîãóëèí Ðåãóëÿð    

                                             │Ó40, Èëåòèí II Ðåãóëàð, Èíñóëèí Ìàêñèðàïèä  

                                             │ÂÎ-Ñ, Èíñóëèí Ìàêñèðàïèä ÕÎ-Ñ, Èíñóëèí ÌÊ   

                                             │ñâèíîé, Èíñóëèí ðàñòâîðèìûé íåéòðàëüíûé     

                                             │ÂÎ-Ñ, Èíñóëèí ðàñòâîðèìûé íåéòðàëüíûé ÕÎ-Ñ, 

                                             │Èíñóëèí Ñ, Èíñóëèí ñâèíîé âûñîêîé î÷èñòêè,  

                                             │Èíñóëèí ñâèíîé âûñîêîî÷èùåííûé ÌÊ, Èíñóëèí  

                                             │ñâèíîé ÌÏ, Èíñóëèí ÷åëîâåêà, Èíñóëèíà       

                                             │÷åëîâåêà ðàñòâîð äëÿ èíúåêöèé, Èíñóëðàï ÑÏÏ, │

                                             │Èíñóìàí Ðàïèä, Èíñóìàí Ðàïèä äëÿ îïòèïåíà,  

                                             │Èíóòðàë ÑÏÏ, Èíóòðàë ×Ì, Êðèñòàëë ñâèíîãî   

                                             │Èíñóëèíà, Ìîíîëèí Ðåãóëÿð Ó-40,             

                                             │Ìîíîñóèíñóëèí ÌÊ, Ìîíîñóèíñóëèí ÌÏ, Íåîñóëèí │

                                             │Ðåãóëÿð Ó-40, Ñóèíñóëèí, Õîìîðàï 40, Õóìóëèí │

                                             │Ð, Õóìóëèí Ðåãóëÿð                          

                                                                                         

│Èíñóëèí-ÄëÄ& - èíñóëèí äëèòåëüíîãî äåéñòâèÿ  │Èíñóëèí Óëüòðàëåíòå ÂÎ-Ñ, Èíñóëèí            

                                             │Óëüòðàëåíòå ÕÎ-Ñ, Èíñóëèí-Ëîíã ÑÌÏ,         

                                             │Èíñóëèí-Óëüòðàëîíã ÑÌÏ, Óëüòðàòàðä HM,      

                                             │Õóìóëèí Ó-Ë                                 

                                                                                         

│Èíñóëèí-Êîìá& - èíñóëèí êîìáèíèðîâàííûé      │Áåðëèíñóëèí Í 10/90 U-40, Áåðëèíñóëèí Í     

                                             │10/90 ïåí, Áåðëèíñóëèí Í 20/80 U-40,        

                                             │Áåðëèíñóëèí Í 20/80 ïåí, Áåðëèíñóëèí Í 30/70 │

                                             │U-40, Áåðëèíñóëèí Í 30/70 ïåí, Áåðëèíñóëèí Í │

                                             │40/60 U-40, Áåðëèíñóëèí Í 40/60 ïåí,        

                                             │Áèîãóëèí 30/70 Ó-100, Èíñóìàí Êîìá 15/85,   

                                             │Èíñóìàí Êîìá 25/75, Èíñóìàí Êîìá 25/75 äëÿ  

                                             │îïòèïåíà, Èíñóìàí Êîìá 50/50, Êîìá-Èíñóëèí  

                                             │Ñ, Ìèêñòàðä 10 HM ïåíôèëë, Ìèêñòàðä 20 HM   

                                             │ïåíôèëë, Ìèêñòàðä 30 HM, Ìèêñòàðä 30 HM     

                                             │ïåíôèëë, Ìèêñòàðä 40 HM ïåíôèëë, Ìèêñòàðä 50 │

                                             │HM ïåíôèëë, Õóìóëèí M2, Õóìóëèí M3          

                                                                                         

│Èíñóëèí-ÑðÄ& - èíñóëèí ñðåäíåãî äåéñòâèÿ     │Á-Èíñóëèí Áåðëèí-Õåìè, Áåðëèíñóëèí Í Áàçàëü 

                                             │U-40, Áåðëèíñóëèí Í Áàçàëü ïåí, Áèîãóëèí NPH │

                                             │Ó-100, Áèîãóëèí NPH Ó-40, Áèîãóëèí Ëåíòå    

                                             │Ó40, Â-Èíñóëèí ÑÖ Áåðëèí-Õåìè, Äåïî-Èíñóëèí 

                                             │Ñ, Èçîôàí Èíñóëèí ×Ì, Èëåòèí II Ë, Èëåòèí II │

                                             │ÍÏÕ, Èíñóëèí Èçîôàíèêóì ÂÎ-Ñ, Èíñóëèí       

                                             │Èçîôàíèêóì ÕÎ-Ñ, Èíñóëèí Ëåíòå ÂÎ-Ñ, Èíñóëèí │

                                             │Ëåíòå ÕÎ-Ñ, Èíñóëèí Ëåíòå ÑÏÏ, Èíñóëèí      

                                             │Ñåìèëåíòå ÂÎ-Ñ, Èíñóëèí Ñåìèëåíòå ÕÎ-Ñ,     

                                             │Èíñóëèí-Ñåìèëîíã ÑÌÊ, Èíñóëèí-Ñåìèëîíã ÑÌÏ, 

                                             │Èíñóëèíà ÷åëîâåêà ñóñïåíçèÿ äëÿ èíúåêöèé,   

                                             │Èíñóëîíã ÑÏÏ, Èíñóìàí Áàçàë, Èíñóìàí Áàçàë  

                                             │100 äëÿ Îïòèïåíà, Ìîíîëèí NPH Ó-40, Ìîíîëèí 

                                             │Ëåíòå Ó-40, Ìîíîòàðä HM, Ìîíîòàðä MC,       

                                             │Íåîñóëèí NPH Ó-40, Íåîñóëèí Ëåíòå Ó-40,     

                                             │Ïðîòàôàí HM, Ïðîòàôàí HM ïåíôèëë, Ïðîòàôàí  

                                             │ÌÑ, Õîìîëîíã 40, Õóìóëèí Ë, Õóìóëèí Í,      

                                             │Õóìóëèí ÍÏÕ                                 

                                                                                         

│Èíòåðôåðîí àëüôà - ÌÈÁÏ -                    │Àëüôàôåðîí, Âýëëôåðîí, Èíòåðëîê, Èíòåðôåðîí 

│èììóíîñòèìóëèðóþùåå ñðåäñòâî                 │ëåéêîöèòàðíûé ÷åëîâå÷åñêèé ñóõîé, Èíòåðôåðîí │

                                             │÷åëîâå÷åñêèé ëåéêîöèòàðíûé â ñâå÷àõ,        

                                             │Èíòåðôåðîí ÷åëîâå÷åñêèé ëåéêîöèòàðíûé äëÿ   

                                             │èíúåêöèé, Èíòåðôåðîí ÷åëîâå÷åñêèé           

                                             │ðåêîìáèíàíòíûé àëüôà-2 (ïîëóôàáðèêàò),      

                                             │Èíòðîí-À, Ëîêôåðîí, Ðåàëüäèðîí, Ðåàëüäèðîí  

                                             │äëÿ èíúåêöèé ñóõîé                          

                                                                                         

│Èíòåðôåðîí àëüôà-2à - ÌÈÁÏ -                 │Âèôåðîí (Èíòåðôåðîí ÷åëîâå÷åñêèé            

│èììóíîñòèìóëèðóþùåå ñðåäñòâî                 │ðåêîìáèíàíòíûé À-2 â ñâå÷àõ)ÁÈÇÍÅÑ          

                                             │ÊÎÍÑÀËÒÈÍà ÈÍÂÅÑÒÌÅÍÒ ÇÀÎ, Âèôåðîí-ìàçü,    

                                             │Èíòåðôåðîí ÷åëîâå÷åñêèé ðåêîìáèíàíòíûé      

                                             │àëüôà-2, Èíòåðôåðîí ÷åëîâå÷åñêèé            

                                             │ðåêîìáèíàíòíûé äëÿ èíúåêöèé ñóõîé,          

                                             │Èíòåðôåðîíà àëüôà-2 ðåêîìáèíàíòíîãî ìàçü íà 

                                             │ãèäðîãåëåâîé îñíî), Ðåàôåðîí äëÿ èíúåêöèé   

                                             │ñóõîé, Ðîôåðîí-À                            

                                                                                         

│Èíòåðôåðîí áåòà - ÌÈÁÏ - èììóíîñòèìóëèðóþùåå │Áåòàôåðîí, Ðåáèô, Ôåðîí                     

│ñðåäñòâî                                                                                 

                                                                                         

│Èïðàòðîïèÿ áðîìèä - ì-õîëèíîáëîêàòîð         │Àðóòðîïèä, Àòðîâåíò, Âàãîñ, Èòðîï           

│Èòðàêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî      │Êàíàçîë, Îðóíãàë                             

                                                                                         

│Èõòàììîë - ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî    │Èõòèîë, Èõòèîëà ðàñòâîð â ãëèöåðèíå 10%,    

│äëÿ ìåñòíîãî ïðèìåíåíèÿ                      │Èõòèîëîâàÿ ìàçü, Èõòèîëîâàÿ ìàçü 10%,       

                                             │Èõòèîëîâàÿ ìàçü 20%, Èõòèîëîâàÿ ìàçü 5%,    

                                             │Ñâå÷è ñ èõòèîëîì                            

                                                                                         

│Éîä& - àíòèñåïòè÷åñêîå ñðåäñòâî              │Éîä, Éîäà ðàñòâîð ñïèðòîâîé, Éîäà ðàñòâîð   

                                             │ñïèðòîâîé 3%, Éîäà ðàñòâîð ñïèðòîâîé 5%,     

                                             │Éîäà ðàñòâîð ñïèðòîâîé 5% â àìïóëàõ, Éîäíûå 

                                             │òàáëåòêè                                    

                                                                                          

│Éîäàìèä - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî       │Éîäàìèä 24%, Éîäàìèä 300, Éîäàìèä-300 äëÿ   

                                             │èíúåêöèé, Éîäàìèä-380 äëÿ èíúåêöèé          

                                                                                         

│Éîêñèòàëàìîâàÿ êèñëîòà - ðåíòãåíîêîíòðàñòíîå │Òåëåáðèêñ 30 ìåãëóìèí, Òåëåáðèêñ 35         

│ñðåäñòâî                                                                                 

                                                                                         

│Éîïîäàò íàòðèÿ - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî│Áèëèìèí, Áèëèìèíà òàáëåòêè 0.5 ã            

                                                                                          

│Éîïðîìèä - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî      │Óëüòðàâèñò-240, Óëüòðàâèñò-300,             

                                             │Óëüòðàâèñò-370                              

                                                                                          

│Éîôåíäèëàò - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî    │Íåéðîòðàñò, Ýòèîòðàñò, Ýòèîòðàñò äëÿ èíúåêöèé│

                                                                                         

│Éîõèìáèíà ãèäðîõëîðèä& - ïîòåíöèè ñòèìóëÿòîð │Èîõèìáèí-Øïèãåëü, Éîõèìáèíà ãèäðîõëîðèäà    

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │òàáëåòêè 0.005 ã                            

                                                                                         

│Êàëèÿ áðîìèä& - ñåäàòèâíîå ñðåäñòâî          │Êàëèÿ áðîìèä, Êàëèÿ áðîìèäà ðàñòâîð ñ       

                                             │ôðóêòîâûì ñèðîïîì, Êàëèÿ áðîìèäà òàáëåòêè   

                                             │0.5 ã                                        

                                                                                         

│Êàëèÿ è ìàãíèÿ àñïàðàãèíàò - ïðåïàðàò êàëèÿ  │Àñïàðêàì, Àñïàðêàì òàáëåòêè, Àñïàðêàì       

│è ìàãíèÿ                                     │òàáëåòî÷íàÿ ìàññà, Êàëèÿ-ìàãíèÿ-àñïàðàãèíàò, │

                                             │Ïàíàíãèí                                    

                                                                                         

│Êàëèÿ éîäèä - ïðåïàðàò éîäà, ðåãóëÿòîð       │Àíòèñòðóìèí, Àíòèñòðóìèí òàáëåòêè,          

│ñèíòåçà òèðîêñèíà                            │Àíòèñòðóìèí-Äàðíèöà, Éîäèä 100, Éîäèä 200,  

                                             │Êàëèÿ éîäèä, Êàëèÿ éîäèä 200 Áåðëèí-Õåìè,   

                                             │Êàëèÿ éîäèäà ðàñòâîð 3%, Êàëèÿ éîäèäà       

                                             │ðàñòâîð 3% (ãëàçíûå êàïëè), Êàëèÿ éîäèäà    

                                             │òàáëåòêè 0.25 ã, Êàëèÿ éîäèäà òàáëåòêè 0.5 ã │

                                                                                         

│Êàëèÿ ïåðõëîðàò - àíòèòèðåîèäíîå ñðåäñòâî    │Ïåðõëîðàò êàëèÿ, Ïåðõëîðàò êàëèÿ òàáëåòêè   

                                             │0.25 ã                                      

                                                                                         

│Êàëèÿ õëîðèä - ïðåïàðàò êàëèÿ                │Ê-Äóð, Ê-Ëàéò, Êàëèé íîðìèí, Êàëèïîç        

                                             │ïðîëîíãàòóì, Êàëèÿ õëîðèä, Êàëèÿ õëîðèä äëÿ 

                                             │èíúåêöèé 1 ã, Êàëèÿ õëîðèäà ðàñòâîð 10%,    

                                             │Êàëèÿ õëîðèäà ðàñòâîð äëÿ èíúåêöèé 4%, Êàëèÿ │

                                             │õëîðèäà òàáëåòêè                            

                                                                                         

│Êàëüöèïîòðèîë - ïðîòèâîïñîðèàòè÷åñêîå        │Äàéâîíåêñ, Ïñîðêóòàí                        

│ñðåäñòâî                                                                                 

                                                                                         

│Êàëüöèòîíèí - ðåãóëÿòîð îáìåíà êàëüöèÿ è     │Êàëüöèòðèí, Ìèàêàëüöèê, Ñèáàêàëüöèí         

│ôîñôîðà                                                                                  

                                                                                         

│Êàëüöèÿ ãëèöåðèëôîñôàò& - ðåãóëÿòîð îáìåíà   │Ãëèöåðîôîñôàòà ãðàíóëû, Êàëüöèÿ             

│êàëüöèÿ è ôîñôîðà                            │ãëèöåðîôîñôàò, Êàëüöèÿ ãëèöåðîôîñôàòà       

                                             │òàáëåòêè, Êàëüöèÿ ãëèöåðîôîñôàòà òàáëåòêè   

                                             │0.2 ã, Êàëüöèÿ ãëèöåðîôîñôàòà òàáëåòêè 0.5 ã │

                                                                                         

│Êàëüöèÿ ãëþêîíàò - ðåãóëÿòîð îáìåíà êàëüöèÿ  │Êàëüöèé-Ñàíäîç, Êàëüöèé-Ñàíäîç ôîðòå,       

│è ôîñôîðà                                    │Êàëüöèÿ ãëþêîíàò, Êàëüöèÿ ãëþêîíàòà 0.25 ã ñ │

                                             │êàêàî òàáëåòêè, Êàëüöèÿ ãëþêîíàòà ðàñòâîð   

                                             │äëÿ èíúåêöèé 10%, Êàëüöèÿ ãëþêîíàòà òàáëåòêè │

                                             │0.5 ã                                       

                                                                                          

│Êàëüöèÿ äîáåçèëàò - àíãèîïðîòåêòîðíîå        │Äîêñèëåê, Äîêñèóì, Êàëüöèÿ äîáåçèëàò,       

│ñðåäñòâî                                     │Êàëüöèÿ äîáåçèëàòà òàáëåòêè 0.25 ã, Êàëüöèÿ 

                                             │äîáåçèëàòà òàáëåòêè 250 ìã                  

                                                                                         

│Êàëüöèÿ êàðáîíàò - àíòàöèäíîå ñðåäñòâî       │Àääèòèâà êàëüöèé, Áàðòåë äðàãç Àíòàöèäíûå   

                                             │òàáëåòêè, Êàëüöèÿ êàðáîíàò îñàæäåííûé,      

                                             │Êàðáîíàò êàëüöèÿ 500 ìã Ñàëüìîí Ôàðìà,      

                                             │Óïñàâèò êàëüöèé                             

                                                                                         

│Êàëüöèÿ êàðáîíàò+Ìàãíèÿ êàðáîíàò& -          │Êàëüöèé è ìàãíèé, Ðåííè, Òàìñ, Ýíäðþñ àíòàöèä│

│àíòàöèäíîå ñðåäñòâî                                                                       

                                                                                         

│Êàëüöèÿ ïàíòîòåíàò - âèòàìèí                 │Ä-Ïàíòîòåíàò êàëüöèÿ, Êàëüöèÿ Ä-ïàíòîòåíàò, 

                                             │Êàëüöèÿ ïàíòîòåíàò (îïòè÷åñêè àêòèâíûé),    

                                             │Êàëüöèÿ ïàíòîòåíàòà ðàñòâîð 20%, Êàëüöèÿ    

                                             │ïàíòîòåíàòà ðàñòâîð äëÿ èíúåêöèé 10%,       

                                             │Êàëüöèÿ ïàíòîòåíàòà òàáëåòêè 0.1 ã          

                                                                                         

│Êàëüöèÿ òðèíàòðèÿ ïåíòåòàò -                 │Ïåíòàöèí, Ïåíòàöèíà ðàñòâîð 5% â àìïóëàõ,    

│êîìïëåêñîîáðàçóþùåå ñðåäñòâî                 │Ïåíòàöèíà ðàñòâîð äëÿ èíúåêöèé 5%           

                                                                                         

│Êàëüöèÿ ôîëèíàò - âèòàìèí                    │Êàëüöèóìôîëèíàò-Ýáåâå, Êàëüöèÿ ôîëèíàò,     

                                             │Êàëüöèÿ ôîëèíàò ëèîôèëèçèðîâàííûé äëÿ       

                                             │èíúåêöèé, Ëåéêîâàðèí-Òåâà, Ëåéêîâîðèí Ca    

                                             │Ëàõåìà 10, Ëåéêîâîðèí Ca Ëàõåìà 25,         

                                             │Ëåéêîâîðèí êàëüöèÿ, Ñàíôèöèíàò, Ôîëèíàò     

                                             │êàëüöèÿ                                     

                                                                                         

│Êàëüöèÿ ôîñôàò îñíîâíîé - ðåãóëÿòîð îáìåíà   │Ãèäðîêñèàïàòèò, Ãèäðîêñèàïàòèò              

│êàëüöèÿ è ôîñôîðà                            │(âûñîêîäèñïåðñíûé), Ãèäðîêñèàïàòèòà ãðàíóëû, │

                                             │Ãèäðîêñèàïàòèòíàÿ ïàñòà                     

                                                                                         

│Êàëüöèÿ õëîðèä - ðåãóëÿòîð îáìåíà êàëüöèÿ è  │Êàëüöèÿ õëîðèä êðèñòàëëè÷åñêèé, Êàëüöèÿ     

│ôîñôîðà                                      │õëîðèä-Äàðíèöà, Êàëüöèÿ õëîðèäà ðàñòâîð 10%, │

                                             │Êàëüöèÿ õëîðèäà ðàñòâîð 5% ñ ôðóêòîâûì      

                                             │ñèðîïîì, Êàëüöèÿ õëîðèäà ðàñòâîð 50%,       

                                             │Êàëüöèÿ õëîðèäà ðàñòâîð äëÿ èíúåêöèé 10%,   

                                             │Êàëüöèÿ õëîðèäà ðàñòâîð äëÿ èíúåêöèé 2.5%   

                                                                                         

│Êàìôîðà& - àíòèñåïòè÷åñêîå ñðåäñòâî          │Êàìôîäåðì Í, Êàìôîðà, Êàìôîðà ðàöåìè÷åñêàÿ, 

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Êàìôîðíàÿ ìàçü 10%, Êàìôîðíîå ìàñëî äëÿ     

                                             │íàðóæíîãî ïðèìåíåíèÿ, Êàìôîðíûé ñïèðò 10%,  

                                             │Êàìôîðíûé ñïèðò 2%, Êàìôîðû ðàñòâîð äëÿ     

                                             │èíúåêöèé â ìàñëå 20%, Êàìôîðû ðàñòâîð äëÿ   

                                             │èíúåêöèé â îëèâêîâîì ìàñëå 20%              

                                                                                         

│Êàíàìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä        │Àíòèñåïòè÷åñêàÿ ãóáêà ñ êàíàìèöèíîì,        

                                             │Êàíàìèöèíà êèñëîãî ñóëüôàò, Êàíàìèöèíà      

                                             │ìîíîñóëüôàò, Êàíàìèöèíà ìîíîñóëüôàòà         

                                             │òàáëåòêè, Êàíàìèöèíà ñóëüôàò, Êàíàìèöèíà    

                                             │ñóëüôàòà ðàñòâîð äëÿ èíúåêöèé 5%, Ïëåíêè    

                                             │ãëàçíûå ñ êàíàìèöèíîì                       

                                                                                         

│Êàïòîïðèë - ÀÊÔ áëîêàòîð                     │Àëêàäèë, Àíãèîïðèë-25, Àïî-Êàïòî, Àöåòåí,   

                                             │Ãåí-Êàïòîïðèë, Êàïîêàðä, Êàïîòåí, Êàïîòåíà  

                                             │òàáëåòêè, Êàïòîïðèë, Êàïòîïðèë 25, Êàïòîïðèë │

                                             │ÎÔ, Êàïòîïðèë ØåíÒîí 25, Êàðäîïðèë, Êàòîïèë, │

                                             │Íîâî-Êàïòîðèë, Ðèëêàïòîí, Ñèñòîïðèë,        

                                             │Òåíçèîìèí, Ýïñèòðîí                         

                                                                                          

│Êàðáàçîõðîì - ãåìîñòàòè÷åñêîå ñðåäñòâî       │Àäðîêñîí, Àäðîêñîíà ðàñòâîð 0.02% â àìïóëàõ 

│Êàðáàëäðàò - àíòàöèäíîå ñðåäñòâî             │Àëþãàñòðèí, Êîìïåíñàí                       

                                                                                          

│Êàðáàìàçåïèí - ïðîòèâîñóäîðîæíîå ñðåäñòâî    │Àïî-Êàðáàìàçåïèí, Ãåí-Êàðïàç, Çàãðåòîë,     

                                             │Çåïòîë, Êàðáàäàê, Êàðáàìàçåïèí, Êàðáàìàçåïèí │

                                             │Ðèâî, Êàðáàìàçåïèí-ÀÊÐÈ òàáëåòêè 0.2 ã,     

                                             │Êàðáàìàçåïèí-Òåâà, Êàðáàïèí, Êàðáàñàí,      

                                             │Êàðáàñàí ðåòàðä, Êàðáàòîë, Ìàçåïèí,          

                                             │Íîâî-Êàðáàìàç, Ñòàçåïèí, Ñòîðèëàò, Òåãðåòîë, │

                                             │Òåãðåòîë ÖÐ, Òèìîíèë, Ôèíëåïñèí, Ôèíëåïñèí  

                                             │ðåòàðä, Ýïèàë                                

                                                                                         

│Êàðáàõîë - ì- è í-õîëèíîìèìåòèê              │Èçîïòî-êàðáàõîë, Êàðáàõîë, Êàðáàõîëèí       

│Êàðáåíäàöèì& - ïðîòèâîãåëüìèíòíîå ñðåäñòâî   │Ìåäàìèí, Ìåäàìèíà òàáëåòêè 0.1 ã            

                                                                                         

│Êàðáåíèöèëëèí - àíòèáèîòèê, ïåíèöèëëèí       │Êàðáåíèöèëëèíà äèíàòðèåâàÿ ñîëü,            

                                             │Êàðáåíèöèëëèíà äèíàòðèåâàÿ ñîëü 1 ã         

                                                                                         

│Êàðáîïëàòèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Áëàñòîêàðá, Êàðáîïëàòèí, Êàðáîïëàòèí-Òåâà,  

                                             │Êàðáîïëàòèí-Ýáåâå, Ïàðàïëàòèí, Öèêëîïëàòèí  

                                                                                         

│Êàðáîöèñòåèí - ìóêîëèòè÷åñêîå ñðåäñòâî       │Áðîíêàòàð, Áðîíõîêîä, Äðèëë îòõàðêèâàþùèé,  

                                             │Êàðáîöèñòåèí, Ìóêîäèí, Ìóêîïðîíò, Ìóêîñîë,  

                                             │Ôëóèôîðò, Ôëþâèê, Ôëþäèòåê                  

                                                                                         

│Êàðáóòàìèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ    │Áóêàðáàí, Îðàíèë                            

│ïåðîðàëüíîãî ïðèåìà                                                                      

                                                                                         

│Êàðâåäèëîë - àëüôà- è áåòà-àäðåíîáëîêàòîð    │Äèëàòðåíä, Êðåäåêñ                          

                                                                                          

│Êàðóáèöèí& - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Êàðìèíîìèöèíà ãèäðîõëîðèä, Êàðìèíîìèöèíà    

                                             │ãèäðîõëîðèä äëÿ èíúåêöèé                    

                                                                                         

│Êàðôåöèëëèí - àíòèáèîòèê, ïåíèöèëëèí         │Êàðôåöèëëèíà íàòðèåâàÿ ñîëü, Êàðôåöèëëèíà   

                                             │íàòðèåâàÿ ñîëü â êàïñóëàõ 0.25 ã            

                                                                                         

│Êåòàìèí - íàðêîçíîå íåèíãàëÿöèîííîå ñðåäñòâî │Âåëîíàðêîí 0.1, Âåëîíàðêîí 0.5, Êàëèïñîë,   

                                             │Êåòàëàð, Êåòàìèí, Êåòàìèí Ïàíôàðìà, Êåòàìèíà │

                                             │ãèäðîõëîðèä, Êåòàìèíà ðàñòâîð äëÿ èíúåêöèé  

                                             │5%, Êåòàíåñò                                

                                                                                          

│Êåòîêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî      │Íèçîðàë, Îðîíàçîë                           

                                                                                         

│Êåòîïðîôåí - ÍÏÂÑ                            │Àêòðîí, Êåòîëèñò ðåòàðä, Êåòîíàë,           

                                             │Êåòîïðîôåí, Êåòîïðîôåí-Ðàòèîôàðì, Êíàâîí,   

                                             │Îðóâåëü, Ïðîôåíèä, Ïðîôåíèä ãåëü 2.5%,      

                                             │Ôàñòóì, Ôëåêñåí                             

                                                                                         

│Êåòîðîëàê - ÍÏÂÑ                             │Äîëàê, Êåòàíîâ, Êåòîðîë, Êåòîðîëàêà         

                                             │òðîìåòàìèí, Êåòðîäîë, Íàòî, Òîðàäîë, Òîðîëàê │

                                                                                         

│Êåòîòèôåí - ïðîòèâîàëëåðãè÷åñêîå ñðåäñòâî    │Àéðèôåí, Àñòàôåí, Äåíåðåë, Çàäèòåí, Çàäèòåí 

                                             │ÑÐÎ, Çåðîñìà, Çåòèôåí, Êàòèôåí, Êåòàñìà,    

                                             │Êåòîòèô, Êåòîòèôåí, Êåòîòèôåí Ñòàäà         

                                             │ìåæäóíàðîäíûé, Êåòîòèôåí-Ðèâîôàðì,          

                                             │Êåòîòèôåíà òàáëåòêè 0.001 ã, Êåòîòèôåíà     

                                             │ôóìàðàò, Êåòîô, Ïîçèòàí, Ïðèâåíò, Ñòàôåí,   

                                             │Òîôåí, Ôðåíàñìà                             

                                                                                         

│Êëàðèòðîìèöèí - àíòèáèîòèê, ìàêðîëèä         │Êëàöèä, Ôðîìèëèä                             

                                                                                         

│Êëåìàñòèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Ðèâòàãèë, Òàâåãèë                           

│áëîêàòîð                                                                                 

                                                                                         

│Êëåíáóòåðîë - áåòà2-àäðåíîñòèìóëÿòîð         │Êîíòðàñïàçìèí, Ñïèðîïåíò                    

│ñåëåêòèâíûé                                                                              

                                                                                         

│Êëèíäàìèöèí - àíòèáèîòèê, ëèíêîçàìèä         │Äàëàöèí, Äàëàöèí Ò, Äàëàöèí Ö, Äàëàöèí Ö    

                                             │ôîñôàò, Êëèìèöèí, Êëèíäàìèöèí, Êëèíäàìèöèíà 

                                             │ãèäðîõëîðèäà ìîíîãèäðàò, Êëèíäàôåð          

                                                                                          

│Êëîçàïèí - àíòèïñèõîòè÷åñêîå                 │Àçàëåïòèí, Àçàëåïòèíà ãðàíóëû äëÿ äåòåé,    

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │Àçàëåïòèíà òàáëåòêè, Àëåìîêñàí, Ëåïîíåêñ    

                                                                                         

│Êëîêñàöèëëèí - àíòèáèîòèê, ïåíèöèëëèí        │Êëîáåêñ, Êëîêñàöèëëèí                       

│Êëîìèïðàìèí - àíòèäåïðåññàíò                 │Àíàôðàíèë, Ãèäèôåí, Êëîìèíàë, Êëîôðàíèë     

                                                                                         

│Êëîìèôåí - àíòèýñòðîãåí                      │Êëîìèä, Êëîìèôåíà öèòðàò, Êëîìèôåíà öèòðàòà 

                                             │òàáëåòêè 0.05 ã, Êëîñòèëáåãèò, Ñåðîôåí,     

                                             │Ñåðïàôàð                                    

                                                                                         

│Êëîíàçåïàì - ïðîòèâîñóäîðîæíîå ñðåäñòâî      │Àíòåëåïñèí 0.25, Àíòåëåïñèí 1, Êëîíàçåïàì,  

                                             │Êëîíîòðèë, Ðèâîòðèë                         

                                                                                         

│Êëîíèäèí - àëüôà2-àäðåíîñòèìóëÿòîð           │Àïî-Êëîíèäèí, Ãåìèòîí, Êàòàïðåñàí,          

│öåíòðàëüíûé                                  │Êëîôåëèí-Äàðíèöà, Êëîôåëèí, Êëîôåëèíà       

                                             │ðàñòâîð â òþáèê-êàïåëüíèöàõ, Êëîôåëèíà       

                                             │ðàñòâîð äëÿ èíúåêöèé 0.01%, Êëîôåëèíà       

                                             │òàáëåòêè 0.000075 ã, Êëîôåëèíà òàáëåòêè     

                                             │0.00015 ã, Êëîôåëèíà òàáëåòêè 0.00015,      

                                             │Êëîôåëèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé       

                                             │ïðîëîíãèðîâàííîãî äåéñòâèÿ, Êëîôåëèíà       

                                             │òàáëåòêè, Õëîôàçîëèí                        

                                                                                         

│Êëîïàìèä - äèóðåòè÷åñêîå ñðåäñòâî            │Áðèíàëäèêñ, Áðèíàëüäèêñ, Êëîïàìèä           

                                                                                         

│Êëîðàçåïàò äèêàëèÿ - àíêñèîëèòè÷åñêîå        │Àïî-Êëîðàçåïàò, Òðàíêñåí                    

│ñðåäñòâî                                                                                  

                                                                                         

│Êëîòðèìàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî      │Àíòèôóíãîë, Âèêàäåðì, Ãèíå-Ëîòðèìèí, Èìèäèë, │

                                             │Éåíàìàçîë, Éåíàìàçîë 100, Éåíàìàçîë 200,    

                                             │Êàíäèáåíå, Êàíäèä, Êàíäèä-B3, Êàíäèä-Â1,    

                                             │Êàíäèä-Â6, Êàíåñòåí, Êàíèçîí, Êëîìàçîë,     

                                             │Êëîòðèìàçîë, Êëîòðèìàçîë-Àêðè ìàçü, Êëîôàí, 

                                             │Ëîòðèìèí, Ôàêòîäèí, Ôóíãèçèä-Ðàòèîôàðì,     

                                             │Ôóíãèíàë, Ôóíãèíàë Â, Ôóíãèöèï              

                                                                                         

│Êî-òðèìîêñàçîë - ïðîòèâîìèêðîáíîå            │Àïî-Ñóëüôàòðèì, Áàêòåêîä, Áàêòîðåäóêò,      

│êîìáèíèðîâàííîå ñðåäñòâî                     │Áàêòðèì, Áàêòðèì ñèðîï, Áàêòðèì ôîðòå,      

                                             │Áåðëîöèä 240, Áåðëîöèä 480, Áåðëîöèä 960,   

                                             │Áèêîòðèì, Áèñåïòîë, Áèñóòðèì, Ãåí-Óëüòðàçîë, │

                                             │Ãðîñåïòîë, Äóî-Ñåïòîë, Èíòðèì,              

                                             │Êî-òðèìîêñàçîë, Êî-òðèìîêñàçîë-480,         

                                             │Êî-òðèìîêñàçîë-ICN, Êî-òðèìîêñàçîë-Àêðè     

                                             │òàáëåòêè 0.12 ã, Êî-òðèìîêñàçîë-Ðèâîôàðì,   

                                             │Êî-òðèìîêñàçîë-Òåâà, Êî-òðèìîêñàçîëà-Àêðè   

                                             │òàáëåòêè 0.48 ã, Êîòðèì-Ðàòèîôàðì,           

                                             │Êîòðèìîêñàçîë, Êîòðèìîë, Êîòðèôàðì 480,     

                                             │Íîâî-Òðèìåë, Îðèïðèì, Ðàíêîòðèì, Ñåïòðèí,   

                                             │Ñåïòðèí-ôîðòå, Ñèíåðñóë, Ñóëîòðèì,          

                                             │Ñóëüôàìåòîêñàçîë/Òðèìåòîïðèì, Ñóìåòðîëèì,   

                                             │ÒÌÑ 480, Òðèì, Òðèìåçîë, Òðèìåòîïðèì è      

                                             │Ñóëüôàìåòîêñàçîë, Òðèìîñóë, Öèïëèí, Ýêñïîçîë │

                                                                                         

│Êîáàìàìèä - ìåòàáîëè÷åñêîå ñðåäñòâî          │Êîáàìàìèä äëÿ èíúåêöèé, Êîáàìàìèäà òàáëåòêè, │

                                             │Êîáàìàìèäà òàáëåòêè ïîêðûòûå îáîëî÷êîé      

                                                                                         

│Êîäåèí - ïðîòèâîêàøëåâîå ñðåäñòâî            │Êîäåèí, Êîäåèíà ôîñôàò, Òóññàìàã ñ êîäåèíîì 

                                                                                         

│Êîêàðáîêñèëàçà - ìåòàáîëè÷åñêîå ñðåäñòâî     │Êîêàðáîêñèëàçû ãèäðîõëîðèä, Êîêàðáîêñèëàçû  

                                             │ãèäðîõëîðèä äëÿ èíúåêöèé, Êîêàðáîêñèëàçû    

                                             │ãèäðîõëîðèä äëÿ èíúåêöèé 0.05 ã             

                                                                                         

│Êîëåêàëüöèôåðîë - ðåãóëÿòîð îáìåíà êàëüöèÿ è │Âèãàíòîë, Âèòàìèí Ä3, Âèòàìèí Ä3 ÁÎÍ        

│ôîñôîðà                                                                                  

                                                                                          

│Êîëåñòèðàìèí - ãèïîëèïèäåìè÷åñêîå ñðåäñòâî   │Êâåñòðàí, Êîëåñòèð                          

                                                                                         

│Êîëõèöèí - ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî    │Êîëõèêóì-äèñïåðò, Êîëõèöèí, Êîëõèöèíà       

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.001 ã         

                                                                                         

│Êîðòèçîí - ãëþêîêîðòèêîñòåðîèä               │Êîðòèçîíà àöåòàò, Êîðòèçîíà àöåòàòà òàáëåòêè │

                                                                                         

│Êîðòèêîòðîïèí - ÀÊÒà                        │Àäðåíîêîðòèêîòðîïíûé ãîðìîí (ÀÊÒÃ),         

                                             │Êîðòèêîòðîïèí                               

                                                                                         

│Êîôåèí - ïñèõîñòèìóëèðóþùåå ñðåäñòâî         │Êîôåèí áåçâîäíûé, Êîôåèíà-áåíçîàò íàòðèÿ,   

                                             │Êîôåèíà-áåíçîàòà íàòðèÿ ðàñòâîð äëÿ         

                                             │èíúåêöèé, Êîôåèíà-áåíçîàòà íàòðèÿ ðàñòâîð   

                                             │äëÿ èíúåêöèé 20%, Êîôåèíà-áåíçîàòà íàòðèÿ   

                                             │ðàñòâîð äëÿ èíúåêöèé â øïðèö-òþáèêàõ,       

                                             │Êîôåèíà-áåíçîàòà íàòðèÿ òàáëåòêè,           

                                             │Êîôåèíà-áåíçîàòà íàòðèÿ òàáëåòêè äëÿ äåòåé  

                                             │0.075 ã                                     

                                                                                         

│Êîôåèí+Ïàðàöåòàìîë& - àíàëüãåòè÷åñêîå        │Äàðâàë, Ìèãðåíîë, Íåéðàìàã Ï, Ïàíàäîë       

│íåíàðêîòè÷åñêîå ñðåäñòâî                     │ýêñòðà, Ïàíàäîë ýêñòðà ñîëþáë, Ýíäðþñ àíñâåð │

                                                                                          

│Êîôåèí+Ïàðàöåòàìîë+Ïðîïèôåíàçîí& -           │Àäîëîðèí, Ãåâàäàë, Ñàðèäîí, Òðèìîë          

│àíàëüãåòè÷åñêîå íåíàðêîòè÷åñêîå ñðåäñòâî                                                 

                                                                                         

│Êðîìîãëèöèíîâàÿ êèñëîòà -                    │Áèêðîìàò, Èíòàë, Èôèðàë, Êðîìî, Êðîìîãåêñàë, │

│ïðîòèâîàëëåðãè÷åñêîå ñðåäñòâî                │Êðîìîãåêñàë Êîìáè, Êðîìîãåí èíãàëÿòîð,      

                                             │Êðîìîãåí ëåãêîå äûõàíèå, Êðîìîãëèí,         

                                             │Êðîìîãëèöèí-Ðàòèîôàðì, Êðîìîëèí, Êðîìîñîë,  

                                             │Êðîïîç, Êóçèêðîì, Ëåêðîëèí, Ëîìóçîë,         

                                             │Íàëõðîì, Îïòèêðîì, Òàëåóì, Õàé êðîì         

                                                                                         

│Êñàíòèíîëà íèêîòèíàò - àíòèàãðåãàíòíîå       │Êîìïëàìèí, Êñàíòèíîëà íèêîòèíàò, Êñàíòèíîëà 

│ñðåäñòâî                                     │íèêîòèíàòà ðàñòâîð äëÿ èíúåêöèé 15%,        

                                             │Êñàíòèíîëà íèêîòèíàòà òàáëåòêè 0.15 ã,      

                                             │Òåîíèêîëà òàáëåòêè 0.15 ã                   

                                                                                         

│Êñèëîìåòàçîëèí - àëüôà-àäðåíîñòèìóëÿòîð      │Ãàëàçîëèí, Äëÿíîñ, Êñèëîáåíå,               

                                             │Êñèëîìåòàçîëèí, Êñèëîìåòàçîëèíà ãèäðîõëîðèä, │

                                             │Êñèìåëèí, Íàçàëüíûé àýðîçîëü äîêòîðà Òàéññà, │

                                             │Íàçåíñïðàé Å-ðàòèîôàðì, Îëèíò, Îòðèâèí      

                                                                                         

│Ëàêòóëîçà - ñëàáèòåëüíîå ñðåäñòâî            │Äþôàëàê, Ëàêòóëîçà, Ëàêòóëîçà ñèðîï,        

                                             │Ëèâî-ëàê, Ëèçàëàê, Íîðìàçå                  

                                                                                         

│Ëàíàòîçèä Ö - êàðäèîòîíè÷åñêîå ñðåäñòâî,     │Öåäèãàëàí, Öåëàíèä, Öåëàíèä êðèñòàëëè÷åñêèé, │

│ñåðäå÷íûé ãëèêîçèä                           │Öåëàíèäà ðàñòâîð 0.05%, Öåëàíèäà ðàñòâîð äëÿ │

                                             │èíúåêöèé 0.02%, Öåëàíèäà òàáëåòêè 0.00025 ã 

                                                                                         

│Ëàíñîïðàçîë - ïðîòèâîÿçâåííîå ñðåäñòâî,      │Ëàíçîïòîë, Ëàíñàï, Ëàíñîïðàçîë, Ëàíñîôåä    

│ïðîòîííîãî íàñîñà èíãèáèòîð                  │0.03 ã â êàïñóëàõ                           

                                                                                          

│Ëåàêàäèí& - èììóíîñòèìóëèðóþùåå ñðåäñòâî     │Ëåàêàäèí, Ëåàêàäèí ëèîôèëèçèðîâàííûé äëÿ    

                                             │èíúåêöèé, Ëåàêàäèíà òàáëåòêè 0.1 ã          

                                                                                         

│Ëåâàìèçîë - ïðîòèâîãåëüìèíòíîå ñðåäñòâî      │Äåêàðèñ, Ëåâàìèçîëà ãèäðîõëîðèäà òàáëåòêè   

                                             │0.15 ã                                      

                                                                                         

│Ëåâîäîïà+Áåíñåðàçèä& -                       │Ìàäîïàð, Ìàäîïàð áûñòðîäåéñòâóþùèå òàáëåòêè 

│äîôàìèí-ñòèìóëÿòîð+äåêàðáîêñèëàçû            │(äèñïåðãèðóåìûå), Ìàäîïàð ÃÑÑ                

│ïåðèôåðè÷åñêîé èíãèáèòîð                                                                 

                                                                                         

│Ëåâîäîïà+Êàðáèäîïà& -                        │Äîïàð 275, Äóýëëèí, Çèìîêñ, Èçèêîì, Èçèêîì  

│äîôàìèí-ñòèìóëÿòîð+äåêàðáîêñèëàçû            │ìèòå, Êàðáèäîïà è Ëåâîäîïà-Òåâà, Êðåäàíèë   

│ïåðèôåðè÷åñêîé èíãèáèòîð                     │25/250, Íàêîì, Ñèíäîïà 110, Ñèíäîïà 275,    

                                             │Ñèíåìåò, Ñèíåìåò ÑÐ, Òèäîìåò ËÑ, Òèäîìåò    

                                             │ïëþñ, Òèäîìåò ôîðòå                         

                                                                                         

│Ëåâîêàðíèòèí - ìåòàáîëè÷åñêîå ñðåäñòâî       │L-Êàðíèòèí, Êàðíèòèíà õëîðèä, Êàðíèòèíà     

                                             │õëîðèäà ðàñòâîð 20%, Êàðíèòèíà õëîðèäà      

                                             │ðàñòâîð äëÿ èíúåêöèé 10% (Àïëåãèí), Ýëüêàðà 

                                             │ðàñòâîð äëÿ èíúåêöèé 10%                    

                                                                                         

│Ëåâîíîðãåñòðåë - ïðîãåñòàãåí                 │Ëåâîíîâà, Ìèêðîëþò, Ìèðåíà, Íîðïëàíò,       

                                             │Ïîñòèíîð                                    

                                                                                         

│Ëåâîðèí& - ïðîòèâîãðèáêîâîå ñðåäñòâî         │Ëåâîðèäîí, Ëåâîðèäîíà ãðàíóëû äëÿ äåòåé 2500 │

                                             │ìêã/ã (125000 ÅÄ/ã), Ëåâîðèäîíà òàáëåòêè    

                                             │çàùå÷íûå, Ëåâîðèí, Ëåâîðèíà íàòðèåâàÿ ñîëü 4 │

                                             │ìã (200000 ÅÄ), Ëåâîðèíà ïîðîøîê äëÿ        

                                             │ñóñïåíçèé 4000000 ÅÄ, Ëåâîðèíà òàáëåòêè     

                                             │500000 ÅÄ, Ëåâîðèíà òàáëåòêè âàãèíàëüíûå,   

                                             │Ëåâîðèíà òàáëåòêè çàùå÷íûå 500000 ÅÄ,       

                                             │Ëåâîðèíîâàÿ ìàçü 500000 ÅÄ/ã                

                                                                                         

│Ëåâîòèðîêñèí - òèðåîèäíîå ñðåäñòâî           │L-òèðîêñèí 25 Áåðëèí-Õåìè, L-òèðîêñèí 50    

                                             │Áåðëèí Õåìè, L-òèðîêñèí-100 Áåðëèí Õåìè,    

                                             │Ë-òèðîê, Òèðî-4, Ýóòèðîêñ                   

                                                                                         

│Ëåâîòèðîêñèí+Ëèîòèðîíèí& - òèðåîèäíîå        │Íîâîòèðàë, Òèðåîòîì, Òèðåîòîì ôîðòå         

│ñðåäñòâî                                                                                 

                                                                                         

│Ëåéïðîðåëèí - ïðîòèâîãîíàäîòðîïíîå ñðåäñòâî  │Ëþêðèí äåïî, Ïðîñòàï                        

                                                                                         

│Ëåîêàèí& - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî     │Ëåîêàèí, Ëåîêàèíà ðàñòâîð 0.3%, Ëåîêàèíà    

                                             │ðàñòâîð 0.3% (ãëàçíûå êàïëè), Ëåîêàèíà      

                                             │ðàñòâîð 0.3% ñ ìåòèëöåëëþëîçîé, Ëåîêàèíà    

                                             │ðàñòâîð 0.3% ñ ìåòèëöåëëþëîçîé (ãëàçíûå     

                                             │êàïëè)                                      

                                                                                         

│Ëèäîêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî     │Êñèêàèí, Êñèëåñòåçèí, Êñèëîäîíò, Êñèëîêàèí, 

                                             │Êñèëîðîëëàíä áåç àäðåíàëèíà, Ëèãíîêàèíà     

                                             │õëîðãèäðàò, Ëèäîêàèí, Ëèäîêàèí-Òåâà,        

                                             │Ëèäîêàèíà ãèäðîõëîðèä, Ëèäîêàèíà ãèäðîõëîðèä │

                                             │1% Áðàóí, Ëèäîêàèíà ãèäðîõëîðèä 2% Áðàóí,   

                                             │Ëèäîêàèíà ãèäðîõëîðèäà ðàñòâîð (ãëàçíûå     

                                             │êàïëè), Ëèäîêàèíà ãèäðîõëîðèäà ðàñòâîð äëÿ  

                                             │èíúåêöèé, Ëèäîêàèíà ãèäðîõëîðèäà ðàñòâîð äëÿ │

                                             │èíúåêöèé 2%, Ëèäîêàðò äëÿ èíúåêöèé, Ëóàí    

                                                                                         

│Ëèäîêàèí+Ýïèíåôðèí& - ìåñòíîàíåñòåçèðóþùåå   │Êñèëîäîíò, Êñèëîêàèí àäðåíàëèí, Êñèëîðîëëàíä │

│ñðåäñòâî                                     │ñ àäðåíàëèíîì, Ëèäîêàèí 2%-àäðåíàëèí,       

                                             │Îêòîêàèí 50                                 

                                                                                         

│Ëèçèí - ñðåäñòâî ïàðåíòåðàëüíîãî ïèòàíèÿ,    │D                                           

│àìèíîêèñëîòà                                                                             

                                                                                         

│Ëèçèíîïðèë - ÀÊÔ áëîêàòîð                    │Äàïðèë, Ëèçèð, Ëèçîðèë, Ïðèíèâèë, Ñèíîïðèë  

│Ëèíåñòðåíîë - ïðîãåñòàãåí                    │Îðãàìåòðèë, Ýêñëþòîí                        

                                                                                          

│Ëèíêîìèöèí - àíòèáèîòèê, ëèíêîçàìèä          │ÊÌÏ-Ëèíêîìèöèí, Ëèíêîìèöèíà ãèäðîõëîðèä,    

                                             │Ëèíêîìèöèíà ãèäðîõëîðèä â êàïñóëàõ 0.25 ã,  

                                             │Ëèíêîìèöèíà ãèäðîõëîðèä ìîíîãèäðàò,         

                                             │Ëèíêîìèöèíà ãèäðîõëîðèäà ðàñòâîð äëÿ        

                                             │èíúåêöèé 30%, Ëèíêîìèöèíîâàÿ ìàçü 2%,       

                                             │Ëèíêîöèí, Ìåäîãëèöèí, Íåëîðåí               

                                                                                         

│Ëèòèÿ êàðáîíàò - íîðìîòèìè÷åñêîå ñðåäñòâî    │Êîíòåìíîë, Ëèòèÿ êàðáîíàò, Ëèòèÿ êàðáîíàòà   

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.3 ã,          

                                             │Ëèòîñàí-ÑÐ, Ìèêàëèò, Ìèêàëèò â êàïñóëàõ 0.5 ã│

                                                                                          

│Ëèòèÿ íèêîòèíàò - íîðìîòèìè÷åñêîå ñðåäñòâî   │Ëèòîíèò, Ëèòîíèòà ðàñòâîð äëÿ èíúåêöèé 10%  

                                                                                         

│Ëèòèÿ îêñèáàò - íîðìîòèìè÷åñêîå ñðåäñòâî     │Ëèòèÿ îêñèáóòèðàò, Ëèòèÿ îêñèáóòèðàòà       

                                             │ðàñòâîð äëÿ èíúåêöèé 20%                    

                                                                                         

│Ëîáåëèí - àíàëåïòè÷åñêîå ñðåäñòâî            │Ëîáåëèíà ãèäðîõëîðèä, Ëîáåëèíà ãèäðîõëîðèäà 

                                             │ðàñòâîð 1% â àìïóëàõ, Ëîáåëèíà ãèäðîõëîðèäà 

                                             │ðàñòâîð äëÿ èíúåêöèé 1% â øïðèö-òþáèêàõ,    

                                             │Ëîáåñèë                                     

                                                                                         

│Ëîâàñòàòèí - ãèïîëèïèäåìè÷åñêîå ñðåäñòâî     │Ëîâàêîð, Ëîâàñòàòèí, Ìåâàêîð, Ìåäîñòàòèí,   

                                             │Ðåêîë, Ðîâàêîð                              

                                                                                         

│Ëîìåôëîêñàöèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,   │Ëîìôëîêñ, Ìàêñàêâèí                         

│ôòîðõèíîëîí                                                                              

                                                                                         

│Ëîïåðàìèä - ïðîòèâîäèàðåéíîå ñðåäñòâî        │Äèàðîë, Èìîäèóì, Ëîïåäèóì, Ëîïåäèóì ÈÇÎ,    

                                             │Ëîïåðàêàï, Ëîïåðàìèä, Ëîïåðàìèä-Àêðè        

                                             │êàïñóëû, Ëîïåðàìèä-Ðàòèîôàðì,               

                                             │Ëîïåðàìèä-Ðèâîôàðì, Ëîïåðàìèäà ãèäðîõëîðèä, 

                                             │Íåî-ýíòåðîñåïòîë, Ñóïåðèëîï, Ýíòåðîáåíå     

                                                                                         

│Ëîðàçåïàì - àíêñèîëèòè÷åñêîå ñðåäñòâî        │Àïî-Ëîðàçåïàì, Ëîðàì, Ìåðëèò, Òðàïåêñ       

                                                                                         

│Ëîðàòàäèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Êëàðèòèí, Ëîìèëàí, Ëîðàòàäèí                

│áëîêàòîð                                                                                 

                                                                                          

│Ìàãàëäðàò - àíòàöèäíîå ñðåäñòâî              │Ìàãàëôèë 800, Ìàãàëüäðàò                    

                                                                                         

│Ìàãíèÿ ãèäðîêñèä - àíòàöèäíîå ñðåäñòâî       │Ëàêñîìàã, Ìèëê îô ìàãíåçèÿ, Íàø âûáîð -     

                                             │Ìàé-ìàãíåçèÿ                                

                                                                                         

│Ìàãíèÿ ãèäðîêñèä+Ïàðàôèí æèäêèé& -           │Ëàêñîôèí, Ìèë-Ïàð                           

│ñëàáèòåëüíîå ñðåäñòâî                                                                    

                                                                                         

│Ìàãíèÿ îêñèä - àíòàöèäíîå ñðåäñòâî           │Ìàãíèÿ îêèñè òàáëåòêè 0.5 ã, Ìàãíèÿ îêèñü   

                                                                                         

│Ìàãíèÿ ñóëüôàò - âàçîäèëàòèðóþùåå ñðåäñòâî   │Êîðìàãíåçèí, Ìàãíèÿ ñóëüôàò, Ìàãíèÿ ñóëüôàòà │

                                             │ðàñòâîð äëÿ èíúåêöèé, Ìàãíèÿ ñóëüôàòà       

                                             │ðàñòâîð äëÿ èíúåêöèé 20%, Ìàãíèÿ ñóëüôàòà   

                                             │ðàñòâîð äëÿ èíúåêöèé 25%, Ìàãíèÿ-Äèàñïîðàë  

                                             │ôîðòå                                       

                                                                                         

│Ìàãíèÿ öèòðàò - ïðåïàðàò ìàãíèÿ              │Ìàãíåñîë, Ìàãíèÿ-Äèàñïîðàë, Ìàãíèÿ-Äèàñïîðàë │

                                             │300                                         

                                                                                         

│Ìàçèïðåäîí - ãëþêîêîðòèêîñòåðîèä             │Äåïåðçîëîí, Ïðåäíèçîë, Ïðåäíèçîëîí          

│Ìàëàòèîí - èíñåêòèöèäíîå ñðåäñòâî            │Àâèäóñò, Ïåäèëèí, Ôóôàíîí                   

                                                                                          

│Ìàííèòîë - äèóðåòè÷åñêîå ñðåäñòâî            │D (-) Ìàííèòîë, Ìàííèòà ðàñòâîð 15%,        

                                             │Ìàííèòîë, Ìàííèòîë 20%                      

                                                                                         

│Ìàïðîòèëèí - àíòèäåïðåññàíò                  │Ëþäèîìèë, Ìàïðîëó, Ìàïðîòèáåíå, Ìàïðîòèëèí  

                                                                                         

│Ìàôåíèä - ïðîòèâîìèêðîáíîå ñðåäñòâî,         │Ìàôåíèäà àöåòàò, Ìàôåíèäà àöåòàòà ìàçü 10%  

│ñóëüôàíèëàìèä                                                                            

                                                                                          

│Ìåáãèäðîëèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ     │Äèàçîëèí, Äèàçîëèíà äðàæå                   

│áëîêàòîð                                                                                 

                                                                                          

│Ìåáåíäàçîë - ïðîòèâîãåëüìèíòíîå ñðåäñòâî     │Âåðìàêàð, Âåðìîêñ, Âîðìèí, Ìåáåêñ,          

                                             │Ìåáåíäàçîë, Òåëìîêñ 100                     

                                                                                         

│Ìåãåñòðîë - ïðîãåñòàãåí                      │Ìåãåéñ, Ìåãåñòðîëà àöåòàò                   

                                                                                         

│Ìåäàçåïàì - àíêñèîëèòè÷åñêîå ñðåäñòâî        │Ìåäàçåïàì ÀÂÄ, Ìåäàçåïàì, Ìåçàïàì, Ìåçàïàìà 

                                             │ãðàíóëû äëÿ äåòåé, Ìåçàïàìà òàáëåòêè 0.01 ã, │

                                             │Íîáðèòåì                                     

                                                                                         

│Ìåäðîêñèïðîãåñòåðîí - ïðîãåñòàãåí            │Äåïî-Ïðîâåðà, Ìåãåñòðîí, ÌÏÀ 250, ÌÏÀ 500,  

                                             │Ïðîâåðà, Ôàðëóòàë, Öèêëîòàë                 

                                                                                         

│Ìåçîêàðá - ïñèõîñòèìóëèðóþùåå ñðåäñòâî       │Ñèäíîêàðá, Ñèäíîêàðáà òàáëåòêè              

│Ìåêëîôåíîêñàò - íîîòðîïíîå ñðåäñòâî          │Àöåôåí, Àöåôåíà òàáëåòêè 0.1 ã, Öåðóòèë     

│Ìåêñèëåòèí - àíòèàðèòìè÷åñêîå ñðåäñòâî       │Ìåêñèòèë, Ðèòàëìåêñ                         

│Ìåëàòîíèí - àäàïòîãåííîå ñðåäñòâî            │Ìåëàêñåí, Ìåëàïóð                            

                                                                                         

│Ìåëôàëàí - ïðîòèâîîïóõîëåâîå ñðåäñòâî        │Àëêåðàí, Ñàðêîëèçèí, Ñàðêîëèçèí (äëÿ        

                                             │ïðèãîòîâëåíèÿ èíúåêöèîííîãî ðàñòâîðà),      

                                             │Ñàðêîëèçèíà òàáëåòêè 0.01 ã                 

                                                                                         

│Ìåíàäèîíà íàòðèÿ áèñóëüôèò - âèòàìèí         │Âèêàñîë, Âèêàñîëà ðàñòâîð äëÿ èíúåêöèé 1%,  

                                             │Âèêàñîëà òàáëåòêè 0.015 ã                   

                                                                                         

│Ìåíîòðîïèíû - ôîëëèêóëîñòèìóëèðóþùåå ñðåäñòâî│Ãîíàäîòðîïèí ìåíîïàóçíûé, Ãîíàäîòðîïèí      

                                             │ìåíîïàóçíûé äëÿ èíúåêöèé, Ìåíîãîí,          

                                             │Ïåðãîãðèí, Ïåðãîíàë, Õóìåãîí                 

                                                                                         

│Ìåíòîëà ðàñòâîð â ìåíòèë èçîâàëåðàòå& -      │Âàëèäîë, Âàëèäîë â êàïñóëàõ, Âàëèäîë â      

│êîðîíàðîäèëàòèðóþùåå ñðåäñòâî                │êàïñóëàõ 0.01 ã, Âàëèäîë-Í, Âàëèäîëà ñ      

                                             │ãëþêîçîé òàáëåòêè 0.06 ã, Âàëèäîëà òàáëåòêè, │

                                             │Âàëèäîëà òàáëåòêè 0.06 ã                    

                                                                                         

│Ìåïàêðèí - ïðîòèâîãåëüìèíòíîå ñðåäñòâî       │Àêðèõèí, Àêðèõèíà òàáëåòêè ïîêðûòûå         

                                             │îáîëî÷êîé 0.05 ã                            

                                                                                         

│Ìåïèâàêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî   │Èçîêàèí 3%, Ìåïèâàñòåçèí, Ìåïèäîíò,         

                                             │Ìåïèêàòîí, Ñêàíäîíåñò                        

                                                                                         

│Ìåïðîáàìàò - àíêñèîëèòè÷åñêîå ñðåäñòâî       │Àïî-Ìåïðîáàìàò, Ìåïðîòàí, Ìåïðîòàíà òàáëåòêè │

                                                                                         

│Ìåðêàïòîïóðèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî   │Ìåðêàïòîïóðèíà òàáëåòêè 0.05 ã, Ïóðè-íåòîë, 

                                             │Òèîèíîçèå                                   

                                                                                         

│Ìåñàëàçèí - ïðîòèâîìèêðîáíîå è               │5-ÀÑÀ, Ìåçàêîë, Ïåíòàñà, Ñàëàçîïèðèäàçèí,   

│ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî               │Ñàëàçîïèðèäàçèíà ñóñïåíçèÿ 5%,               

                                             │Ñàëàçîïèðèäàçèíà òàáëåòêè 0.5 ã, Ñàëîçèíàë, 

                                             │Ñàëîôàëüê, Ñâå÷è ñ ñàëàçîïèðèäàçèíîì 0.5 ã  

                                                                                          

│Ìåñíà - ìóêîëèòè÷åñêîå ñðåäñòâî              │Ìèñòàáðîí, Ìóêîôëþèä, Óðîìèòåêñàí,          

                                             │Óðîìèòåêñàí 400 ìã, Óðîìèòåêñàí 600 ìã      

                                                                                         

│Ìåòàìèçîë íàòðèÿ - àíàëüãåòè÷åñêîå           │Àíàëüãèí, Àíàëüãèí â êàïñóëàõ 0.25 ã,       

│íåíàðêîòè÷åñêîå ñðåäñòâî                     │Àíàëüãèí äëÿ èíúåêöèé, Àíàëüãèí èíúåêò ÁÕ,  

                                             │Àíàëüãèíà ðàñòâîð â àìïóëàõ, Àíàëüãèíà      

                                             │òàáëåòêè, Àíàëüãèíà òàáëåòêè 0.5 ã, Áàðàëãèí │

                                             │Ì, Äåâàëæèí, Èëâàãèí, Ìåòàìèçîë íàòðèÿ,     

                                             │Íåáàãèí, Íîáîë, Îïòàëüãèí-Òåâà, Ñïàçäîëçèí, 

                                             │Ñóïïîçèòîðèè ðåêòàëüíûå ñ àíàëüãèíîì äëÿ    

                                             │äåòåé                                       

                                                                                         

│Ìåòàìèçîë+Ïèòîôåíîí+Ôåíïèâåðèíèÿ áðîìèä& -   │Áàðàëãèí, Áåðëîí, Áðàë, Çîëîãàí, Ìàêñèãàí,  

│àíàëüãåòè÷åñêîå è ñïàçìîëèòè÷åñêîå ñðåäñòâî  │Ìèíàëüãàí, Íåáàëãàí, Ñïàçâèí, Ñïàçãàí,      

                                             │Ñïàçìàëãèí, Ñïàçìàëãîí, Ñïàçìîãàðä, Ñïàçíèë, │

                                             │Òðèãàí                                       

                                                                                         

│Ìåòàíäèåíîí - àíàáîëè÷åñêîå ñòåðîèäíîå       │Ìåòàíäðîñòåíîëîí, Ìåòàíäðîñòåíîëîíà òàáëåòêè │

│ñðåäñòâî                                     │0.001 ã, Ìåòàíäðîñòåíîëîíà òàáëåòêè 0.005 ã 

                                                                                         

│Ìåòàíäðèîë - àíàáîëè÷åñêîå ñòåðîèäíîå        │Ìåòèëàíäðîñòåíäèîë, Ìåòèëàíäðîñòåíäèîëà     

│ñðåäñòâî                                     │òàáëåòêè                                    

                                                                                         

│Ìåòàöèêëèí - àíòèáèîòèê, òåòðàöèêëèí         │Ìåòàöèêëèíà ãèäðîõëîðèä, Ìåòàöèêëèíà        

                                             │ãèäðîõëîðèä â êàïñóëàõ, Ðîíäîìèöèí          

                                                                                         

│Ìåòåíàìèí - ïðîòèâîìèêðîáíîå ñðåäñòâî        │Ãåêñàìåòèëåíòåòðàìèí (Óðîòðîïèí),            

                                             │Ãåêñàìåòèëåíòåòðàìèíà ðàñòâîð äëÿ èíúåêöèé  

                                             │40%, Ãåêñàìåòèëåíòåòðàìèíà òàáëåòêè         

                                                                                          

│Ìåòèëäèãîêñèí - êàðäèîòîíè÷åñêîå ñðåäñòâî,   │Ëàíèòîï, Ìåäèëàçèä, Ìåäèëàçèäà òàáëåòêè     

│ñåðäå÷íûé ãëèêîçèä                           │0.0001 ã                                    

                                                                                         

│Ìåòèëäîïà - àëüôà2-àäðåíîñòèìóëÿòîð          │Àëüäîìåò, Àëüôàäîïà, Äîïàíîë, Äîïåãèò, Ýêèáàð│

│öåíòðàëüíûé                                                                              

                                                                                         

│Ìåòèëìåòèîíèíñóëüôîíèé - âèòàìèí             │Ìåòèëìåòèîíèíñóëüôîíèÿ õëîðèä (âèòàìèí U),  

                                             │Ìåòèëìåòèîíèíñóëüôîíèÿ õëîðèäà (âèòàìèí U)  

                                             │òàáëåòêè 0.05 ã                             

                                                                                         

│Ìåòèëïðåäíèçîëîí - ãëþêîêîðòèêîñòåðîèä       │Äåïî-Ìåäðîë, Ìåäðîë, Ìåòèëïðåäíèçîëîí,      

                                             │Ìåòèïðåä, Ñîëó-Ìåäðîë, Óðáàçîí              

                                                                                         

│Ìåòèëòåñòîñòåðîí - àíäðîãåí                  │Ìåòèëòåñòîñòåðîíà òàáëåòêè 0.005 ã,         

                                             │Ìåòèëòåñòîñòåðîíà òàáëåòêè 0.01 ã           

                                                                                          

│Ìåòèëòèîíèíèÿ õëîðèä - àíòèñåïòè÷åñêîå       │Ìåòèëåíîâîãî ñèíåãî ðàñòâîð âîäíûé 1%,      

│ñðåäñòâî                                     │Ìåòèëåíîâîãî ñèíåãî ðàñòâîð ñïèðòîâîé 1%,   

                                             │Ìåòèëåíîâûé ñèíèé                           

                                                                                         

│Ìåòèëóðàöèë& - ðåãåíåðàöèè ñòèìóëÿòîð        │Ìåòèëóðàöèë, Ìåòèëóðàöèëà òàáëåòêè 0.5 ã,   

                                             │Ìåòèëóðàöèëîâàÿ ìàçü 10%, Ìåòóðàêîë, Ñâå÷è ñ │

                                             │ìåòèëóðàöèëîì 0.5 ã                         

                                                                                         

│Ìåòèëýðãîìåòðèí - àëüôà-àäðåíîñòèìóëÿòîð     │Ìåòèëýðãîáðåâèí, Ìåòèëýðãîìåòðèí            

                                                                                         

│Ìåòèîíèí - ìåòàáîëè÷åñêîå ñðåäñòâî           │L-Ìåòèîíèí, Ìåòèîíèí, Ìåòèîíèíà òàáëåòêè    

                                             │ïîêðûòûå îáîëî÷êîé 0.25 ã                   

                                                                                         

│Ìåòîêëîïðàìèä - ïðîòèâîðâîòíîå ñðåäñòâî,     │Àïî-Ìåòîêëîï, Ãàñòðîñèë, Äèáåðòèë, Êëîìåòîë, │

│äîôàìèí áëîêàòîð öåíòðàëüíûé                 │Ìåòàìîë, Ìåòîêëîïðàìèä, Ïåðèíîðì, Ðåãëàí,   

                                             │Öåðóêàë, Öåðóëàí                            

                                                                                         

│Ìåòîïðîëîë - áåòà1-àäðåíîáëîêàòîð ñåëåêòèâíûé│Áåòàëîê, Âàçîêàðäèí, Êîðâèòîë, Ëîïðåñîð,    

                                             │Ìåòîãåêñàë, Ìåòîêàðä, Ìåòîëîë, Ìåòîïðîëîë,  

                                             │Ìåòîïðîëîë ÎÔ, Ìåòîïðîëîë ÎÔ 200 ðåòàðä,    

                                             │Ìåòîïðîëîë-Ðàòèîôàðì, Ìåòîïðîëîë-Òåâà,      

                                             │Ñïåñèêîð                                     

                                                                                         

│Ìåòîòðåêñàò - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Ìåòîòðåêñàò (Ýìòåêñàò), Ìåòîòðåêñàò äëÿ     

                                             │èíúåêöèé, Ìåòîòðåêñàò äëÿ èíúåêöèé 0.005 ã, 

                                             │Ìåòîòðåêñàò-Òåâà, Ìåòîòðåêñàò-Ýáåâå,        

                                             │Ìåòîòðåêñàòà òàáëåòêè ïîêðûòûå îáîëî÷êîé    

                                             │0.0025 ã, Òðåêñàí, Òðèêñèëåì                

                                                                                         

│Ìåòîöèíèÿ éîäèä - ì-õîëèíîáëîêàòîð           │Ìåòàöèí, Ìåòàöèíà ðàñòâîð äëÿ èíúåêöèé 0.1%, │

                                             │Ìåòàöèíà òàáëåòêè 0.002 ã                   

                                                                                         

│Ìåòðàëèíäîë& - àíòèäåïðåññàíò                │Èíêàçàí, Èíêàçàíà òàáëåòêè 0.025 ã          

                                                                                         

│Ìåòðîíèäàçîë - ïðîòèâîìèêðîáíîå ñðåäñòâî     │Àïî-Ìåòðîíèäàçîë, Àðèëèí, Ãåí-Çîëåðîë,      

                                             │Äåôëàìîí, Êàìåçîë, Êëèîí, Ìåäàçîë, Ìåòðîãèë, │

                                             │Ìåòðîêñàí, Ìåòðîíèäàçîë, Ìåòðîíèäàçîë â/â   

                                             │Áðàóí, Ìåòðîíèäàçîë Êâàëèìåä, Ìåòðîíèäàçîë  

                                             │Íèêîìåä, Ìåòðîíèäàçîë-Òåâà, Ìåòðîíèäàçîëà   

                                             │áåíçîàò, Ìåòðîíèäàçîëà ãåìèñóêöèíàò,        

                                             │Ìåòðîíèäàçîëà ãåìèñóêöèíàò äëÿ èíúåêöèé,    

                                             │Ìåòðîíèäàçîëà òàáëåòêè 0.25 ã, Íèäàçîë,     

                                             │Íîâî-Íèäàçîë, Îðâàãèë, Ïðîòàìåò, Òðèõàçîë,  

                                             │Òðèõîïåêñ, Òðèõîïîë, Ôèëìåò, Ôëàãèë, Ýôëîðàí │

                                                                                         

│Ìåòôîðìèí - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ     │Ãëèêîí, Ãëèôîðìèí, Ãëèôîðìèíà òàáëåòêè 0.25 

│ïåðîðàëüíîãî ïðèåìà                          │ã, Ãëþêîôàã, Ìåòôîðìèí, Ìåòôîðìèí-ÁÌÑ,      

                                             │Ñèîôîð 500, Ñèîôîð 850                      

                                                                                          

│Ìåôåíàìîâàÿ êèñëîòà - ÍÏÂÑ                   │Ìåôåíàìèíà íàòðèåâàÿ ñîëü, Ìåôåíàìèíîâàÿ    

                                             │êèñëîòà, Ìåôåíàìèíîâîé êèñëîòû òàáëåòêè     

                                                                                          

│Ìèàíñåðèí - àíòèäåïðåññàíò                   │Ëåðèâîí, Ìèàíñàí, Ìèàíñåðèí                 

│Ìèäàçîëàì - ñíîòâîðíîå ñðåäñòâî              │Äîðìèêóì, Ôëîðìèäàë                         

                                                                                         

│Ìèêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî        │Ãèíåçîë 7, Ãèíî-Äàêòàíîë, Ãèíî-Äàêòàðèí,    

                                             │Äàêòàíîë, Äàêòàðèí, Ëàíàäåðì                

                                                                                         

│Ìèëäðîíàò& - ìåòàáîëè÷åñêîå ñðåäñòâî         │Ìèëäðîíàò, Ìèëäðîíàò â êàïñóëàõ 0.25 ã,     

                                             │Ìèëäðîíàòà ðàñòâîð äëÿ èíúåêöèé 10%         

                                                                                         

│Ìèíîêñèäèë - âàçîäèëàòèðóþùåå ñðåäñòâî       │Àëîïåêñè, Ëîíèòåí, Ðåãåéí                   

                                                                                          

│Ìèòîêñàíòðîí - ïðîòèâîîïóõîëåâîå ñðåäñòâî    │Ìèòîêñàíòðîí ÀÂÄ, Ìèòîêñàíòðîí ÀÂÄ 25,      

                                             │Íîâàíòðîí                                   

                                                                                         

│Ìèòîìèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Ìèòîìèöèí-Ñ Êèîâà, Ìóòàìèöèí                

│Ìèòîòàí - ïðîòèâîîïóõîëåâîå ñðåäñòâî         │Õëîäèòàí, Õëîäèòàíà òàáëåòêè 0.5 ã          

                                                                                         

│Ìîêñîíèäèí - àëüôà2-àäðåíîñòèìóëÿòîð         │Ôèçèîòåíç, Öèíò                             

│öåíòðàëüíûé                                                                               

                                                                                         

│Ìîëñèäîìèí - âàçîäèëàòèðóþùåå ñðåäñòâî       │Êîðâàìèí, Êîðâàòîí, Ìîëñèäîìèí, Ñèäíîôàðì   

│Ìîíîôîñòèàìèí - âèòàìèí                      │Òèàìèíà ôîñôàò, Ôîñôîòèàìèíà òàáëåòêè       

                                                                                         

│Ìîðàöèçèí - àíòèàðèòìè÷åñêîå ñðåäñòâî        │Ýòìîçèí, Ýòìîçèíà ðàñòâîð äëÿ èíúåêöèé 2.5%, │

                                             │Ýòìîçèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé        

                                                                                         

│Ìîðôèí - àíàëüãåòè÷åñêîå íàðêîòè÷åñêîå       │Äîëòàðä, Ìîðôèëîíã, Ìîðôèí, Ìîðôèíà          

│ñðåäñòâî                                     │ãèäðîõëîðèä, Ìîðôèíà ãèäðîõëîðèäà ðàñòâîð 1% │

                                             │â øïðèö-òþáèêàõ, Ìîðôèíà ãèäðîõëîðèäà       

                                             │ðàñòâîð äëÿ èíúåêöèé 1%, Ìîðôèíà            

                                             │ãèäðîõëîðèäà òàáëåòêè 0.01 ã, Ìîðôèíà       

                                             │ñóëüôàò, ÌÑÒ êîíòèíóñ                       

                                                                                         

│Ìî÷åâèíû ïåðîêñèä - àíòèñåïòè÷åñêîå ñðåäñòâî │Ãèäðîïåðèò, Ãèäðîïåðèòà òàáëåòêè 1.5 ã      

│Íàáóìåòîí - ÍÏÂÑ                             │Ðåëàôåí, Ðîäàíîë S                          

│Íàäîëîë - áåòà-àäðåíîáëîêàòîð                │Êîðãàðä, Êîðãàðä 80, Íàäîëîë                

                                                                                         

│Íàëèäèêñîâàÿ êèñëîòà - ïðîòèâîìèêðîáíîå      │Íåâèãðàìîí, Íåãðàì                           

│ñðåäñòâî, õèíîëîí                                                                        

                                                                                         

│Íàëîðôèí - îïèîèäíûõ ðåöåïòîðîâ              │Íàëîðôèíà ðàñòâîð â àìïóëàõ, Òèäèãåñèê      

│àãîíèñò-àíòàãîíèñò                                                                       

                                                                                         

│Íàíäðîëîí - àíàáîëè÷åñêîå ñòåðîèäíîå ñðåäñòâî│Äåêà-äóðàáîëèí, Ðåòàáîëèë, Ôåíîáîëèí,       

                                             │Ôåíîáîëèíà ðàñòâîð äëÿ èíúåêöèé â ìàñëå     

                                                                                          

│Íàïðîêñåí - ÍÏÂÑ                             │Àëèâ, Àïî-Íàïðîêñåí, Àïðàíàêñ, Äàïðîêñ      

                                             │ýíòåðî, Íàëãåçèí, Íàëãåçèí ôîðòå, Íàïðèîñ,  

                                             │Íàïðîáåíå, Íàïðîêñåí, Íàïðîêñåí-ICN,        

                                             │Íàïðîêñåí-Òåâà, Íàïðîêñåíà íàòðèåâàÿ ñîëü,  

                                             │Íàïðîñèí, Íîðèòèñ, Ñàíàïðîêñ                

                                                                                         

│Íàòðèÿ àìèäîòðèçîàò - ðåíòãåíîêîíòðàñòíîå    │Òðèîìáðàñò äëÿ èíúåêöèé, Òðèîìáðèí,         

│ñðåäñòâî                                     │Òðèîìáðèí ðàñòâîð 50%, Óðîãðàôèí, Óðîòðàñò  

                                                                                         

│Íàòðèÿ ãèäðîêàðáîíàò& - àíòèàöèäåìè÷åñêîå    │Íàòðèÿ ãèäðîêàðáîíàò, Íàòðèÿ ãèäðîêàðáîíàò  

│ñðåäñòâî                                     │äëÿ èíúåêöèé 4 ã, Íàòðèÿ ãèäðîêàðáîíàòà     

                                             │ðàñòâîð äëÿ èíúåêöèé 4%, Íàòðèÿ             

                                             │ãèäðîêàðáîíàòà òàáëåòêè, Íàòðèÿ             

                                             │ãèäðîêàðáîíàòà òàáëåòêè 0.5 ã, Ñâå÷è ñ      

                                             │íàòðèÿ ãèäðîêàðáîíàòîì                      

                                                                                         

│Íàòðèÿ ãèïîõëîðèò - äåçèíôèöèðóþùåå ñðåäñòâî │Àìóêèí, Áåëåí, Ãèïîõëîðèò íàòðèÿ, Ãèïîõëîðèò │

                                             │íàòðèÿ (âûðàáàòûâàåìûé íà óñòàíîâêå         

                                             │ÓÄÐ-01"), Ãèïîõëîðèò íàòðèÿ (âûðàáàòûâàåìûé 

                                             │íà óñòàíîâêå Õëîðýôñ"), Ãèïîõëîðèò íàòðèÿ   

                                             │(âûðàáàòûâàåìûé íà óñòàíîâêå Ýêîìèð-1"),    

                                             │Ãèïîõëîðèò íàòðèÿ (âûðàáàòûâàåìûé           

                                                                                         

│Íàòðèÿ äåçîêñèðèáîíóêëåàò& - ëåéêîïîýçà      │Äåçîêñèíàò (Íàòðèÿ äåçîêñèðèáîíóêëåàò),     

│ñòèìóëÿòîð                                   │Äåçîêñèíàòà ðàñòâîð 0.25%, Äåçîêñèíàòà      

                                             │ðàñòâîð äëÿ èíúåêöèé 0.5%, Íàòðèåâàÿ ñîëü   

                                             │äâóñïèðàëüíîé ðèáîíóêëåèíîâîé êèñëîòû,      

                                             │Íàòðèÿ äåçîêñèðèáîíóêëåàò (ÄÍÊ-Na), Íàòðèÿ  

                                             │äåçîêñèðèáîíóêëåàòà ðàñòâîð äëÿ èíúåêöèé    

                                             │1.5% (Äåðèíàò), Íàòðèÿ äåçîêñèðèáîíóêëåàòà  

                                             │ðàñòâîð äëÿ íàðóæíîãî ïðèìåíåíèÿ, Íàòðèÿ    

                                             │íóêëåèíàò                                   

                                                                                          

│Íàòðèÿ îêñèáàò - íàðêîçíîå íåèíãàëÿöèîííîå   │Íàòðèÿ îêñèáóòèðàò, Íàòðèÿ îêñèáóòèðàòà     

│ñðåäñòâî                                     │ðàñòâîð 20% â àìïóëàõ, Íàòðèÿ îêñèáóòèðàòà  

                                             │ðàñòâîð 66.7%, Íàòðèÿ îêñèáóòèðàòà ðàñòâîð  

                                             │äëÿ èíúåêöèé 20%, Íàòðèÿ îêñèáóòèðàòà ñèðîï 

                                             │5%                                          

                                                                                         

│Íàòðèÿ ïèêîñóëüôàò - ñëàáèòåëüíîå ñðåäñòâî   │Ãóòòàëàêñ, Ëàêñèãàë                         

                                                                                          

│Íàòðèÿ òåòðàáîðàò& - èíñåêòèöèäíîå ñðåäñòâî  │Àñìóð, Íàòðèÿ òåòðàáîðàò, Íàòðèÿ òåòðàáîðàòà │

                                             │(Áóðû) ðàñòâîð â ãëèöåðèíå 20%, ÎÏÒ-I       

                                                                                          

│Íàòðèÿ òåòðàäåöèëñóëüôàò -                   │Äåöèëàòà ðàñòâîð äëÿ èíúåêöèé, Äåöèëàòà     

│âåíîñêëåðîçèðóþùåå ñðåäñòâî                  │ðàñòâîð êîíöåíòðèðîâàííûé, Òðîìáîâàð,       

                                             │Ôèáðî-Âåéí                                  

                                                                                         

│Íàòðèÿ ôîñôàò - ñëàáèòåëüíîå ñðåäñòâî        │Íàòðèÿ ôîñôàò (äâóçàìåùåííûé), Ýíèìàêñ ýíèìà │

                                                                                         

│Íàòðèÿ ôòîðèä - ïðåïàðàò ôòîðà               │Êîðåáåðîí, Íàòðèóì ôëóîðàòóì, Íàòðèÿ ôòîðèä, │

                                             │Íàòðèÿ ôòîðèä äëÿ äåòåé, Íàòðèÿ ôòîðèäà     

                                             │ðàñòâîð, Íàòðèÿ ôòîðèäà òàáëåòêè äëÿ äåòåé, 

                                             │Îññèí, Ôëþîðåòò                             

                                                                                         

│Íàòðèÿ öèòðàò - ãåìîêîíñåðâàíò,              │Íàòðèÿ ãèäðîöèòðàò (äâóçàìåùåííûé), Íàòðèÿ  

│âñïîìîãàòåëüíîå âåùåñòâî                     │öèòðàò äëÿ èíúåêöèé, Ðàñòâîð Öèòðàòà íàòðèÿ 

                                             │4%                                          

                                                                                         

│Íàôàçîëèí - àëüôà-àäðåíîñòèìóëÿòîð           │Íàôòèçèí, Íàôòèçèíà ðàñòâîð, Íàôòèçèíà      

                                             │ðàñòâîð 0.05%, Íàôòèçèíà ðàñòâîð 0.1%,      

                                             │Ñàíîðèí                                     

                                                                                          

│Íåäîêðîìèë - ïðîòèâîàëëåðãè÷åñêîå ñðåäñòâî   │Òàéëåä, Òàéëåä ìèíò, Òèëàâèñò, Òèëàðèí      

                                                                                         

│Íåîìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä         │Íåîìèöèíà ñóëüôàò, Íåîìèöèíà ñóëüôàò        

                                             │(Ìèöåðèí), Íåîìèöèíà ñóëüôàòà òàáëåòêè,     

                                             │Íåîìèöèíîâàÿ ìàçü                           

                                                                                         

│Íåîìèöèí+Ôëóîöèíîëîí& -                      │Ñèíàëàð Í, Ôëóêîðò Í, Ôëóöèíàð Í            

│ãëþêîêîðòèêîñòåðîèä+ïðîòèâîìèêðîáíîå ñðåäñòâî│                                             

                                                                                         

│Íåîñòèãìèíà ìåòèëñóëüôàò -                   │Ïðîçåðèí, Ïðîçåðèíà ãðàíóëû äëÿ äåòåé,      

│àíòèõîëèíýñòåðàçíîå ñðåäñòâî                 │Ïðîçåðèíà ðàñòâîð äëÿ èíúåêöèé 0.05%,       

                                             │Ïðîçåðèíà òàáëåòêè 0.015 ã                  

                                                                                         

│Íèêåòàìèä - àíàëåïòè÷åñêîå ñðåäñòâî          │Äèýòèëàìèä íèêîòèíîâîé êèñëîòû, Êîðäèàìèí,  

                                             │Êîðäèàìèí äëÿ èíúåêöèé, Êîðäèàìèí äëÿ       

                                             │èíúåêöèé â øïðèö-òþáèêàõ                     

                                                                                         

│Íèêëîçàìèä - ïðîòèâîãåëüìèíòíîå ñðåäñòâî     │Ôåíàñàë, Ôåíàñàëà òàáëåòêè 0.25 ã           

                                                                                          

│Íèêîòèí - ñðåäñòâî îáëåã÷åíèÿ îòêàçà îò      │Íèêîðåòòå, Íèêîòèíåëë ÒÒÑ 10, Íèêîòèíåëë ÒÒÑ │

│êóðåíèÿ                                      │20, Íèêîòèíåëë ÒÒÑ 30                       

                                                                                         

│Íèêîòèíàìèä - âèòàìèí                        │Íèêîòèíàìèä ôàðìà, Íèêîòèíàìèäà ðàñòâîð äëÿ 

                                             │èíúåêöèé, Íèêîòèíàìèäà òàáëåòêè,            

                                             │Íèêîòèíàìèäà òàáëåòêè 0.015 ã               

                                                                                         

│Íèêîòèíîâàÿ êèñëîòà - âèòàìèí                │Íèàöèí ÞÑÏ, Íèêîòèíîâàÿ êèñëîòà, Íèêîòèíîâîé │

                                             │êèñëîòû ðàñòâîð äëÿ èíúåêöèé 1%, Íèêîòèíîâîé │

                                             │êèñëîòû òàáëåòêè, Íèêîòèíîâîé êèñëîòû       

                                             │òàáëåòêè 0.05 ã, Ýíäóðàöèí                  

                                                                                         

│Íèêîòèíîèëãàììà-àìèíîìàñëÿíàÿ êèñëîòà& -     │Ïèêàìèëîí, Ïèêàìèëîíà ðàñòâîð äëÿ èíúåêöèé, 

│íîîòðîïíîå ñðåäñòâî                          │Ïèêàìèëîíà òàáëåòêè                         

                                                                                         

│Íèìåñóëèä - ÍÏÂÑ                             │Ìåñóëèä, Íàéç, Íèìóëèä, Ôëîëèä              

│Íèìîäèïèí - ÁÌÊÊ                             │Íåìîòàí, Íèìîòîï                            

                                                                                         

│Íèñòàòèí& - ïðîòèâîãðèáêîâîå ñðåäñòâî        │Íèñòàòèí, Íèñòàòèíà ãðàíóëû äëÿ äåòåé 100000 │

                                             │ÅÄ/ã, Íèñòàòèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé, │

                                             │Íèñòàòèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 500000 │

                                             │ÅÄ, Íèñòàòèíîâàÿ ìàçü 100000 ÅÄ/ã, Ñâå÷è ñ  

                                             │íèñòàòèíîì, Ñóïïîçèòîðèè âàãèíàëüíûå ñ      

                                             │íèñòàòèíîì                                  

                                                                                         

│Íèòðàçåïàì - ñíîòâîðíîå ñðåäñòâî             │Áåðëèäîðì 10, Áåðëèäîðì 5, Íèòðàçàäîí,      

                                             │Íèòðàçåïàì, Íèòðàçåïàìà òàáëåòêè, Íèòðàì,   

                                             │Íèòðîñàí, Ðàäåäîðì 5, Ýóíîêòèí              

                                                                                         

│Íèòðåíäèïèí - ÁÌÊÊ                           │Ëþñîïðåññ, Íèòðåíäèïèí, Íèòðåïèí, Óíèïðåñ   

                                                                                         

│Íèòðîãëèöåðèí - âàçîäèëàòèðóþùåå ñðåäñòâî    │Äåïîíèò 10, Äåïîíèò 5, Íèðìèí, Íèñêîíèòðèí, 

                                             │Íèò-ðåò, Íèòðàíãèí, Íèòðàíãèí ëèêâèäóì,     

                                             │Íèòðî, Íèòðî Ìàê, Íèòðî Ìàê ðåòàðä, Íèòðî   

                                             │Ïîëü Èíôóç, Íèòðî-äóð, Íèòðîãëèöåðèí,       

                                             │Íèòðîãëèöåðèí ìèêðîãðàíóëû, Íèòðîãëèöåðèí   

                                             │Íèêîìåä, Íèòðîãëèöåðèí ñ ãëþêîçîé,          

                                             │Íèòðîãëèöåðèíà êîíöåíòðàò äëÿ èíôóçèé 1%,   

                                             │Íèòðîãëèöåðèíà ïðîëîíãèðîâàííîãî òàáëåòêè,  

                                             │Íèòðîãëèöåðèíà ðàñòâîð 1%, Íèòðîãëèöåðèíà   

                                             │ðàñòâîð â ìàñëå 1% â êàïñóëàõ,              

                                             │Íèòðîãëèöåðèíà ðàñòâîð äëÿ èíúåêöèé 0.1%,   

                                             │Íèòðîãëèöåðèíà òàáëåòêè 0.0005 ã,           

                                             │Íèòðîãðàíóëîíã, Íèòðîãðàíóëîíãà òàáëåòêè    

                                             │ïîêðûòûå îáîëî÷êîé, Íèòðîäåðì ÒÒÑ 10,       

                                             │Íèòðîäåðì ÒÒÑ 5, Íèòðîäæåêò,                 

                                             │Íèòðîëèíãâàë-àýðîçîëü, Íèòðîìèíò, Íèòðîíã,  

                                             │Íèòðîíã ôîðòå, Íèòðîïåðêóòåí ÒÒÑ, Íèòðîñîë, 

                                             │Ïåðëèíãàíèò, Ñóñòàê, Ñóñòàê ôîðòå,          

                                             │Ñóñòàê-ìèòå, Ñóñòîíèò, Òðèíèòðîëîíã         

                                                                                         

│Íèòðîêñîëèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,     │5-íèòðîêñ, 5-ÍÎÊ, Íèòðîêñîëèí, Íèòðîêñîëèíà 

│îêñèõèíîëèí                                  │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.05 ã          

                                                                                         

│Íèòðîïðóññèä íàòðèÿ - âàçîäèëàòèðóþùåå       │Íàíèïðóñ, Íàòðèÿ íèòðîïðóññèä, Íàòðèÿ       

│ñðåäñòâî                                     │íèòðîïðóññèä äëÿ èíúåêöèé                   

                                                                                          

│Íèòðîôóðàë - àíòèñåïòè÷åñêîå ñðåäñòâî        │Ëèôóçîëü, Ôóðàöèëèí, Ôóðàöèëèíà ðàñòâîð     

                                             │0.02% (ñòåðèëüíûé), Ôóðàöèëèíà ðàñòâîð      

                                             │ñïèðòîâîé 1:1500, Ôóðàöèëèíà òàáëåòêè 0.1 ã, │

                                             │Ôóðàöèëèíà òàáëåòêè äëÿ íàðóæíîãî           

                                             │óïîòðåáëåíèÿ 0.02 ã, Ôóðàöèëèíîâàÿ ìàçü     

                                             │0.2%, Ôóðàöèëèíîâàÿ ïàñòà                   

                                                                                         

│Íèòðîôóðàíòîèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,  │Àïî-Íèòðîôóðàíòîèí, Ôóðàäîíèí, Ôóðàäîíèíà   

│íèòðîôóðàí                                   │òàáëåòêè, Ôóðàäîíèíà òàáëåòêè 0.05 ã,       

                                             │Ôóðàäîíèíà òàáëåòêè äëÿ äåòåé 0.03 ã        

                                             │(ðàñòâîðèìûå â êèøå÷íèêå, Ôóðàäîíèíà        

                                             │òàáëåòêè ðàñòâîðèìûå â êèøå÷íèêå 0.1 ã      

                                                                                         

│Íèôåäèïèí - ÁÌÊÊ                             │Àäàëàò, Àäàëàò ÑË, Àíèôåä, Àïî-Íèôåä,       

                                             │Ãèïåðíàë, Ãèïåðíàë 10, Ãèïåðíàë 5, Ãèïåðíàë 

                                             │êàïëè, Äåïèí-Å, Çåíóñèí, Êàëüöèãàðä ðåòàðä, 

                                             │Êàëüöèãàðä-10, Êàëüöèãàðä-5, Êîðäàôåí,      

                                             │Êîðäàôëåêñ, Êîðäèïèí, Êîðäèïèí XL,          

                                             │Êîðäèïèí-ðåòàðä, Êîðèíôàð, Êîðèíôàð ÓÍÎ,    

                                             │Íèêàðäèÿ, Íèêàðäèÿ ÑÄ ðåòàðä, Íèôåáåíå,     

                                             │Íèôåãåêñàë, Íèôåäåêñ, Íèôåäèêàï, Íèôåäèêîð, 

                                             │Íèôåäèïàò-10, Íèôåäèïàò-5, Íèôåäèïàò-ðåòàðä, │

                                             │Íèôåäèïèí, Íèôåäèïèí 20 ðåòàðä,             

                                             │Íèôåäèïèí-Õ-Ðàòèîôàðì, Íèôåêàðä, Íèôåëàò,   

                                             │Íèôåëàò Q, Íèôåëàò Ð, Íèôèêàðä,             

                                             │Íîâî-Íèôåäèí, Îñìî-Àäàëàò, Ðîíèàí,          

                                             │Ñàíôèäèïèí, Ñïîíèô 10, Ôåíàìîí, Ôåíèãèäèí,  

                                             │Ôåíèãèäèíà òàáëåòêè, Ôåíèãèäèíà òàáëåòêè    

                                             │0.01 ã, Ôëåêîð-Í, Ýêîäèïèí                  

                                                                                          

│Íèôëóìîâàÿ êèñëîòà - ÍÏÂÑ                    │Äîíàëãèí, Íèôëóãåëü, Íèôëóðèë               

                                                                                         

│Íèôóðîêñàçèä - ïðîòèâîìèêðîáíîå ñðåäñòâî,    │Äèàñòàò, Íèôóðîêñàçèä, Ýðñåôóðèë, Ýðöåôóðèë 

│íèòðîôóðàí                                                                               

                                                                                         

│Íèöåðãîëèí - àëüôà-àäðåíîáëîêàòîð            │Íèöåëèí, Íèöåðãîëèí, Íèöåðãîëèí äëÿ èíúåêöèé │

                                             │0.004 ã, Ñåðìèîí, Ñåðìèîí òàáëåòêè ïîêðûòûå 

                                             │îáîëî÷êîé 0.01 ã, Ýðãîòîï                   

                                                                                         

│Íîíîêñèíîë - êîíòðàöåïòèâíîå ìåñòíîå ñðåäñòâî│ÀÁÔ ïëåíêà, Êîíöåïòðîë, Ïàòåíòåêñ Îâàëü,    

                                             │Ñòåðèëèí                                     

                                                                                         

│Íîðôëîêñàöèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,    │Àíêâèí, Áàêòèíîð, Ãèðàáëîê, Êâèíîëîêñ,      

│ôòîðõèíîëîí                                  │Ëîêñîí 400, Íåãàôëîêñ, Íîëèöèí, Íîðáàêòèí,  

                                             │Íîðèëåò, Íîðìàêñ, Íîðîêñèí, Íîðôëîêñàöèí,   

                                             │Ðåíîð, Ñîôàçèí, Ñïåêòðàìà, ×èáðîêñèí, Þòèáèä │

                                                                                         

│Íîðýïèíåôðèí - àëüôà-àäðåíîñòèìóëÿòîð        │Íîðàäðåíàëèíà ãèäðîòàðòðàò, Íîðàäðåíàëèíà   

                                             │ãèäðîòàðòðàòà ðàñòâîð äëÿ èíúåêöèé 0.2%     

                                                                                         

│Íîðýòèñòåðîí - ïðîãåñòàãåí                   │Ìèêðîíîð, Íîðêîëóò, Ïðèìîëþò-íîð            

                                                                                          

│Îçîêåðàôèí& - ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî │Îçîêåðàôèí, Îçîêåðàôèíîâàÿ ñàëôåòêà         

│äëÿ ìåñòíîãî ïðèìåíåíèÿ                                                                  

                                                                                         

│Îêñàçåïàì - àíêñèîëèòè÷åñêîå ñðåäñòâî        │Àïî-Îêñàçåïàì, Íîçåïàì, Íîçåïàìà òàáëåòêè   

                                             │0.01 ã, Îêñàçåïàì-Ðàòèîôàðì, Îêñàçåïàì,     

                                             │Òàçåïàì                                     

                                                                                         

│Îêñàöèëëèí - àíòèáèîòèê, ïåíèöèëëèí          │Îêñàöèëëèí íàòðèåâàÿ ñîëü - êîìïàêò,        

                                             │Îêñàöèëëèí íàòðèåâàÿ ñîëü - ïîðîøîê,        

                                             │Îêñàöèëëèíà íàòðèåâàÿ ñîëü, Îêñàöèëëèíà     

                                             │íàòðèåâàÿ ñîëü 0.25 ã â êàïñóëàõ,           

                                             │Îêñàöèëëèíà íàòðèåâàÿ ñîëü ñòåðèëüíàÿ,      

                                             │Îêñàöèëëèíà íàòðèåâîé ñîëè òàáëåòêè,        

                                             │Ïðîñòàôëèí                                  

                                                                                         

│Îêñèáóòèíèí - ñïàçìîëèòè÷åñêîå ñðåäñòâî      │Äðèïòàí, Íîâèòðîïàí, Îêñèáóòèí, Öèñòðèí      

                                                                                         

│Îêñèìåòàçîëèí - àëüôà-àäðåíîñòèìóëÿòîð       │4-Âýé, Àëêà-Çåëüòöåð ïëþñ àýðîçîëü          

                                             │íàçàëüíûé, Àôðèí, Áàðòåë Äðàãç              

                                             │Ïðîòèâîîòå÷íûé ñïðåé äëÿ íîñà 12-òè ÷àñîâîãî │

                                             │äåéñòâèÿ, Âèê Ñàéíåêñ, Ëåêîíèë, Ëåêîíèë Ï,  

                                             │Íàçèâèí, Íàçîë, Ôàçèí                       

                                                                                         

│Îêñèìåòèëóðàöèë& - èììóíîñòèìóëèðóþùåå       │Îêñèìåòèëóðàöèë, Îêñèìåòèëóðàöèëà òàáëåòêè  

│ñðåäñòâî                                     │0.25 ã                                      

                                                                                         

│Îêñèòåòðàöèêëèí - àíòèáèîòèê, òåòðàöèêëèí    │Èííîëèð 1%, Îêñèòåòðàöèêëèíà ãèäðîõëîðèä,   

                                             │Îêñèòåòðàöèêëèíà äèãèäðàò                   

                                                                                         

│Îêñèòîöèí - ðîäîâîé äåÿòåëüíîñòè ñòèìóëÿòîð, │Îêñèòîöèí ñèíòåòè÷åñêèé, Îêñèòîöèíà ðàñòâîð 

│ïðåïàðàò îêñèòîöèíà                          │äëÿ èíúåêöèé                                

                                                                                         

│Îêñèôåíèñàòèí - ñëàáèòåëüíîå ñðåäñòâî        │Èçàôåíèí, Èçàôåíèíà òàáëåòêè 0.01 ã         

│Îêñèýòèëêðàõìàë& - ïëàçìîçàìåùàþùåå ñðåäñòâî │6 Õ.Å.Ñ., Âîëåêàì                           

                                                                                         

│Îêñîëèíîâàÿ êèñëîòà - ïðîòèâîìèêðîáíîå       │Ãðàìóðèí, Äèîêñàöèí, Äèîêñàöèíà òàáëåòêè    

│ñðåäñòâî, õèíîëîí                            │0.25 ã                                      

                                                                                          

│Îêòèöèë& - ïðîòèâîãðèáêîâîå ñðåäñòâî         │Îêòèöèë, Îêòèöèëà ðàñòâîð 1%, Îêòèöèëîâàÿ   

                                             │ìàçü 1%                                     

                                                                                         

│Îëåàíäîìèöèí - àíòèáèîòèê, ìàêðîëèä          │Îëåàíäîìèöèíà ôîñôàò, Îëåàíäîìèöèíà ôîñôàòà 

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 125000 ÅÄ       

                                                                                         

│Îëåàíäîìèöèí+Òåòðàöèêëèí& - àíòèáèîòèê       │Îëåòåòðèí â êàïñóëàõ 0.25 ã (250000 ÅÄ),    

│êîìáèíèðîâàííûé                              │Îëåòåòðèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé,     

                                             │Òåòðàîëåàí                                  

                                                                                         

│Îìåïðàçîë - ïðîòèâîÿçâåííîå ñðåäñòâî,        │Äåìåïðàçîë, Çåðîöèä, Çîëñåð, Ëîêèò, Ëîìàê,  

│ïðîòîííîãî íàñîñà èíãèáèòîð                  │Ëîñåê, Îìåç, Îìåçîë, Îìåïàð, Îìåïðàçîë,     

                                             │Îìåïðàçîë ïåëëåòû, Îìåïðîë, Îìèçàê, Îðòàíîë, │

                                             │Îöèä, Ïåïòèêóì, Ïðîñåïòèí, Ðîìåñåê          

                                                                                         

│Îíäàíñåòðîí - ïðîòèâîðâîòíîå ñðåäñòâî,       │Çîôðàí, Ëàòðàíà ðàñòâîð äëÿ èíúåêöèé 0.2%,  

│ñåðîòîíèíîâûõ ðåöåïòîðîâ àíòàãîíèñò          │Ëàòðàíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.004 ã, │

                                             │Îíäàçàí, Îíäàíñåòðîíà ãèäðîõëîðèä äèãèäðàò, 

                                             │Îñåòðîí, Ýìåñåò                              

                                                                                         

│Îïèíèàçèä& - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî   │Ñàëþçèä ðàñòâîðèìûé, Ñàëþçèäà ðàñòâîðèìîãî  

                                             │ðàñòâîð 5% â àìïóëàõ                        

                                                                                         

│Îðíèòèí - ãèïîàçîòåìè÷åñêîå ñðåäñòâî         │Ãåïà-Ìåðö, Îðíèöåòèë                        

│Îðîòîâàÿ êèñëîòà                             │êàëèåâàÿ ñîëü - ìåòàáîëè÷åñêîå ñðåäñòâî     

                                                                                         

│Îðöèïðåíàëèí - áåòà2-àäðåíîñòèìóëÿòîð        │Àëóïåíò, Àñòìîïåíò                           

│ñåëåêòèâíûé                                                                              

                                                                                         

│Îñàëìèä - æåë÷åãîííîå ñðåäñòâî               │Îêñàôåíàìèä, Îêñàôåíàìèäà òàáëåòêè          

                                                                                         

│Îôëîêñàöèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,      │Ãëàóôîñ, Çàíîöèí, Êèðîëë, Îôëèí, Îôëî,      

│ôòîðõèíîëîí                                  │Òàðèâèä, Óðîñèí, Ôëîêñàë                    

                                                                                         

│Ïàãëþôåðàë& - ïðîòèâîñóäîðîæíîå ñðåäñòâî     │Ïàãëþôåðàë 1, Ïàãëþôåðàë 2, Ïàãëþôåðàë 3    

│Ïàêëèòàêñåë - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Èíòàêñåë, Ïàêëèòàêñåë-Ýáåâå, Òàêñîë, Þòàêñàí │

                                                                                         

│Ïàëüìû ïîëçó÷åé ýêñòðàêò& - ñðåäñòâî ëå÷åíèÿ │Ïåðìèêñîí, Ïðîñòàãóò, Ïðîñòàïëàíò,          

│àäåíîìû ïðîñòàòû ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ │Ïðîñòàñåðåí, Ïðîñòåññ, Ïðîñòåññ Óíî, Ñåðïåíñ │

                                                                                         

│Ïàíêðåàòèí& - ïèùåâàðèòåëüíîå ôåðìåíòíîå     │Âåñòàë, Çèìåò, Êðåîí, Êðåîí 10000, Êðåîí    

│ñðåäñòâî                                     │25000, Ëèêðåàçà, Ìåçèì ôîðòå, Ìåçèì ôîðòå   

                                             │10000, Ìåçèì ôîðòå 16000, Ìåçèì ôîðòå 3500, 

                                             │Ïàíêðåàëü Êèðøíåð, Ïàíêðåàòèí,              

                                             │Ïàíêðåàòèí-êîíöåíòðàò, Ïàíêðåàòèíà òàáëåòêè 

                                             │(ðàñòâîðèìûå â êèøå÷íèêå) 0.25 ã, Ïàíêðåîí  

                                             │10000, Ïàíöèòðàò, Òðèôåðìåíò, Ôåñòàë Í      

                                                                                         

│Ïàíêóðîíèÿ áðîìèä - ìèîðåëàêñèðóþùåå ñðåäñòâî│Ìóñêóðîí, Ïàâóëîí                            

                                                                                         

│Ïàíòîêðèí& - àäàïòîãåííîå ñðåäñòâî           │Ïàíòîêðèí, Ïàíòîêðèí äëÿ èíúåêöèé,          

                                             │Ïàíòîêðèíà êîíöåíòðàò, Ïàíòîêðèíà òàáëåòêè  

                                                                                         

│Ïàïàâåðèíà ãèäðîõëîðèä - ñïàçìîëèòè÷åñêîå    │Ïàïàâåðèíà ãèäðîõëîðèäà ðàñòâîð 2%,         

│ñðåäñòâî                                     │Ïàïàâåðèíà ãèäðîõëîðèäà òàáëåòêè 0.04 ã,    

                                             │Ïàïàâåðèíà ãèäðîõëîðèäà òàáëåòêè äëÿ äåòåé  

                                             │0.01 ã, Ñâå÷è ñ ïàïàâåðèíà ãèäðîõëîðèäîì (íà │

                                             │ïîëèýòèëåíîêñèäíîé îñíîâå), Ñâå÷è ñ         

                                             │ïàïàâåðèíîì ãèäðîõëîðèäà 0.02 ã             

                                                                                          

│Ïàðàôèí æèäêèé& - ñëàáèòåëüíîå ñðåäñòâî      │Âàçåëèíîâîå ìàñëî, Âàçåëèíîâîå ìàñëî ÁÃÌ-30ì │

                                                                                         

│Ïàðàöåòàìîë - àíàëüãåòè÷åñêîå                │Àêàìîë-Òåâà, Àëêà-Çåëüòöåð ïëþñ             

│íåíàðêîòè÷åñêîå ñðåäñòâî                     │áîëåóòîëÿþùåå è æàðîïîíèæàþùåå ñðåäñòâî,    

                                             │Àëüäîëîð, Àìèíàäîë, Àöåòàìèíîôåí, Áàðòåë    

                                             │äðàãç Îáåçáîëåâàþùåå ñðåäñòâî àïàï, Áèíäàðä, │

                                             │Äàéíàôåä ÅÕ, Äàéíàôåä þíèîð, Äåìèíîôåí,     

                                             │Äåòñêèé Ïàíàäîë, Äîëî, Äîëîìîë, Èôèìîë,     

                                             │Êàëïîë, Êàëïîë 6 ïëþñ, Ëåêàäîë, Ëóïîöåò,    

                                             │Ìåäèïèðèí 500, Ìåêñàëåí, Íàïà, Íàø âûáîð -  

                                             │Ïàðàöåòàìîë, Íîâî-Äæåñèê, Ïàìîë, Ïàíàäîë,   

                                             │Ïàíàäîë áýáè ýíä èíôàíò, Ïàíàäîë äæóíèîð,   

                                             │Ïàíàäîë êàïñóëû, Ïàíàäîë òàáëåòêè, Ïàíàäîë  

                                             │òàáëåòêè äëÿ ðàñòâîðåíèÿ, Ïàðàöåò,          

                                             │Ïàðàöåòàìîë, Ïàðàöåòàìîë (Àöåòîôåí),        

                                             │Ïàðàöåòàìîë 120 Áåðëèí-Õåìè, Ïàðàöåòàìîë    

                                             │200, Ïàðàöåòàìîë 200 Áåðëèí-Õåìè,           

                                             │Ïàðàöåòàìîë 325 ìã, Ïàðàöåòàìîë 500,        

                                             │Ïàðàöåòàìîë Áåðëèí-Õåìè,                    

                                             │Ïàðàöåòàìîë-Ðàòèîôàðì, Ïàðàöåòàìîë-Ðèâîôàðì, │

                                             │Ïàðàöåòàìîëà ñèðîï 2.4%, Ïàðàöåòàìîëà       

                                             │òàáëåòêè, Ïàðàöåòàìîëà òàáëåòêè 0.2 ã,      

                                             │Ïàðàöåòàìîëà òàáëåòêè 0.5 ã, Ïàñåìîë,       

                                             │Ïàöèìîë, Ïèðàíîë, Ïèðèìîë, Ïðîõîäîë,        

                                             │Ïðîõîäîë äåòñêèé, Ñàíèäîë, Ñóïïîçèòîðèè     

                                             │ðåêòàëüíûå ñ ïàðàöåòàìîëîì 0.5 ã,           

                                             │Ñóïïîçèòîðèè ðåêòàëüíûå ñ ïàðàöåòàìîëîì äëÿ 

                                             │äåòåé, Òàéëåíîë, Òàéëåíîë îò ïðîñòóäû,      

                                             │Ôåáðèöåò, Ýôôåðàëãàí                        

                                                                                          

│Ïàðàöåòàìîë+Àñêîðáèíîâàÿ êèñëîòà& -          │Ãðèïïîñòàä, Ìåêñàâèò, Öèòðèïàí,             

│àíàëüãåòè÷åñêîå íåíàðêîòè÷åñêîå ñðåäñòâî     │Öèòðèïàí÷åê-ãðàíóëÿò, Ýôôåðàëãàí ñ âèòàìèíîì │

                                             │C                                           

                                                                                         

│Ïàðàöåòàìîë+Ôåíèëýôðèí+Àñêîðáèíîâàÿ êèñëîòà& │Êîëäðåêñ ÕîòÐåì ñî âêóñîì ëèìîíà, Êîëäðåêñ  

│- ñðåäñòâî óñòðàíåíèÿ ñèìïòîìîâ ÎÐÇ è        │ÕîòÐåì ñî âêóñîì ÷åðíîé ñìîðîäèíû           

│ïðîñòóäû                                                                                 

                                                                                          

│Ïàðàöåòàìîë+Ôåíèëýôðèí+Õëîðôåíàìèí& -        │Àíàêîëä, Ëîðåéí                             

│ñðåäñòâî óñòðàíåíèÿ ñèìïòîìîâ ÎÐÇ è ïðîñòóäû │                                            

                                                                                         

│Ïåìïèäèí - ãàíãëèîáëîêàòîð                   │Ïèðèëåí, Ïèðèëåíà òàáëåòêè 0.005 ã          

                                                                                         

│Ïåíèöèëëàìèí - ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî│Àðòàìèí, Áèàíîäèí, Êóïðåíèë, Ïåíèöèëëàìèí,  

                                             │Ïåíèöèëëàìèí â êàïñóëàõ 0.15 ã              

                                                                                          

│Ïåíèöèëëèí ïðîêàèí - àíòèáèîòèê, ïåíèöèëëèí  │Áåíçèëïåíèöèëëèíà íîâîêàèíîâàÿ ñîëü, Ïðîêàèí │

                                             │ïåíèöèëëèí G 3 ìåãà, Ïðîêàèí-Áåíçèëïåíèöèëëèí│

                                                                                          

│Ïåíòàçîöèí - àíàëüãåòè÷åñêîå íàðêîòè÷åñêîå   │Ôîðòâèí, Ôîðòðàë                            

│ñðåäñòâî                                                                                 

                                                                                         

│Ïåíòàêðàõìàë - ïëàçìîçàìåùàþùåå ñðåäñòâî     │Èíôóêîë ÃÝÊ 10%, Èíôóêîë ÃÝÊ 6%, Ðåôîðòàí,  

                                             │Ðåôîðòàí ïëþñ, Ñòàáèçîë, ÕÀÅÑ-ñòåðèë 10%,   

                                             │ÕÀÅÑ-ñòåðèë 6%                              

                                                                                         

│Ïåíòàýðèòðèòèëà òåòðàíèòðàò -                │Äèëêîðàí 80, Ïåíòàëîíã, Ýðèíèò, Ýðèíèòà     

│âàçîäèëàòèðóþùåå ñðåäñòâî                    │òàáëåòêè, Ýðèíèòà òàáëåòî÷íàÿ ìàññà         

                                                                                         

│Ïåíòîêñèôèëëèí - âàçîäèëàòèðóþùåå ñðåäñòâî   │Àãàïóðèí, Àãàïóðèí 600 ðåòàðä, Àãàïóðèí     

                                             │ðåòàðä, Àðáèôëåêñ, Àöóïåíòàò-400, Âàçîíèò,  

                                             │Äàðòåëèí, Ïåíòàìîí, Ïåíòèëèí, Ïåíòèëèí      

                                             │ôîðòå, Ïåíòîêñ-400, Ïåíòîêñèôèëëèí,         

                                             │Ïåíòîêñèôèëëèí Ðèâî, Ïåíòîêñèôèëëèí-Àêðè    

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.1 ã,          

                                             │Ïåíòîêñèôèëëèí-Ðàòèîôàðì, Ïåíòîêñèôèëëèíà   

                                             │ðàñòâîð äëÿ èíúåêöèé 2%, Ïåíòîêñèôèëëèíà    

                                             │òàáëåòêè 0.1 ã (ðàñòâîðèìûå â êèøå÷íèêå),   

                                             │Ïåíòîìåð, Ðàäîìèí, Ðàëîôåêò, Ðàëîôåêò 300 Í, │

                                             │Òðåíòàë, Òðåíòàë 400, Ôëåêñèòàë             

                                                                                         

│Ïåðèíäîïðèë - ÀÊÔ áëîêàòîð                   │Êîâåðåêñ, Ïðåñòàðèóì                        

                                                                                         

│Ïåðìåòðèí - èíñåêòèöèäíîå ñðåäñòâî           │Àìèçîëü, Àíäèæàí-Ó, Àíòèñåêò, Àíòèýíòîì,    

                                             │Àðçîëü-Ë, Àðçîëü-Ï, Àðìîëü, Áèî êèëë,       

                                             │Áèîñèì, Áëàíòåêñ, Âåäà, Âåäà øàìïóíü         

                                             │ïåäèêóëèöèäíûé, Âåêóðèí, Âèòàð, Âóïðîòîêñ,  

                                             │Ãåëåíèò, Ãëîðöèä, Ãìèçèí, Ãðèíöèä-Ó, Äàñò,  

                                             │Äàñò áðèêåò, Äàñò ïëàñòèíà, Çåáðèê-Òåâà,    

                                             │Èíñåêòèöèäíîå ìûëî Äåç-Ï, Èíñåêòèöèäíîå     

                                             │ìûëî-Ï, Èíñåêòîêðåì, Èíòîêñ, Êàäèìà, Êàíîí  

                                             │Ïëþñ, Êèì-Ï, Ìåäèôîêñ, Ìåäèôîêñ-ñóïåð,      

                                             │Ìîëèí, Íèêñ, Íèòòèôîð, ÍÎÊ., Îêñèòîêñ,      

                                             │Ïåäèçîë, Ïåðìîöèä, Ïåðîë, Ïîëèòîêñ, Ðåéä àíò │

                                             │Êèëëåð ïàóäåð, Ñèòè òàáëåòêè, Ñòàãèôîð,     

                                             │Òàëëà, Òåðìà-Ôîã-Ï, Óíèâåðñàëüíûé           

                                             │(Óíèâåðñàë), ×èñòîòåë-Ì, ×óá-÷èê, Øàíñ, Øèï-1│

                                                                                         

│Ïåðôåíàçèí - àíòèïñèõîòè÷åñêîå               │Ýòàïåðàçèí, Ýòàïåðàçèíà òàáëåòêè ïîêðûòûå   

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │îáîëî÷êîé 0.006 ã                           

                                                                                         

│Ïåôëîêñàöèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,     │Àáàêòàë, Ïåëîêñ-400, Ïåðòè, Ïåðôëîêñ,       

│ôòîðõèíîëîí                                  │Ïåôëàöèí, Ïåôëîáèä, Ïåôëîêñàöèí, Ïåôëîêñàöèí │

                                             │ìåòàí ñóëüôîíàò äèãèäðàò, Ïåôëîêñàöèíà      

                                             │ìåçèëàò, Ïåôëîêñàöèíà ìåçèëàòà òàáëåòêè      

                                             │ïîêðûòûå îáîëî÷êîé 0.2 ã, Ïåôëîêñàöèíà      

                                             │ìåçèëàòà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.4 ã, 

                                             │Ïåôëîêñàöèíà ìåñèëàò, Þíèêïåô               

                                                                                         

│Ïèëîêàðïèí - ì-õîëèíîìèìåòèê                 │Èçîïòî-êàðïèí, Îôòàí Ïèëîêàðïèí, Ïèëîãåëü,  

                                             │Ïèëîêàðïèí, Ïèëîêàðïèíà ãèäðîõëîðèä,        

                                             │Ïèëîêàðïèíà ãèäðîõëîðèäà ðàñòâîð 1%,        

                                             │Ïèëîêàðïèíà ãèäðîõëîðèäà ðàñòâîð 1% â       

                                             │òþáèê-êàïåëüíèöàõ, Ïèëîêàðïèíà ãèäðîõëîðèäà 

                                             │ðàñòâîð 1% ñ ìåòèëöåëëþëîçîé, Ïèëîêàðïèíà   

                                             │ãèäðîõëîðèäà ðàñòâîð 6%, Ïèëîêàðïèíîâàÿ     

                                             │ìàçü, Ïëåíêè ãëàçíûå c ïèëîêàðïèíîì         

                                             │ãèäðîõëîðèäîì                               

                                                                                          

│Ïèëîêàðïèí+Òèìîëîë& - ïðîòèâîãëàóêîìíîå      │Òèìïèëî, Ôîòèë, Ôîòèë ôîðòå                 

│ñðåäñòâî                                                                                 

                                                                                         

│Ïèïåìèäîâàÿ êèñëîòà - ïðîòèâîìèêðîáíîå       │Ïàëèí, Ïèìèäåëü, Ïèïåãàë, Óðîïèìèä,         

│ñðåäñòâî, õèíîëîí                            │Óðîòðàêòèí                                  

                                                                                         

│Ïèïåðàçèíà àäèïàò - ïðîòèâîãåëüìèíòíîå       │Ïèïåðàçèí, Ïèïåðàçèíà àäèïèíàò, Ïèïåðàçèíà  

│ñðåäñòâî                                     │àäèïèíàòà ðàñòâîð äëÿ äåòåé 5%, Ïèïåðàçèíà  

                                             │àäèïèíàòà òàáëåòêè, Ïèïåðàçèíà àäèïèíàòà    

                                             │òàáëåòêè 0.2 ã, Ïèïåðàçèíà àäèïèíàòà        

                                             │òàáëåòêè 0.5 ã                              

                                                                                         

│Ïèïåðàöèëëèí - àíòèáèîòèê, ïåíèöèëëèí        │Ïèïðàêñ, Ïèïðàöèë, Ïèöèëëèí                 

                                                                                         

│Ïèïîòèàçèí - àíòèïñèõîòè÷åñêîå               │Ïèïîðòèë, Ïèïîðòèë Ë4                       

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                                                               

                                                                                         

│Ïèïîôåçèí - àíòèäåïðåññàíò                   │Àçàôåí, Àçàôåíà òàáëåòêè 0.025 ã            

                                                                                          

│Ïèðàçèíàìèä - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî  │Êàâèçèä, Ëèíàìèä, Ï.Ò.Á., Ïè-êîêñ, Ïèçèíà,  

                                             │Ïèðàçèíàìèä, Ïèðàçèíàìèäà òàáëåòêè 0.5 ã,   

                                             │Ïèðàôàò, Òèáèìèä, Òèçàìèä                   

                                                                                         

│Ïèðàíòåë - ïðîòèâîãåëüìèíòíîå ñðåäñòâî       │Ãåëüìèíòîêñ, Êîìáàíòðèí, Íåìîöèä, Ïèðàíòåë  

                                                                                         

│Ïèðàöåòàì - íîîòðîïíîå ñðåäñòâî              │Íîîòðîïèë, Îéêàìèä, Ïèðàáåíå, Ïèðàìåì,      

                                             │Ïèðàöåòàì, Ïèðàöåòàì â êàïñóëàõ 0.4 ã,      

                                             │Ïèðàöåòàì-Ðàòèîôàðì, Ïèðàöåòàìà ãðàíóëû äëÿ 

                                             │äåòåé, Ïèðàöåòàìà ðàñòâîð äëÿ èíúåêöèé 20%, 

                                             │Ïèðàöåòàìà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.2  

                                             │ã, Ñòàìèí, Öåðåáðèë, Öåðåáðèë 48 ìã/ìë      

                                                                                         

│Ïèðâèíèÿ ýìáîíàò - ïðîòèâîãåëüìèíòíîå        │Ïèðâèíèóì, Ïèðêîí                           

│ñðåäñòâî                                                                                 

                                                                                         

│Ïèðåíçåïèí - ì-õîëèíîáëîêàòîð                │Ãàñòðèë, Ãàñòðîçåì, Ãàñòðîìåí, Ãàñòðîïèí,   

                                             │Ãàñòðîöåïèí, Ïèðåãåêñàë, Ïèðåí,             

                                             │Ïèðåíçåïèí-Ðàòèîôàðì, Ïèðåíöåïèí            

                                                                                         

│Ïèðåòàíèä - äèóðåòè÷åñêîå ñðåäñòâî           │Àðåëèêñ, Àðåëèêñ ÐР                        

                                                                                         

│Ïèðèäîêñàëü ôîñôàò - ìåòàáîëè÷åñêîå ñðåäñòâî │Ïèðèäîêñàëüôîñôàò, Ïèðèäîêñàëüôîñôàò äëÿ    

                                             │èíúåêöèé, Ïèðèäîêñàëüôîñôàòà òàáëåòêè       

                                             │ïîêðûòûå îáîëî÷êîé                          

                                                                                         

│Ïèðèäîêñèí - âèòàìèí                         │Áàðòåë äðàãç Âèòàìèí Â6, Âèòàìèí Â6,        

                                             │Ïèðèäîáåíå, Ïèðèäîêñèíà ãèäðîõëîðèä,        

                                             │Ïèðèäîêñèíà ãèäðîõëîðèä (âèòàìèí Â6),       

                                             │Ïèðèäîêñèíà ãèäðîõëîðèäà ðàñòâîð äëÿ        

                                             │èíúåêöèé, Ïèðèäîêñèíà ãèäðîõëîðèäà ðàñòâîð  

                                             │äëÿ èíúåêöèé 5%, Ïèðèäîêñèíà ãèäðîõëîðèäà   

                                             │ðàñòâîð äëÿ èíúåêöèé 5%, Ïèðèäîêñèíà        

                                             │ãèäðîõëîðèäà òàáëåòêè, Ïèðèäîêñèíà          

                                             │ãèäðîõëîðèäà òàáëåòêè 0.002 ã, Ïèðèäîêñèíà  

                                             │ãèäðîõëîðèäà òàáëåòêè 0.01 ã                

                                                                                         

│Ïèðèäîñòèãìèíà áðîìèä - àíòèõîëèíýñòåðàçíîå  │Êàëèìèí 60 Í, Êàëèìèí ôîðòå, Ìåñòèíîí       

│ñðåäñòâî                                                                                 

                                                                                         

│Ïèðèêàðáàò - àíãèîïðîòåêòîðíîå ñðåäñòâî      │Àíãèíèí, Ïàðìèäèí, Ïàðìèäèíà òàáëåòêè 0.25  

                                             │ã, Ïàðìèäèíîâàÿ ìàçü 5%                     

                                                                                         

│Ïèðèìåòàìèí - ïðîòèâîìàëÿðèéíîå ñðåäñòâî     │Äàðàïðèì, Õëîðèäèí, Õëîðèäèíà òàáëåòêè      

                                                                                         

│Ïèðèòèíîë - íîîòðîïíîå ñðåäñòâî              │Ïèðèäèòîë, Ïèðèäèòîëà òàáëåòêè ïîêðûòûå      

                                             │îáîëî÷êîé, Öåðåáîë, Ýíåðáîë, Ýíöåôàáîë      

                                                                                         

│Ïèðëèíäîë - àíòèäåïðåññàíò                   │Ïèðàçèäîë, Ïèðàçèäîëà òàáëåòêè, Ïèðàçèäîëà  

                                             │òàáëåòêè 0.025 ã, Ïèðàçèäîëà òàáëåòêè 0.05 ã │

                                                                                         

│Ïèðîêñèêàì - ÍÏÂÑ                            │Àïî-Ïèðîêñèêàì, Áðåêñèê-ÄÒ, Ãåí-Ïèðîêñèêàì, 

                                             │Êàëìîïèðîë, Íîâî-Ïèðîêàì, Ïèðîêàì, Ïèðîêñ,  

                                             │Ïèðîêñèêàì, Ïèðîêñèêàì 10 Ñòàäà             

                                             │ìåæäóíàðîäíûé Òàá, Ïèðîêñèêàì 20 Ñòàäà      

                                             │ìåæäóíàðîäíûé Òàá, Ïèðîêñèêàì-Éåíàôàðì,     

                                             │Ïèðîêñèêàì-Ðàòèîôàðì, Ïèðîêñèêàì-Òåâà,      

                                             │Ïèðîêñèôåð, Ïèðîðåóì, Ïèðîôëàì, Ðåóêàì,     

                                             │Ðîêñèêàì, Ñàíèêàì, Ôåëüäåí, Ôëåêñàçå,       

                                             │Õîòåìèí, Ýðàçîí                             

                                                                                         

│Ïëàòèôèëëèí& - ì-õîëèíîáëîêàòîð              │Ïëàòèôèëëèíà ãèäðîòàðòðàò, Ïëàòèôèëëèíà     

                                             │ãèäðîòàðòðàòà ðàñòâîð äëÿ èíúåêöèé 0.2%,    

                                             │Ïëàòèôèëëèíà ãèäðîòàðòðàòà òàáëåòêè 0.005 ã 

                                                                                         

│Ïîâèäîí - äåçèíòîêñèêàöèîííîå ñðåäñòâî       │Ãåìîäåç, Ãåìîäåç-Í, Êîëëèäîí 12 PF, Êîëëèäîí │

                                             │17 PF, Êîëëèäîí 25                          

                                                                                          

│Ïîâèäîí-Éîä - àíòèñåïòè÷åñêîå ñðåäñòâî       │Áåòàäèí, Áåòàäèíå, Âîêàäèí, Éîäîâèäîí,      

                                             │Éîäîâèäîíà ðàñòâîð 1%, Éîäîïîâèäîí 30/06,   

                                             │Éîäîïîâèäîí 30/06 Ì10, Ïîâèäîí-Éîä, Ïîëèéîäèí│

                                                                                         

│Ïîäîðîæíèêà áîëüøîãî ëèñò& - ðàñòèòåëüíîãî   │Ïîäîðîæíèêà áîëüøîãî ëèñò ðåçàííûé,         

│ïðîèñõîæäåíèÿ ñðåäñòâî                       │Ïîäîðîæíèêà áîëüøîãî ëèñò ñâåæèé,           

                                             │Ïîäîðîæíèêà áîëüøîãî ëèñòà áðèêåò           

                                                                                          

│Ïîäîôèëëîòîêñèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî │Êîíäèëàéí Íèêîìåä, Êîíäèëèí                 

                                                                                         

│Ïîëèâèíîêñ& - àíòèñåïòè÷åñêîå ñðåäñòâî       │Âèíèëèí (Øîñòàêîâñêîãî áàëüçàì), Âèíèëèí â  

                                             │êàïñóëàõ                                    

                                                                                         

│Ïîëèìèêñèí Ì - àíòèáèîòèê, ïîëèïåïòèä        │Ïîëèìèêñèíà Ì ñóëüôàòà ëèíèìåíò 10000 ÅÄ/ã, 

                                             │Ïîëèìèêñèíà Ì ñóëüôàòà òàáëåòêè 500000 ÅÄ,  

                                             │Ïîëèìèêñèíà-Ì-ñóëüôàò,                      

                                             │Ïîëèìèêñèíà-Ì-ñóëüôàòà òàáëåòêè 500000 ÅÄ,  

                                             │Ïîëèìèêñèíîâàÿ ìàçü                         

                                                                                          

│Ïðàçîçèí - àëüôà-àäðåíîáëîêàòîð              │Àäâåðçóòåí 1, Àäâåðçóòåí 5, Ìèíèïðåññ,      

                                             │Íîâî-Ïðàçèí, Ïîëüïðåññèí, Ïðàçîçèí,         

                                             │Ïðàçîçèí-Ôàðìàõèì, Ïðàçîçèíà òàáëåòêè,      

                                             │Ïðàçîçèíáåíå                                

                                                                                         

│Ïðàëëåòðèí& - èíñåêòèöèäíîå ñðåäñòâî         │Ãëîáîëü - ôóìèãàòîð-îñâîáîäèòåëü,           

                                             │Ðàïòîð-ñòàíäàðò ïëþñ, Ôóìèòîêñ, Ýòîê-10     

                                                                                          

│Ïðåäíèçîëîí - ãëþêîêîðòèêîñòåðîèä            │Äåêîðòèí Í20, Äåêîðòèí Í5, Äåêîðòèí Í50,    

                                             │Íîâî-Ïðåäíèçîëîí, Ïðåäíèçîëîí, Ïðåäíèçîëîí  

                                             │Õàôñëóíä Íèêîìåä, Ïðåäíèçîëîí-Ì.Äæ.,        

                                             │Ïðåäíèçîëîí-Ðèâîôàðì, Ïðåäíèçîëîíà àöåòàò,  

                                             │Ïðåäíèçîëîíà ãåìèñóêöèíàò, Ïðåäíèçîëîíà     

                                             │ãåìèñóêöèíàò ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé 

                                             │0.02, Ïðåäíèçîëîíà ãåìèñóêöèíàò             

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé, Ïðåäíèçîëîíà │

                                             │òàáëåòêè, Ïðåäíèçîëîíîâàÿ ìàçü 0.5%,        

                                             │Ñîëþ-Äåêîðòèí Í10, Ñîëþ-Äåêîðòèí Í25,       

                                             │Ñîëþ-Äåêîðòèí Í250, Ñîëþ-Äåêîðòèí Í50,      

                                             │Øåðèçîëîí                                   

                                                                                         

│Ïðåäíèçîí - ãëþêîêîðòèêîñòåðîèä              │Àïî-Ïðåäíèçîí, Ïðåäíèçîí, Ïðåäíèçîí         

                                             │20-áåòà-îêñèïðîèçâîäíîå, Ïðåäíèçîíà àöåòàò, 

                                             │Ïðåäíèçîíà àöåòàòà òàáëåòêè                 

                                                                                         

│Ïðèìèäîí - ïðîòèâîñóäîðîæíîå ñðåäñòâî        │Ãåêñàìèäèí, Ãåêñàìèäèíà òàáëåòêè, Ìèñîëèí   

│Ïðèôèíèÿ áðîìèä - ì-õîëèíîáëîêàòîð           │Íî-ñïàçì, Ðèàáàë                            

                                                                                         

│Ïðîãåñòåðîí - ïðîãåñòàãåí                    │Ïðîãåñòåðîíà ðàñòâîð, Ïðîãåñòåðîíà ðàñòâîð  

                                             │äëÿ èíúåêöèé â ìàñëå                         

                                                                                         

│Ïðîãóàíèë - ïðîòèâîìàëÿðèéíîå ñðåäñòâî       │Áèãóìàëü, Áèãóìàëÿ äðàæå 0.1 ã, Áèãóìàëÿ    

                                             │òàáëåòêè                                    

                                                                                         

│Ïðîêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî      │Íîâîêàèí, Íîâîêàèíà îñíîâàíèå, Íîâîêàèíà    

                                             │ðàñòâîð äëÿ èíúåêöèé, Íîâîêàèíà ðàñòâîð äëÿ 

                                             │èíúåêöèé (âî ôëàêîíàõ), Íîâîêàèíà ðàñòâîð   

                                             │äëÿ èíúåêöèé 0.25%, Íîâîêàèíà ðàñòâîð äëÿ   

                                             │èíúåêöèé 0.5%, Íîâîêàèíà ðàñòâîð äëÿ        

                                             │èíúåêöèé 2%, Íîâîêàèíîâàÿ ìàçü 10%, Ïðîêàèí 

                                             │ãèäðîõëîðèä, Ñâå÷è ñ íîâîêàèíîì 0.1 ã       

                                                                                         

│Ïðîêàèíàìèä - àíòèàðèòìè÷åñêîå ñðåäñòâî      │Íîâîêàèíàìèä, Íîâîêàèíàìèäà ðàñòâîð äëÿ     

                                             │èíúåêöèé 10%, Íîâîêàèíàìèäà òàáëåòêè 0.25 ã 

                                                                                         

│Ïðîìàçèí - àíòèïñèõîòè÷åñêîå                 │Ïðîïàçèí, Ïðîïàçèíà äðàæå, Ïðîïàçèíà ðàñòâîð │

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │2.5% â àìïóëàõ, Ïðîïàçèíà òàáëåòêè ïîêðûòûå 

                                             │îáîëî÷êîé                                   

                                                                                          

│Ïðîìåòàçèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ      │Äèïðàçèí, Äèïðàçèíà äðàæå, Äèïðàçèíà ðàñòâîð │

│áëîêàòîð                                     │äëÿ èíúåêöèé 2.5%, Äèïðàçèíà òàáëåòêè       

                                             │ïîêðûòûå îáîëî÷êîé 0.025 ã, Äèïðàçèíà       

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé äëÿ äåòåé,      

                                             │Ïèïîëüôåí                                   

                                                                                         

│Ïðîïàôåíîí - àíòèàðèòìè÷åñêîå ñðåäñòâî       │Ïðîïàôåíîí ÎÔ 150, Ïðîïàôåíîí ÎÔ 300,       

                                             │Ïðîôåíàí, Ðèòìîíîðì                         

                                                                                         

│Ïðîïèëéîäîí - ðåíòãåíîêîíòðàñòíîå ñðåäñòâî   │Ïðîïèëéîäîí 10 ã, Ïðîïèëéîäîíà âîäíàÿ       

                                             │ñóñïåíçèÿ 50%                               

                                                                                         

│Ïðîïðàíîëîë - áåòà-àäðåíîáëîêàòîð            │Àíàïðèëèí, Àíàïðèëèíà ðàñòâîð 1% (ãëàçíûå   

                                             │êàïëè), Àíàïðèëèíà ðàñòâîð äëÿ èíúåêöèé     

                                             │0.25%, Àíàïðèëèíà òàáëåòêè, Àíàïðèëèíà      

                                             │òàáëåòêè 0.01 ã, Àíàïðèëèíà òàáëåòêè 0.04 ã, │

                                             │Àïî-Ïðîïðàíîëîë, Èíäåðàë, Èíäåðàë ËÀ,       

                                             │Èíäèêàðäèí, Íîâî-Ïðàíîë, Îáçèäàí,           

                                             │ïìñ-Ïðîïðàíîëîë, Ïðîëîë, Ïðîïðà-Ðàòèîôàðì,  

                                             │Ïðîïðàíîáåíå, Ïðîïðàíîëîë, Ïðîïðàíîëîë      

                                             │Íèêîìåä, Ïðîïðàíîëîëà ãèäðîõëîðèä           

                                                                                         

│Ïðîðîêñàí - àëüôà-àäðåíîáëîêàòîð             │Ïèððîêñàí, Ïèððîêñàíà ðàñòâîð äëÿ èíúåêöèé  

                                             │1%, Ïèððîêñàíà òàáëåòêè 0.015 ã             

                                                                                         

│Ïðîñèäîë& - àíàëüãåòè÷åñêîå íàðêîòè÷åñêîå    │Ïðîñèäîë, Ïðîñèäîëà ðàñòâîð äëÿ èíúåêöèé 1%, │

│ñðåäñòâî                                     │Ïðîñèäîëà ðàñòâîð äëÿ èíúåêöèé              

                                             │ñòàáèëèçèðîâàííûé 1%, Ïðîñèäîëà òàáëåòêè    

                                                                                         

│Ïðîñïèäèÿ õëîðèä - ïðîòèâîîïóõîëåâîå ñðåäñòâî│Ïðîñïèäèí, Ïðîñïèäèí ëèîôèëèçèðîâàííûé äëÿ  

                                             │èíúåêöèé 0.1 ã, Ïðîñïèäèí ëèîôèëèçèðîâàííûé 

                                             │äëÿ èíúåêöèé äëÿ äåòåé 0.05 ã, Ïðîñïèäèíà   

                                             │ìàçü                                        

                                                                                          

│Ïðîòèîíàìèä - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî  │Ïåòåõà, Ïðîíèöèä, Ïðîòèîíàìèä               

                                                                                         

│Ïðîòèðåëèí - ÒÒà ðèëèçèíã ôàêòîð             │Ðèôàòèðîèí, Ðèôàòèðîèí äëÿ èíúåêöèé 0.0005  

                                             │ã, ÒÐà Áåðëèí-Õåìè                          

                                                                                         

│Ïðîõëîðïåðàçèí - àíòèïñèõîòè÷åñêîå           │Ìåòåðàçèí, Ìåòåðàçèíà òàáëåòêè ïîêðûòûå     

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │îáîëî÷êîé                                   

                                                                                         

│Ïñåâäîýôåäðèí+Áðîìãåêñèí& - îòõàðêèâàþùåå    │Ñîëâèí ïëþñ, Ñîëüâèí ýêñïåêòîðàíò           

│ñðåäñòâî                                                                                 

                                                                                          

│Ïñåâäîýôåäðèí+Ïàðàöåòàìîë+Õëîðôåíàìèí& -     │ÀíòèÔëó, Íàø âûáîð - ñðåäñòâî îò ãðèïïà è   

│ñðåäñòâî óñòðàíåíèÿ ñèìïòîìîâ ÎÐÇ è ïðîñòóäû │ïðîñòóäû, Òåðàôëþ                           

                                                                                          

│Ïóìèòåïà - ïðîòèâîîïóõîëåâîå ñðåäñòâî        │Ôîïóðèí, Ôîïóðèí ëèîôèëèçèðîâàííûé äëÿ      

                                             │èíúåêöèé 0.04 ã                             

                                                                                         

│Ðàíèòèäèí - H2-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Àïî-Ðàíèòèäèí, Àöèäåêñ, Àöèëîê-Å,           

│áëîêàòîð                                     │Ãåí-Ðàíèòèäèí, Ãåðòîêàëì, Ãè-êàð, Ãèñòàê,   

                                             │Äóîðàí, Çàíòàê, Çîðàí, Íåîñåïòèí-Ð,         

                                             │Íîâî-Ðàíèäèí, Ïåïòîðàí, Ðàíèáåðë 150,       

                                             │Ðàíèãàñò, Ðàíèñàí, Ðàíèñîí, Ðàíèòàá,        

                                             │Ðàíèòàë, Ðàíèòàðä, Ðàíèòèäèí, Ðàíèòèäèí-ÁÌÑ, │

                                             │Ðàíèòèäèí-Ðàòèîôàðì, Ðàíèòèäèíà ãèäðîõëîðèä, │

                                             │Ðàíèòèäèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé,     

                                             │Ðàíèòèí èíúåêöèè, Ðàíèòèí-150, Ðàíèòèí-300, 

                                             │Ðàíòàã, Ðàíòàê, Ðèíòèä, Ðýíêñ, Óëêîäèí,     

                                             │Óëêîñàí, Óëüêóðàí, Óëüñåðåêñ, ßçèòèí        

                                                                                         

│Ðåçåðïèí+Äèãèäðàëàçèí+Ãèäðîõëîðîòèàçèä& -    │Àäåëüôàí-ýçèäðåêñ, Àíòèãèïåðòîíèí, Áàðîôàí  

│ãèïîòåíçèâíîå êîìáèíèðîâàííîå ñðåäñòâî       │Çèäðåêñ, Ðåëñèäðåêñ-Ã, Òðèíèòîí, Ôåíñèäðåêñ-Í│

                                                                                         

│Ðåçåðïèí+Äèãèäðîýðãîêðèñòèí+Êëîïàìèä& -      │Àöåíîçèí, Áðèíåðäèí, Êðèñòåïèí, Íîðìàòåíñ   

│ãèïîòåíçèâíîå êîìáèíèðîâàííîå ñðåäñòâî                                                   

                                                                                          

│Ðåçîðöèíîë& - àíòèñåïòè÷åñêîå ñðåäñòâî       │Ðåçîðöèí, Ðåçîðöèíà ðàñòâîð ñïèðòîâîé       

                                                                                         

│Ðåòèíîë - âèòàìèí                            │Áàðòåë Äðàãç Âèòàìèí À, Âèòàäðàë, Âèòàìèí À, │

                                             │Âèòàìèí À àöåòàò 500 ïîðîøêîîáðàçíûé,       

                                             │Âèòàìèí À-àöåòàò 500 ñóõîé, Âèòàìèí À-àöåòàò │

                                             │ìàñëÿíàÿ ôîðìà, Âèòàìèí À-ïàëüìèòàò 500     

                                             │ñóõîé, Âèòàìèí À-ïàëüìèòàò ìàñëÿíàÿ ôîðìà,  

                                             │Âèòàìèí À-ïðîïèîíàò ìàñëÿíàÿ ôîðìà, Ðåòèíîëà │

                                             │àöåòàò, Ðåòèíîëà àöåòàòà ãðàíóëû (âèòàìèí À) │

                                             │500000 ÌÅ/ã, Ðåòèíîëà àöåòàòà äðàæå 0.00114 

                                             │ã (âèòàìèí À 3300 ÌÅ), Ðåòèíîëà àöåòàòà     

                                             │ðàñòâîð â ìàñëå, Ðåòèíîëà àöåòàòà ðàñòâîð â 

                                             │ìàñëå â êàïñóëàõ, Ðåòèíîëà àöåòàòà ðàñòâîð  

                                             │äëÿ èíúåêöèé â ìàñëå, Ðåòèíîëà àöåòàòà      

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé, Ðåòèíîëà       

                                             │ïàëüìèòàò, Ðåòèíîëà ïàëüìèòàòà 0.00182 ã    

                                             │äðàæå (âèòàìèí À 3300 ÌÅ), Ðåòèíîëà         

                                             │ïàëüìèòàòà ðàñòâîð 1.651%, Ðåòèíîëà         

                                             │ïàëüìèòàòà ðàñòâîð â êàïñóëàõ 100000 ÌÅ     

                                             │(âèòàìèí À), Ðåòèíîëà ïàëüìèòàòà ðàñòâîð â  

                                             │ìàñëå, Ðåòèíîëà ïàëüìèòàòà ðàñòâîð â ìàñëå  

                                             │100000 ÌÅ/ìë (âèòàìèí À), Ðåòèíîëà          

                                             │ïàëüìèòàòà ðàñòâîð â ìàñëå 55%, Ðåòèíîëà    

                                             │ïàëüìèòàòà òàáëåòêè ïîêðûòûå îáîëî÷êîé      

                                             │0.01816 ã (âè                               

                                                                                         

│Ðèáàâèðèí - ïðîòèâîâèðóñíîå ñðåäñòâî         │Âèðàçîë, Ðèáàìèäèë, Ðèáàìèäèëà òàáëåòêè 0.2 ã│

                                                                                         

│Ðèáîôëàâèí - âèòàìèí                         │Ðèáîôëàâèí (âèòàìèí Â2),                    

                                             │Ðèáîôëàâèí-ìîíîíóêëåîòèä,                   

                                             │Ðèáîôëàâèí-ìîíîíóêëåîòèäà ðàñòâîð äëÿ       

                                             │èíúåêöèé 1%, Ðèáîôëàâèíà òàáëåòêè,          

                                             │Ðèáîôëàâèíà òàáëåòêè (âèòàìèí Â2)           

                                                                                         

│Ðèìàíòàäèí - ïðîòèâîâèðóñíîå ñðåäñòâî        │Ïîëèðåì, Ïîëèðåìà òàáëåòêè 0.139 ã,         

                                             │Ðåìàíòàäèí, Ðåìàíòàäèíà òàáëåòêè 0.05 ã,    

                                             │Ðåìàíòàäèíà òàáëåòêè 50 ìã, Ðåìàíòàäèíà     

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.05 ã, Ôëóìàäèí │

                                                                                         

│Ðèîäèïèí& - ÁÌÊÊ                             │Ôîðèäîí, Ôîðèäîíà ðàñòâîð äëÿ èíúåêöèé      

                                             │0.01%, Ôîðèäîíà òàáëåòêè 0.01 ã             

                                                                                         

│Ðèôàìïèöèí - àíòèáèîòèê                      │Áåíåìèöèí, Ð-öèí, Ðèìàêòàí, Ðèìïàöèí,       

                                             │Ðèìïèí, Ðèñèìà, Ðèôàäèí, Ðèôàìîð, Ðèôàìïèí, 

                                             │Ðèôàìïèöèí, Ðèôàìïèöèí â êàïñóëàõ,          

                                             │Ðèôàìïèöèí â êàïñóëàõ 0.15 ã, Ðèôàìïèöèí äëÿ │

                                             │èíúåêöèé 0.15 ã, Ðèôàðåí, Ðèôîãàë, Òèáèíèë, 

                                             │Òèáèöèí, Òóáîöèí, Ýðåìôàò 600               

                                                                                         

│Ðîêñèòðîìèöèí - àíòèáèîòèê, ìàêðîëèä         │Ðîêñèáèä, Ðîêñèìèçàí, Ðîêñèòåì, Ðóëèä       

                                                                                          

│Ðòóòè õëîðèä& - äåçèíôèöèðóþùåå ñðåäñòâî     │Ðòóòè äèõëîðèä (Ñóëåìà), Ðòóòè äèõëîðèäà    

                                             │òàáëåòêè                                    

                                                                                          

│Ðóòîçèä - àíãèîïðîòåêòîðíîå ñðåäñòâî         │Âåíîðóòîí, Âåíîðóòîí ôîðòå, Ðóòèí, Ðóòèíà   

                                             │òàáëåòêè 0.02 ã                             

                                                                                         

│Ðóôîêðîìîìèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî  │Áðóíåîìèöèí, Áðóíåîìèöèí äëÿ èíúåêöèé,      

                                             │Áðóíåîìèöèí êèñëîòà                         

                                                                                         

│Ñàëèöèëîâàÿ êèñëîòà - ÍÏÂÑ                   │Ìåòèëñàëèöèëàò, Ìåòèëñàëèöèëàòà ìàçü 10%,   

                                             │Íàòðèÿ ñàëèöèëàò, Íàòðèÿ ñàëèöèëàòà ðàñòâîð 

                                             │10% â àìïóëàõ, Íàòðèÿ ñàëèöèëàòà òàáëåòêè,  

                                             │Ñàëèöèëîâàÿ êèñëîòà, Ñàëèöèëîâàÿ ìàçü,      

                                             │Ñàëèöèëîâàÿ ìàçü 2%, Ñàëèöèëîâàÿ ìàçü 4%,   

                                             │Ñàëèöèëîâîé êèñëîòû ðàñòâîð ñïèðòîâîé,      

                                             │Ñàëèöèëîâîé êèñëîòû ðàñòâîð ñïèðòîâîé 1%,   

                                             │Ñàëèöèëîâîé êèñëîòû ðàñòâîð ñïèðòîâîé 2%    

                                                                                         

│Ñàëìåòåðîë - áåòà2-àäðåíîñòèìóëÿòîð          │Ñàëüìåòåð, Ñåðåâåíò                         

│ñåëåêòèâíûé                                                                              

                                                                                         

│Ñàëüáóòàìîë - áåòà2-àäðåíîñòèìóëÿòîð         │Àëîïðîë, Àñìàäèë, Àñòàëèí, Áðîíõîâàëåàñ,    

│ñåëåêòèâíûé                                  │Âåíòîäèñê, Âåíòîëèí, Âåíòîëèí ëåãêîå        

                                             │äûõàíèå, Âîëìàêñ, Ãåí-Ñàëüáóòàìîë, Ñàëìî,    

                                             │Ñàëüáóòàìîë, Ñàëüáóòàìîëà ãåìèñóêöèíàò,     

                                             │Ñàëüáóòàìîëà ãåìèñóêöèíàòà òàáëåòêè ïîêðûòûå │

                                             │îáîëî÷êîé, Ñàëüáóòàìîëà ïîðîøîê äëÿ         

                                             │èíãàëÿöèé, Ñàëüáóòîë, Ñàëüãèì, Ñòåðèíåá     

                                             │Ñàëàìîë, Ýêîâåíò                            

                                                                                         

│Ñàíãâèðèòðèí& - àíòèõîëèíýñòåðàçíîå ñðåäñòâî │Ãóáêà êîëëàãåíîâàÿ ñ ñàíãâèðèòðèíîì,        

                                             │Ñàíãâèðèòðèí, Ñàíãâèðèòðèíà ëèíèìåíò 1%,    

                                             │Ñàíãâèðèòðèíà ðàñòâîð 0.2%, Ñàíãâèðèòðèíà   

                                             │òàáëåòêè 0.005 ã                            

                                                                                          

│Ñàõàðèí - çàìåíèòåëü ñàõàðà                  │Ñàõàðèí ðàñòâîðèìûé, Ñàõàðèíà òàáëåòêè 0.04 ã│

                                                                                         

│Ñåëåãèëèí - ÌÀÎ èíãèáèòîð                    │Êîãíèòèâ, Íèàð, Ñåëãèí, Ñåëåãèëèí-ÑÒÑ,      

                                             │Ñåëåãîñ, Ýëäåïðèë, Þìåêñ                    

                                                                                         

│Ñåëåíà ñóëüôèä - àíòèñåïòè÷åñêîå ñðåäñòâî    │Ñóëüñåí, Ñóëüñåíà ïàñòà 2.5%                

                                                                                         

│Ñåííîçèäû À+Â& - ñëàáèòåëüíîå ñðåäñòâî       │Àíòðàñåííèí, Àíòðàñåííèíà òàáëåòêè 0.07 ã,  

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Áåêóíèñ, Ãëàêñåííà, Èêñ-Ïðåï, Ïóðñåííèä,    

                                             │Ðåãóëàêñ, Ñåíàäå, Ñåíàäåêñ, Ñåíàäåêñèí,     

                                             │Ñåííà, Ñåííîçèä-Òåâà, Òèñàñåí               

                                                                                         

│Ñåðåáðà íèòðàò - àíòèñåïòè÷åñêîå ñðåäñòâî    │Ëÿïèñíûé êàðàíäàø, Ñåðåáðà íèòðàò           

                                                                                         

│Ñåðîòîíèí& - ãåìîñòàòè÷åñêîå ñðåäñòâî        │Ñåðîòîíèíà àäèïèíàò, Ñåðîòîíèíà àäèïèíàòà   

                                             │ðàñòâîð äëÿ èíúåêöèé 1%                      

                                                                                         

│Ñèãåòèí& - ðîäîâîé äåÿòåëüíîñòè ñòèìóëÿòîð   │Ñèãåòèí, Ñèãåòèí-ñòàíäàðò, Ñèãåòèíà ðàñòâîð 

                                             │1% â àìïóëàõ, Ñèãåòèíà òàáëåòêè 0.1 ã       

                                                                                         

│Ñèçîìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä        │Ñèçîìèöèíà ñóëüôàò, Ñèçîìèöèíà ñóëüôàòà     

                                             │ðàñòâîð äëÿ èíúåêöèé                        

                                                                                         

│Ñèëèáèíèí - ãåïàòîïðîòåêòîðíîå ñðåäñòâî      │Êàðñèë, Êàðñèë äðàæå, Ëåãàëîí, Ëåãàëîí-35,   

                                             │Ëåïðîòåê, Ñèëåãîí, Ñèëèìàðèí                

                                                                                         

│Ñèìàëäðàò - àíòàöèäíîå ñðåäñòâî              │Ãåëóñèë ëàê, Ãåëóñèë-ñóñïåíçèÿ, Ãåëþñèë     

│Ñêîïîëàìèí - ì-õîëèíîáëîêàòîð                │Ñêîïîëàìèíà ãèäðîáðîìèä, Ñêîïîëàìèíà êàìôîðàò│

                                                                                         

│Ñëèâû àôðèêàíñêîé êîðû ýêñòðàêò& - ñðåäñòâî  │Òàäåíàí, Òðèàíîë                            

│ëå÷åíèÿ àäåíîìû ïðîñòàòû ðàñòèòåëüíîãî                                                   

│ïðîèñõîæäåíèÿ                                                                            

                                                                                         

│Ñîìàòîñòàòèí - ñîìàòîñòàòèí                  │Ìîäóñòàòèí, Ñòèëàìèí                        

                                                                                          

│Ñîìàòðîïèí - ñîìàòîòðîïíûé ãîðìîí            │Áèîñîìà, Ãåíîòðîïèí, Íîðäèòðîïèí,           

                                             │Íîðäèòðîïèí ïåíñåò, Ñàéçåí, Ñîìàòîòðîïèí    

                                             │÷åëîâåêà, Õóìàòðîï                          

                                                                                         

│Ñîðáèòîë - äèóðåòè÷åñêîå ñðåäñòâî            │D-ñîðáèò, Ñîðáèòà ðàñòâîð äëÿ èíúåêöèé 20%  

                                                                                         

│Ñîòàëîë - áåòà-àäðåíîáëîêàòîð                │Ãèëóêîð, Äàðîá, Ëîðèòìèê 160, Ëîðèòìèê 80,  

                                             │Ñîòàãåêñàë, Ñîòàëåêñ, Ñîòàëîëà ãèäðîõëîðèä, 

                                             │Òàõèòàëîë 160, Òàõèòàëîë 80                 

                                                                                         

│Ñïåêòèíîìèöèí - àíòèáèîòèê                   │Êèðèí, Òîãîïëþñ, Òðîáèöèí                   

                                                                                         

│Ñïèðîíîëàêòîí - äèóðåòè÷åñêîå                │Àëüäàêòîí, Àëüäîïóð, Âåðîøïèðîí, Ñïèðèêñ,   

│êàëèéñáåðåãàþùåå ñðåäñòâî                    │Ñïèðî, Ñïèðîíàêñàí, Ñïèðîíîáåíå, Ñïèðîíîë,  

                                             │Ñïèðîíîëàêòîí, Ñïèðîíîëàêòîí (Óíèëàí),      

                                             │Ñïèðîíîëàêòîí-Ðàòèîôàðì, Ñïèðîíîëàêòîíà     

                                             │òàáëåòêè 0.025 ã, Óðàêòîí                   

                                                                                         

│Ñòðåïòîêèíàçà - ôèáðèíîëèòè÷åñêîå ñðåäñòâî   │Àâåëèçèí, Àâåëèçèí Áðàóí, Êàáèêèíàçà,        

                                             │Ñòðåïòàçà, Ñòðåïòîêèíàçà äëÿ äèàãíîñòè÷åñêèõ │

                                             │öåëåé, Ñòðåïòîêèíàçà ñòàíäàðò, Öåëèàçà      

                                                                                          

│Ñòðåïòîìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä     │Ñòðåïòîìèöèí-õëîðêàëüöèåâûé êîìïëåêñ,       

                                             │Ñòðåïòîìèöèíà ñóëüôàò, Ñòðåïòîìèöèíà ñóëüôàò │

                                             │ñòåðèëüíûé                                  

                                                                                         

│Ñòðîôàíòèí& - êàðäèîòîíè÷åñêîå ñðåäñòâî,     │Ñòðîôàíòèäèíà àöåòàò, Ñòðîôàíòèäèíà àöåòàòà 

│ñåðäå÷íûé ãëèêîçèä                           │ðàñòâîð äëÿ èíúåêöèé 0.05%, Ñòðîôàíòèí Ê,   

                                             │Ñòðîôàíòèí-à 0.250 ìã Éåíàôàðì, Ñòðîôàíòèíà 

                                             │Ê ðàñòâîð äëÿ èíúåêöèé, Ñòðîôàíòèíà Ê       

                                             │ðàñòâîð äëÿ èíúåêöèé 0.025%                 

                                                                                         

│Ñóêðàëüôàò - ïðîòèâîÿçâåííîå ñðåäñòâî        │Àëñóêðàë, Àíêðóñàë, Âåíòåð, Êåàë, Ñóêðàáåñò, │

                                             │Ñóêðàëôàò-Ðàòèîôàðì, Ñóêðàëüôàò, Ñóêðàëüôàò 

                                             │ñóñïåíçèÿ, Ñóêðàñ, Ñóêðàò, Ñóêðàôèë         

                                                                                         

│Ñóêñàìåòîíèÿ éîäèä - ìèîðåëàêñèðóþùåå        │Äèòèëèí, Äèòèëèíà ðàñòâîð äëÿ èíúåêöèé 2%   

│ñðåäñòâî                                                                                  

                                                                                         

│Ñóêñàìåòîíèÿ õëîðèä - ìèîðåëàêñèðóþùåå       │Äèòèëèí - À ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé, 

│ñðåäñòâî                                     │Ëèñòåíîí, Ñóêñàìåòîíèÿ õëîðèä               

                                                                                         

│Ñóëüïèðèä - äîôàìèí-áëîêàòîð                 │Ïðîñóëüïèí, Ñóëüïèðèä, Ýãëîíèë, Ýãëîíèëà    

                                             │òàáëåòêè ôîðòå 0.2 ã                        

                                                                                         

│Ñóëüòàìèöèëëèí - àíòèáèîòèê,                 │Àìïèñèä, Óíàçèí                              

│ïåíèöèëëèí+áåòà-ëàêòàìàç èíãèáèòîð                                                       

                                                                                         

│Ñóëüòîïðèä - àíòèïñèõîòè÷åñêîå               │Áàðíåòèë, Òîïðàë                            

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                                                              

                                                                                         

│Ñóëüôàãóàíèäèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,  │Ñóëüãèí, Ñóëüãèíà òàáëåòêè 0.5 ã,           

│ñóëüôàíèëàìèä                                │Ñóëüôàãóàíèäèí                              

                                                                                         

│Ñóëüôàäèàçèí ñåðåáðà - ïðîòèâîìèêðîáíîå      │Äåðìàçèí, Ñèëüâåðäèí, Ñóëüôàçèíà ñåðåáðÿíàÿ 

│ñðåäñòâî, ñóëüôàíèëàìèä                      │ñîëü, Ñóëüôàðãèí                            

                                                                                          

│Ñóëüôàäèìåòîêñèí - ïðîòèâîìèêðîáíîå          │Ñóëüôàäèìåòîêñèíà òàáëåòêè,                 

│ñðåäñòâî, ñóëüôàíèëàìèä                      │Ñóëüôàäèìåòîêñèíà òàáëåòêè 0.2 ã,           

                                             │Ñóëüôàäèìåòîêñèíà òàáëåòêè 0.5 ã            

                                                                                         

│Ñóëüôàäèìèäèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,   │Ñóëüôàäèìåçèí, Ñóëüôàäèìåçèíà òàáëåòêè,     

│ñóëüôàíèëàìèä                                │Ñóëüôàäèìèäèí                               

                                                                                         

│Ñóëüôàêàðáàìèä - ïðîòèâîìèêðîáíîå ñðåäñòâî,  │Óðîñóëüôàí, Óðîñóëüôàíà òàáëåòêè 0.5 ã      

│ñóëüôàíèëàìèä                                                                            

                                                                                         

│Ñóëüôàëåí - ïðîòèâîìèêðîáíîå ñðåäñòâî,       │Ñóëüôàëåí äëÿ èíúåêöèé, Ñóëüôàëåí-ìåãëþìèíà 

│ñóëüôàíèëàìèä                                │ðàñòâîð äëÿ èíúåêöèé, Ñóëüôàëåíà òàáëåòêè   

                                             │0.2 ã                                        

                                                                                         

│Ñóëüôàìåòîêñèïèðèäàçèí - ïðîòèâîìèêðîáíîå    │Ïëåíêè ãëàçíûå c ñóëüôàïèðèäàçèíà-íàòðèåì,  

│ñðåäñòâî, ñóëüôàíèëàìèä                      │Ñóëüôàïèðèäàçèí, Ñóëüôàïèðèäàçèí íàòðèé,    

                                             │Ñóëüôàïèðèäàçèíà òàáëåòêè 0.5 ã             

                                                                                         

│Ñóëüôàìîíîìåòîêñèí+Òðèìåòîïðèì& -            │Ñóëüôàòîí, Ñóëüôàòîí äëÿ èíúåêöèé           

│ïðîòèâîìèêðîáíîå êîìáèíèðîâàííîå ñðåäñòâî                                                

                                                                                         

│Ñóëüôàíèëàìèä - ïðîòèâîìèêðîáíîå ñðåäñòâî,   │Ñòðåïòîöèä, Ñòðåïòîöèä áåëûé, Ñòðåïòîöèä    

│ñóëüôàíèëàìèä                                │áåëûé ðàñòâîðèìûé, Ñòðåïòîöèäà ëèíèìåíò 5%, 

                                             │Ñòðåïòîöèäà ðàñòâîðèìîãî ëèíèìåíò 5%,       

                                             │Ñòðåïòîöèäà òàáëåòêè, Ñòðåïòîöèäîâàÿ ìàçü 10%│

                                                                                         

│Ñóëüôàòèàçîë - ïðîòèâîìèêðîáíîå ñðåäñòâî,    │Íîðñóëüôàçîë, Íîðñóëüôàçîë ðàñòâîðèìûé,     

│ñóëüôàíèëàìèä                                │Íîðñóëüôàçîëà òàáëåòêè, Ñóëüôàòèàçîë,       

                                             │Ñóëüôàòèàçîë íàòðèÿ                         

                                                                                         

│Ñóëüôàöåòàìèä - ïðîòèâîìèêðîáíîå ñðåäñòâî,   │Ñóëüôàöåòàìèä íàòðèÿ, Ñóëüôàöèë íàòðèÿ,     

│ñóëüôàíèëàìèä                                │Ñóëüôàöèë íàòðèÿ ðàñòâîð 20%, Ñóëüôàöèë     

                                             │ðàñòâîðèìûé, Ñóëüôàöèë-íàòðèÿ ðàñòâîð 20%,  

                                             │Ñóëüôàöèë-íàòðèÿ ðàñòâîð 20% â              

                                             │òþáèê-êàïåëüíèöàõ, Ñóëüôàöèë-íàòðèÿ ðàñòâîð 

                                             │30%, Ñóëüôàöèë-íàòðèÿ ðàñòâîð 30% â         

                                             │òþáèê-êàïåëüíèöàõ, Ñóëüôàöèë-íàòðèÿ ðàñòâîð 

                                             │äëÿ èíúåêöèé 30%, Ñóëüôàöèëà ðàñòâîðèìîãî   

                                             │ðàñòâîð 10% ñ ìåòèëöåëëþëîçîé, Ñóëüôàöèëîâàÿ │

                                             │ìàçü 30%                                     

                                                                                         

│Ñóëüôàýòèäîë - ïðîòèâîìèêðîáíîå ñðåäñòâî,    │Ýòàçîë, Ýòàçîë ðàñòâîðèìûé, Ýòàçîë-íàòðèÿ   

│ñóëüôàíèëàìèä                                │ãðàíóëû äëÿ äåòåé, Ýòàçîë-íàòðèÿ ðàñòâîð äëÿ │

                                             │èíúåêöèé, Ýòàçîëà òàáëåòêè                  

                                                                                         

│Òàëèíîëîë - áåòà1-àäðåíîáëîêàòîð ñåëåêòèâíûé │Êîðäàíóì, Êîðäàíóì 100, Êîðäàíóì 50         

                                                                                         

│Òàìîêñèôåí - àíòèýñòðîãåí                    │Áèëåì, Ãåí-Òàìîêñèôåí, Çèòàçîíèóì, Èíòàì-10, │

                                             │Éåíîêñèôåí 10, Éåíîêñèôåí 20, Éåíîêñèôåí 30, │

                                             │Íîâîôåí, Íîëâàäåêñ, Íîëâàäåêñ Ä, Òàìèôåí,   

                                             │Òàìîêñåí, Òàìîêñèôåí, Òàìîêñèôåí            

                                             │(Òàìîïëåêñ), Òàìîêñèôåí-Ðàòèîôàðì,          

                                             │Òàìîêñèôåí-Ýáåâå, Òàìîêñèôåíà öèòðàò,       

                                             │Òàìîêñèôåíà öèòðàòà òàáëåòêè 0.01 ã,        

                                             │Òàìîêñèôåíáåíå, Òàìîôåí                     

                                                                                         

│Òàóðèí& - ìåòàáîëè÷åñêîå ñðåäñòâî            │Òàóôîí, Òàóôîíà ðàñòâîð 4% (ãëàçíûå êàïëè), 

                                             │Òàóôîíà ðàñòâîð äëÿ èíúåêöèé 4%, Òàóôîíà    

                                             │òàáëåòêè                                     

                                                                                         

│Òåãàôóð - ïðîòèâîîïóõîëåâîå ñðåäñòâî         │Ôòîðàôóð, Ôòîðàôóð â êàïñóëàõ 0.4 ã,        

                                             │Ôòîðàôóð-Òåâà, Ôòîðàôóðà ìàçü 5%, Ôòîðàôóðà 

                                             │ðàñòâîð äëÿ èíúåêöèé 4%                     

                                                                                         

│Òåíîêñèêàì - ÍÏÂÑ                            │Òåíèêàì, Òåíîêòèë, Òèëêîòèë, Òîáèòèë        

                                                                                         

│Òåîôèëëèí - áðîíõîäèëàòèðóþùåå ñðåäñòâî      │Àôîíèëóì ÑÐ, Âåíòàêñ, Äèôôóìàë 24,          

                                             │Äóðîôèëèí, Íåîòåîïýê À, Ðåòàôèë, Ñâå÷è c    

                                             │òåîôèëëèíîì 0.2 ã (íà ïîëèýòèëåíîêñèäíîé    

                                             │îñíîâå), Ñëîó-áèä, Ñëîó-Ôèëëèí, Ñïîôèëëèí   

                                             │ðåòàðä 100, Ñïîôèëëèí ðåòàðä 250, Òåî,      

                                             │Òåîáèîëîíã, Òåîäèë, Òåîïýê, Òåîñòàò,         

                                             │Òåîòàðä, Òåîôèëëèí, Òåîôèëëèí áåçâîäíûé,    

                                             │Òåîôèëëèí ãðàíóëÿò Í, Óíè-äóð, Óíèëýð       

                                                                                          

│Òåðàçîçèí - àëüôà-àäðåíîáëîêàòîð             │Êîðíàì, Õàéòðèí                             

                                                                                         

│Òåðáóòàëèí - áåòà2-àäðåíîñòèìóëÿòîð          │Áðèêàíèë, Áðèêàíèë èíõàëåð, Áðèêàíèë        

│ñåëåêòèâíûé                                  │òóðáóõàëåð                                  

                                                                                         

│Òåðêóðîíèé& - ìèîðåëàêñèðóþùåå ñðåäñòâî      │Òåðêóðîíèé, Òåðêóðîíèÿ ðàñòâîð äëÿ èíúåêöèé 

                                             │0.5%                                        

                                                                                          

│Òåðôåíàäèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ      │Áðîíàë, Ãèñòàäèí, Äýéëåðò, Êàðàäîíåë, Ðèòåð, │

│áëîêàòîð                                     │Òàìàãîí, Òåðèäèí, Òåðèäèí ôîðòå, Òåðôåä,    

                                             │Òåðôåíàäèí 60 Ñòàäà ìåæäóíàðîäíûé, Òîôðèí,  

                                             │Òðåêñèë                                     

                                                                                         

│Òåñòîñòåðîí - àíäðîãåí                       │Àíäðèîë, Íóâèð, Îìíàäðåí 250, Ñóñòàíîí 250, 

                                             │Ñóñòàíîí-250, Òåñòîñòåðîí-ïðîïèîíàò,        

                                             │Òåñòîñòåðîíà èçîêàïðîíàò, Òåñòîñòåðîíà      

                                             │êàïðîíàò, Òåñòîñòåðîíà ïðîïèîíàò,           

                                             │Òåñòîñòåðîíà ïðîïèîíàòà ðàñòâîð äëÿ èíúåêöèé │

                                             │â ìàñëå 1%, Òåñòîñòåðîíà ïðîïèîíàòà ðàñòâîð 

                                             │äëÿ èíúåêöèé â îëèâêîâîì ìàñëå, Òåñòîñòåðîíà │

                                             │ôåíèëïðîïèîíàò, Òåñòîñòåðîíà ýíàíòàò,       

                                             │Òåñòýíàò äëÿ èíúåêöèé 10%, Òåòðàñòåðîí      

                                                                                         

│Òåòðàêàèí - ìåñòíîàíåñòåçèðóþùåå ñðåäñòâî    │Äèêàèí, Äèêàèí (áåòà ôîðìà), Äèêàèíà (áåòà  

                                             │ôîðìà) ðàñòâîð 0.3% (ãëàçíûå êàïëè), Äèêàèíà │

                                             │(áåòà ôîðìà) ðàñòâîð 0.3% ñ ìåòèëöåëëþëîçîé 

                                             │(ãëàçíûå ïëåíêè), Ïëåíêè ãëàçíûå ñ äèêàèíîì 

                                                                                         

│Òåòðàöèêëèí - àíòèáèîòèê, òåòðàöèêëèí        │Èìåêñ, Òåòðàöèêëèí, Òåòðàöèêëèí â êàïñóëàõ, 

                                             │Òåòðàöèêëèí-Òåâà, Òåòðàöèêëèíà ãèäðîõëîðèä, 

                                             │Òåòðàöèêëèíà ãèäðîõëîðèäà òàáëåòêè ïîêðûòûå 

                                             │îáîëî÷êîé, Òåòðàöèêëèíà òàáëåòêè ïîêðûòûå   

                                             │îáîëî÷êîé, Òåòðàöèêëèíà òàáëåòêè ïîêðûòûå   

                                             │îáîëî÷êîé 50000 ÅÄ, Òåòðàöèêëèíîâàÿ ìàçü 3%, │

                                             │Òåòðàöèêëèíîâàÿ ìàçü ãëàçíàÿ 10000 ÅÄ/ã     

                                                                                         

│Òåòðèçîëèí - àëüôà-àäðåíîñòèìóëÿòîð          │Âèçèí, Îêòèëèÿ, Òèçèí                       

                                                                                         

│Òèàìàçîë - àíòèòèðåîèäíîå ñðåäñòâî           │Ìåðêàçîëèë, Ìåðêàçîëèëà òàáëåòêè 0.005 ã,   

                                             │Ìåòèçîë, Òèðîçîë                            

                                                                                         

│Òèàìèí - âèòàìèí                             │Áåíôîòèàìèí, Áåíôîòèàìèíà òàáëåòêè, Âèòàìèí 

                                             │Â-1, Âèòàìèí Â1, Íåóðî-Ðàòèîôàðì, Òèàáåíå,  

                                             │Òèàìèíà áðîìèä (âèòàìèí Â1), Òèàìèíà áðîìèäà │

                                             │ðàñòâîð äëÿ èíúåêöèé, Òèàìèíà áðîìèäà       

                                             │òàáëåòêè, Òèàìèíà ãèäðîõëîðèä, Òèàìèíà      

                                             │õëîðèä (âèòàìèí Â1), Òèàìèíà õëîðèäà ðàñòâîð │

                                             │äëÿ èíúåêöèé, Òèàìèíà õëîðèäà ðàñòâîð äëÿ   

                                             │èíúåêöèé 5%, Òèàìèíà õëîðèäà òàáëåòêè,      

                                             │Òèàìèíà õëîðèäà òàáëåòêè ïîêðûòûå îáîëî÷êîé 

                                             │0.1 ã                                        

                                                                                         

│Òèàïðèä - àíòèïñèõîòè÷åñêîå                  │Òèàïðèäà ðàñòâîð äëÿ èíúåêöèé 5%, Òèàïðèäà  

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │òàáëåòêè 0.1 ã, Òèàïðèäàë                   

                                                                                         

│Òèàïðîôåíîâàÿ êèñëîòà - ÍÏÂÑ                 │Ñóðãàì, Ñóðãàì íîêòå, Ñóðãàì ÑÀ             

│Òèêëîïèäèí - àíòèàãðåãàíòíîå ñðåäñòâî        │Òàãðåí, Òèêëèä                              

                                                                                         

│Òèìîãåí& - èììóíîñòèìóëèðóþùåå ñðåäñòâî      │Òèìîãåí, Òèìîãåí ëèîôèëèçèðîâàííûé äëÿ      

                                             │èíúåêöèé 0.0001 ã, Òèìîãåíà ðàñòâîð 0.01%,  

                                             │Òèìîãåíà ðàñòâîð äëÿ èíúåêöèé 0.01%         

                                                                                          

│Òèìîëîë - áåòà-àäðåíîáëîêàòîð                │Àðóòèìîë, Ãëàóìîë, Ãëóêîìîë 0.25%, Ãëóêîìîë 

                                             │0.5%, Íèîëîë, Íîâàë, Îêóìåä, Îêóìîë,        

                                             │Îêóïðåñ-Å, Îêóðèë, Îïòèìîë, Îôòàí Òèìîëîë,  

                                             │Îôòåíñèí, Òèìîãåêñàë, Òèìîëîë, Òèìîëîë-ïîñ, 

                                             │Òèìîïòèê, Òèìîïòèê-äåïî                     

                                                                                         

│Òèíèäàçîë - ïðîòèâîïðîòîçîéíîå ñðåäñòâî      │Òèçîë, Òèíàïðîò, Òèíèáà, Òèíèäàçîë, Òèíèìåä, │

                                             │Òèíèñàí, Ôàçèæèí                             

                                                                                         

│Òèîàöåòàçîí - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî  │Ñîëþòèçîí, Òèîàöåòàçîí (Òèáîí), Òèîàöåòàçîíà │

                                             │òàáëåòêè                                     

                                                                                         

│Òèîãóàíèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Ëàíâèñ, Òèîãóàíèí, Òèîãóàíèíà òàáëåòêè 0.04 ã│

│Òèîêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî       │Ãèíî-Òðîçèä, Òðîçèä                         

                                                                                         

│Òèîêòîâàÿ êèñëîòà - ãåïàòîïðîòåêòîðíîå       │Ëèïàìèä, Ëèïàìèäà òàáëåòêè ïîêðûòûå         

│ñðåäñòâî                                     │îáîëî÷êîé 0.025 ã, Ëèïîåâàÿ êèñëîòà,        

                                             │Ëèïîåâîé êèñëîòû ðàñòâîð äëÿ èíúåêöèé 0.5%, 

                                             │Ëèïîåâîé êèñëîòû òàáëåòêè ïîêðûòûå          

                                             │îáîëî÷êîé, Òèîêòàöèä 100 Ò, Òèîêòàöèä 200,  

                                             │Òèîêòàöèä 600, Òèîêòàöèä 600 Ò, Ýñïà-Ëèïîí  

                                                                                         

│Òèîïåíòàë íàòðèÿ - íàðêîçíîå íåèíãàëÿöèîííîå │Ïåíòîòàë, Òèîïåíòàë, Òèîïåíòàë íàòðèé       

│ñðåäñòâî                                     │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé, Òèîïåíòàë   

                                             │íàòðèÿ ñòåðèëüíûé, Òèîïåíòàë-íàòðèÿ         

                                                                                         

│Òèîðèäàçèí - àíòèïñèõîòè÷åñêîå               │Àïî-Òèîðèäàçèí, Ìåëëåðèë, Ñîíàïàêñ,          

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │Òèîäàçèí, Òèîðèë-100, Òèîðèë-25             

                                                                                         

│Òèîòåïà - ïðîòèâîîïóõîëåâîå ñðåäñòâî         │Òèîòåïà-Òèîïëåêñ, Òèîôîñôàìèä, Òèîôîñôàìèä  

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé              

                                                                                         

│Òèïåïèäèí - ïðîòèâîêàøëåâîå ñðåäñòâî         │Áèòèîäèí, Áèòèîäèíà òàáëåòêè ïîêðûòûå       

                                             │îáîëî÷êîé 0.01 ã                            

                                                                                         

│Òèðåîèäèí& - òèðåîèäíîå ñðåäñòâî             │Òèðåîèäèí, Òèðåîèäèíà ãðàíóëû äëÿ äåòåé,    

                                             │Òèðåîèäèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé,     

                                             │Òèðåîèäèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.05 ã│

                                                                                         

│Òèðîëèáåðèí - àíòèäåïðåññàíò                 │Ïëåíêè ñ òèðîëèáåðèíîì, Ïëåíêè ñ            

                                             │òèðîëèáåðèíîì (Ëèáåðîë), Òèðîëèáåðèí        

                                                                                         

│Òîáðàìèöèí - àíòèáèîòèê, àìèíîãëèêîçèä       │Áðóëàìèöèí, Íåáöèí, Òîáðàìèöèí, Òîáðàìèöèíà 

                                             │ñóëüôàò äëÿ èíúåêöèé 0.08 ã, Òîáðàöèí-ÀÄÑ,  

                                             │Òîáðåêñ                                     

                                                                                         

│Òîëáóòàìèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ    │Áóòàìèä, Áóòàìèäà òàáëåòêè, Îðàáåò          

│ïåðîðàëüíîãî ïðèåìà                                                                      

                                                                                         

│Òîñèëõëîðàìèä íàòðèÿ - äåçèíôèöèðóþùåå       │Òðèõëîðîëü, Õëîðèíà                         

│ñðåäñòâî                                                                                  

                                                                                         

│Òðàçîäîí - àíòèäåïðåññàíò                    │Àçîíà, Òðèòòèêî                             

                                                                                          

│Òðàìàäîë - àíàëüãåòè÷åñêîå ñðåäñòâî          │Ìàáðîí, Ïðîòðàäîí, Ñèíòðàäîí, Òðàäîë,       

│öåíòðàëüíîãî äåéñòâèÿ                        │Òðàìàãèò, Òðàìàäîë Ëàííàõåð, Òðàìàäîë       

                                             │Íèêîìåä, Òðàìàäîë Ñòàäà ìåæäóíàðîäíûé,      

                                             │Òðàìàäîë-ÀÊÐÈ êàïñóëû, Òðàìàäîë, Òðàìàäîëà  

                                             │ãèäðîõëîðèä, Òðàìàë ðåòàðä, Òðàìàë ñâå÷è 0.1 │

                                             │ã, Òðàìàë ñâå÷íàÿ ìàññà, Òðàìàë, Òðàìóíäèí  

                                             │ðåòàðä                                      

                                                                                          

│Òðàíåêñàìîâàÿ êèñëîòà - ãåìîñòàòè÷åñêîå      │Òðàíñàì÷à, Öèêëîêàïðîí, Ýêçàöèë             

│ñðåäñòâî                                                                                 

                                                                                          

│Òðåïèðèÿ éîäèä& - ãàíãëèîáëîêàòîð            │Ãèãðîíèé, Ãèãðîíèé äëÿ èíúåêöèé 0.1 ã       

│Òðåòèíîèí - ðåãåíåðàöèè ñòèìóëÿòîð           │Àéðîë, Âåñàíîèä, Ëîêàöèä, Ðåòèí-À           

                                                                                         

│Òðèàìöèíîëîí - ãëþêîêîðòèêîñòåðîèä           │Àçìàêîðò, Áåðëèêîðò, Äåëôèêîðò, Êåíàêîðò,   

                                             │Êåíàëîã, Êåíàëîã 40, Êåíàëîã Îðàáåéç,       

                                             │Íàçàêîðò, Ïîëüêîðòîëîí, Òðèàêîðò, Òðèàì-Äåíê │

                                             │40 äëÿ èíúåêöèé, Òðèàìñèíîëîí, Òðèàìñèíîëîí 

                                             │àöåòîíèä, Òðèàìöèíîëîí, Òðèàìöèíîëîí        

                                             │Íèêîìåä, Òðèàìöèíîëîíà àöåòîíèä,            

                                             │Òðèàìöèíîëîíà òàáëåòêè 0.004 ã, Òðèêîðò,    

                                             │Ôòîðîêîðò, Öèíàêîðò                         

                                                                                         

│Òðèãåêñèôåíèäèë - í-õîëèíîáëîêàòîð           │Àïî-Òðàéãåêñ, Ïàðêîïàí 2, Ïàðêîïàí 5,       

│öåíòðàëüíûé                                  │Ðîìïàðêèí, Òðèôåí, Öèêëîäîë, Öèêëîäîëà      

                                             │òàáëåòêè                                    

                                                                                         

│Òðèìåäîêñèí áðîìèä - ðåàêòèâàòîð             │Äèïèðîêñèì, Äèïèðîêñèìà ðàñòâîð 15% â àìïóëàõ│

│õîëèíýñòåðàçû                                                                            

                                                                                         

│Òðèìåïåðèäèíà ãèäðîõëîðèä& - àíàëüãåòè÷åñêîå │Ïðîìåäîë, Ïðîìåäîëà ðàñòâîð â øïðèö-òþáèêàõ, │

│íàðêîòè÷åñêîå ñðåäñòâî                       │Ïðîìåäîëà ðàñòâîð äëÿ èíúåêöèé 2%, Ïðîìåäîëà │

                                             │ðàñòâîð äëÿ èíúåêöèé, Ïðîìåäîëà òàáëåòêè    

                                             │0.025 ã                                     

                                                                                          

│Òðèìåòèäèíèÿ äèéîäèä& - ãàíãëèîáëîêàòîð      │Êàìôîíèé, Êàìôîíèÿ ðàñòâîð äëÿ èíúåêöèé 1%, 

                                             │Êàìôîíèÿ òàáëåòêè                           

                                                                                         

│Òðèìåòîïðèì - ïðîòèâîìèêðîáíîå ñðåäñòâî,     │ÒÌÏ-Ðàòèîôàðì, Òðèìåòîïðèì, Òðèìîïàí, Òðèïðèì│

│ôîëèåâîé êèñëîòû àíòàãîíèñò                                                              

                                                                                         

│Òðèïòîðåëèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Äåêàïåïòèë, Äåêàïåïòèë äåïî                 

                                                                                          

│Òðèôëóîïåðàçèí - àíòèïñèõîòè÷åñêîå           │Àïî-Òðèôëóîïåðàçèí, Ñòåëàçèí, Òðàçèí,       

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │Òðèôòàçèí, Òðèôòàçèíà ðàñòâîð â àìïóëàõ     

                                             │0.2%, Òðèôòàçèíà òàáëåòêè ïîêðûòûå          

                                             │îáîëî÷êîé, Òðèôòàçèíà òàáëåòêè ïîêðûòûå     

                                             │îáîëî÷êîé 0.005 ã                           

                                                                                         

│Òðèôîñàäåíèí - ìåòàáîëè÷åñêîå ñðåäñòâî       │Àäåíîçèíòðèôoñôîðíàÿ êèñëîòà, Áèîñèíò       

                                             │(íàòðèÿ àäåíîçèíòðèôîñôàò ñóõîé), Íàòðèÿ    

                                             │àäåíîçèíòðèôîñôàò äâóçàìåùåííûé, Íàòðèÿ     

                                             │àäåíîçèíòðèôîñôàòà ðàñòâîð 1% â àìïóëàõ,    

                                             │Íàòðèÿ àäåíîçèíòðèôîñôàòà ðàñòâîð äëÿ       

                                             │èíúåêöèé 1%, Ôîñôîáèîí                      

                                                                                         

│Òðèõîìîíàöèä& - ïðîòèâîïðîòîçîéíîå ñðåäñòâî  │Ñóïïîçèòîðèè âàãèíàëüíûå ñ òðèõîìîíàöèäîì,  

                                             │Òðèõîìîíàöèä, Òðèõîìîíàöèäà òàáëåòêè 0.05 ã 

                                                                                          

│Òðîêëîñåí íàòðèÿ - äåçèíôèöèðóþùåå ñðåäñòâî  │Äîìåñòîñ, Æàâåëü ñîëèä, Êëîðñåïò, Ïðåñåïò,  

                                             │Ïþðæàâåëü (Ïàòñèëü Æàâååëü Ýôôåðâåññàíò),   

                                             │Ñòåðèíîâà                                    

                                                                                         

│Òðîìåòàìîë - äèóðåòè÷åñêîå ñðåäñòâî          │Òðèñàìèí, Òðèñàìèíà ðàñòâîð äëÿ èíúåêöèé    

                                             │3.66%                                       

                                                                                         

│Òðîïèêàìèä - ì-õîëèíîáëîêàòîð                │Ìèäðèàöèë, Ìèäðóì, Òðîïèêàìèä               

                                                                                         

│Òðîïîäèôåíà ãèäðîõëîðèä& -                   │Òðîïàôåí, Òðîïàôåí ëèîôèëèçèðîâàííûé äëÿ    

│àëüôà-àäðåíîáëîêàòîð                         │èíúåêöèé 0.02 ã                              

                                                                                         

│Óáèäåêàðåíîí - êàðäèîòîíè÷åñêîå ñðåäñòâî     │Ìàðèíèë Êó10, Ñóïåð Êó 10-30 ìã, Óáèíîí,    

                                             │Óáèíîíà êàïñóëû 0.015 ã                     

                                                                                         

│Óíäåöèëåíîâàÿ êèñëîòà - ïðîòèâîãðèáêîâîå     │Ìèêîöåì, Óíäåöèëåíîâîé êèñëîòû ìåäíàÿ ñîëü, 

│ñðåäñòâî                                     │Öèíêà óíäåöèëåíàò                           

                                                                                         

│Óðîêèíàçà - ôèáðèíîëèòè÷åñêîå ñðåäñòâî       │Ïóðîöèí, Óêèäàí, Óðîêèíàçà                  

                                                                                         

│Óðîôîëëèòðîïèí - ôîëëèêóëîñòèìóëèðóþùåå      │Ìåòðîäèí, Ìåòðîäèí Â×                       

│ñðåäñòâî                                                                                 

                                                                                         

│Óðñîäåîêñèõîëèåâàÿ êèñëîòà -                 │Óðñî 100, Óðñîñàí, Óðñîôàëüê                 

│ãåïàòîïðîòåêòîðíîå ñðåäñòâî                                                              

                                                                                         

│Ôàêòîð ñâåðòûâàíèÿ êðîâè II                  │VII                                          

                                                                                         

│Ôàêòîð ñâåðòûâàíèÿ êðîâè IX& -               │Àãåìôèë Â, Àèìàôèêñ Ä.È., Áåáóëèí ÒÈÌ 4     

│ãåìîñòàòè÷åñêîå ñðåäñòâî                     │(Ôàêòîð IX ÷åëîâåêà êîíöåíòðèðîâàííûé),     

                                             │Èììóíèí, Îêòàíàéí, Ðåïëåíèí, Ôàêòîð IX Ï,   

                                             │Ôàêòîðà IX ñòàíäàðò                         

                                                                                         

│Ôàêòîð ñâåðòûâàíèÿ êðîâè VIII& -             │Àíòèãåìîôèëüíûé ôàêòîð ÷åëîâåêà-Ì (AHF-M),  

│ãåìîñòàòè÷åñêîå ñðåäñòâî                     │Ãåìîôèë Ì, Êîýéò-ÕÏ, Êðèîáóëèí ÒÈÌ 3 (Ôàêòîð │

                                             │VIII ÷åëîâåêà êîíöåíòðèðîâàííûé),           

                                             │Êðèîïðåöèïèòàò, Êðèîïðåöèïèòàò ñóõîé,       

                                             │Îêòàâè, Óìàí Êðàé Ä.È., Ôàêòîð VIII Y (ÁÏË), │

                                             │Õåìàòý Ï, Ýìîêëîò Ä.È.                      

                                                                                         

│Ôàìîòèäèí - H2-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Àíòîäèí, Àïî-Ôàìîòèäèí, Àöèïåï, Áëîêàöèä,   

│áëîêàòîð                                     │Ãàñòåðîãåí, Ãàñòðîñèäèí, Êâàìàòåë, Ëåöåäèë, 

                                             │Íåâîôàì, Ïåïñèäèí, Òîïöèä, Óëüôàìèä,        

                                             │Óëüöåðàí, Ôàìîäàð, Ôàìîíèò, Ôàìîïñèí,       

                                             │Ôàìîñàí, Ôàìîòèäèí, Ôàìîòèäèí-Àêðè òàáëåòêè 

                                             │ïîêðûòûå îáîëî÷êîé, Ôàìîöèä, Ôóäîí          

                                                                                         

│Ôåíàçåïàì& - àíêñèîëèòè÷åñêîå ñðåäñòâî       │Ôåíàçåïàì, Ôåíàçåïàìà ðàñòâîð äëÿ èíúåêöèé  

                                             │0.1%, Ôåíàçåïàìà ðàñòâîð äëÿ èíúåêöèé 3%,   

                                             │Ôåíàçåïàìà òàáëåòêè                         

                                                                                          

│Ôåíàçîí - ÍÏÂÑ                               │Àíòèïèðèí, Àíòèïèðèíà òàáëåòêè, Àíòèïèðèíà  

                                             │òàáëåòêè 0.25 ã                             

                                                                                         

│Ôåíèêàáåðàí& - ñïàçìîëèòè÷åñêîå ñðåäñòâî     │Ôåíèêàáåðàí, Ôåíèêàáåðàíà ðàñòâîð äëÿ       

                                             │èíúåêöèé 0.25%, Ôåíèêàáåðàíà òàáëåòêè       

                                             │ïîêðûòûå îáîëî÷êîé 0.02 ã                   

                                                                                         

│Ôåíèëáóòàçîí - ÍÏÂÑ                          │Áóòàäèîí, Áóòàäèîíà òàáëåòêè 0.15 ã,         

                                             │Áóòàäèîíà òàáëåòêè ïîêðûòûå îáîëî÷êîé,      

                                             │Ôåíèëáóòàçîí                                

                                                                                          

│Ôåíèëïðîïàíîëàìèí+Õëîðôåíàìèí& -             │Áàðòåë äðàãç Ïðîòèâîîòå÷íûå è               

│ïðîòèâîêîíãåñòèâíîå ñðåäñòâî                 │Àíòèãèñòàìèííûå êàïñóëû, Êîëäàêò, Êîëäàð,   

                                             │Êîíòàê 400, Íàø âûáîð - ñèðîï òðîéíîãî      

                                             │äåéñòâèÿ, Îðèíîë, Ýôôåêò                    

                                                                                         

│Ôåíèëïðîïàíîëàìèí+Õëîðôåíàìèí+               │HL-Êîëä, Íàø âûáîð - øèïó÷èå òàáëåòêè îò    

│Àöåòèëñàëèöèëîâàÿ êèñëîòà& - ñðåäñòâî        │ïðîñòóäû, Ýëêàïèí ïëþñ                      

│óñòðàíåíèÿ ñèìïòîìîâ ÎÐÇ è ïðîñòóäû                                                       

                                                                                         

│Ôåíèëïðîïàíîëàìèí+Õëîðôåíàìèí+Ïàðàöåòàìîë& - │Ëîðåéí. Ñðåäñòâî îò ïðîñòóäû è ãðèïïà äëÿ   

│ñðåäñòâî óñòðàíåíèÿ ñèìïòîìîâ ÎÐÇ è ïðîñòóäû │äåòåé, Ýôôåêò ïëþñ                          

                                                                                         

│Ôåíèëýôðèí - àëüôà-àäðåíîñòèìóëÿòîð          │Ìåçàòîí, Ìåçàòîíà ðàñòâîð 1% â àìïóëàõ (ñ   

                                             │äîáàâëåíèåì ãëèöåðèíà)                      

                                                                                         

│Ôåíèíäèîí - àíòèêîàãóëÿíò, âèòàìèíà Ê        │Ôåíèëèí, Ôåíèëèíà òàáëåòêè 0.03 ã           

│àíòàãîíèñò                                                                               

                                                                                         

│Ôåíèòîèí - ïðîòèâîñóäîðîæíîå ñðåäñòâî        │Äèôåíèí, Äèôåíèíà òàáëåòêè 0.117 ã          

                                                                                         

│Ôåíîáàðáèòàë - ñíîòâîðíîå ñðåäñòâî           │Ôåíîáàðáèòàë (Ëþìèíàë), Ôåíîáàðáèòàë,        

                                             │Ôåíîáàðáèòàëà ðàñòâîð äëÿ äåòåé 0.2%,       

                                             │Ôåíîáàðáèòàëà òàáëåòêè äëÿ äåòåé 0.005 ã,   

                                             │Ôåíîáàðáèòàëà òàáëåòêè                      

                                                                                         

│Ôåíîêñèìåòèëïåíèöèëëèí - àíòèáèîòèê,         │V-Ïåíèöèëëèí Ñëîâàêîôàðìà, Âåïèêîìáèí,      

│ïåíèöèëëèí                                   │Êëèàöèë, Ìåãàöèëëèí îðàë, Îñïåí, Îñïåí 750, 

                                             │Îñïåí-750 ñèðîï, Ïåí-îñ, Ïåíèöèëëèí-Ôàó,    

                                             │Ôåíîêñèìåòèëïåíèöèëëèí,                     

                                             │Ôåíîêñèìåòèëïåíèöèëëèí (äëÿ ñóñïåíçèè),     

                                             │Ôåíîêñèìåòèëïåíèöèëëèíà äðàæå 100000 ÅÄ,    

                                             │Ôåíîêñèìåòèëïåíèöèëëèíà òàáëåòêè            

                                                                                         

│Ôåíîë& - àíòèñåïòè÷åñêîå ñðåäñòâî            │Ôåíîë ÷èñòûé, Ôåíîë ÷èñòûé æèäêèé, Ôåíîëà   

                                             │ðàñòâîð â ãëèöåðèíå, Ôåíîëîâàÿ ìàçü 2%      

                                                                                         

│Ôåíîëôòàëåèí - ñëàáèòåëüíîå ñðåäñòâî         │Ïóðãåí, Ôåíîëôòàëåèí, Ôåíîëôòàëåèíà òàáëåòêè │

                                                                                         

│Ôåíîòåðîë - áåòà2-àäðåíîñòèìóëÿòîð           │Àðóòåðîë, Áåðîòåê, Áåðîòåê-100, Ïàðòóñèñòåí, │

│ñåëåêòèâíûé                                  │Ïàðòóñèñòåí èíòðàïàðòàëüíûé, Ôåíîòåðîë,     

                                             │Ôòàãèðîë                                    

                                                                                         

│Ôåíîòðèí - ñðåäñòâî óíè÷òîæåíèÿ ýêòîïàðàçèòîâ│Àíòè-áèò, ÁÈÍ, Ãëîáîëü-áîêñ-ïðèìàíêà,       

                                             │Èíñåêòèöèäíîå ìûëî Äåç-Ô, Èíñåêòèöèäíûé äóñò │

                                             │íà îñíîâå Ñóìèòðèíà, Èíñåêòèöèäíûé øàìïóíü  

                                             │íà îñíîâå Ñóìèòðèíà, Ìûëî Äåç-Ô, Ñóìèòðèí   

                                             │10% Sec, Ôåíîëîí                            

                                                                                          

│Ôåíîôèáðàò - ãèïîëèïèäåìè÷åñêîå ñðåäñòâî     │Ãðîôèáðàò, Ëèïàíòèë 200 Ì, Ëîôàò            

                                                                                         

│Ôåíòàíèë - àíàëüãåòè÷åñêîå íàðêîòè÷åñêîå     │Ôåíòàíèë, Ôåíòàíèëà ðàñòâîð äëÿ èíúåêöèé    

│ñðåäñòâî                                     │0.005%                                      

                                                                                         

│Ôåíòîëàìèí - àëüôà-àäðåíîáëîêàòîð            │Ôåíòîëàìèíà ãèäðîõëîðèä, Ôåíòîëàìèíà        

                                             │ãèäðîõëîðèäà òàáëåòêè 0.025 ã               

                                                                                          

│Ôåïðîçèäíèí - àíòèäåïðåññàíò                 │Ñèäíîôåí, Ñèäíîôåíà òàáëåòêè 0.005 ã        

│Ôèíàñòåðèä - àíòèàíäðîãåí                    │Ïðîñêàð, Ôèíàñò                             

│Ôèïðîíèë - èíñåêòèöèäíîå ñðåäñòâî            │Ãîëèàô, Ãîëèàô Áàéò Ñòåéøíñ                 

                                                                                         

│Ôèòîìåíàäèîí - ãåìîñòàòè÷åñêîå ñðåäñòâî      │Ôèòîìåíàäèîí (âèòàìèí K1), Ôèòîìåíàäèîíà    

                                             │(Âèòàìèíà Ê1) ðàñòâîð â ìàñëå 10% â êàïñóëàõ │

                                             │0.                                          

                                                                                         

│Ôëàâèíàäåíèíà äèíóêëåîòèä& - âèòàìèí         │Ôëàâèíàò, Ôëàâèíàò äëÿ èíúåêöèé 0.002 ã     

                                                                                         

│Ôëóàöèçèí& - àíòèäåïðåññàíò                  │Ôòîðàöèçèí, Ôòîðàöèçèíà ðàñòâîð 1.25% â     

                                             │àìïóëàõ, Ôòîðàöèçèíà òàáëåòêè ïîêðûòûå      

                                             │îáîëî÷êîé 0.025 ã                           

                                                                                          

│Ôëóäðîêîðòèçîí - ãëþêîêîðòèêîñòåðîèä         │Êîðòèíåôô, Ôëîðèíåô                         

│Ôëóêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî       │Äèôëþêàí, Ìåäîôëþêîí, Ôîðêàí                

                                                                                         

│Ôëóìåòàçîí - ãëþêîêîðòèêîñòåðîèä äëÿ         │Ëîêàêîðòåí, Ëîðèíäåí, Ôëóâåò                

│ìåñòíîãî ïðèìåíåíèÿ                                                                       

                                                                                         

│Ôëóìåòàçîí+Ñàëèöèëîâàÿ êèñëîòà& -            │Ëîêàñàëåí, Ëîðèíäåí À                       

│ãëþêîêîðòèêîñòåðîèä äëÿ ìåñòíîãî ïðèìåíåíèÿ                                              

                                                                                         

│Ôëóíèòðàçåïàì - ñíîòâîðíîå ñðåäñòâî          │Ðîãèïíîë, Ñîìíóáåíå, Ôëóíèòðàçåïàì-Òåâà     

                                                                                         

│Ôëóîêñåòèí - àíòèäåïðåññàíò                  │Àïî-Ôëóîêñåòèí, Äåïðåêñ, Ïîðòàë, Ïðîäåï,    

                                             │Ïðîçàê, Ôëóâàë, Ôëóêñîíèë, Ôëóîêñåòèí        

                                             │Ëàííàõåð, Ôëóîêñåòèí Íèêîìåä,               

                                             │Ôëóîêñåòèí-Àêðè êàïñóëû, Ôëóîêñåòèíà        

                                             │ãèäðîõëîðèä, Ôëþäàê                         

                                                                                         

│Ôëóîðåñöåèí íàòðèÿ - äèàãíîñòèêóì            │Ôëóîðåñöåèí ðàñòâîðèìûé, Ôëþîðåñöèò,        

                                             │Ôëþðåíàòà ðàñòâîð äëÿ èíúåêöèé 10%          

                                                                                         

│Ôëóîöèíîëîí+Êëèîõèíîë& -                     │Ñèíàëàð Ê, Ôëóêîðò-Ö                        

│ãëþêîêîðòèêîñòåðîèä+ïðîòèâîìèêðîáíîå ñðåäñòâî│                                            

                                                                                         

│Ôëóîöèíîëîíà àöåòîíèä - ãëþêîêîðòèêîñòåðîèä  │Ñèíàëàð, Ñèíàôëàí, Ñèíàôëàíà ëèíèìåíò       

│äëÿ ìåñòíîãî ïðèìåíåíèÿ                      │0.025%, Ñèíàôëàíà ìàçü 0.025%, Ñèíîäåðì,    

                                             │Ôëóêîðò, Ôëóîçîí, Ôëóîöèíîëîí àöåòîíèä,     

                                             │Ôëóöèíàð, Ýçàöèíîí                          

                                                                                         

│Ôëóðáèïðîôåí - ÍÏÂÑ                          │Îêóôëþð, Îêóôëþð ëèêâèôèëì, Ôëóãàëèí        

                                                                                         

│Ôëóòàìèä - àíòèàíäðîãåí                      │Íèôòîëèä, Íèôòîëèäà ìàçü 2.5%, Íèôòîëèäà    

                                             │òàáëåòêè 0.25 ã, Ôëóòàêàí, Ôëóòàìèä,        

                                             │Ôëóöèíîì, Ôëþòàìèä, Ôðóãèë                  

                                                                                         

│Ôëóòèêàçîí - ãëþêîêîðòèêîñòåðîèä äëÿ         │Êóòèâåéò, Ôëèêñîíàçå, Ôëèêñîòèä             

│ìåñòíîãî ïðèìåíåíèÿ                                                                      

                                                                                          

│Ôëóôåíàçèí - àíòèïñèõîòè÷åñêîå               │Ëèîðîäèí-äåïî, Ìèðåíèë, Ìîäåêåéò, Ìîäèòåí,  

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │Ìîäèòåí äåïî, Ìîäèòåí-äåïî, Ïðîëèíàò        

                                                                                          

│Ôîñêàðíåò íàòðèÿ - ïðîòèâîâèðóñíîå ñðåäñòâî  │Òðèàïòåí, Ôîñêàðíåò íàòðèÿ                  

                                                                                         

│Ôîñôýñòðîë - ýñòðîãåí                        │Ôîñôýñòðîëà ðàñòâîð 6% â àìïóëàõ,           

                                             │Ôîñôýñòðîëà òàáëåòêè 0.1 ã, Õîíâàí          

                                                                                         

│Ôîòðåòàìèí& - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Ôîòðèí, Ôîòðèí äëÿ èíúåêöèé 0.02 ã          

│Ôðàìèöåòèí - àíòèáèîòèê, àìèíîãëèêîçèä       │Èçîôðà, Ðèíèë                               

│Ôðóêòîçà - ìåòàáîëè÷åñêîå ñðåäñòâî           │Ëåâóëîçà, Ôðóêòîçà                           

                                                                                         

│Ôòàëèëñóëüôàïèðèäàçèí& - ïðîòèâîìèêðîáíîå    │Ôòàçèí, Ôòàçèíà òàáëåòêè 0.5 ã              

│ñðåäñòâî, ñóëüôàíèëàìèä                                                                   

                                                                                         

│Ôòàëèëñóëüôàòèàçîë - ïðîòèâîìèêðîáíîå        │Ôòàëàçîë, Ôòàëàçîë-Äàðíèöà, Ôòàëàçîëà       

│ñðåäñòâî, ñóëüôàíèëàìèä                      │òàáëåòêè 0.5 ã, Ôòàëèëñóëüôàòèàçîë          

                                                                                         

│Ôòîðóðàöèë - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │5-Ôòîðóðàöèë-Ýáåâå, Ôëóîðî-óðàöèë Ðîø,      

                                             │Ôëóðîêñ, Ôòîðóðàöèë, Ôòîðóðàöèë-Òåâà,       

                                             │Ôòîðóðàöèëà ðàñòâîð 5% â àìïóëàõ,           

                                             │Ôòîðóðàöèëà ðàñòâîð äëÿ èíúåêöèé 5% â àìïóëàõ│

                                                                                         

│Ôóáðîãîíèé& - ãàíãëèîáëîêàòîð                │Ôóáðîìåãàí, Ôóáðîìåãàíà òàáëåòêè 0.03 ã     

                                                                                         

│Ôóçèäèåâàÿ êèñëîòà - àíòèáèîòèê              │Ôóçèäèåâîé êèñëîòû ãðàíóëû äëÿ ñóñïåíçèé,   

                                             │Ôóçèäèí, Ôóçèäèí-íàòðèé, Ôóçèäèí-íàòðèÿ     

                                             │òàáëåòêè, Ôóçèäèí-íàòðèÿ òàáëåòêè ïîêðûòûå  

                                             │îáîëî÷êîé                                   

                                                                                         

│Ôóðàçèäèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,       │Ôóðàãèí, Ôóðàãèí ðàñòâîðèìûé, Ôóðàãèí       

│íèòðîôóðàí                                   │ðàñòâîðèìûé 10% ñ íàòðèÿ õëîðèäîì 90%,      

                                             │Ôóðàãèí-ñòàíäàðò, Ôóðàãèíà ðàñòâîðèìîãî 0.05 │

                                             │ã ñ ìàãíèÿ êàðáîíàòîì îñíîâíûì êàïÈÎÑ ÀÍ    

                                             │ËÀÒÂÈÈ, Ôóðàãèíà òàáëåòêè 0.05 ã             

                                                                                         

│Ôóðàçîëèäîí - ïðîòèâîìèêðîáíîå ñðåäñòâî,     │Ôóðàçîëèäîíà 50 ìã, Ôóðàçîëèäîíà ãðàíóëû äëÿ │

│íèòðîôóðàí                                   │äåòåé, Ôóðàçîëèäîíà òàáëåòêè 0.05 ã         

                                                                                         

│Ôóðàëòàäîí - ïðîòèâîìèêðîáíîå ñðåäñòâî,      │Ôóðàçîëèí, Ôóðàçîëèíà òàáëåòêè 0.05 ã       

│íèòðîôóðàí                                                                               

                                                                                         

│Ôóðîñåìèä - äèóðåòè÷åñêîå ñðåäñòâî           │Àïî-Ôóðîñåìèä, Äèóñåìèä, Äèôóðåêñ, Êèíåêñ,  

                                             │Ëàçèêñ, Íîâî-Ñåìèä, Òàñåê, Òàñèìàéä, Óðèêñ, 

                                             │Ôëîðèêñ, Ôðóñåìèä, Ôóðîí, Ôóðîðåçå,         

                                             │Ôóðîñåìèä, Ôóðîñåìèä (Ìèôàð), Ôóðîñåìèä     

                                             │Ëàííàõåð, Ôóðîñåìèä-Ðàòèîôàðì,              

                                             │Ôóðîñåìèä-Òåâà, Ôóðîñåìèäà ãðàíóëû äëÿ      

                                             │äåòåé, Ôóðîñåìèäà ðàñòâîð äëÿ èíúåêöèé 1%,  

                                             │Ôóðîñåìèäà òàáëåòêè 0.04 ã, Ôóðîñåìèäà      

                                             │òàáëåòêè 40 ìã, Ôóðñåìèä                    

                                                                                         

│Ôóðîñåìèä+Ñïèðîíîëàêòîí& - äèóðåòè÷åñêîå     │Ëàçèëàêòîí, Ôóðî-Àëüäîïóð, Ôóðî-Àëüäîïóð    

│êîìáèíèðîâàííîå ñðåäñòâî                     │ôîðòå                                       

                                                                                         

│Õåíîäåîêñèõîëåâàÿ êèñëîòà - ñðåäñòâî ëå÷åíèÿ │Õåíîñàí, Õåíîôàëê, Õåíîõîë                  

│õîëåëèòèàçà                                                                              

                                                                                         

│Õèíèäèí - àíòèàðèòìè÷åñêîå ñðåäñòâî          │Êèíèäèí äóðóëåñ, Õèíèäèíà ñóëüôàò, Õèíèïýê  

                                                                                         

│Õèíèí - ïðîòèâîìàëÿðèéíîå ñðåäñòâî           │Õèíèíà ãèäðîõëîðèä, Õèíèíà ãèäðîõëîðèäà     

                                             │òàáëåòêè, Õèíèíà äèãèäðîõëîðèä, Õèíèíà      

                                             │äèãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé 50%,    

                                             │Õèíèíà ñóëüôàò, Õèíèíà ñóëüôàòà òàáëåòêè    

                                                                                         

│Õèíèîôîí - ïðîòèâîïðîòîçîéíîå ñðåäñòâî       │Õèíèîôîí (ßòðåí), Õèíèîôîíà òàáëåòêè 0.25 ã 

                                                                                         

│Õèôåíàäèí& - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ      │Ôåíêàðîë, Ôåíêàðîëà òàáëåòêè                

│áëîêàòîð                                                                                 

                                                                                          

│Õëîðàìáóöèë - ïðîòèâîîïóõîëåâîå ñðåäñòâî     │Ëåéêåðàí, Õëîðáóòèí, Õëîðáóòèíà òàáëåòêè    

                                                                                         

│Õëîðàìôåíèêîë - àíòèáèîòèê                   │Ëåâîâèíèçîëü, Ëåâîìèöåòèí, Ëåâîìèöåòèí â    

                                             │êàïñóëàõ, Ëåâîìèöåòèí â êàïñóëàõ 0.25 ã,    

                                             │Ëåâîìèöåòèí-Àêðè ëèíèìåíò 1%,               

                                             │Ëåâîìèöåòèí-Àêðè ëèíèìåíò 2.5%,             

                                             │Ëåâîìèöåòèí-Àêðè ëèíèìåíò 5%, Ëåâîìèöåòèíà  

                                             │ðàñòâîð 0.25%, Ëåâîìèöåòèíà ðàñòâîð         

                                             │ñïèðòîâîé, Ëåâîìèöåòèíà ñòåàðàò,            

                                             │Ëåâîìèöåòèíà ñòåàðàòà òàáëåòêè 0.25 ã,      

                                             │Ëåâîìèöåòèíà ñóêöèíàò íàòðèÿ, Ëåâîìèöåòèíà  

                                             │ñóêöèíàòà íàòðèåâàÿ ñîëü, Ëåâîìèöåòèíà      

                                             │òàáëåòêè, Ëåâîìèöåòèíà òàáëåòêè ïîêðûòûå    

                                             │îáîëî÷êîé 0.25 ã, Ëåâîìèöåòèíà òàáëåòêè     

                                             │ïðîëîíãèðîâàííîãî äåéñòâèÿ 0.65 ã,          

                                             │Ñèíòîìèöèí, Ñèíòîìèöèíà ëèíèìåíò,           

                                             │Ñóïïîçèòîðèè âàãèíàëüíûå ñ ñèíòîìèöèíîì 0.25 │

                                             │ã (íà ëàçóïîëå G, Õëîðàìôåíèêîë,            

                                             │Õëîðàìôåíèêîë Ëåâî, Õëîðàìôåíèêîëà íàòðèÿ   

                                             │ñóêöèíàò                                    

                                                                                         

│Õëîðãåêñèäèí - äåçèíôèöèðóþùåå ñðåäñòâî      │Ãèáèñêðàá, Ãèáèòàí, Êàòåäæåëü Ñ, Êîðñîäèë,  

                                             │Ìàíóñàí, Ïëèâàñåïò, Ïëèâàñåïò 5% êîíöåíòðàò 

                                             │ñ ÏÀÂ, Ïëèâàñåïò ãëþêîíàò 5% áåç ÏÀÂ,       

                                             │Ïëèâàñåïò Í, Ïëèâàñåïò ïåíîîáðàçóþùèé,      

                                             │Ïëèâàñåïò ñèíèé, Ïëèâàñåïò òèíêòóðà, Ôåðâåêñ │

                                             │îò áîëè â ãîðëå, Õëîðãåêñèäèí áèãëþêîíàò,   

                                             │Õëîðãåêñèäèí Æèôðåð, Õëîðãåêñèäèíà          

                                             │áèãëþêîíàòà ðàñòâîð 0.05%, Õëîðãåêñèäèíà    

                                             │áèãëþêîíàòà ðàñòâîð 20%, Õëîðãåêñèäèíà      

                                             │ãëþêîíàò 20% ðàñòâîð                        

                                                                                         

│Õëîðãåêñèäèí+Ëèäîêàèí& - àíòèñåïòè÷åñêîå     │Èíñòèëëàãåëü, Êàòåäæåëü ñ ëèäîêàèíîì,       

│ñðåäñòâî                                     │Ëèäîõëîð                                    

                                                                                         

│Õëîðäèàçåïîêñèä - àíêñèîëèòè÷åñêîå ñðåäñòâî  │Àïî-Õëîðäèàçåïîêñèä, Íàïîòîí, Ðàäåïóð 10,   

                                             │Õëîçåïèä, Õëîçåïèäà òàáëåòêè ïîêðûòûå       

                                             │îáîëî÷êîé 0.005 ã, Ýëåíèóì                   

                                                                                         

│Õëîðíèòðîôåíîë - ïðîòèâîãðèáêîâîå ñðåäñòâî   │Íèòðîôóíãèí, Íèõëîðãèí, Íèõëîðãèíà ðàñòâîð  

                                             │1%, Íèõëîôåí, Íèõëîôåíà ðàñòâîð 1%          

                                                                                         

│Õëîðîõèí - ïðîòèâîìàëÿðèéíîå ñðåäñòâî        │Äåëàãèë, Õèíãàìèí, Õèíãàìèíà òàáëåòêè 0.25 ã │

│Õëîðïèðèôîñ - èíñåêòèöèäíîå ñðåäñòâî         │Äóðñáàí Ïðî, Ìàñòåð 25 ì.ê., Ìèêðîôîñ       

                                                                                         

│Õëîðïðîìàçèí - àíòèïñèõîòè÷åñêîå             │Àìèíàçèí, Àìèíàçèíà äðàæå, Àìèíàçèíà ðàñòâîð │

│(íåéðîëåïòè÷åñêîå) ñðåäñòâî                  │äëÿ èíúåêöèé 2.5%, Àìèíàçèíà òàáëåòêè       

                                             │ïîêðûòûå îáîëî÷êîé äëÿ äåòåé 0.01 ã,        

                                             │Õëîðïðîìàçèí                                 

                                                                                         

│Õëîðïðîïàìèä - ñàõàðîñíèæàþùåå ñðåäñòâî äëÿ  │Àïî-Õëîðïðîïàìèä, Õëîðïðîïàìèä,             

│ïåðîðàëüíîãî ïðèåìà                          │Õëîðïðîïàìèäà òàáëåòêè 0.1 ã, Õëîðïðîïàìèäà 

                                             │òàáëåòêè 0.25 ã                             

                                                                                         

│Õëîðòàëèäîí - äèóðåòè÷åñêîå ñðåäñòâî         │Àïî-Õëîðòàëèäîí, Ãèãðîòîí, Îêñîäîëèí,       

                                             │Îêñîäîëèíà òàáëåòêè 0.05 ã                  

                                                                                          

│Õëîðôàñèíîí - ðîäåíòèöèäíîå ñðåäñòâî         │Ðîäåôàñèí-Ê, Ðîäåôàñèí-Ó                    

                                                                                         

│Õëîðõèíàëäîë - ïðîòèâîìèêðîáíîå ñðåäñòâî,    │Õëîðõèíàëäèí, Õëîðõèíàëüäîë, Õëîðõèíàëüäîëà 

│îêñèõèíîëèí                                  │ãðàíóëû äëÿ äåòåé, Õëîðõèíàëüäîëà òàáëåòêè  

                                             │ïîêðûòûå îáîëî÷êîé 0.1 ã, Õëîðõèíàëüäîëà    

                                             │òàáëåòêè ïîêðûòûå îáîëî÷êîé äëÿ äåòåé 0.03 ã │

                                                                                         

│Õëîðýòèëàìèíîóðàöèë& - ïðîòèâîîïóõîëåâîå     │Äîïàí, Äîïàíà òàáëåòêè 0.002 ã              

│ñðåäñòâî                                                                                 

                                                                                         

│Õîëèíà ñàëèöèëàò - ÍÏÂÑ                      │Ìóíäèçàë ãåëü, Îòèíóì, Ñàõîë                

                                                                                         

│Õîíäðîèòèí ñóëüôàò íàòðèÿ - ðåãåíåðàöèè      │Ìóêîñàò, Ñòðóêòóì, Õîíäðîèòèíñóëüôàò,       

│ñòèìóëÿòîð                                   │Õîíäðîêñèä ìàçü 5%, Õîíäðîëîí, Õîíñóðèä     

                                                                                         

│Õîðèîíè÷åñêèé ãîíàäîòðîïèí -                 │Ãîíàäîòðîïèí õîðèîíè÷åñêèé, Ãîíàäîòðîïèí    

│ôîëëèêóëîñòèìóëèðóþùåå ñðåäñòâî              │õîðèîíè÷åñêèé â ïîðîøêå, Ãîíàäîòðîïèí       

                                             │õîðèîíè÷åñêèé äëÿ èíúåêöèé, Ïðåãíèë,        

                                             │Ïðîôàçè, Õîðàãîí                            

                                                                                         

│Öåòèðèçèí - H1-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Çèðòåê, Öåòðèí                              

│áëîêàòîð                                                                                 

                                                                                         

│Öåôàäðîêñèë - àíòèáèîòèê, öåôàëîñïîðèí       │Áèîäðîêñèë, Äóðàöåô, Èáèäðîêñèë, Ëàéäðîêñèë, │

                                             │Öåäðîêñ, Öåôðàäóð                           

                                                                                         

│Öåôàçîëèí - àíòèáèîòèê, öåôàëîñïîðèí         │Àíöåô, Àòðàëöåô, Âóëìèçîëèí, Çîëôèí,        

                                             │Èíòðàçîëèí, Èôèçîë, Êåôçîë, Ëèçîëèí,        

                                             │Îðèçîëèí, Ïðîçîëèí, Ðåôëèí, Òîòàöåô,        

                                             │Öåçîëèí, Öåôàçîëèí, Öåôàçîëèí íàòðèÿ,       

                                             │Öåôàçîëèí Íèêîìåä, Öåôàçîëèí-Òåâà,          

                                             │Öåôàçîëèíà íàòðèåâàÿ ñîëü, Öåôàçîëèíà       

                                             │íàòðèåâàÿ ñîëü êðèñòàëëè÷åñêàÿ ñòåðèëüíàÿ,  

                                             │Öåôàçîëèíà íàòðèåâàÿ ñîëü ñòåðèëüíàÿ,       

                                             │Öåôàìåçèí, Öåôàïðèì, Öåôçîëèí, Öåôîïðèä     

                                                                                         

│Öåôàêëîð - àíòèáèîòèê, öåôàëîñïîðèí          │Àëüôàöåò, Âåðöåô, Òàðàöåô, Öåê, Öåêëîð,     

                                             │Öåêëîð ÌÀ, Öåôòîð                           

                                                                                         

│Öåôàëåêñèí - àíòèáèîòèê, öåôàëîñïîðèí        │Àïî-Öeôàëåêñ, Êåôëåêñ, Êëîðöåô, Íîâî-Ëåêñèí, │

                                             │Îñïåêñèí, Ïàëèòðåêñ, Ïèàññàí, Ïðèëåêñ,      

                                             │Ïðîëåêñèí, Ñåô, Ñîëåêñèí, Ñïîðèäåêñ,        

                                             │Òîðëàñïîðèí, Óëåêñ, Ôåëåêñèí, Öåïîðåêñ,     

                                             │Öåôàäàð, Öåôàêëåí, Öåôàëåêñèí, Öåôàëåêñèí â 

                                             │êàïñóëàõ 0.25 ã, Öåôàëåêñèí-Ðàòèîôàðì,      

                                             │Öåôàëåêñèí-Òåâà, Öåôàëåêñèíà ïîðîøîê äëÿ    

                                             │ñóñïåíçèé 2.5 ã, Öåôàëåêñèíà òàáëåòêè       

                                             │ïîêðûòûå îáîëî÷êîé 0.25 ã                    

                                                                                         

│Öåôàëîòèí - àíòèáèîòèê, öåôàëîñïîðèí         │Öåôàëîòèíà íàòðèåâàÿ ñîëü, Öåôàëîòèíà       

                                             │íàòðèåâàÿ ñîëü äëÿ èíúåêöèé, Öåôàëîòèíà     

                                             │íàòðèåâàÿ ñîëü ñòåðèëüíàÿ                   

                                                                                         

│Öåôàìàíäîë - àíòèáèîòèê, öåôàëîñïîðèí        │Ìàíäîë, Öåôàìàíäîë, Öåôàìàíäîëà íàôàò       

                                             │ñòåðèëüíûé                                  

                                                                                         

│Öåôîêñèòèí - àíòèáèîòèê, öåôàëîñïîðèí        │Àòðàëêñèòèí, Áîíöåôèí, Ìåôîêñèí             

│Öåôîïåðàçîí - àíòèáèîòèê, öåôàëîñïîðèí       │Äàðäóì, Ëîðèçîí, Ìåäîöåô, Öåôîáèä           

                                                                                          

│Öåôîòàêñèì - àíòèáèîòèê, öåôàëîñïîðèí        │Áàéîòàêñ, Èíòðàòàêñèì, Êåôîòåêñ, Êëàôîðàí,  

                                             │Êëàôîòàêñèì, Ëèôîðàí, Ñïèðîçèí, Òàêñèì,     

                                             │Òàëöåô, Òàðöåôîêñèì, Õàëòåêñ, Öåôàíòðàë,    

                                             │Öåôîòàêñèì, Öåôîòàêñèì íàòðèÿ, Öåôîòàêñèì   

                                             │íàòðèÿ ñòåðèëüíûé, Öåôîòàêñèìà íàòðèåâàÿ    

                                             │ñîëü, Öåôîòàêñèìà íàòðèåâàÿ ñîëü ñòåðèëüíàÿ, │

                                             │Öåôîòàì                                     

                                                                                         

│Öåôòàçèäèì - àíòèáèîòèê, öåôàëîñïîðèí        │Àìæåöåôò, Êåôàäèì, Ìèðîöåô, Òàçèöåô, Ôîðòóì, │

                                             │Öåôàçèä                                     

                                                                                          

│Öåôòðèàêñîí - àíòèáèîòèê, öåôàëîñïîðèí       │Áåòàñïîðèíà, Èôèöåô, Ëåíäàöèí, Ëîíãàöåô,    

                                             │Îôðàìàêñ, Ðîöåôèí, Òîðîöåô, Öåôàêñîí,       

                                             │Öåôàòðèí, Öåôòðèàêñîíà íàòðèåâàÿ ñîëü,      

                                             │Öåôòðèàêñîíà íàòðèåâàÿ ñîëü ñòåðèëüíàÿ      

                                                                                          

│Öåôóðîêñèì - àíòèáèîòèê, öåôàëîñïîðèí        │Àêñåòèí, Çèíàöåô, Çèííàò, Êåòîöåô, Êåôóðîêñ, │

                                             │Ìóëüòèñåô, Ñóïåðî, Óöåôàêñèì, Öåôîãåí,      

                                             │Öåôóðîêñèì íàòðèÿ                           

                                                                                         

│Öèàíîêîáàëàìèí - âèòàìèí                     │Áàðòåë äðàãç Âèòàìèí Â12, Â12 Àíêåðìàí,     

                                             │Âèòàìèí Â-12, Âèòàìèí Â12, Âèòàìèí Â12 0.1% 

                                             │ÑÄ, Âèòàìèí Â12 1% ÑÄ, Âèòàìèí Â12          

                                             │êðèñòàëëè÷åñêèé, Äîäåêñ, Íåéðîáåíå,          

                                             │Öèàíîêîáàëàìèí, Öèàíîêîáàëàìèí-Äàðíèöà      

                                             │(Âèòàìèí Â12-Äàðíèöà), Öèàíîêîáàëàìèíà      

                                             │ðàñòâîð äëÿ èíúåêöèé, Öèàíîêîáàëàìèíà       

                                             │ðàñòâîð äëÿ èíúåêöèé (âèòàìèí Â12)          

                                                                                         

│Öèçàïðèä - ïðîòèâîðâîòíîå ñðåäñòâî, äîôàìèí  │Êîîðäèíàêñ, Ïåðèñòèë, Ñèçàïðî, Öèñàï, Öèñàïèä│

│áëîêàòîð öåíòðàëüíûé                                                                     

                                                                                         

│Öèêëîâàëîí - æåë÷åãîííîå ñðåäñòâî            │Öèêâàëîí, Öèêâàëîíà òàáëåòêè 0.1 ã          

                                                                                         

│Öèêëîïåíòèàçèä - äèóðåòè÷åñêîå ñðåäñòâî      │Öèêëîìåòèàçèä, Öèêëîìåòèàçèäà òàáëåòêè      

                                             │0.0005 ã                                    

                                                                                         

│Öèêëîïèðîêñ - ïðîòèâîãðèáêîâîå ñðåäñòâî      │Áàòðàôåí, Äàôíåäæèí                         

                                                                                         

│Öèêëîñïîðèí - èììóíîäåïðåññèâíîå ñðåäñòâî    │Êîíñóïðåí, Ñàíäèììóí, Ñàíäèììóí-Íåîðàë,     

                                             │Öèêëîñïîðèí                                 

                                                                                         

│Öèêëîôîñôàìèä - ïðîòèâîîïóõîëåâîå ñðåäñòâî   │Ëåäîêñèíà, Öèêëîôîñôàìèä-Òåâà, Öèêëîôîñôàí, 

                                             │Öèêëîôîñôàíà òàáëåòêè ïîêðûòûå îáîëî÷êîé    

                                             │0.05 ã, Öèòîêñàí, Ýíäîêñàí                  

                                                                                         

│Öèëàçàïðèë - ÀÊÔ áëîêàòîð                    │Èíõèáåéñ, Ïðèëàçèä                          

                                                                                         

│Öèìåòèäèí - H2-ãèñòàìèíîâûõ ðåöåïòîðîâ       │Àëüòðàìåò, Àïî-Öèìåòèäèí, Áåëîìåò, Ãèñòîäèë, │

│áëîêàòîð                                     │Éåíàìåòèäèí, Íåéòðîíîðì, Íîâî-Öèìåòèí,      

                                             │Ïðèìàìåò, Ñèìåñàí, Òàãàìåò, Óëêóçàë,         

                                             │Óëüêîìåòèí, Öåìèäèí, Öèãàìåò, Öèìåò,        

                                             │Öèìåòèäèí, Öèìåòèäèí Ëàííàõåð, Öèìåòèäèí    

                                             │Ñòàäà ìåæäóíàðîäíûé, Öèìåòèäèí-Ðèâîôàðì     

                                                                                         

│Öèíêà îêèñü& - ïðîòèâîâîñïàëèòåëüíîå         │Äåñèòèí, Äèàäåðì, Öèíêà îêèñè ëèíèìåíò,     

│ñðåäñòâî äëÿ ìåñòíîãî ïðèìåíåíèÿ             │Öèíêà îêèñü, Öèíêîâàÿ ìàçü, Öèíêîâàÿ ïàñòà  

                                                                                         

│Öèííàðèçèí - ÁÌÊÊ                            │Âåðòèçèí, Âåðòèçèí ôîðòå, Äèçèðîí, Ñòóãåðîí, │

                                             │Öèíàçèí, Öèíàðèí, Öèíåäèë, Öèííàðèçèí,      

                                             │Öèííàðèçèí Èíáèîòåõ, Öèííàðèçèí ôîðòå,      

                                             │Öèííàðèçèí ôîðòå-Ðàòèîôàðì,                  

                                             │Öèííàðèçèí-Ìèëâå, Öèííàðèçèíà òàáëåòêè ËÕ   

                                             │0.025 ã, Öèííàðèçèíà òàáëåòêè 0.025 ã,      

                                             │Öèííàðîí, Öèííàñàí, Öèðèçèí                 

                                                                                         

│Öèïåðìåòðèí - èíñåêòèöèäíîå ñðåäñòâî         │Àäæèîöèïåð 25% ê.ý., Àêâà-Âèð, Àëüôàòîêñ,   

                                             │Áðþìèëàê Ê 94, Âèòîêñ, Èíñåêòîãåëü-Ö,       

                                             │Èíñîðáöèä-Íåî, Èíòà-Âèð, Ìàøåíüêà-Íåî,      

                                             │Ìèêðîöèí, Ðàïòîð-àýðîçîëü (äëÿ íåëåòàþùèõ), 

                                             │Ðîòàð, Ñóïåð-Êîáðà (äëÿ íåëåòàþùèõ),        

                                             │Ôóìèòîêñ, Ôüþðè, Ôüþðè-ìåä, Õàêèò, Õàëåê,   

                                             │Öèíîôô, Öèïåð-Ôëàé, Öèïåðøàíñ, Öèïè 25%     

                                             │Ê.Ý., Öèòêîð                                

                                                                                          

│Öèïðîòåðîí - àíòèàíäðîãåí                    │Àíäðîêóð, Àíäðîêóð-äåïî                     

                                                                                         

│Öèïðîôëîêñàöèí - ïðîòèâîìèêðîáíîå ñðåäñòâî,  │Àðôëîêñ, Àôåíîêñèí, Çèíäîëèí 250, Èôèöèïðî, 

│ôòîðõèíîëîí                                  │Êâèíòîð, Êâèïðî, Ëàéïðîêâèí, Ìåäîöèïðèí,    

                                             │Ìèêðîôëîêñ, Íåîôëîêñèí, Ðåöèïðî, Ñèôëîêñ,   

                                             │Òàöèï, Öåïðîâà, Öåôîáàê, Öèëîêñàí, Öèïëîêñ, 

                                             │Öèïðèíîë, Öèïðîáàé, Öèïðîáèä, Öèïðîâà,      

                                             │Öèïðîäàð, Öèïðîêâèí, Öèïðîëåò, Öèïðîìåä,    

                                             │Öèïðîíàò, Öèïðîïàí, Öèïðîñàí, Öèïðîñîë,     

                                             │Öèïðîôëîêñàöèí, Öèïðîôëîêñàöèíà ãèäðîõëîðèä, │

                                             │Öèïðîöèíàë, Öèòåðàë, Öèôëîçèí, Öèôëîêñèíàë, 

                                             │Öèôëîñèí, Öèôðàí                            

                                                                                         

│Öèñïëàòèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Àêñèïëàò, Áëàñòîëåì, Êåìîïëàò, Îíêîïëàòèí,  

                                             │Ïëàòàìèí, Ïëàòèäèàì, Ïëàòèìèò, Ïëàòèíîë,    

                                             │Öèñàíïëàò, Öèñïëàòèë, Öèñïëàòèí, Öèñïëàòèí  

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé 0.01 ã,      

                                             │Öèñïëàòèí-Òåâà, Öèñïëàòèí-Ýáåâå             

                                                                                         

│Öèñòåèí - ñðåäñòâî ïàðåíòåðàëüíîãî ïèòàíèÿ,  │L-Öèñòåèí, Öèñòåèí                          

│àìèíîêèñëîòà                                                                             

                                                                                          

│Öèòàðàáèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî       │Àëåêñàí, Öèòàðàáèí, Öèòàðàáèí               

                                             │ëèîôèëèçèðîâàííûé äëÿ èíúåêöèé 0.1 ã,       

                                             │Öèòîçàð, Öèòîíàë                            

                                                                                         

│Öèòèçèí - í-õîëèíîìèìåòèê                    │Ïëåíêè ñ öèòèçèíîì, Òàáåêñ, Öèïåðêóòåí ÒÒÑ, 

                                             │Öèòèçèí                                     

                                                                                         

│Öèòîõðîì Ñ& - ìåòàáîëè÷åñêîå ñðåäñòâî        │Öèòî-Ìàê, Öèòîõðîì-Ñ äëÿ èíúåêöèé,          

                                             │Öèòîõðîì-Ñ äðîææåâîé äëÿ èíúåêöèé 0.01 ã,   

                                             │Öèòîõðîì-Ñ äðîææåâîé ëèîôèëèçèðîâàííûé,     

                                             │Öèòîõðîì-Ñ ëèîôèëèçèðîâàííûé, Öèòîõðîìà-Ñ   

                                             │òàáëåòêè (ðàñòâîðèìûå â êèøå÷íèêå)          

                                                                                          

│Öèôëóòðèí - èíñåêòèöèäíîå ñðåäñòâî           │Áàéãîí - àýðîçîëü (äëÿ ëåòàþùèõ), Áàéãîí -  

                                             │àýðîçîëü (äëÿ íåëåòàþùèõ), Áàéãîí - Ìàñòåð, 

                                             │Áàéãîí Èíñåêòåí - ñïðåé, Áàéãîí Ìîòïàïèð,   

                                             │Áàéãîí Ìîòòåí Êèññåí, Áàéãîí ïåíà, Áàéãîí   

                                             │ñïèðàëü, Ñîëüôàê ÝÊ-050                     

                                                                                         

│×àáðåöà òðàâà& - ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ │×àáðåöà òðàâà, ×àáðåöà òðàâû áðèêåò, ×àáðåöà │

│ñðåäñòâî                                     │òðàâû áðèêåò êðóãëûé, ×àáðåöà ýêñòðàêò æèäêèé│

                                                                                         

│Ýâêàëèìèí& - ïðîòèâîìèêðîáíîå ñðåäñòâî       │Ñóïïîçèòîðèè âàãèíàëüíûå ñ ýâêàëèìèíîì 0.05 

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │ã, Ñóïïîçèòîðèè ðåêòàëüíûå ñ ýâêàëèìèíîì    

                                             │0.05 ã, Ýâêàëèìèí, Ýâêàëèìèíà ðàñòâîð       

                                             │ñïèðòîâîé                                   

                                                                                          

│Ýäåòîâàÿ êèñëîòà - êîìïëåêñîîáðàçóþùåå       │Òåòàöèí-êàëüöèé, Òåòàöèí-êàëüöèÿ ðàñòâîð äëÿ │

│ñðåäñòâî                                     │èíúåêöèé 10%, Ýòèëåíäèàìèíîòåòðàóêñóñíîé    

                                             │êèñëîòû äèíàòðèåâîé ñîëè ðàñòâîð ä          

                                                                                         

│Ýêîíàçîë - ïðîòèâîãðèáêîâîå ñðåäñòâî         │Ãèíî-Ïåâàðèë, Ïåâàðèë, Ýêàëèí, Ýêîäàêñ      

                                                                                         

│Ýìåòèí - ïðîòèâîàìåáíîå ñðåäñòâî             │Ýìåòèíà ãèäðîõëîðèä, Ýìåòèíà ãèäðîõëîðèäà   

                                             │ðàñòâîð äëÿ èíúåêöèé 1%                     

                                                                                         

│Ýìîêñèïèí& - ðåòèíîïðîòåêòîð                 │Ýìîêñèïèí, Ýìîêñèïèíà ðàñòâîð 1% (ãëàçíûå    

                                             │êàïëè), Ýìîêñèïèíà ðàñòâîð äëÿ èíúåêöèé 1%, 

                                             │Ýìîêñèïèíà ðàñòâîð äëÿ èíúåêöèé 3%          

                                                                                          

│Ýíàëàïðèë - ÀÊÔ áëîêàòîð                     │Àïî-Ýíàëàïðèë, Áåðëèïðèë 5, Âàçîëàïðèë,     

                                             │Âàçîïðåí, Èíâîðèë, Êàëüïèðåí, Êîðàíäèë,     

                                             │Ìèîïðèë, Ðåíèòåê, Ýäíèò, Ýíàëàïðèë,         

                                             │Ýíàëàïðèë-ICN, Ýíàëàïðèëà ìàëåàò, Ýíàì,     

                                             │Ýíàï, Ýíàï-5, Ýíàïðèë, Ýíâàñ, Ýíïðèë        

                                                                                         

│Ýïèíåôðèí - àëüôà- è áåòà-àäðåíîñòèìóëÿòîð   │Àäðåíàëèí, Àäðåíàëèí ñèíòåòè÷åñêèé,         

                                             │Àäðåíàëèíà ãèäðîòàðòðàò, Àäðåíàëèíà         

                                             │ãèäðîòàðòðàòà ðàñòâîð äëÿ èíúåêöèé 0.18%,   

                                             │Àäðåíàëèíà ãèäðîõëîðèäà ðàñòâîð 0.1%        

                                                                                          

│Ýïèðóáèöèí - ïðîòèâîîïóõîëåâîå ñðåäñòâî      │Ôàðìîðóáèöèí áûñòðîðàñòâîðèìûé, Ýïèëåì      

                                                                                         

│Ýïîýòèí áåòà - ãåìîïîýçà ñòèìóëÿòîð          │Ðåêîðìîí, Ýðèòðîïîýòèí ÷åëîâåêà             

                                             │ðåêîìáèíàíòíûé, Ýðèòðîñòèì, Ýðèòðîñòèì äëÿ  

                                             │èíúåêöèé                                    

                                                                                         

│Ýðãîêàëüöèôåðîë - âèòàìèí                    │Ýðãîêàëüöèôåðîë (âèòàìèí D2),               

                                             │Ýðãîêàëüöèôåðîëà (âèòàìèí D2) äðàæå 500 ÌÅ, 

                                             │Ýðãîêàëüöèôåðîëà (âèòàìèí D2) ðàñòâîð â     

                                             │ìàñëå 0.0625%, Ýðãîêàëüöèôåðîëà (âèòàìèí D2) │

                                             │ðàñòâîð â ñïèðòå 0.5%, Ýðãîêàëüöèôåðîëà     

                                             │(Âèòàìèíà D2) ðàñòâîð â ìàñëå 0.5%,         

                                             │Ýðãîêàëüöèôåðîëà ðàñòâîð â ìàñëå 0.125%,    

                                             │Ýðãîêàëüöèôåðîëà ðàñòâîð â ìàñëå â êàïñóëàõ 

                                                                                         

│Ýðãîìåòðèí - àëüôà-àäðåíîñòèìóëÿòîð          │Ýðãîìåòðèí, Ýðãîìåòðèíà ìàëåàò, Ýðãîìåòðèíà 

                                             │ìàëåàòà ðàñòâîð 0.02% â àìïóëàõ, Ýðãîìåòðèíà │

                                             │ìàëåàòà òàáëåòêè 0.0002 ã                   

                                                                                         

│Ýðèòðîìèöèí - àíòèáèîòèê, ìàêðîëèä           │Ãðþíàìèöèí ñèðîï, Èëîçîí, Ñâå÷è ñ           

                                             │ýðèòðîìèöèíîì äëÿ äåòåé, Ýðèãåêñàë, Ýðèäåðì, │

                                             │Ýðèòðàí, Ýðèòðîìèöèí, Ýðèòðîìèöèí 250,      

                                             │Ýðèòðîìèöèí ëàêòîáèîíàò, Ýðèòðîìèöèí Ïñè    

                                             │Äèñïåðòàá, Ýðèòðîìèöèí ñòåàðàò, Ýðèòðîìèöèí 

                                             │ñòåàðåéò, Ýðèòðîìèöèí-Ðàòèîôàðì,            

                                             │Ýðèòðîìèöèí-Òåâà, Ýðèòðîìèöèíà òàáëåòêè,    

                                             │Ýðèòðîìèöèíà òàáëåòêè ñ êèøå÷íîðàñòâîðèìûì  

                                             │ïîêðûòèåì, Ýðèòðîìèöèíà ôîñôàò,             

                                             │Ýðèòðîìèöèíîâàÿ ìàçü 10000 ÅÄ/ã, Ýðèòðîïåä, 

                                             │Ýðìèöåä                                     

                                                                                         

│Ýñáèîë - èíñåêòèöèäíîå ñðåäñòâî              │Ðàïòîð-ñòàíäàðò, Ðàïòîð-ñóïåð               

                                                                                         

│Ýñòðàäèîë - ýñòðîãåí                         │Äåðìåñòðèë, Äèâèãåëü, Êëèìàðà, Ìåíîðåñò,    

                                             │Ïðîãèíîâà, Ýñòðàäèîëà äèïðîïèîíàò,          

                                             │Ýñòðàäèîëà äèïðîïèîíàòà ðàñòâîð â ìàñëå 0.1% │

                                             │â àìïóëàõ, Ýñòðîôåì                         

                                                                                         

│Ýñòðàäèîë+Íîðýòèñòåðîí& -                    │Êëèîãåñò, Òðèñåêâåíñ                        

│ïðîòèâîêëèìàêòåðè÷åñêîå ñðåäñòâî                                                          

                                                                                         

│Ýñòðèîë - ýñòðîãåí                           │Îâåñòèí, Îðòî-ãèíåñò                        

│Ýñòðîãåíû êîíúþãèðîâàííûå& - ýñòðîãåí        │Ê.Ý.Ñ., Ïðåìàðèí, Ýñòðîôåìèíàë              

                                                                                         

│Ýñôåí âàëåðàò& - èíñåêòèöèäíîå ñðåäñòâî      │Ïåñãàðä àëüôà 5 Ôëîó, Ïåñãàðä àëüôà 5 ÝÊ,   

                                             │Ïåñãàðä ÍÑ, Ïåñãàðä ÍÒ-35, Ïåñãàðä ÏÑ 102,  

                                             │Ïåñãàðä Ôà                                 

                                                                                         

│Ýñöèí - âåíîòîíèçèðóþùåå ñðåäñòâî            │Àýñöèí, Âåíèòàí, Êîíöåíòðèí, Ðåïàðèë,       

│ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ                  │Ðåïàðèë-ãåëü Í, Öèêëîâåí ôîðòå, Ýñöèí       

                                                                                          

│Ýòàêðèäèí - àíòèñåïòè÷åñêîå ñðåäñòâî         │Ýòàêðèäèí (Ðèâàíîë), Ýòàêðèäèíà ëàêòàòà ìàçü │

                                             │3%, Ýòàêðèäèíà ðàñòâîð ñïèðòîâîé 0.1%       

                                                                                         

│Ýòàìáóòîë - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî    │Àïáóòîë, ÅÌÁ-Ôàòîë 400, Êîìáóòîë, Ëè-áóòîë, 

                                             │Ìèêîáóòîë, Òåìèáóòîë, Ýíáóòîë, Ýòàìáóòîë,   

                                             │Ýòàìáóòîëà ãèäðîõëîðèä                      

                                                                                         

│Ýòàìçèëàò - ãåìîñòàòè÷åñêîå ñðåäñòâî         │Äèöèíîí, Ýòàìçèëàò, Ýòàìçèëàòà ðàñòâîð 5%,  

                                             │Ýòàìçèëàòà ðàñòâîð äëÿ èíúåêöèé 12.5%,      

                                             │Ýòàìçèëàòà òàáëåòêè 0.05 ã, Ýòàìçèëàòà      

                                             │òàáëåòêè 0.25 ã, Ýòàìçèëàòà òàáëåòêè 250 ìã 

                                                                                         

│Ýòàíîë - àíòèñåïòè÷åñêîå ñðåäñòâî            │Ýòèëîâûé ñïèðò, Ýòèëîâûé ñïèðò 95%, Ýòèëîâûé │

                                             │ñïèðò ñèíòåòè÷åñêèé äëÿ íàðóæíîãî           

                                             │ïðèìåíåíèÿ, Ýòîë, Ýòîë 96%                  

                                                                                         

│Ýòàôåäðèí - àëüôà-àäðåíîñòèìóëÿòîð           │Ôåòàíîë, Ôåòàíîëà ðàñòâîð äëÿ èíúåêöèé 1%,  

                                             │Ôåòàíîëà òàáëåòêè ïîêðûòûå îáîëî÷êîé 0.005 ã │

                                                                                          

│Ýòàöèçèí& - àíòèàðèòìè÷åñêîå ñðåäñòâî        │Ýòàöèçèí, Ýòàöèçèíà ðàñòâîð äëÿ èíúåêöèé    

                                             │2.5%, Ýòàöèçèíà òàáëåòêè ïîêðûòûå îáîëî÷êîé 

                                             │0.5 ã                                       

                                                                                         

│Ýòåáåíåöèä& - ïðîòèâîïîäàãðè÷åñêîå ñðåäñòâî  │Ýòàìèä, Ýòàìèäà òàáëåòêè 0.35 ã             

                                                                                         

│Ýòèë áèñêóìàöåòàò - àíòèêîàãóëÿíò, âèòàìèíà  │Íåîäèêóìàðèí, Íåîäèêóìàðèíà òàáëåòêè,       

│Ê àíòàãîíèñò                                 │Ïåëåíòàí                                     

                                                                                         

│Ýòèëìîðôèí - ïðîòèâîêàøëåâîå ñðåäñòâî        │Ýòèëìîðôèíà ãèäðîõëîðèä (Äèîíèí),           

                                             │Ýòèëìîðôèíà ãèäðîõëîðèäà òàáëåòêè           

                                                                                         

│Ýòèëôåíàöèí - ðîäåíòèöèäíîå ñðåäñòâî         │Áàðüåð-Ý, Áàðüåð-Ý 1 ê, Áàðüåð-Ý 1 ó,       

                                             │Áàðüåð-Ý 3 ê, Áàðüåð-Ý 3 ó, Ðàïòîð-ñàíèòàð  

                                             │(îò êðûñ), Ýòèëôåíàöèí, Ýòèëôåíàöèí ïàñòà 2, │

                                             │ÝÔÀ                                         

                                                                                         

│Ýòèëõëîðèä - íàðêîçíîå èíãàëÿöèîííîå ñðåäñòâî│Õëîðýòèë - àýðîçîëü, Õëîðýòèë               

                                                                                          

│Ýòèìèçîë& - àíàëåïòè÷åñêîå ñðåäñòâî          │Ýòèìèçîë, Ýòèìèçîëà ðàñòâîð 1.5% â àìïóëàõ, 

                                             │Ýòèìèçîëà òàáëåòêè 0.1 ã                    

                                                                                          

│Ýòèíèëýñòðàäèîë - ýñòðîãåí                   │Ìèêðîôîëëèí ôîðòå, Ýòèíèëýñòðàäèîë,         

                                             │Ýòèíèëýñòðàäèîëà òàáëåòêè                   

                                                                                         

│Ýòèíèëýñòðàäèîë+Ãåñòîäåí& - êîíòðàöåïòèâíîå  │Ìèëâàíå, Ìèíóëåò, Ôåìîäåí                   

│ñðåäñòâî                                                                                 

                                                                                         

│Ýòèíèëýñòðàäèîë+Äåçîãåñòðåë& -               │Ìàðâåëîí, Ìåðñèëîí                          

│êîíòðàöåïòèâíîå ñðåäñòâî                                                                 

                                                                                         

│Ýòèíèëýñòðàäèîë+Ëåâîíîðãåñòðåë& -            │Àíòåîâèí, Ìèêðîãèíîí, Ìèíèçèñòîí, Òðè-ðåãîë, │

│êîíòðàöåïòèâíîå ñðåäñòâî                     │Òðèçèñòîí, Òðèêâèëàð                        

                                                                                         

│Ýòèíèëýñòðàäèîë+Íîðãåñòðåë& -                │Ëî-ôåìåíàë, Îâèäîí, Ðèãåâèäîí               

│êîíòðàöåïòèâíîå ñðåäñòâî                                                                 

                                                                                         

│Ýòèíèëýñòðàäèîë+Ýòèíîäèîë& - êîíòðàöåïòèâíîå │Äåìóëåí 1/35, Äåìóëåí 1/50                  

│ñðåäñòâî                                                                                 

                                                                                         

│Ýòèîíàìèä - ïðîòèâîòóáåðêóëåçíîå ñðåäñòâî    │Ìèîáèò-250, Ðåãèíèöèä, Ýòèä, Ýòèîíàìèä      

│Ýòèñòåðîí - ïðîãåñòàãåí                      │Ïðåãíèí, Ïðåãíèíà òàáëåòêè 0.01 ã           

│Ýòîìèäàò - íàðêîçíîå íåèíãàëÿöèîííîå ñðåäñòâî│Ãèïíîìèäàò, Ðàäåíàðêîí                       

                                                                                         

│Ýòîïîçèä - ïðîòèâîîïóõîëåâîå ñðåäñòâî        │Âåïåçèä, Ëàñòåò, Ôèòîçèä, Ýòîçèä, Ýòîïîçèä, 

                                             │Ýòîïîçèä-Ýáåâå, Ýòîïîñ                      

                                                                                         

│Ýòîôåíàìàò - ïðîòèâîâîñïàëèòåëüíîå ñðåäñòâî  │Ðåâìîí ãåëü, Òðàâìîí ãåëü, Òðàâìîí ñïðåé,   

│äëÿ ìåñòíîãî ïðèìåíåíèÿ                      │Ýòîãåëü, Ýòîôåí                             

                                                                                         

│Ýòïåíàë& - í-õîëèíîáëîêàòîð öåíòðàëüíûé      │Ýòïåíàë, Ýòïåíàëà ðàñòâîð äëÿ èíúåêöèé,     

                                             │Ýòïåíàëà òàáëåòêè 0.05 ã                    

                                                                                         

│Ýôåäðèí - àëüôà- è áåòà-àäðåíîñòèìóëÿòîð     │Ýôåäðèíà ãèäðîõëîðèä, Ýôåäðèíà ãèäðîõëîðèäà 

                                             │ðàñòâîð äëÿ èíúåêöèé 5% â øïðèö-òþáèêàõ,    

                                             │Ýôåäðèíà ãèäðîõëîðèäà ðàñòâîð äëÿ èíúåêöèé  

                                             │5%, Ýôåäðèíà ãèäðîõëîðèäà ðàñòâîð, Ýôåäðèíà 

                                             │ãèäðîõëîðèäà òàáëåòêè 0.025 ã, Ýôåäðèíà     

                                             │ãèäðîõëîðèäà òàáëåòêè äëÿ äåòåé             

                                                                                         

│Ýôèð äèýòèëîâûé - íàðêîçíîå èíãàëÿöèîííîå    │Ýôèð äëÿ íàðêîçà ñòàáèëèçèðîâàííûé, Ýôèð äëÿ │

│ñðåäñòâî                                     │íàðêîçà, Ýôèð ìåäèöèíñêèé                   

└─────────────────────────────────────────────┴─────────────────────────────────────────────┘


 

Ïðèëîæåíèå 3.

 

ÏÅÐÅ×ÅÍÜ È ÐÀÑØÈÔÐÎÂÊÀ ÊÎÄÎÂ

ÀÍÀÒÎÌÎ-ÒÅÐÀÏÅÂÒÈ×ÅÑÊÎ-ÕÈÌÈ×ÅÑÊÎÉ

ÊËÀÑÑÈÔÈÊÀÖÈÈ (ÀÒÑ)

 ÐÅÄÀÊÖÈÈ 1998 Ã.

 

  ┌────────────────────┬───────────────────────────────────┐

        Êîä                     Îïèñàíèå                

                                                        

  │A                   │Ïèùåâàðèòåëüíûé òðàêò è îáìåí     

                      │âåùåñòâ                           

                                                        

  │A01                 │Ñòîìàòîëîãè÷åñêèå ïðåïàðàòû       

  │A01A                │Ñòîìàòîëîãè÷åñêèå ïðåïàðàòû       

  │A01AA               │Ïðåïàðàòû äëÿ ïðîôèëàêòèêè êàðèåñà │

  │A01AA01             │Íàòðèÿ ôòîðèä                     

  │A01AA30             │Êîìáèíèðîâàííûå ïðåïàðàòû         

                                                         

  │A01AB               │Ïðîòèâîìèêðîáíûå ïðåïàðàòû äëÿ    

                      │ìåñòíîãî ëå÷åíèÿ çàáîëåâàíèé      

                      │ïîëîñòè ðòà                       

                                                         

  │A01AB03             │Õëîðãåêñèäèí                      

  │A01AB04             │Àìôîòåðèöèí                      

  │A01AB06             │Äîìèôåíà áðîìèä                   

  │A01AB08             │Íåîìèöèí                          

  │A01AB11             │Ïðî÷èå                            

  │A01AB12             │Ãåêñåòèäèí                        

  │A01AB13             │Òåòðàöèêëèí                       

  │A01AB16             │Ìåïàðòðèöèí                       

  │A01AB18             │Êëîòðèìàçîë                       

                                                        

  │A01AC               │Ãëþêîêîðòèêîñòåðîèäû äëÿ ìåñòíîãî 

                      │ëå÷åíèÿ çàáîëåâàíèé ïîëîñòè ðòà   

                                                         

  │A01AC01             │Òðèàìöèíîëîí                      

                                                        

  │A01AD               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ïîëîñòè ðòà           

                                                        

  │A01AD02             │Áåíçèäàìèí                        

                                                        

  │A01AD11             │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ïîëîñòè ðòà           

                                                        

  │A02                 │Àíòàöèäû, ïðåïàðàòû äëÿ ëå÷åíèÿ   

                      │ÿçâåííîé áîëåçíè æåëóäêà è        

                      │äâåíàäöàòèïåðñòíîé êèøêè è        

                      │ìåòåîðèçìà                        

                                                        

  │A02A                │Àíòàöèäû                           

  │A02AA               │Ïðåïàðàòû ìàãíèÿ                  

  │A02AA01             │Ìàãíèÿ êàðáîíàò                   

  │A02AA02             │Ìàãíèÿ îêñèä                      

  │A02AA03             │Ìàãíèÿ ïåðîêñèä                   

  │A02AA04             │Ìàãíèÿ ãèäðîêñèä                  

  │A02AA05             │Ìàãíèÿ ñèëèêàò                    

  │A02AA10             │Êîìáèíàöèÿ ïðåïàðàòîâ ìàãíèÿ      

  │A02AB               │Ïðåïàðàòû àëþìèíèÿ                

  │A02AB02             │Àëãåëäðàò                         

  │A02AB03             │Àëþìèíèÿ ôîñôàò                   

                                                        

  │A02AB04             │Äèãèäðîêñèàëþìèíèÿ íàòðèÿ êàðáîíàò │

                      │(Êàðáàëäðàò)                      

                                                        

  │A02AC               │Ïðåïàðàòû êàëüöèÿ                 

  │A02AC01             │Êàëüöèÿ êàðáîíàò                  

                                                         

  │A02AD               │Êîìáèíàöèÿ ïðåïàðàòîâ àëþìèíèÿ,   

                      │êàëüöèÿ è ìàãíèÿ                  

                                                        

  │A02AD01             │Ïðîñòîå ñî÷åòàíèå ñîëåé           

  │A02AD02             │Ìàãàëäðàò                         

  │A02AD04             │Ãèäðîòàëöèò                       

  │A02AD05             │Àëìàñèëàò (Ñèìàëäðàò)             

                                                         

  │A02AF               │Àíòàöèäû â ñî÷åòàíèè ñ            

                      │âåòðîãîííûìè ïðåïàðàòàìè          

                                                        

  │A02AF01             │Ìàãàëäðàò è âåòðîãîííûå ïðåïàðàòû 

                                                        

  │A02AF02             │Ïðîñòîå ñî÷åòàíèå ñîëåé è         

                      │âåòðîãîííûõ ïðåïàðàòîâ            

                                                        

  │A02AH               │Àíòàöèäû â ñî÷åòàíèè ñ íàòðèÿ     

                      │áèêàðáîíàòîì                      

                                                        

  │A02AX               │Àíòàöèäû â ñî÷åòàíèè ñ äðóãèìè    

                      │ïðåïàðàòàìè                       

                                                        

  │A02B                │Ïðîòèâîÿçâåííûå ïðåïàðàòû         

                                                        

  │A02BA               │Áëîêàòîðû H2-ãèñòàìèíîâûõ         

                      │ðåöåïòîðîâ                        

                                                        

  │A02BA01             │Öèìåòèäèí                         

  │A02BA02             │Ðàíèòèäèí                          

  │A02BA03             │Ôàìîòèäèí                         

  │A02BA04             │Íèçàòèäèí                         

  │A02BA06             │Ðîêñàòèäèí                        

  │A02BA07             │Ðàíèòèäèíà âèñìóòà öèòðàò         

  │A02BB               │Ïðîñòàãëàíäèíû                    

  │A02BB01             │Ìèçîïðîñòîë                       

  │A02BC               │Èíãèáèòîðû ïðîòîíîâîãî íàñîñà     

  │A02BC01             │Îìåïðàçîë                          

  │A02BC02             │Ïàíòîïðàçîë                       

  │A02BC03             │Ëàíñîïðàçîë                       

                                                        

  │A02BX               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ÿçâåííîé áîëåçíè æåëóäêà è        

                      │äâåíàäöàòèïåðñòíîé êèøêè          

                                                        

  │A02BX01             │Êàðáåíîêñîëîí                     

  │A02BX02             │Ñóêðàëôàò                         

  │A02BX03             │Ïèðåíçåïèí                        

  │A02BX05             │Âèñìóòà òðèêàëèÿ äèöèòðàò         

  │A02BX12             │Âèñìóòà ñóáíèòðàò                 

  │A02D                │Âåòðîãîííûå ïðåïàðàòû             

  │A02DA               │Âåòðîãîííûå ïðåïàðàòû             

  │A02DA01             │Äèìåòèêîí                         

                                                        

  │A03                 │Ñïàçìîëèòèêè è àíòèõîëèíýðãè÷åñêèå │

                      │ïðåïàðàòû                         

                                                        

  │A03A                │Ñèíòåòè÷åñêèå ñïàçìîëèòèêè è      

                      │õîëèíîáëîêàòîðû                   

                                                        

  │A03AA               │Ñèíòåòè÷åñêèå õîëèíîáëîêàòîðû -   

                      │ýôèðû ñ òðåòè÷íîé àìèíîãðóïïîé    

                                                        

  │A03AA05             │Òðèìåáóòèí                        

  │A03AA07             │Äèöèêëîâåðèí                      

                                                        

  │A03AB               │Ñèíòåòè÷åñêèå õîëèíîáëîêàòîðû -   

                      │÷åòâåðòè÷íûå àììîíèåâûå ñîåäèíåíèÿ │

                                                        

  │A03AB06             │Îòèëîíèÿ áðîìèä                   

  │A03AB18             │Ïðèôèíèÿ áðîìèä                    

  │A03AD               │Ïàïàâåðèí è åãî ïðîèçâîäíûå       

  │A03AD01             │Ïàïàâåðèí                         

  │A03AD02             │Äðîòàâåðèí                        

                                                        

  │A03AD51             │Ïàïàâåðèí â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │A03AX               │Äðóãèå ñèíòåòè÷åñêèå              

                      │õîëèíîáëîêàòîðû                   

                                                        

  │A03AX04             │Ïèíàâåðèé                         

  │A03B                │Áåëëàäîííà è åå ïðîèçâîäíûå       

                                                        

  │A03BA               │Àëêàëîèäû áåëëàäîííû, òðåòè÷íûå   

                      │àìèíû                             

                                                        

  │A03BA01             │Àòðîïèí                            

  │A03BA03             │Ãèîñöèàìèí                        

  │A03BA04             │Ñóììà àëêàëîëèäîâ áåëëàäîííû      

                                                        

  │A03BB               │Ïîëóñèíòåòè÷åñêèå àëêàëîèäû       

                      │áåëëàäîííû, ÷åòâåðòè÷íûå          

                      │àììîíèåâûå ñîåäèíåíèÿ             

                                                        

  │A03BB01             │Ãèîñöèíà áóòèëáðîìèä              

                                                        

  │A03D                │Ñïàçìîëèòèêè â êîìáèíàöèè ñ       

                      │àíàëüãåòèêàìè                     

                                                         

  │A03DB               │Áåëëàäîííà è åå ïðîèçâîäíûå â     

                      │êîìáèíàöèè ñ àíàëüãåòèêàìè        

                                                        

  │A03E                │Ñïàçìîëèòèêè è õîëèíîáëîêàòîðû â  

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                        

  │A03ED               │Ñïàçìîëèòèêè â êîìáèíàöèè ñ       

                      │ïðî÷èìè ïðåïàðàòàìè               

                                                        

  │A03F                │Ñòèìóëÿòîðû ìîòîðèêè ÆÊÒ          

  │A03FA               │Ñòèìóëÿòîðû ìîòîðèêè ÆÊÒ          

  │A03FA01             │Ìåòîêëîïðàìèä                     

  │A03FA02             │Öèçàïðèä                          

  │A03FA03             │Äîìïåðèäîí                        

  │A03FA04             │Áðîìîïðèä                         

  │A04                 │Ïðîòèâîðâîòíûå ïðåïàðàòû          

  │A04A                │Ïðîòèâîðâîòíûå ïðåïàðàòû          

  │A04AA               │Àíòàãîíèñòû ñåðîòîíèíà            

  │A04AA01             │Îíäàíñåòðîí                       

  │A04AA02             │Ãðàíèçåòðîí                       

  │A04AA03             │Òðîïèçåòðîí                       

  │A04AD               │Ïðî÷èå ïðîòèâîðâîòíûå ïðåïàðàòû   

                                                        

  │A05                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ïå÷åíè è æåë÷åâûâîäÿùèõ ïóòåé     

                                                        

  │A05A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │æåë÷íîãî ïóçûðÿ                   

                                                         

  │A05AA               │Ïðåïàðàòû æåë÷íûõ êèñëîò          

  │A05AA01             │Õåíîäåîêñèõîëåâàÿ êèñëîòà         

  │A05AA02             │Óðñîäåîêñèõîëèåâàÿ êèñëîòà        

                                                        

  │A05AB               │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │æåë÷åâûâîäÿùèõ ïóòåé              

                                                        

  │A05AB01             │Ãèäðîêñèìåòèëíèêîòèíàìèä          

                                                        

  │A05AX               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé æåë÷åâûâîäÿùèõ ïóòåé  

                                                        

  │A05AX02             │Ãèìåêðîìîí                        

                                                        

  │A05B                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ïå÷åíè                            

                                                         

  │A05BA               │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ïå÷åíè                            

                                                        

  │A05BA01             │Àðãèíèí                           

  │A05BA03             │Ñèëèáèíèí                         

                                                        

  │A05C                │Êîìáèíàöèÿ ïðåïàðàòîâ äëÿ ëå÷åíèÿ 

                      │çàáîëåâàíèé ïå÷åíè è              

                      │æåë÷åâûâîäÿùèõ ïóòåé              

                                                        

  │A06                 │Ñëàáèòåëüíûå                      

  │A06A                │Ñëàáèòåëüíûå                       

  │A06AA               │Ñìÿã÷àþùèå ïðåïàðàòû              

  │A06AA02             │Äîêóçàò íàòðèÿ                    

  │A06AB               │Êîíòàêòíûå ñëàáèòåëüíûå           

  │A06AB02             │Áèñàêîäèë                         

  │A06AB04             │Ôåíîëôòàëåèí                      

  │A06AB05             │Êàñòîðîâîå ìàñëî                  

  │A06AB06             │Ñåííû ãëèêîçèäû                   

                                                        

  │A06AB56             │Ñåííû ãëèêîçèäû â êîìáèíàöèè ñ    

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │A06AB58             │Íàòðèÿ ïèêîñóëüôàò â êîìáèíàöèè ñ 

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │A06AC               │Ñëàáèòåëüíûå, óâåëè÷èâàþùèå îáúåì 

                      │êèøå÷íîãî ñîäåðæèìîãî             

                                                         

  │A06AD               │Îñìîòè÷åñêèå ñëàáèòåëüíûå         

  │A06AD04             │Ìàãíèÿ ñóëüôàò                    

  │A06AD11             │Ëàêòóëîçà                         

  │A06AD13             │Íàòðèÿ ñóëüôàò                    

  │A06AG               │Ñëàáèòåëüíûå ïðåïàðàòû â êëèçìàõ  

  │A06AG01             │Íàòðèÿ ôîñôàò                     

  │A06AG04             │Ãëèöåðîë                          

  │A06AX               │Ïðî÷èå ñëàáèòåëüíûå               

  │A07                 │Ïðîòèâîäèàðåéíûå ïðåïàðàòû        

                                                        

  │A07A                │Êèøå÷íûå ïðîòèâîìèêðîáíûå è       

                      │ïðîòèâîâîñïàëèòåëüíûå ïðåïàðàòû   

                                                        

  │A07AA               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû       

  │A07AA02             │Íèñòàòèí                          

  │A07AA03             │Íàòàìèöèí                         

  │A07AA05             │Ïîëèìèêñèí                        

  │A07AA06             │Ïàðîìîìèöèí                       

  │A07AA08             │Êàíàìèöèí                         

  │A07AB               │Ñóëüôàíèëàìèäû                    

  │A07AB02             │Ôòàëèëñóëüôàòèàçîë                

  │A07AB03             │Ñóëüôàãóàíèäèí                    

  │A07AC               │Ïðîèçâîäíûå èìèäàçîëà             

                                                        

  │A07AX               │Ïðî÷èå êèøå÷íûå ïðîòèâîìèêðîáíûå  

                      │ïðåïàðàòû                         

                                                        

  │A07AX03             │Íèôóðîêñàçèä                      

  │A07B                │Êèøå÷íûå àäñîðáåíòû               

  │A07BA               │Ïðåïàðàòû óãëÿ                    

  │A07BA01             │Àêòèâèðîâàííûé óãîëü              

  │A07BB               │Âèñìóòà ñóáãàëàò                  

  │A07BC               │Ïðî÷èå êèøå÷íûå àäñîðáåíòû        

  │A07BC01             │Ïåêòèí                            

  │A07BC04             │Àòòàïóëãèò                        

  │A07C                │Ýëåêòðîëèòû ñ óãëåâîäàìè          

                                                         

  │A07CA               │Ðåãèäðàòàíòû äëÿ ïåðîðàëüíîãî     

                      │ïðèåìà                            

                                                        

  │A07D                │Ïðåïàðàòû, ñíèæàþùèå ìîòîðèêó ÆÊÒ 

  │A07DA               │Ïðåïàðàòû, ñíèæàþùèå ìîòîðèêó ÆÊÒ 

  │A07DA03             │Ëîïåðàìèä                         

                                                        

  │A07E                │Êèøå÷íûå ïðîòèâîâîñïàëèòåëüíûå    

                      │ïðåïàðàòû                         

                                                        

  │A07EC               │Àìèíîñàëèöèëîâàÿ êèñëîòà è        

                      │àíàëîãè÷íûå ïðåïàðàòû             

                                                        

  │A07EC01             │Ñóëüôàñàëàçèí                     

  │A07EC02             │Ìåñàëàçèí                         

  │A07F                │Àíèäèàððåéíûå ìèêðîîðãàíèçìû      

  │A07FA               │Àíèäèàððåéíûå ìèêðîîðãàíèçìû      

                                                        

  │A07FA01             │Ìèêðîîðãàíèçìû, ïðîäóöèðóþùèå     

                      │ìîëî÷íóþ êèñëîòó                  

                                                         

  │A07FA02             │Ñàõàðîìèöåòû Boulardii            

                                                        

  │A08                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ îæèðåíèÿ    

                      │(èñêëþ÷àÿ äèåòè÷åñêèå ïðîäóêòû)   

                                                        

  │A08A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ îæèðåíèÿ    

                      │(èñêëþ÷àÿ äèåòè÷åñêèå ïðîäóêòû)   

                                                         

  │A08AA               │Ïðåïàðàòû äëÿ ëå÷åíèÿ îæèðåíèÿ    

                      │öåíòðàëüíîãî äåéñòâèÿ             

                                                        

  │A08AA02             │Ôåíôëóðàìèí                        

  │A08AA03             │Àìôåïðàìîí                        

  │A08AA04             │Äåêñôåíôëóðàìèí                   

                                                        

  │A09                 │Ïðåïàðàòû, ñïîñîáñòâóþùèå         

                      │ïèùåâàðåíèþ (âêëþ÷àÿ ôåðìåíòíûå   

                      │ïðåïàðàòû)                        

                                                        

  │A09A                │Ïðåïàðàòû, ñïîñîáñòâóþùèå         

                      │ïèùåâàðåíèþ (âêëþ÷àÿ ôåðìåíòíûå   

                      │ïðåïàðàòû)                        

                                                        

  │A09AA               │Ïèùåâàðèòåëüíûå ôåðìåíòíûå        

                      │ïðåïàðàòû                         

                                                        

  │A09AA02             │Ïàíêðåàòèí                        

  │A09AA03             │Ïåïñèí                            

  │A09AB               │Êèñëîòû                            

  │A09AB01             │Ãëóòàìèíîâîé êèñëîòû ãèäðîõëîðèä  

  │A09AB02             │Áåòàèí                            

  │A09AB03             │Õëîðèñòîâîäîðîäíàÿ êèñëîòà        

                                                        

  │A09AC               │Êîìáèíàöèÿ ïèùåâàðèòåëüíûõ        

                      │ôåðìåíòíûõ ïðåïàðàòîâ è           

                      │êèñëîòîñîäåðæàùèõ ïðåïàðàòîâ      

                                                         

  │A09AC01             │Ïåïñèí è êèñëîòîñîäåðæàùèå        

                      │ïðåïàðàòû                         

                                                        

  │A10                 │Ñðåäñòâà äëÿ ëå÷åíèÿ ñàõàðíîãî    

                      │äèàáåòà                           

                                                        

  │A10A                │Èíñóëèíû                          

                                                        

  │A10AB               │Èíñóëèíû è àíàëîãè, áûñòðîãî      

                      │äåéñòâèÿ                          

                                                        

  │A10AB04             │Ëèçïðîèíñóëèí                     

                                                        

  │A10AC               │Èíñóëèíû è àíàëîãè, ñðåäíåãî      

                      │äåéñòâèÿ                          

                                                        

  │A10AD               │Èíñóëèíû è àíàëîãè, ñðåäíåãî      

                      │äåéñòâèÿ â êîìáèíàöèè ñ èíñóëèíàìè │

                      │áûñòðîãî äåéñòâèÿ                 

                                                        

  │A10AE               │Èíñóëèíû è àíàëîãè, äëèòåëüíîãî   

                      │äåéñòâèÿ                          

                                                        

  │A10B                │Ñàõàðîñíèæàþùèå ïðåïàðàòû äëÿ     

                      │ïåðîðàëüíîãî ïðèåìà               

                                                        

  │A10BA               │Áèãóàíèäû                         

  │A10BA02             │Ìåòôîðìèí                         

  │A10BA03             │Áóôîðìèí                           

  │A10BB               │Ïðîèçâîäíûå ñóëüôîíèëìî÷åâèíû     

  │A10BB01             │Ãëèáåíêëàìèä                      

  │A10BB02             │Õëîðïðîïàìèä                      

  │A10BB03             │Òîëáóòàìèä                         

  │A10BB04             │Ãëèáîðíóðèä                       

  │A10BB05             │Òîëàçàìèä                         

  │A10BB06             │Êàðáóòàìèä                        

  │A10BB07             │Ãëèïèçèä                          

  │A10BB08             │Ãëèêâèäîí                         

  │A10BB09             │Ãëèêëàçèä                         

  │A10BB12             │Ãëèìåïèðèä                        

  │A10BF               │Àëüôà ãëþêîçèäàçû èíãèáèòîðû      

  │A10BF01             │Àêàðáîçà                          

  │A10BX               │Ïðî÷èå ñàõàðîñíèæàþùèå ïðåïàðàòû  

  │A10BX01             │Ãóàðîâàÿ ñìîëà                    

                                                        

  │A10X                │Ïðî÷èå ëåêàðñòâåííûå ïðåïàðàòû äëÿ │

                      │ëå÷åíèÿ ñàõàðíîãî äèàáåòà         

                                                        

  │A10XA               │Àëüäîçîðåäóêòàçû èíãèáèòîðû       

  │A11                 │Âèòàìèíû                           

  │A11A                │Ïîëèâèòàìèíû                      

                                                        

  │A11AA               │Ïîëèâèòàìèíû ñ ìèíåðàëüíûìè       

                      │âåùåñòâàìè                        

                                                        

  │A11AA01             │Ïîëèâèòàìèíû ñ æåëåçîì            

  │A11AA02             │Ïîëèâèòàìèíû ñ êàëüöèåì           

                                                         

  │A11AA03             │Ïîëèâèòàìèíû ñ ïðî÷èìè ìèíåðàëàìè 

                      │è èõ êîìáèíàöèÿìè                 

                                                        

  │A11AA04             │Ïîëèâèòàìèíû è ìèêðîýëåìåíòû      

  │A11AB               │Ïîëèâèòàìèíû â äðóãèõ êîìáèíàöèÿõ 

  │A11B                │Ïîëèâèòàìèíû                      

  │A11BA               │Ïîëèâèòàìèíû                      

  │A11C                │Âèòàìèí A è D è èõ êîìáèíàöèÿ     

  │A11CA               │Âèòàìèí A                         

  │A11CA01             │Ðåòèíîë                           

  │A11CB               │Êîìáèíàöèÿ âèòàìèíîâ A è D        

  │A11CC               │Âèòàìèí D è åãî ïðîèçâîäíûå       

  │A11CC01             │Ýðãîêàëüöèôåðîë                   

  │A11CC02             │Äèãèäðîòàõèñòåðîë                 

  │A11CC03             │Àëüôàêàëüöèäîë                    

  │A11CC04             │Êàëüöèòðèîë                       

  │A11CC05             │Êîëåêàëüöèôåðîë                   

  │A11CC20             │Êîìáèíàöèÿ ïðîèçâîäíûõ âèòàìèíîâ D │

                                                        

  │A11D                │Âèòàìèí B1 è åãî êîìáèíàöèÿ ñ     

                      │âèòàìèíàìè B6 è B12               

                                                        

  │A11DA               │Âèòàìèí B1                        

  │A11DA01             │Òèàìèí                            

                                                        

  │A11DB               │Êîìáèíàöèÿ âèòàìèíà B1 ñ          

                      │âèòàìèíàìè B6 è B12               

                                                        

  │A11E                │Êîìïëåêñ âèòàìèíîâ ãðóïïû B,      

                      │âêëþ÷àÿ êîìáèíàöèè ñ äðóãèìè      

                      │ïðåïàðàòàìè                       

                                                        

  │A11EA               │Âèòàìèíû ãðóïïû B                  

                                                        

  │A11G                │Àñêîðáèíîâàÿ êèñëîòà, âêëþ÷àÿ     

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                        

  │A11GA               │Àñêîðáèíîâàÿ êèñëîòà â ÷èñòîì âèäå │

  │A11GA01             │Àñêîðáèíîâàÿ êèñëîòà              

                                                        

  │A11GB               │Àñêîðáèíîâàÿ êèñëîòà â êîìáèíàöèè 

                      │ñ äðóãèìè ïðåïàðàòàìè             

                                                        

  │A11GB01             │Àñêîðáèíîâàÿ êèñëîòà â êîìáèíàöèè 

                      │ñ ïðåïàðàòàìè êàëüöèÿ             

                                                        

  │A11H                │Ïðî÷èå âèòàìèíû                   

  │A11HA               │Ïðî÷èå âèòàìèíû â ÷èñòîì âèäå     

  │A11HA01             │Íèêîòèíàìèä                       

  │A11HA02             │Ïèðèäîêñèí                         

  │A11HA03             │Âèòàìèí Å                         

  │A11HA04             │Ðèáîôëàâèí                        

  │A11HA06             │Ïèðèäîêñàëü ôîñôàò                

  │A11HA30             │Äåêñïàíòåíîë                      

  │A11HA31             │Êàëüöèÿ ïàíòîòåíàò                

  │A11HA32             │Ïàíòåòèí                          

                                                        

  │A11J                │Âèòàìèíû â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                        

  │A11JA               │Âèòàìèíû â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                        

                                                        

  │A11JB               │Âèòàìèíû â êîìáèíàöèè ñ           

                      │ìèíåðàëüíûìè âåùåñòâàìè           

                                                        

  │A11JC               │Âèòàìèíû â ñî÷åòàíèè ñ ïðî÷èìè    

                      │ïðåïàðàòàìè                       

                                                        

  │A12                 │Ìèíåðàëüíûå äîáàâêè               

  │A12A                │Ïðåïàðàòû êàëüöèÿ                 

  │A12AA               │Ïðåïàðàòû êàëüöèÿ                 

  │A12AA01             │Êàëüöèÿ ôîñôàò                    

  │A12AA03             │Êàëüöèÿ ãëþêîíàò                  

  │A12AA05             │Êàëüöèÿ ëàêòàò                    

  │A12AA06             │Êàëüöèÿ ëàêòàò ãëþêîíàò           

  │A12AA08             │Êàëüöèÿ ãëèöåðèëôîñôàò            

  │A12AA11             │Êàëüöèÿ ïàíãàìàò                  

  │A12AA12             │Êàëüöèÿ àöåòàò                    

  │A12AA20             │Êîìáèíàöèÿ ðàçëè÷íûõ ñîëåé êàëüöèÿ │

                                                        

  │A12AX               │Ïðåïàðàòû êàëüöèÿ â êîìáèíàöèè ñ  

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │A12B                │Ïðåïàðàòû êàëèÿ                   

  │A12BA               │Ïðåïàðàòû êàëèÿ                   

  │A12BA01             │Êàëèÿ õëîðèä                      

  │A12BA30             │Êîìáèíàöèÿ ðàçëè÷íûõ ñîëåé êàëèÿ  

                                                        

  │A12BA51             │Êàëèÿ õëîðèä â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè                

                                                        

  │A12C                │Ïðî÷èå ìèíåðàëüíûå âåùåñòâà       

  │A12CA               │Ïðåïàðàòû íàòðèÿ                  

  │A12CA01             │Íàòðèÿ õëîðèä                     

  │A12CB               │Ïðåïàðàòû öèíêà                   

  │A12CB01             │Öèíêà ñóëüôàò                     

  │A12CC               │Ïðåïàðàòû ìàãíèÿ                  

  │A12CC04             │Ìàãíèÿ öèòðàò                     

  │A12CC05             │Ìàãíèÿ àñïàðàãèíàò                

  │A12CC06             │Ìàãíèÿ ëàêòàò                     

  │A12CC09             │Ìàãíèÿ îðîòàò                     

  │A12CC30             │Êîìáèíàöèÿ ðàçëè÷íûõ ñîëåé ìàãíèÿ 

  │A12CD               │Ïðåïàðàòû ôòîðà                   

  │A12CD01             │Íàòðèÿ ôòîðèä                     

  │A12CX               │Ïðî÷èå ìèíåðàëüíûå âåùåñòâà       

  │A13                 │Îáùåòîíèçèðóþùå ïðåïàðàòû         

  │A13A                │Îáùåòîíèçèðóþùå ïðåïàðàòû         

                                                        

  │A14                 │Àíàáîëè÷åñêèå ñòåðîèäíûå ïðåïàðàòû │

                      │äëÿ ñèñòåìíîãî èñïîëüçîâàíèÿ      

                                                        

  │A14A                │Àíàáîëè÷åñêèå ñòåðîèäíûå ïðåïàðàòû │

  │A14AA               │Ïðîèçâîäíûå àíäðîñòàíà            

  │A14AA03             │Ìåòàíäèåíîí                       

  │A14AA08             │Îêñàíäðîëîí                        

                                                        

  │A14AB               │Àíàáîëè÷åñêèå ñòåðîèäíûå ïðåïàðàòû │

                      │- ýôèðû                           

                                                         

  │A14AB01             │Íàíäðîëîí                         

                                                        

  │A14B                │Ïðî÷èå àíàáîëè÷åñêèå ñòåðîèäíûå   

                      │ïðåïàðàòû                         

                                                        

  │A15                 │Ñòèìóëÿòîðû àïïåòèòà              

                                                        

  │A16                 │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ÆÊÒ è íàðóøåíèÿ îáìåíà │

                      │âåùåñòâ                           

                                                        

  │A16A                │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ÆÊÒ è íàðóøåíèÿ îáìåíà │

                      │âåùåñòâ                           

                                                        

  │A16AA               │Àìèíîêèñëîòû è èõ ïðîèçâîäíûå     

  │A16AA01             │Ëåâîêàðíèòèí                      

  │A16AA02             │Àäåìåòèîíèí                       

  │A16AB               │Ôåðìåíòíûå ïðåïàðàòû              

  │A16AB01             │Àëãëóöåðàçà                       

                                                         

  │A16AX               │Ðàçëè÷íûå ïðî÷èå ïðåïàðàòû äëÿ    

                      │ëå÷åíèÿ çàáîëåâàíèé ÆÊÒ è îáìåíà  

                      │âåùåñòâ                           

                                                         

  │B01                 │Àíòèêîàãóëÿíòû                    

  │B01A                │Àíòèêîàãóëÿíòû                    

                                                        

  │B01AA               │Àíòèêîàãóëÿíòû íåïðÿìûå (âèòàìèíà 

                      │K àíòàãîíèñòû)                    

                                                        

  │B01AA02             │Ôåíèíäèîí                         

  │B01AA03             │Âàðôàðèí                          

  │B01AA07             │Àöåíîêóìàðîë                      

  │B01AA08             │Ýòèë áèñêóìàöåòàò                 

                                                        

  │B01AB               │Àíòèêîàãóëÿíòû ïðÿìûå (ãåïàðèí è  

                      │åãî ïðîèçâîäíûå)                  

                                                        

  │B01AB01             │Ãåïàðèí                           

  │B01AB02             │Àíòèòðîìáèí III                   

  │B01AB04             │Äàëòåïàðèí                         

  │B01AB05             │Ýíîêñàïàðèí                       

  │B01AB06             │Íàäðîïàðèí                        

  │B01AB08             │Ðåâèïàðèí                         

  │B01AB11             │Ñóëîäåêñèä                         

                                                        

  │B01AC               │Èíãèáèíîðû àãðåãàöèè òðîìáîöèòîâ  

                      │(èñêëþ÷àÿ ãåïàðèí)                

                                                        

  │B01AC04             │Êëîïèäîãðåë                       

  │B01AC05             │Òèêëîïèäèí                        

  │B01AC07             │Äèïèðèäàìîë                       

  │B01AC10             │Èíäîáóôåí                         

  │B01AC13             │Àáöèêñèìàá                        

  │B01AD               │Ôåðìåíòíûå ïðåïàðàòû              

  │B01AD01             │Ñòðåïòîêèíàçà                     

  │B01AD02             │Àëòåïëàçà                         

  │B01AD04             │Óðîêèíàçà                         

  │B01AD05             │Ôèáðèíîëèçèí                      

  │B02                 │Ãåìîñòàòèêè                       

  │B02A                │Ãåìîñòàòèêè                       

  │B02AA               │Àìèíîêèñëîòû                       

  │B02AA01             │Àìèíîêàïðîíîâàÿ êèñëîòà           

  │B02AA02             │Òðàíåêñàìîâàÿ êèñëîòà             

  │B02AA03             │Àìèíîìåòèëáåíçîéíàÿ êèñëîòà       

  │B02AB               │Èíãèáèòîðû ïðîòåèíîëèçà            

  │B02AB01             │Àïðîòèíèí                         

  │B02B                │Âèòàìèí K è äðóãèå ãåìîñòàòèêè    

  │B02BA               │Âèòàìèí K                         

  │B02BA01             │Ôèòîìåíàäèîí                      

  │B02BA02             │Ìåíàäèîí                          

  │B02BC               │Ìåñòíûå ãåìîñòàòèêè               

  │B02BC01             │Æåëàòèíîâàÿ àáñîðáèðóþùàÿ ãóáêà   

  │B02BC02             │Öåëëþëîçà îêèñëåííàÿ              

  │B02BC07             │Êîëëàãåí                          

  │B02BD               │Ôàêòîðû ñâåðòûâàíèÿ êðîâè         

                                                        

  │B02BD01             │Ôàêòîð ñâåðòûâàíèÿ êðîâè II, VII, 

                      │IX è X â êîìáèíàöèè               

                                                        

  │B02BD02             │Ôàêòîð ñâåðòûâàíèÿ êðîâè VIII     

  │B02BD04             │Ôàêòîð ñâåðòûâàíèÿ êðîâè IX       

  │B02BD30             │Òðîìáèí                            

  │B02BX               │Ïðî÷èå ñèñòåìíûå ãåìîñòàòèêè      

  │B02BX01             │Ýòàìçèëàò                         

  │B02BX02             │Êàðáàçîõðîì                       

  │B03                 │Ñòèìóëÿòîðû ãåìîïîýçà              

  │B03A                │Ïðåïàðàòû æåëåçà                  

                                                        

  │B03AA               │Ïðåïàðàòû Fe++ äëÿ ïåðîðàëüíîãî   

                      │ïðèåìà                            

                                                        

  │B03AA02             │Æåëåçà ôóìàðàò                    

  │B03AA03             │Æåëåçà ãëþêîíàò                   

  │B03AA05             │Æåëåçà õëîðèä                     

  │B03AA07             │Æåëåçà ñóëüôàò                    

                                                        

  │B03AB               │Ïðåïàðàòû Fe+++ äëÿ ïåðîðàëüíîãî  

                      │ïðèåìà                            

                                                        

  │B03AB05             │Æåëåçà ïîëèèçîìàëüòîçàò           

                                                        

  │B03AC               │Ïðåïàðàòû Fe+++ äëÿ               

                      │ïàðåíòåðàëüíîãî ïðèìåíåíèÿ        

                                                        

  │B03AC03             │Æåëåçà-ñîðáèòîëà-ëèìîííîé êèñëîòû 

                      │êîìïëåêñ                          

                                                        

  │B03AD               │Ïðåïàðàòû æåëåçà â êîìáèíàöèè ñ   

                      │ôîëèåâîé êèñëîòîé                 

                                                        

  │B03AD02             │Æåëåçà ôóìàðàò â êîìáèíàöèè ñ     

                      │ôîëèåâîé êèñëîòîé                 

                                                        

  │B03AD03             │Æåëåçà ñóëüôàò â êîìáèíàöèè ñ     

                      │ôîëèåâîé êèñëîòîé                  

                                                        

  │B03AE               │Ïðåïàðàòû æåëåçà â êîìáèíàöèè ñ   

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │B03AE01             │Ïðåïàðàòû æåëåçà, âèòàìèí B12 è   

                      │ôîëèåâàÿ êèñëîòà                  

                                                        

  │B03AE02             │Ïðåïàðàòû æåëåçà â êîìáèíàöèè ñ   

                      │ïîëèâèòàìèíàìè è ôîëèåâîé êèñëîòîé │

                                                        

  │B03AE03             │Ïðåïàðàòû æåëåçà â êîìáèíàöèè ñ   

                      │ïîëèâèòàìèíàìè                    

                                                        

  │B03AE04             │Æåëåçî, ïîëèâèòàìèíû è ìèíåðàëüíûå │

                      │âåùåñòâà                          

                                                        

  │B03AE10             │Ïðåïàðàòû æåëåçà â êîìáèíàöèè ñ   

                      │ïðî÷èìè ïðåïàðàòàìè               

                                                        

  │B03B                │Âèòàìèí B12 è ôîëèåâàÿ êèñëîòà    

  │B03BA               │Öèàíîêîáàëàìèí è åãî ïðîèçâîäíûå  

  │B03BA01             │Öèàíîêîáàëàìèí                    

  │B03BA03             │Ãèäðîêñîêîáàëàìèí                 

  │B03BA04             │Êîáàìàìèä                         

                                                         

  │B03BA51             │Öèàíîêîáàëàìèí â êîìáèíàöèè ñ     

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │B03BB               │Ôîëèåâàÿ êèñëîòà è åå ïðîèçâîäíûå 

  │B03BB01             │Ôîëèåâàÿ êèñëîòà                  

                                                        

  │B03BB51             │Ôîëèåâàÿ êèñëîòà â êîìáèíàöèè ñ   

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │B03X                │Ïðî÷èå ñòèìóëÿòîðû ãåìîïîýçà      

  │B03XA               │Ïðî÷èå ñòèìóëÿòîðû ãåìîïîýçà      

  │B03XA01             │Ýïîýòèí áåòà                      

                                                        

  │B05                 │Ïëàçìàçàìåùàþùèå è ïåðôóçèîííûå   

                      │ðàñòâîðû                          

                                                        

  │B05A                │Ïðåïàðàòû êðîâè                   

                                                        

  │B05AA               │Ïðåïàðàòû ïëàçìû êðîâè è          

                      │ïëàçìîçàìåùàþùèå ïðåïàðàòû        

                                                         

  │B05AA01             │Àëüáóìèí                          

  │B05AA03             │Ôòîðêàðáîíîâûå êðîâåçàìåíèòåëè    

  │B05AA05             │Äåêñòðàí                          

  │B05AA06             │Ïðåïàðàòû æåëàòèíà                

  │B05AA07             │Ïîëèãèäðîêñèýòèëêðàõìàë           

  │B05B                │Ðàñòâîðû äëÿ â/â ââåäåíèÿ         

                                                        

  │B05BA               │Ïðåïàðàòû äëÿ ïàðåíòåðàëüíîãî     

                      │ïèòàíèÿ                           

                                                        

  │B05BA01             │Àìèíîêèñëîòû                      

  │B05BA02             │Æèðîâûå ýìóëüñèè                   

  │B05BA03             │Óãëåâîäû                          

  │B05BA04             │Ãèäðîëèçàòû áåëêîâ                

                                                        

  │B05BA10             │Êîìáèíèðîâàííûå ïðåïàðàòû äëÿ     

                      │ïàðåíòåðàëüíîãî ïèòàíèÿ           

                                                        

  │B05BB               │Ðàñòâîðû, âëèÿþùèå íà             

                      │âîäíî-ýëåêòðîëèòíûé áàëàíñ        

                                                        

  │B05BB01             │Ýëåêòîëèòû                        

                                                        

  │B05BB02             │Ýëåêòðîëèòû â ñî÷åòàíèè ñ         

                      │óãëåâîäàìè                        

                                                        

  │B05BB03             │Òðîìåòàìîë                        

  │B05BC               │Îñìîäèóðåòèêè                     

  │B05BC01             │Ìàííèòîë                           

  │B05BC02             │Ìî÷åâèíà                          

  │B05C                │Èððèãàöèîííûå ðàñòâîðû            

  │B05CB               │Ñîëåâûå ðàñòâîðû                  

  │B05CB01             │Íàòðèÿ õëîðèä                     

  │B05CB02             │Íàòðèÿ öèòðàò                     

  │B05CB04             │Íàòðèÿ ãèäðîêàðáîíàò              

  │B05CX               │Ïðî÷èå èððèãàöèîííûå ðàñòâîðû     

  │B05CX01             │Äåêñòðîçà                          

  │B05CX02             │Ñîðáèòîë                          

  │B05CX03             │Ãëèöèí                            

                                                        

  │B05D                │Ïðåïàðàòû äëÿ ïåðèòîíåàëüíîãî     

                      │äèàëèçà                           

                                                        

  │B05X                │Äîáàâêè ê ðàñòâîðàì äëÿ â/â       

                      │ââåäåíèÿ                          

                                                        

  │B05XA               │Ýëåêòîëèòíûå ðàñòâîðû             

  │B05XA01             │Êàëèÿ õëîðèä                      

  │B05XA04             │Àììîíèÿ õëîðèä                    

  │B05XA05             │Ìàãíèÿ ñóëüôàò                    

  │B05XA07             │Êàëüöèÿ õëîðèä                    

  │B05XA16             │Êàðäèîïëåãè÷åñêèå ðàñòâîðû        

  │B05XB               │Àìèíîêèñëîòû                      

  │B05XB01             │Àðãèíèíà ãèäðîõëîðèä              

  │B05XB03             │Ëèçèí                             

  │B06                 │Ïðî÷èå ãåìàòîëîãè÷åñêèå ïðåïàðàòû 

  │B06A                │Ïðî÷èå ãåìàòîëîãè÷åñêèå ïðåïàðàòû 

  │B06AA               │Ôåðìåíòíûå ïðåïàðàòû              

  │B06AB               │Ïðî÷èå ãåìàòîëîãè÷åñêèå ïðåïàðàòû 

                                                        

  │C01                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ñåðäöà                            

                                                        

  │C01A                │Ñåðäå÷íûå ãëèêîçèäû               

  │C01AA               │Äèãèòàëèñíûå ãëèêîçèäû            

  │C01AA02             │Àöåòèëäèãîêñèí                    

  │C01AA03             │Äèãèòàëèñà ãëèêîçèäîâ ñóììà       

  │C01AA04             │Äèãèòîêñèí                        

  │C01AA05             │Äèãîêñèí                          

  │C01AA06             │Ëàíàòîçèä Ö                        

  │C01AA08             │Ìåòèëäèãîêñèí                     

  │C01AB               │Ãëèêîçèäû ìîðñêîãî ëóêà           

  │C01AC               │Ãëèêîçèäû ñòðîôàíòà               

  │C01AC01             │Ñòðîôàíòèí                        

  │C01AX               │Ïðî÷èå ñåðäå÷íûå ãëèêîçèäû        

                                                        

  │C01B                │Àíòèàðèòìè÷åñêèå ïðåïàðàòû I è III │

                      │êëàññîâ                           

                                                        

  │C01BA               │Àíòèàðèòìè÷åñêèå ïðåïàðàòû Ià     

                      │êëàññà                            

                                                        

  │C01BA01             │Õèíèäèí                           

  │C01BA02             │Ïðîêàèíàìèä                       

  │C01BA03             │Äèçîïèðàìèä                       

  │C01BA05             │Àéìàëèí                           

  │C01BA08             │Ïðàéìàëèíà áèòàðòðàò              

                                                        

  │C01BB               │Àíòèàðèòìè÷åñêèå ïðåïàðàòû Ib     

                      │êëàññà                            

                                                        

  │C01BB01             │Ëèäîêàèí                          

  │C01BB02             │Ìåêñèëåòèí                        

                                                        

  │C01BC               │Àíòèàðèòìè÷åñêèå ïðåïàðàòû Ic     

                      │êëàññà                            

                                                        

  │C01BC03             │Ïðîïàôåíîí                        

                                                         

  │C01BD               │Àíòèàðèòìè÷åñêèå ïðåïàðàòû III    

                      │êëàññà                            

                                                        

  │C01BD01             │Àìèîäàðîí                         

  │C01BD02             │Áðåòèëèÿ òîñèëàò                  

  │C01BD05             │Èáóòèëèä                          

                                                        

  │C01BG               │Ïðî÷èå àíòèàðèòìè÷åñêèå ïðåïàðàòû 

                      │I êëàññà                          

                                                        

  │C01BG01             │Ìîðàöèçèí                         

                                                        

  │C01C                │Êàðäèîòîíè÷åñêèå ñðåäñòâà         

                      │íåãëèêîçèäíîãî ïðîèñõîæäåíèÿ      

                                                        

  │C01CA               │Àäðåíî- è äîïàìèí-ñòèìóëÿòîðû     

  │C01CA03             │Íîðýïèíåôðèí                      

  │C01CA04             │Äîïàìèí                           

  │C01CA05             │Íîðôåíåôðèí                       

  │C01CA06             │Ôåíèëýôðèí                        

  │C01CA07             │Äîáóòàìèí                         

  │C01CA16             │Èáîïàìèí                          

  │C01CA17             │Ìèäîäðèí                          

  │C01CA24             │Ýïèíåôðèí                         

  │C01CX               │Ïðî÷èå êàðäèîòîíè÷åñêèå ñðåäñòâà  

  │C01CX06             │Àíãèîòåíçèíàìèä                   

                                                        

  │C01D                │Âàçîäèëàòàòîðû äëÿ ëå÷åíèÿ        

                      │çàáîëåâàíèé ñåðäöà                 

                                                        

  │C01DA               │Îðãàíè÷åñêèå íèòðàòû              

  │C01DA02             │Íèòðîãëèöåðèí                     

  │C01DA05             │Ïåíòàýðèòðèòèëà òåòðàíèòðàò       

  │C01DA08             │Èçîñîðáèäà äèíèòðàò               

  │C01DA14             │Èçîñîðáèäà ìîíîíèòðàò             

                                                        

  │C01DX               │Ïðî÷èå âàçîäèëàòàòîðû äëÿ ëå÷åíèÿ 

                      │çàáîëåâàíèé ñåðäöà                

                                                        

  │C01DX02             │Ïðåíèëàìèí                        

  │C01DX05             │Êàðáîêðîìåí                       

  │C01DX12             │Ìîëñèäîìèí                        

  │C01DX17             │Òðèìåòàçèäèí                      

                                                        

  │C01E                │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ñåðäöà                

                                                        

  │C01EA               │Ïðîñòàãëàíäèíû                    

  │C01EA01             │Àëïðîñòàäèë                       

  │C01EB               │Ïðî÷èå êàðäèîòîíè÷åñêèå ïðåïàðàòû 

  │C01EB02             │Êàìôîðà                           

  │C01EB05             │Êðåàòèíîëôîñôàò                   

  │C01EB09             │Óáèäåêàðåíîí                      

  │C01EB10             │Àäåíîçèíà ôîñôàò                  

  │C01EB11             │Òèðàöèçèí                         

                                                        

  │C01EX               │Ïðî÷èå êîìáèíèðîâàííûå ïðåïàðàòû  

                      │äëÿ ëå÷åíèÿ çàáîëåâàíèé ñåðäöà    

                                                        

  │C02                 │Ãèïîòåíçèâíûå ïðåïàðàòû           

  │C02A                │Àäðåíîñòèìóëÿòîðû öåíòðàëüíûå     

  │C02AA               │Ðàóôîëüôèè àëêàëîèäû              

  │C02AA02             │Ðåçåðïèí                          

                                                        

  │C02AA52             │Ðåçåðïèí â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                        

  │C02AA53             │Ðàóâîëüôèè àëêàëîèäîâ ñóììà â     

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                        

  │C02AB               │Ìåòèëäîïà                         

  │C02AB02             │Ìåòèëäîïà (ðàöåìè÷åñêàÿ ñìåñü)    

                                                        

  │C02AC               │Àëüôà2-àäðåíîìèìåòèêè öåíòðàëüíûå, │

                      │ïðîèçâîäíûå èìèäàçîëèíà           

                                                        

  │C02AC02             │Ãóàíôàöèí                         

  │C02AC05             │Ìîêñîíèäèí                        

  │C02B                │Ãàíãëèîáëîêàòîðû                   

  │C02BB               │Âòîðè÷íûå è òðåòè÷íûå àìèíû       

  │C02BC               │Äèèçîïðîïèëàìèí                   

                                                        

  │C02C                │Àíòèàäðåíåðãè÷åñêèå ïðåïàðàòû      

                      │ïåðèôåðè÷åñêîãî äåéñòâèÿ          

                                                        

  │C02CA               │Àëüôà-àäðåíîáëîêàòîðû             

  │C02CA01             │Ïðàçîçèí                          

  │C02CA04             │Äîêñàçîçèí                        

  │C02CA05             │Òåðàçîçèí                         

  │C02CA06             │Óðàïèäèë                          

  │C02CB               │Àëüôà- è áåòà-àäðåíîáëîêàòîðû     

  │C02CB01             │Ëàáåòàëîë                         

  │C02CC               │Ïðîèçâîäíûå ãóàíåòèäèíà           

  │C02CC02             │Ãóàíåòèäèí                        

  │C02D                │Ìèîëèòèêè ïðÿìûå                  

  │C02DA               │Òèàçèäíûå ïðîèçâîäíûå             

  │C02DA01             │Äèàçîêñèä                         

  │C02DB               │Ãèäðàçèíîôòàëàçèíîâûå ïðîèçâîäíûå 

  │C02DB02             │Ãèäðàëàçèí                        

  │C02DC               │Ïèðèìèäèíîâûå ïðîèçâîäíûå         

  │C02DC01             │Ìèíîêñèäèë                        

  │C02DD               │Íèòðîôåððèöèàíèäíûå ïðîèçâîäíûå   

  │C02DD01             │Íèòðîïðóññèä íàòðèÿ               

  │C02DG               │Ãóàíèäèíîâûå ïðîèçâîäíûå           

  │C02K                │Ïðî÷èå ãèïîòåíçèâíûå ïðåïàðàòû    

  │C02KD               │Ñåðîòîíèíà àíòàãîíèñòû            

  │C02KD01             │Êåòàíñåðèí                        

                                                        

  │C02L                │Ãèïîòåíçèâíûå ïðåïàðàòû â         

                      │êîìáèíàöèè ñ äèóðåòèêàìè          

                                                        

  │C02LA               │Ðàóâîëüôèè àëêàëîèäû â êîìáèíàöèè 

                      │ñ äèóðåòèêàìè                     

                                                        

  │C02LA51             │Ðåçåðïèí+äèóðåòèêè â êîìáèíàöèè ñ 

                      │äðóãèìè ïðåïàðàòàìè               

                                                         

  │C03                 │Äèóðåòèêè                         

  │C03A                │Òèàçèäû                           

  │C03AA               │Òèàçèäû                           

  │C03AA03             │Ãèäðîõëîðîòèàçèä                  

  │C03AA07             │Öèêëîïåíòèàçèä                    

                                                        

  │C03B                │Íåòèàçèäíûå äèóðåòèêè, äåéñòâóþùèå │

                      │íà êîðòèêàëüíûé ñåãìåíò ïåòëè Ãåíëå│

                                                        

  │C03BA               │Ñóëüôîíàìèäû                      

  │C03BA03             │Êëîïàìèä                          

  │C03BA04             │Õëîðòàëèäîí                       

  │C03BA10             │Êñèïàìèä                          

  │C03BA11             │Èíäàïàìèä                         

                                                        

  │C03BK               │Ñóëüôîíàìèäû â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │C03C                │Ïåòëåâûå äèóðåòèêè                

  │C03CA               │Ñóëüôàíèëàìèäíûå äèóðåòèêè        

  │C03CA01             │Ôóðîñåìèä                         

  │C03CA02             │Áóìåòàíèä                         

  │C03CA03             │Ïèðåòàíèä                         

                                                        

  │C03CC               │Ïðîèçâîäíûå àðèëîêñèóêñóñíîé      

                      │êèñëîòû                           

                                                        

  │C03CC01             │Ýòàêðèíîâàÿ êèñëîòà               

  │C03D                │Êàëèéñáåðåãàþùèå äèóðåòèêè        

  │C03DA               │Àëüäîñòåðîíà àíòàãîíèñòû          

  │C03DA01             │Ñïèðîíîëàêòîí                     

  │C03DB               │Ïðî÷èå êàëèéñáåðåãàþùèå äèóðåòèêè 

  │C03DB02             │Òðèàìòåðåí                         

                                                        

  │C03E                │Êîìáèíàöèÿ äèóðåòèêîâ ñ           

                      │êàëèéñáåðåãàþùèìè ïðåïàðàòàìè     

                                                        

  │C03EA               │Äèóðåòèêè, äåéñòâóþùèå íà         

                      │êîðòèêàëüíûé ñåãìåíò ïåòëè Ãåíëå â │

                      │êîìáèíàöèè ñ êàëèéñáåðåãàþùèìè    

                      │ïðåïàðàòàìè                       

                                                        

  │C03EA01             │Ãèäðîõëîðîòèàçèä â êîìáèíàöèè ñ   

                      │êàëèéñáåðåãàþùèìè ïðåïàðàòàìè     

                                                        

  │C03EA14             │Áóòèçèä â êîìáèíàöèè ñ            

                      │êàëèéñáåðåãàþùèìè ïðåïàðàòàìè     

                                                        

  │C03EB               │Ïåòëåâûå äèóðåòèêè â êîìáèíàöèè ñ 

                      │êàëèéñáåðåãàþùèìè ïðåïàðàòàìè     

                                                        

  │C03EB01             │Ôóðîñåìèä â êîìáèíàöèè ñ          

                      │êàëèéñáåðåãàþùèìè ïðåïàðàòàìè     

                                                         

  │C04                 │Ïåðèôåðè÷åñêèå âàçîäèëàòàòîðû     

  │C04A                │Ïåðèôåðè÷åñêèå âàçîäèëàòàòîðû     

  │C04AA               │Ïðîèçâîäíûå 2-àìèíî-1-ôåíèëýòàíîëà │

  │C04AA31             │Áàìåòàí                           

  │C04AB               │Ïðîèçâîäíûå èìèäàçîëà             

  │C04AB01             │Ôåíòîëàìèí                        

  │C04AB02             │Òîëàçîëèí                         

                                                        

  │C04AC               │Íèêîòèíîâàÿ êèñëîòà è åå          

                      │ïðîèçâîäíûå                       

                                                        

  │C04AD               │Ïóðèíû                            

  │C04AD02             │Êñàíòèíîëà íèêîòèíàò              

  │C04AD03             │Ïåíòîêñèôèëëèí                    

  │C04AE               │Ñïîðûíüè àëêàëîèäû                

  │C04AE02             │Íèöåðãîëèí                        

                                                         

  │C04AE51             │Ýðãîëîèäà ìåñèëàò â êîìáèíàöèè ñ  

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │C04AX               │Ïðî÷èå ïåðèôåðè÷åñêèå             

                      │âàçîäèëàòàòîðû                    

                                                        

  │C04AX07             │Âèíêàìèí                          

  │C04AX11             │Áåíöèêëàí                          

  │C04AX21             │Íàôòèäðîôóðèë                     

  │C05                 │Àíãèîïðîòåêòîðû                   

                                                        

  │C05A                │Ïðîòèâîãåìîððîèäàëüíûå ïðåïàðàòû  

                      │äëÿ ìåñòíîãî ïðèìåíåíèÿ           

                                                        

  │C05AA               │Ãëþêîêîðòèêîñòåðîèäû äëÿ ìåñòíîãî 

                      │ëå÷åíèÿ ãåìîððîÿ                  

                                                        

  │C05AA01             │Ãèäðîêîðòèçîí                     

                                                        

  │C05AB               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû äëÿ   

                      │ìåñòíîãî ëå÷åíèÿ ãåìîððîÿ         

                                                        

  │C05AD               │Ìåñòíûå àíåñòåòèêè äëÿ ëå÷åíèÿ    

                      │ãåìîððîÿ                          

                                                        

  │C05AD03             │Áåíçîêàèí                         

  │C05AD05             │Ïðîêàèí                           

  │C05AD07             │Ïðàìîêàèí                         

                                                         

  │C05AX               │Ïðî÷èå ïðåïàðàòû äëÿ ìåñòíîãî     

                      │ëå÷åíèÿ ãåìîððîÿ                  

                                                        

  │C05AX02             │Âèñìóòà ñîëè â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │C05AX03             │Ïðî÷èå ïðåïàðàòû è èõ êîìáèíàöèè  

  │C05AX04             │Öèíêà ïðåïàðàòû                   

  │C05AX05             │Òðèáåíîçèä                        

                                                        

  │C05B                │Ëå÷åíèå ñèíäðîìà âàðèêîçíîãî      

                      │ðàñøèðåíèÿ âåí                     

                                                        

  │C05BA               │Ãåïàðèí-ñîäåðæàùèå ïðåïàðàòû äëÿ  

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │C05BA01             │Ãåïàðèíîèäû îðãàíè÷åñêèå          

                                                        

  │C05BA53             │Ãåïàðèí â êîìáèíàöèè ñ äðóãèìè    

                      │ïðåïàðàòàìè                       

                                                        

  │C05BB               │Âåíîñêëåðîçèðóþùèå ïðåïàðàòû      

  │C05BB02             │Ïîëèäîêàíîë                       

  │C05BB04             │Íàòðèÿ òåòðàäåöèëñóëüôàò          

  │C05BX               │Ïðî÷èå âåíîñêëåðîçèðóþùèå ïðåïàðàòû│

  │C05BX01             │Êàëüöèÿ äîáåçèëàò                 

                                                        

  │C05C                │Ïðåïàðàòû, ñíèæàþùèå ïðîíèöàåìîñòü │

                      │êàïèëëÿðîâ                         

                                                        

  │C05CA               │Áèîôëàâîíîèäû                     

  │C05CA01             │Ðóòîçèä                           

  │C05CA04             │Òðîêñåðóòèí                       

                                                        

  │C05CA51             │Ðóòîçèäû â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                         

  │C05CA53             │Äèðñìèí â êîìáèíàöèè ñ äðóãèìè    

                      │ïðåïàðàòàìè                       

                                                        

  │C05CX               │Ïðî÷èå ïðåïàðàòû, ñíèæàþùèå       

                      │ïðîíèöàåìîñòü êàïèëëÿðîâ          

                                                        

  │C07                 │Áåòà-àäðåíîáëîêàòîðû              

  │C07A                │Áåòà-àäðåíîáëîêàòîðû              

  │C07AA               │Áåòà-àäðåíîáëîêàòîðû íåñåëåêòèâíûå │

  │C07AA02             │Îêñïðåíîëîë                       

  │C07AA03             │Ïèíäîëîë                          

  │C07AA05             │Ïðîïðàíîëîë                       

  │C07AA06             │Òèìîëîë                           

  │C07AA07             │Ñîòàëîë                           

  │C07AA12             │Íàäîëîë                           

  │C07AA17             │Áîïèíäîëîë                        

  │C07AB               │Áåòà-àäðåíîáëîêàòîðû ñåëåêòèâíûå  

  │C07AB02             │Ìåòîïðîëîë                        

  │C07AB03             │Àòåíîëîë                          

  │C07AB04             │Àöåáóòîëîëà ãèäðîõëîðèä           

  │C07AB05             │Áåòàêñîëîë                         

  │C07AB07             │Áèñîïðîëîë                        

  │C07AB09             │Ýñìîëîë                           

  │C07AG               │Àëüôà-áåòà àäðåíîáëîêàòîðû        

  │C07AG02             │Êàðâåäèëîë                        

                                                        

  │C07B                │Áåòà-àäðåíîáëîêàòîðû â êîìáèíàöèè 

                      │ñ òèàçèäàìè                       

                                                         

  │C07BB               │Áåòà-àäðåíîáëîêàòîðû ñåëåêòèâíûå â │

                      │êîìáèíàöèè ñ òèàçèäàìè            

                                                        

  │C07BB02             │Ìåòîïðîëîë â êîìáèíàöèè ñ òèàçèäàìè│

  │C07BB03             │Àòåíîëîë â êîìáèíàöèè ñ òèàçèäàìè 

                                                        

  │C08                 │Áëîêàòîðû ìåäëåííûõ êàëüöèåâûõ    

                      │êàíàëîâ                           

                                                        

  │C08C                │Áëîêàòîðû ìåäëåííûõ êàëüöèåâûõ    

                      │êàíàëîâ ñåëåêòèâíûå               

                                                        

  │C08CA               │Äèãèäðîïèðèäèíîâûå ïðîèçâîäíûå    

  │C08CA01             │Àìëîäèïèí                         

  │C08CA02             │Ôåëîäèïèí                         

  │C08CA03             │Èñðàäèïèí                         

  │C08CA04             │Íèêàðäèïèí                        

  │C08CA05             │Íèôåäèïèí                         

  │C08CA06             │Íèìîäèïèí                         

  │C08CA07             │Íèçîëäèïèí                        

  │C08CA08             │Íèòðåíäèïèí                       

  │C08CA09             │Ëàöèäèïèí                         

                                                        

  │C08CX               │Äðóãèå ñåëåêòèâíûå ÁÌÊÊ ñ         

                      │ïðåèìóùåñòâåííûì âëèÿíèåì íà òîíóñ │

                      │ñîñóäîâ                           

                                                        

  │C08CX01             │Ìèáåôðàäèë                        

                                                         

  │C08D                │Áëîêàòîðû ìåäëåííûõ êàëüöèåâûõ    

                      │êàíàëîâ ñåëåêòèâíûå ñ ïðÿìûì      

                      │âëèÿíèåì íà êàðäèîìèîöèòû         

                                                         

  │C08DA               │Ïðîèçâîäíûå ôåíèëàëêèëàìèíà       

  │C08DA01             │Âåðàïàìèë                         

  │C08DA02             │Ãàëëîïàìèë                        

  │C08DB               │Ïðîèçâîäíûå áåíçîòèàçåïèíîâ       

  │C08DB01             │Äèëòèàçåì                         

                                                        

  │C08E                │Áëîêàòîðû ìåäëåííûõ êàëüöèåâûõ    

                      │êàíàëîâ íåñåëåêòèâíûå             

                                                        

  │C08EA               │Ïðîèçâîäíûå ôåíèëàëêèëàìèíîâ      

  │C08EA01             │Ôåíäèëèí                          

  │C08EA02             │Áåïðèäèë                          

                                                        

  │C09                 │Ïðåïàðàòû, âëèÿþùèå íà ñèñòåìó    

                      │ðåíèí-àíãèîòåíçèí                 

                                                        

  │C09A                │Àíãèîòåíçèí-êîíâåðòèðóþùåãî       

                      │ôåðìåíòà (ÀÊÔ) èíãèáèòîðû         

                                                        

  │C09AA               │ÀÊÔ èíãèáèòîðû                    

  │C09AA01             │Êàïòîïðèë                         

  │C09AA02             │Ýíàëàïðèë                         

  │C09AA03             │Ëèçèíîïðèë                        

  │C09AA04             │Ïåðèíäîïðèë                       

  │C09AA05             │Ðàìèïðèë                           

  │C09AA06             │Õèíàïðèë                          

  │C09AA07             │Áåíàçåïðèë                        

  │C09AA08             │Öèëàçàïðèë                        

  │C09AA09             │Ôîçèíîïðèë                         

  │C09AA10             │Òðàíäîëàïðèë                      

  │C09AA11             │Ñïèðàïðèë                         

  │C09AA13             │Ìîýêñèïðèë                        

                                                        

  │C09B                │ÀÊÔ èíãèáèòîðû â êîìáèíàöèè ñ     

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │C09BA               │ÀÊÔ èíãèáèòîðû â êîìáèíàöèè ñ     

                      │äèóðåòèêàìè                       

                                                        

  │C09BA01             │Êàïòîïðèë â êîìáèíàöèè ñ          

                      │äèóðåòèêàìè                       

                                                        

  │C09BA02             │Ýíàëàïðèë â êîìáèíàöèè ñ          

                      │äèóðåòèêàìè                       

                                                        

  │C09C                │Àíãèîòåíçèíà II àíòàãîíèñòû       

  │C09CA               │Àíãèîòåíçèíà II àíòàãîíèñòû       

  │C09CA01             │Ëîçàðòàí                          

  │C09CA02             │Ýïðîçàðòàí                        

  │C09CA03             │Âàëçàðòàí                         

  │C09CA04             │Èðáåçàðòàí                        

                                                        

  │C09D                │Àíãèîòåíçèíà II àíòàãîíèñòû â     

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                        

  │C09DA               │Àíãèîòåíçèí II àíòàãîíèñòû â      

                      │êîìáèíàöèè ñ äèóðåòèêàìè          

                                                         

  │C09DA01             │Ëîçàðòàí â êîìáèíàöèè ñ äèóðåòèêàìè│

  │C10                 │Ãèïîëèïèäåìè÷åñêèå ïðåïàðàòû      

                                                        

  │C10A                │Ãèïîõîëåñòåðèíåìè÷åñêèå è         

                      │ãèïîòðèãëèöåðèäåìè÷åñêèå ïðåïàðàòû │

                                                        

  │C10AA               │HMG CoA ðåäóêòàçû èíãèáèòîðû      

  │C10AA01             │Ñèìâàñòàòèí                       

  │C10AA02             │Ëîâàñòàòèí                        

  │C10AA03             │Ïðàâàñòàòèí                       

  │C10AA04             │Ôëóâàñòàòèí                       

  │C10AA04             │Àòîðâàñòàòèí                      

  │C10AB               │Ôèáðàòû                           

  │C10AB02             │Áåçàôèáðàò                        

  │C10AB04             │Ãåìôèáðîçèë                       

  │C10AB05             │Ôåíîôèáðàò                        

  │C10AB08             │Öèïðîôèáðàò                       

  │C10AB09             │Ýòîôèáðàò                         

                                                        

  │C10AC               │Ïðåïàðàòû, ñâÿçûâàþùèå æåë÷íûå    

                      │êèñëîòû                           

                                                        

  │C10AC01             │Êîëåñòèðàìèí                      

  │C10AC02             │Êîëåñòèïîë                        

                                                         

  │C10AD               │Íèêîòèíîâàÿ êèñëîòà è åå          

                      │ïðîèçâîäíûå                       

                                                        

  │C10AD02             │Íèêîòèíîâàÿ êèñëîòà                

  │C10AD06             │Àöèïèìîêñ                         

  │C10AX               │Äðóãèå ãèïîëèïèäíûå ïðåïàðàòû     

  │C10AX02             │Ïðîáóêîë                          

  │C10AX06             │Îìåãà-3 òðèãëèöåðèäû              

                                                        

  │D01                 │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ëå÷åíèÿ çàáîëåâàíèé êîæè          

                                                        

  │D01A                │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │D01AA               │Ïðîòèâîãðèáêîâûå àíòèáèîòèêè      

  │D01AA01             │Íèñòàòèí                          

  │D01AA02             │Íàòàìèöèí                         

  │D01AA08             │Ãðèçåîôóëüâèí                     

  │D01AC               │Ïðîèçâîäíûå èìèäàçîëà             

  │D01AC01             │Êëîòðèìàçîë                       

  │D01AC02             │Ìèêîíàçîë                         

  │D01AC03             │Ýêîíàçîë                          

  │D01AC05             │Èçîêîíàçîë                        

  │D01AC07             │Òèîêîíàçîë                        

  │D01AC08             │Êåòîêîíàçîë                       

  │D01AC10             │Áèôîíàçîë                         

                                                        

  │D01AE               │Ïðî÷èå ïðîòèâîãðèáêîâûå ïðåïàðàòû 

                      │äëÿ ìåñòíîãî ïðèìåíåíèÿ           

                                                        

  │D01AE04             │Óíäåöèëåíîâàÿ êèñëîòà             

  │D01AE12             │Ñàëèöèëîâàÿ êèñëîòà                

  │D01AE13             │Ñåëåíà ñóëüôèä                    

  │D01AE14             │Öèêëîïèðîêñ                       

  │D01AE15             │Òåðáèíàôèí                        

  │D01AE16             │Àìîðîëôèí                         

  │D01AE17             │Äèìàçîë                           

  │D01AE18             │Òîëíàôòàò                         

  │D01AE19             │Òîëöèêëàò                         

  │D01AE20             │Êîìáèíèðîâàííûå ïðåïàðàòû         

  │D01AE22             │Íàôòèôèí                          

                                                        

  │D01B                │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ñèñòåìíîãî ïðèìåíåíèÿ             

                                                        

  │D01BA               │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ñèñòåìíîãî ïðèìåíåíèÿ             

                                                        

  │D01BA01             │Ãðèçåîôóëüâèí                     

  │D01BA02             │Òåðáèíàôèí                        

  │D02                 │Äåðìàòîïðîòåêòîðû                 

  │D02A                │Äåðìàòîïðîòåêòîðû                 

  │D02AB               │Öèíêà ïðåïàðàòû                   

  │D02AE               │Ìî÷åâèíû ïðîèçâîäíûå              

  │D02AE01             │Ìî÷åâèíû ïåðîêñèä                 

  │D02AF               │Ñàëèöèëîâîé êèñëîòû ïðåïàðàòû     

  │D02AX               │Äåðìàòîïðîòåêòîðû ïðî÷èå          

  │D02B                │Ôîòîçàùèòíûå ïðåïàðàòû            

                                                        

  │D02BA               │Ôîòîçàùèòíûå ïðåïàðàòû äëÿ        

                      │ìåñòíîãî èñïîëüçîâàíèÿ             

                                                        

  │D02BB               │Ôîòîïðîòåêòîðû äëÿ ñèñòåìíîãî     

                      │èñïîëüçîâàíèÿ                     

                                                        

  │D02BB01             │Áåòàêàðîòåí                       

  │D03                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ ðàí è ÿçâ   

                                                        

  │D03A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │ãèïåððóáöåâàíèÿ                   

                                                        

  │D03AA               │Ìàñëà ïå÷åíè òðåñêè ïðåïàðàòû     

                                                        

  │D03AX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ãèïåððóáöåâàíèÿ                   

                                                        

  │D03AX03             │Äåêñïàíòåíîë                      

  │D03B                │Ôåðìåíòíûå ïðåïàðàòû              

  │D03BA               │Ïðîòåîëèòè÷åñêèå ôåðìåíòû         

  │D03BA01             │Òðèïñèí                           

                                                        

  │D03BA52             │Êëîñòðèäèîïåïòèäàçà â êîìáèíàöèè ñ │

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │D04                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çóäà êîæè   

                      │(âêëþ÷àÿ àíòèãèñòàìèííûå ïðåïàðàòû │

                      │è àíåñòåòèêè)                     

                                                        

  │D04A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çóäà êîæè   

                      │(âêëþ÷àÿ àíòèãèñòàìèííûå ïðåïàðàòû │

                      │è àíåñòåòèêè)                     

                                                        

  │D04AA               │Àíòèãèñòàìèííûå ïðåïàðàòû äëÿ     

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │D04AA13             │Äèìåòèíäåí                        

  │D04AA32             │Äèôåíãèäðàìèí                     

  │D04AB               │Ìåñòíîàíåñòåçèðóþùèå ïðåïàðàòû    

  │D04AB01             │Ëèäîêàèí                          

  │D04AB04             │Áåíçîêàèí                         

  │D04AX               │Ïðîòèâîçóäíûå ïðåïàðàòû ïðî÷èå    

  │D05                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ ïñîðèàçà    

                                                        

  │D05A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ ïñîðèàçà äëÿ │

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │D05AC               │Àíòðàöåíà ïðîèçâîäíûå             

  │D05AC01             │Äèòðàíîë                          

  │D05AD               │Ïñîðàëåíû äëÿ ìåñòíîãî ïðèìåíåíèÿ 

  │D05AD02             │Ìåòîêñàëåí                        

                                                        

  │D05AX               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ïñîðèàçà äëÿ ìåñòíîãî ïðèìåíåíèÿ  

                                                        

  │D05AX02             │Êàëüöèïîòðèîë                     

                                                        

  │D05B                │Ïðåïàðàòû äëÿ ëå÷åíèÿ ïñîðèàçà äëÿ │

                      │ñèñòåìíîãî èñïîëüçîâàíèÿ          

                                                         

  │D05BA               │Ïñîðàëåíû äëÿ ñèñòåìíîãî ïðèìåíåíèÿ│

  │D05BA02             │Ìåòîêñàñàëåí                      

  │D05BB               │Ðåòèíîèäû äëÿ ëå÷åíèÿ ïñîðèàçà    

  │D05BB02             │Àöèòðåòèí                         

                                                        

  │D06                 │Àíòèáàêòåðèàëüíûå ïðåïàðàòû è     

                      │ïðîòèâîìèêðîáíûå ïðåïàðàòû äëÿ    

                      │ëå÷åíèÿ çàáîëåâàíèé êîæè          

                                                        

  │D06A                │Àíòèáàêòåðèàëüíûå ïðåïàðàòû äëÿ   

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │D06AA               │Òåòðàöèêëèí è åãî ïðîèçâîäíûå     

  │D06AA04             │Òåòðàöèêëèí                       

                                                        

  │D06AX               │Ïðî÷èå àíòèáàêòåðèàëüíûå ïðåïàðàòû │

                      │äëÿ ìåñòíîãî ïðèìåíåíèÿ           

                                                        

  │D06AX01             │Ôóçèäèåâàÿ êèñëîòà                

  │D06AX02             │Õëîðàìôåíèêîë                     

  │D06AX04             │Íåîìèöèí                          

  │D06AX05             │Áàöèòðàöèí                        

  │D06AX07             │Ãåíòàìèöèí                        

  │D06AX09             │Ìóïèðîöèí                         

  │D06AX12             │Àìèêàöèí                           

                                                        

  │D06B                │Ïðîòèâîìèêðîáíûå ïðåïàðàòû äëÿ    

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                         

  │D06BA               │Ñóëüôàíèëàìèäû                    

  │D06BA01             │Ñóëüôàäèàçèí ñåðåáðà              

  │D06BA02             │Ñóëüôàòèàçîë ñåðåáðà              

  │D06BA03             │Ìàôåíèä                           

                                                        

  │D06BA51             │Ñóëüôàäèàçèí ñåðåáðà â êîìáèíàöèè 

                      │ñ äðóãèìè ïðåïàðàòàìè             

                                                        

  │D06BB               │Ïðîòèâîâèðóñíûå ïðåïàðàòû         

  │D06BB02             │Òðîìàíòàäèí                       

  │D06BB03             │Àöèêëîâèð                         

  │D06BB04             │Ïîäîôèëëîòîêñèí                   

  │D06BB06             │Ïåíöèêëîâèð                       

  │D06BX               │Ïðîòèâîìèêðîáíûå ïðåïàðàòû ïðî÷èå 

  │D06BX01             │Ìåòðîíèäàçîë                      

                                                        

  │D06C                │Êîìáèíàöèÿ àíòèáèîòèêîâ ñ         

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                        

  │D07                 │Ãëþêîêîðòèêîñòåðîèäû äëÿ ìåñòíîãî 

                      │ëå÷åíèÿ çàáîëåâàíèé êîæè          

                                                        

  │D07A                │Ãëþêîêîðòèêîñòåðîèäû              

                                                        

  │D07AA               │Ãëþêîêîðòèêîñòåðîèäû ñëàáîàêòèâíûå │

                      │(Ãðóïïà I)                        

                                                        

  │D07AA01             │Ìåòèëïðåäíèçîëîí                  

  │D07AA02             │Ãèäðîêîðòèçîí                      

  │D07AA03             │Ïðåäíèçîëîí                       

                                                        

  │D07AB               │Ãëþêîêîðòèêîñòåðîèäû ñ óìåðåííîé  

                      │àêòèâíîñòüþ (Ãðóïïà II)           

                                                        

  │D07AB01             │Êëîáåòàçîë                        

  │D07AB03             │Ôëóìåòàçîí                        

  │D07AB09             │Òðèàìöèíîëîí                      

                                                        

  │D07AB30             │Êîìáèíàöèÿ êîðòèêîñòåðîèäîâ äëÿ   

                      │ìåñòíîãî ïðèìåíåíèÿ               

                                                        

  │D07AC               │Ãëþêîêîðòèêîñòåðîèäû àêòèâíûå     

                      │(Ãðóïïà III)                      

                                                        

  │D07AC01             │Áåòàìåòàçîí                       

  │D07AC04             │Ôëóîöèíîëîíà àöåòîíèä             

  │D07AC09             │Áóäåñîíèä                         

  │D07AC12             │Ãàëîìåòàçîí                       

  │D07AC13             │Ìîìåòàçîí                         

  │D07AC17             │Ôëóòèêàçîí                        

  │D07AC18             │Ïðåäíèêàðáàò                      

                                                        

  │D07B                │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ àíòèñåïòèêàìè                   

                                                        

  │D07BA               │Ãëþêîêîðòèêîñòåðîèäû ñëàáîàêòèâíûå │

                      │â êîìáèíàöèè ñ àíòèñåïòèêàìè      

                                                         

  │D07BA01             │Ïðåäíèçîëîí â êîìáèíàöèè ñ        

                      │àíòèñåïòèêàìè                     

                                                        

  │D07BA04             │Ãèäðîêîðòèçîí â êîìáèíàöèè ñ      

                      │àíòèñåïòèêàìè                     

                                                        

  │D07BB               │Êîðèòèêîñòåðîèäû ñ óìåðåííîé      

                      │àêòèâíîñòüþ â êîìáèíàöèè ñ        

                      │àíòèñåïòèêàìè                     

                                                        

  │D07BB01             │Ôëóìåòàçîí â êîìáèíàöèè ñ         

                      │àíòèñåïòèêàìè                     

                                                        

  │D07BC               │Ãëþêîêîðòèêîñòåðîèäû àêòèâíûå â   

                      │êîìáèíàöèè ñ àíòèñåïòèêàìè        

                                                        

  │D07BC01             │Áåòàìåòàçîí â êîìáèíàöèè ñ        

                      │àíòèñåïòèêàìè                     

                                                        

  │D07BC02             │Ôëóîöèíîëîí â êîìáèíàöèè ñ        

                      │àíòèñåïòèêàìè                     

                                                        

  │D07C                │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ àíòèáèîòèêàìè                   

                                                         

  │D07CA               │Ãëþêîêîðòèêîñòåðîèäû ñëàáîàêòèâíûå │

                      │â êîìáèíàöèè ñ àíòèáèîòèêàìè      

                                                        

  │D07CA01             │Ãèäðîêîðòèçîí â êîìáèíàöèè ñ      

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CA03             │Ïðåäíèçîëîí â êîìáèíàöèè ñ        

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CB               │Ãëþêîêîðòèêîñòåðîèäû ñ óìåðåííîé  

                      │àêòèâíîñòüþ â êîìáèíàöèè ñ        

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CB01             │Òðèàìöèíîëîí â êîìáèíàöèè ñ       

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CB04             │Äåêñàìåòàçîí â êîìáèíàöèè ñ       

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CC               │Ãëþêîêîðòèêîñòåðîèäû àêòèâíûå â   

                      │êîìáèíàöèè ñ àíòèáèîòèêàìè        

                                                        

  │D07CC01             │Áåòàìåòàçîí â êîìáèíàöèè ñ        

                      │àíòèáèîòèêàìè                     

                                                        

  │D07CC02             │Ôëóîöèíîëîíà àöåòîíèä â êîìáèíàöèè │

                      │ñ àíòèáèîòèêàìè                   

                                                        

  │D07X                │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ äðóãèìè ïðåïàðàòàìè             

                                                        

  │D07XA               │Ãëþêîêîðòèêîñòåðîèäû ñëàáîàêòèâíûå │

                      │â êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè │

                                                        

  │D07XA01             │Ãèäðîêîðòèçîí â êîìáèíàöèè ñ      

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │D07XB               │Ãëþêîêîðòèêîñòåðîèäû ñ óìåðåííîé  

                      │àêòèâíîñòüþ â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │D07XB01             │Ôëóìåòàçîí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │D07XB05             │Äåêñàìåòàçîí â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │D07XC               │Êîðòèêîñòåðîèäû ñèëüíûå â         

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                         

  │D07XC01             │Áåòàìåòàçîí â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │D07XD               │Ãëþêîêîðòèêîñòåðîèäû î÷åíü        

                      │àêòèâíûå â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                        

  │D08                 │Àíòèñåïòèêè è äåçèíôèöèðóþùèå     

                      │ïðåïàðàòû                         

                                                        

  │D08A                │Àíòèñåïòèêè è äåçèíôèöèðóþùèå     

                      │ïðåïàðàòû                          

                                                        

  │D08AA               │Àêðèäèíà ïðîèçâîäíûå              

  │D08AA01             │Ýòàêðèäèí                         

  │D08AB               │Àëþìèíèÿ ïðåïàðàòû                

  │D08AC               │Áèãóàíèäû è àìèäèíû               

  │D08AC02             │Õëîðãåêñèäèí                      

                                                        

  │D08AC52             │Õëîðãåêñèäèí â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │D08AD               │Áîðíàÿ êèñëîòà è ïðåïàðàòû íà åå  

                      │îñíîâå                            

                                                        

  │D08AE               │Ôåíîë è åãî ïðîèçâîäíûå           

  │D08AE02             │Ïîëèêðåçóëåí                      

  │D08AE03             │Ôåíîë                             

  │D08AF               │Ïðîèçâîäíûå ôóðàíà                

  │D08AF01             │Íèòðîôóðàë                        

  │D08AG               │Ïðåïàðàòû éîäà                    

  │D08AG02             │Ïîâèäîí-Éîä                       

  │D08AG03             │Éîä                               

  │D08AH               │Õèíîëèíà ïðîèçâîäíûå              

  │D08AH01             │Äåêâàëèíèÿ õëîðèä                 

  │D08AJ               │×åòâåðòè÷íûå àììîíèåâûå ñîåäèíåíèÿ │

  │D08AJ01             │Áåíçàëêîíèÿ õëîðèä                

  │D08AJ06             │Äèäåöèëäèìåòèëàììîíèÿ õëîðèä      

  │D08AK               │Ðòóòü, ñîäåðæàùèå ïðåïàðàòû       

  │D08AK01             │Ðòóòè àìèäîõëîðèä                 

  │D08AK03             │Ðòóòè õëîðèä                       

  │D08AK30             │Ðòóòè éîäèä                       

  │D08AL               │Ñåðåáðîñîäåðæàùèå ïðåïàðàòû       

  │D08AL01             │Ñåðåáðà íèòðàò                    

                                                        

  │D08AX               │Àíòèñåïòèêè è äåçèíôèöèðóþùèå     

                      │ïðåïàðàòû ïðî÷èå                  

                                                        

  │D08AX01             │Ïåðåêèñü âîäîðîäà                 

  │D08AX04             │Òîñèëõëîðàìèä íàòðèÿ              

  │D09                 │Ïåðåâÿçî÷íûé ìàòåðèàë             

  │D09A                │Ïåðåâÿçî÷íûé ìàòåðèàë             

                                                        

  │D09AA               │Ïåðåâÿçî÷íûé ìàòåðèàë, ïðîïèòàííûé │

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                        

  │D09AA05             │Áåíçîäîäåöèíèÿ õëîðèä             

  │D10                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ óãðåâîé ñûïè │

                                                        

  │D10A                │Ïðåïàðàòû äëÿ ìåñòíîãî ëå÷åíèÿ    

                      │óãðåâîé ñûïè                      

                                                        

  │D10AD               │Ðåòèíîèäû äëÿ ìåñòíîãî ëå÷åíèÿ    

                      │óãðåâîé ñûïè                      

                                                        

  │D10AD01             │Òðåòèíîèí                          

  │D10AD02             │Ðåòèíîë                           

  │D10AD04             │Èçîòðåòèíîèí                      

  │D10AE               │Ïåïðåêèñè                         

  │D10AE01             │Áåíçîèëà ïåðåêèñü                  

                                                        

  │D10AF               │Ïðîòèâîìèêðîáíûå ïðåïàðàòû äëÿ    

                      │ëå÷åíèÿ óãðåâîé ñûïè              

                                                        

  │D10AF01             │Êëèíäàìèöèí                       

  │D10AF02             │Ýðèòðîìèöèí                       

                                                        

  │D10AF52             │Ýðèòðîìèöèí â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │D10AX               │Ïðî÷èå ïðåïàðàòû äëÿ ìåñòíîãî     

                      │ëå÷åíèÿ óãðåâîé ñûïè              

                                                        

  │D10AX02             │Ðåçîðöèíîëà ìîíîàöåòàò            

  │D10AX03             │Àçåëàíîâàÿ êèñëîòà                

                                                        

  │D10AX30             │Ðàçëè÷íûå ïðî÷èå êîìáèíèðîâàííûå  

                      │ïðåïàðàòû äëÿ ìåñòíîãî ëå÷åíèÿ    

                      │óãðåâîé ñûïè                      

                                                        

  │D10B                │Ïðåïàðàòû äëÿ ñèñòåìíîãî ëå÷åíèÿ  

                      │óãðåâîé ñûïè                      

                                                        

  │D10BA               │Ðåòèíîèäû äëÿ ñèñòåìíîãî ëå÷åíèÿ  

                      │óãðåâîé ñûïè                      

                                                        

  │D10BA01             │Èçîòðåòèíîèí                      

                                                        

  │D10BX               │Ïðî÷èå ïðåïàðàòû äëÿ ñèñòåìíîãî   

                      │ëå÷åíèÿ óãðåâîé ñûïè              

                                                        

  │D10BX01             │Èõòàììîë                          

                                                        

  │D11                 │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé êîæè                  

                                                        

  │D11A                │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé êîæè                  

                                                        

  │D11AC               │Øàìïóíè ëå÷åáíîãî äåéñòâèÿ        

  │D11AC06             │Ïîâèäîí-Éîä                       

                                                        

  │D11AF               │Ïðåïàðàòû äëÿ ëå÷åíèÿ îìîçîëåëîñòè │

                      │è áîðîäàâîê                       

                                                        

  │D11AX               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé êîæè                  

                                                        

  │D11AX01             │Ìèíîêñèäèë äëÿ ìåñòíîãî ïðèìåíåíèÿ │

                                                        

  │G01                 │Àíòèñåïòèêè è ïðîòèâîìèêðîáíûå    

                      │ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │ãèíåêîëîãè÷åñêèõ çàáîëåâàíèé      

                                                         

  │G01A                │Àíòèñåïòèêè è ïðîòèâîìèêðîáíûå    

                      │ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │ãèíåêîëîãè÷åñêèõ çàáîëåâàíèé      

                      │(èñêëþ÷àÿ êîìáèíàöèè ñ             

                      │êîðòèêîñòåðîèäàìè)                

                                                        

  │G01AA               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû       

  │G01AA01             │Íèñòàòèí                          

  │G01AA02             │Íàòàìèöèí                         

  │G01AA05             │Õëîðàìôåíèêîë                     

  │G01AA08             │Êàðôåöèëëèí                       

  │G01AA10             │Êëèíäàìèöèí                       

  │G01AB               │Ìûøüÿêîâèñòûå ñîåäèíåíèÿ          

  │G01AB01             │Àöåòàðñîë                         

  │G01AC               │Ïðîèçâîäíûå õèíîëèíà              

  │G01AC03             │Õëîðõèíàëäîë                      

  │G01AC30             │Îêñèõèíîëèí                       

  │G01AF               │Ïðîèçâîäíûå èìèäàçîëà             

  │G01AF01             │Ìåòðîíèäàçîë                      

  │G01AF02             │Êëîòðèìàçîë                       

  │G01AF04             │Ìèêîíàçîë                          

  │G01AF05             │Ýêîíàçîë                          

  │G01AF07             │Èçîêîíàçîë                        

  │G01AF11             │Êåòîêîíàçîë                       

  │G01AF20             │Èìèäàçîëà ïðîèçâîäíûõ êîìáèíàöèÿ  

                                                        

  │G01AX               │Äðóãèå àíòèñåïòèêè è              

                      │ïðîòèâîìèêðîáíûå ïðåïàðàòû äëÿ    

                      │ëå÷åíèÿ ãèíåêîëîãè÷åñêèõ          

                      │çàáîëåâàíèé                       

                                                        

  │G01AX05             │Íèôóðàòåë                         

  │G01AX06             │Ôóðàçîëèäîí                        

  │G01AX11             │Ïîâèäîí-Éîä                       

  │G01AX12             │Öèêëîïèðîêñ                       

                                                        

  │G02                 │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ãèíåêîëîãè÷åñêèõ çàáîëåâàíèé      

                                                        

  │G02A                │Óòåðîòîíèçèðóþùèå ïðåïàðàòû       

  │G02AB               │Ñïîðûíüè àëêàëîèäû                

  │G02AB01             │Ìåòèëýðãîìåòðèí                   

  │G02AB02             │Ñïîðûíüè àëêàëîèäû                

  │G02AB03             │Ýðãîìåòðèí                        

  │G02AD               │Ïðîñòàãëàíäèíû                    

  │G02AD01             │Äèíîïðîñò                         

  │G02AD02             │Äèíîïðîñòîí                       

  │G02AX               │Óòåðîòîíèçèðóþùèå ïðåïàðàòû ïðî÷èå │

                                                        

  │G02B                │Êîíòðàöåïòèâû äëÿ ìåñòíîãî        

                      │ïðèìåíåíèÿ                        

                                                        

  │G02BA               │Âíóòðèìàòî÷íûå êîíòðàöåïòèâû      

  │G02BA02             │Ïëàñòèêîâûå ìåäü-ñîäåðæàùèå ñïèðàëè│

  │G02BB               │Èíòðàâàãèíàëüíûå êîíòðàöåïòèâû    

                                                        

  │G02C                │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ãèíåêîëîãè÷åñêèõ çàáîëåâàíèé      

                                                        

  │G02CA               │Òîêîëèòè÷åñêèå ïðåïàðàòû -        

                      │ñèìïàòîìèìåòèêè                   

                                                         

  │G02CA01             │Ðèòîäðèí                          

  │G02CA03             │Ôåíîòåðîë                         

  │G02CB               │Ïðîëàêòèíà ñåêðåöèè èíãèáèòîðû    

  │G02CB03             │Êàáåðãîëèí                        

  │G02CB04             │Õèíàãîëèä                         

  │G03                 │Ïîëîâûå ãîðìîíû                   

                                                        

  │G03A                │Ãîðìîíàëüíûå ïåðîðàëüíûå          

                      │êîíòðàöåïòèâû                     

                                                        

  │G03AA               │Ïðîãåñòàãåíû è ýñòðîãåíû          

                      │(ôèêñèðîâàííûå ñî÷åòàíèÿ)         

                                                        

  │G03AA01             │Ýòèíîäèîë è ýñòðîãåíû             

  │G03AA05             │Íîðýòèñòåðîí è ýñòðîãåíû          

  │G03AA06             │Íîðãåñòðåë è ýñòðîãåíû            

  │G03AA07             │Ëåâîíîðãåñòðåë è ýñòðîãåíû        

  │G03AA09             │Äåçîãåñòðåë è ýñòðîãåíû           

  │G03AA10             │Ãåñòîäåí è ýñòðîãåíû              

  │G03AA11             │Íîðãåñòèìàò è ýñòðîãåíû           

                                                        

  │G03AB               │Ïðîãåñòàãåíû è ýñòðîãåíû (äëÿ     

                      │êàëåíäàðíîãî ïðèåìà)              

                                                        

  │G03AB03             │Ëåâîíîðãåñòðåë è ýñòðîãåíû        

  │G03AB04             │Íîðýòèñòåðîí è ýñòðîãåíû          

  │G03AC               │Ïðîãåñòàãåíû                      

  │G03AC03             │Ëåâîíîðãåñòðåë                    

  │G03B                │Àíäðîãåíû                          

  │G03BA               │Ïðîèçâîäíûå 3-îêñîàíäðîñòåíà      

  │G03BA02             │Ìåòèëòåñòîñòåðîí                  

  │G03BA03             │Òåñòîñòåðîí                       

  │G03BB               │Ïðîèçâîäíûå 5-àíäðîñòàíîíà        

  │G03BB01             │Ìåñòåðîëîí                        

  │G03C                │Ýñòðîãåíû                         

                                                        

  │G03CA               │Ïðèðîäíûå è ïîëóñèíòåòè÷åñêèå     

                      │ýñòðîãåíû                         

                                                        

  │G03CA01             │Ýòèíèëýñòðàäèîë                   

  │G03CA03             │Ýñòðàäèîë                         

  │G03CA04             │Ýñòðèîë                           

  │G03CA07             │Ýñòðîí                            

  │G03CA57             │Ýñòðîãåíû êîíúþãèðîâàííûå         

  │G03CB               │Ñèíòåòè÷åñêèå ýñòðîãåíû           

  │G03CB02             │Äèýòèëñòèëüáýñòðîë                

  │G03D                │Ïðîãåñòàãåíû                      

  │G03DA               │Ïðîèçâîäíûå ïðåãíåíà              

  │G03DA01             │Ãåñòîíîðîí êàïðîàò                

  │G03DA02             │Ìåäðîêñèïðîãåñòåðîí               

  │G03DA03             │Ãèäðîêñèïðîãåñòåðîí               

  │G03DA04             │Ïðîãåñòåðîí                       

  │G03DB               │Ïðîèçâîäíûå ïðåãíàäèåíà           

  │G03DB01             │Äèäðîãåñòåðîí                     

  │G03DB02             │Ìåãåñòðîë                         

  │G03DC               │Ïðîèçâîäíûå ýñòðåíà               

  │G03DC01             │Àëëèëýñòðåíîë                     

  │G03DC02             │Íîðýòèñòåðîí                       

  │G03DC03             │Ëèíåñòðåíîë                       

  │G03DC04             │Ýòèñòåðîí                         

  │G03DC05             │Òèáîëîí                           

                                                        

  │G03E                │Àíäðîãåíû â êîìáèíàöèè ñ æåíñêèìè 

                      │ïîëîâûìè ãîðìîíàìè                

                                                        

  │G03EA               │Àíäðîãåíû è ýñòðîãåíû             

  │G03EA03             │Ïðàñòåðîí è ýñòðîãåíû             

                                                        

  │G03F                │Ïðîãåñòàãåíû è ýñòðîãåíû â        

                      │êîìáèíàöèè                        

                                                        

  │G03FA               │Ïðîãåñòàãåíû è ýñòðîãåíû          

                      │(ôèêñèðîâàííîå ñî÷åòàíèå)         

                                                        

  │G03FA09             │Íîðýòèíîäðåë è ýñòðîãåíû          

  │G03FA12             │Ìåäðîêñèïðîãåñòåðîí è ýñòðîãåíû   

                                                        

  │G03FB               │Ïðîãåñòàãåíû è ýñòðîãåíû (äëÿ     

                      │ïîñëåäîâàòåëüíîãî êàëåíäàðíîãî    

                      │ïðèåìà)                           

                                                        

  │G03FB08             │Äèäðîãåñòåðîí è ýñòðîãåíû         

                                                         

  │G03G                │Ãîíàäîòðîïèíû è äðóãèå ñòèìóëÿòîðû │

                      │îâóëÿöèè                          

                                                        

  │G03GA               │Ãîíàäîòðîïèíû                      

  │G03GA01             │Ãîíàäîòðîïèí õîðèîíè÷åñêèé        

  │G03GA02             │Ãîíàäîòðîïèí ìåíîïàóçíûé          

  │G03GA04             │Óðîôîëëèòðîïèí                    

                                                        

  │G03GA05             │Ôîëëèêóëîñòèìóëèðóþùèé ãîðìîí     

                      │÷åëîâå÷åñêèé (ÔÑÃ)                

                                                        

  │G03GB               │Ñòèìóëÿòîðû îâóëÿöèè ñèíòåòè÷åñêèå │

  │G03GB02             │Êëîìèôåí                          

  │G03H                │Àíòèàíäðîãåíû                     

  │G03HA               │Àíòèàíäðîãåíû                     

  │G03HA01             │Öèïðîòåðîí                        

  │G03HB               │Àíòèàíäðîãåíû è ýñòðîãåíû         

  │G03HB01             │Öèïðîòåðîí è ýñòðîãåíû            

  │G03X                │Ïðî÷èå ïîëîâûå ãîðìîíû            

  │G03XA               │Àíòèãîíàäîòðîïèíû                 

  │G03XA01             │Äàíàçîë                            

  │G03XA02             │Ãåñòðèíîí                         

                                                        

  │G04                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │óðîëîãè÷åñêèõ çàáîëåâàíèé         

                                                        

  │G04A                │Óðîàíòèñåïòèêè                    

  │G04AA               │Ìåòåíàìèíà ïðåïàðàòû              

  │G04AA01             │Ìåòåíàìèí                          

  │G04AB               │Õèíîëîíà ïðîèçâîäíûå              

  │G04AB01             │Íàëèäèêñîâàÿ êèñëîòà              

  │G04AB03             │Ïèïåìèäèíîâàÿ êèñëîòà             

  │G04AB04             │Îêñîëèíèåâàÿ êèñëîòà              

  │G04AB05             │Öèíîêñàöèí                        

  │G04AC               │Íèòðîôóðàíà ïðîèçâîäíûå           

  │G04AC01             │Íèòðîôóðàíòîèí                    

  │G04AD               │Ñàëèöèëàòû                        

  │G04AD01             │Ôåíèëñàëèöèëàò                    

  │G04AG               │Ïðî÷èå óðîàíòèñåïòèêè             

  │G04AG06             │Íèòðîêñîëèí                       

                                                        

  │G04AK               │Óðîàíòèñåïòèêîâ êîìáèíàöèÿ        

                      │(èñêëþ÷àÿ êîìáèíàöèè ñ            

                      │ñóëüôàíèëàìèäàìè)                 

                                                        

  │G04B                │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │óðîëîãè÷åñêèõ çàáîëåâàíèé, âêëþ÷àÿ │

                      │ñïàçìîëèòèêè                      

                                                        

  │G04BC               │Ïðåïàðàòû äëÿ ëå÷åíèÿ              

                      │íåôðîóðîëèòèàçà                   

                                                        

  │G04BD               │Ñïàçìîëèòèêè                      

  │G04BD02             │Ôëàâîêñàò                         

  │G04BD04             │Îêñèáóòèíèí                       

                                                        

  │G04BE               │Ïðåïàðàòû äëÿ ëå÷åíèÿ íàðóøåíèé   

                      │ýðåêöèè                           

                                                        

  │G04BE04             │Éîõèìáèí                          

                                                        

  │G04BX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │óðîëîãè÷åñêèõ çàáîëåâàíèé         

                                                        

  │G04C                │Ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │äîáðîêà÷åñòâåííîé ãèïåðòðîôèè     

                      │ïðîñòàòû                           

                                                        

  │G04CA               │Àëüôà-àäðåíîáëîêàòîðû             

  │G04CA01             │Àëüôóçîçèí                        

  │G04CA02             │Òàìñóëîçèí                         

                                                        

  │G04CB               │Òåñòîñòåðîíà5-àëüôà ðåäóêòàçû     

                      │èíãèáèòîðû                        

                                                        

  │G04CB01             │Ôèíàñòåðèä                        

                                                        

  │G04CX               │Ïðî÷èå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │äîáðîêà÷åñòâåííîé ãèïåðòðîôèè     

                      │ïðîñòàòû                          

                                                        

  │G04CX01             │Ñëèâû àôðèêàíñêîé ïðåïàðàò        

  │G04CX02             │Ïàëüìû ïîëçó÷åé ïðåïàðàò          

                                                        

  │H01                 │Ãèïîòàëàìî-ãèïîôèçàðíûå ãîðìîíû è 

                      │èõ àíàëîãè                        

                                                        

  │H01A                │Ãîðìîíû ïåðåäíåé äîëè ãèïîôèçà è  

                      │èõ àíàëîãè                        

                                                        

  │H01AA               │ÀÊÒà                             

  │H01AA01             │Êîðòèêîòðîïèí                      

  │H01AA02             │Òåòðàêîçàêòèä                     

  │H01AC               │Ñîìàòðîïèí è åãî àíàëîãè          

  │H01AC01             │Ñîìàòðîïèí                        

  │H01B                │Ãîðìîíû çàäíåé äîëè ãèïîôèçà      

  │H01BA               │Âàçîïðåññèí è åãî àíàëîãè         

  │H01BA02             │Äåñìîïðåññèí                      

  │H01BA04             │Òåðëèïðåññèí                      

  │H01BB               │Îêñèòîöèí è åãî ïðîèçâîäíûå       

  │H01BB01             │Äåìîêñèòîöèí                      

  │H01BB02             │Îêñèòîöèí                         

  │H01C                │Ãîðìîíû ãèïîòàëàìóñà              

  │H01CA               │Ãîíàäîòðîïèí-ðåëèçèíã ãîðìîíû     

  │H01CA01             │Ãîíàäîðåëèí                       

  │H01CA02             │Íàôàðåëèí                         

  │H01CB               │Ãîðìîíû, çàìåäëÿþùèå ðîñò         

  │H01CB01             │Ñîìàòîñòàòèí                      

  │H01CB02             │Îêòðåîòèä                          

  │H01CB03             │Ëàíðåîòèä                         

                                                        

  │H02                 │Êîðòèêîñòåðîèäû äëÿ ñèñòåìíîãî    

                      │èñïîëüçîâàíèÿ                     

                                                        

  │H02A                │Êîðòèêîñòåðîèäû äëÿ ñèñòåìíîãî    

                      │èñïîëüçîâàíèÿ                     

                                                         

  │H02AA               │Ìèíåðàëîêîðòèêîñòåðîèäû           

  │H02AA02             │Ôëóäðîêîðòèçîí                    

  │H02AA03             │Äåçîêñèêîðòîí                     

  │H02AB               │Ãëþêîêîðòèêîñòåðîèäû               

  │H02AB01             │Áåòàìåòàçîí                       

  │H02AB02             │Äåêñàìåòàçîí                      

  │H02AB04             │Ìåòèëïðåäíèçîëîí                  

  │H02AB06             │Ïðåäíèçîëîí                       

  │H02AB07             │Ïðåäíèçîí                         

  │H02AB08             │Òðèàìöèíîëîí                      

  │H02AB09             │Ãèäðîêîðòèçîí                     

  │H02AB10             │Êîðòèçîí                          

                                                        

  │H03                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ùèòîâèäíîé æåëåçû                 

                                                        

  │H03A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ùèòîâèäíîé æåëåçû                 

                                                        

  │H03AA               │Ùèòîâèäíîé æåëåçû ãîðìîíû         

  │H03AA01             │Ëåâîòèðîêñèí                      

  │H03AA02             │Ëèîòèðîíèí                        

                                                        

  │H03AA03             │Ëåâîòèðîêñèí â êîìáèíàöèè ñ       

                      │ëèîòèðîíèíîì                      

                                                        

  │H03AA05             │Ïðåïàðàòû èç òêàíè ùèòîâèäíîé     

                      │æåëåçû                            

                                                         

  │H03B                │Àíòèòèðåîèäíûå ïðåïàðàòû          

  │H03BA               │Òèîóðàöèëû                        

  │H03BA02             │Ïðîïèëòèîóðàöèë                   

                                                         

  │H03BB               │Ñåðà-ñîäåðæàùèå ïðîèçâîäíûå       

                      │èìèäàçîëà                         

                                                        

  │H03BB02             │Òèàìàçîë                          

  │H03BC               │Ïåðõëîðàòû                        

  │H03BC01             │Êàëèÿ ïåðõëîðàò                   

  │H03BX               │Àíòèòèðåîèäíûå ïðåïàðàòû ïðî÷èå   

  │H03C                │Ïðåïàðàòû éîäà                    

  │H03CA               │Ïðåïàðàòû éîäà                    

  │H04                 │Ãîðìîíû ïîäæåëóäî÷íîé æåëåçû      

  │H04A                │Ãîðìîíû, ðàñùåïëÿþùèå ãëèêîãåí    

  │H04AA               │Ãîðìîíû, ðàñùåïëÿþùèå ãëèêîãåí    

  │H04AA01             │Ãëþêàãîí                          

                                                        

  │H05                 │Ãîðìîíû äëÿ ëå÷åíèÿ çàáîëåâàíèé   

                      │ïàðàùèòîâèäíîé æåëåçû             

                                                         

  │H05B                │Àíòèïàðàòèðåîèäíûå ãîðìîíû        

  │H05BA               │Ïðåïàðàòû êàëüöèîòîíèíà           

  │H05BA01             │Êàëüöèòîíèí                       

                                                        

  │J01                 │Àíòèáàêòåðèàëüíûå ïðåïàðàòû äëÿ   

                      │ñèñòåìíîãî èñïîëüçîâàíèÿ          

                                                        

  │J01A                │Òåòðàöèêëèíû                      

  │J01AA               │Òåòðàöèêëèíû                      

  │J01AA02             │Äîêñèöèêëèí                       

  │J01AA05             │Ìåòàöèêëèí                        

  │J01AA07             │Òåòðàöèêëèí                        

  │J01AA08             │Ìèíîöèêëèí                        

  │J01B                │Àìôåíèêîëû                        

  │J01BA               │Àìôåíèêîëû                        

  │J01BA01             │Õëîðàìôåíèêîë                     

  │J01BA02             │Òèàìôåíèêîë                       

                                                        

  │J01C                │Áåòà-ëàêòàìíûå àíòèáàêòåðèàëüíûå  

                      │ïðåïàðàòû - Ïåíèöèëëèíû           

                                                        

  │J01CA               │Ïåíèöèëèíû øèðîêîãî ñïåêòðà       

                      │äåéñòâèÿ                          

                                                        

  │J01CA01             │Àìïèöèëëèí                        

  │J01CA03             │Êàðáåíèöèëëèí                     

  │J01CA04             │Àìîêñèöèëëèí                      

  │J01CA06             │Áàêàìïèöèëëèí                     

  │J01CA09             │Àçëîöèëëèí                         

  │J01CA12             │Ïèïåðàöèëëèí                      

  │J01CA20             │Êîìáèíèðîâàííûå ïðåïàðàòû         

                                                        

  │J01CE               │Ïåíèöèëëèíû                       

                      │ïåíèöèëëèíàçà-÷óâñòâèòåëüíûå      

                                                        

  │J01CE01             │Áåíçèëïåíèöèëëèí                  

  │J01CE02             │Ôåíîêñèìåòèëïåíèöèëëèí            

  │J01CE06             │Ïåíàìåöèëëèí                      

  │J01CE08             │Áåíçàòèí áåíçèëïåíèöèëëèí         

  │J01CE09             │Ïåíèöèëëèí ïðîêàèí                

  │J01CE30             │Êîìáèíèðîâàííûå ïðåïàðàòû         

                                                        

  │J01CF               │Ïåíèöèëëèíû                       

                      │ïåíèöèëëèíàçà-óñòîé÷èâûå          

                                                        

  │J01CF01             │Äèêëîêñàöèëëèí                    

  │J01CF02             │Êëîêñàöèëëèí                      

  │J01CF04             │Îêñàöèëëèí                        

  │J01CF05             │Ôëóêëîêñàöèëëèí                   

  │J01CG               │Èíãèáèòîðû áåòà-ëàêòàìàç          

  │J01CG01             │Ñóëüáàêòàì                        

                                                        

  │J01CR               │Ïåíèöèëëèíû â êîìáèíàöèè ñ        

                      │èíãèáèòîðàìè áåòà-ëàêòàìàç        

                                                        

  │J01CR01             │Àìïèöèëëèí â êîìáèíàöèè ñ         

                      │èíãèáèòîðàìè áåòà-ëàêòàìàç        

                                                         

  │J01CR02             │Êëàâóëàíîâàÿ êèñëîòà+àìîêñèöèëëèí 

  │J01CR03             │Êëàâóëàíîâàÿ êèñëîòà+òèêàðöèëëèí  

  │J01CR04             │Ñóëüòàìèöèëëèí                    

                                                        

  │J01CR05             │Ïèïåðàöèëëèí â êîìáèíàöèè ñ       

                      │èíãèáèòîðàìè áåòà-ëàêòàìàç        

                                                        

  │J01CR50             │Êîìáèíàöèÿ ïåíèöèëëèíîâ           

                                                        

  │J01D                │Áåòà-ëàêòàìíûå àíòèáàêòåðèàëüíûå  

                      │ïðåïàðàòû ïðî÷èå                  

                                                         

  │J01DA               │Öåôàëîñïîðèíû                     

  │J01DA01             │Öåôàëåêñèí                        

  │J01DA03             │Öåôàëîòèí                         

  │J01DA04             │Öåôàçîëèí                         

  │J01DA05             │Öåôîêñèòèí                        

  │J01DA06             │Öåôóðîêñèì                        

  │J01DA07             │Öåôàìàíäîë                        

  │J01DA08             │Öåôàêëîð                          

  │J01DA09             │Öåôàäðîêñèë                       

  │J01DA10             │Öåôîòàêñèì                        

  │J01DA11             │Öåôòàçèäèì                        

  │J01DA13             │Öåôòðèàêñîí                       

  │J01DA14             │Öåôîòåòàí                         

  │J01DA22             │Öåôòèçîêñèì                       

  │J01DA23             │Öåôèêñèì                          

  │J01DA24             │Öåôåïèì                           

  │J01DA25             │Öåôîäèçèì                          

  │J01DA27             │Öåôïèðàìèä                        

  │J01DA30             │Öåôàïèðèí                         

  │J01DA31             │Öåôðàäèí                          

  │J01DA32             │Öåôîïåðàçîí                       

  │J01DA33             │Öåôïîäîêñèì                       

  │J01DA37             │Öåôïèðîì                          

  │J01DA39             │Öåôòèáóòåí                        

  │J01DA40             │Öåôìåòàçîë                         

  │J01DF               │Ìîíîáàêòàìû                       

  │J01DF01             │Àçòðåîíàì                         

  │J01DH               │Êàðáàïåíåìû                       

  │J01DH02             │Ìåðîïåíåì                          

  │J01DH51             │Èìèïåíåì                          

  │J01E                │Ñóëüôàíèëàìèäû è òðèìåòîïðèì      

  │J01EA               │Òðèìåòîïðèì è åãî ïðîèçâîäíûå     

  │J01EA01             │Òðèìåòîïðèì                       

  │J01EB               │Ñóëüôàíèëàìèäû êîðîòêîãî äåéñòâèÿ 

  │J01EB03             │Ñóëüôàäèìèäèí                     

  │J01EB06             │Ñóëüôàíèëàìèä                     

  │J01EB07             │Ñóëüôàòèàçîë                      

                                                        

  │J01EC               │Ñóëüôàíèëàìèäû ñðåäíåé            

                      │äëèòåëüíîñòè äåéñòâèÿ             

                                                        

  │J01EC02             │Ñóëüôàäèàçèí                      

  │J01ED               │Ñóëüôàíèëàìèäû äëèòåëüíîãî äåéñòâèÿ│

  │J01ED01             │Ñóëüôàäèìåòîêñèí                  

  │J01ED02             │Ñóëüôàëåí                         

  │J01ED05             │Ñóëüôàìåòîêñèïèðèäàçèí            

                                                        

  │J01EE               │Ñóëüôàíèëàìèäû â êîìáèíàöèè ñ     

                      │òðèìåòîïðèìîì è åãî ïðîèçâîäíûìè  

                                                        

  │J01EE01             │Êî-òðèìîêñàçîë                    

                                                        

  │J01EE02             │Ñóëüôàäèàçèí â êîìáèíàöèè ñ       

                      │òðèìåòîïðèìîì                     

                                                        

  │J01EE03             │Ñóëüôàìåòðîë â êîìáèíàöèè ñ       

                      │òðèìåòîïðèìîì                     

                                                         

  │J01F                │Ìàêðîëèäû è ëèíêîçàìèäû           

  │J01FA               │Ìàêðîëèäû                         

  │J01FA01             │Ýðèòðîìèöèí                       

  │J01FA02             │Ñïèðàìèöèí                        

  │J01FA03             │Ìèäåêàìèöèí                       

  │J01FA05             │Îëåàíäîìèöèí                      

  │J01FA06             │Ðîêñèòðîìèöèí                     

  │J01FA07             │Äæîçàìèöèí                        

  │J01FA09             │Êëàðèòðîìèöèí                     

  │J01FA10             │Àçèòðîìèöèí                       

  │J01FF               │Ëèíêîçàìèäû                       

  │J01FF01             │Êëèíäàìèöèí                       

  │J01FF02             │Ëèíêîìèöèí                        

                                                        

  │J01G                │Àìèíîãëèêîçèäíûå àíòèáàêòåðèàëüíûå │

                      │ïðåïàðàòû                         

                                                         

  │J01GA               │Ñòðåïòîìèöèíû                     

  │J01GA01             │Ñòðåïòîìèöèí                      

  │J01GB               │Äðóãèå àìèíîãëèêîçèäû             

  │J01GB01             │Òîáðàìèöèí                        

  │J01GB03             │Ãåíòàìèöèí                        

  │J01GB04             │Êàíàìèöèí                         

  │J01GB06             │Àìèêàöèí                          

  │J01GB07             │Íåòèëìèöèí                         

  │J01GB08             │Ñèçîìèöèí                         

                                                        

  │J01M                │Ïðîòèâîìèêðîáíûå ïðåïàðàòû -      

                      │ïðîèçâîäíûå õèíîëîíà               

                                                        

  │J01MA               │Ôòîðõèíîëîíû                      

  │J01MA01             │Îôëîêñàöèí                        

  │J01MA02             │Öèïðîôëîêñàöèí                    

  │J01MA03             │Ïåôëîêñàöèí                       

  │J01MA04             │Ýíîêñàöèí                         

  │J01MA06             │Íîðôëîêñàöèí                      

  │J01MA07             │Ëîìåôëîêñàöèí                     

                                                        

  │J01MB               │Äðóãèå õèíîëîíû (èñêëþ÷àÿ         

                      │ïåðå÷èñëåííûå â ï. G04AB)         

                                                        

  │J01R                │Êîìáèíàöèÿ ïðîòèâîìèêðîáíûõ       

                      │ïðåïàðàòîâ                        

                                                        

  │J01RA               │Êîìáèíàöèÿ àíòèáèìèêðîáíûõ        

                      │ïðåïàðàòîâ                         

                                                        

  │J01X                │Äðóãèå àíòèáàêòåðèàëüíûå ïðåïàðàòû │

                                                        

  │J01XA               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû       

                      │ãëèêîïåïòèäíîé ñòðóêòóðû          

                                                        

  │J01XA01             │Âàíêîìèöèí                        

  │J01XB               │Ïîëèìèêñèíû                        

  │J01XB01             │Êîëèñòèí                          

  │J01XB02             │Ïîëèìèêñèí                        

  │J01XC               │Àíòèáèîòèêè ñòåðîèäíîé ñòðóêòóðû  

  │J01XC01             │Ôóçèäèåâàÿ êèñëîòà                

  │J01XD               │Ïðîèçâîäíûå èìèäàçîëà             

  │J01XD01             │Ìåòðîíèäàçîë                      

  │J01XD02             │Òèíèäàçîë                         

  │J01XD03             │Îðíèäàçîë                         

  │J01XX               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû ïðî÷èå │

  │J01XX01             │Ôîñôîìèöèí                        

  │J01XX04             │Ñïåêòèíîìèöèí                     

                                                        

  │J02                 │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ñèñòåìíîãî èñïîëüçîâàíèÿ          

                                                        

  │J02A                │Ïðîòèâîãðèáêîâûå ïðåïàðàòû äëÿ    

                      │ñèñòåìíîãî èñïîëüçîâàíèÿ          

                                                        

  │J02AB               │Èìèäàçîëà ïðîèçâîäíûå             

  │J02AB02             │Êåòîêîíàçîë                       

  │J02AC               │Òðèàçîëà ïðîèçâîäíûå               

  │J02AC01             │Ôëóêîíàçîë                        

  │J02AC02             │Èòðàêîíàçîë                       

  │J04                 │Ïðîòèâîòóáåðêóëåçíûå ïðåïàðàòû    

  │J04A                │Ïðîòèâîòóáåðêóëåçíûå ïðåïàðàòû    

                                                        

  │J04AA               │Àìèíîñàëèöèëîâàÿ êèñëîòà è åå     

                      │ïðîèçâîäíûå                       

                                                        

  │J04AA01             │Àìèíîñàëèöèëîâàÿ êèñëîòà          

  │J04AB               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû       

  │J04AB01             │Öèêëîñåðèí                        

  │J04AB02             │Ðèôàìïèöèí                        

  │J04AB04             │Ðèôàáóòèí                         

  │J04AB30             │Êàïðåîìèöèí                       

  │J04AC               │Ãèäðàçèäû                         

  │J04AC01             │Èçîíèàçèä                         

  │J04AD               │Ïðîèçâîäíûå òèîêàðáàìèäà          

  │J04AD01             │Ïðîòèîíàìèä                       

  │J04AD03             │Ýòèîíàìèä                         

                                                        

  │J04AK               │Ïðîòèâîòóáåðêóëåçíûå ïðåïàðàòû    

                      │ïðî÷èå                            

                                                        

  │J04AK01             │Ïèðàçèíàìèä                       

  │J04AK02             │Ýòàìáóòîë                         

                                                        

  │J04AM               │Ïðîòèâîòóáåðêóëåçíûõ ïðåïàðàòîâ   

                      │êîìáèíàöèÿ                        

                                                        

  │J04AM01             │Ñòðåïòîìèöèí â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │J04AM02             │Ðèôàìïèöèí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │J04B                │Ïðîòèâîëåïðîçîéíûå ïðåïàðàòû      

  │J04BA               │Ïðîòèâîëåïðîçîéíûå ïðåïàðàòû      

  │J04BA02             │Äàïñîí                             

                                                        

  │J05                 │Ïðîòèâîâèðóñíûå ïðåïàðàòû äëÿ     

                      │ñèñòåìíîãî ïðèìåíåíèÿ             

                                                         

  │J05A                │Ïðîòèâîâèðóñíûå ïðåïàðàòû ïðÿìîãî 

                      │äåéñòâèÿ                          

                                                        

  │J05AB               │Íóêëåîòèäû                        

  │J05AB01             │Àöèêëîâèð                         

  │J05AB04             │Ðèáàâèðèí                         

  │J05AB05             │Çèäîâóäèí                         

  │J05AB06             │Ãàíöèêëîâèð                       

  │J05AB07             │Äèäàíîçèí                         

  │J05AB08             │Çàëöèòàáèí                        

  │J05AB09             │Ôàìöèêëîâèð                       

  │J05AB10             │Ëàìèâóäèí                         

  │J05AB11             │Âàëàöèêëîâèð                      

  │J05AC               │Öèêëè÷åñêèå àìèíû                 

  │J05AC02             │Ðèìàíòàäèí                        

  │J05AD               │Ôîñôîíîâîé êèñëîòû ïðîèçâîäíûå    

  │J05AD01             │Ôîñêàðíåò íàòðèÿ                  

  │J05AE               │HIV-ïðîòåèíàçû èíãèáèòîðû         

  │J05AE01             │Ñàãâèíàâèð                        

  │J05AE02             │Èíäèíàâèð                         

  │J05AE04             │Íåëôèíàâèð                        

  │J05AX               │Ïðîòèâîâèðóñíûå ïðåïàðàòû ïðî÷èå  

  │J05AX04             │Ñòàâóäèí                          

  │J05AX05             │Èíîçèí Ïðàíîáåêñ                  

                                                         

  │J06                 │Èììóííàÿ ñûâîðîòêà è              

                      │èììóíîãëîáóëèíû                   

                                                        

  │J06A                │Èììóííàÿ ñûâîðîòêà                 

  │J06AA               │Èììóííàÿ ñûâîðîòêà                

  │J06AA01             │Äèôòåðèéíûé àíàòîêñèí             

  │J06AA02             │Ñòîëáíÿ÷íûé àíàòîêñèí             

  │J06AA03             │Çìåèíàÿ àíòèñûâîðîòêà             

  │J06AA04             │Áîòóëèíîâûé àíòèòîêñèí            

  │J06AA05             │Àíòèãàíãðåíîçíàÿ ñûâîðîòêà        

  │J06B                │Èììóíîãëîáóëèíû                   

                                                        

  │J06BA               │Èììóíîãëîáóëèíû îáû÷íûé           

                      │÷åëîâå÷åñêèé                      

                                                        

  │J06BA02             │Èììóíîãëîáóëèí (â/â ââåäåíèå)     

  │J06BB               │Èììóíîãëîáóëèíû ñïåöèôè÷åñêèå     

  │J06BB01             │Èììóíîãëîáóëèí Àíòè-D(Rh)         

  │J06BB02             │Èììóíîãëîáóëèí ïðîòèâ ñòîëáíÿêà   

  │J06BB04             │Èììóíîãëîáóëèí ïðîòèâ ãåïàòèòà B  

  │J06BB05             │Èììóíîãëîáóëèí ïðîòèâ áåøåíñòâà   

  │J06BB08             │Èììóíîãëîáóëèí ñòàôèëîêîêêîâûé    

  │J06BB10             │Èììóíîãëîáóëèí ïðîòèâîäèôòåðèéíûé 

                                                        

  │J06BB12             │Èììóíîãëîáóëèí ïðîòèâ êëåùåâîãî   

                      │ýíöåôàëèòà                        

                                                        

  │J06BB13             │Èììóíîãëîáóëèí ïðîòèâîêîêëþøíûé   

  │J06BC               │Äðóãèå èììóíîãëîáóëèíû            

  │J07                 │Âàêöèíû                           

  │J07A                │Ïðîòèâîáàêòåðèàëüíûå âàêöèíû      

  │J07AC               │Ïðîòèâîñèáèðåÿçâåííûå âàêöèíû     

  │J07AC01             │Ñèáèðåÿçâåííûé àíòèãåí             

  │J07AD               │Ïðîòèâîáðóöåëëåçíûå âàêöèíû       

  │J07AD01             │Áðóöåëëåçíûé àíòèãåí              

  │J07AE               │Ïðîòèâîõîëåðíûå âàêöèíû           

                                                        

  │J07AE01             │Èíàêòèâèðîâàííûé öåëüíûé âèáðèîí  

                      │õîëåðû                            

                                                        

  │J07AE02             │Æèâîé îñëàáëåííûé âèáðèîí õîëåðû  

                                                        

  │J07AG               │Âàêöèíû ïðîòèâ Hemophilus         

                      │influenza B                       

                                                        

  │J07AG01             │Âàêöèíà ïðîòèâ Hemophilus         

                      │influenza B, êîíúþãèðîâàííàÿ      

                                                        

  │J07AH               │Ïðîòèâîìåíèíãîêîêêîâûå âàêöèíû    

                                                         

  │J07AH01             │Ìåíèíãîêîêêîâûé A î÷èùåííûé       

                      │ïîëèñàõàðèäíûé àíòèãåí            

                                                        

  │J07AH05             │Äðóãèå ìåíèíãîêîêêîâûå            

                      │ïîëèâàëåíòíûå î÷èùåííûå           

                      │ïîëèñàõàðèäíûå àíòèãåíû           

                                                        

  │J07AK               │Ïðîòèâî÷óìíûå âàêöèíû             

                                                        

  │J07AK01             │×óìíàÿ âàêöèíà - èíàêòèâèðîâàííûå 

                      │öåëüíûå áàêòåðèè                  

                                                         

  │J07AM               │Ïðîòèâîñòîëáíÿ÷íûå âàêöèíû        

                                                        

  │J07AM51             │Ñòîëáíÿ÷íûé òîêñèí â êîìáèíàöè ñ  

                      │äèôòåðèéíûì òîêñèíîì              

                                                        

  │J07AN               │Ïðîòèâîòóáåðêóëåçíûå âàêöèíû      

                                                        

  │J07AN01             │Òóáåðêóëåçíàÿ æèâàÿ îñëàáëåííàÿ   

                      │âàêöèíà                           

                                                        

  │J07AP               │Ïðîòèâîáðþøíîòèôîçíûå âàêöèíû     

                                                        

  │J07AP01             │Áðþøíîòèôîçíûå áàêòåðèè æèâûå     

                      │îñëàáëåííûå - äëÿ ïåðîðàëüíîãî    

                      │ïðèåìà                            

                                                        

  │J07AP03             │Áðþøíîòèôîçíûõ áàêòåðèé î÷èùåííûé 

                      │ïîëèñàõàðèäíûé àíòèãåí            

                                                        

  │J07AR               │Ïðîòèâîñûïíîòèôîçíûå âàêöèíû      

                                                        

  │J07AR01             │Ñûïíîãî òèôà âîçáóäèòåëè -        

                      │èíàêòèâèðîâàííûå öåëüíûå áàêòåðèè 

                                                        

  │J07AX               │Äðóãèå ïðîòèâîáàêòåðèàëüíûå âàêöèíû│

  │J07B                │Ïðîòèâîâèðóñíûå âàêöèíû           

  │J07BA               │Ïðîòèâîýíöåôàëèòíûå âàêöèíû       

                                                        

  │J07BA01             │Âèðóñ êëåùåâîãî ýíöåôàëèòà -      

                      │èíàêòèâèðîâàííûé öåëüíûé âèðóñ    

                                                        

  │J07BA02             │Âèðóñ ÿïîíñêîãî ýíöåôàëèòà -      

                      │èíàêòèâèðîâàííûé öåëüíûé âèðóñ    

                                                        

  │J07BB               │Ïðîòèâîãðèïïîçíûå âàêöèíû         

                                                        

  │J07BB01             │Âèðóñ ãðèïïà - èíàêòèâèðîâàííûé   

                      │öåëüíûé âèðóñ                     

                                                        

  │J07BC               │Ïðîòèâîãåïàòèòíûå âàêöèíû         

                                                        

  │J07BC01             │Âèðóñ ãåïàòèòà B - î÷èùåííûé      

                      │àíòèãåí                           

                                                        

  │J07BC02             │Âèðóñ ãåïàòàòèòà A - î÷èùåííûé    

                      │àíòèãåí                            

                                                        

  │J07BD               │Ïðîòèâîêîðåâûå âàêöèíû            

  │J07BD01             │Âèðóñ êîðè - æèâîé îñëàáëåííûé    

                                                        

  │J07BD52             │Âèðóñ êîðè â êîìáèíàöèè ñ âèðóñàìè │

                      │ïàðîòèòà è êðàñíóõè - æèâîé       

                      │îñëàáëåííûé                       

                                                         

  │J07BE               │Ïðîòèâîïàðîòèòíûå âàêöèíû         

  │J07BE01             │Âèðóñ ïàðòîòèòà - æèâîé îñëåáëåííûé│

  │J07BF               │Ïðîòèâîïîëèîìèåëèòíûå âàêöèíû     

                                                         

  │J07BF02             │Âèðóñ ïîëèåìèåëèòà - òðåõâàëåíòíûé │

                      │äëÿ ïåðîðàëüíîãî ïðèåìà           

                                                        

  │J07BF03             │Âèðóñ ïîëèåìèåëèòà - òðåõâàëåíòíûé │

                      │èíàêòèâèðîâàííûé                  

                                                        

  │J07BG               │Âàêöèíû ïðîòèâ áåøåíñòâà          

                                                        

  │J07BG01             │Âèðóñ áåøåíñòâà - èíàêòèâèðîâàííûé │

                      │öåëüíûé                           

                                                        

  │J07BJ               │Âàêöèíû ïðîòèâ êðàñíóõè           

  │J07BJ01             │Âèðóñ êðàñíóõè - æèâîé îñëàáëåííûé │

  │J07BL               │Âàêöèíû ïðîòèâ æåëòîé ëèõîðàäêè   

                                                        

  │J07BL01             │Âèðóñ æåëòîé ëèõîðàäêè -          

                      │îñëàáëåííûé æèâîé                 

                                                        

  │J07BX               │Äðóãèå ïðîòèâîâèðóñíûå âàêöèíû    

                                                        

  │J07C                │Êîìáèíàöèÿ ïðîòèâîâèðóñíûõ è      

                      │ïðîòèâîáàêòåðèàëüíûõ âàêöèí       

                                                        

  │J07CA               │Êîìáèíàöèÿ ïðîòèâîâèðóñíûõ è      

                      │ïðîòèâîáàêòåðèàëüíûõ âàêöèí       

                                                        

  │J07CA02             │Âàêöèíà ïðîòèâ                    

                      │äèôòåðèè-êîêëþøà-ñòîëáíÿêà        

                                                         

  │L01                 │Ïðîòèâîîïóõîëåâûå ïðåïàðàòû       

  │L01A                │Àëêèëèðóþùèå ïðåïàðàòû            

  │L01AA               │Àçîòèñòîãî èïðèòà ïðîèçâîäíûå     

  │L01AA01             │Öèêëîôîñôàìèä                     

  │L01AA02             │Õëîðàìáóöèë                       

  │L01AA03             │Ìåëôàëàí                          

  │L01AA06             │Èôîñôàìèä                         

  │L01AB               │Àëêèëñóëüôîíàòû                   

  │L01AB01             │Áóñóëüôàí                         

  │L01AC               │Ýòèëåíèìèíà ïðîèçâîäíûå           

  │L01AC01             │Òèîòåïà                           

  │L01AD               │Íèòðîçîìî÷åâèíû ïðîèçâîäíûå       

  │L01AD01             │Êàðìóñòèí                         

  │L01AD02             │Ëîìóñòèí                          

  │L01AD04             │Ñòðåïòîçîöèí                      

  │L01AD05             │Ôîòåìóñòèí                        

  │L01AD06             │Íèìóñòèí                           

  │L01AX               │Àëêèëèðóþùèå ïðåïàðàòû ïðî÷èå     

  │L01AX04             │Äàêàðáàçèí                        

  │L01B                │Àíòèìåòàáîëèòû                    

  │L01BA               │Ôîëèåâîé êèñëîòû àíàëîãè          

  │L01BA01             │Ìåòîòðåêñàò                       

  │L01BB               │Ïóðèíîâûå àíàëîãè                 

  │L01BB02             │Ìåðêàïòîïóðèí                     

  │L01BB03             │Òèîãóàíèí                          

  │L01BB05             │Ôëóäàðàáèí                        

  │L01BC               │Ïèðèìèäèíîâûå àíàëîãè             

  │L01BC01             │Öèòàðàáèí                         

  │L01BC02             │Ôòîðóðàöèë                         

  │L01BC03             │Òåãàôóð                           

  │L01BC05             │Ãåìöèòàáèí                        

                                                        

  │L01BC52             │Ôòîðóðàöèë â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │L01C                │Àëêàëîèäû ðàñòèòåëüíîãî           

                      │ïðîèñõîæäåíèÿ                     

                                                        

  │L01CA               │Áàðâèíêà àëêàëîèäû è åãî àíàëîãè  

  │L01CA01             │Âèíáëàñòèí                        

  │L01CA02             │Âèíêðèñòèí                        

  │L01CA03             │Âèíäåñèí                          

  │L01CA04             │Âèíîðåëüáèí                       

  │L01CB               │Ïîäîôèëëîòîêñèíà ïðîèçâîäíûå      

  │L01CB01             │Ýòîïîçèä                          

  │L01CB02             │Òåíèïîçèä                          

  │L01CC               │Êîëõèöèíà ïðîèçâîäíûå             

  │L01CC01             │Äåìåêîëöèí                        

  │L01CD               │Òàêñàíû                           

  │L01CD01             │Ïàêëèòàêñåë                       

  │L01CD02             │Äîöåòàêñåë                        

  │L01D                │Ïðîòèâîîïóõîëåâûå àíòèáèîòèêè     

  │L01DA               │Àêòèíîìèöèíû                      

  │L01DA01             │Äàêòèíîìèöèí                      

  │L01DB               │Àíòðàöèêëèíû                      

  │L01DB01             │Äîêñîðóáèöèí                      

  │L01DB02             │Äàóíîðóáèöèí                      

  │L01DB03             │Ýïèðóáèöèí                         

  │L01DB06             │Èäàðóáèöèí                        

  │L01DB07             │Ìèòîêñàíòðîí                      

                                                        

  │L01DC               │Ïðîòèâîîïóõîëåâûå àíòèáèîòèêè     

                      │äðóãèå                            

                                                        

  │L01DC01             │Áëåîìèöèí                         

  │L01DC03             │Ìèòîìèöèí                         

  │L01X                │Ïðîòèâîîïóõîëåâûå ïðåïàðàòû äðóãèå │

  │L01XA               │Ïëàòèíà-ñîäåðæàùèå ïðåïàðàòû      

  │L01XA01             │Öèñïëàòèí                         

  │L01XA02             │Êàðáîïëàòèí                       

  │L01XB               │Ìåòèëãèäðàçèíû                    

  │L01XB01             │Ïðîêàðáàçèí                       

  │L01XX               │ïðîòèâîîïóõîëåâûå ïðåïàðàòû ïðî÷èå │

  │L01XX01             │Àìñàêðèí                          

  │L01XX02             │Àñïàðàãèíàçà                      

  │L01XX03             │Àëòðåòàìèí                        

  │L01XX05             │Ãèäðîêñèêàðáàìèä                  

  │L01XX11             │Ýñòðàìóñòèí                       

  │L01XX14             │Òðåòèíîèí                          

  │L01XX19             │Èðèíîòåêàí                        

                                                        

  │L01XY               │Ïðîòèâîîïóõîëåâûõ ïðåïàðàòîâ      

                      │êîìáèíàöèÿ                         

                                                        

  │L02                 │Ïðîòèâîîïóõîëåâûå ãîðìîíàëüíûå    

                      │ïðåïàðàòû                         

                                                        

  │L02A                │Ãîðìîíû è èõ ïðîèçâîäíûå          

  │L02AA               │Ýñòðîãåíû                         

  │L02AA04             │Ôîñôåñòðîë                        

  │L02AB               │Ïðîãåñòàãåíû                      

                                                        

  │L02AE               │Ãîíàäîòðîïèí-ðåëèçèíã ãîðìîíà     

                      │àíàëîãè                           

                                                        

  │L02AE01             │Áóñåðåëèí                         

  │L02AE02             │Ëåéïðîðåëèí                       

  │L02AE03             │Ãîçåðåëèí                         

  │L02AE04             │Òðèïòîðåëèí                       

  │L02B                │Ãîðìîíîâ àíòàãîíèñòû è èõ àíàëîãè 

  │L02BA               │Àíòèýñòðîãåíû                     

  │L02BA01             │Òàìîêñèôåí                        

  │L02BA02             │Òîðåìèôåí                         

  │L02BB               │Àíòèàíäðîãåíû                      

  │L02BB01             │Ôëóòàìèä                          

  │L02BB02             │Íèëóòàìèä                         

  │L02BB03             │Áèêàëóòàìèä                       

  │L02BG               │Ôåðìåíòîâ èíãèáèòîðû              

  │L02BG01             │Àìèíîãëþòåòèìèä                   

  │L02BG03             │Àíàñòðîçîë                        

  │L02BG04             │Ëåòðîçîë                          

  │L03                 │Èììóíîìîäóëÿòîðû                  

  │L03A                │Èììóíîñòèìóëÿòîðû                 

  │L03AA               │Öèòîêèíèíû                        

  │L03AA01             │Àëäåñëåéêèí                       

  │L03AA02             │Ôèëãðàñòèì                        

  │L03AA03             │Ìîëãðàìîcòèì                      

  │L03AA04             │Èíòåðôåðîí àëüôà                  

  │L03AA10             │Ëåíîãðàñòèì                       

  │L03AA11             │Èíòåðôåðîí áåòà                   

  │L03AX               │Èììóíîñòèìóëÿòîðû äðóãèå          

  │L04                 │Èììóíîäåïðåññàíòû                 

  │L04A                │Èììóíîäåïðåññàíòû                 

  │L04AA               │Èììóíîäåïðåññàíòû ñåëåêòèâíûå     

  │L04AA01             │Öèêëîñïîðèí                        

  │L04AA02             │Ìóðîìîíàá-ÖÄ3                     

  │L04AA03             │Èììóíîãëîáóëèí àíòèëèìôîöèòàðíûé  

  │L04AA04             │Èììóíîãëîáóëèí àíòèòèìîöèòàðíûé   

  │L04AA06             │Ìîôåòèëà ìèêîôåíîëàò              

  │L04AX               │Èììóíîäåïðåññàíòû äðóãèå          

  │L04AX01             │Àçàòèîïðèí                        

                                                        

  │M01                 │Ïðîòèâîâîñïàëèòåëüíûå è           

                      │ïðîòèâîðåâìàòè÷åñêèå ïðåïàðàòû    

                                                        

  │M01A                │Íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå │

                      │ïðåïàðàòû                         

                                                        

  │M01AA               │Áóòèëïèðàçîëèäîíû                 

  │M01AA05             │Êëîôåçîí                          

  │M01AB               │Óêñóñíîé êèñëîòû ïðîèçâîäíûå      

  │M01AB01             │Èíäîìåòàöèí                        

  │M01AB02             │Ñóëèíäàê                          

  │M01AB03             │Òîëìåòèí                          

  │M01AB05             │Äèêëîôåíàê                        

  │M01AB08             │Ýòîäîëàê                           

  │M01AB11             │Àöåìåòàöèí                        

  │M01AB15             │Êåòîðîëàê                         

  │M01AB16             │Àöåêëîôåíàê                       

                                                        

  │M01AB55             │Äèêëîôåíàê â ñî÷åòàíèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │M01AC               │Îêñèêàìû                          

  │M01AC02             │Òåíîêñèêàì                        

  │M01AC05             │Ëîðíîêñèêàì                       

  │M01AC06             │Ìåëîêñèêàì                        

  │M01AE               │Ïðîïèîíîâîé êèñëîòû ïðîèçâîäíûå   

  │M01AE02             │Íàïðîêñåí                         

  │M01AE03             │Êåòîïðîôåí                        

  │M01AE04             │Ôåíîïðîôåí                        

  │M01AE09             │Ôëóðáèïðîôåí                      

  │M01AE11             │Òèàïðîôåíîâàÿ êèñëîòà             

                                                        

  │M01AE51             │Èáóïðîôåí â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │M01AG               │Ôåíàìàòû                          

  │M01AG01             │Ìåôåíàìîâàÿ êèñëîòà               

                                                        

  │M01AX               │Íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå │

                      │ïðåïàðàòû äðóãèå                  

                                                        

  │M01AX01             │Íàáóìåòîí                         

  │M01AX02             │Íèôëóìîâàÿ êèñëîòà                 

  │M01AX05             │Ãëþêîçàìèí                        

  │M01AX12             │Ìóêàðòðèí                         

  │M01AX17             │Íèìåñóëèä                         

  │M01AX22             │Ìîðíèôëóìàò                       

                                                        

  │M01B                │Ïðîòèâîâîñïàëèòåëüíûõ ïðåïàðàòîâ  

                      │êîìáèíàöèè                        

                                                        

  │M01BA               │Íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå │

                      │ïðåïàðàòû â êîìáèíàöèè ñ          

                      │ãëþêîêîðòèêîñòåðîèäàìè            

                                                        

  │M01BA01             │Ôåíèëáóòàçîí â êîìáèíàöèè ñ       

                      │ãëþêîêîðòèêîñòåðîèäàìè            

                                                        

  │M01C                │Áàçèñíûå ïðîòèâîâîñïàëèòåëüíûå    

                      │ïðåïàðàòû                          

                                                        

  │M01CB               │Ïðåïàðàòû çîëîòà                  

  │M01CB01             │Íàòðèÿ àóðîòèîìàëàò               

  │M01CB03             │Àóðàíîôèí                         

  │M01CB05             │Àóðîòèîïðîë                       

                                                        

  │M01CC               │Ïåíèöèëëàìèí è åìó ïîäîáíûå       

                      │ïðåïàðàòû                          

                                                        

  │M01CC01             │Ïåíèöèëëàìèí                      

                                                        

  │M02                 │Ïðåïàðàòû äëÿ ìåñòíîãî ëå÷åíèÿ    

                      │çàáîëåâàíèé îïîðíî-äâèãàòåëüíîãî  

                      │àïïàðàòà                          

                                                        

  │M02A                │Ïðåïàðàòû äëÿ ìåñòíîãî ëå÷åíèÿ    

                      │çàáîëåâàíèé îïîðíî-äâèãàòåëüíîãî  

                      │àïïàðàòà                          

                                                        

  │M02AA               │Íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå │

                      │ïðåïàðàòû äëÿ ìåñòíîãî ïðèìåíåíèÿ 

                                                        

  │M02AA01             │Ôåíèëáóòàçîí                      

  │M02AA05             │Áåíçèäàìèí                        

  │M02AA06             │Ýòîôåíàìàò                        

  │M02AA07             │Ïèðîêñèêàì                        

  │M02AA10             │Êåòîïðîôåí                        

  │M02AA13             │Èáóïðîôåí                         

  │M02AA15             │Äèêëîôåíàê                         

  │M02AA17             │Íèôëóìîâàÿ êèñëîòà                

  │M02AA19             │Ôëóðáèïðîôåí                      

  │M02AA23             │Èíäîìåòàöèí                       

  │M02AB               │Ïðåïàðàòû íà îñíîâå ïåðöà         

                                                        

  │M02AC               │Ïðåïàðàòû ñ ïðîèçâîäíûìè          

                      │ñàëèöèëîâîé êèñëîòû               

                                                         

  │M02AX               │Äðóãèå ïðåïàðàòû äëÿ ìåñòíîãî     

                      │ëå÷åíèÿ çàáîëåâàíèé               

                      │îïîðíî-äâèãàòåëüíîãî àïïàðàòà     

                                                         

  │M02AX03             │Äèìåòèë ñóëüôîêñèä                

  │M02AX10             │Ïðî÷èå ïðåïàðàòû                  

  │M03                 │Ìèîðåëàêñàíòû                     

                                                        

  │M03A                │Ìèîðåëàêñàíòû ïåðèôåðè÷åñêîãî     

                      │äåéñòâèÿ                          

                                                        

  │M03AA               │Àëêàëîèäû êóðàðå                  

  │M03AA01             │Àëêóðîíèÿ õëîðèä                  

  │M03AA02             │Òóáîêóðàðèí õëîðèä                

  │M03AB               │Õîëèíà ïðîèçâîäíûå                

  │M03AB01             │Ñóêñàìåòîíèÿ õëîðèä               

                                                        

  │M03AC               │×åòâåðòè÷íûå àììîíèåâûå ñîåäèíåíèÿ │

                      │äðóãèå                            

                                                        

  │M03AC01             │Ïàíêóðîíèÿ áðîìèä                 

  │M03AC03             │Âåêóðîíèÿ áðîìèä                  

  │M03AC04             │Àòðàêóðèÿ áåñèëàò                 

  │M03AC06             │Ïèïåêóðîíèÿ áðîìèä                

  │M03AC10             │Ìèâàêóðèÿ õëîðèäå                 

  │M03AC11             │Öèçàòðàêóðèé                      

                                                        

  │M03AX               │Ìèîðåëàêñàíòû ïåðèôåðè÷åñêîãî     

                      │äåéñòâèÿ äðóãèå                   

                                                        

  │M03AX01             │Áîòóëèíè÷åñêèé òîêñèí             

  │M03B                │Ìèîðåëàêñàíòû öåíòðàëüíîãî äåéñòâèÿ│

                                                         

  │M03BB               │Îêñàçîëà, òèàçèíà è òðèàçèíà      

                      │ïðîèçâîäíûå                       

                                                        

  │M03BB53             │Õëîðçîêñàçîí â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè (èñêëþ÷àÿ     

                      │ïñèõîòðîïíûå ïðåïàðàòû)           

                                                        

  │M03BX               │Ìèîðåëàêñàíòû öåíòðàëüíîãî        

                      │äåéñòâèÿ äðóãèå                   

                                                        

  │M03BX01             │Áàêëîôåí                          

  │M03BX02             │Òèçàíèäèí                         

  │M03BX04             │Òîëïåðèçîí                        

  │M03BX07             │Òåòðàçåïàì                        

  │M03C                │Ìèîðåëàêñàíòû ïðÿìîãî äåéñòâèÿ    

  │M03CA               │Äàíòðîëåí è åãî ïðîèçâîäíûå       

  │M03CA01             │Äàíòðîëåí                          

  │M04                 │Ïðîòèâîïîäàãðè÷åñêèå ïðåïàðàòû    

  │M04A                │Ïðîòèâîïîäàãðè÷åñêèå ïðåïàðàòû    

                                                        

  │M04AA               │Ìî÷åâîé êèñëîòû îáðàçîâàíèÿ       

                      │èíãèáèòîðû                        

                                                        

  │M04AA01             │Àëëîïóðèíîë                       

                                                         

  │M04AA51             │Àëëîïóðèíîë â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │M04AB               │Ïðåïàðàòû, óâåëè÷èâàþùèå âûâåäåíèå │

                      │ìî÷åâîé êèñëîòû                   

                                                        

  │M04AB02             │Ñóëüôèíïèðàçîí                    

  │M04AB03             │Áåíçáðîìàðîí                      

                                                        

  │M04AC               │Ïðîòèâîïîäàãðè÷åñêèå ïðåïàðàòû, íå │

                      │âëèÿþùèå íà ìåòàáîëèçì ìî÷åâîé    

                      │êèñëîòû                           

                                                        

  │M04AC01             │Êîëõèöèí                          

                                                        

  │M04AX               │Ïðîòèâîïîäàãðè÷åñêèå ïðåïàðàòû    

                      │äðóãèå                            

                                                        

  │M05                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │êîñòåé                            

                                                         

  │M05B                │Ïðåïàðàòû, âëèÿþùèå íà            

                      │ìèíåðàëèçàöèþ êîñòåé              

                                                        

  │M05BA               │Áèôîñôîíàòû                       

  │M05BA01             │Ýòèäðîíîâàÿ êèñëîòà               

  │M05BA02             │Êëîäðîíîâàÿ êèñëîòà               

  │M05BA03             │Ïàìèäðîíîâàÿ êèñëîòà              

  │M05BA04             │Àëåíäðîíîâàÿ êèñëîòà              

  │M05BA05             │Òèëóäðîíîâàÿ êèñëîòà              

  │M05BA06             │Èáàíäðîíîâàÿ êèñëîòà              

                                                        

  │M05BX               │Äðóãèå ïðåïàðàòû, âëèÿþùèå íà     

                      │ìèíåðàëèçàöèþ êîñòåé              

                                                        

  │M05BX01             │Èïðèôëàâîí                        

                                                        

  │M09                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │îïîðíî-äâèãàòåëüíîãî àïïàðàòà     

                      │äðóãèå                            

                                                        

  │M09A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │îïîðíî-äâèãàòåëüíîãî àïïàðàòà     

                      │äðóãèå                            

                                                        

  │M09AX               │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │îïîðíî-äâèãàòåëüíîãî àïïàðàòà     

                      │ïðî÷èå                            

                                                        

  │M09AX02             │Õîíäðîèòèí ñóëüôàò                

  │N01                 │Àíåñòåòèêè                        

  │N01A                │Àíåñòåòèêè îáùèå                  

  │N01AA               │Ýôèðû                             

  │N01AA01             │Ýôèð äèýòèëîâûé                   

  │N01AB               │Ãàëîãåíèçèðîâàííûå ãèäðîêàðáîíû   

  │N01AB01             │Ãàëîòàí                           

  │N01AB02             │Õëîðîôîðì                         

  │N01AB03             │Ìåòîêñèôëóðàí                     

  │N01AB04             │Ýíôëóðàí                          

  │N01AB05             │Òðèõëîðîýòèëåí                    

  │N01AB06             │Èçîôëóðàí                         

  │N01AF               │Áàðáèòóðàòû                        

  │N01AF03             │Òèîïåíòàë íàòðèÿ                  

  │N01AH               │Íàðêîòè÷åñêèå àíàëüãåòèêè         

  │N01AH01             │Ôåíòàíèë                          

  │N01AX               │Àíåñòåòèêè îáùèå äðóãèå           

  │N01AX01             │Äðîïåðèäîë                        

  │N01AX03             │Êåòàìèí                           

  │N01AX04             │Ïðîïàíèäèä                        

  │N01AX07             │Ýòîìèäàò                          

  │N01AX10             │Ïðîïîôîë                          

  │N01AX13             │Äèíèòðîãåí îêñèä                  

  │N01B                │Àíåñòåòèêè ìåñòíûå                

  │N01BA               │Àìèíîáåíçîéíîé êèñëîòû ýôèðû      

  │N01BA02             │Ïðîêàèí                           

  │N01BA03             │Òåòðàêàèí                         

                                                        

  │N01BA52             │Ïðîêàèí â êîìáèíàöèè ñ äðóãèìè    

                      │ïðåïàðàòàìè                       

                                                        

  │N01BB               │Àìèäû                             

  │N01BB01             │Áóïèâàêàèí                        

  │N01BB03             │Ìåïèâàêàèí                        

  │N01BB08             │Àðòèêàèí                          

                                                        

  │N01BB52             │Ëèäîêàèí â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                        

                                                        

  │N01BB58             │Àðòèêàèí â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                         

  │N01BC               │Ýôèðû áåíçîéíîé êèñëîòû           

  │N01BC01             │Êîêàèí                            

  │N01BX               │Àíåñòåòèêè ìåñòíûå äðóãèå         

  │N01BX01             │Õëîðýòèë                          

  │N01BX02             │Äèêëîíèí                          

  │N02                 │Àíàëüãåòèêè                       

  │N02A                │Îïèîèäû                           

  │N02AA               │Îïèÿ àëêàëîèäû ïðèðîäíûå          

  │N02AA01             │Ìîðôèí                            

  │N02AA05             │Îêñèêîäîí                         

  │N02AA08             │Äèãèäðîêîäåèí                     

  │N02AC               │Äèôåíèëïðîïèëàìèíà ïðîèçâîäíûå    

  │N02AC02             │Ìåòàäîí                           

  │N02AC03             │Ïèðèòðàìèä                        

  │N02AD               │Áåíçîìîðôàíà ïðîèçâîäíûå          

  │N02AD01             │Ïåíòàçîöèí                        

  │N02AE               │Îðèïàâèíà ïðîèçâîäíûå             

  │N02AE01             │Áóïðåíîðôèí                       

  │N02AF               │Ìîðôèíà ïðîèçâîäíûå               

  │N02AF01             │Áóòîðôàíîë                        

  │N02AX               │Îïèîèäû äðóãèå                     

  │N02AX01             │Òèëèäèí                           

  │N02AX02             │Òðàìàäîë                          

  │N02B                │Àíàëüãåòèêè-àíòèïèðåòèêè äðóãèå   

                                                         

  │N02BA               │Ñàëèöèëîâàÿ êèñëîòà è åå          

                      │ïðîèçâîäíûå                       

                                                        

  │N02BA01             │Àöåòèëñàëèöèëîâàÿ êèñëîòà         

  │N02BA03             │Õîëèí ñàëèöèëàò                   

  │N02BA05             │Ñàëèöèëàìèä                       

  │N02BA11             │Äèôëóíèçàë                        

  │N02BA13             │Àöòåëèñàëèöèëàò ëèçèíà            

                                                        

  │N02BA51             │Àöåòèëñàëèöèëîâàÿ êèñëîòà â       

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                      │(èñêëþ÷àÿ ïñèõîòðîïíûå ïðåïàðàòû) 

                                                         

  │N02BA71             │Àöåòèëñàëèöèëîâàÿ êèñëîòà â       

                      │êîìáèíàöèè ñ ïñèõîòðîïíûìè        

                      │ïðåïàðàòàìè                       

                                                         

  │N02BB               │Ïèðàçîëîíû                        

  │N02BB01             │Ôåíàçîí                           

  │N02BB02             │Ìåòàìèçîë íàòðèÿ                  

  │N02BB03             │Àìèíîôåíàçîí                       

                                                        

  │N02BB52             │Ìåòàìèçîë íàòðèÿ â êîìáèíàöèè ñ   

                      │äðóãèìè ïðåïàðàòàìè (èñêëþ÷àÿ     

                      │ïñèõîòðîïíûå ïðåïàðàòû)           

                                                        

  │N02BB53             │Àìèíîôåíàçîí â êîìáèíàöèè ñ       

                      │äðóãèìè ïðåïàðàòàìè (èñêëþ÷àÿ     

                      │ïñèõîòðîïíûå ïðåïàðàòû)           

                                                        

  │N02BB54             │Ïðîïèëôåíàçîí â êîìáèíàöèè ñ      

                      │äðóãèìè ïðåïàðàòàìè (èñêëþ÷àÿ     

                      │ïñèõîòðîïíûå ïðåïàðàòû)           

                                                         

  │N02BB72             │Ìåòàìèçîë íàòðèÿ â êîìáèíàöèè ñ   

                      │ïñèõîòðîïíûìè ïðåïàðàòàìè         

                                                        

  │N02BE               │Àíèëèíû                            

  │N02BE01             │Ïàðàöåòàìîë                       

  │N02BE03             │Ôåíàöåòèí                         

  │N02BE05             │Ïðîïàöåòàìîë                      

                                                         

  │N02BE51             │Ïàðàöåòàìîë â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè (èñêëþ÷àÿ ïñèõîòðîïíûå │

                      │ïðåïàðàòû)                        

                                                        

  │N02BE71             │Ïàðàöåòàìîë â êîìáèíàöèè ñ        

                      │ïñèõîòðîïíûìè ïðåïàðàòàìè         

                                                        

  │N02BE73             │Ôåíàöåòèí â êîìáèíàöèè ñ          

                      │ïñèõîòðîïíûìè ïðåïàðàòàìè         

                                                        

  │N02BG               │Àíàëüãåòèêè-àíòèïèðåòèêè ïðî÷èå   

  │N02BG02             │Ðèìàçîëèé ìåòèëñóëüôàò            

  │N02BG06             │Íåôîïàì                           

  │N02C                │Àíòèìèãðåíîçíûå ïðåïàðàòû         

  │N02CA               │Ñïîðûíüè àëêàëîèäû                

  │N02CA01             │Äèãèäðîýðãîòàìèí                  

  │N02CA02             │Ýðãîòàìèí                         

                                                        

  │N02CA51             │Äèãèäðîýðãîòàìèí â êîìáèíàöèè ñ   

                      │äðóãèìè ïðåïàðàòàìè               

                                                         

  │N02CA52             │Ýðãîòàìèí â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè (èñêëþ÷àÿ ïñèõîòðîïíûå │

                      │ïðåïàðàòû)                        

                                                         

  │N02CA72             │Ýðãîòàìèí â êîìáèíàöèè ñ          

                      │ïñèõîòðîïíûìè ïðåïàðàòàìè         

                                                        

  │N02CB               │Ãëþêîêîðòèêîñòåðîèäîâ ïðîèçâîäíûå 

  │N02CC03             │Çîëìèòðèïòàí                      

  │N02CX               │Àíòèìèãðåíîçíûå ïðåïàðàòû äðóãèå  

  │N02CX01             │Ïèçîòèôåí                         

  │N02CX03             │Èïðàçîõðîì                        

  │N02CX04             │Ñóìàòðèïòàí                       

  │N03                 │Ïðîòèâîýïèëåïòè÷åñêèå ïðåïàðàòû   

  │N03A                │Ïðîòèâîýïèëåïòè÷åñêèå ïðåïàðàòû   

  │N03AA               │Áàðáèòóðàòû è èõ ïðîèçâîäíûå      

  │N03AA02             │Ôåíîáàðáèòàë                      

  │N03AA03             │Ïðèìèäîí                          

  │N03AA04             │Áàðáåêñàêëîí                      

  │N03AB               │Ãèäàíòîèíà ïðîèçâîäíûå            

  │N03AB02             │Ôåíèòîèí                           

                                                        

  │N03AB52             │Ôåíèòîèí â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                         

  │N03AC               │Îêñàçîëèäèíà ïðîèçâîäíûå          

  │N03AC02             │Òðèìåòàäèîí                       

  │N03AD               │Ñóêöèíèìèäà ïðîèçâîäíûå           

  │N03AD01             │Ýòîñóêñèìèä                       

  │N03AE               │Áåíçîäèàçåïèíîâ ïðîèçâîäíûå       

  │N03AE01             │Êëîíàçåïàì                        

  │N03AF               │Êàðáîêñàìèäà ïðîèçâîäíûå          

  │N03AF01             │Êàðáàìàçåïèí                      

  │N03AG               │Æèðíûõ êèñëîò ïðîèçâîäíûå         

  │N03AG01             │Âàëüïðîåâàÿ êèñëîòà               

  │N03AG02             │Âàëüïðîìèä                        

  │N03AG03             │Ãàììà-àìèíîìàñëÿíàÿ êèñëîòà       

  │N03AG04             │Âèãàáàòðèí                        

                                                        

  │N03AX               │Ïðîòèâîýïèëåïòè÷åñêèå ïðåïàðàòû   

                      │äðóãèå                            

                                                         

  │N03AX09             │Ëàìîòðèäæèí                       

  │N03AX30             │Áåêëàìèä                          

  │N04                 │Àíòèïàðêèíñîíè÷åñêèå ïðåïàðàòû    

  │N04A                │Õîëèíîáëîêàòîðû öåíòðàëüíûå       

  │N04AA               │Òðåòè÷íûå àìèíû                   

  │N04AA01             │Òðèãåêñèôåíèäèë                   

  │N04AA02             │Áèïåðèäåí                         

  │N04B                │Äîïàìèíýðãè÷åñêèå ïðåïàðàòû       

  │N04BA               │Äîïà è åå ïðîèçâîäíûå             

  │N04BA01             │Ëåâîäîïà                          

  │N04BA02             │Ëåâîäîïà+Êàðáèäîïà                

  │N04BB               │Àäàìàíòàíà ïðîèçâîäíûå             

  │N04BB01             │Àìàíòàäèí                         

  │N04BC               │Äîïàìèíîâûõ ðåöåïòîðîâ ñòèìóëÿòîðû │

  │N04BC01             │Áðîìîêðèïòèí                      

  │N04BC02             │Ïåðãîëèä                          

  │N04BC05             │Ïðàìèïåêñîë                       

                                                        

  │N04BD               │Ìîíîàìèíîîêñèäàçû (òèï B)         

                      │èíãèáèòîðû                        

                                                        

  │N04BD01             │Ñåëåãèëèí                         

  │N04BX               │Äîïàìèíýðãè÷åñêèå ïðåïàðàòû äðóãèå │

  │N04BX01             │Òîëêàïîí                          

  │N05                 │Ïñèõîòðîïíûå ïðåïàðàòû            

  │N05A                │Íåéðîëåïòèêè (Àíòèïñèõîòèêè)      

                                                        

  │N05AA               │Ôåíîòèàçèíû ñ                     

                      │äèìåòèëàìèíîïðîïèëüíîé ãðóïïîé    

                                                        

  │N05AA01             │Õëîðïðîìàçèí                      

  │N05AA02             │Ëåâîìåïðîìàçèí                    

  │N05AA03             │Ïðîìàçèí                          

                                                        

  │N05AB               │Ôåíîòèàçèíû ñ ïèïåðàçèíîâîé       

                      │ñòðóêòóðîé                        

                                                         

  │N05AB02             │Ôëóôåíàçèí                        

  │N05AB03             │Ïåðôåíàçèí                        

  │N05AB04             │Ïðîõëîðïåðàçèí                    

  │N05AB06             │Òðèôëóîïåðàçèí                     

  │N05AB08             │Òèîïðîïåðàçèí                     

                                                        

  │N05AC               │Ôåíîòèàçèíû ñ ïèïåðèäèíîâîé       

                      │ñòðóêòóðîé                        

                                                        

  │N05AC01             │Ïåðèöèàçèí                        

  │N05AC02             │Òèîðèäàçèí                        

  │N05AC04             │Ïèïîòèàçèí                        

  │N05AD               │Áóòèðîôåíîíîâ ïðîèçâîäíûå         

  │N05AD01             │Ãàëîïåðèäîë                       

  │N05AD04             │Ìîïåðîí                           

  │N05AD07             │Áåíïåðèäîë                        

  │N05AF               │Òèîêñàíòåíà ïðîèçâîäíûå           

  │N05AF01             │Ôëóïåíòèêñîë                      

  │N05AF03             │Õëîðïðîòèêñåí                     

  │N05AF05             │Çóêëîïåíòèêñîë                    

  │N05AG               │Äèôåíèëáóòèëïèïåðèäèíà ïðîèçâîäíûå │

  │N05AG01             │Ôëóñïèðèëåí                       

  │N05AG02             │Ïèìîçèä                           

  │N05AG03             │Ïåíôëóðèäîë                       

  │N05AH               │Äèáåíçîäèàçåïèíû è èõ ïðîèçâîäíûå 

  │N05AH02             │Êëîçàïèí                          

  │N05AH03             │Îëàíçàïèí                         

  │N05AL               │Áåíçàìèäû                         

  │N05AL01             │Ñóëüïèðèä                          

  │N05AL02             │Ñóëüòîïðèä                        

  │N05AL03             │Òèàïðèä                           

  │N05AN               │Ëèòèé                             

  │N05AN01             │Ëèòèÿ ñîëè                         

  │N05AX               │Íåéðîëåïòèêè äðóãèå               

  │N05AX08             │Ðèñïåðèäîí                        

  │N05B                │Àíêñèîëèòèêè                      

  │N05BA               │Áåíçîäèàçåïèíà ïðîèçâîäíûå        

  │N05BA01             │Äèàçåïàì                          

  │N05BA02             │Õëîðäèàçåïîêñèä                   

  │N05BA03             │Ìåäàçåïàì                         

  │N05BA04             │Îêñàçåïàì                         

  │N05BA05             │Êëîðàçåïàò äèêàëèÿ                

  │N05BA06             │Ëîðàçåïàì                         

  │N05BA08             │Áðîìàçåïàì                        

  │N05BA09             │Êëîáàçàì                          

  │N05BA12             │Àëïðàçîëàì                        

  │N05BA23             │Òîôèçîïàì                         

  │N05BB               │Äèôåíèëìåòàíà ïðîèçâîäíûå         

  │N05BB01             │Ãèäðîêñèçèí                       

  │N05BC               │Êàðáàìàòû                          

  │N05BC01             │Ìåïðîáàìàò                        

  │N05BX               │Àíêñèîëèòèêè äðóãèå               

  │N05C                │Ñíîòâîðíûå è ñåäàòèâíûå ñðåäñòâà  

  │N05CA               │Áàðáèòóðàòû                       

  │N05CA02             │Àìîáàðáèòàë                       

  │N05CA15             │Ìåòîãåêñèòàë                      

  │N05CA16             │Ãåêñîáàðáèòàë                     

  │N05CA22             │Ïðîêñèáàðáàë                      

                                                        

  │N05CB               │Áàðáèòóðàòû â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                         

  │N05CB02             │Áàðáèòóðàòû â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │N05CC               │Àëüäåãèäû è èõ ïðîèçâîäíûå        

  │N05CC01             │Õëîðàë ãèäðàò                     

  │N05CD               │Áåíçîäèàçåïèíîâ ïðîèçâîäíûå       

  │N05CD01             │Ôëóðàçåïàì                        

  │N05CD02             │Íèòðàçåïàì                        

  │N05CD03             │Ôëóíèòðàçåïàì                     

  │N05CD04             │Ýñòàçîëàì                         

  │N05CD05             │Òðèàçîëàì                         

  │N05CD07             │Òåìàçåïàì                         

  │N05CD08             │Ìèäàçîëàì                         

  │N05CD09             │Áðîòèçîëàì                        

  │N05CF               │Öèêëîïèððîëîíû                    

  │N05CF01             │Çîïèêëîí                          

  │N05CG               │Èìèäàçîïèðèäèíû                   

  │N05CG01             │Çîëïèäåì                          

                                                        

  │N05CM               │Ñíîòâîðíûå è ñåäàòèâíûå ïðåïàðàòû 

                      │äðóãèå                            

                                                        

  │N05CM02             │Êëîìåòèàçîë                       

  │N05CM03             │Áðîìèçîâàë                        

  │N05CM05             │Ñêîïîëàìèí                         

  │N05CM11             │Áðîìèäû                           

                                                        

  │N05CX               │Ñíîòâîðíûå è ñåäàòèâíûå ïðåïàðàòû 

                      │(èñêëþ÷àÿ áàðáèòóðàòû) â          

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                        

  │N06                 │Ïñèõîàíàëåïòèêè                   

  │N06A                │Àíòèäåïðåññàíòû                   

                                                        

  │N06AA               │Ìîíîàìèíîâ îáðàòíîãî çàõâàòà      

                      │èíãèáèòîðû íåñåëåêòèâíûå          

                                                        

  │N06AA01             │Äåçèïðàìèí                        

  │N06AA02             │Èìèïðàìèí                         

  │N06AA04             │Êëîìèïðàìèí                       

  │N06AA05             │Îïèïðàìîë                         

  │N06AA06             │Òðèìèïðàìèí                       

  │N06AA09             │Àìèòðèïòèëèí                      

  │N06AA12             │Äîêñåïèí                          

  │N06AA21             │Ìàïðîòèëèí                        

                                                         

  │N06AB               │Ñåðîòîíèíà îáðàòíîãî çàõâàòà      

                      │èíãèáèòîðû ñåëåêòèâíûå            

                                                        

  │N06AB03             │Ôëóîêñåòèí                        

  │N06AB04             │Öèòàëîïðàì                        

  │N06AB05             │Ïàðîêñåòèí                        

  │N06AB06             │Ñåðòðàëèí                         

  │N06AB08             │Ôëóâîêñàìèí                        

                                                        

  │N06AF               │Ìîíîàìèíîîêñèäàçû èíãèáèòîðû      

                      │íåñåëåêòèâíûå                     

                                                         

  │N06AF02             │Íèàëàìèä                          

                                                        

  │N06AG               │Ìîíîàìèíîîêñèäàçû èíãèáèòîðû (òèï 

                      │A)                                

                                                        

  │N06AG02             │Ìîêëîáåìèä                        

  │N06AX               │Àíòèäåïðåññàíòû äðóãèå            

  │N06AX03             │Ìèàíñåðèí                         

  │N06AX05             │Òðàçîäîí                          

  │N06B                │Ïñèõîñòèìóëÿòîðû è íîîòðîïû       

  │N06BA               │Ñèìïàòîìèìåòèêè öåíòðàëüíûå       

  │N06BA01             │Àìôåòàìèí                         

  │N06BA04             │Ìåòèëôåíèäàò                      

  │N06BC               │Êñàíòèíîâûå ïðîèçâîäíûå           

  │N06BC01             │Êîôåèí                            

  │N06BX               │Ïñèõîñòèìóëÿòîðû è íîîòðîïû äðóãèå │

  │N06BX01             │Ìåêëîôåíîêñàò                     

  │N06BX02             │Ïèðèòèíîë                         

  │N06BX03             │Ïèðàöåòàì                         

  │N06BX06             │Öèòèêîëèí                         

  │N06BX13             │Èäåáåíîí                          

  │N06BX18             │Âèíïîöåòèí                        

  │N06BX19             │Ãèíãî Áèëîáà                      

                                                        

  │N06C                │Ïñèõîëåïòèêè è ïñèõîàíàëåïòèêè â  

                      │êîìáèíàöèè                        

                                                        

  │N06CA               │Àíòèäåïðåññàíòû â êîìáèíàöèè ñ    

                      │ïñèõîëåïòèêàìè                     

                                                        

  │N06CA01             │Àìèòðèïòèëèí â êîìáèíàöèè ñ       

                      │ïñèõîëåïòèêàìè                    

                                                        

  │N07                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │íåðâíîé ñèñòåìû äðóãèå            

                                                        

  │N07A                │Ïàðàñèìïàòîìèìåòèêè               

  │N07AA               │Àíòèõîëèíýñòåðàçíûå ïðåïàðàòû     

  │N07AA01             │Íåîñòèãìèíà áðîìèä                

  │N07AA02             │Ïèðèäîñòèãìèíà áðîìèä             

  │N07AA03             │Äèñòèãìèíà áðîìèä                 

  │N07AA05             │Äîíåïåçèë                         

  │N07AA30             │Àìáåíîíèÿ õëîðèä                  

  │N07AX               │Ïàðàñèìïàòîìèìåòèêè äðóãèå        

  │N07AX01             │Ïèëîêàðïèí                        

  │N07AX02             │Õîëèí àëüôîñöåðàò                 

  │N07B                │Ñðåäñòâà ïðîòèâ òàáàêîêóðåíèÿ     

  │N07BA               │Ñðåäñòâà ïðîòèâ òàáàêîêóðåíèÿ     

  │N07BA01             │Íèêîòèí                           

                                                        

  │N07C                │Ñðåäñòâà äëÿ óñòðàíåíèÿ           

                      │ãîëîâîêðóæåíèÿ                    

                                                        

  │N07CA               │Ñðåäñòâà äëÿ óñòðàíåíèÿ           

                      │ãîëîâîêðóæåíèÿ                    

                                                        

  │N07CA01             │Áåòàãèñòèí                        

  │N07CA02             │Öèííàðèçèí                         

  │N07CA03             │Ôëóíàðèçèí                        

                                                        

  │N07X                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │íåðâíîé ñèñòåìû äðóãèå            

                                                        

  │N07XX               │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │íåðâíîé ñèñòåìû ïðî÷èå            

                                                        

  │N07XX01             │Òèðèëàçàäà ìåçèëàò                

  │P01                 │Àíòèïðîòîçîéíûå ïðåïàðàòû         

                                                        

  │P01A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ àìåáèàçà è  

                      │äðóãèõ ïðîòîçîéíûõ èíôåêöèé       

                                                        

  │P01AA               │Ãèäðîêñèõèíîëèíà ïðîèçâîäíûå      

  │P01AA04             │Õëîðõèíàëäîë                      

  │P01AB               │Íèòðîèìèäàçîëà ïðîèçâîäíûå        

  │P01AB06             │Íèìîðàçîë                         

  │P01AC               │Äèõëîðîàöåòàìèäà ïðîèçâîäíûå      

  │P01AC03             │Ýòîôàìèä                          

  │P01AR               │Ìûøüÿê-ñîäåðæàùèå ïðåïàðàòû       

  │P01AX               │Àíòèïðîòîçîéíûå ïðåïàðàòû äðóãèå  

  │P01AX01             │Õèíèîôîí                          

  │P01AX02             │Ýìåòèí                            

  │P01AX05             │Ìåïàêðèí                           

  │P01B                │Ïðåïàðàòû äëÿ ëå÷åíèÿ ìàëÿðèè     

  │P01BA               │Àìèíîõèíîëèíû                     

  │P01BA01             │Õëîðîõèí                          

  │P01BA02             │Ãèäðîêñèõëîðîõèí                   

  │P01BA03             │Ïðèìàêâèí                         

  │P01BB               │Áèãóàíèäû                         

  │P01BB01             │Ïðîãóàíèë                         

  │P01BC               │Õèíèíîâûå àëêàëîèäû               

  │P01BC01             │Õèíèí                             

  │P01BD               │Äàìèíîïèðèìèäèíû                  

  │P01BD01             │Ïèðèìåòàìèí                       

                                                        

  │P01BD51             │Ïèðèìåòàìèí â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │P01BX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ìàëÿðèè                           

                                                        

  │P01C                │Ïðåïàðàòû äëÿ ëå÷åíèÿ ëåéøìàíèîçà 

                      │è òðèïàíîñîìîçà                   

                                                         

  │P01CB               │Ñóðüìû ñîåäèíåíèÿ                 

  │P01CB01             │Ìåãëóìèí, àíòèìîíàò               

  │P01CC               │Íèòðîôóðàíà ïðîèçâîäíûå           

  │P01CC02             │Íèòðîôóðàë                        

  │P01CD               │Ìûøüÿê-ñîäåðæàùèå ñîåäèíåíèÿ      

                                                        

  │P01CX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │ëåéøìàíèîçà è òðèïàíîñîìîçà       

                                                        

  │P01CX01             │Ïåíòàìèäèí                        

  │P02                 │Àíòèãåëüìèíòíûå ïðåïàðàòû         

  │P02B                │Ïðåïàðàòû äëÿ ëå÷åíèÿ òðåìàòîäîçà 

  │P02BA               │Õèíîëèíà ïðîèçâîäíûå              

  │P02BA01             │Ïðàçèêâàíòåë                      

  │P02C                │Ïðåïàðàòû äëÿ ëå÷åíèÿ íåìàòîäîçà  

  │P02CA               │Áåíçèìèäàçîëà ïðîèçâîäíûå         

  │P02CA01             │Ìåáåíäàçîë                        

  │P02CA03             │Àëáåíäàçîë                        

  │P02CB               │Ïèïåðàçèí è åãî ïðîèçâîäíûå       

  │P02CB01             │Ïèïåðàçèí                         

  │P02CB02             │Äèýòèëêàðáàìàçèí                  

  │P02CC               │Òåòðàãèäðîïèðèìèäèíà ïðîèçâîäíûå  

  │P02CC01             │Ïèðàíòåë                          

  │P02CE               │Èìèäàçîòèàçîëà ïðîèçâîäíûå        

  │P02CE01             │Ëåâàìèçîë                         

                                                        

  │P02CX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │íåìàòîäîçà                        

                                                         

  │P02CX01             │Ïèðâèíèÿ õëîðèä                   

  │P02CX02             │Áåôåíèÿ ãèäðîêñèíàôòîàò           

  │P02D                │Ïðåïàðàòû äëÿ ëå÷åíèÿ öåñòîäîçîâ  

  │P02DA               │Ñàëèöèëîâîé êèñëîòû ïðîèçâîäíûå   

  │P02DA01             │Íèêëîçàìèä                        

                                                        

  │P03                 │Ïðåïàðàòû äëÿ óíè÷òîæåíèÿ         

                      │ýêòîïàðàçèòîâ (âêëþ÷àÿ ÷åñîòî÷íîãî │

                      │êëåùà, èíñåêòèöèäà è ðåïåëëåíòû)  

                                                        

  │P03A                │Ïðåïàðàòû äëÿ óíè÷òîæåíèÿ         

                      │ýêòîïàðàçèòîâ (âêëþ÷àÿ ÷åñîòî÷íîãî │

                      │êëåùà)                            

                                                        

  │P03AC               │Ïèðåòðèíû                         

  │P03AC02             │Áèîàëëåòðèí                       

  │P03AC03             │Ôåíîòðèí                          

  │P03AC04             │Ïåðìåòðèí                         

                                                        

  │P03AC51             │Ïèðåòðóì â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                        

  │P03AC53             │Ôåíîòðèí â êîìáèíàöèè ñ äðóãèìè   

                      │ïðåïàðàòàìè                       

                                                        

  │P03AX               │Äðóãèå ïðåïàðàòû äëÿ óíè÷òîæåíèÿ  

                      │ýêòîïàðàçèòîâ                     

                                                        

  │P03AX01             │Áåíçèë áåíçîàò                    

  │P03AX03             │Ìàëàòèîí                          

  │P03B                │Èíñåêòèöèäû è ðåïåëëåíòû          

  │P03BA               │Ïèðåòðèíû                         

  │P03BA01             │Öèôëóòðèí                         

  │P03BA02             │Öèïåðìåòðèí                       

  │P03BA04             │Òåòðàìåòðèí                       

  │P03BX               │Äðóãèå èíñåêòèöèäû è ðåïåëëåíòû   

  │P03BX01             │Äèýòèëòîëóàìèä                    

  │P03BX02             │Äèìåòèëôòàëàò                     

  │P03BX03             │Äèáóòèëôòàëàò                     

  │R01                 │Íàçàëüíûå ïðåïàðàòû               

                                                         

  │R01A                │Àíòèêîíãåñòàíòû è äðóãèå íàçàëüíûå │

                      │ïðåïàðàòû äëÿ ìåñòíîãî ïðèìåíåíèÿ 

                                                        

  │R01AA               │Ñèìïàòîìèìåòèêè                   

  │R01AA05             │Îêñèìåòàçîëèí                     

  │R01AA06             │Òåòðèçîëèí                        

  │R01AA07             │Êñèëîìåòàçîëèí                    

  │R01AA08             │Íàôàçîëèí                         

  │R01AA09             │Òðàìàçîëèí                        

                                                        

  │R01AB               │Ñèìïàòîìèìåòèêè â êîìáèíàöèè ñ    

                      │äðóãèìè ïðåïàðàòàìè (èñêëþ÷àÿ     

                      │ãëþêîêîðòèêîñòåðîèäû              

                                                        

  │R01AB01             │Ôåíèëýôðèí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                         

  │R01AC               │Àíòèàëëåðãè÷åñêèå ïðåïàðàòû       

                      │(èñêëþ÷àÿ ãëþêîêîðòèêîñòåðîèäû)   

                                                        

  │R01AC01             │Êðîìîãëèöèíîâàÿ êèñëîòà           

  │R01AC02             │Ëåâîêàáàñòèí                      

  │R01AC03             │Àöåëàñòèí                         

  │R01AC04             │Àíòàçîëèí                         

  │R01AC07             │Íåäîêðîìèë                         

                                                        

  │R01AC51             │Êðîìîãëèöèíîâàÿ êèñëîòà â         

                      │êîìáèíàöèè ñ äðóãèìè ïðåïàðàòàìè  

                                                         

  │R01AD               │Ãëþêîêîðòèêîñòåðîèäû              

  │R01AD01             │Áåêëîìåòàçîí                      

  │R01AD08             │Ôëóòèêàçîí                        

  │R01AX               │Äðóãèå íàçàëüíûå ïðåïàðàòû        

  │R01AX03             │Èïðàòðîïèÿ áðîìèä                 

  │R01AX06             │Ìóïèðîöèí                         

  │R01AX10             │Ïðî÷èå ïðåïàðàòû                  

  │R01AX30             │Êîìáèíèðîâàííûå ïðåïàðàòû         

                                                        

  │R01B                │Àíòèêîíãåñòàíòû äëÿ ñèñòåìíîãî    

                      │èñïîëüçîâàíèÿ                     

                                                        

  │R01BA               │Ñèìïàòîìèìåòèêè                   

  │R01BA01             │Ôåíèëïðîïàíîëàìèí                 

                                                        

  │R01BA51             │Ôåíèëïðîïàíîëàìèí â ñî÷åòàíèè ñ   

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │R01BA52             │Ïñåâäîýôåäðèí â êîìáèíàöèè ñ      

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │R02                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ãîðëà                             

                                                        

  │R02A                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ãîðëà                             

                                                        

  │R02AA               │Àíòèñåïòèêè                       

  │R02AA01             │Àìáàçîí                            

  │R02AA02             │Äåêâàëèíèÿ õëîðèä                 

  │R02AA05             │Õëîðãåêñèäèí                      

  │R02AA09             │Áåíçåòîíèÿ õëîðèä                 

  │R02AA15             │Ïîâèäîí-Éîä                       

  │R02AA20             │Ïðî÷èå ïðåïàðàòû                  

  │R02AB               │Àíòèáàêòåðèàëüíûå ïðåïàðàòû       

  │R02AB03             │Ôóçàôóíæèí                        

  │R02AB30             │Ãðàìèöèäèí                        

                                                        

  │R03                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ áðîíõèàëüíîé │

                      │àñòìû                             

                                                        

  │R03A                │Ñèìïàòîìèìåòèêè èíãàëÿöèîííûå     

                                                        

  │R03AB               │Áåòà-àäðåíîñòèìóëÿòîðû            

                      │íåñåëåêòèâíûå                     

                                                         

  │R03AB03             │Îðöèïðåíàëèí                      

  │R03AC               │Áåòà2-àäðåíîñòèìóëÿòîðû ñåëåêòèâíûå│

  │R03AC02             │Ñàëüáóòàìîë                       

  │R03AC03             │Òåðáóòàëèí                        

  │R03AC04             │Ôåíîòåðîë                         

  │R03AC06             │Ãåêñîïðåíàëèí                     

  │R03AC12             │Ñàëìåòåðîë                        

  │R03AC13             │Ôîðìîòåðîë                         

                                                        

  │R03AK               │Ñèìïàòîìèìåòèêè â êîìáèíàöèè ñ    

                      │äðóãèìè ïðåïàðàòàìè               

                                                         

  │R03AK03             │Ôåíîòåðîë â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │R03AK04             │Ñàëüáóòàìîë â êîìáèíàöèè ñ äðóãèìè │

                      │ïðåïàðàòàìè                       

                                                        

  │R03B                │Äðóãèå èíãàëÿöèîííûå ïðåïàðàòû äëÿ │

                      │ëå÷åíèÿ áðîíõèàëüíîé àñòìû        

                                                        

  │R03BA               │Ãëþêîêîðòèêîñòåðîèäû              

  │R03BA01             │Áåêëîìåòàçîí                      

  │R03BA02             │Áóäåñîíèä                         

  │R03BA03             │Ôëóíèçîëèä                        

  │R03BA05             │Ôëóòèêàçîí                        

  │R03BB               │Õîëèíîáëîêàòîðû                   

  │R03BB01             │Èïðàòðîïèÿ áðîìèä                 

  │R03BB02             │Îêñèòðîïèÿ áðîìèä                 

                                                        

  │R03BC               │Àíòèàëëåðãè÷åñêèå ïðåïàðàòû       

                      │(èñêëþ÷àÿ ãëþêîêîðòèêîñòåðîèäû)   

                                                        

  │R03BC01             │Êðîìîãëèöèíîâàÿ êèñëîòà           

  │R03BC03             │Íåäîêðîìèë                        

                                                        

  │R03BX               │Èíãàëÿöèîííûå ïðåïàðàòû äëÿ       

                      │ëå÷åíèÿ áðîíõèàëüíîé àñòìû ïðî÷èå 

                                                        

  │R03C                │Ñèìïàòîìèìåòèêè äëÿ ñèñòåìíîãî    

                      │èñïîëüçîâàíèÿ                      

                                                        

  │R03CA               │Àëüôà- è áåòà-àäðåíîñòèìóëÿòîðû   

  │R03CA02             │Ýôåäðèí                           

                                                        

  │R03CB               │Áåòà-àäðåíîñòèìóëÿòîðû            

                      │íåñåëåêòèâíûå                     

                                                        

  │R03CB01             │Èçîïðåíàëèí                       

  │R03CB03             │Îðöèïðåíàëèí                      

  │R03CC               │Áåòà2-àäðåíîñòèìóëÿòîðû ñåëåêòèâíûå│

  │R03CC02             │Ñàëüáóòàìîë                       

  │R03CC03             │Òåðáóòàëèí                        

  │R03CC04             │Ôåíîòåðîë                         

  │R03CC05             │Ãåêñîïðåíàëèí                     

  │R03CC13             │Êëåíáóòåðîë                       

                                                        

  │R03CK               │Ñèìïàòîìèìåòèêè â êîìáèíàöèè ñ    

                      │äðóãèìè ïðåïàðàòàìè               

                                                        

  │R03D                │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │áðîíõèàëüíîé àñòìû äëÿ ñèñòåìíîãî 

                      │èñïîëüçîâàíèÿ                     

                                                        

  │R03DA               │Êñàíòèíû                          

  │R03DA01             │Äèïðîôèëëèí                        

  │R03DA02             │Õîëèíà òåîôèëëèíàò                

  │R03DA04             │Òåîôèëëèí                         

  │R03DA05             │Àìèíîôèëëèí                       

  │R03DA07             │Òåîáðîìèí                          

                                                        

  │R03DA57             │Òåîáðîìèí â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │R03DC               │Ëåéêîòðèåíîâûõ ðåöåïòîðîâ         

                      │àíòàãîíèñòû                       

                                                        

  │R03DC01             │Çàôèðëóêàñò                       

  │R03DC03             │Ìîíòåëóêàñò                       

                                                        

  │R03DX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │áðîíõèàëüíîé àñòìû äëÿ ñèñòåìíîãî 

                      │èñïîëüçîâàíèÿ                     

                                                        

  │R03DX03             │Ôåíñïèðèä                         

                                                        

  │R05                 │Ïðåïàðàòû äëÿ óñòðàíåíèÿ ñèìïòîìîâ │

                      │ïðîñòóäû è êàøëÿ                  

                                                        

  │R05C                │Îòõàðêèâàþùèå ïðåïàðàòû           

  │R05CA               │Îòõàðêèâàþùèå ïðåïàðàòû           

  │R05CA02             │Êàëèÿ éîäèä                       

  │R05CA03             │Ãâàéôåíåçèí                       

  │R05CA10             │Êîìáèíàöèÿ îòõàðêèâàþùèõ ïðåïàðàòîâ│

  │R05CB               │Ìóêîëèòèêè                         

  │R05CB01             │Àöåòèëöèñòåèí                     

  │R05CB02             │Áðîìãåêñèí                        

  │R05CB03             │Êàðáîöèñòåèí                      

  │R05CB05             │Ìåñíà                              

  │R05CB06             │Àìáðîêñîë                         

  │R05CB10             │Êîìáèíàöèÿ ìóêîëèòèêîâ            

                                                        

  │R05D                │Ïðîòèâîêàøëåâûå ïðåïàðàòû         

                      │(èñêëþ÷àÿ êîìáèíàöèþ ñ            

                      │îòõàðêèâàþùèìè ïðåïàðàòàìè)       

                                                        

  │R05DA               │Àëêàëîèäû îïèÿ è åãî ïðîèçâîäíûå  

  │R05DA01             │Ýòèëìîðôèí                        

  │R05DA04             │Êîäåèí                            

                                                        

  │R05DA20             │Êîìáèíàöèÿ ïðîòèâîêàøëåâûõ        

                      │ïðåïàðàòîâ                        

                                                        

  │R05DB               │Ïðîòèâîêàøëåâûå ïðåïàðàòû ïðî÷èå  

  │R05DB02             │Áåíïðîïåðèí                       

  │R05DB05             │Ïåíòîêñèâåðèí                     

  │R05DB09             │Îêñåëàäèí                         

  │R05DB13             │Áóòàìèðàò                         

  │R05DB18             │Ïðåíîêñäèàçèí                     

  │R05DB20             │Êîìáèíèðîâàííûå ïðåïàðàòû         

  │R05DB24             │Òèïåïèäèí                         

                                                        

  │R05F                │Ïðîòèâîêàøëåâûå ïðåïàðàòû â       

                      │êîìáèíàöèè ñ îòõàðêèâàþùèìè       

                      │ïðåïàðàòàìè                       

                                                        

  │R05FA               │Ïðîèçâîäíûå îïèÿ â êîìáèíàöèè ñ   

                      │îòõàðêèâàþùèìè ïðåïàðàòàìè        

                                                        

  │R05FA02             │Ïðîèçâîäíûå îïèÿ â êîìáèíàöèè ñ   

                      │îòõàðêèâàþùèìè ïðåïàðàòàìè        

                                                        

  │R05FB               │Äðóãèå ïðîòèâîêàøëåâûå ïðåïàðàòû â │

                      │êîìáèíàöèè ñ îòõàðêèâàþùèìè       

                      │ïðåïàðàòàìè                       

                                                        

  │R05FB02             │Ïðîòèâîêàøëåâûå ïðåïàðàòû â       

                      │êîìáèíàöèè ñ îòõàðêèâàþùèìè       

                      │ïðåïàðàòàìè                       

                                                        

  │R05X                │Äðóãèå êîìáèíöèè ïðåïàðàòîâ äëÿ   

                      │óñòðàíåíèÿ ñèìïòîìîâ ïðîñòóäû     

                                                        

  │R06                 │Àíòèãèñòàìèííûå ïðåïàðàòû         

                      │ñèñòåìíîãî äåéñòâèÿ               

                                                        

  │R06A                │Àíòèãèñòàìèííûå ïðåïàðàòû         

                      │ñèñòåìíîãî äåéñòâèÿ               

                                                        

  │R06AA               │Àìèíîàëêèëüíûå ýôèðû              

  │R06AA02             │Äèôåíãèäðàìèí                     

  │R06AA04             │Êëåìàñòèí                         

  │R06AA08             │Êàðáèíîêñàìèí                     

  │R06AA09             │Äîêñèëàìèí                        

  │R06AB               │Àëêèëàìèíû çàìåùåííûå             

  │R06AB03             │Äèìåòèíäåí                        

  │R06AB04             │Õëîðôåíàìèí                        

  │R06AB07             │Òàëàñòèí                          

  │R06AC               │Ýòèëåíäèàìèíû çàìåùåííûå          

  │R06AC03             │Õëîðîïèðàìèí                      

  │R06AD               │Ôåíîòèàçèíà ïðîèçâîäíûå           

  │R06AD01             │Àëèìåìàçèí                        

  │R06AD02             │Ïðîìåòàçèí                        

  │R06AD03             │Òèýòèëïåðàçèí                     

                                                        

  │R06AD52             │Ïðîìåòàçèí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │R06AE               │Ïðîèçâîäíûå ïèïåðàçèíà            

  │R06AE04             │Õëîðöèêëèçèí                      

  │R06AE05             │Ìåêëîçèí                          

  │R06AE06             │Îêñàòîìèä                         

  │R06AE07             │Öåòèðèçèí                         

                                                         

  │R06AX               │Àíòèãèñòàìèííûå ïðåïàðàòû         

                      │ñèñòåìíîãî äåéñòâèÿ äðóãèå        

                                                        

  │R06AX01             │Áàìèïèí                           

  │R06AX02             │Öèïðîãåïòàäèí                     

  │R06AX03             │Òåíàëèäèí                         

  │R06AX11             │Àñòåìèçîë                         

  │R06AX12             │Òåðôåíàäèí                         

  │R06AX13             │Ëîðàòàäèí                         

  │R06AX15             │Ìåáãèäðîëèí                       

  │R06AX17             │Êåòîòèôåí                         

  │R06AX18             │Àêðèâàñòèí                         

  │R06AX19             │Àöåëàñòèí                         

  │R06AX22             │Ýáàñòèí                           

                                                        

  │R07                 │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé îðãàíîâ äûõàíèÿ       

                                                        

  │R07A                │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé îðãàíîâ äûõàíèÿ       

                                                        

  │R07AA               │Ëåãî÷íûå ñóðôàêòàíòû              

  │R07AA01             │Êîëôîñöåðèëà ïàëüìèòàò            

  │R07AB               │Ñòèìóëÿòîðû äûõàòåëüíîãî öåíòðà   

  │R07AB02             │Íèêåòàìèä                         

  │R07AB03             │Ïåíòåòðàçîë                       

  │R07AB05             │Áåìåãðèä                          

                                                        

  │S01                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ãëàç                              

                                                        

  │S01A                │Ïðîòèâîìèêðîáíûå ïðåïàðàòû        

  │S01AA               │Àíòèáèîòèêè                       

  │S01AA01             │Õëîðàìôåíèêîë                     

  │S01AA04             │Îêñèòåòðàöèêëèí                   

  │S01AA09             │Òåòðàöèêëèí                       

  │S01AA11             │Ãåíòàìèöèí                         

  │S01AA12             │Òîáðàìèöèí                        

  │S01AA15             │Äèãèäðîñòðåïòîìèöèí               

  │S01AA16             │Ðèôàìèöèí                         

                                                         

  │S01AA20             │Àíòèáèîòèêîâ êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │S01AA30             │Êîìáèíàöèÿ ðàçëè÷íûç àíòèáèîòèêîâ 

  │S01AB               │Ñóëüôîíàìèäû                      

  │S01AB04             │Ñóëüôàöåòàìèä                     

  │S01AD               │Ïðîòèâîâèðóñíûå ïðåïàðàòû         

  │S01AD01             │Èäîêñóðèäèí                       

  │S01AD03             │Àöèêëîâèð                         

  │S01AX               │Ïðîòèâîìèêðîáíûå ïðåïàðàòû äðóãèå 

  │S01AX11             │Îôëîêñàöèí                        

  │S01AX12             │Íîðôëîêñàöèí                      

  │S01AX13             │Öèïðîôëîêñàöèí                    

  │S01AX16             │Ïèêëîêñèäèí                       

  │S01B                │Ïðîòèâîâîñïàëèòåëüíûå ïðåïàðàòû   

  │S01BA               │Ãëþêîêîðòèêîñòåðîèäû              

  │S01BA01             │Äåêñàìåòàçîí                      

  │S01BA02             │Ãèäðîêîðòèçîí                     

  │S01BA04             │Ïðåäíèçîëîí                       

  │S01BA06             │Áåòàìåòàçîí                       

  │S01BA07             │Ôòîðìåòîëîí                       

  │S01BA11             │Äåñîíèä                           

                                                        

  │S01BC               │Íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå │

                      │ïðåïàðàòû                          

                                                        

  │S01BC01             │Èíäîìåòàöèí                       

  │S01BC03             │Äèêëîôåíàê                        

  │S01BC04             │Ôëóðáèïðîôåí                       

                                                        

  │S01C                │Ïðîòèâîâîñïàëèòåëüíûå ïðåïàðàòû â 

                      │êîìáèíàöèè ñ ïðîòèâîìèêðîáíûìè    

                      │ïðåïàðàòàìè                       

                                                        

  │S01CA               │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè   

                                                        

  │S01CA01             │Äåêñàìåòàçîí â êîìáèíàöèè ñ       

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                        

  │S01CA02             │Ïðåäíèçîëîí â êîìáèíàöèè ñ        

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                        

  │S01CA05             │Áåòàìåòàçîí â êîìáèíàöèè ñ        

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                         

  │S01E                │Ïðîòèâîãëàóêîìíûå ïðåïàðàòû è     

                      │ìèîòèêè                           

                                                        

  │S01EA               │Ñèìïàòîìèìåòèêè äëÿ ëå÷åíèÿ       

                      │ãëàóêîìû                          

                                                        

  │S01EA02             │Äèïèâåôðèí                        

  │S01EA04             │Êëîíèäèí                           

  │S01EB               │Ïàðàñèìïàòîìèìåòèêè               

  │S01EB01             │Ïèëîêàðïèí                        

  │S01EB02             │Êàðáàõîë                          

  │S01EB05             │Ôèçîñòèãìèí                        

  │S01EB08             │Àöåêëèäèí                         

  │S01EB09             │Àöåòèëõîëèí                       

                                                        

  │S01EB51             │Ïèëîêàðïèí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │S01EC               │Èíãèáèòîðû êàðáîàíãèäðàçû         

  │S01EC01             │Àöåòàçîëàìèä                      

  │S01ED               │Áåòà-àäðåíîáëîêàòîðû              

  │S01ED01             │Òèìîëîë                           

  │S01ED02             │Áåòàêñîëîë                        

  │S01ED03             │Ëåâîáóíîëîë                       

  │S01ED04             │Ìåòèïðàíîëîë                      

  │S01EX               │Ïðîòèâîãëàóêîìíûå ïðåïàðàòû äðóãèå │

  │S01EX03             │Ëàòàíîïðîñò                       

  │S01F                │Ìèäðèàòèêè                        

  │S01FA               │Õîëèíîáëîêàòîðû                   

  │S01FA01             │Àòðîïèí                           

  │S01FA04             │Öèêëîïåíòîëàò                     

  │S01FA05             │Ãîìàòðîïèíà ãèäðîáðîìèä           

  │S01FA06             │Òðîïèêàìèä                        

                                                        

  │S01FB               │Ñèìïàòîìèìåòèêè (èñêëþ÷àÿ         

                      │ïðîòèâîãëàóêîìíûå ïðåïàðàòû)      

                                                         

  │S01FB01             │Ôåíèëýôðèí                        

                                                        

  │S01G                │Äåêîíãåñòàíòû è àíòèàëëåðãè÷åñêèå 

                      │ïðåïàðàòû                          

                                                        

  │S01GA               │Ñèìïàòîìèìåòèêè, èñïîëüçóåìûå â   

                      │êà÷åñòâå äåêîíãåñòàíòîâ           

                                                        

  │S01GA01             │Íàôàçîëèí                         

  │S01GA02             │Òåòðèçîëèí                        

  │S01GA04             │Îêñèìåòàçîëèí                     

                                                        

  │S01GA51             │Íàôàçîëèí â êîìáèíàöèè ñ äðóãèìè  

                      │ïðåïàðàòàìè                       

                                                        

  │S01GA52             │Òåòðèçîëèí â êîìáèíàöèè ñ äðóãèìè 

                      │ïðåïàðàòàìè                       

                                                        

  │S01GX               │Àíòèàëëåðãè÷åñêèå ïðåïàðàòû äðóãèå │

  │S01GX01             │Êðîìîãëèöèíîâàÿ êèñëîòà           

  │S01GX02             │Ëåâîêàáàñòèí                      

  │S01GX04             │Íåäîêðîìèë                        

  │S01GX05             │Ëîäîêñàìèä                        

  │S01H                │Àíåñòåòèêè ìåñòíûå                

  │S01HA               │Àíåñòåòèêè ìåñòíûå                

  │S01HA03             │Òåòðàêàèí                         

  │S01HA07             │Ëèäîêàèí                          

  │S01HA30             │Êîìáèíèðîâàííûå ïðåïàðàòû         

  │S01J                │Äèàãíîñòè÷åñêèå ïðåïàðàòû         

  │S01JA               │Êðàñÿùèå âåùåñòâà                 

  │S01JA01             │Ôëóîðåñöåèí íàòðèÿ                

                                                        

  │S01JX               │Äðóãèå ïðåïàðàòû äëÿ ëå÷åíèÿ      

                      │çàáîëåâàíèé ãëàç                  

                                                        

  │S01K                │Ïðåïàðàòû, èñïîëüçóåìûå â õîäå    

                      │õèðóðãè÷åñêèõ îôòàëüìîëîãè÷åñêèõ  

                      │âìåøàòåëüñòâ                      

                                                        

  │S01KA               │Âèñêîçîýëàñòè÷íûå ñîåäèíåíèÿ      

  │S01KA02             │Ãèïðîìåëëîçà                      

                                                        

  │S01KX               │Äðóãèå ïðåïàðàòû, èñïîëüçóåìûå â  

                      │õîäå õèðóðãè÷åñêèõ                

                      │îôòàëüìîëîãè÷åñêèõ âìåøàòåëüñòâ   

                                                        

  │S01X                │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ãëàç ïðî÷èå                       

                                                        

  │S01XA               │Ïðåïàðàòû äëÿ ëå÷åíèÿ çàáîëåâàíèé 

                      │ãëàç ïðî÷èå                       

                                                        

  │S01XA02             │Ðåòèíîë                           

  │S01XA04             │Êàëèÿ éîäèä                       

  │S01XA12             │Äåêñàïàíòåíîë                     

                                                        

  │S01XA20             │Èñêóññòâåííûå ñëåçû è ïðî÷èå      

                      │èíäèôôåðåíòíûå ïðåïàðàòû          

                                                        

  │S02                 │Ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │îòîëîãè÷åñêèõ çàáîëåâàíèé         

                                                         

  │S02A                │Ïðîòèâîìèêðîáíûå ïðåïàðàòû        

  │S02AA               │Ïðîòèâîìèêðîáíûå ïðåïàðàòû        

                                                        

  │S02AA30             │Êîìáèíàöèÿ ïðîòèâîìèêðîáíûõ       

                      │ïðåïàðàòîâ                        

                                                        

  │S02B                │Ãëþêîêîðòèêîñòåðîèäû              

  │S02BA               │Ãëþêîêîðòèêîñòåðîèäû              

  │S02BA06             │Äåêñàìåòàçîí                      

                                                        

  │S02C                │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè   

                                                        

  │S02CA               │Ãëþêîêîðòèêîñòåðîèäû â êîìáèíàöèè 

                      │ñ ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè   

                                                        

  │S02CA06             │Äåêñàìåòàçîí â êîìáèíàöèè ñ       

                      │ïðîòèâîìèêðîáíûìè ïðåïàðàòàìè     

                                                        

  │S02D                │Ïðåïàðàòû äëÿ ëå÷åíèÿ             

                      │îòîëîãè÷åñêèé çàáîëåâàíèé ïðî÷èå  

                                                        

  │V01                 │Àëëåðãåíû                         

  │V01A                │Àëëåðãåíû                         

  │V01AA               │Àëëåðãåíîâ ýñòðàêò                 

  │V01AA02             │Àëëåðãåíû ïûëüöû òðàâû            

  │V01AA03             │Àëëåðãåíû äîìàøíåé ïûëè           

  │V01AA04             │Àëëåðãåíû ãðèáîâ                  

  │V01AA05             │Àëëåðãåíû ïûëüöû äåðåâüåâ         

  │V01AA07             │Àëëåðãåíû íàñåêîìûõ               

  │V01AA08             │Àëëåðãåíû ïèùåâûå                 

  │V01AA10             │Àëëåðãåíû öâåòîâ                  

  │V01AA11             │Àëëåðãåíû æèâîòíûõ                

  │V01AA20             │Àëëåðãåíû ïðî÷èå                  

  │V03                 │Äðóãèå òåðàïåâòè÷åñêèå ïðîäóêòû   

  │V03A                │Äðóãèå òåðàïåâòè÷åñêèå ïðîäóêòû   

                                                        

  │V03AA               │Ïðåïàðàòû äëÿ ëå÷åíèÿ õðîíè÷åñêîãî │

                      │àëêîãîëèçìà                       

                                                        

  │V03AA01             │Äèñóëüôèðàì                       

  │V03AB               │Àíòèäîòû                           

  │V03AB02             │Íàëîðôèí                          

  │V03AB03             │Ýäåòîâàÿ êèñëîòà                  

  │V03AB06             │Íàòðèÿ òèîñóëüôàò                 

  │V03AB07             │Àïîìîðôèí                          

  │V03AB08             │Íàòðèÿ íèòðèò                     

  │V03AB14             │Ïðîòàìèíà ñóëüôàò                 

  │V03AB15             │Íàëîêñîí                          

  │V03AB17             │Ìåòèëòèîíèíèÿ õëîðèä              

  │V03AB18             │Êàëèÿ ïåðìàíãàíàò                 

  │V03AB22             │Àìèëíèòðèò                        

  │V03AB24             │Äèãèòàëèñíûé àíòèòîêñèí           

  │V03AB25             │Ôëóìàçåíèë                        

  │V03AB30             │Íàëòðåêñîí                        

  │V03AC               │Æåëåçîñâÿçûâàþùèå ïðåïàðàòû       

  │V03AC01             │Äåôåðîêñàìèí                      

                                                        

  │V03AF               │Ïðåïàðàòû, ñíèæàþùèå òîêñè÷íîñòü  

                      │öèòîñòàòè÷åñêîé òåðàïèè           

                                                        

  │V03AF01             │Ìåñíà                             

  │V03AF03             │Êàëüöèÿ ôîëèíàò                   

  │V03AF05             │Àìèôîñòèí                         

  │V03AN               │Ìåäèöèíñêèå ãàçû                  

  │V03AX               │Äðóãèå ëåêàðñòâåííûå ïðåïàðàòû    

                                                         

  │V03AZ               │Ïðåïàðàòû óãíåòàþùèå íåðâíóþ      

                      │ñèñòåìó                           

                                                        

  │V04                 │Äèàãíîñòè÷åñêèå ïðåïàðàòû         

  │V04B                │Òåñòû äëÿ àíàëèçà ìî÷è            

  │V04C                │Äèàãíîñòè÷åñêèå ïðåïàðàòû ïðî÷èå  

                                                        

  │V04CC               │Òåñòû äëÿ îïðåäåëåíèÿ ïðîõîäèìîñòè │

                      │æåë÷íîãî ïðîòîêà                  

                                                        

  │V04CC04             │Öåðóëåòèä                         

                                                        

  │V04CG               │Òåñòû äëÿ îïðåäåëåíèÿ æåëóäî÷íîé  

                      │ñåêðåöèè                          

                                                        

  │V04CG03             │Ãèñòàìèí                          

  │V04CG04             │Ïåíòàãàñòðèí                      

  │V04CH               │Òåñòû äëÿ îïðåäåëåíèÿ ôóíêöèè ïî÷åê│

  │V04CH02             │Èíäèãî êàðìèí                     

                                                        

  │V04CJ               │Òåñòû äëÿ îïðåäåëåíèÿ ôóíêöèè     

                      │ùèòîâèäíîé æåëåçû                 

                                                        

  │V04CJ02             │Ïðîòèðåëèí                        

                                                        

  │V04CL               │Òåñòû äëÿ âûÿâëåíèÿ àëëåðãè÷åñêèõ 

                      │çàáîëåâàíèé                       

                                                        

  │V04CX               │Äèàãíîñòè÷åñêèå ïðåïàðàòû ïðî÷èå  

  │V06                 │Ñðåäñòâà ïèòàíèÿ                  

                                                        

  │V06A                │Äèåòè÷åñêèå ñðåäñòâà äëÿ ëå÷åíèÿ  

                      │îæèðåíèÿ                          

                                                        

  │V06AA               │Íèçêîêàëîðèéíûå äèåòû             

  │V06C                │Äåòñêèå ñìåñè                     

  │V06CA               │Ñðåäñòâà ïèòàíèÿ áåç ôåíèëàëàíèíà 

  │V06D                │Ñðåäñòâà ïèòàíèÿ ïðî÷èå           

                                                        

  │V06DB               │Æèðîâ, óãëåâîäîâ, ìèíåðàëîâ è     

                      │âèòàìèíîâ ñî÷åòàíèÿ               

                                                        

  │V06DC               │Óãëåâîäû                          

  │V06DC02             │Ôðóêòîçà                          

  │V06DF               │Çàìåíèòåëè ìîëîêà                 

  │V06DX               │Ñî÷åòàíèÿ ñðåäñòâ ïèòàíèÿ äðóãèå  

  │V07                 │Äðóãèå íåëå÷åáíûå ñðåäñòâà        

  │V07A                │Äðóãèå íåëå÷åáíûå ñðåäñòâà        

  │V07AA               │Ïëàñòûðè                          

  │V07AB               │Ðàñòâîðèòåëè                       

                                                        

  │V07AC               │Âñïîìîãàòåëüíûå ñðåäñòâà äëÿ      

                      │ãåìîòðàíñôóçèè                    

                                                        

  │V07AT               │Êîñìåòèêà                         

  │V07AV               │Äåçèíôåêòàíòû òåõíè÷åñêèå         

  │V07AX               │Ìîþùèå âåùåñòâà                   

  │V07AY               │Âñïîìîãàòåëüíûå âåùåñòâà äðóãèå   

                                                        

  │V07AZ               │Õèìè÷åñêèå ðåàãåíòû äëÿ           

                      │ëàáîðàòîðíîãî àíàëèçà             

                                                        

  │V08                 │Êîíòðàñòíûå âåùåñòâà              

                                                        

  │V08A                │Ðåíòãåíîêîíòðàñòíûå éîäñîäåæàùèå  

                      │âåùåñòâà                          

                                                         

  │V08AA               │Âîäîðàñòâîðèìûå âûñîêîîñìîëÿðíûå  

                      │ðåíîòðîïíûå âåùåñòâà              

                                                        

  │V08AA01             │Íàòðèÿ àìèäîòðèçîàò               

  │V08AA03             │Éîäàìèä                           

  │V08AA04             │Éîòàëàìîâàÿ êèñëîòà               

  │V08AA05             │Éîêñèòàëàìîâàÿ êèñëîòà            

  │V08AA10             │Äèéîäîí                            

                                                        

  │V08AB               │Ðåíîòðîïíûå ðåíòãåíîêîíòðàñòíûå   

                      │âîäîðàñòâîðèìûå íèçêîîñìîëÿðíûå   

                      │âåùåñòâà                           

                                                        

  │V08AB01             │Ìåòðèçàìèä                        

  │V08AB02             │Éîãåêñîë                          

  │V08AB03             │Éîêñàãëîâàÿ êèñëîòà               

  │V08AB04             │Éîïàìèäîë                         

  │V08AB05             │Éîïðîìèä                          

  │V08AB09             │Èîäèêñàíîë                        

  │V08AB11             │Éîáèòðèäîë                        

                                                        

  │V08AC               │Ãåïàòîòðîïíûå ðåíòãåíîêîíòðàñòíûå 

                      │âîäîðàñòâîðèìûå âåùåñòâà          

                                                        

  │V08AC04             │Àäèïèîäîí                         

  │V08AC06             │Éîïàíîåâàÿ êèñëîòà                

  │V08AC08             │Éîïîäàò íàòðèÿ                    

                                                        

  │V08AD               │Ðåíòãåíîêîíòðàñòíûå               

                      │âîäîíåðàñòâîðèìûå âåùåñòâà        

                                                        

  │V08AD03             │Ïðîïèëéîäîí                       

  │V08AD04             │Éîôåíäèëàò                        

                                                        

  │V08B                │Ðåíòãåíîêîíòðàñòíûå íåéîäèðîâàííûå │

                      │âåùåñòâà                          

                                                         

  │V08BA               │Áàðèÿ ñóëüôàò-ñîäåðæàùèå ñðåäñòâà 

  │V08BA02             │Áàðèÿ ñóëüôàò                     

                                                        

  │V08C                │Êîíòðàñòíûå âåùåñòâà äëÿ          

                      │ÿäåðíî-ñàãíèòíîãî ðåçîíàíàñà      

                                                        

  │V08CA               │Ïàðàìàãíèòíûå êîíòðàñòíûå ñðåäñòâà │

  │V08CA01             │Ãàäîïåíòåíîâàÿ êèñëîòà            

  │V08CA02             │Ãàäîòåðîâàÿ êñèëîòà               

  │V08CA03             │Ãàäîäèàìèä                        

                                                        

  │V08D                │Êîíòðàñòíûå ñðåäñòâà äëÿ          

                      │óëüòðàçâóêîâîé äèàãíîñòèêè        

                                                        

  │V08DA               │Êîíòðàñòíûå ñðåäñòâà äëÿ          

                      │óëüòðàçâóêîâîé äèàãíîñòèêè        

                                                        

  │V08DA02             │Ãàëàêòîçû ìèêðî÷àñòèöû            

                                                        

  │V09                 │Ðàäèîôàðìàöåâòè÷åñêèå ñðåäñòâà    

                      │äèàãíîñòè÷åñêèå                   

                                                        

  │V09A                │Ðàäèîôàðìàöåâòè÷åñêèå ñðåäñòâà äëÿ │

                      │âûÿâëåíèÿ çàáîëåâàíèé ÖÍÑ         

                                                        

  │V09AA               │Òåõíåöèé 99m-ñîäåðæàùèå ïðåïàðàòû 

                                                        

  │V09E                │Ðàäèîôàðìàöåâòè÷åñêèå ñðåäñòâà äëÿ │

                      │âûÿâëåíèÿ çàáîëåâàíèé îðãàíîâ     

                      │äûõàíèÿ                           

                                                        

  │V09EB               │Òåõíåöèé 99m êîëëîèäíûé äëÿ       

                      │èíúåêöèé                           

                                                        

  │V09EB02             │Òåõíåöèé 99m ìèêðîñôåðû           

                                                        

  │V09G                │Ðàäèîôàðìàöåâòè÷åñêèå ïðåïàðàòû   

                      │äëÿ äèàãíîñòèêè çàáîëåâàíèé       

                      │ñåðäå÷íî-ñîñóäèñòîé ñèñòåìû       

                                                        

  │V09GA               │Òåõíåöèé 99m-ñîäåðæàùèå ïðåïàðàòû 

  │V09GA02             │Òåõíåöèé 99m òåòðîôîñìèí          

                                                        

  │V09GX               │Ðàäèîôàðìàöåâòè÷åñêèå ïðåïàðàòû   

                      │äëÿ äèàãíîñòèêè çàáîëåâàíèé       

                      │ñåðäå÷íî-ñîñóäèñòîé ñèñòåìû äðóãèå │

                                                        

  │V09GX01             │Òàëëèé-201 õëîðèä                 

                                                        

  │V09X                │Ðàäèîôàðìàöåâòè÷åñêèå ïðåïàðàòû   

                      │Äðóãèå                            

                                                        

  │V09XA               │Éîä-131-ñîäåðæàùèå ñðåäñòâà       

                                                        

  │V09XX               │Ðàçëè÷íûå ïðî÷èå äèàãíîñòè÷åñêèå  

                      │ðàäèîôàðìàöåâòè÷åñêèå ïðåïàðàòû   

                                                        

  │V10                 │Ðàäèîòåðàïåâòè÷åñêèå ñðåäñòâà     

                                                        

  │V10B                │Ðàäèîòåðàïåâòè÷åñêèå              

                      │ïðîòèâîîïóõîëåâûå (êîñòíàÿ òêàíü) 

                      │ñðåäñòâà                           

                                                        

  │V10BX               │Ðàçëè÷íûå ïðî÷èå ïðåïàðàòû äëÿ    

                      │ïàëëèàòèâíîãî ëå÷åíèÿ êîñòíûõ     

                      │ìåòàñòàçîâ                        

                                                        

  │V10BX01             │Ñòðîíöèé õëîðèä-89                

  └────────────────────┴───────────────────────────────────┘

 

 

 

 

 

Ïðèëîæåíèå 4.

 

ÏÅÐÅ×ÅÍÜ ÏÐÅÏÀÐÀÒÎÂ,

ÐÅÃÈÑÒÐÀÖÈß È ÂÂÎÇ ÊÎÒÎÐÛÕ Â ÐÎÑÑÈÞ

ÏÐÈÎÑÒÀÍÎÂËÅÍÛ

 

ÓÊÀÇÀÍÈÅ

 

18 ôåâðàëÿ 1998 ã.

 

N 133-Ó

 

Î ÏÐÈÎÑÒÀÍÎÂÊÅ ÂÂÎÇÀ ÈÍÑÓËÈÍÎÂ

ÒÀÐÕÎÌÈÍÑÊÎÃÎ ÔÀÐÌÀÖÅÂÒÈ×ÅÑÊÎÃÎ ÇÀÂÎÄÀ "ÏÎËÜÔÀ ÀÎ"

(ÏÎËÜØÀ) Â ÐÎÑÑÈÞ

 

Ìèíèñòåðñòâîì çäðàâîîõðàíåíèÿ Ðîññèéñêîé Ôåäåðàöèè áûëî ïðåäóñìîòðåíî ïðîâåäåíèå â 1997 ãîäó ïîñòðåãèñòðàöèîííûõ êëèíè÷åñêèõ èñïûòàíèé èíñóëèíîâ ïðîèçâîäñòâà Òàðõîìèíñêîãî ôàðìàöåâòè÷åñêîãî çàâîäà "Ïîëüôà ÀÎ", Ïîëüøà. Îäíàêî äî íàñòîÿùåãî âðåìåíè çàâîä, íåñìîòðÿ íà ïîâòîðíûå íàïîìèíàíèÿ Ìèíçäðàâà Ðîññèè, íå îáåñïå÷èë èõ îðãàíèçàöèþ.

1. Íà÷àëüíèêó Óïðàâëåíèÿ ãîñóäàðñòâåííîãî êîíòðîëÿ ëåêàðñòâåííûõ ñðåäñòâ è ìåäèöèíñêîé òåõíèêè Õàáðèåâó Ð.Ó., çàìåñòèòåëþ íà÷àëüíèêà Óïðàâëåíèÿ îðãàíèçàöèè îáåñïå÷åíèÿ ëåêàðñòâàìè è ìåäèöèíñêîé òåõíèêîé Íåêðàñîâó Ý.Í. ïðèîñòàíîâèòü ââîç â Ðîññèþ èíñóëèíîâ ïðîèçâîäñòâà Òàðõîìèíñêîãî ôàðìàöåâòè÷åñêîãî çàâîäà "Ïîëüôà ÀÎ" (Ïîëüøà), äî ïðîâåäåíèÿ èõ ïîñòðåãèñòðàöèîííûõ êëèíè÷åñêèõ èñïûòàíèé â ñîîòâåòñòâèè ñ ðåøåíèÿìè, ïðèíÿòûìè Ôàðìàêîëîãè÷åñêèì ãîñóäàðñòâåííûì êîìèòåòîì.

2. Íà÷àëüíèêó Óïðàâëåíèÿ Ãîñóäàðñòâåííîãî êîíòðîëÿ ëåêàðñòâåííûõ ñðåäñòâ è ìåäèöèíñêîé òåõíèêè Õàáðèåâó Ð.Ó.:

2.1. Ïîäãîòîâèòü ïèñüìî Òàðõîìèíñêîìó ôàðìàöåâòè÷åñêîìó çàâîäó "Ïîëüôà ÀÎ" (Ïîëüøà) î ïðèîñòàíîâêå ðåãèñòðàöèè èíñóëèíîâ â Ðîññèéñêîé Ôåäåðàöèè äî ïðîâåäåíèÿ ïîñòðåãèñòðàöèîííûõ êëèíè÷åñêèõ èñïûòàíèé.

2.2. Ðàçðåøåíèå î ââîçå â Ðîññèþ èíñóëèíîâ ïðîèçâîäñòâà Òàðõîìèíñêîãî ôàðìàöåâòè÷åñêîãî çàâîäà "Ïîëüôà ÀÎ" (Ïîëüøà) ïðèíÿòü ïî ðåçóëüòàòàì ïîñòðåãèñòðàöèîííûõ êëèíè÷åñêèõ èñïûòàíèé.

 

Ïåðâûé çàìåñòèòåëü Ìèíèñòðà

çäðàâîîõðàíåíèÿ

Ðîññèéñêîé Ôåäåðàöèè

À.Ì.ÌÎÑÊÂÈ×ÅÂ


 

ÏÅÐÅ×ÅÍÜ ÈÍÑÓËÈÍÎÂ

ÏÐÎÈÇÂÎÄÑÒÂÀ ÒÀÐÕÎÌÈÍÑÊÎÃÎ ÔÀÐÌÀÖÅÂÒÈ×ÅÑÊÎÃÎ ÇÀÂÎÄÀ

"ÏÎËÜÔÀ ÀÎ" (ÏÎËÜØÀ), ÇÀÐÅÃÈÑÒÐÈÐÎÂÀÍÍÛÕ Â ÐÔ

 

1. Èíñóëèí       
Èçîôàíèêóì "ÂÎ-Ñ"

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005184
27.07.94

2. Èíñóëèí       
Èçîôàíèêóì "ÕÎ-Ñ"

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005185
27.07.94

3. Èíñóëèí Ëåíòå 
"ÂÎ-Ñ"        

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005179
27.07.94

4. Èíñóëèí Ëåíòå 
"ÕÎ-Ñ"        

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005181
27.07.94

5. Èíñóëèí       
Ìàêñèðàïèä "ÂÎ-Ñ"

Èíñóëèí-ÁÄ

Ðàñòâîð         
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005187
27.07.94

6. Èíñóëèí       
Ìàêñèðàïèä "ÕÎ-Ñ"

Èíñóëèí-ÁÄ

Ðàñòâîð        
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005186
27.07.94

7. Èíñóëèí       
ðàñòâîðèìûé      
íåéòðàëüíûé "ÂÎ-Ñ"

Èíñóëèí-ÁÄ

Ðàñòâîð        
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005188
27.07.94

8. Èíñóëèí       
ðàñòâîðèìûé      
íåéòðàëüíûé "ÕÎ-Ñ"

Èíñóëèí-ÁÄ

Ðàñòâîð        
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005189
27.07.94

9. Èíñóëèí       
Ñåìèëåíòå  "ÂÎ-Ñ"

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005183
27.07.94

10. Èíñóëèí      
Ñåìèëåíòå  "ÕÎ-Ñ"

Èíñóëèí-ÑðÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005182
27.07.94

11. Èíñóëèí      
Óëüòðàëåíòå "ÂÎ-Ñ"

Èíñóëèí-ÄëÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005178
27.07.94

12. Èíñóëèí      
Óëüòðàëåíòå "ÕÎ-Ñ"

Èíñóëèí-ÄëÄ

Ñóñïåíçèÿ      
äëÿ èíúåêöèé   
(ôëàêîíû)      
400,800 ÌÅ-10ìë

Polfa, Tarchomin
Pharmaceutical  
Works, Ïîëüøà   

Ï-8-242
N 005180
27.07.94

 

 



Âñå íîðìàòèâíî-ïðàâîâûå àêòû ïî ìåäèöèíå // Çäðàâîîõðàíåíèå, çäîðîâüå, çàáîëåâàíèÿ, ëå÷åíèå, ëåêàðñòâà, äîêòîðà, áîëüíèöû //

ßíäåêñ öèòèðîâàíèÿ

Copyright © Ìåäèöèíñêèé èíôîðìàöèîííûé ðåñóðñ www.hippocratic.ru, 2012 - 2024